Saturday, 25 February - EAU Annual Congress

Welcome to 

Paris! 

Contents: flip page

Contents 

Welcome 3 

EAU Patrons and Contributors 4 

Synopsis & Venue 

EAU Award Winners 6 

Floorplans 10 

Synopsis 13 

Exhibition Floorplans 28 

Alphabetical list of Exhibitors 32 

General 

General Information 37 

Speaker Guidelines 44 

Accreditation 46 

EU-ACME Programme 47 

About Paris 49 

Congress Hotels 51 

EAU Programme Friday, 24 February 57 

EAU Programme Saturday, 25 February 75 

EAU Programme Sunday, 26 February 151 

EAU Programme Monday, 27 February 239 

EAU Programme Tuesday, 28 February 315 

ESU Courses and Hands-on Training Courses 

ESU Courses 319 

ESU/ESUT Hands-on Training Courses 369 

Sponsored Sessions 379 

13th International Meeting of the EAUN 407 

About EAU 

EAU Membership 431 

EAU Offices 432 

Historical Overview EAU Congresses 434 

Indices 

Abstract Authors 435 

Abstracts sorted by Topic 471 

Sessions sorted by Topic 474 

List of Speakers (not abstracts) 475 

2 Programme Book

Welcome to Paris 

by the EAU Secretary General and the Congress President 

Dear friends and colleagues, 

We are very pleased to welcome you to Paris for the 27 th Annual EAU Congress! 

Urologists from all around the world will convene in Paris for in-depth lectures, updates on the 

latest scientific breakthroughs and insights into urological technology. Welcome to the Palais 

des Congrès, a modern venue with all facilities required to make this year another success. 

Also, thanks to the venue’s central location, most landmarks are only a few metro stops away. 

With a city as beautiful as Paris, it should come as no surprise that this is already the third time 

that the European Association of Urology has chosen to hold its Annual Congress in the French 

capital. As a city with a long history as a centre of urological innovation, Paris’s visual beauty 

is matched by its relevance to the field. The universities and hôpitaux have produced many 

urological pioneers, and have attracted surgeons and academics from all across Europe. 

The Scientific Congress Office has once again delivered a complete and diverse Scientific 

Programme, covering a wide range of urological topics and giving visitors a chance to be 

informed on the latest developments. This year, Plenary Sessions are followed by a selection of 

Thematic Sessions, each of which brings together presentations of a similar topic. The choice 

of Thematic Session allows each delegate to compile a programme that interests them. The 

Plenary, Thematic and ESU Sessions will feature 700 speakers. In addition, some 1,100 speakers 

will be presenting their research in abstract sessions. 

The Urology Beyond Europe international sessions on the first day always provide an important 

opportunity for the EAU, as well as for its members, to strengthen its ties abroad. Be sure to 

make use of the chance that this Annual EAU Congress provides to meet up with your international 

colleagues, and to make new acquaintances. 

A technological Exhibit will take place for the duration of the Congress. Here, a multitude of 

companies will present the latest healthcare innovations. 

After the full congress programme has engorged your mind, why not enjoy an evening out in 

the city of light? The glamorous, varieté-themed EAU Evening is held at the Grande Halle de 

la Villette. It will also be an occasion to enjoy French cuisine and wine. The park in which the 

venue is located is famous for its iconic deconstructivist follies and is a beautiful backdrop for 

the party. 

Allow us to say on behalf of the EAU: Bienvenue à Paris! 

Per-Anders 

Abrahamsson 

EAU Secretary 

General 

Clement- 

Claude Abbou 

Congress 

President 

EAU Paris 2012 

3

EAU Patrons & Contributors 

EAU Platinum Corporate sponsors 

AMGEN 

ASTELLAS 

GLAXOSMITHKLINE 

OLYMPUS 

EAU Gold Corporate Sponsors 

AMERICAN MEDICAL SYSTEMS 

ELI LILLY AND COMPANY 

FERRING PHARMACEUTICALS 

INTUITIVE SURGICAL 

IPSEN 

JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON 

KARL STORZ GMBH & CO.KG 

NOVARTIS ONCOLOGY 

PIERRE FABRE MÉDICAMENT 

SANOFI ONCOLOGY 

EAU Congress Contributors 

ALLERGAN 

BAYER HEALTHCARE 

BERLIN CHEMIE AG/ MENARINI 

COOK MEDICAL 

GALIL MEDICAL 

IBSA INSTITUT BIOCHIMIQUE SA 

LUMENIS 

OM PHARMA 

PHOTOCURE 

PORGÈS – A COLOPLAST DIVISION 

PFIZER 

RECORDATI 

STEBA BIOTECH 

TERUMO 

4 Programme Book

EAU Member 

Benefits at EAU 2012! 

EAU members are kindly invited to collect the following complementary 

items: 

EAU Extended and Pocket Guidelines 2012 

Collect your copy of the EAU Extended Guidelines 2012 edition at the EAU booth 1N01 on 

level 1. 

The Pocket Guidelines - a booklet and CD including the EAU Guidelines 2012 - 

can be collected at OLYMPUS booth 2M100 on level 2. 

The distribution is supported by OLYMPUS. 

EAU members are kindly invited to the EAU booth 1N01 on level 1, to 

collect the following complementary items: 

Historia Volume 19 

The latest volume of “De Historia Urologiae Europaeae” will feature a wide range 

of articles on the history of urology in Europe, from pioneers in the field to the 

institutions that produced them. 

Bladder Cancer: Second Edition 2012 

The EAU and ICUD are pleased to present the results of the 2nd International 

Consultation on Bladder Cancer, which took place at the 26th Annual EAU Congress 

in Vienna. Edited by Dr. Mark Soloway and Dr. S. Khoury, the publication summarizes 

the conclusions of 100 experts in the field of bladder cancer, on topics ranging from 

screening to treatment. 

Congress delegates are kindly invited to collect the following 

complementary items: 

EAU Abstract CD 2012 

A CD containing all presented abstracts during the 27th Annual EAU Congress can be 

collected at FERRING booth 2M110 on level 2. 

Supported by an educational grant from FERRING PHARMACEUTICALS. 

ESU Courses CD 2012 

A CD including all presentations and course materials of the ESU Courses given during 

the congress can be collected at MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY 

booth 2M13 on level 2. 

Supported by an unrestricted educational grant from MILLENNIUM: THE TAKEDA 

ONCOLOGY COMPANY. 

EAU Poster DVD 2012 

A DVD containing the majority of the posters presented during the 27th Annual EAU 

Congress. The EAU Poster DVD can be collected at AMGEN booth 1P73 on level 1. 

Supported by an unrestricted educational grant from AMGEN. 

�� 

� �� 

� �� 

�� 

�� 

�� 

� �� 

� �� 

� �� 

�� 

� �� 

European 

Association 

of Urology 

Guidelines 

2012 edition 

European 

Association 

of Urology 

EAU Poster DVD 

27th Annual EAU Congress 

Pocket Guidelines 

2012 edition 

EUROPEAN EUROPEAN UROLOGY UROLOGY 

Abstracts 

SUPPLEMENTS 

SUPPLEMENTS 

EU-ACME 

accredited 

content 


ESU Courses 2012 


www.eauparis2012.org

Awards 

EAU Award Winners 

EAU Willy Gregoir Medal 2012 

For a significant contribution to the development of the urological specialty in Europe 

M.J. Marberger, Vienna (AT) 

EAU Frans Debruyne Life Time Achievement Award 2012 

For a longstanding and important contribution to the activities and development of the EAU 

R.E. Hautmann, Neu-Ulm (DE) 

EAU Crystal Matula Award 2012 

For a young promising European urologist 

P.J. Bastian, Munich (DE) 

Supported by an unrestricted educational grant from LABORIE 

EAU Hans Marberger Award 2012 

For the best European paper published on Minimally Invasive Surgery (in Urology) 

A. Alcaraz, Barcelona (ES) 

Feasibility of Transvaginal Natural Orifice Transluminal Endoscopic Surgery–Assisted Living 

Donor Nephrectomy: Is Kidney Vaginal Delivery the Approach of the Future? 

European Urology (2011), doi: 10/1016/j.eururo.2011.03.021 

Supported by an unrestricted educational grant from KARL STORZ GMBH & Co. KG 

EAU Innovators in Urology Award 2012 

For inventions and clinical contributions which have had a major impact on influencing the 

treatment and/or diagnosis of a urological disease 

J.E.A. Wickham, Westcott (GB) 

Prize for the Best Paper published on Fundamental Research in the Urological Literature 

in 2011 

W. Everaerts, M. Gees, Y.A. Alpizar, R. Farre, C. Leten, A. Apetrei, I. Dewachter I, 

F. Van Leuven, R. Vennekens, D. De Ridder, B. Nilius, T. Voets, K. Talavera (Leuven, 

Belgium) 

The Capsaicin Receptor TRPV1 Is a Crucial Mediator of the Noxious Effects of Mustard Oil 

Current Biology 21 (2011), doi: 10.1016/j.cub.2011.01.031 

Prize for the Best Paper published on Clinical Research in the Urological Literature in 

2011 

M. Van Hemelrijck, H. Garmo, L. Holmberg, P. Stattin, J. Adolfsson (London, United 

Kingdom; Uppsala, Umed, Stockholm, Sweden) 

Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following 

Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden 

European Urology (2011), doi: 10.1016/j.eururo.2011.09.010 

Prize for the Best Scientific Paper published in European Urology in 2011 

V.R. Patel, A. Sivaraman, R.F. Coelho, S. Chauhan, K.J. Palmer, M.A. Orvieto, I. Camacho, 

G. Coughlin, B. Rocco (Florida, United States of America; Sao Paulo, Brazil; Milan, Italy) 

Pentafecta: A New Concept for Reporting Outcomes of Robot-Assisted Laparoscopic Radical 

Prostatectomy 

European Urology, Volume 59 (2011), Pages 702-707 

Supported by an unrestricted educational grant from ELSEVIER 

Prize for the Best Scientific Paper published on Fundamental Research in European 

Urology by a young urologist in 2011 

A. Turner, R. Subramanian, D.F.M. Thomas, J. Hinley, Syed Khawar Abbas, 

Jens Stahlschmidt, Jennifer Southgate (York, Leeds, Manchester, United Kingdom) 

Transplantation of Autologous Differentiated Urothelium in an Experimental Model of 

Composite Cystoplasty 


Supported by an unrestricted educational grant from ELSEVIER 

6 Programme Book

Prize for the Best Scientific Paper published on Clinical Research in European Urology by 

a young urologist in 2011 

D.C. Chade, S.F. Shariat, A.M. Cronin, C.J. Savage, R.J. Karnes, M.L. Blute, A. Briganti, 

F. Montorsi, H.G. van der Poel, H. Van Poppel, S. Joniau, G. Godoy, A. Hurtado-Coll, 

M.E. Gleave, M. Dall’Oglio, M. Srougi, P.T. Scardino, J.A. Eastham, New York (US) 

Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional 

Collaboration 


The European Urology Platinum Award 

M. Menon, Detroit (US) 

First Prize for the Best Abstract (Oncology) 

M. Durand, A. Aggarwal, B. Robinson, A. Srivastava, P. Sooriakumaran, J. Mtui, D. Brooks, 

D. Flomenbaum, J. Sterling, S. Mukherjee, R. Leung, A.K. Tewari (Nice, France; New York, 

United States of America - Abstract 246 

Real-time, in vivo multiphoton microscopy imaging is a promising tool to identify prostate 

tissue during rat survival surgery 

Second Prize for the Best Abstract (Oncology) 

O.R. Brouwer, H.G. Van Der Poel, N. Van Den Berg, B.W. Van Rhijn, A. Bex, 

W. Meinhardt, R.A. Valdés Olmos, F.W.B. Van Leeuwen, S. Horenblas (Amsterdam, 

The Netherlands) - Abstract 519 

A hybrid radioactive and fluorescent tracer for sentinel node biopsy in penile carcinoma as a 

potential replacement for blue dye 

Third Prize for the Best Abstract (Oncology) 

M.A. Brausi, J.R. Oddens, R.J. Sylvester, A.V. Bono, C. Van De Beek, G. Van Andel, 

P. Gontero, W. Hoeltl, L. Turkeri, S. Collette, W. Oosterlinck (Modena, Varese, Novara, Italy; 

‘s-Hertogenbosch, Maastricht, Amsterdam, The Netherlands; Brussels, Ghent, Belgium; 

Vienna, Austria; Istanbul, Turkey) - Abstract 1050 

Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of 

maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle 

invasive bladder cancer 

First Prize for the Best Abstract (Non-Oncology) 

F. Friedersdorff, F. Engelken, B. Hamm, T.F. Fuller, S. Deger, A. Magheli, K. Budde, 

K. Miller, G. Diederichs (Berlin, Germany - Abstract 316 

Pre-operative assessment of living renal transplant donors with state-of-the-art imaging 

modalities: Computed tomography angiography vs. magnetic resonance angiography in 118 

patients 

Second Prize for the Best Abstract (Non-Oncology) 

S. Finke, B. Stubendorff, M. Walter, T. Steiner, G. Wolf, O. Kniemeyer, 

F. Von Eggeling, T. Gruschwitz, M.O. Grimm, K. Junker, H. Wunderlich (Jena, Erfurt, 

Germany) - Abstract 210 

Differences in protein properties of postoperative urine samples enable the prediction of early 

allograft rejection 

Third Prize for the Best Abstract (Non-Oncology) 

J. Corcos, W. Mahfouz, O. Loutochin, J. Galipeau (Montreal, Canada; Atlanta, United States 

of America) - Abstract 1069 

Bone marrow mesenchymal stromal cell therapy for restoration of bladder wall defects 


7 

Awards

Awards 

EAU Award Winners 

Best video EUVJ 

Q.D. Trinh, S. Sukumar, K.R. Ghani, J. Sammon, W. Jeong, J. Jhaveri, F. Muhletaler, M. Ehlert, M. Menon, C.G. Rogers 

(Detroit, United States of America) - Video: V28 

Complications during robot-assisted kidney surgery 

First video prize 

R. Autorino, H.K. Laydner, R. Yakoubi, A. Kassab, W. Isac, E. Rizkala, R.J. Stein, J.H. Kaouk (Cleveland, United States of 

America) - Video: V33 

Second generation instruments for robotic single site kidney surgery: Early experience in a cadaver model 

Second video prize 

E. Drapier, A. Smirnoff, L. De Poncheville (La Rochelle, France) - Video: V32 

Difficulties of the single port laparoscopic surgery, how to come round them and adapt the surgical gestures with the example of 

sacrocolpopexies 

Third video prize 

G.L. Martin, R. Weston, G. Coughlin, D. Cahill, D. Moon, D.G. Murphy (Melbourne, Brisbane, Australia; London, United 

Kingdom) - Video: V51 

Laparoscopic management of urinary tract trauma is feasible in many circumstances: A multi-institution perspective 

First Prize for the Best Abstract by a resident 

R.P. Pal, E.J. Hollox, L. Cresswell, J.H. Pringle, C.D. Veal, R. Hew, J.K. Mellon, R.C. Kockelbergh, J.G. Barwell (Leicester, 

United Kingdom) - Abstract 424 

ERG immunocytochemistry can identify prostate cancer patients prior to prostate biopsy 

Second Prize for the Best Abstract by a resident 

F. Abdollah, U. Capitanio, N. Passoni, N. Suardi, R. Matloob, L.F. Da Pozzo, E. Farina, N. Di Muzio, C. Cozzarini, A. Briganti 

(Milan, Italy) - Abstract 421 

Identifying patients at real risk of dying from prostate cancer. A novel risk score for the selection of patients candidate for 

adjuvant radiation therapy 

Third Prize for the Best Abstract by a resident 

I. Kyriazis, P. Kallidonis, O. Andrikopoulos, I. Georgiopoulos, D. Liourdi, A. Marazioti, A. Papapetropoulos, J.U. Stolzenburg, 

E. Liatsikos (Patras, Greece; Leipzig, Germany) - Abstract 218 

Pretreatment with vardenafil attenuates renal ischemia-reperfusion injury. An experimental study in rats 

Resident’s Corner Awards for the Best Scientific Papers published in European Urology by residents in 2011 

F. Abdollah, M. Sun, J. Schmitges, Z. Tian, C. Jeldres, A. Briganti, S.F. Shariat, P. Perrotte, F. Montorsi, P.I. Karakiewicz 

(Montreal, Canada; Milan, Italy; Hamburg, Germany; New York, United States of America) 

Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: 

Competing-Risks Analysis of a Large North American Population-Based Cohort 


D. Duijvesz, Th. Luider, C.H. Bangma, G. Jenster (Rotterdam, The Netherlands) 

Exosomes as Biomarker Treasure Chests for Prostate Cancer 


8 Programme Book 

As of last year, the EAU Congress has its own EAU Award Gallery. Here, you can find 

a complete overview of all the EAU Awards that will be handed out during the Paris 

Congress. It will also feature information on past winners of the most prestigious urology 

prizes. 

The EAU Award Gallery provides a great opportunity to take in all the important 

developments and breakthroughs in recent years. It can be found on Level 3, be sure to 

visit it!

The EAU presents interesting recent developments in the field of education and technological 

innovations. Education & Innovation offers you a hands-on experience with exciting technology, such 

as virtual simulators, smart phone apps and innovative devices. 

Visit Education & Innovation in the Exhibition Hall on the first floor, booth 1N05 

We would like to thank the following companies for their support: 

ELMED, EPONA MEDICAL LAPX, GERMAN CANCER RESEARCH CENTER, HEILBRONN UNIVERSITY, iURO, 

MIMIC TECHNOLOGIES INC.

Floorplan 

10 Programme Book


11 

Floorplan

Floorplan 

12 Programme Book

Programme Friday, 24 February 

eURO Auditorium Concorde Paris Concorde Centre Concorde Neuilly Room Bordeaux Room Havane Room 351 Room 352 A/B Room 341 

08.00 08.00-15.45 

08.30 

09.00 

09.30 

10.00 

10.30 10.30-13.00 

Urology beyond Europe 

11.00 

11.30 

12.00 

12.30 

13.00 

Joint Session of the 

European Association 

of Urology (EAU) and 

the Korean Urological 

Association (KUA) 

page 59 

13.15 13.15-15.45 


13.30 

14.00 

14.30 

15.00 

15.30 

15.45 




the Confederaçion 

Americana de Urologica 

(CAU) 

page 66 

10.30-13.00 





the Chinese Urological 

Association (CUA) 

page 61 

13.15-15.45 





the Japanese Urological 

Association (JUA) 

page 67 

10.30-13.00 





the Arab Association of 

Urology (AAU) 

page 62 

13.15-15.45 



European Association of 

Urology (EAU) and the 

Indonesian Urological 

Association (IUAI) 

page 68 

16.00 16.00-17.30 

Symposium 

16.30 

17.00 

17.30 

18.00 18.00-21.00 

21.00 

EAU Opening Ceremony 

and Welcome Cocktail 

page 73 

Guiding lights and 

rising stars: Present 

and future directions in 

RCC and CRPC 

BAYER HEALTHCARE 

page 379 

Reports of the 

Committees of the 

ICUD-EAU International 

Consultation on 

Incontinence (5th 

ICI) 2012 

page 57 

16.00-17.30 

Symposium 

5mm HD and 3D - What 

does the future hold 

in MIS? 

OLYMPUS 

page 381 

10.30-13.00 





the Urological Society 

of India (USI) 

page 64 

13.15-15.45 


EAU - International: 

Caucasus and Central 

Asia Session 

page 69 

13.15-15.45 





the Maghreb Union 

Countries 

page 71 

10.30-13.00 





the Iranian Urological 

Association (IUA) 

page 65 

13.15-15.45 




Urology (EAU) and the 

Pan-African Urological 

Surgeons' Association 

(PAUSA) 

page 72 

16.00-17.30 

Workshop 

Cryo - a true minimally 

invasive treatment: 

Current evidence and 

future development 

GALIL MEDICAL 

page 380 


13 

Synopsis & Venue


Programme Saturday, 25 February, Morning 

eURO Auditorium Concorde Paris Concorde Centre Concorde Neuilly Room Bordeaux Room 251 Room 252 A/B Room 242 A/B Room 243 Room Bleu 

07.30 07.30-08.30 

08.00 

08.30 08.30-10.15 

Plenary Session 1 

09.00 

09.30 

Urothelial cancer 

08.30-08.35 

Introduction 

Urothelial cancer 

08.35-08.45 

Update 

Chemo-radiotherapy 

in muscle 

invasive bladder 

cancer 

08.45-08.55 

Update 

Outcomes of cystectomy: 

Contemporary 

results 

08.55-09.45 

Case discussion 

Finding the optimal 

treatment for 

muscle invasive 

bladder cancer 

09.45-10.15 

EAU Guidelines 

Office 

The urothelial 

cancer pathway: A 

patient's journey 

according to the 


page 76 

08.30-10.00 

Poster Session 1 

BPH: Basic research 

1-12 

page 78 


08.30-10.00 


Focal therapy: 

What is new and 

improved 

13-24 

page 80 

08.30-10.00 


Robotic partial 

nephrectomy 

25-35 

page 82 

EAU General 

Assembly 

page 75 

10.00 10.00-16.45 

10.30 

11.00 

11.30 

12.00 

10.15-17.30 

Meeting of the EAU 

Section of Uro- 

Technology (ESUT) 

in cooperation 

with ERUS, EULIS 

and ESIU 

Navigated videoassisted 

surgery 

and beyond 

AMERICAN 

MEDICAL SYSTEMS, 

ETHOS-SURGICAL, 

INTUITIVE 

SURGICAL, IPSEN, 

KARL STORZ 

GMBH & CO.KG, 

OLYMPUS, SIEMENS, 

STARMEDTEC, 

STEBA BIOTECH 

page 95 

10.15-14.00 


Section of Female 

and Functional 

Urology (ESFFU) 

including Reports 

from Committees 

of the 5th International 

Consultation 

on Incontinence 

From international 

recommendations 

to clinical practice 

page 98 

10.15-14.00 

Meeting of the 

EAU Section of 

Andrological 

Urology (ESAU) and 

the EAU Section of 

Urological Imaging 

(ESUI) 

Imaging in 

andrology 

page 99 

10.15-14.00 


Section of Infections 

in Urology (ESIU) 

Core issues at all 

times in all fields of 

urology 

page 102 

Residents 

Day - organised 

by the Young 

Urologists Office 

in collaboration 

with the European 

Society of Residents 

in Urology (ESRU) 

page 112 

08.30-10.00 


Prostate biopsy, 

prostatitis and 

epididymitis 

36-47 

page 84 

08.30-10.00 


Male infertility 

48-61 

page 86 

10.15-14.00 



Genitourinary 

Reconstructive Surgeons 

(ESGURS) 

Urethral reconstruction 

and re-do 

surgery in reconstructive 

urology 

page 104 

08.30-10.00 


Improving our 

surgical environment: 

Simulation 

and safety 

62-73 

page 88 

10.15-14.00 



Transplantation 

Urology (ESTU) 

Standardised and 

individualised 

approaches in renal 

transplantation 

- aiming for the 

optimum 

page 106 

08.30-10.00 


Renal tumours: 

Medical therapy 

74-83 

page 90 

10.00-14.00 

Joint Meeting of the 

European Organisation 

for Research 

and Treatment of 

Cancer Genito- 

Urinary Group 

(EORTC-GU Group), 


Urological Research 

(ESUR), the EAU 

Section of Oncological 

Urology (ESOU) 

and the EAU Section 

of Uropathology 

(ESUP) 

Current issues in 

prostate, renal and 


page 108

Room Maillot Room Passy Room 352 A Room 352 B Room 353 Room 341 Room 342 A Room 343 Room Havane Room 351 

08.30-10.00 


Surgery for RCC: 

Cytoreduction, 

metastases, vena 

cava, LESS, nodes 

84-96 

page 92 

10.15-14.00 


Section of Urolithiasis 

(EULIS) 

Urolithiasis - 

new insights in 

pathophysiology 

- challenges in 

education - trends 

in treatment 

page 110 

08.30-10.00 


Stones: Risk factors, 

new treatment options 

and training 

97-107 

page 94 

08.30-10.30 

EAUN Workshop 

Urodynamics 

page 408 

11.00-13.00 


Optimisation of 

peri-operative 

care in advanced 


surgery 

page 409 

08.30-10.30 


Catheter management 

page 407 

11.00-13.00 


Incontinent patients 

- Transfer from 

hospital to home 

care and back 

page 410 


07.30 

08.00 

08.30 

09.00 

09.30 

10.00 

10.30 

11.00 

11.30 

12.00 

15 

Synopsis & Venue


Programme Saturday, 25 February, Afternoon 

eURO Auditorium Concorde Paris Concorde Centre Concorde Neuilly Room Bordeaux Room 251 Room 252 A/B Room 242 A/B Room 243 Room Bleu 

12.00 10.15-17.30 



Uro-Technology 

(ESUT) in cooperation 

with ERUS, EULIS 

and ESIU 

12.30 

13.00 

13.15 

13.30 

14.00 

Navigated videoassisted 

surgery and 

beyond 

AMERICAN MEDICAL 

SYSTEMS, ETHOS- 

SURGICAL, INTUITIVE 

SURGICAL, IPSEN, 

KARL STORZ GMBH & 

CO.KG, OLYMPUS, SIE- 

MENS, STARMEDTEC, 

STEBA BIOTECH 

page 95 

10.15-14.00 


Section of Female and 

Functional Urology 

(ESFFU) including 

Reports from Committees 

of the 5th International 

Consultation 

on Incontinence 

From international 

recommendations to 

clinical practice 

page 98 

14.15 14.15-15.45 


14.30 

14.45 

15.00 

15.15 

15.30 

15.45 

BPH: Etiology and 

medical treatment 

108-120 

page 115 

16.00 16.00-17.30 


16.15 

16.30 

16.45 

17.00 

17.15 

17.30 

17.45 17.45-19.15 

Symposium 

19.15 

Evidence and rationale 

for initial treatment 

of patients with 

symptomatic BPH at 

risk of progression 

GLAXOSMITHKLINE 

page 387 

BPH: Assessment and 

epidemiology 

219-232 

page 133 

17.45-19.15 

Symposium 

Moving forward in 

prostate cancer: Hormones 

and beyond 

IPSEN 

page 388 


10.15-14.00 



Andrological Urology 

(ESAU) and the EAU 

Section of Urological 

Imaging (ESUI) 

Imaging in andrology 

page 99 

14.15-15.45 


Treatment of advanced 

prostate cancer 

121-132 

page 117 

16.00-17.30 


Prostate cancer: Novel 

therapies 

233-246 

page 135 

17.45-19.15 

Symposium 

OAB: New solutions 

for an old challenge 

ASTELLAS 

page 383 

10.15-14.00 


Section of Infections 

in Urology (ESIU) 

Core issues at all 

times in all fields of 

urology 

page 102 

14.15-15.45 


Partial nephrectomy: 

Outcome 

133-144 

page 119 

16.00-17.30 


Partial nephrectomy: 

Outcome, ischemia 

and renal function 

247-257 

page 137 

10.00-16.45 

Residents Day - 

organised by the 

Young Urologists 

Office in collaboration 

with the European 

Society of Residents 

in Urology (ESRU) 

page 112 

17.45-19.15 

Symposium 

Nocturia with nocturnal 

polyuria now and 

in the future 

FERRING 

PHARMACEUTICALS 

page 386 

14.15-15.45 


Prostate biopsies 1 

145-158 

page 121 

16.00-17.30 


Prostate biopsies 2 

151-270 

page 138 

17.45-19.15 

Symposium 

The longer the better: 

Treatment of BPH 

symptoms with Serenoa 

repens (safety 

and efficacy) 

BERLIN CHEMIE AG/ 

MENARINI 

page 384 

10.15-14.00 


Section of Genitourinary 

Reconstructive 

Surgeons (ESGURS) 

Urethral reconstruction 

and re-do 

surgery in reconstructive 

urology 

page 104 

14.15-15.45 


Genetic and 

epigenetic events in 

urothelial carcinoma 

159-170 

page 123 

16.00-17.30 


Chronic pelvic pain 

syndrome 

271-280 

page 140 

17.45-19.15 

Symposium 

Reviving naturalness - 

ED management then 

and now 

ELI LILLY AND 

COMPANY 

page 385 

10.15-14.00 



Transplantation 


Standardised and 

individualised 

approaches in renal 

transplantation - aiming 

for the optimum 

page 106 

14.15-15.45 


Incontinence surgery: 

How to choose the 

right technique? 

171-182 

page 125 

16.00-17.30 


Male incontinence 

281-292 

page 141 

17.45-19.15 

Symposium 

Confronting the challenges 

of Tuberous 

Sclerosis Complex: 

Strategies for treatment 

and management 

of associated 

angiomyolipomas 

NOVARTIS 

page 389 

14.15-15.45 


Urinary tract infection 

183-194 

page 127 

16.00-17.30 

Poster Session 25 

Infection miscellaneous 

293-304 

page 143 

10.00-14.00 

Joint Meeting of the 

European Organisation 

for Research and 

Treatment of Cancer 

Genito-Urinary Group 

(EORTC-GU Group), 


Urological Research 

(ESUR), the EAU 

Section of Oncological 

Urology (ESOU) and 


Uropathology (ESUP) 

Current issues in 

prostate, renal and 


page 108 

14.15-15.45 

Video Session 1 

New developments in 

partial nephrectomy 

V1-V7 

page 114 

16.00-17.30 


Pelvic and urethral 

reconstruction 

V8-V14 

page 132 

17.45-19.15 

Symposium 

Case-based 

update on the optimal 

management of bone 

metastases from 


AMGEN 

page 382

Room Maillot Room Passy Room 352 A Room 352 B Room 353 Room 341 Room 342 A Room 343 Room Havane Room 351 

10.15-14.00 


Section of Urolithiasis 

(EULIS) 

Urolithiasis - new 

insights in pathophysiology 

- challenges in 

education - trends in 

treatment 

page 110 

14.15-15.45 


Renal tumours: Basic 

research 1 

195-205 

page 129 

16.00-17.30 


Renal tumours: Basic 

research 2 

305-315 

page 145 

17.45-19.15 

Symposium 

The guidelines 

offer more than 

antibioprophylaxis 

to manage recurrent 

urinary tract infections 

OM PHARMA 

page 390 

14.15-15.45 


Kidney transplant: 

From lab to clinic 

206-218 

page 130 

16.00-17.30 


Living donor 

kidney transplant and 

outcomes 

316-327 

page 147 

14.30-17.30 

ESU Course 1 

Prostate cancer – 

Screening, diagnosis 

and staging 

page 319 

14.30-17.30 

ESU Course 2 

Female pelvic floor 

problems 

page 320 

14.30-17.30 

ESU Course 3 

Update on stone 

disease 

page 321 

17.45-19.15 

Workshop 

Innovation in laparoscopic 

robotics: The 

handheld Kymerax 

Robot – Benefits and 

clinical experience 

TERUMO 

page 391 

14.30-17.30 

ESU Course 4 

Retropubic radical 

prostatectomy – Tips, 

tricks and pitfalls 

page 322 

14.30-17.30 

ESU Course 5 

Office management 

of male sexual 

dysfunction 

page 323 

14.30-17.30 

ESU Course 6 

Robot-assisted 

laparoscopic prostatectomy 

page 324 

11.00-13.00 


Optimisation of 

peri-operative care 

in advanced bladder 

cancer surgery 

page 409 

13.15-14.15 

Symposium 

Optimising care 

for bladder cancer 

patients 

IPSEN & PHOTOCURE 

page 411 

14.30-15.00 


Nursing solutions in 

difficult cases: Case 

studies 

page 412 

15.15-15.30 

EAUN Opening 

Ceremony 

EAUN Opening 

Ceremony 

page 412 

15.30-15.45 

EAUN Lecture 

Evidence-based 

Guidelines for Best 

Practice in Health 

Care: Catheterisation 

- Indwelling catheters 

in adults, uretheral 

and suprapubic - Introduction 

of the new 

EAUN guideline 

page 413 

16.00-17.00 

Symposium 

The practical 

and motivational 

side of teaching 

men intermittent 

catheterisation: A 

workshop naming 

the challenges met 

while teaching men 

intermittent selfcatheterisation 

COLOPLAST AS 

page 414 

11.00-13.00 


Incontinent patients 

- Transfer from 

hospital to home care 

and back 

page 410 

14.30-15.15 


State-of-the-art 

lecture: Cystectomy 

and bladder reconstruction: 

The nurse’s 

role in France 

page 412 


12.00 

12.30 

13.00 

13.15 

13.30 

14.00 

14.15 

14.30 

14.45 

15.00 

15.15 

15.30 

15.45 

16.00 

16.15 

16.30 

16.45 

17.00 

17.15 

17.30 

17.45 

19.15 

17 

Synopsis & Venue


Programme Sunday, 26 February, Morning 

eURO Auditorium Concorde Paris Concorde Centre Concorde Neuilly Room Bordeaux Room 251 Room 252 A/B Room 242 A/B Room 243 Room Bleu Room Maillot 

07.30 07.30-11.00 


08.00 

08.30 

09.00 

Functional urology 

07.30-08.00 

Highlight session 1 

08.00-08.05 

Introduction 

Functional urology 

08.05-08.15 

Update 

OAB treatment in 

the male 

08.15-08:25 

Update 

What is new in 

pharmacotherapy 

08:25-08.35 

Update 

Botulinum toxin: 

Coming of age? 

08.35-08.45 

Update 

Neuromodulation 

08.45-09.10 


Which therapy for 

which patient 

09.15 

09.10-09.30 


Office 

09.15-10.45 


What do the new 

guidelines say? 

09.30-09.45 

Urinary tests 

for urothelial 

carcinoma 


lecture 

328-339 

09.30 

Female sexual 

dysfunction 

10.00 

10.30 

10.45 

09.45-09.55 

Update 

Incontinence 

associated with 

prolapse 

09.55-10.05 

Update 

Laparoscopic 

surgery for pelvic 

floor dysfunction 

10.05-10.40 


Complications of 

sling and prolapse 

surgery 

10.40-11.00 

Société Internationale 

d'Urologie (SIU) 

lecture 

What is proven in 

surgery for pelvic 

organ prolapse 

and urinary 

incontinence 

page 151 

11.00 11.00-12.00 

Thematic Session 1 

11.30 

12.00 

Andrology 

page 172 

page 154 

11.00-12.00 


Update in paediatric 

urology 

page 173 


09.15-10.45 


Nerve-sparing 

radical prostatectomy 

and hormonal 

issues 

340-350 

page 156 

11.00-12.00 


Renal cancer - 

Choice of treatment 

page 175 

09.15-10.45 


Prostate cancer: 

High risk disease 

351-362 

page 158 

11.00-12.00 


Infection and 

inflammation in 

urology 

page 176 

11.00-12.00 


Transplant and cancer: 

Controversies 

and challenges 

page 177 

09.15-10.45 


Bladder pharmacology 

363-374 

page 160 

09.15-10.45 


Stones: Flexible 

URS 

375-387 

page 162 

11.00-12.00 


History of urology 

in France 

page 178 

09.15-10.45 


Foreskin, hypospadias 

and testis 

388-400 

page 164 

09.15-10.45 


Testis and penis 

401-412 

page 166 

11.00-13.00 

European Urology 

Session 

Surgery in Motion 

page 181 

09.15-10.45 


Brachy- and 

radiotherapy 

413-423 

page 168 

11.00-12.00 


Urogenital imaging: 

A session by the 

European Society 

of Urogenital Radiology 

page 179

Room Passy Room 352 A Room 352 B Room 353 Room 341 Room 342 A Room 342 B Room 343 Room 253 Room Havane Room 351 

09.15-10.45 



Novel biomarkers 1 

424-437 

page 170 

08.30-11.30 

ESU Course 7 

Management 

of small renal 

tumours 

page 326 

08.30-11.30 

ESU Course 8 

Laparoscopic and 

robot-assisted 

laparoscopic radical 

cystectomy 

page 327 

08.30-11.30 

ESU Course 9 

Advanced course on 

upper tract laparoscopy 

(UPJ, adrenal 

and stones) 

page 328 

08.30-11.30 

ESU Course 10 

Advanced course 

on laparoscopic 

nephrectomy 

page 330 

08.30-11.30 

ESU Course 11 

Painful bladder 

/ chronic pelvic 

pain; In men and 

women 

page 332 

09.00-11.00 

ESU/ESUT 

Hands-on training 

Laparoscopy/LESS 

course 1 

KARL STORZ GMBH 

& CO.KG and COOK 

MEDICAL 

page 370 

08.30-11.30 

ESU Course 12 

Lower urinary tract 

dysfunction and 

urodynamics 

page 333 

09.00-10.30 

ESU/ERUS/ESUT 



urologic surgery 

course 1 

page 369 

11.00-12.30 

ESU/ERUS/ESUT 




course 2 

page 369 

08.30-10.30 

Sponsored 

Workshop 

Safety in urinary 

catheterisation. 

Transurethral 

and suprapubic 

drainage 

B.BRAUN 

page 415 

11.00-13.30 

ESU Course 1 

Writing an abstract, 

making a poster 

page 418 

08.30-09.30 


Understanding 

principles, side 

effects and their 

management in targeted 

therapies for 

metastasised Renal 

Cell Cancer (mRCC), 

a new challenge for 

urology nurses 

page 416 

09.30-10.00 


EAUN Fellowships: 

Everything you 

always wanted 

to know about 

fellowships 

page 416 

11.00-13.00 


Shopping for tools 

to optimise nursing 

care in cancer 

patients 

page 417 


07.30 

08.00 

08.30 

09.00 

09.15 

09.30 

10.00 

10.30 

10.45 

11.00 

11.30 

12.00 

19 

Synopsis & Venue


Programme Sunday, 26 February, Afternoon 

eURO Auditorium Concorde Paris Concorde Centre Concorde Neuilly Room Bordeaux Room 251 Room 252 A/B Room 242 A/B Room 243 Room Bleu Room Maillot 

12.00 11.00-13.00 


Session 

12.15 12.15-13.45 


12.30 

12.45 

13.00 

13.15 

13.30 

13.45 

Tips and tricks in 

robotic prostatic 

surgery 

V15-V21 

page 182 

14.00 14.00-15.30 


14.30 

14.45 

Challenging robotic 

surgery 

V22-V28 

12.15-13.45 


Screening for 

urothelial carcinoma: 

Methods and 

implications 

438-448 

page 183 

14.00-15.30 


Staging and predicting 

outcomes 

from urothelial 

carcinoma 

550-562 


12.15-13.45 


Radical 

prostatectomy: 

Complications and 

learning curve 

449-460 

page 185 

14.00-15.30 


Radical prostatectomy: 

Improvement 

of surgical 

technique 

563-573 

12.15-13.45 


Management of 

NDO: Botulinum 

toxin, antimuscarinics 

and more 

461-472 

page 187 

14.00-15.30 


Lower urinary tract 

symptoms and 

quality of life 

574-585 

15.00 15.00-17.00 

Special Session 

15.15 

15.30 

page 200 

page 201 

page 203 

page 205 

dVP 3D Video and 

live narration 

15.45 15.45-17.15 


16.00 

16.15 

16.30 

16.45 

17.00 

17.15 

LESS 

V29-V35 

page 219 

15.45-17.15 


Novel therapeutic 

approaches 

in urothelial 

carcinoma 

659-670 

page 220 

17.30 17.30-19.00 

Symposium 

17.45 

19.00 

LUTS/BPH: From 

guidelines to 

clinical practice 

RECORDATI 

page 400 

15.45-17.15 



Quality of 

life and quality 

control 

671-682 

page 222 

17.30-19.00 

Symposium 

Redefining treatment 

standards 

in metastatic 

castration-resistant 


JANSSEN 

PHARMACEUTI- 

CAL COMPANIES 

OF JOHNSON & 

JOHNSON 

page 396 

15.45-17.15 


Hot topics in the 

management 

of OAB 

683-694 

page 224 

17.30-19.00 

Symposium 

New data on ADT 

for prostate cancer: 

What does it mean 

for your patients? 

FERRING 

PHARMACEUTICALS 

page 394 

INTUITIVE 

SURGICAL 

page 218 

17.30-19.00 

Symposium 

Revolution in the 

management of 

male LUTS? 

ASTELLAS 

page 393 

12.15-13.45 


Sexual dysfunction: 

Basic research 

473-486 

page 189 

14.00-15.30 



Diagnosis and 

treatment 

586-599 

page 207 

15.45-17.15 



Miscellaneous 

695-707 

page 226 

17.30-19.00 

Symposium 

Non muscle 

invasive bladder 

cancer management 

in 2012: From 

recommendations 

to real life clinical 

practice 

IPSEN/PHOTOCURE 

page 395 

12.15-13.45 


Stones: URS 

487-499 

page 191 

14.00-15.30 


Invasive bladder 

cancer: Technique 

of surgery 

600-610 

page 209 

15.45-17.15 


Invasive bladder 

cancer: Reducing 

morbidity of 

surgery 

708-720 

page 228 

17.30-19.00 

Symposium 

Optimising the 

management of 

senior adults with 


SANOFI ONCOLOGY 

page 401 

12.15-13.45 


Reflux, UTI, OAB, 

hydronephrosis, 

Wilms tumor, 

exstrophy and 

varicocele 

500-513 

page 193 

14.00-15.30 


Strictures and 

urethroplasty 1 

611-621 

page 211 

15.45-17.15 


Strictures and 

urethroplasty 2 

721-730 

page 230 

17.30-19.00 

Symposium 

Sifting through 

the evidence in GU 

malignancies: A 

day in the clinic 

NOVARTIS 

page 398 

12.15-13.45 


Penile cancer 

514-523 

page 195 

14.00-15.30 


Diagnostic tests in 

bladder function 

622-633 

page 212 

15.45-17.15 


New insights into 

bladder control 

731-742 

page 231 

17.30-19.00 

Workshop 

Holmium Laser 

Enucleation of the 

Prostate (HoLEP) - 

the true alternative 

to TURP and open 

prostatectomy 

LUMENIS 

page 397 

Surgery in Motion 

page 181 

17.30-19.00 

Symposium 

Finding a way forward 

in OAB care 

PFIZER 

page 399 

12.15-13.45 


Vaginal surgery: 

Prolapse, urethral 

diverticulae and 

fistulae 

524-535 

page 196 

14.00-15.30 


BPH: Surgical 

technique and new 

medical strategy 

634-644 

page 214 

15.45-17.15 


BPH: Medical 

therapy 

743-755 

page 233 

17.30-19.00 

Symposium 

Injecting DIGNITY 

into your neurogenic 

detrusor 

overactivity (NDO) 

patient treatment 

paradigm - The role 

of botulinum toxin 

type A 

ALLERGAN 

page 392

Room Passy Room 352 A Room 352 B Room 353 Room 341 Room 342 A Room 342 B Room 343 Room 253 Room Havane Room 351 

12.15-13.45 



Novel biomarkers 2 

536-549 

page 198 

14.00-15.30 


Cancer Initiating 

Cells (CICs) and 

Epithelial Mesenchymal 

Transition 

(EMT) 

645-658 

page 216 

15.45-17.15 



Pathology, biopsy 

and predictors in 

active surveillance 

756-766 

page 235 

12.00-15.00 

ESU Course 13 

Robot surgery in 

urology – How 

to start 

page 334 

15.30-17.30 

ESU Course 19 

Robot renal surgery 

page 342 

12.00-14.00 

ESU Course 14 

Surgical 

management of 

locally advanced 

and metastatic 

renal cancer 

page 336 

14.30-17.30 

ESU Course 20 

How to write a 

manuscript and 

get it published in 


page 343 

12.00-14.00 

ESU Course 15 

Laparoscopy for 

beginners 

page 337 

14.30-17.30 

ESU Course 21 

Vaginal surgery for 

urologists 

page 345 

12.00-14.00 

ESU Course 16 

Testicular cancer 

page 338 

14.30-17.30 

ESU Course 22 

Radical cystectomy 

and orthotopic 

bladder substitution 

– Surgical tricks 


of complications 

page 347 

12.00-14.00 

ESU Course 17 

Minimally invasive 


therapy 

page 339 

14.30-17.30 

ESU Course 23 

Surgery or 

radiotherapy for 

localised and 

locally advanced 


page 348 

12.00-14.00 

ESU/ESUT 


Laparoscopy/LESS 

course 2 



MEDICAL 

page 371 

15.00-17.00 

ESU/ESUT 


Transurethral 

Therapy of LUTS 

- Bipolar TURP 

course 1 



MEDICAL 

page 372 

12.00-14.00 

ESU Course 18 

Metastatic prostate 

cancer 

page 341 

14.30-17.30 

ESU Course 24 

Flexible 

ureterorenoscopy 

and retrograde 

intrarenal surgery: 

Instrumentation, 

technique, tips and 

tricks, indications 

page 350 

11.00-12.30 

ESU/ERUS/ESUT 




course 2 

page 369 

13.00-14.30 

ESU/ERUS/ESUT 




course 3 

page 369 

11.00-13.30 

ESU Course 1 

Writing an abstract, 

making a poster 

page 418 

14.00-14.30 



lecture: Innovative 

interactive multimedia 

techniques 

in urology care-A 

big step forward 

or still one step 

too far? 

page 419 

14.45-16.30 

Abstract Session 

Poster Session 

P1-P9 

page 421 

16.45-17.30 



lecture: Assessment 


of osteonecrosis of 

the jaw 

page 422 

11.00-13.00 


Shopping for tools 

to optimise nursing 

care in cancer 

patients 

page 417 

14.00-16.30 

ESU Course 2 

Urinary infections 

page 420 

16.45-17.45 


EAUN Nursing 

Research Competition 

page 423 


12.00 

12.15 

12.30 

12.45 

13.00 

13.15 

13.30 

13.45 

14.00 

14.30 

14.45 

15.00 

15.15 

15.30 

15.45 

16.00 

16.15 

16.30 

16.45 

17.00 

17.15 

17.30 

17.45 

19.00 

21 

Synopsis & Venue


Programme Monday, 27 February, Morning 

eURO Auditorium Concorde Paris Concorde Centre Concorde Neuilly Room Bordeaux Room 251 Room 252 A/B Room 242 A/B Room 243 

07.30 07.30-11.00 


08.00 

08.30 

09.00 

Technology and new 

techniques in urology: 

An update 

07.30-08.00 

Highlight session 2 

08.00-08.05 

Introduction 

Technology and new 

techniques in urology: 

An update 

19.15 09.15-10.45 


08.05-08:20 

State-of-the-art lecture 

Optimising the outcome 

of PCNL 

08.30-08.40 

Update 

SWL: Do we still need the 

technology? 

08.40-09.15 


Stone disease 

09.15-09.35 


The role of simulation 

in training 

09.35-09.45 

Update 

Simulation in urology 

and the EAU 

09.45-10.05 


From laparoscopy to 

robotics: 20 years of 

minimally invasive 

surgery 

10.05-10:25 

American Urological Association 

(AUA) lecture 

Regenerative medicine: 

New approaches to 

healthcare 

10:25-11.00 

Debate and case 

discussion 

Choice of minimally 

invasive surgery 

page 239 

page 242 


09.15-10.45 


page 244 

09.15-10.45 


Urothelial carcinoma: Pelvic lymph node Prostate cancer: 

09.30 

Upper tract disease and dissection at radical 

Diagnosis 

outcomes from surgery prostatectomy and 

08:20-08.30 

general issues 

10.00 Update 

New aspects in 

ureteroscopy 

767-777 

778-789 

790-801 

10.00-12.00 

Robotic surgery 

Live surgery: da Vinci 

10.15 


10.30 

10.45 

11.00 11.00-12.00 


11.30 

12.00 

Cancer induced bone 

disease 

page 258 

11.00-12.00 


Genital cancer in 

the male 


11.00-12.00 


BPH: Primum non nocere 

page 260 

page 246 

11.00-12.00 


The personalised treatment 

of urinary stone 

disease 

page 261 



09.15-10.45 


Reconstructive 

surgery: Models and new 

directions 

802-813 

page 248 

11.00-12.00 


Female stress 

incontinence 

page 263 

09.15-10.45 


Prostate biopsies and 

imaging 

814-825 


11.00-12.00 


Joint EAU-European 

Society of Surgical Oncology 

Session 

page 264 

09.15-10.45 



826-837 


11.00-12.00 


Molecular diagnostics in 


page 265 

09.15-10.45 



Molecular and (epi) 

genetic basis 

838-849 

page 253

Room Maillot Room 352 A Room 352 B Room 353 Room 341 Room 342 A Room 342 B Room 343 Room 241 Room Havane 

09.15-10.45 


Stones: Medical treatment 

and research 

850-862 


11.00-12.00 


EAU Guidelines Office: 

An update 

page 267 

08.30-11.30 

ESU Course 25 

The infertile couple - 

Urological aspects 

page 352 

08.30-11.30 

ESU Course 27 

Diagnosis and 

management of 

Non-Muscle Invasive 

Bladder Cancer 

(NMIBC) 

page 354 

08.30-11.30 

ESU Course 28 

Advanced management 

of urethral 

stricture disease 

page 356 

08.30-11.30 

ESU Course 29 

Interventional 

therapies for BPH 

page 357 

09.00-11.00 

ESU/ESUT 


Transurethral Therapy 

of LUTS - Bipolar 

TURP course 2 



MEDICAL 

page 373 

08.30-11.30 

ESU Course 30 

Paediatric urology for 

the adult urologist: A 

practical update 

page 358 

09.00-10.30 

ESU/ESUT 


in Transurethral 

therapy of LUTS - 

Green light laser 

course 1 


SYSTEMS 

page 376 

11.00-12.30 

ESU/ESUT 

Hands-on training in 

Transurethral therapy 

of LUTS - Green light 

laser course 2 


SYSTEMS 

page 377 

10.15-11.15 

Symposium 

Indwelling vs. 

intermittent 

catheterisation in 

voiding difficulties: 

What does it mean for 

patients, caregivers 

and society? 

ASTRA TECH 

page 424 

11.30-12.00 



lecture: Ketamineassociated 

ulcerative 

cystitis, a new clinical 

entity 

page 425 


07.30 

08.00 

08.30 

09.00 

19.15 

09.30 

10.00 

10.15 

10.30 

10.45 

11.00 

11.30 

12.00 

23 

Synopsis & Venue


Programme Monday, 27 February, Afternoon 

12.00 

eURO Auditorium Concorde Paris Concorde Centre Concorde Neuilly Room Bordeaux Room 251 Room 252 A/B Room 242 A/B Room 243 

12.15 12.15-13.45 


12.30 

12.45 

13.00 

13.15 

13.30 

13.45 

Laparoscopic renal 

surgery 

V36-V43 

page 270 

14.00 14.00-15.30 


14.30 

15.00 

15.30 

Miscellaneous 

V44-V51 

page 287 

15.45 15.45-17.15 


16.00 

16.30 

17.00 

17.15 

19.00 

Video Award Session 

V28-V51 

page 302 

17.30-19.00 

Symposium 

Back to the future with 

hormonal therapy 

for CRPC 

ASTELLAS 

page 403 

12.15-13.45 


Advanced urothelial 

carcinoma 

863-872 

page 271 

14.00-15.30 


Non-muscle invasive 

urothelial cancer: 

High risk disease and 

technologies 

955-966 

page 288 

15.45-17.15 


Non-muscle invasive 

urothelial cancer: Low 

risk and clinical trials 

1040-1051 

page 303 

17.30-19.00 

Symposium 

Focal treatment and 

quality of life: Localised 

prostate cancer. Vascular 

Targeted Photodynamic 

(VTP) therapy with 

TOOKAD® soluble 

STEBA BIOTECH 

page 405 


12.15-13.45 


Radical prostatecomy: 

Pathological issues and 

surgical margins 

873-882 

page 273 

14.00-15.30 



PSA, nomograms and 

predictors of oncological 

outcome 

967-977 

page 290 

15.45-17.15 



Outcome on erectile 

function and continence 

1052-1062 

page 305 

12.15-13.45 



Prognosis 

883-894 

page 275 

14.00-15.30 


HIFU, cryotherapy and 

androgen deprivation 

therapy 

978-989 

page 292 

15.45-17.15 


BioEngineering in 

functional urology 

1063-1072 

page 307 

17.30-19.00 

Symposium 

GAGs therapy of urinary 

tract infections: Clinical 

and economic issues 

IBSA INSTITUT 

BIOCHIMIQUE SA 

page 404 

14.00-16.00 

Robotic surgery 

Live surgery: da Vinci 

prostatectomy 



17.30-19.00 

Symposium 

Title to be confirmed 

SANOFI 

12.15-13.45 


Prognostic biomarkers in 


895-906 

page 277 

14.00-15.30 


LUTS: Can we improve 

the accuracy of the 

diagnosis? 

990-1001 

page 294 

15.45-17.15 


Reconstructive surgery: 

Lessons and outcomes 

1073-1085 

page 308 

12.15-13.45 



Biomarkers 

907-918 

page 279 

14.00-15.30 


How to improve prostate 

cancer staging? 

1002-1013 

page 296 

15.45-17.15 


Prostate cancer: Active 

surveillance 

1086-1097 

page 309 

12.15-13.45 


Renal tumours: Diagnosis 

and prognosis 

919-930 

page 281 

14.00-15.30 



Prognosis 

1014-1025 

page 298 

15.45-17.15 


Adrenals and trauma 

1098-1110 

page 311 

12.15-13.45 


Prostate cancer: AR 

signalling 

931-942 

page 283 

14.00-17.00 

European Urological 

Scholarship Programme 

(EUSP) Session 

page 269

oon 

Room Maillot Room 352 A Room 352 B Room 353 Room 341 Room 342 A Room 342 B Room 343 Room 241 Room Havane 

12.15-13.45 


Stones: Diagnostics 

and ESWL 

943-954 

page 285 

14.00-15.30 


Stones: Open and 

percutaneous 

1026-1039 

page 300 

15.45-17.15 



Minimally invasive 

treatments and 

surveillance 

1111-1121 

page 313 

12.00-14.00 

ESU Course 31 

Renal transplantation: 

Technical aspects, 

diagnosis and 

management of early 

and late urological 

complications 

page 359 

14.30-16.30 

ESU Course 36 

Medical uro-oncology 

page 366 

13.30-15.30 

ESU Course 37 

Post-surgical urinary 

incontinence in 

males 

page 367 

12.00-14.00 

ESU Course 32 

Advanced course 

on laparoscopic 

prostatectomy 

page 360 

14.30-16.30 

ESU Course 38 

General neurourology 

page 368 

17.30-19.00 

Workshop 

Practical and live 

procedure workshop 

for managing patients 

with neurogenic 

bladder 

ALLERGAN and 

PORGES, a COLOPLAST 

Division 

page 402 

12.00-14.00 

ESU Course 33 

Management and 

outcome in invasive 

and locally advanced 


page 362 

14.30-17.30 

ESU Course 26 

Single port 

surgery and hybrid 

procedures 

page 353 

12.00-14.00 

ESU Course 34 

Urinary tract and 

genital trauma 

page 364 

12.00-13.30 

ESU/ESUT 


Ureterorenoscopy 

course 1 



MEDICAL 

page 374 

14.00-15.30 

ESU/ESUT 


Ureterorenoscopy 

course 2 



MEDICAL 

page 375 

12.00-14.00 

ESU Course 35 

Ultrasound for the 

urologist - TRUS 

and TRUS guided 

biopsies 

page 365 

11.00-12.30 

ESU/ESUT 






SYSTEMS 

page 377 

13.00-14.30 

ESU/ESUT 






SYSTEMS 

page 378 

12.30-12.45 

Quiz 

EAUN Urology Nursing 

Quiz 

page 426 

12.45-13.15 



lecture: Focal 

cryoablation of 


page 427 

13.15-13.45 

EAUN Session 

EAUN Annual General 

Meeting (AGM) 

page 428 

14.00-15.45 


Poster session 

P10 - P18 

page 429 

16.15-16.30 


Award Session 

page 430 


12.00 

12.15 

12.30 

12.45 

13.00 

13.15 

13.30 

13.45 

14.00 

14.30 

15.00 

15.30 

15.45 

16.00 

16.30 

17.00 

17.15 

19.00 

25 

Synopsis & Venue


Programme Tuesday, 28 February 


eURO Auditorium 

08.00 08.00-12.40 


12.45 

Personalised treatment for low and intermediate risk prostate cancer 

08.00-10.00 

Souvenir session by the EAU Scientific Congress Office 

10.00-10.05 

Introduction 

Personalised treatment for low and intermediate risk prostate cancer 

10.05-10.15 

Update 

The PIVOT trial - What have we learnt? 

10.15-10.25 

Update 

SPCG4: Messages after 15 years 

10.25-10.35 

Update 

The experience and impact of prostate biopsy: Evidence from the ProtecT and PROBE studies 

10.35-11.15 

Debate 

The relevance of co-morbidity in managing early prostate cancer 

11.15-11.35 

Personalised therapy for the prostate cancer patient 

11.35-11.50 

MDV3100, an androgen receptor signaling inhibitor (ARSI), improves overall survival in patients with prostate cancer post 

docetaxel: Results from the Phase 3 AFFIRM study 

11.50-12.05 

Urological Research Section (URS) lecture 

Androgen axis in prostate cancer - from bench to bedside 

12.05-12.55 

Late breaking news 

12.40-12.45 

Closing remarks 

page 315

All sessions showing the webcast symbol will 

be available online at www.eauparis2012.org 

and in the EAU Resource Centre

Exhibition 

Level 1 

LEVEL 1 


HALL TERNES 

CHARGE AND 

CONNECT AREA 

1N01 

BEST 

POSTERS 

AREA 

1N03 

EAU 

HISTORICAL EXHIBITION 

RESEARCH FOUNDATION 

EAU 2013 MILAN 

EBU 

ESRU 

1N05 

1PA09 

EDUCATION & 

INNOVATION 

UPCOMING 

MEETINGS 

AREA 

EURO AUDITORIUM 

1N09 

1N08 1N07 

SIU ITALIA ANATOMY 

1N10 FOR UROLOGY 

1N11 1N12 

ESSM 

1PA01 

1N15 1N14 1N13 

ELMEDICAL 

1N16 1N18 

MEDA NANOENTEK 


VIDEO 

LIBRARY 

1N21 1N20 1N19

1PA01 

1N15 1N14 1N13 

ELMEDICAL 

1N16 1N18 

MEDA NANOENTEK 


VIDEO 

LIBRARY 

1N21 1N20 1N19 

WCE 2012 ECKERT & ZIEGLER BEBIG 

1N22 1N23 1N24 

WFIP EUROPA UROSPHERE 

UOMO 

WILEY-BLACKWELL1N25 

1P118 

ALLERGAN 

1P125 

ORION PHARMA 

QUANTA 

1P110 

SYSTEM 1P52 

1P53 

TTMED 1P54 

ROTTAPHARM I 

UROLOGY 

MADAUS 

MEL 

1P96 

RECORDATI 

1P27 

UROTISS 

1P28 

1P50 

1P108 

APOGEPHA IBSA 

1P60 1P73 

1P86 

1P100 

1P114 

1P25 

IPSEN 

AMERICAN 

LABORIE 

1P30 

1P26 

MEDICAL 

BOSTON 

SIU 

SYSTEMS 

ELI AMGEN ASTELLAS GLAXOSMITHKLINE 

SCIENTIFIC 

LILLY 

BAYER 

HEALTHCARE 1P31 

1P06 1P07 1P115 

MEDAC 

BECKMAN RUDOLF 

COOK MEDICAL 

COULTER MEDICAL 

1P128 

1P120 

1P80 1P82 

1P79 

KITALPHA 

JANSSEN 

TAKEDA 

KARL STORZ 

STORZ MEDICAL 

PFIZER 

ROOM PASSY 

CATERING CATERING 

CATERING 

1P04 

1P11 

NEOTRACT SIGMA-TAU 1P17 

1P33 

1P44 1P45 

1P03 1P08 1P13 ASTRA 

MIACOM PHYSION SPHINX TECH GEN-PROBE 

BARD NOVARTIS 

1P02 1P09 1P14 

TIME CRYOLIFE 

1P23 1P35 

RESEARCH NOVARTIS 

1P01 1P10 1P15 

ASCLEPION OM 

MCUBE T-DOC MYRIAD LIFE-TECH 

PHARMA 1P42 1P41 

1P22 

1P20 

TEKNO- PNN 

ALLIUM 

MEDICAL MEDICAL 

MEDICAL 

1P16 

INTERNET 

1P21 

1P37 

1P40 

CORNER 

VISION-SCIENCES 

ETHOS AYMED 


29 

Exhibition

Exhibition 

Level 2 


2M04 

UROVISION 

2M03 

OCEANA 

2M01 

KLS 

MARTIN 

GROUP 

2M11 

SANOFI- 

AVENTIS 

SANOFI 

PASTEUR 

COLOPLAST - 

PORGÈS 

2M23 

2M15 

DORNIER 

MEDTECH 

2M25 

KYOWA 

HAKKO 

KIRIN 

2M18 

ENDOCARE 

2M13 

MILLENNIUM 

2M19 

VIKING 

2M16 SYSTEMS 

2M05 2M06 2M07 

MMS 

ELSEVIER NEOMEDIC 

DEXTERITE 

2M21 

UROMED 

CATERING 

CATERING 

LEVEL 2 

251 



2M52 

2M117 

DIREX 

2M54 

2M115 

ZEPHYR 

2M72 

EURO HIFU 

2M89 

ROCAMED & 

ELMED 

SOCOMED 

2M15 

2M130 

2M18 

2M111 

2M50 

2M120 

ASPIDE 

MÉDICAL 

2M55 2M70 2M73 2M87 

2M90 2M110 

2M131 

2M13 

BERLIN- KESSEL 

2M19 

CHEMIE PAJUNK 2M86 

PIERRE 

LUMENIS 

2M125 

FABRE 

EUROPEAN 

2M75 2M85 

2M16 

MÉDICAMENT 2M65 

INTUITIVE SURGICAL FERRING 

UROLOGY 

MEDTRONIC 

2M05 2M06 2M07 

2M132 2M133 2M134 

2M21 

2M76 2M84 

2M127 

PROME- LIMMER 

DON LASER 

2M04 

2M137 2M136 2M135 

2M11 2M23 

2M146 

2M48 

2M80 

2M100 

2M03 

2M45 2M46 2M47 

B.BRAUN 

2M138 2M139 

SANOFI- 

AESCULAP 

AVENTIS 

HITACHI 

2M01 

2M147 

2M43 

MEDICAL 

2M141 2M140 

SYSTEMS 

OLYMPUS 

SANOFI 

PASTEUR 

2M82 

2M142 2M143 

2M25 

2M38 2M39 2M40 

2M148 

2M34 

KYOWA TERUMO 

HAKKO 

2M37 2M36 2M35 

2M149 

KIRIN 

2M144 

2M28 

2M150 2M145 

2M29 2M30 2M31 2M32 

URO- 

TECH 

AME- 

TELEFLEX 

COLOPLAST - 

PORGÈS ENDOCARE 

RICHARD 

SIEMENS 

WOLF 

MILLENNIUM 

CL MEDICAL 

VIKING 

SYSTEMS 

CARE- 

MMS 

SONO 

ELSEVIER 

EDAP 

DEXTERITE 

UROMED 

TMS 

WISEPRESS 

UROVISION 

GALIL 

CURAN STELLAR 

SMU 

MEDICAL 

OCEANA 

DORNIER MEDI LEONI 

INTEGRA ISMH 

MEDTECH WATCH FIBER 

ERBE 

KLS 

KOELIS 

MARTIN 

A.M.I. 

ENDO- CUA 

CONTROL CANADA 

GROUP 

TAEWOONG 

CATERING 

CO 

STARMEDTEC 

EMD CIG 

MEDICAL 

ROOM MAILLOT 

AUA 

BK MEDICAL 

BIOLITEC SIUI AST 

CUA 

CHINA 

TRISTEL 

CATERING 

CATERING 

EMS HISTOSCANNING 

INTERNET 

MEDISPEC 

BY AMD 

CORNER 

EEZ 

NEOMEDIC LISA MED- GRAND 

LASER COM MEDICAL 

COUSIN 

BIOTECH 

2M52 

TELEFLEX 

2M50 

RICHARD 

WOLF 

2M45 2M46 2M47 

MEDI LEONI 

WATCH FIBER 

2M43 ERBE 

KOELIS 

SESSION ROOMS 

2M38 2M39 2M40 

TERUMO 

2M37 2M36 2M35 

AME- 

CO 

STARMEDTEC 

BIOLITEC SIUI AST 

ROOM BLEU 

EURO AUDITORIUM 

2M54 

ZEPHYR 

2M55 2M70 

PIERRE 

FABRE 

MÉDICAMENT 

2M48 

HITACHI 

MEDICAL 

SYSTEMS 

BERLIN- 

CHEMIE 

2M65 

2M34 

BK MEDICAL 

2M28 2M29 2M30 2M31 2M32 

URO- 

HISTOSCANNING 

TECH 

TM 

MEDISPEC 

COUSIN EMS 

BIOTECH BY AMD 

243 

SESSION ROOMS 

2M72 

ROCAMED & 

SOCOMED 

EDAP 

TMS 

242 

241 

2M73 2M87 

KESSEL 

PAJUNK 2M86 

CL 

MEDICAL 

2M75 2M85 

CARE- I 

SONO EEZ 

2M76 2M84 

PROME- LIMMER 

DON LASER 

2M80 

B.BRAUN 

AESCULAP 

2M82 

TAE- 

WOONG 

MEDICAL 

2

EL 

CAL 

ER 

LASER 

NG 

CAL 


2M100 

OLYMPUS 

2M89 

ELMED 

2M115 

EURO HIFU 

2M90 2M110 

FERRING 

2M117 

DIREX 

2M111 

SIEMENS 

ROOM MAILLOT 

2M120 

2M130 

2M131 

LUMENIS 

2M125 

EUROPEAN 

UROLOGY 

MEDTRONIC 

WISEPRESS 

2M146 

GALIL 

MEDICAL 

2M147 

A.M.I. 

2M148 

AUA 

2M149 

CUA 

CHINA 

ASPIDE 

MÉDICAL 

2M127 

2M132 2M133 2M134 

LISA MED- GRAND 

LASER COM MEDICAL 

2M137 2M136 2M135 

CURAN STELLAR 

SMU 

2M138 2M139 

INTEGRA ISMH 

2M141 2M140 

ENDO- CUA 

CONTROL CANADA 

2M142 2M143 

CATERING EMD CIG 

2M150 

INTERNET 

CORNER 

2M144 

TRISTEL 

2M145 


31 

Exhibition

Exhibitors 

Alphabetical list of Exhibitors 

Please note that this list and the floor plans on the previous pages will not be comprehensive due to the printing date of this programme book 

(list and floor plans are updated through 12 January 2012). 

EXHIBITOR LEVEL/BOOTH NR. 

A 

A.M.I. GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M147 

ALLERGAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P118 

ALLIUM LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P22 

AMECO MEDICAL SYSTEMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M39 

AMERICAN MEDICAL SYSTEMS, INC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P50 

AMERICAN UROLOGICAL ASSOCIATION (AUA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M148 

AMGEN (EUROPE) GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P73 

ANATOMY FOR UROLOGY - PRIMAL PICTURES LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N07 

APOGEPHA ARZNEIMITTEL GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P27 

ASCLEPION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P23 

ASPIDE MÉDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M130 

AST GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M35 

ASTELLAS PHARMA EUROPE LTD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P86 

ASTRA TECH AB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1P17 

AYMED MEDICAL TECHNOLOGY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P40 

B 

B. BRAUN AESCULAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M80 

BARD LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P44 

BAYER HEALTHCARE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P26 

BECKMAN COULTER, INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P06 

BERLIN-CHEMIE AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M70 

BIOLITEC BIOMEDICAL TECHNOLOGY GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M37 

BJUI / WILEY-BLACKWELL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N25 

BK MEDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M34 

BOSTON SCIENTIFIC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P114 

C 

CANADIAN UROLOGICAL ASSOCIATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M140 

CARESONO TECHNOLOGY CO., LTD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M75 

CHARGE AND CONNECT AREA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N01 

CHINESE UROLOGICAL ASSOCIATION (CUA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M149 

CL MEDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M86 

COCHRANE INCONTINENCE GROUP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M143 

COLOPLAST - PORGÈS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M15 

COOK MEDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1P115 

COUSIN BIOTECH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M30 

CRYOLIFE EUROPA, LTD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P09 

CURAN MEDICAL BV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M137 

D 

DEXTÉRITÉ SURGICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M06 

DIREX GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M117 

DORNIER MEDTECH EUROPE GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M23 

32 Programme Book

E 

EAU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N03 

EAU HISTORICAL EXHIBITION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N03 

EAU MILAN 2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N03 

EAU RESEARCH FOUNDATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N03 

EAU VIDEO LIBRARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1PA01 

ECKERT & ZIEGLER BEBIG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N19 

EDAP TMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M65 

EDUCATION & INNOVATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N05 

EEZ TECHNOLOGIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M85 

ELI LILLY AND COMPANY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P60 

ELMED LITHOTRIPSY SYSTEMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M89 

ELMEDICAL LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N13 

ELSEVIER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M05 

EMD MEDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M142 

EMS ELECTRO MEDICAL SYSTEMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M31 

ENDOCARE, INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M18 

ENDOCONTROL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M141 

ERBE ELEKTROMEDIZIN GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M47 

ESRU (EUROPEAN SOCIETY FOR RESIDENTS IN UROLOGY) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N03 

ESSM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N12 

ETHOS SURGICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P37 

EURO HIFU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M115 

EUROPA UOMO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N23 

EUROPEAN BOARD OF UROLOGY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N03 

EUROPEAN UROLOGY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M120 

F 

FERRING INTERNATIONAL CENTER S.A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M110 

G 

GALIL MEDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M146 

GEN-PROBE INCORPORATED . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P33 

GLAXOSMITHKLINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P100 

GRAND MEDICAL LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M134 

H 

HISTOSCANNING BY AMD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M32 

HITACHI MEDICAL SYSTEMS EUROPE HOLDING AG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M48 

I 

IBSA INSTITUT BIOCHIMIQUE SA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P28 

INTEGRA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M138 

INTERNET CORNER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1P16 & 2M150 

INTUITIVE SURGICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M90 

IPSEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P108 

ISMH (INTERNATIONAL SOCIETY OF MEN’S HEALTH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M139 

J 

JANSSEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P128 


33 

Exhibitors

Exhibitors 

Alphabetical list of Exhibitors 

K 

KARL STORZ GMBH & CO. KG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P82 

KESSEL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M87 

KITALPHA MED LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P80 

KLS MARTIN GROUP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M01 

KOELIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M43 

KYOWA HAKKO KIRIN UK LTD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M25 

L 

LABORIE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P25 

LEONI FIBER OPTICS GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M46 

LIFE-TECH, INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P20 

LIMMER LASER GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M84 

LISA LASER PRODUCTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M132 

LUMENIS DEUTSCHLAND GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M131 

M 

MCUBE TECHNOLOGY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P01 

MEDA CO., LTD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N16 

MEDAC GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1P31 

MEDCOM GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M133 

MEDICAL MEASUREMENT SYSTEMS B.V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M16 

MEDISPEC LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M29 

MEDIWATCH PLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M45 

MEDTRONIC INTERNATIONAL TRADING SÀRL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M125 

MEXICAN SOCIETY OF UROLOGY (SMU) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M135 

MIACOM DIAGNOSTICS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P03 

MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M13 

MYRIAD GENETICS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1P15 

N 

NANOENTEK INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N18 

NEOMEDIC INTERNATIONAL S.L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M07 

NEOTRACT, INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P04 

NOVARTIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P14 & 1P45 

O 

OCEANA THERAPEUTICS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M03 

OLYMPUS MEDICAL SYSTEMS EUROPA GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M100 

OM PHARMA SA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P35 

ORION PHARMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P125 

P 

PAJUNK GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M73 

PFIZER FRANCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P79 

PHYSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P08 

PIERRE FABRE MÉDICAMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M55 

PNN MEDICAL A/S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P41 

PROMEDON S.A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M76 

Q 

QUANTA SYSTEM SPA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P52 

34 Programme Book

R 

RECORDATI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P96 

RICHARD WOLF GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M50 

ROCAMED & SOCOMED (PROMEPLA GROUP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M72 

ROTTAPHARM | MADAUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P110 

RUDOLF MEDICAL GMBH + CO. KG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P07 

S 

SANOFI-AVENTIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M11 

SANOFI PASTEUR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M11 

SHANTOU INSTITUTE OF ULTRASONIC INSTRUMENTS CO., LTD. (SIUI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M36 

SIEMENS AG HEALTHCARE SECTOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M111 

SIGMA-TAU HEALTHSCIENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1P11 

SIU SOCIETÀ ITALIANA DI UROLOGIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N09 

SOCIÉTÉ INTERNATIONALE D’UROLOGIE (SIU) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P30 

SPHINX MEDICAL LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1P13 

STARMEDTEC GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M40 

STELLAR PHARMACEUTICALS INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M136 

STORZ MEDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P82 

SYNERGO-MEDICAL ENTERPRISES (MEL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P54 

T 

T-DOC COMPANY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P10 

TAEWOONG MEDICAL, CO. LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M82 

TAKEDA PHARMACEUTICALS EUROPE LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P120 

TEKNO-MEDICAL OPTIK-CHIRURGIE GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P42 

TELEFLEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M52 

TERUMO EUROPE N.V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M38 

TIME RESEARCH LIMITED . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P02 

TRISTEL SOLUTIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M144 

TTMED UROLOGY (THOMSON REUTERS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P53 

U 

UPCOMING MEETINGS AREA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1PA09 

UROMED KURT DREWS GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M21 

UROSPHERE SAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1N24 

UROTECH GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M28 

UROTISS GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1P27 

UROVISION GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2M04 

V 

VIKING SYSTEMS INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M19 

VISION-SCIENCES, INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1P21 

W 

WCE 2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N21 

WISEPRESS ONLINE BOOKSHOP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M127 

WORLD FEDERATION OF INCONTINENT PATIENTS - WFIP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1N22 

Z 

ZEPHYR SURGICAL IMPLANTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2M54 


35 

Exhibitors

�� 

Visit us in Level 2, booth n° 2M48 

�� 

www.hitachi-medical-systems.eu 

�� 

�� 

�� 

Hitachi and Aloka 

�� 

�� 

�� 

�� 

�� 

��

General information 

Abstracts 

More than 1.193 abstracts have been accepted for 

presentation during poster and video sessions at the 

27th Annual EAU Congress in Paris. 

The EAU Abstract CD 2012 will be distributed to all 

congress delegates by FERRING PHARMACEUTICALS 

(booth 2M110 on level 2 in the exhibition). The EAU 

Poster DVD 2012 will be distributed to all congress 

delegates by AMGEN (booth 1P73 on level 1 in the 

exhibition). All abstracts and PDFs of the posters are 

available online at www.eauparis2012.org. At the EAU 

Resource Centre a computer and printer are available 

to print paper copies of abstracts and posters which 

are presented during the congress. 

The EAU Poster DVD 2012 is supported by an 

unrestricted educational grant from AMGEN 

The EAU Abstract CD 2012 is supported by an 

educational grant from FERRING PHARMACEUTICALS 

Access to the Session Rooms 

Seating is regulated on a first-come, first-served 

basis. We recommend delegates to go to the session 

room well in advance of the session. Due to safety 

regulations, the organisers will close the access to 

the session room when all seats are taken. It is not 

allowed for delegates to stand in the aisles of the 

rooms. 

Address and Accessibility 

Congress Centre 

Le Palais des Congrès de Paris is easily accessible by 

public transport. The public transport system is easy 

to use and a very efficient way to get around the 

city. Congress delegates may collect a complimentary 

transportation pass in the registration area on level 3, 

see “Transportation Pass”. 

Address congress centre: 

Le Palais des Congrès de Paris 

2 Place de la Porte Maillot 

75853 Paris Cedex 17, France 

T: +33 1 5381 7809 

office@acv.at 

www.viparis.com 

Metro / car parking: 

The nearest metro station is “Line 1 – Porte Maillot– 

Palais des Congrès” which has direct access to the 

congress centre. 

Car parking is available 24 hours a day at the congress 

centre. 

Airport Shuttle Bus 

The 27th Annual EAU Congress offers all delegates 

the opportunity to book a free shuttle bus from the 

Palais des Congrès de Paris to Airport Charles de 

Gaulle or Paris Orly Airport. Delegates who wish to 

use this service need to book at least 24 hours before 

departure time at http://supershuttleparis.hudsonltd. 

net/res?USERIDENTRY=VIPARISEAU&LOGON=GO. 

Alternatively, Air France shuttle buses depart next to 

the congress centre, in front of the Meridien hotel. It 

runs every 30 minutes from 06.00 am to 11.00 pm. 

It takes 30-45 minutes to Airport Charles de Gaulle 

outside rush hours. It is not necessary to book but 

there is a cost. 

App - Your smart congress 

Paris 

companion 

The EAU Paris App will bring the 27th Annual EAU 

Congress to your smartphone. The application offers 

the best mobile overview of this scientific event – with 

instant access to congress abstracts, exhibition booth 

locations and the latest news from before, during and 

after the meeting! This year you will find a whole new 

set of features and you won’t need internet access to 

navigate the information. Please, check under EAU 

2012 in your App Store to get your smart congress 

companion. 

Award Gallery 

The EAU Congress features an EAU Award Gallery. 

Here you can find a complete overview of all awards 

that were handed out by the European Association of 

Urology this year (see also page 6-8 for an overview of 

the award winners). It will also feature information on 

past winners of the most prestigious prizes. 

The EAU Award Gallery provides a great opportunity 

to take in all the important developments and 

breakthroughs in recent years. It can be found on level 

3 next to the EAU Resource Centre, be sure to visit it! 

Badge Tracking System 

Congress delegates have a barcode on their badge 

which enables them to leave their contact details with 

exhibitors in a quick and easy way. The barcode will 

also be scanned at the entrance of the session rooms 

to gather CME and statistic information. 


37 

General

General 


Badges 

The badge classification is as follows: 

Blue badge : EAU member 

White badge : Delegate 

Brown badge : Nurse 

Green badge : Exhibitor 

Red badge : Press 

Purple badge : Accompanying person 

Pink badge : Day-, session 

registration 

Yellow badge : Organising staff 

Bank, Exchange and Credit Cards 

The national currency in France is the Euro (€). An ATM 

machine is available in the main entrance hall on level 

0. An exchange office is available on level -1 near the 

Hotel Concorde La Fayette. There are banks near the 

congress centre, please go to the EAU Information Desk 

on level 0 for detailed information. 

Best Posters Area 

In the Best Posters Area on level 1 of the exhibition, a 

selection of the best scientific posters are displayed 

and are accessible during exhibition hours. These 

posters can also be viewed through the congress 

website during and after the congress. 

Business Centre 

There is a business centre available at the Hotel 

Concorde La Fayette, accessible through level 0 of the 

congress centre. 

Car park 

There is an underground car park under the Palais des 

Congrès which has direct access to the congress centre 

and is available 24 hours a day. 

Congress Hours 


Certificate of Attendance 

A Certificate of Attendance for the 27th Annual EAU 

Congress can be printed in the registration area only 

during the last day of the congress or afterwards 

online at www.eauparis2012.org. You will need your 

registration number (under barcode on the badge) to 

print the Certificate of Attendance. Information on CME 

accreditation is available in this programme book on 

page 46. 

Cloakroom / Luggage 

The cloakroom is located in the foyer of the eURO 

Auditorium on level 0,5 and open during congress 

hours. Please be sure to collect all personal 

belongings at the end of the day. 

CME Accreditation 

The 27th Annual EAU Congress is accredited by the 

UEMS/EACCME through the European Board of Urology. 

More information on national credit systems and 

credits recognition is available in this programme book 

on page 46-47. 

Congress Bag 

Each delegate can collect a congress bag in the 

registration area on level 3. 

The congress bags are sponsored by ASTELLAS 

Daily Congress Newsletter: 

European Urology Today Special 

Edition 

Special daily congress newsletters are available on 

Saturday 25, Sunday 26 and Monday 27 February. The 

newsletters cover on-site news, congress session 

information and background information on a 

variety of subjects. The first edition also contains an 

Exhibition Overview. The newsletters will also be 

available online at www.eauparis2012.org during and 

after the congress. 

EAU Central 

Research Office 

The EAU Central Research Office initiates and 

coordinates, as well as refines investigator initiated 

Speaker Service Registration Sessions/ Sponsored Exhibition Cloakroom 

Centre 

Resource Centre sessions 

Thursday, 23 February 14.00-19.00 

Friday, 24 February 07.00-19.00 07.00-20.00 08.00-21.00 16.00-17.30 07.00-21.30 

Saturday, 25 February 07.00-19.30 07.00-19.45 07.30-19.15 17.45-19.15 09.00-18.00 07.00-19.45 

Sunday, 26 February 07.00-19.00 07.00-19.30 07.30-19.00 17.30-19.00 09.00-18.00 07.00-19.30 

Monday, 27 February 07.00-19.00 07.15-19.30 07.30-19.00 17.30-19.00 09.00-18.00 07.00-19.30 

Tuesday, 28 February 07.00-13.00 07.45-12.45 08.00-12.45 07.30-13.15

and other clinical research protocols. It also acts to 

facilitate all aspects of clinical research and expand 

the current network of active research centres and 

investigators - basic and clinical - both within the 

EAU member states and its international affiliates. The 

office coordinates clinical and translational research in 

close liaison with the Basic Research Committee of the 

EAU Research Foundation. The EAU Central Research 

Office can be visited at the EAU Square (booth 1N03) in 

the exhibition on level 1. 

EAU Congress Office 

Managing Directors 

Jacqueline Roelofswaard 

j.roelofswaard@uroweb.org 

Maurice Schlief 

m.schlief@uroweb.org 

Congress Manager 

Patricia de Bont 

p.debont@congressconsultants.com 

Exhibition Manager 

Henriet Wieringa 

h.wieringa@congressconsultants.com 

Manager Business Relations 

Peter Hazenberg 

p.hazenberg@uroweb.org 

Congress Consultants B.V. 

PO Box 30016 

6803 AA Arnhem 

The Netherlands 

T +31 (0)26 389 1751 

F +31 (0)26 389 1752 

info@congressconsultants.com 

www.eauparis2012.org 

EAU Education Office 

(European School of 

Urology) 

The European School of Urology (ESU), working with 

European faculties, aims to provide high quality 

international educational courses in urology. The ESU 

has a special booth on level 3 (Hall Bordeaux) with 

extensive information on its activities. Registration for 

the courses can be made at the ESU registration desks 

in the registration area on level 3. An ESU Courses CD 

2012 will be distributed at the EAU desk next to the 

MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY booth 

(booth 2M13 on level 2 in the exhibition) to all congress 

delegates. 

The ESU Courses CD 2012 is supported by an unrestricted 

educational grant from MILLENNIUM: THE TAKEDA 

ONCOLOGY COMPANY 

Fees ESU Courses (for congress registered delegates 

only) 

2 hrs. 3 hrs. 

EAU members € 31 € 46 

Non-EAU members € 46 € 67 

Residents (members/non-members) € 21 € 21 

Prices are excl. VAT 

Hands-on training sessions on Laparoscopy, 

Ureterorenoscopy, Bipolar TURP, Robot-assisted 

urologic surgery and Green Light laser are organized 

by the ESU in cooperation with the EAU Robotic 

Urology Section (ERUS), the EAU Section of Uro- 

Technology (ESUT) and the EAU Section of Urolithiasis 

(EULIS). 

Registration can be made at the ESU registration desk. 

The registration fee is € 25 per course excl. VAT. 

The Hands-on training sessions are supported by 

educational grants from KARL STORZ GMBH & CO.KG, 

COOK MEDICAL, AMERICAN MEDICAL SYSTEMS and 

supported by MIMIC. 

EAU ID Card 

The EAU ID Card functions as 

a membership card for all 

EAU members and enables 

easy printing of Certificates 

Sweden 

P-A. Abrahamsson 

EAU Member ID 106985 

of Attendance. The card cannot be used for registration 

purposes. 

EAU Square 

The EAU Square (booth 1N03 on level 1 in the 

exhibition) consists of the EAU Membership Booth, 

EBU Corner, ESRU Corner, EAU Milan 2013 Promotion 

Counter, Clinical Research Office and the EAU Historical 

Exhibition. 

There is also information on European Urology and 

other EAU publications. The EAU Membership Booth 

provides information on membership status and 

membership benefits. Non-members are welcome to 

visit the EAU Square for further information and to 

apply for EAU membership. 

Education & 

Innovation 

Education & Innovation (booth 1N05 on level 1 in the 


39 

General

General 


exhibition), a joint effort of the ESU and the ESUT, 

offers urologists a hands-on experience with notable 

technological innovations in urological treatment and 

training. 

Electricity 

The electricity in France runs on 220 volts and the 

frequency is 50 Hz. Plugs have two round pins and 

a 3rd round male pin permanently mounted in the 

socket. A plug adaptor will be required if incompatible 

electronic devices are used. 

Emergency Phone Numbers 

In case of an emergency call 112 for police, fire brigade 

and ambulance service. In case of an emergency in the 

congress centre contact a security guard immediately. 

EU-ACME Desk 

Information on the EU-ACME programme, CME/CPD 

credits, membership status & benefits, accredited CME 

activities and national CME credits systems can be 

obtained at the EU-ACME Desk in the registration area. 

For more information see page 47. 


Urology Nurses (EAUN) 

The 13th International Meeting of the European 

Association of Urology Nurses (EAUN) is a 3-day 

scientific meeting that will be held in conjunction with 

the 27th Annual EAU Congress from 25-27 February 

in support of their goal to continually upgrade the 

nursing skills of urology nurses. Scheduled are for 

example abstract and learning sessions as well as 

hands-on-training sessions and expert nurses and 

urologists will give lectures, workshops and courses. 

See page 407 for the extensive EAUN programme. 

European Board of 

Urology (EBU) 

The European Board of Urology (EBU) operates as an 

independent section of the UEMS (European Union of 

Medical Specialists) charged with regulatory matters. 

Visit the EBU Corner at the EAU Square (booth 1N03 on 

level 1 in the exhibition) to obtain more information on 

EBU’s core activities: 

�� 

�� 

�� 

Professional Development (CME & CPD) 

�� 

Residency Training Programmes in Urology 



European Urology, the official journal of the EAU, has 

been a respected urological forum for over 20 years 

and is currently read by more than 10,000 urologists 

across the globe. With an impact factor of 8.843 

the Platinum Journal remains the leading scientific 

publication in the field of urology. To keep up with the 

rapidly evolving world of medicine, technology and 

surgical techniques, European Urology is constantly 

updating and innovating its features and layout in 

order to provide the best clinical guidance, research 

and education for urologists across Europe and the 

world. The recently implemented electronic features 

and platforms make reading the articles and viewing 

the videos even more interesting! Come see European 

Urology for yourself - visit either European Urology 

(booth 2M120 on level 2 in the exhibition) or the EAU 

Square (booth 1N03 on level 1 in the exhibition). 

Excursions, Restaurant 

Reservations and Paris 

Information 

Information on Paris and excursions will be available 

at the Concierge Desk in the registration area on level 

3. The concierge will also be able to assist you with 

restaurant reservations. 

Exhibition 

An extensive technical exhibition will be held jointly 

with the congress. The exhibition is open to technical 

equipment manufacturers, pharmaceutical companies 

and scientific publishers. The official opening will take 

place on Saturday, 25 February at 09.00 hrs. 

Exhibition Hours 

Saturday, 25 February 09.00-18.00 hrs 

Sunday, 26 February 09.00-18.00 hrs 

Monday, 27 February 09.00-18.00 hrs 

First Aid 

There is a medical unit present for first aid in room 

315 on level 3 indicated on the directional signs with 

. In case of emergency, contact a security guard 

immediately. 

Guidelines 

EAU Extended guidelines 

The EAU Extended urological guidelines edition 2012, 

are distributed at the EAU Square (booth 1No3 on level 1 

in the exhibition). Members can collect the guidelines 

free of charge. This publication is also available for 

purchase.

EAU Pocket guidelines 

EAU urological guidelines in pocket format including a 

CD are distributed by Olympus (booth 2M100 on level 2 

in the exhibition) to EAU members only. 

The distribution of the EAU Pocket Guidelines 2012 is 

supported by OLYMPUS 

Historical Exhibition 

The members of the EAU History Office have set up 

a historical exhibit located at the EAU Square (booth 

1N03 on level 1 in the exhibition). The exhibit will 

present “The urologist and his intrument maker”. 

Hospitality Suites Companies 

AMS Level 2,5; Room 231/232Mz 

ASTELLAS Level 3,5; Le Club 

COOK MEDICAL Level 1,5; Room 124/125/126/127Mz 

OLYMPUS Level 2,5; Room 224/225Mz 

Hotel Accommodation 

The EAU has contracted the company K.I.T. Group 

GmbH to deal with the housing for the congress. 

K.I.T. staff will be available at the Hotel Desk in the 

registration area on level 3. 

Insurance 

The organisers do not accept responsibility for 

any personal damage. Participants are strongly 

recommended to arrange their own personal 

insurance. 

Internet Corners 

The EAU Internet Corners are at your disposal at 

different locations in the exhibition (booth 1P16 on 

level 1 and booth 2M150 on level 2). The internet 

corners offer free use of internet and printers. See also 

WiFi / Connect and Charge Area. 

Language 

All presentations during the EAU Congress will be 

conducted in English, the official language of the EAU. 

There will be no translation provided. 

Learning Objectives EAU Congress 

The EAU Congress provides a forum for presenting 

original unpublished data and sharing ideas for 

urological innovation as well as disseminating 

evidence-based knowledge of primary clinical 

relevance. 

Urologists and affiliated professionals attending the 

EAU Congress will be able to: 

�� 

advances in the field of urology and its 

subspecialities 

�� 

studies in clinical and translational research 

�� 

approaches to the management of urological 

disease 

�� 

risk-assessment strategies in the management of 

urological disease 

�� 

educational activities, including hands-on-training 

and courses 

�� 

and new cutting edge technology in the field of 

pharmaceutical research and medical technology 

through visiting the EAU Congress Exhibition 

�� 

representatives of a large international audience 

– medical professionals, national urological 

societies, patient groups, medical industry and the 

media. 

Lost and Found 

Found items should be returned to the Information 

Desk in the main entrance hall on level 0. If you lose 

something, please report to this desk for assistance. 

Media Policy 

Photography, filming and interviews during the 

congress (with the exception of the EAU Press 

Centre and EAU Press Conference Room) are 

prohibited without written permission from the 

EAU Communication Officer Ms. Ivanka Moerkerken 

(i.moerkerken@uroweb.org). 

Message Service 

A message service is available at the congress website: 

www.eauparis2012.org. 

You can use the congress website to retrieve your 

messages and to send messages to other congress 

delegates. 

Mobile Phones 

Mobile phones must be switched off during all 

sessions. 

Personal Planner 

Do not miss anything during this year’s congress, use 

the EAU Personal Planner! 

�� 

of the congress. 


41 

General

General 


�� 

private appointments. 

�� 

appointments will be automatically displayed. 

�� 

or print it out. 

For more information, please visit the congress 

website: http://www.eauparis2012.org/scientificprogramme/eau-personal-planner/ 

Poster Builder Service 

Poster presenters who created their posters for the 

27th Annual EAU Congress through the EAU Online 

Poster Builder Service, can collect their posters at the 

Speaker Service Centre on level 3. 

Poster DVD 

A DVD with a collection of posters from the 27th 

Annual EAU Congress will be distributed by AMGEN 

(booth 1P73 on level 1 in the exhibition). 

The EAU Poster DVD 2012 is supported by an 

unrestricted educational grant from AMGEN 

Prayer Room 

A special room dedicated to prayer is located in room 

364 on level 3. 

Presentation Training Centre 

Mr. Paul Casella (Iowa, USA) gives Individual 

Presentation Skills Training Sessions to help improve 

presentation and delivery skills. The one-on-one half 

hour sessions are free of charge and available to all 

speakers. Please go to the Speaker Service Centre to 

make an appointment for this very popular training 

session. 

Press Centre 

Journalists and medical/science writers can obtain free 

registration to the Congress. Journalists will receive a 

press pack, to be collected at the EAU Press Centre on 

the yellow level (ground floor). All press are invited to 

report to the EAU Press Centre to obtain the assistance 

and information they require. Internet access, printer 

and photocopier are provided. 

Resource Centre 

Urology Science and Learning 

The 27th Annual EAU Congress will introduce delegates 

to the EAU Resource Centre: A new way to re-live 

the congress once it’s over. The Resource Centre is a 

website (www.eauresourcecentre.org) that delivers 

EAU contents to users on-demand and allows to select 


lectures and presentations that might otherwise be 

missed, or want to watch them again. Before heading 

home, you can use the Resource Centre computers to 

make a selection of the sessions, presentations and 

seminars that were recorded. After you’ve made your 

selection, you will receive a unique code that allows 

you to view the contents on your own computer, at 

your convenience. The EAU Resource centre is located 

next to the registration area on level 3. 

Safety 

All bags may be subject to inspection. Security is 

present for your safety. Please take all personal effects 

with you when leaving a session room. 

Smoking Policy 

Smoking is prohibited inside the congress centre and 

in the exhibition area. 

Speaker Service Centre 

For extensive speaker information see page 44. 

Taxi Service 

Taxis will be available in the taxi rank in front of 

restaurant Chez Clement next to the congress centre 

(on the left side when you exit the congress centre). 

There is also a taxi rank in front of the Meridien hotel 

or alternatively in front of the Hotel Concorde LaFayette. 

Rates: 

- From the congress centre to airport Charles de 

Gaulle approx. €80/ 90 

- From the congress centre to the city centre 

(Chatelet) approx. 15 - 20 min for €30. However 

you are advised to take the metro which is direct 

and takes only 10 minutes. 

If you wish to book a taxi in Paris by phone we 

recommend to call the following company who has 

reasonable and fixed rates: 

Taxis G7: +33 1 47 39 47 39 

Transportation Pass 

Congress delegates may collect a complimentary 

transportation pass in the registration area which 

is valid for 10 rides. The pass covers underground, 

tram and bus within the city limits of Paris (zone 

1-2). Delegates are kindly requested to return unused 

passes to the special boxes which are located in the 

registration area. They will be donated to a local 

charity. 

Upcoming Meetings 

Posters and other information on upcoming

meetings can be displayed in the “Upcoming 

Meetings” promotion area (booth 1PA09 on level 1 

in the exhibition). It is strictly forbidden to put up 

promotional material at any other location in the 

building. 

Video Library 

The EAU Video Library (booth 1PA01 on level 1 in the 

exhibition) will be operational during exhibition hours. 

A wide choice of EAU videos, including all videos 

presented in Paris and at previous EAU Congresses, 

can be viewed on individual monitors. 

All videos can be copied to a DVD which can be 

collected at the ASTELLAS booth (booth 1P86 on level 

1 in the exhibition), a service that is provided free of 

charge to all congress delegates. 

The Video Library is supported by an unrestricted 

educational grant from ASTELLAS 

Webcasts ( ) & Live Streams ( ) 

Many sessions will be webcasted via the EAU Resource 

Centre: www.eauresourcecentre.org. The webcasted 

sessions are indicated with a special logo in the 

synopsis and will be online within several hours after 

the session. The webcasts have not been edited and 

are exactly as presented. The statements and the 

opinions featured in the webcasts are solely those 

of the individual presenters and not of the European 

Association of Urology (EAU). Webcasts are not 

accredited and no CME credits can be obtained by 

watching the webcasts. 

In addition to the webcasts there will be live streams 

of several sessions available at the congress website: 

www.eauparis2012.org. These sessions are also 

indicated in the synopsis with a special logo. 

WIFI / Charge and Connect Area 

Free wireless internet will be available throughout 

the congress centre except in the exhibition areas. 

Please search for EAU-WiFi and enter your first 

name, surname and email address. You will then 

be connected to the internet. A special Charge and 

Connect Area with tables and power outlets are 

available in the exhibition on level 1 (booth 1N01). 


43 

General

General 

Speaker guidelines 

Speaker Service Centre 

Only digital presentations will be accepted during the 

congress and all presentations should be handed in 

at the Speaker Service Centre (Level 3) at least three 

hours prior to the start of the session. Failure to do 

so could result in presentations not being available 

for projection when required. If you have an early 

presentation, please hand in your presentation the 

previous day! 

Opening hours 

Thursday, 23 February 14.00 - 19.00 hrs 

Friday, 24 February 07.00 - 19.00 hrs 

Saturday, 25 February 07.00 - 19.30 hrs 

Sunday, 26 February 07.00 - 19.00 hrs 

Monday, 27 February 07.00 - 19.00 hrs 

Tuesday, 28 February 07.00 - 13.00 hrs 

If you are a chair 

Locate your session room in time. Please be in your 

session room at least 15 minutes prior to the start of 

the session. 

Please note that: 

�� 

�� 

institution and country of origin. 

If you are presenting a poster 

Posters must be put up in the room 15 minutes prior 

to the start of the session. The poster boards are 

numbered and your poster should be mounted on the 

board which corresponds to your abstract number. 

Pushpins are available in the session room. Please 

remove your poster immediately at the end of the session. 

A maximum of five PowerPoint slides is allowed 

during extended poster presentation. For standard 

poster presentations, a maximum of two PowerPoint 

slides is allowed. 

Disclose links to the industry 

The EAU Scientific Congress Office requests that you 

disclose to the audience any links you may have with 

the industry related to the topic of your lecture at 

the beginning of your session. A link can be: Being a 

member of an advisory board or having a consultancy 

agreement with a specific company. 

Presentation Training Centre 

Mr. Paul Casella (Iowa, USA) gives Individual 

Presentation Skills Training Sessions to help improve 

presentation and delivery skills. The one-on-one half 

hour sessions are free of charge and available to all 


speakers. Please go to the Speaker Service Centre to 

make an appointment for this very popular training 

session.

Download the App 

and lighten your congress bag 

Get the official EAU Congress App from 

the Android Marketplace or iPhone App Store 

Paris 

Scientific Programme 

The entire programme book at your fingertips. 

Abstracts 

Browse abstracts on a wide range of topics. 

News 

Read the latest news, opinion articles and interviews. 

Exhibition 

Finding your way at the exhibition is now easier than ever. 

Favourites 

Save your favourite sessions to a handy list. 

27th Annual Congress 

News Abstracts stracts 

Programme 

This EAU Congress App will bring the 27th Annual EAU Congress to your iPhone or Android phone and can 

also be used offline - search for ‘EAU 2012’ in your store. 

Exhibitors tors 

List 

Visit the official website of the 27th Annual EAU Congress to find out more about the event - www.eauparis2012.org 

To learn more about the EAU - www.uroweb.org

General 

CME Accreditation 

Accreditation of the EAU Congress 

The European Association of Urology is accredited 

by the EACCME/EBU to provide the following Live 

Educational Event for medical specialists. The EACCME 

(European Accreditation Council for Continuing 

Medical Education) and the EBU (European Board 

of Urology are institutions of the European Union of 

Medical Specialists (UEMS), www.uems.net. 

The ‘27th Annual EAU Congress’ is designated for a 

maximum of 27 hours of European external CME credits 

(including ESU Courses). 

Each medical specialist should claim only those hours 

of credit that he/she actually spent in the educational 

activity. 

CME credits 

The EACCME/EBU credit system is based on 1 ECMEC 

per hour with a maximum of 3 ECMECs for half a day 

and 6 ECMECs for a full-day event. 

Please scan your EAU congress badge when entering 

the lecture room to have CME credits registered 

automatically. 

The CME credit registration is carried out by the EU- 

ACME Office and during the congress you can find their 

desk at the registration area on level 3. 

CME credits per Country 

The EBU/EACCME CME Credits are recognised by most 

of the national CME authorities in Europe, which have 

agreed to cooperate in this European system. 

All CME activities approved by the EBU/EACCME are 

recognised in the following countries: 

Austria, Belgium, Cyprus, Czech Republic, Denmark, 

Finland, Georgia, Greece, Hungary, Ireland, Latvia, 

Luxembourg, Malta, The Netherlands, Norway, Region 

Lombardia, Romania, Slovakia, Slovenia, Spain, Turkey 

and United Kingdom. 

CME credits per Speciality 

All CME activities approved by the EBU/EACCME are 

recognised in the following specialities: 


Dermatology and Venerology, Paediatric Surgery, 

Physical and Rehabilitation Medicine, Anaesthesiology, 

Child and Adolescent Psychiatry and Psychotherapy, 

Endocrinology, Geriatrics, Intensive Care (MJC), 

Internal Medicine, Neurology, Neurosurgery, Nuclear 

Medicine, Oral and Maxillofacial Surgery, Pathology, 

Plastic Surgery, Cardiology (EBAC), Sports Medicine 

(MJC), Genetics (MJC), Microbiology, Pneumology 

(EBAP), Infectious Diseases (EBAID), Surgery, Urology, 

Oncology (ACCO). 

If your country or speciality is not listed above please 

either contact the EU-ACME Office for more information 

or send a copy of the attendance certificate to 

your National Urological Society and/or National 

Accreditation Body. 

CME credits outside Europe 

Through an agreement between the European Union 

of Medical Specialists and the American Medical 

Association, physicians may convert EACCME credits 

to an equivalent number of AMA PRA Category 

1 Credits. Information on the process to convert 

EACCME credit to AMA credit can be found at www. 

ama-assn.org/go/internationalcme. 

If you attended a conference in Europe and received 

a certificate for EACCME credit you can convert it to 

the AMA PRA Category 1 Credit. To receive the credit, 

the conference must appear on the list of approved 

activities posted in the EACCME section of the UEMS 

Website. 

To apply for conversion of EACCME credit to AMA PRA 

Category 1 Credit, download the Application for 

EACCME Credit Conversion and submit the completed 

application by fax or mail, a copy of the EACCME credit 

certificate and appropriate processing fee. A certificate 

of AMA PRA Category 1 Credit will be mailed within 

four weeks. 

If you wish to receive information about the conversion 

procedure of EACCME credits to AMA PRA category 1 

credits, please contact the AMA. 

Live educational activities, occurring outside of 

Canada, recognized by the UEMS-EACCME for ECMEC 

credits are deemed to be Accredited Group Learning 

Activities (Section 1) as defined by the Maintenance 

of Certification Program of The Royal College of 

Physicians and Surgeons of Canada.

EU-ACME Programme 

The EU-ACME Programme - the initiative resulting 

from a close collaboration between the European 

Board of Urology (EBU) and the European Association 

of Urology (EAU) - stands for European Urology - 

Accredited Continuing Medical Education. Its primary 

task is assistance in the implementation, promotion 

and organization of Continuing Medical Education 

(CME) and Continuing Professional Development (CPD) 

among European urologists. Urologists have access to 

an online system - in compliance with the EBU/UEMS 

regulations - which helps them to keep track of their 

educational activities, irrespective of the country they 

practice in or where they have participated in 

accredited CME/CPD activities. 

CME/CPD activities are generally geared towards 

practising physicians and are designed to provide 

information that is both relevant and essential to 

medical practice. 

The EU-ACME office acts as a central ‘institution’ 

where all information forwarded by urologists, (inter) 

national urological associations and CME organisers/ 

providers is kept. 

As a service institution the EU-ACME office offers: 

�� 

urological society participating in the EU ACME 

programme, 

�� 

webpage www.eu-acme.org, 

�� ticipating 

in the programme, 

�� 

CME/CPD credit points, 

�� 

European level CME events, 

�� 

The international urological societies as European 

Association of Urology, European Society of Paediatric 

Urology and International Continence Society as well 

as national urological societies from: Austria, Bulgaria, 

Czech Republic, Cyprus, Denmark, Estonia, Greece, 

Hungary, Italy, Latvia, Malta, The Netherlands, Poland, 

Romania, Serbia, Slovakia, Slovenia, Spain, Turkey 

have already joined the programme. For more information, 

please visit the website: www.eu-acme.org. 

Information on the EU-ACME programme, your 

acquired CME/CPD credits and membership cards can 

be obtained at the EU-ACME information desk in the 

registration are. 


47 

General

www.emucbarcelona2012.org 

Embracing Excellence 

in Prostate, Bladder 

and Kidney Cancer 

16-18 November 2012 

Barcelona, Spain 

Abstract Deadline: 

2 July 2012 

4 th European Multidisciplinary Meeting on Urological Cancers organised by:

About Paris 

Known as the ‘City of Light’, the French capital has 

long been a global centre. Its multiculturalism, Belle 

Epoque splendour and historical significance give the 

city its deserved reputation as a cultural hub in the 

Western world. In the 21st century, the city and suburbs’ 

twelve million inhabitants make Paris one of the 

largest and most diverse conurbations in Europe. 

Key Attractions 

The Eiffel Tower dominates Paris’s skyline at 324 meters, 

and it was the tallest structure in the world when 

it was completed. Intended to stand for only twenty 

years, its effectiveness as an antenna at the dawn of 

radio broadcasting kept it standing. To this day, it still 

serves as a radio/television transmitter, and it is a 

popular tourist destination. Some seven million 

tourists visit the tower each year. It has three accessible 

floors, and it hosts two restaurants in its frame. 

Historical Axis 

Far from relying on a single landmark, Paris is blessed 

with a wealth of sights in the shape of architecture, 

commemorative works and cultural facilities like museums. 

The Arc de Triomphe, at the centre of the city’s 

‘historical axis’, forms the hub of the city’s more 

memorable attractions. The axis begins in the West 

with the 1990-built Grande Arche in the modern business 

district of La Défense. It also encompasses the 

famous Champs-Élysées. For a long time, this shopping 

street was the most expensive piece of real estate 

in Europe. The Historical axis ends with the Louvre in 

the East. 

Museums 

This former fortress and royal palace now houses the 

The Arc de Triomphe is but one of three arches 

along the Axe Historique. It is accompanied by the 

smaller Arc de Triomphe du Carrousel, and was 

later paid homage to by the imposing Grande Arche 

of La Défense. 

world’s premier art collection. Perhaps the single most 

famous museum in the world, the Louvre now features 

an iconic glass pyramid in its courtyard, which serves 

as the main entrance. The Louvre’s collection contains 

ancient artefacts, renaissance masterpieces like the 

Mona Lisa and Venus de Milo, all the way up to art 

from the nineteenth century. 

The Louvre is just one of dozens of museums around 

Paris. The Musée National d’Art Moderne, housed in 

the high-tech Centre Pompidou, is among the largest 

collections of modern art in the world. Works by 

Picasso and Rodin have their own dedicated museums. 

The artistic, left-bank area of Montparnasse has a 

local museum, exhibiting art from the artists clustered 

in the area, and a history of the neighbourhood. In 

Montmartre, the Espace Dalí hosts France’s largest 

collection of the surrealist master. 

Religious Architecture 

Far from being just a city of modernity, the influence 

of medieval French Catholicism can be felt in the 

Gothic architecture of Notre Dame Cathedral. Religion 

also literally towers over the city from the peak of 

Montmartre. The Basilique du Sacré-Cœur was built 

as the hill’s crown, as a symbol of healing after the 

socio-political turmoil of the 19th century. Les Invalides 

is a large complex that features museums of France’s 

military history, a veterans’ hospital and retirement 

home, and a chapel. Its tombs house distinguished 

figures from French history, including the sarcophagus 

with the remains of Emperor Napoleon I. 

Versailles 

Once a quiet village playing host to a modest royal 

hunting lodge, King Louis XIV’s vanity transformed 

Versailles into a court town with a palace of epic 

proportions over the course of the 17th century. 

Together with its stretching symmetrical gardens, the 

palace represents the peak of 17th century French 

Baroque architectural splendour. 


49 

General

General 

About Paris 

Tickets 

Tickets are available separately for each museum and 

historical site. However, all of them including the 

Palace of Versailles, are covered in the Paris Museum 

Pass, which can be valid for different lengths. At €35 

for two days, the pass can save you a lot if you are 

planning to visit more than three of these sites. It will 

also spare you from the long queues that these popular 

sights attract. Individual tickets, as well as the Paris 

Museum Pass can be bought in advance here: 

http://en.parisinfo.com/express-booking/ 

Nightlife 

Famous for its roaring nightlife, and of course its tradition 

of cabaret, one could do a lot worse than visiting 

Paris for some nocturnal entertainment. From the 

exclusive clubs along the Champs-Élysées to the more 

low-key bars in artsy districts, visitors are guaranteed 

a lively time in the aptly-titled City of Lights. 

The extravagant cabaret shows at the famous Moulin 

Rouge should make the evening one to remember. The 

club is located in the Montmartre area, a hill overlooking 

the city centre. Montmartre has a bohemian 

reputation from its illustrious turn-of-the-century 

history as an artists’ and intellectuals’ hangout, and its 

history of falling outside of city jurisdiction. Nowadays, 

it remains a lively area of Paris with many smaller 

clubs and cultural events. 

Shopping 

As a centre for fashion and design, Paris has much to 

offer shoppers. The Champs-Élysées and the surrounding 

streets in the 8th district are home the most exclusive 

brands, whereas more regular department stores 

can be found on the Boulevard Haussman. Smaller 

boutiques are to be found in the Marais district, in the 

4th district. Shops are generally open until 19.00, and 

The dough of the iconic French baguette is 

protected by law. Regulations state that the bread 

must contain only flour, water, yeast and salt. No 

preservatives may be added, giving a loaf a shelf 

life of one day only. 


closed on Sundays and sometimes Mondays. 

Dining 

Paris also has a justified reputation as the city for 

food-lovers. French cuisine is a global phenomenon, 

setting the standard for all Western cuisine. Dishes like 

Fruits de Mer, accompanied by French bread and wine 

are a delight for any visitor. From cafés, bistros, and 

brasseries to exclusive restaurants, the passion and 

professionalism of the city’s chefs means gastronomic 

enjoyment can be had at any budget. Lunch is generally 

served from 12.00 to 13.30, and dinner from 19.30 

to 22.30. 

Getting Around 

The Eiffel Tower is not the only benefit that Paris 

gained from hosting a world’s fair: the esteemed 

metro system was established in 1900, on the occasion 

of the Exposition Universelle. The Art Nouveau style of 

the fair was carried over into the first generation of the 

metro network, and it is still visible at some restored 

stations. The Paris Metro is the best way of getting 

around town, with its dense network and frequent 

departure times. 

A single ticket for the metro or RER costs € 1.60, and it 

allows you a single trip to any destination within the 

city. Visitors can also buy a Paris Visite pass, valid for 

a range of days in a choice of zones. These offer the 

greatest amount of flexibility for visitors, but can be 

pricey if one is not on and off of public transport for 

the entire day. 

For those keen to see more of the cityscape while 

getting around, the city recently introduced the Vélib’ 

system. This affordable, automated bicycle rental 

service allows travellers to hire bicycles and deposit 

them at the destination for the next commuter to use. 

The Batobus is a shuttle boat that allows you to experience 

Paris from the Seinne. It stops at several touristic 

hotspots, and has several ticket types, including an 

€ 11 all-day ticket. Alternatively, there are also several 

options for guided tours along the river.

Congress hotels 

Acacia Etoile 

11 Rue des Acacias 

75017 Paris 

T +33 1 43806022 

F +33 1 48889640 

http://acacias-paris-hotel.com 

1 km walking distance 

Adagio 

35 Cours Michelet 

La Défense 10 

92060 Paris La Défense 

T +33 1 47739090 

F +33 1 47764436 

www.accorhotels.com 

Metro M1 at Esplanade de la 

Défense 

Amarante Arc De 

Triomphe 

25 Rue Théodore de Banville 

75017, Paris 

T +33 1 47637669 

F +33 1 43806396 

www.amarantearcdetriomphe.com 

Bus PC3 Porte de Courcelles 

Amarante Beau 

Manoir 

6 Rue de l’Arcade 

75008 Paris 

T +33 1 53432828 

F +33 1 53432888 

www.hotelbeaumanoir.com 

Metro M1 Concorde 

Amarante Champs 

Elysées 

19 Rue Vernet 

75008 Paris 

T +33 1 47204173 

F +33 1 47233215 

www.amarantechampselysees.com 

Metro M1 George V 

Balmoral 

6 Rue du Général Lanrezac 

75017 Paris 

T +33 1 43803050 

F +33 1 43805156 

www.balmoral-paris-hotel.com 

Metro M1 Charles de Gaulle Etoile 

Belfast 

10 Avenue Carnot 

75017 Paris 

T +33 1 43801210 

F +33 1 43803493 

www.hotelbelfastparis.com 

1,3 km walking distance 

Best Western Etoile 

Saint Ferdinand 

36 Rue Saint Ferdinand 

75017 Paris 

T +33 1 45726666 

F +33 1 45741292 

www.bestwestern.com 


Best Western Premier 

Pergolèse 

3 Rue Pergolèse 

75116 PARIS 

T +33 1 53640404 

F +33 1 53640440 

www.pergolese.com 


Best Western Premier 

Regent’s Garden 

6 Rue Pierre-Demours 

75017 Paris 

T +33 1 45740730 

F +33 1 40550142 

www.bestwestern-regents.com 


Best Western Star 

Champs Elysées 

18 Rue De L’Arc De Triomphe 

75017 Paris 

T +33 1 43802769 

F +33 1 40549484 

www.bestwestern.com 


Cecilia 

11 Avenue mac Mahon 

75017 Paris 

T +33 1 43803210 

F +33 1 43803210 

www.hotel-cecilia.fr 


Concorde La Fayette 

3 Place du Général Kœnig 

75017 Paris 

T +33 1 40685068 

F +33 1 40685043 

http://lafayette.concordehotels.com 


Concorde 

Montparnasse 

40 Rue du Commandant 

Mouchotte, Place Catalogne 

75014 Paris 

T +33 1 56548400 

F +33 1 56548444 

www.concordehotels.com 

Metro M13 Gaité /change M1 

Concorde Opéra 

108 Rue Saint-Lazare 

75008 Paris 

T +33 1 40084444 

F +33 1 42930120 

www.concordehotels.com 

Metro M3 Saint Lazare/change 

M1 at Pont du Garigliano-Hopital 

Européen Georges Pompidou 

Courtyard Paris 

Neuilly 

58 Blvd. Victor Hugo 

92200 Neuilly Sur Seine 

T +33 1 55636465 

F +33 1 55636466 

www.marriott.com 

Bus 82 Bineau Château 

Etoile Péreire 

146 Boulevard Péreire 

75017 Paris 

T +33 1 42676000 

F +33 1 42610290 

www.etoilepereire.com 

Bus PC1 at Porte de Champerret 


51 

General

General 


Hilton Arc de 

Triomphe Paris 

51/57 Rue de Courcelles 

75008 Paris 

T +33 1 58366700 

F +33 1 58366777 

www.hilton.com 

Bus 43 Haussmann-Courcelles 

Hilton Paris la 

Défense 

2 Place de la Défense CNIT 

Paris 92053 BP 210 

T +33 1 46921010 

F +33 1 46921050 

http://www1.hilton.com 

Metro M2 Place de Clichy/ 

change M1 

Holiday Inn Bastille 

11 Rue de Lyon 

75012 Paris 

T +33 1 53022000 

F +33 1 5302200 

www.holidayinn.com 

Metro M1 Gare de Lyon 

Holiday Inn Express 

Canal de la Villette 

8 Quai de la Seine 

75019 Paris 

T +33 1 44650101 

F +33 1 44650102 


Metro M7 at Crimée/change to M1 

at Musée du Louvre 

Holiday Inn Paris 

Notre Dame 

4 Rue Danton 

75006 Paris 

T +33 1 81690060 

F +33 1 81690061 


Metro M4 Saint-Michel/change M1 



Opera 

38 Rue de l’échiquier 

75010 Paris 

T +33 1 42469275 

F +33 1 42470397 


Metro M8 Bonne Nouvelle/ 

change M1 


Porte de Clichy 

2 Rue du 8 Mai 1945 

92110 Clichy 

T +33 1 76687700 

F +33 1 7668770 


Bus PC3 Porte de Clichy 

Hôtel Acacias Etoile 

11 Rue des Acacias 

75017 Paris 

T +33 1 43806022 

F +33 1 48889640 

http://acacias-paris-hotel.com 

1,4 km walking distance or Metro 

M1 at Argentine – Metro 

Hôtel Astrid 


75017 Paris 

T +33 1 44092600 

F +33 9 72130031 

www.hotel-astrid.com 

Bus 73 Charles de Gaulles Etoile – 

Grande Armée 

Hotel De Banville 

166 Boulevard Berthier 

75017 PARIS 

T +33 (0)1 42 67 70 16 

F +33 (0)1 44 40 42 77 

www.hotelbanville.fr 

Metro M3 Porte de Champerret 

station 

Hôtel Champlain Paris 

99 Bis Rue de Rome 

75017 Paris 

T +33 1 42274952 

F +33 1 47639509 

www.hotelchamplainparis.com 

Walk to Rome Metro Station - 

Metro M2 at Marechal de Lattre 

de Tassigny/change to M1 at La 

Défense Grand Arche 

Hôtel Château 

Frontenac 

54 Rue Pierre Charron 

75008 Paris 

T +33 1 53231313 

F +33 1 53231301 

www.hfrontenac.com 

Metro M1 Georges V 

Hôtel Duret 

30 Rue Duret 

75116 Paris 

T +33 1 45004260 

F +33 1 45005589 

www.hotelduret.com 


Hotel Franklin 

Roosevelt 

18 Rue Clément Marot 

75008 Paris 

T +33 1 53574950 

F +33 1 53574959 

www.hroosevelt.com 

Metro M1 Franklin D-Roosevelt 

Hotel Le Baltimore 

88 Bis Avenue Kleber 

75116 Paris 

T +33 1 44345454 

F +33 1 44345444 

www.accorhotels.com 

Bus 82 Lubeck 

Hôtel Paris Neuilly 

1 Avenue de Madrid 

92200 Neuilly-sur-Seine 

T +33 1 47471467 

F +33 1 47479742 

www.hotel-paris-neuilly.com 

Metro M1 at Pont de Neuilly

Hôtel Villa Brunel 

46 Rue Brunel 

75017 Paris 

T +33 1 45747451 

F +33 1 45744090 

www.villabrunel.com 


Ibis Defense Center 

4 Boulevard de Neuilly La Défense 

1 Pont de Neuilly Paris La Défense 

Cedex 

92081 – La Défense 

T +33 1 41974040 

F +33 1 41974050 

www.ibishotel.com 

Metro M1 at Esplanade de la 

Défense 

Ibis Porte de Clichy 

Centre 

15 Boulevard Victor Hugo 

Place des Nations-Unies 

92110 Paris 

T +33 1 41401890 

F +33 1 41401891 


Bus PC3 at Porte de Clichy 

Ibis Tour Eiffel 

2 Rue Cambronne 

75015 Paris 

T +33 1 40612121 

F +33 1 40612299 


Metro M6 at Cambronne/change to 

M1 at Charles de Gaulle Etoile 

Intercontinental Paris 

Le Grand 

2 Rue Scribe 

75009 Paris 

T +33 1 40073232 

F +33 1 40073232 

www.intercontinental.com 

Metro M7 Opéra/change M1 

La Ville des Ternes 

97 Avenue des Ternes 

75017 Paris 

T +33 1 53819494 

F +33 1 53819494 

www.paris-hotel-ternes.com 


Le Méridien Etoile 

81 Boulevard Gouvion Saint-Cyr 

75848 Cedex 17 

75017 Paris 

T +33 1 40683434 

F +33 1 40683131 

www.starwoodhotels.com 

Bus PC1 Général Koenig 

Median Paris Congres 

6/8 Boulevard de Douaumont 

75017 Paris 

T +33 1 47560400 

F +33 1 47561477 

www.medianhotels.com 

Bus RC3 at les Hauts de 

Malesherbes 

Melia Alexander 

Boutique Hôtel 

102 Avenue Victor Hugo 

75016 Paris 

T +33 1 56906100 

F +33 1 56906101 

http://fr.solmelia.com 

1,5 km walking distance or Metro 

M2 Victor Hugo 

Melia Colbert 

Boutique Hotel 

7 Rue Hotel Colbert 

75005 Paris 

T +33 1 56811900 

F +33 1 56811902 


RER C Saint Michel Notre Dame 

Melia Royal Alma 

Boutique Hotel 

35 Rue Jean Goujon 

75008 Paris 

T +33 1 53936300 

F +33 1 53936301 


Metro M9 Alma Marceau/ 

change M1 

Melia Vendôme 

Boutique Hôtel 

8 Rue Cambon 

75001 Paris 

T +33 1 44775400 

F +33 1 44775401 


Metro M1 Concorde 

Mercure Arc De 

Triomphe Etoile 

27 Avenue des Ternes 

75017 Paris 

T +33 8 25801919 

F +33 1 47637791 

www.mercure.com 


Mercure Arc de 

Triomphe Wagram 

3 Rue Brey 

75017 -Paris 

T +33 1 56680001 

F +33 1 56680002 


1,3 km walking distance/Metro M1 

at Charles de Gaulle-Etoile 

Mercure Défense 5 

18-30 Rue Baudin 

Place Charras 

92400 Courbevoie 


F +33 1 47688332 


Walk to Alma-Baudin/Bus 275 to La 

Défense Metro-RER/change to M1 

at La Défense Grand Arche 


53 

General

General 


Mercure Suffren Tour 

Eiffel 

20 Rue Jean Rey 

75015 Paris 


F +33 1 45789142 


Metro M6 Champs de Mars – Tour 

Eiffel/change M1 

Neuilly Park Hotel 

23 Rue Madeleine Michelis 

92200 Paris Neuilly 

T +33 1 46401115 

F +33 1 46401478 

www.hotelneuillypark.com 

900 m walking distance 

Novotel Défense 

2 Boulevard de Neuilly 

Paris la Défense 1 CEDEX 

92081 La Défense 

T +33 1 41452323 

F +33 1 41452324 

www.novotel.com 

Metro M1 Esplanade de la Défense 

Novotel Les Halles 

8 Place Marguerite de Navarre 

75001 Paris 

T +33 1 42213131 

F +33 1 40260579 


Metro M1 Chatelet 

Novotel Tour Eiffel 

61 Quai de Grenelle 

75015 Paris 

T +33 1 40582000 

F +33 1 40582444 


RER C Kennedy Radio France 


Pullman 

Montparnasse 

19 Rue Commandant René 

Mouchotte 

75014 Paris 

T +33 1 44364436 

F +33 1 44364700 

www.pullmanhotels.com 

Metro M13 Gaite/change to M1 at 

Champs Elysées 

Pullman Paris La 

Défense 

11 Avenue de l’Arche 

Paris La Défense 6 CEDEX 


T +33 1 47175000 

F +33 1 47175678 


Metro M1 La Défense 

Pullman Paris Rive 

Gauche 

8-12 Rue Louis Armand 

75015 Paris 

T +33 1 40603030 

F +33 1 40603000 


Metro M8 Balard/change to M1 at 

Concorde 

Pullman Tour Eiffel 

18 Avenue de Suffren 

Entrée au 22 rue Jean Rey 

75015 Paris 

T +33 1 44385600 

F +33 1 44385610 


Metro M6 Bir-Hakeim/change to M1 

at Charles de Gaulle Etoile 

Radisson Blu Paris 

Boulogne 

33 Avenue Edouard Vaillant 

92100 Paris 

T +33 1 46088500 

F +33 1 46088501 

www.radissonblu.com 

Walk to Porte de Saint Cloud- 

Murat/Take Bus PC1 

Renaissance Arc de 

Triomphe 

39 Avenue de Wagram 

75 017 Paris 

T +33 1 55375537 

F +33 1 55375538 


Bus 43 Ternes 

Renaissance Le Parc 

Trocadéro 

55-57 Avenue Raymond Poincaré 

75116 Paris 

T +33 1 44056666 

F +33 1 44056600 


Bus 82 Victor Hugo-Poincare 

Renaissance Paris la 

Défense 

60 Jardin de Valmy 

92918 Paris La Défense Cedex 

T +33 1 41975050 

F +33 1 41975151 


Metro M1 La Défense 

Résidence Impériale 

155 Avenue de Malakoff 

75116 Paris 

T +33 1 45002345 

F +33 1 45018882 

www.paris-hotel-residenceimperiale.com 


Rochester Champs 

Elysées 

92 Rue La Boétie 

75008 Paris 

T +33 1 56696900 

F +33 1 56696901 

www.hrochester.com 

Metro M1 Franklin Roosevelt

Sofitel Arc de 

Triomphe 

14 Rue Beaujon 

75008 Paris 

T +33 1 53895050 

F +33 1 53895051 

www.sofitel.com 

Bus 73 George V 

Sofitel Défense Center 

34 Cours Michelet 


T +33 1 47764443 

F +33 1 47767210 

www.sofitel.com 

Metro M1 Esplanade de la Défense 

Splendid Etoile 


75017 Paris 

T +33 1 45727200 

F +33 1 45 727201 

www.hsplendid.com 

Metro M1 Charles de Gaulle – Etoile 

Tilsitt Etoile 

23 Rue Brey 

75017 Paris 

T +33 1 43803971 

F +33 1 47663763 

www.tilsitt.com 

Metro M1 at Charles de Gaulle 

Etoile 

W Paris Opéra 

4 Rue Meyerbeer 

75009 Paris 

T +33 1 40683138 

F To be announced soon 

www.wparisopera.com 

Metro M8 Opera 

Waldorf Arc de 

Triomphe & Spa 

36 Rue Pierre Demours 

75017 Paris 

T +33 1 47646767 

F +33 1 40539134 

www.hotelswaldorfparis.com 

1,1 km Walking distance 

Waldorf Madeleine 

12 Boulevard Malesherbes 

75008 Paris 

T +33 1 42657206 

F +33 1 40071045 


Metro M1 Madeleine 

Waldorf Trocadéro 

97 Rue Lauriston 

75116 Paris 

T +33 1 45538330 

F +33 1 47559252 


1,2 Walking distance or Bus 82 

Boissière 

Warwick Champs 

Elysées 

5 Rue de Berri 

75008 Paris 

T +33 1 45631411 

F +33 1 45637581 

http://warwickparis.com 

Metro M1 Georges V 

Westin Paris 

3 Rue De Castiglione 

75001 Paris 

T +33 1 44771111 

F +33 1 44771460 

www.starwoodhotels.com 

Metro M1 Tuileries 

Westminster 

13 Rue de la Paix 

75002 Paris 

T +33 1 42615746 

F +33 1 42603066 

www.warwickhotels.com 

Metro M8 Opera/change to M1 at 

Concorde 


55 

General

Are you attending an event? 

Think AIR FRANCE and KLM. 

�� 

�� 

�� 

�� 

� �� 

��www.airfranceklm-globalmeetings.com�� 

�� 

�� 

��

Friday, 24 February - EAU Programme 


08.00 - 15.45 Reports of the Committees of the ICUD-EAU International Consultation 

on Incontinence (5th ICI) 2012 

Room Bordeaux - Level 3 

Chairs: P. Abrams, Bristol (GB) 

L.D. Cardozo, London (GB) 

A.J. Wein, Philadelphia (US) 

08.00 - 08.30 Committee 1: Epidemiology 

I. Milsom, Gothenburg (SE) 

08.30 - 08.55 Committee 2: Cell biology 

C. Fry, London (GB) 

08.55 - 09.20 Committee 3: Neural control 

L. Birder, Pittsburgh (US) 

09.20 - 09.50 Committee 4: Pathophysiology 

H. Kolbl, Mainz (DE) 

09.50 - 10.20 Committee 5: Assessment 

D.R. Staskin, Boston (US) 

10.20 - 10.50 Committee 7: Imaging and other tests 

A. Tubaro, Rome (IT) 

10.50 - 11.15 Committee 9: Children 

J.M. Nijman, Groningen (NL) 

11.15 - 11.40 Committee 11: Frail elderly 

A. Wagg, London (GB) 

11.40 - 12.05 Committee 12: Conservative management 

K.N. Moore, Edmonton, Alberta (CA) 

12.05 - 12.30 Lunch 

12.30 - 12.50 Committee 15: Surgery for POP 

C. Maher, Brisbane (AU) 

12.50 - 13.10 Committee 16: Faecal incontinence, conservative 

D. Bliss, Minneapolis (US) 

13.10 - 13.30 Committee 17: Faecal incontinence, surgery 

R. Madoff, Minneapolis (US) 

13.30 - 13.55 Committee 18: Fistulas 

D.J.M.K. De Ridder, Leuven (BE) 

13.55 - 14.20 Committee 19: Bladder pain syndrome 

P. Hanno, Philadelphia (US) 


57 

Friday

Friday 

14.20 - 14.40 Committee 20: Continence products 

A. Cottenden, London (GB) 

14.40 - 15.00 Committee 21: Continence promotion 

D.K. Newman, Philadelphia (US) 

15.00 - 15.20 Committee 22: Economics 

K. Moore, Sydney (AU) 

15.20 - 15.45 Committee 23: Research 

L. Brubaker, Maywood (US) 


Committees 6, 8, 10, 13 and 14 will present their reports at the start of the EAU Section of Female Urology 

Meeting on Saturday, 25 February at 10.15 in Room Concorde Paris on Level 4



10.30 - 13.00 Joint Session of the European Association of Urology (EAU) and the 

Korean Urological Association (KUA) 

Room Concorde Paris - Level 4 

Chairs: M.K. Chung, Yangsan (KR) 

A. Patel, London (GB) 

10.30 - 10.35 Introduction 

M.K. Chung, Yangsan (KR) 


10.35 - 11.15 Prostate surgery and complications 

Moderators: J.Z. Lee, Busan (KR) 


10.35 - 10.55 Surgical treatment outcomes and training for LUTS-BPE 

F. Desgrandchamps, Paris (FR) 

10.55 - 11.15 Management of post prostatectomy incontinence 

S.J. Oh, Seoul (KR) 

11.15 - 11.55 Stone disease 

Moderators: A. Patel, London (GB) 

G.T. Sung, Busan (KR) 

11.15 - 11.35 New developments in PCNL and SWL 

D.H. Han, Seoul (KR) 

11.35 - 11.55 Tips and tricks for ureteroscopy 


11.55 - 12.55 KUA Young Urologists Challenge 

Panel: J. Cheon, Seoul (KR) 


Y.G. Lee, Seoul (KR) 

J.A. Schalken, Nijmegen (NL) 

11.55 - 12.05 Bladder sensation as a triggering key for voiding 

D.K. Kim, Daejeon (KR) 

12.05 - 12.10 Questions and answers 

12.10 - 12.20 Predictive factors for the progression to CRPC 

C. Kwak, Seoul (KR) 

12.20 - 12.25 Questions and answers 

12.25 - 12.35 Basic research in prostate cancer chemoprevention 

T.W. Kang, Gwangju (KR) 


59 

Friday

Friday 


12.40 - 12.50 Basic research in CRPC 

H. Ha, Busan (KR) 


12.55 - 13.00 Closing remarks and prize giving 

M.K. Chung, Yangsan (KR) 


60 Programme Book




Chinese Urological Association (CUA) 

Room Concorde Centre - Level 4 

Chairs: W. Artibani, Verona (IT) 

L.P. Xie, Hangzhou (CN) 


W. Artibani, Verona (IT) 


10.35 - 10.50 Urology training in Europe 


10.50 - 11.05 Endoscopic surgery skill training in China 

Y. Zhang, Beijing (CN) 

11.05 - 11.20 Discussion 

11.20 - 11.35 Laparoscopic partial nephrectomy with segmental renal artery clamping 

C.J. Yin, Nanjing (CN) 

11.35 - 11.50 Contemporary management of small renal masses 

M.P. Laguna, Amsterdam (NL) 


12.05 - 12.20 Laparoendoscopic single-site radical prostatectomy: Technique and initial experience 

G. Zhu, Beijing (CN) 

12.20 - 12.35 Focal therapy of prostate cancer: Rationale and ongoing trials 

M. Lazzeri, Florence (IT) 


12.50 - 13.00 Summary and conclusion 




61 

Friday

Friday 





Arab Association of Urology (AAU) 

Room Concorde Neuilly - Level 4 

Chairs: H. Abol-Enein, Mansoura (EG) 

D. Jacqmin, Strasbourg (FR) 


H. Abol-Enein, Mansoura (EG) 


S. Kayal, Damascus (SY) 

10.40 - 11.50 Session I: Prostate cancer and urinary stones 

10.40 - 10.55 Do we still need to do TURP for BPH? 

M. Marberger, Vienna (AT) 

10.55 - 11.10 Watchful waiting in prostate cancer patient: End point 

B. Tombal, Brussels (BE) 


11.15 - 11.30 Do we still need open surgery for urinary stones in 2012? 

A.N. Shunaigat, Amman (JO) 

11.30 - 11.45 How to prevent stone recurrence 

Y. Nouira, Ariana (TN) 


11.50 - 12.55 Session II: Reconstructive urology and how I do it? 

11.50 - 12.05 Treatment of long segment ureteral stricture 


12.05 - 12.20 Which patients need which operation for stress incontinence? 

F.R. Cruz, Porto (PT) 

12.20 - 12.25 Discussion 

12.25 - 12.35 Nerve sparing radical cystectomy 

A. Mosbah, Mansoura (EG) 

12.35 - 12.45 Nerve sparing radical prostatectomy 

A. Heidenreich, Aachen (DE) 

12.45 - 12.50 Laparoscopic donor right nephrectomy: Kidney transplantation 

I. Al-Oraifi, Dhahran (SA) 

12.50 - 12.55 Laparoscopic donor left nephrectomy: Kidney transplantation 

R.B. Khauli, Beirut (LB)

12.55 - 13.00 Closing remarks 



S. Kayal, Damascus (SY) 


63 

Friday

Friday 





Urological Society of India (USI) 

Room Havane - Level 3 

Chairs: J.N. Kulkarni, Mumbai (IN) 

M. Wirth, Dresden (DE) 

10.30 - 10.50 Total pelvic floor repair in females 

R. Kappor, Lucknow (IN) 

10.50 - 11.10 Selection of approach in the management of recto urethral fistula 

S.K. Singh, Chandigarh (IN) 

11.10 - 11.30 PCNL in stag horn calculi 

M. Chiruvella, Hyderabad (IN) 

11.30 - 11.50 T1G3 bladder cancer: What is the best choice for patients? 


11.50 - 12.10 Treatment of low risk bladder cancer 

M. Babjuk, Prague (CZ) 

12.10 - 12.30 Lymph node management in penile cancer 

O.W. Hakenberg, Rostock (DE) 

12.30 - 13.00 Case discussion in uro oncology 

J.N. Kulkarni, Mumbai (IN)




Iranian Urological Association (IUA) 

Room 352 A/B - Level 3 

Chairs: S.J. Hosseini, Tehran (IR) 

V. Mirone, Naples (IT) 


S.J. Hosseini, Tehran (IR) 


10.35 - 11.45 Session 1: Managing biochemical recurrence in prostate cancer 

10.35 - 10.50 Patient follow-up after curative intent 

S. Shakeri, Shiraz (IR) 

10.50 - 11.05 When and how to treat patients with biochemical failure 

H. Van Poppel, Leuven (BE) 


11.15 - 11.30 Interactive clinical case 1 

M.A. Zargar Shoshtari, Tehran (IR) 

11.30 - 11.45 Interactive clinical case 2 

B. Djavan, New York (US) 

11.45 - 12.20 Session 2: Urethral surgery 

11.45 - 12.05 What I should do in urethroplasty 

G. Barbagli, Arezzo (IT) 

12.05 - 12.20 What I should not do in urethroplasty 


12.20 - 13.00 Session 3: Infertility 

An update on the identification and management of male factors 

12.20 - 12.35 M.A. Sadighi Gilani, Tehran (IR) 

12.35 - 12.50 N. Sofikitis, Ioannina (GR) 



65 

Friday

Friday 





Confederaçion Americana de Urologica (CAU) 


Chairs: F.R. Cruz, Porto (PT) 

P. Palma, Campinas (BR) 

13.15 - 13.20 Welcome address 


P. Palma, Campinas (BR) 

13.20 - 13.40 New technologies in urology 

F.M.J. Debruyne, Arnhem (NL) 

13.40 - 14.00 Renal transplant: From cadaver to chain transplantation 

A. Breda, Barcelona (ES) 

14.00 - 14.20 Robotic surgery in urology: What is now and what is next 

A. Mottrie, Aalst (BE) 

14.20 - 14.50 Point counterpoint session 

Testosterone replacement in hypogonadic curative intention treated prostate cancer patients 

14.20 - 14.35 I. Moncada, Madrid (ES) 

14.35 - 14.50 S. Glina, Sao Paulo (BR) 

14.50 - 15.10 Endourology: Has it reached its limits for stones? 

F.P. Daels, Buenos Aires (AR) 

15.10 - 15.30 New perspectives in the management of OAB 


15.30 - 15.40 How and why to publish in European Urology 

A.R. Zlotta, Toronto (CA) 



P. Palma, Campinas (BR)




Japanese Urological Association (JUA) 


Chairs: C.R. Chapple, Sheffield (GB) 

H. Kakizaki, Asahikawa (JP) 

13.15 - 13.20 Opening remarks 

C.R. Chapple, Sheffield (GB) 

13.20 - 14.20 Session I: Urology update 

Moderators: C.R. Chapple, Sheffield (GB) 

H. Kakizaki, Asahikawa (JP) 

13.20 - 13.50 Male infertility 

13.20 - 13.35 H. Okada, Koshigaya (JP) 

13.35 - 13.50 W.H.G. Weidner, Giessen (DE) 

13.50 - 14.20 Acute obstructive pyelonephritis due to urolithiasis 

13.50 - 14.05 R. Hamasuna, Kitakyushu (JP) 

14.05 - 14.20 M. Marberger, Vienna (AT) 

14.20 - 15.00 Session II: Case discussion 

Moderators: N. Nonomura, Osaka (JP) 


14.20 - 14.40 Treatment approach to high risk prostate cancer and PSA recurrence after radical prostatectomy 

Panel: K. Nishimura, Osaka (JP) 


14.40 - 15.00 How to diagnose and treat high stage upper urothelial cancer 

Panel: T. Harabayashi, Sapporo (JP) 


15.00 - 15.40 Session III: State-of-the-art lectures 

Moderators: C.H. Bangma, Rotterdam (NL) 

Y. Homma, Tokyo (JP) 

15.00 - 15.20 Current status of kidney transplantation in Japan 

K. Tanabe, Tokyo (JP) 

15.20 - 15.40 Prostate cancer - State of the art based on the Rotterdam study 

C.H. Bangma, Rotterdam (NL) 



Y. Homma, Tokyo (JP) 


67 

Friday

Friday 





Indonesian Urological Association (IUAI) 


Chairs: M. Marberger, Vienna (AT) 

S. Sugandi, Bandung (ID) 




13.20 - 13.35 Is the indication for SWL of upper tract urolithiasis changing? 

N.P. Buchholz, London (GB) 

13.35 - 13.50 Ureteroscopy can solve all problems 


13.50 - 14.05 PCNL today: Messages from CROESS 

J.J.M.C.H. De La Rosette, Amsterdam (NL) 

14.05 - 14.20 Epidemiology of stone disease in Indonesia 

A.T. Sihombing, Bandung (ID) 

14.20 - 14.35 The role of infection in stone disease 

T. Djojodimedjo, Surabaya (ID) 

14.35 - 14.50 Problems in prevention of urinary stone disease 

B.B. Purnomo, Malang (ID) 

14.50 - 15.35 Panel discussion 

Moderators: M. Marberger, Vienna (AT) 


Panel: N.P. Buchholz, London (GB) 


T. Djojodimedjo, Surabaya (ID) 

B.B. Purnomo, Malang (ID) 

A.T. Sihombing, Bandung (ID) 

15.35 - 15.45 Summary and conclusion 


S. Sugandi, Bandung (ID)



13.15 - 15.45 EAU - International: Caucasus and Central Asia Session 


Chairs: P. Alken, Mannheim (DE) 

A. Muradyan, Yerevan (AM) 

A. Usupbaev, Bishkek (KG) 

13.15 -13.20 Introduction 

P. Alken, Mannheim (DE) 

13.20 -13.33 Latest urological Armenian news 

S. Yazichyan, Yerevan (AM) 

13.33 -13.46 Modern achievements of urology in Azerbaijan 

S. Javad-Zada, Baku (AZ) 

13.46 -13.59 One stage urethroplasty with vaginal flap in hermaphrodites 


13.59 -14.12 Treatment of the cystic kidney 

I. Nusratulloev, Dushanbe (TJ) 

14.12 -14.25 Upper urinary tract reconstruction (UPJ, ureteral replacement) 

Z. Tchanturaia, Tbilisi (GE) 

14.25 -14.38 Robotic pyeloplasty: Update 

F. Atug, Istanbul (TR) 

14.38 -14.51 Urolithiasis 

G. Managadze, Tbilisi (GE) 

14.51 -15.04 Distribution of urolithiasis in Tajikistan 

I. Korsakova, Dushanbe (TJ) 

15.04 -15.17 Stone disease in Uzbekistan: Epidemiology, diagnosis, current management options, prevention 

F. Akilov, Tashkent (UZ) 

15.17 -15.45 General debate and closing remarks 

P. Alken, Mannheim (DE) 

A. Kadioglu, Istanbul (TR) 




69 

Friday

Friday 


Invited guests from the represented countries: 

Armenia: 


S. Yazichyan, Yerevan (AM) 

Azerbaijan: 

I. Figarov, Baku (AZ) 

S. Javad-Zada, Baku (AZ) 

Georgia: 

G. Managadze, Tbilisi (GE) 

Z. Tchanturaia, Tbilisi (GE) 

N. Turmanidze, Tbilisi (GE) 

Kyrgyzstan: 

Z. Khakimkhodzhaev, Bishkek (KG) 


Tajikistan: 

S. Daler, Dushanbe (TJ) 

I. Korsakova, Dushanbe (TJ) 

I. Nusratulloev, Dushanbe (TJ) 

Turkey: 

F. Atug, Istanbul (TR) 

A. Kadioglu, Istanbul (TR) 

Uzbekistan: 

F. Akilov, Tashkent (UZ) 

A. Gaybullayev, Tashkent (UZ)




Maghreb Union Countries 

Room 351 - Level 3 

Chairs: C-C. Abbou, Creteil (FR) 

A. Joual, Casablanca (MA) 

13.15 - 13.20 Introduction Progress of urology in the Maghreb: What is expected in the near future 

C-C. Abbou, Creteil (FR) 


13.30 -14.40 Session 1: High risk prostate cancer 

Moderators: C-C. Abbou, Creteil (FR) 


13.30 -13.40 First experience of the single port in Morocco 

R. Rabii, Casablanca (MA) 

13.40 -14.00 Definition of high risk cancer 

S. Benjelloun, Casablanca (MA) 


14.00 -14.15 Surgery 

B. Guillonneau, Paris (FR) 

K. Touijer, New York (US) 

14.15 -14.25 Radiotherapy 

R. Valdagni, Milan (IT) 

14.25 -14.40 Discussion 

14.40 -15.40 Session 2: Panel case discussion 

Panel: C-C. Abbou, Creteil (FR) 

K. Atallah, Tunis (TN) 


K. Hachi, Alger (DZ) 



14.40 -15.00 Kidney cancer 

R. Rabii, Casablanca (MA) 

15.00 -15.20 Bladder tumours 

K. Atallah, Tunis (TN) 

15.20 -15.40 Prostate cancer 

K. Hachi, Alger (DZ) 

15.40 -15.45 Closing remarks 




71 

Friday

Friday 





Pan-African Urological Surgeons’ Association (PAUSA) 


Chairs: M. Eissa, Cairo (EG) 

M. Grabe, Malmö (SE) 

E. Oluwabunmi Olapade-Olaopa, Ibadan (NG) 


M. Eissa, Cairo (EG) 


13.20 - 14.05 Male genital cancer 

13.20 - 13.35 Modern view on the management of advanced prostate cancer 

G.M. Ahlgren, Malmö (SE) 

13.35 - 13.50 Prostate cancer in Africa - controversies in diagnosis and management 

S. Mutambirwa, Pretoria (ZA) 

13.50 - 14.05 Circumcision, HIV and penis cancer 

J. Krieger, Seattle (US) 

14.05 - 14.35 Urothelial cancer 

14.05 - 14.20 Non-muscle invasive bladder cancer (NMIBC), the Egyptian experience 

B. Ali-El-Dein, Mansoura (EG) 

14.20 - 14.35 Intravesical treatment of bladder cancer 


14.35 - 15.20 Reconstructive surgery 

14.35 - 14.50 Vesico-vaginal fistula (VVF): Epidemiology and size of the problem 

S.M. Gueye, Dakar (SN) 

14.50 - 15.05 Surgical approach to VVF 

M.C. Bishop, Nottingham (GB) 

15.05 - 15.20 VVF preventive programme in Rwanda 

E. Rwamasirabo, Kigali (RW) 

15.20 - 15.35 Cooperation EAU-PAUSA 

15.20 - 15.35 HORIZONS, a cooperation project 

J.M.O. N’Dow, Aberdeen (GB) 

15.35 - 15.45 Discussion and conclusion 

M. Eissa, Cairo (EG) 

M. Grabe, Malmö (SE)


18.00 - 19.30 EAU Opening Ceremony 

eURO Auditorium - Level 1 

Opening Show - Part I 

Opening addresses 

P-A. Abrahamsson, Malmö (SE), EAU Secretary General 

C-C. Abbou, Paris (FR), EAU Congress President 

Announcement of the new EAU Honorary Members 

Citation by P-A. Abrahamsson, Malmö (SE) 

New Honorary Members: L. Boccon-Gibod, Paris (FR) 

K.G.W. Mansson, Lund (SE) 

A. Mendoza-Valdes, Mexico City (MX) 

Presentation of the EAU Willy Gregoir Medal 2012 


Presented to: M. Marberger, Vienna (AT) 

The EAU is proud to present the Willy Gregoir Medal to an important senior urologist who contributed in an 

extraordinary way to the development of urology in Europe. 

Presentation of the EAU Frans Debruyne Life Time Achievement Award 2012 


Presented to: R.E. Hautmann, Neu-Ulm (DE) 

The EAU wishes both to honour and acknowledge the important and longstanding contribution by a 

distinguished colleague to the activities and development of the EAU 

Presentation of the EAU Crystal Matula Award 2012 


Presented to: P.J. Bastian, Munich (DE) 

This prestigious prize is granted to a promising younger urological academician 

Supported by an unrestricted educational grant from LABORIE 

Presentation of the EAU Hans Marberger Award 2012 


Presented to: A. Alcaraz, Barcelona (ES) 

The Hans Marberger Award is awarded for the best European paper published in 2011 on minimally 

invasive surgery in urology 

Supported by an unrestricted educational grant from KARL STORZ GMBH & CO.KG 

Presentation of the EAU Innovators in Urology Award 2012 


Presented to: J.E.A. Wickham, Westcott (UK) 

The Innovators in Urology Award is to acknowledge and highlight inventions and clinical contributions 

which have had a major impact on influencing the treatment and/or diagnosis of an urological disease 

Opening Show - Part II 

19.30 - 21.00 EAU Welcome Cocktail 

Hall Ternes – Level 1 


73 

Friday

Friday 



Workshop Overview 

16.00 - 17.30 Cryo - a true minimally invasive treatment: Current evidence and future development page 380 

Room 341 - Level 3 Sponsored by GALIL MEDICAL 

Symposia Overview 

16.00 - 17.30 Guiding lights and rising stars: Present and future directions in RCC and CRPC page 379 

Room Concorde Neuilly - Level 4 Sponsored by BAYER HEALTHCARE 

16.00 - 17.30 5mm HD and 3D - What does the future hold in MIS? page 381 

Room Bordeaux - Level 3 Sponsored by OLYMPUS

Saturday, 25 February - EAU Programme 


07.30 - 08.30 EAU General Assembly 

This session is only accessible for EAU Members. Only Active and Honorary EAU Members are entitled to 

vote during the EAU General Assembly. 


Welcome by the EAU Secretary General 

Approval minutes General Assembly of 19 March 2011, Vienna, Austria 

General report by the EAU Secretary General 

P-A. Abrahamsson, Malmö (SE) 

Report by the EAU Treasurer 


Specific reports on the EAU Offices by the EAU Executive 

Approval of the election of EAU Adjunct Secretary General Education 


Approval of the re-election of EAU Treasurer 


Approval of the new EAU Office chairmen for: 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

Report by the Secretary General on the EAU Membership Office 

�� 

�� 

Other business 

Future Congresses 

�� 


75 

Saturday

Saturday 




08.30 - 10.15 Urothelial cancer 


Chairs: J.W.F. Catto, Sheffield (GB) 


08.30 - 08.35 Introduction Urothelial cancer 


08.35 - 08.45 Update Chemo-radiotherapy in muscle invasive bladder cancer 

�� 

Aims and objectives 

�� 

muscle invasive bladder cancer. 

�� 

�� 

�� 

radiotherapy as an alternative, particularly in less fit or elderly patients. There is a misconception that 

�� 

�� 

�� 

outcomes such as recurrence, salvage cystectomy rates and overall survival. 

08.45 - 08.55 Update Outcomes of cystectomy: Contemporary results 

�� 


�� 

�� 

�� 

�� 

�� 

neobladder in male and female patients and the advantages and disadvantages of using robot-assisted 

laparoscopy. 

08.55 - 09.45 Case discussion Finding the optimal treatment for muscle invasive bladder cancer 

Moderator:� �� 

Panel:� �� 

� � �� 

� � �� 

� � �� 


�� 

��

09.45 - 10.15 EAU Guidelines Office The urothelial cancer pathway: A patient’s journey according to the EAU Guidelines 

�� 

�� 


�� 

non-muscle invasive and muscle-invasive bladder cancer. 


77 






08.30 - 10.00 BPH: Basic research 



Chairs: R.S. Pickard, Newcastle upon Tyne (GB) 

R.W.G. Watson, Dublin (IE) 

�� 

�� 

by 2 minutes for discussion. 

* 1 The cAMP effector EPAC activates the transcription factor Elk1 in prostate smooth muscle and is a minor 

regulator of α1-adrenergic prostate contraction 

M. Hennenberg�� 

(Munich, Germany) 

2 Differential distribution of stromal and glandular proteoglycans in benign prostatic hyperplasia and in the 

transition zone of normal prostates 

�� 

�� 

3 The JNK inhibitors SP600125 and BI-78D3 inhibit the alpha1-adrenergic contraction of human prostate 

tissue 

�� 

�� 

America) 

4 Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study 

in rabbit 

��M. Gacci�� 

�� 

5 Silodosin and tadalafil have additive inhibitory effects on nerve-mediated contractions of human and rat 

isolated prostates 

�� 

6 Single nucleotide polymorphisms in genes regulating steroid hormones metabolism are independently 

associated with increased prostate volume in men with prostate cancer 

�� 

�� 

7 Alpha1-adrenoceptors in the human prostate activate the transcription factors Elk1 and SRF 

M. Hennenberg�� 

�� 

America) 

8 Protein kinase B/Akt is activated by alpha1-adrenoceptors in the human prostate, but dispensable for 

regulation of smooth muscle tone 

�� 

Germany)

9 Increased urine NGF associated with LUTS and the serum NOx deficiency in men with BPH 

�� 

�� 

10 Metabolomics profiles of prostatic secretions from patients treated by Pygeum Africanum for low urinary 

tract symptoms related to benign prostatic hyperplasia 

�� 

11 Marked alterations of gene transcription in the stroma and the epithelium of human benign prostatic 

hyperplasia 

�� 

12 Molecular markers of bladder wall remodeling in LUTS/BPH patients undergoing surgery 

��D. Mitropoulos (Athens, Greece) 


79 






08.30 - 10.00 Focal therapy: What is new and improved 



Chairs: A.R. Azzouzi, Angers (FR) 

M. Emberton, London (GB) 

�� 

�� 


* 13 Candidate selection for hemiablative focal therapy of prostate cancer through a combination of extended 

14-core biopsy and MRI 

�� 

�� 

14 Can prostatic MRI help us to choose focal therapy for prostate cancer? 

�� 

�� 

15 MR-Guided laser focal therapy for low-intermediate risk localized prostate cancer 

U. Lindner�� 

�� 

16 MR (magnetic resonance) guided focused ultrasound in locally non-advanced prostate cancer 

�� 

17 Morbidity of focal therapy in the treatment of localized prostate cancer 

E. Barret�� 

�� 

* 18 8-year experience with focal cryotherapy in 75 men with unilateral low-intermediate risk prostate cancer 

�� 

19 Erectile dysfunction after low dose-rate prostate brachytherapy – a chronological process? 

�� 

20 Evolution of the pathological outcomes after radical prostatectomy with increasing use of active 

surveillance in the UK: Implication for focal therapy 

�� 

* 21 Salvage and primary 17G cryosurgery for prostate cancer – 10 year European experience 

�� 

�� 

* 22 Patterns of prostate cancer on template prostate mapping biopsies in 291 men: Implications for focal 

therapy 

H.U. Ahmed�� 

United Kingdom)

23 Long-term biochemical results of patients with prostate cancer treated by high-intensity focused 

ultrasound 

�� 

Korea) 

24 MR-directed selective HIFU therapy of prostate cancer using a TRUS guidance platform 

�� 

Kingdom) 


81 






08.30 - 10.00 Robotic partial nephrectomy 



Chairs: P. Fornara, Halle (DE) 


�� 

�� 


25 Proposal of an efficiency index to define learning curve of robotic partial nephrectomy 

�� 

America) 

26 Retroperitoneal versus transperitoneal robot-assisted partial nephrectomy for posterior renal tumors: 

A matched pair analysis 

�� (Aalst, Belgium; 

�� 

27 Robot-assisted laparoscopic partial nephrectomy: Outcome of initial cases in a medium-size center 

�� 

28 Multi-center intermediate-term oncologic outcomes of robot-assisted partial nephrectomy for pT1 renal 

cell carcinoma 

�� 

S.B. Bhayani�� 

29 Trifecta (safety, oncological and functional outcomes) in robot-assisted partial nephrectomy: A single high 

volume institution experience 

G. Lista�� 

�� 

30 Robot assisted laparoscopic partial nephrectomy: Cumulative single institution experience with over 300 

cases 

�� 

�� 

31 Robot-assisted partial nephrectomy in very complex cases: Multi-institutional experience 

�� 

�� 

32 Comparison of robot-assisted partial nephrectomy and open partial nephrectomy: Clinical outcome and 

complication analysis 

K.T. Kim�� 

33 Comparison of robotic and open partial nephrectomy: Single-surgeon matched cohort study of 108 patients 

�� 

34 Comparison of perioperative outcomes of transperitoneal versus retroperitoneal robot assisted partial 

nephrectomy - a matched pair analysis by nephrometry 

S.Y. Lee�� 

��

* 35 Predictors of warm ischemia time and perioperative complications in a multicenter, international series of 

robot-assisted partial nephrectomy 

�� 

�� 


83 






08.30 - 10.00 Prostate biopsy, prostatitis and epididymitis 

Room 251 - Level 2 


Chairs: A. Ali, Newcastle upon Tyne (GB) 

F.M.E. Wagenlehner, Giessen (DE) 

�� 

�� 


36 A prospective study of the rectal flora of a cohort undergoing trans-rectal ultrasound guided (TRUS) 

prostate biopsy to assess the incidence of colonization with antimicrobial resistant (AMR) enterobacteriace 

to inform decision making for antibiotic prophylaxis 

�� 

�� 

* 37 Infective complications after prostate biopsy: Outcome of the Global Prevalence of Infections in Urology 

(GPIU) prostate biopsy side study 2010 – a multinational, multicenter study 

�� 

�� 

�� 

38 In the era of emerging fluoroquinolone resistant enterobacteria, shall we modify our antibiotic prophylaxis 

for transrectal ultrasound-guided prostate biopsies? 

�� 

�� 

39 Fluoroquinolone-resistant ST131 E. coli identified in men prior to transrectal prostate biopsy 

M.A. Liss�� 

United States of America) 

40 Determination of doripenem penetration into human prostate tissue 

�� 

�� 

* 41 The protective antimicrobial effect of raised prostate specific antigen levels during male urinary tract 

infection 

�� 

Kingdom) 

42 Acute bacterial prostatitis: How to prevent and manage chronic infection? 

�� 

43 Clinical course of acute prostatitis caused by urologic procedure: Comparison with spontaneous acute 

prostatitis 

D.H. Kim�� 

44 Prevalence of erectile and ejaculatory dysfunction in men with chronic prostatitis/chronic pelvic pain 

syndrome 

V. Magri, A. Trinchieri��

45 Comparative, single-centre, randomized, placebo-controlled study of efficacy and safety of flupirtine and 

celecoxib in CPPS/CP IIIB 

�� 

46 Empiric antibiotic therapy in acute epididymitis: Are guideline recommendations adequate? 

�� 

47 Review of epididymoorchitis management in 3 UK centres: Are we still not doing enough? 

�� 

�� 


85 






08.30 - 10.00 Male infertility 

Room 252 A/B - Level 2 


Chairs: S. Minhas, London (GB) 

W.H.G. Weidner, Giessen (DE) 

�� 

�� 

48 ApoE-/- LDL receptor -/- double knockout mouse as a novel model for studying of the atherosclerosis 

mediated infertility in men 

�� 

P. Stieger, M. Bergmann, W. Weidner (Giessen, Germany) 

49 A novel bovine model for studies on sperm epigenome and its contribution to early embryo development 

U. Schagdarsurengin�� 

Munich, Germany) 

50 The relevance of acetylated histone H4 at lysine 12 (H4K12ac) for RNA transcripts in human spermatozoa, 

mouse pronucleus formation and parthenogenetic activation of murine oocytes 

�� 

�� 

�� 

51 Expression pattern of testicular claudin-11 in infertile men 

�� 

52 Young age in Klinefelter-patients increases chances for successful testicular sperm extraction: Predictive 

factors for a positive spermatozoal yield 

�� 

53 Fertility in men with acquired undescended testis, where spontaneous testicular descent was awaited 

until puberty: Spontaneous descend versus orchiopexy 

�� 

�� 

54 The effect of prednisone on spermatogenesis, apoptosis, and Sertoli cell of contralateral testis after 

unilateral testicular torsion 

�� 

55 Counting sperms at home - comparison of two novel at-home sperm analyzers on their mechanisms and 

performance 

�� 

56 Expression of E-cadherin and α-catenin in a varicocele-induced infertility rat model 

�� 

57 Characterization of semen of nonobstructive azoospermia men after varicocele repair: Predictors of sperm 

recovery and azoospermia relapse 

T. Abdel-Meguid��

58 Effect of varicocelectomy on fertility measured by sperm functional tests, nuclear maturation and 

acrosome reaction 

L. Paras�� 

59 Significant improving of sperm DNA quality after microsurgical repair of varicocele 

K. Matsushita�� 

60 Percutaneous retrograde sclero-therapy in the treatment of varicocele: Effectiveness and safety of the 

procedure 

�� 

61 Is it necessary to detect HPV in ejaculate in infertile men? 

�� 


87 






08.30 - 10.00 Improving our surgical environment: Simulation and safety 



Chairs: T. Hanus, Prague (CZ) 

M.P. Laguna, Amsterdam (NL) 

�� 

�� 


* 62 Elaborating a learning program on laparoscopy: Assessment of the evolution of the novices’ performance 

according to initial training with simulator or animal model 

�� 

63 Introducing The Productive Operating Theatre (TPOT) programme in urology theatre suites 

K. Ahmed�� 

United Kingdom) 

64 Delays, pitfalls and shortcomings in endourology theatre time utilisation 

S. Kachrilas�� 

Athens, Greece) 

65 Establishing the minimal number of simulator training sessions necessary to develop basic laparoscopic 

skills competence: Evaluation of the learning curve 

�� 

66 Short-phase training on a robotic virtual reality simulator (Mimic dV Trainer) 

S.G. Kang�� 

67 Crisis simulations for robotic procedures: Development of a training module and initial results 

�� 

�� 

68 Implementation of a quality improvement programme in a urology cancer multidisciplinary team 

B.W. Lamb�� 

69 The Freiburg index of patient satisfaction (FIPS): Proposal for a new questionnaire 

M. Schoenthaler�� 

70 Delirium in elderly patients hospitalized and undergoing urologic surgery. Incidence and predictive role of 

Multidimensional Geriatric Evaluation (MGE) to define a high-risk population and prevent complications: 

Results of a prospective study 

M. Brausi�� 

71 Single site laparoscopic urologic surgery: An expanding experience for 108 cases 

�� 

Patras, Greece) 

72 Applicability of the reusable X-Cone single port laparoscopy system for pelvic lymphadenectomy and other 

basic urologic procedures 

�� 

(Berlin, Germany)

73 Laparoscopic 3D solo-surgery: First clinical application of a robotic-controlled stereoscopic high definition 

optical system (EinsteinVision) 

�� 

Sindelfingen, Germany) 


89 






08.30 - 10.00 Renal tumours: Medical therapy 



Chairs: T.M. De Reijke, Amsterdam (NL) 

G. Kramer, Vienna (AT) 

�� 

�� 


74 The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being 

treated for subependymal giant cell astrocytoma 

�� 

�� 

�� 

�� 

75 STAT3 polymorphism can predict clinical benefits of interferon-α in patients with metastatic renal cell 

carcinoma 

M. Eto�� 

�� 

�� 

76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal 


�� 

�� 

77 Newly onset hyperparathyroidism during sunitinib administration in mRCC patients 

A. Lapini�� 

78 Primary tumor downsizing in renal cell carcinoma is more prominent in smaller tumors and may enable 

nephron sparing strategies 

B.K. Kroon�� 

79 How to further solidify data on systemic therapy in metastatic renal cell carcinoma (mRCC) – the German 

mRCC registry on the treatment reality 

�� 

�� 

* 80 Everolimus in the treatment of angiomyolipoma in patients with tuberous sclerosis complex or sporadic 

lymphangioleiomyomatosis: Results from EXIST-2 

K. Budde�� 

�� 

�� 

�� 

��

* 81 Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal 

cell carcinoma (mRCC) 

B. Escudier�� 

�� 

London, United Kingdom) 

* 82 Influence of angiotensin system inhibitors and HMG-CoA reductase inhibitors on outcome of targeted 

therapy in patients with metastatic renal cell carcinoma 

�� 

* 83 International, expanded-access programme of everolimus in patients with metastatic renal cell carcinoma 

who progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: 

Sub-analysis of European patients 

S. Bracarda�� 

�� 

�� 

America) 


91 






08.30 - 10.00 Surgery for RCC: Cytoreduction, metastases, vena cava, LESS, nodes 

Room Maillot - Level 2 


Chairs: P.A. Geavlete, Bucharest (RO) 


�� 

�� 


84 A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma 

M. Bianchi�� 

Germany) 

85 Patient-reported health-related quality of life outcomes following cytoreductive nephrectomy 

��, S.B. Kim, A.A. Wagner (Boston, United States of America) 

86 Teaching status and hospital volume effectively determine blood transfusion rates and total hospital 

charges after cytoreductive nephrectomy 

�� 

87 The effect of nodal coding schemes on cancer-specific mortality after cytoreductive nephrectomy 

�� 

88 Surgical management of renal cell carcinoma (RCC) with venous invasion 

��V.B. Matveev�� 

89 Long term outcomes following resection and grafting of the inferior vena cava for advanced renal cancer 

A. Patel�� 

90 Impact of renal function immediately after radical nephrectomy on cardiovascular events in patients with 

kidney cancer 

�� 

�� 

91 Obesity and morbid obesity are associated with a greater conversion rate to open surgery for standard but 

not hand assisted laparoscopic radical nephrectomy 

H. Gabr, �� 

America) 

92 Gasless laparoendoscopic single-port retroperitoneal radical nephrectomy for renal tumors in dialysis 

patients: Perioperative outcomes of 81 consecutive cases 

K. Kihara, H. Masuda�� 

�� 

93 Evaluating clinical outcomes and systemic stress response in laparoendoscopic single-site versus 

conventional multi-port laparoscopic radical nephrectomy in patients with renal cell carcinoma 

��

94 Risk factors for conversions and postoperative complications in urologic laparoendoscopic single-site 

surgery (LESS): Worldwide multi-institutional analysis of 1163 cases 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

* 95 Staging lymphadenectomy in renal cell carcinoma must be extended: A sensitivity curve analyses 

�� 

�� 

* 96 Survival impact, clinical prognostic factors and safety of metastasectomy for treatment of advanced renal 


L. Tosco�� 


93 






08.30 - 10.00 Stones: Risk factors, new treatment options and training 

Room Passy - Level 1 


Chairs: T. Bach, Hamburg (DE) 

P.J. Osther, Fredericia (DK) 

�� 

�� 


* 97 A comparative study of risk factors for stone formation, stone characteristics and management in morbidly 

obese and non-obese patients 

S.V. Sellaturay�� 

98 Is flexible ureteroscopy effective for renal stones in overweight and obese patients? 

G. Atis�� 

99 Osteopenia/osteoporosis in patients with calcium nephrolithiasis 

��, 

�� 

100 In vitro comparison of the novel spear headed pneumatic intracorporeal lithotriptor with Holmium YAG 

laser 

�� 

101 Contact electric pulse impact on urinary tract wall in dogs: 1-year experimental morphological study 

�� 

102 Raman spectroscopy: In-vitro analysis of urinary stone composition at different excitation wavelengths 

�� 

103 Acceleration of competency in renal access skills by using Virtual Reality Perc-Mentor Trainer 

�� 

104 Sponge trainer: A novel simple training model for percutaneous renal access 

��A.M. El-Bahnasy�� 

105 Training of upper urinary tract endoscopy - experience with a new model using porcine urinary tract 

�� 

106 Efficacy of tamsulosin 0.2mg/day in relieving double-J stent-related symptoms: A randomized controlled 

study 

�� 

107 Silodosin effectively reduces pressure of the obstructed rat ureter in vivo with limited effects on systemic 

blood pressure 

L. Villa��

Saturday, 25 February - EAU Section Meetings 

Meeting of the EAU Section of Uro-Technology 

(ESUT) in cooperation with ERUS, EULIS and ESIU 

10.15 - 17.15 Navigated video-assisted surgery and beyond 


10.15 - 17.15 Live broadcasts from the Department of Urology, University of Paris-Creteil (FR), Department of Urology, 

University of Mannheim (DE), Department of Urology, Aalst (BE) 

10.15 - 10.45 Prologue 

Coordinators in Creteil: 

�� 

�� 

Coordinators in eURO Auditorium: 

�� 

�� 

Moderators:� �� 

� � �� 

� � �� 

� � �� 

�� ESUT-Fellow 2010-2011 

G. Pini, Heilbronn (DE) 

�� Outcome of last year’s live surgery 

�� 

�� The history of laparoscopic and robotic radical prostatectomy 

�� 

�� VTP for focal ablation of localised prostate cancer (video) 


10.45 - 13.15 Live surgery: Use of fluorescence and 3D during endoscopic surgery 

Pelvic lymph node dissection with indocyanine green 

�� 

Laparoscopic radical prostatectomy - The Montsouris Technique 2012 

�� 

Robot-assisted laparoscopic radical prostatectomy 2012 

�� 

NBI-assisted URS 

�� 

3D-CT-assisted PCNL 

M.S. Michel, Mannheim (DE) 

ETHOS-chair for 3D-assisted laparoscopic radical prostatectomy with PDD 

�� 


95 



13.15 - 15.15 Live surgery: Navigation and more - Part 1 



� � �� 

� � �� 

� � �� 

3D-assisted laparoscopic pyeloplasty 

�� 

NOTES-nephrectomy 

�� 

�� 

Robot-assisted partial nephrectomy with indocyanine green 


Combined supine PCNL and flexible URS 

�� 

�� 

NBI HD cystoscopy 

�� 

PDD-assisted vaporesection of bladder tumour 

�� 

Green-light laser XPS 

�� 

15.15 - 17.15 Live surgery: Navigation and more - Part 2 


T. Knoll, Sindelfingen (DE) 

� � �� 

� � �� 

� � �� 

Hybrid - LESS - Nephrectomy 


�� 

LESS-nephrectomy 

�� 

LESS-robotic pyeloplasty 

�� 

�� 

PDD-cystectomy 

�� 

Thulium laser for BPH - Vela XL and new morcellator 


P. Krombach, Mannheim (DE) 


�� 

��

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

split screen technology. 

�� 

�� 

�� 

�� 

�� 

available online 

�� 

�� 

�� 


97 





Meeting of the EAU Section of Female and 

Functional Urology (ESFFU) 

10.15 - 14.00 From international recommendations to clinical practice 


Chair: J.P.F.A. Heesakkers, Nijmegen (NL) 


�� 

10.20 - 12.25 Reports of the Committees of the ICUD-EAU International Consultation on Incontinence (5th ICI) 

�� Committee 6: Dynamic testing 

�� 

�� Committee 8: Pharmacology 

K-E. Andersson, Lund (SE) 

�� Committee 10: Neurogenic patients 

�� 

�� Committee 13: Surgery in men 

�� 

�� Committee 14: Surgery in women 

�� 

12.25 - 12.30 Break 

12.30 - 14.00 EAU Section of Female and Functional Urology (ESFFU) 

�� Sexual funcation and pelvic floor surgery 

�� 

�� Cases: Troubleshooting in SIU surgery and complications: Tape exposure, voiding dysfunction, de novo OAB, 

pain, sexual dysfunction 



� � �� 

� � �� 

� � �� 


�� 

�� 

�� 

discussed. A lively debate on the latest state of the art on these topics is anticipated. Thereafter a hot topic on 

�� 

��


Meeting of the EAU Section of Andrological 

Urology (ESAU) and the EAU Section of 

Urological Imaging (ESUI) 

10.15 - 14.00 Imaging in andrology 


Chairs: V. Mirone, Naples (IT) 

J. Walz, Marseille (FR) 


�� 

�� 

10.20 - 11.10 Male infertility, varicocele and testis 


� � �� 

�� The role of imaging in the exploration of male infertility 

�� 

�� The role of imaging in the exploration and therapy of varicoceles 

�� 

�� How to manage imaging findings in the treatment of male infertility? 

�� 

�� Which imaging study for testicular exploration? Cryptorchidism, orchitis, cysts, testalgia 

�� 

�� How to manage imaging findings in the diagnosis and treatment of epididymal pathologies? Obstructive 

azoospermia, cysts, epididymitis 

�� 

11.10 - 11.40 Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS), vesiculitis 


� � �� 

�� The role of imaging in the exploration and treatment of hematospermia/seminal vesicle infection? 

�� 

�� The role of imaging in the exploration of prostatitis and Chronic Pelvic Pain Syndrome (CP/CPPS) 

�� 

�� How to manage imaging findings in the diagnosis and treatment of prostatitis, vesiculitis and CP/CPPS? 


11.40 - 12.50 Penile pathologies 


� � �� 


99 



11.40 - 12.00 Erectile dysfunction 

�� The role of imaging in the exploration of erectile dysfunction 

�� 

�� How to manage imaging findings in the treatment of erectile dysfunction? 

�� 

12.00 - 12.20 Peyronie’s disease 

�� The role of imaging in the exploration of Peyronie’s disease 

A. Hauptmann, Giessen (DE) 

�� How to manage imaging findings in the treatment of Peyronie’s disease 

�� 

12.20 - 12.40 Priapism 

�� The role of imaging in the exploration of priapism 

�� 

�� How to manage imaging in priapism? 

�� 

12.40 - 13.10 EAU Section of Urological Imaging 



� � �� 

�� ESUI Vision Award 2012 

�� 

What is new in imaging in 2012? Kidney, prostate, bladder, lymph nodes, testis and penis 

�� 

�� 

13.10 - 13.40 EAU Section of Andrological Urology: What is new in andrology in 2012? 



�� Infertilify 

�� 

�� Sexual dysfunction 

E. Wespes, Brussels (BE) 

�� Hypogonadism 

�� 

13.40 - 14.00 Summary and close 

�� 

�� 


�� 

of imaging studies in the management of several andrological pathologies are addressed, such as infertility, 

�� 

��

�� 

these imaging studies are addressed based on the state of the art management of the different andrological 

pathologies. 

�� 

�� 

�� 

�� 


101 





Meeting of the EAU Section of Infections in 

Urology (ESIU) 

10.15 - 14.00 Core issues at all times in all fields of urology 

10.15 - 11.10 The male foreskin 


Chair: T.E. Bjerklund Johansen, Århus (DK) 

Moderators: M. Grabe, Malmö (SE) 

� � �� 

�� The male foreskin - historical, religious and medical aspects 

�� 

�� The role of circumcision in preventing HIV/Aids in today’s Africa 

�� 

�� HPV in the male foreskin and the role of circumcision in developed countries 

�� 

�� Panel discussion 

11.10 - 12.00 Male fertility and infection 


� � �� 

�� New understanding of host protective mechanisms in the prostate 

�� 

�� New insights into microbial involvement in Chronic Prostatitis/Chronic Pelvic Pain Syndrome 

�� 

�� Phytotherapy, a new treatment option in chronic pelvic pain syndrome 

�� 

�� Questions and comments 

12.00 - 12.50 Urologists’ best friend and worst enemy: Catheters 


� � �� 

�� Evidence based interventions to reduce CAUTI during short term catheterisation 

�� 

�� The measures we’ve taken to reduce deaths from CAUTI in the UK 

�� 

�� Surface matters, micropatterned catheters reduce migration of E Coli 

T.b.c.


12.50 - 13.55 Bladder cancer and infections 


� � �� 

�� New insight into HPV in urothelial carcinoma and the role of vaccination 

�� 

�� Benefits and complications of BCG-treatment of urothelial carcinoma 

�� 

�� Prevalence and prevention of infections in open cystectomy, conduits and neobladders 

�� 

�� Size matters, minilaparotomy reduces postoperative complications after cystectomy 

�� 


13.55 - 14.00 Close 

�� 


�� 

�� 

�� 

opinion leaders 

�� 

�� 

�� 

�� 

�� 


103 





Meeting of the EAU Section of Genitourinary 

Reconstructive Surgeons (ESGURS) 

10.15 - 14.00 Urethral reconstruction and re-do surgery in reconstructive urology 


Chair: S.D. Deger, Ostfildern (DE) 

10.15 - 11.05 Part 1: Debate: Non-transecting versus transecting urethroplasty 


�� A retrospective analysis of non-transecting versus transecting urethroplasty 

�� 

�� A new technique for non-transecting urethroplasty 

D.E. Andrich, London (GB) 

�� Sexual complications following urethroplasty 

�� 

�� Debate/case demonstration 

D.E. Andrich, London (GB) 

�� 

�� 

11.05 - 11.30 Part 2 


� � �� 

�� Re-do urethroplasty 

�� 

�� Re-do ureteral stricture 

�� 

11.30 - 12.15 Part 3 


�� Re-do penile prosthesis 

�� 

�� Re-do artificial sphincter 

�� 

�� Has laparoscopy a place in re-do cases? 

S.D. Deger, Ostfildern (DE) 

12.15 - 13.45 Part 4 


� � ��

�� Re-do surgery after enhancement phalloplasties 

�� 

�� Re-do in urinary diversion 

K.G.W. Månsson, Lund (SE) 

�� Tissue engineering, how far are we? 

�� 

�� Two needles tubulovasostomy in obstructive azoospermia 

�� 

13.45 - 14.00 ESGURS activities 2012-2013 

S.D. Deger, Ostfildern (DE) 


�� 

�� 

reconstruction. 


105 





Meeting of the EAU Section of Transplantation 


10.15 - 14.00 Standardised and individualised approaches in renal transplantation - 

aiming for the optimum 


Chairs: A.J. Figueiredo, Coimbra (PT) 

M. Giessing, Düsseldorf (DE) 

10.15 - 10.25 Introduction 

�� 

�� 

10.25 - 11.25 Past and present in renal transplantation 


� � �� 

�� René Küss - a transplant pioneer in Paris 

D. Schultheiss, Giessen (DE) 

�� New perspectives in immunosuppression 

K. Budde, Berlin (DE) 

�� The new EAU Guidelines on renal transplantation - what’s really new? 

�� 

�� Paediatric KTX: Techniques - immunology - psychology 

�� 

�� 

11.25 - 12.10 Increasing the donor and recipient pool 


� � �� 

�� Expanded criteria in living donors (inc. nephrolithiasis) 

�� 

�� 

�� Dual renal transplantation 

�� 

�� 

�� HIV in renal transplantation 

�� 

�� 

12.10 - 12.55 Optimising transplantation outcome: Medical and technical innovations 


E. Lledo-Garcia, Madrid (ES) 

�� Strategies to reduce ischemia-reperfusion injury (including hypothermic renal perfusion for preservation) 

E. Lledo-Garcia, Madrid (ES)

�� Minimal invasive living donor kidney retrieval - techniques, risks and benefits 


�� Minimal invasive ‘repair’ after KTX: UCN, partial nephrectomy, LC, native nephrectomy 

�� 

12.55 - 13.55 Round table discussion: Eligibility of difficult cases for transplantation 


� � �� 

� � �� 

� � �� 

�� Small renal masses in donors 

�� 

�� Borderline function and small kidneys 

�� 

�� Increased age/age difference 

P. Dinis Oliveira, Porto (PT) 

�� Complex vascular situation 

�� 

13.55 - 14.00 Conclusion 

�� 

�� 


�� 

�� 

�� 

�� 

�� 

�� 

�� 

inconsistent or contradictory recommendations on specific donor and recipient conditions and as individual 

�� 

�� 

�� 

�� 

�� 

�� 

be recruited in the future. 


107 





Joint Meeting of the European Organisation 

for Research and Treatment of Cancer Genito- 

Urinary Group (EORTC-GU Group), the EAU 

Section of Urological Research (ESUR), the EAU 

Section of Oncological Urology (ESOU) and the 

EAU Section of Uropathology (ESUP) 

10.00 - 14.00 Current issues in prostate, renal and bladder cancer 

Room Bleu - Level 2 

10.00 - 11.55 EORTC-GU Group and ESUR: From basic science to clinical implementation in 

urological cancers 

Chairs: �� 

� � �� 


�� 

10.05 - 10.25 Future therapy in prostate cancer using siltuximab, an IL-6 antibody 

�� 

10.25 - 10.45 Biomarkers in renal cell carcinoma - an update 

�� 

10.45 - 11.05 Combination therapy for high risk and metastatic renal cell carcinoma 

�� 

11.05 - 11.25 Biomarker profiling in urothelial cancer 

�� 

11.25 - 11.45 Current status of neo-adjuvant and adjuvant chemotherapy in muscle invasive bladder cancer 

�� 

11.45 - 11.55 Close 

�� 

11.55 - 14.00 ESOU and ESUP 

�� 

� � �� 

11.55 - 12.10 Grading in uropathology 

�� 

12.10 - 13.00 Radical prostatectomy vs radiotherapy for clinically localised PCa: Long term results and late complications 

�� Radical prostatectomy 


�� Radiotherapy 

T. Wiegel, Ulm (DE)

�� Radical prostatectomy: Late complications 

�� 

�� Radiotherapy: Late complications 


13.00 - 13.15 Immunotherapy in PCa: New developments 

�� 

13.15 - 13.45 Immediate radical cystectomy for high grade T1 TCC of the bladder 

�� Pro 

�� 

�� Con 

�� 

13.45 - 13.55 Is ischemia time so crucial in nephron sparing surgery? New data 

�� 

13.55 - 14.00 Close 

�� 

�� 

The International Urological Oncology Award will be handed out during this session 


�� 

�� 

focused areas of uro-oncology and translational science and to bring together the concepts of translational 

�� 

�� 

sub-stratified in order to predict prognosis more effectively and to target treatment more appropriately. 

�� 

�� 

and renal tumours. 

�� 

�� 

�� 

�� 

bladder tumours. 

�� 

�� 

�� 


109 





Meeting of the EAU Section of Urolithiasis (EULIS) 

10.15 - 14.00 Urolithiasis - new insights in pathophysiology - challenges in 

education - trends in treatment 


Chair: P.J. Osther, Fredericia (DK) 


�� 

10.20 - 11.20 New insights in pathophysiology 


� � �� 

S. Oehlschläger, Dresden (DE) 

� � �� 

�� Endothelial cell dysfunction hypothesis 

�� 

�� Pathogenetic information from stone analysis 

�� 

�� Mineralogical signatures of stone formation mechanisms 

�� 

11.20 - 12.10 Challenges in education 


� � �� 


� � �� 

�� EULIS honorary lecture: Educational challenges in urolithiasis: The global perspective 

�� 

�� Safe and effective training in interventional stone therapy: From residency to advanced endourology 

T. Bach, Hamburg (DE) 

12.10 - 13.50 Trends in treatment 


� � �� 

� � �� 

M. Straub, Munich (DE) 

�� Mini PCNL - is it worthwhile? 

�� 

�� ESWL - New technologies and future directions 

�� 

�� EULIS young researcher’s podium: Technical evolution and current limitations of flexible URS 

��

�� Ureteral damage during flexible URS: Myth or reality? 

�� 

�� New developments in ureteral stents 

�� 

13.50 - 14.00 Announcements and final remarks 

�� 


�� 

�� 

perspectives in metaphylaxis. 

�� 

�� 

�� 

�� 

modalities have to be mastered in order to select the right patient for the right treatment. Aspects on these 

�� 

�� 

�� 

lecture as a stimulation of an upcoming young urolithiasis researcher. 


111 






10.00 - 16.30 Residents Day - organised by the Young Urologists Office in 

collaboration with the European Society of Residents in Urology 

(ESRU) 


Chairs: J.P.M. Sedelaar, Nijmegen (NL) 

M.S. Silay, Istanbul (TR) 

10.00 - 10.15 Opening and introduction 

�� 

�� 

10.15 - 11.15 What is the evidence? 

�� Minimally invasive treatment of BPH 

�� 

�� Neuromodulation therapies 

�� 

�� Vesicoureteral reflux 

�� 

�� Retrograde intrarenal surgery for stone therapy 


11.15 - 11.55 URORAIL: The journey of the young urologist to find the best working environment. Benefits and risks of 

seeking an academic career 

Chairs:� �� 

� � �� 

�� The Italian experience 

�� 

�� The French experience 

�� 

�� The Turkish experience 

�� 

�� The Professors experience 

�� 

11.55 - 12.05 Scholarship opportunities at the EAU/EUSP 

�� 

12.05 - 12.35 Campbell Team Challenge Quiz 

Quizmasters:� �� 

� � ��

12.35 - 13.30 Break 

13.30 - 14.30 Debate on supraspecialities: Which path to follow? Advantages, disadvantages and recommendations for 

each supraspeciality programme 

Chairs: �� 

� � �� 

�� Andrology 

�� 

�� Paediatric urology 

�� 

�� Functional urology 

�� 

�� Endourology and stone disease 


�� Uro-oncology 

�� 

�� Robotic urology 


14.30 - 15.15 Panel discussion: Residents duty hour regulations. The optimal working hours for a resident: Personal 

choice? 

Chairs:� �� 

� � �� 

�� Introduction: Reality and philosophy 

�� 

�� The educational impact of working hour regulations 


� � �� 

� � �� 


P. Whelan, Leeds (GB) 

15.15 - 16.15 Nightmare session: Presentations of clinical problems that have preplexed residents 

�� 

G. Khvadagiani, Tbilisi (GE) 

� � �� 

Panel: M. Marberger, Vienna (AT) 

� � �� 

16.15 - 16.30 Prizes and awards 

�� 

�� 


113 






14.15 - 15.45 New developments in partial nephrectomy 



Chairs: A. Messas, Nanterre (FR) 

M.J. Ribal Caparros, Barcelona (ES) 

�� 

V1 Enucleation techniques for challenging robot-assisted partial nephrectomy cases 

�� 

�� 

V2 The usefulness of retroperitoneal ‘lumboscopic’ robotic-assisted partial nephrectomy for difficult 

posteriorly located renal tumours 

�� 

V3 Robot-assisted lower pole heminephrectomy for ureteral duplication in a pediatric patient 

�� 

(Detroit, United States of America) 

V4 Demonstration of robot-assisted partial nephrectomy with early unclamping and sliding clip renorrhaphy 

�� 

V5 Robot-assisted left partial nephrectomy for endophytic hilar renal mass 

H. Baumert�� 

�� 

V6 Robotic zero-ischemia partial nephrectomy for hilar tumors 

A.L. Abreu, �� 

States of America) 

V7 Clamp-off laser assisted laparoscopic partial nephrectomy: Procedure, challenges and one year follow up 

W.Y. Khoder��



14.15 - 15.45 BPH: Etiology and medical treatment 



Chairs: S. Gravas, Larissa (GR) 

M. Oelke, Hanover (DE) 

�� 

�� 

108 Effect of silodosin on bladder microcirculation in a rat bladder outlet obstruction model: Evaluation using a 

pencil lens charge-coupled device microscopy system 

�� 

109 Muscarinic receptor subtypes in the human prostate; characterisation by radioligand binding 

�� 

110 Expression and alpha1-adrenergic regulation of caldesmon in human prostate smooth muscle 

S. Walther�� 

Germany) 

111 Three key chemokines (CCL2, CXCL10 AND IL8) involved in benign prostatic hyperplasia inflammation are 

reduced by Permixon® treatment 

A. Latil�� 

112 A dual 5α-reductase inhibitor dutasteride caused reduction in vascular density and area in benign 

prostatic hyperplasia 

�� 

113 Serum high density lipoprotein (HDL) levels are strongly correlated to histologic features of inflammatory 

infiltrate and weight of prostatic adenoma in men treated with prostatectomy for benign prostatic 

hyperplasia 

M. Gacci�� 

�� 

114 The prostate after anabolic androgenic steroids. A morphometrical study in rats 

�� 

�� 

115 Fluctuation of nocturia among men allocated to placebo in a double-blind, randomized controlled trial 

with one year follow-up 

�� 

�� 


116 What predicts the development of nocturia? A population-based study in older men 

B. Van Doorn�� 

117 The correlation between insulin resistance and prostatic growth in healthy Korean men: A 2-year 

longitudinal study 

�� 


115 



118 Withdrawn 

119 Metabolic syndrome can be related to the development of prostatic inflammation in men with benign 

prostatic hyperplasia 

M. Gacci�� 

�� 

120 Metabolic syndrome is an independent risk factor for benign prostatic hyperplasia 

�� 

116 Programme Book



14.15 - 15.45 Treatment of advanced prostate cancer 



Chairs: T.A. Borkowski, Warsaw (PL) 

L.N. Türkeri, Istanbul (TR) 

�� 

�� 


121 Detection of nodal micro metastases with serial section, immunohistochemistry and real time-polymerase 

chain reaction in intermediate and high risk prostate cancer patients submitted to radical prostatectomy 

with extended pelvic lymph node dissection: A perspective study 

�� 

�� 

122 A single positive lymph node has no detrimental effect on survival of patients with prostate cancer treated 

with extended pelvic lymph node dissection. Results of a matched controlled analysis 

A. Briganti�� 

�� 

123 Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic 

castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials 

�� 

�� 

124 Activity and safety of the investigational agent orteronel (ortl, TAK-700) in men with nonmetastatic 

castration-resistant prostate cancer (CRPC) and rising prostate-specific antigen (PSA): Results of a phase 2 

study 

M. Hussain�� 

�� 

Durham, United States of America; London, United Kingdom) 

125 Baseline bone metabolism markers as predictors for progression-free survival of patients with treatmentnaïve 

bone-metastatic prostate cancer treated with zoledronic acid plus combined androgen blockade 

�� 

�� 

�� 

126 Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in 

chemotherapy naïve patients with metastatic castrate-resistant prostate cancer 

�� 

�� 

�� 

127 Improved survival in elderly (> 75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients 

upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based 

chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phse III study 

�� 

�� 

�� 


117 



128 Cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer previously 

treated with a docetaxel-containing regimen: Interim analysis on treatment associated side effects 

resulting from a compassionate-use programme (CUP) 

A. Heidenreich�� 

�� 

Oldenburg, Hanover, Mannheim, Kassel, Dresden, Germany) 

129 Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life 

(QOL) data from the UK early access programme 

A.K. Bahl�� 

�� 

�� 

* 130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in 

the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III 

randomized trial (ALSYMPCA) 

�� 

�� 

�� 

Middlesex, Leeds, Birmingham, Wirral, Hemel Hempstead, United Kingdom; Bergen, Oslo, Trondheim, 

�� 

�� 

* 131 Finnprostate study VII: Intermittent versus continuous androgen deprivation in patients with advanced 


�� 

�� 

* 132 Pooled analysis of two protocols of intermittent hormonal therapy, in advance prostatic cancer 

�� 

�� 

�� 

118 Programme Book



14.15 - 15.45 Partial nephrectomy: Outcome 



Chairs: A. Minervini, Florence (IT) 

F. Porpiglia, Turin (IT) 

�� 

�� 


133 Age distribution for partial and radical nephrectomy - who’s nephrons are being spared? 

�� 

134 Disparities in the utilization of partial nephrectomy in The United States: A case for concern? 

�� 

�� 

�� 

135 Significant regional differences in the treatment of small renal cancers in Sweden 

E.O. Gudmundsson�� 

�� 

136 External validation of PADUA classification for the renal tumor enucleation technique 

G. Vittori, A. Minervini, M. Salvi, A. Tuccio, G. Siena, A. Mantella, A. Sebastianelli, O. Saleh, S. Serni, 

�� 

137 PADUA score accurately predicts the risk and grade of complication and ischemic time in patients who are 

candidates for nephron sparing surgery 

�� 

�� 

138 Comparison of results of laparoscopic partial nephrectomy renal in lesions minor and major 4cm 

S. Bollini, �� 

139 Surgical and oncological outcomes of laparoscopic partial nephrectomy: A Japanese multi-institutional 

study of 1,375 patients 

H. Saito�� 

�� 

140 The benefit of laparoscopic partial nephrectomy in high body mass index patients 

�� 

141 Computer-aided simulation of organ-sparing operations in renal tumours 

�� 

142 Comparing open versus laparoscopic partial nephrectomy for large renal tumors of stage cT1b 

�� 

of America) 


119 



* 143 Feasibility of gasless single-port clampless partial nephrectomy for peripheral renal tumor: An experience 

of 118 consecutive cases 

K. Kihara, �� 

�� 

* 144 Complications of partial nephrectomy (PN): Data from the prospective multicentric NEPHRON study 

H. Baumert�� 

�� 

�� 

�� 

�� 

120 Programme Book



14.15 - 15.45 Prostate biopsies 1 



Chairs: M. Burchardt, Greifswald (DE) 

V. Scattoni, Milan (IT) 

�� 

�� 

145 A risk calculator for prostate cancer risk 4 years after negative screening findings: ERSPC Rotterdam 

�� 

146 Development of a nomogram for predicting positive repeat prostate biopsy in patients with a previous 

negative biopsy 

�� 

�� 

147 Can the Prostate Risk Calculator based on western population be applied to Asian population? 

�� 

�� 

1122 Prevalence of prostate carcinoma and its precursor lesions in Russian Caucasian and Japanese men in 

autopsy specimens: A prospective comparative international study with central pathology review 

�� 

�� 

148 Pretreatment tables for the prediction of pathological outcomes of patients with locally advanced prostate 

cancer 

�� 

�� 

�� 

149 Pathological review of prostate biopsy specimens affects eligibility for active surveillance programs 

H.A. Van Vugt�� 

�� 

150 Misclassification of micro-focus prostate cancer decreases with the extent of biopsy sampling. Importance 

of accurate detection 

L. Villa�� 

�� 

152 Screening failures in Finland: Improving prostate cancer screening 

T. Kilpeläinen, T. Tammela�� 

�� 

153 Impact on histo-pathological reporting with different specimen collection protocols for TRUS biopsy of the 

prostate 

�� 

154 Prostate needle biopsy: The learning curve 

�� 

�� 


121 



155 Limited template appears equivalent to saturation approach in transperineal prostate biopsies 

�� 

156 Withdrawn 

157 High rates of significant prostate cancer are detectable in repeat biopsies 

�� 

�� 

Hamburg, Germany) 

158 Stratification of high-risk prostate cancer into prognostic categories; a European multi-institutional study 

�� 

�� 

�� 

122 Programme Book



14.15 - 15.45 Genetic and epigenetic events in urothelial carcinoma 



Chairs: M. Sanchez-Carbayo Martin, Madrid (ES) 

E.C. Zwarthoff, Rotterdam (NL) 

�� 

�� 

159 Urothelial cancer of the bladder: Antiapoptotic and cell cycle regulating biomarkers are upregulated in 

lymph node metastases and predict survival independently 

�� 

160 Expression of cell cycle-associated proteins in non-muscle invasive bladder cancer: Correlation with 

intravesical recurrence following transurethral resection 

�� 

161 Twist1 and Y-box-binding protein-1 are potential prognosis factors in bladder cancer 

Y.H. Song�� 

162 A novel apoptotic pathways mediated by tumor suppressive microRNA-1 through direct inhibition of 

splicing factor arginine/serine-rich 9 (SRSF9/SRp30c) in bladder cancer 

H. Yoshino�� 

�� 

163 Aberrant methylation of a panel of miRNA genes as a novel biomarker of bladder cancer 

�� 

�� 

164 Aberration of a cell adhesion molecule, CADM1, and its pathological or biological significance in urinary 


�� 

�� 

165 Epigenetic changes in bladder tumours of young patients 

�� 

�� 

166 Differences in DNA methylation pattern of primary bladder tumours correlate with their metastatic 

potential 

B. Stubendorff�� 

�� 

167 A DNA hypermethylation profile for bladder cancer diagnosis and prognosis 

�� 

�� 

168 Genetic alterations of the KEAP1/NRF2 pathway in transitional cell carcinomas of the bladder 

�� 


123 



169 MicroRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature 

predictive of aggressiveness and prognosis of muscle-invasive bladder cancer 

G. Pignot�� 

�� 

170 Identification of novel microRNAs associated with epithelial-mesenchymal transition in human bladder 

cancer by miRNA chip array profiling 

�� 

124 Programme Book



14.15 - 15.45 Incontinence surgery: How to choose the right technique? 



Chairs: L. Brubaker, Maywood (US) 

B.A. Dybowski, Warsaw (PL) 

�� 

�� 


* 171 Twenty-four month outcomes of randomized equivalence trial of retropubic and transobturator 

midurethral slings (TOMUS) 

�� 

�� (San Diego, Boston, Dallas, Birmingham, Baltimore, 

�� 

America) 

172 Five year continence rates, satisfaction and adverse events of Burch urethropexy and fascial sling surgery 

for urinary incontinence 

�� 

173 A prospective randomized comparative study between tension free vaginal tape inside-out and 

suburethral single incision sling for the treatment of female stress urinary incontinence; 24 month follow 

up 

W.K. Lee, �� 

* 174 Condition specific quality of life 24 months after retropubic and transobturator sling surgery for stress 

urinary incontinence 

L.T. Sirls�� 

�� 

�� 

175 Long-term results of artificial urinary sphincters for women with type III stress urinary incontinence 

G. Poinas�� 

�� 

* 176 Sexual activity and function in women for two years after midurethral slings 

�� 

177 A prospective randomized study comparing the safety and efficacy of transobturator tape (TOT) versus 

tension free vaginal tape (TVT) in treatment of female stress urinary incontinence 

��D.E. El-Sayed�� 

178 Final office evaluation findings in E-SISTER participants at one center: A glimpse into the long-term results 

of stress incontinence surgery 

�� 

179 The use of autologous rectus fascia and polypropylene mesh as a combined sling for treatment of female 

stress urinary incontinence 

O. El-Gamal, M.G. Soliman, ��, A. Abd-Elraheem (Tanta, Egypt) 


125 



180 Anterior transvaginal mesh - how “serious” are the complications and are they reversible? 

�� (Dallas, Texas, Shreveport, Louisiana, United 


181 Redo midurethral synthetic sling after failure of the initial anti-incontinence surgery 

�� (Seoul, South Korea) 

182 Feasibility of post-operative adjustability of a novel single-incision sling: An animal study 

�� 

�� 

126 Programme Book



14.15 - 15.45 Urinary tract infection 



Chairs: T.E. Bjerklund Johansen, Århus (DK) 

H.M. Çek, Istanbul (TR) 

�� 

�� 


* 183 Release of the anti-microbial peptide beta-defensin 2 protects against attack by flagellated Escherichia 

coli in human urothelium 

A.S.M. Ali�� 

�� 

184 Pseudomonal urinary tract infections: Effects of the secretory virulence factor pyocyanin on human 

urothelium 

��G.D. Grant�� 

�� 

185 Urine cytokines profile in women with recurrent urinary tract infections and renal scarring 

�� 

186 Community-acquired UTIs in pregnant women: Etiology and antimicrobial susceptibility in Russia in 2010- 

2011 (DARMIS study) 

�� 

187 Urinary tract infection associated with bacteremia – a 10 year epidemiological survey 

�� 

188 The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: To treat or 

not to treat 

�� 

�� 

189 Novel office-based rapid UTI detection system 

�� 

190 Clinical courses of adults with acute pyelonephritis correlated with APN grading using computed 

tomography 

�� 

191 Relationship between chronic lower urinary tract infection and pathogenicity of E.coli, isolated from urine 

�� 

�� 

192 Urinary antibacterial activity of nitroxolin 250 mg versus trimethoprim 200 mg against uropathogens after 

single oral administration 

�� 

�� 


127 



193 Efficacy of trigone fulguration in the management of recurrent urinary tract infections in women 

�� (Dallas, Tulsa, United States of America) 

194 Kidney preservation protocol for management of emphysematous pyelonephritis: Treatment modalities and 

follow-up 

�� 

Egypt) 

128 Programme Book



14.15 - 15.45 Renal tumours: Basic research 1 



Chairs: M. Kuczyk, Hanover (DE) 

B. Ljungberg, Umeå (SE) 

�� 

�� 


195 New insights into the role of FAK during renal tumorigenesis 

�� 

�� 

196 Inhibition of the growth and tumor angiogenesis of renal cell carcinoma by a STAT3 inhibitor WP1066 

A. Horiguchi�� 

�� 

197 Incomplete thermal ablation induces increased proliferation of renal carcinoma cells in a murine model 

�� 

�� 

198 High-fat diet increased Leptin, and the antitumor sensitization effect due to survivin inhibition in 

simvastatin treatment for renal cancer 

�� 

199 PHD3 expression is a predictor of progression-free survival in clear cell renal cell carcinoma 

�� 

200 Combination of sunitinib and mAb cG250 in nude mice bearing human renal cell carcinoma xenografts 

�� 

201 Antisense oligodeoxynucleotides targeted against clusterin increase the sensitivity of renal cell carcinoma 

to sorafenib 

Y. Kusuda�� 

202 Establishment of a multicolour fluorescence in situ hybridization based assay for subtyping of renal cell 

tumors 

�� 

�� 

203 The association of vascular cell adhesion molecule-1 expression with the effect of sorafenib in renal cell 

carcinoma 

Y. Ohno�� 

* 204 New insights into vitamin D3 derivates for the prevention and the treatment of renal cell carcinoma 

V. Dormoy, �� 

�� 

* 205 Transactivation of the EGFR cell survival pathway under hypoxia mediates mTOR activation and induction 

of HIF-α proteins and resistance to rapamycin especially in wild-type VHL renal cell carcinoma 

M. Sumitomo�� 


129 






14.15 - 15.45 Kidney transplant: From lab to clinic 



Chairs: A.B. Chkhotua, Tbilisi (GE) 

A.J. Figueiredo, Coimbra (PT) 

�� 

�� 


206 The role of ozone oxidative postconditioning in long-term changes after renal ischemic reperfusion injury 

�� 

207 Role of mitochondrial swelling in renal injury caused by renal ischemia-reperfusion. Experimental design 

E. Lledo-Garcia�� 

�� 

208 Distribution and expression of fibroblast specific protein, chemokine CCL21 and chemokine receptor CCR7 

in the renal allograft biopsies 

�� 

209 Independent and cumulative detrimental effects of both hypothermic storage and rewarming: 

Experimental design with cell cultures 

E. Lledo-Garcia�� 

(Madrid, Spain) 

* 210 Differences in protein properties of postoperative urine samples enable the prediction of early allograft 

rejection 

��B. Stubendorff�� 

�� 

* 211 Pig kidney xenotransplantation in baboons: Persistent rejection despite an important immunosuppression 

protocol 

�� 

�� 

* 212 Experimental model of laparoscopic kidney transplantation 

�� 

�� 

213 Central venous pressure (CVP) continuous monitoring at the early stage after renal transplantation 

��Y.T. Wang�� 

214 Closure of the asymptomatic arteriovenous fistula corrects left ventricular hypertrophy in renal transplant 

recipients 

�� 

215 Correlation between vascular resistance index and histological study in kidney allografts with reduced 

viability 

A. Vilaseca�� 

(Barcelona, Spain)

216 Preserved renal volume and donor renal function at 1 year follow-up 

�� 

�� 

217 Graft kidney function prediction based on the ratio of donated kidney volume to recipient body surface 

area 

�� 

218 Pretreatment with vardenafil attenuates renal ischemia-reperfusion injury. An experimental study in rats 

�� 

�� 


131 






16.00 - 17.30 Pelvic and urethral reconstruction 



Chairs: M.J. Drake, Bristol (GB) 

M. Fall, Gothenburg (SE) 

�� 

V8 Presentation of a potential appropriate method for bulbar urethroplasty with tissue-engineered oral 

mucosa graft (MukoCell®) 

�� 

�� 

V9 Failed epispadias in adult: Radical approach with satisfactory outcome 

�� 

V10 The stricture of the distal urethra and the meatus due to lichen sclerosis - a new technique of the 

reconstruction 

��, A. Pandey, H. Keller (Hof, Germany) 

V11 Vessel-sparing anastomotic urethroplasty for posterior urethral strictures 

�� 

V12 Extraperitoneal (EXPERT) sacrocolpopexy for the treatment of advanced uterovaginal and vault prolapse: 

Midterm results 

��A. Tepeler�� 

�� 

V13 Robot assisted repair of a complex vesicovaginal fistula using an omental flap, according to Kiricuta & 

Goldstein technique 

�� 

V14 The robot assisted sakro-colpopexy 

��D. Kusche��



16.00 - 17.30 BPH: Assessment and epidemiology 



Chairs: J. Carballido, Madrid (ES) 

A. Galfano, Milan (IT) 

�� 

�� 

219 The effects of anxiety and depression on nocturia-induced sleep problems 

H.W. Kim�� 

220 Patients with urinary disorders, evocative of BPH: What are their expectations in France, in Italy and in 

Portugal ? 

P. Perrin�� 

221 Translation and validation of the International Prostate Symptom Score and quality of life (IPSS+QoL) for a 

non English speaking population 

�� 

222 The validation of IPSS (International Prostate Symptom Score) questionnaire in a Uzbek-language 

population 

�� 

223 New methodology to estimate the burden of acute urinary retention (AUR) potentially attributable to 

benign prostatic hyperplasia (BPH) in France 

��A. Lafuma�� 

�� 

224 Rapid increases in health care utilization and cost due to benign prostatic hyperplasia in South Korean 

males: Retrospective population-based analysis 

S.H. Song�� 

Do, Bundang, South Korea) 

225 Efficacy of measurement of prostate volumes by digital rectal examination 

P.H. Song�� 

226 Pocket-size ultrasound – the new “urologic stethoscope”? 

�� 

�� 

227 Withdrawn 

228 Relationships between prostate-specific antigen, prostate volume and components of metabolic syndrome 

in Korean healthy man 

�� 

229 Is increased prostatic urethral angle a cause of lower urinary tract symptoms in benign prostatic 

hyperplasia/lower urinary tract symptom in male? 

�� 


133 



230 Correlation of prostatic urethral angulation and peak flow rate and urinary symptoms scores in men with 

lower urinary tract symptoms 

H.W. Kim�� 

�� 

231 Partial urethral outflow obstruction alters spontaneous peristaltic ureter activity in vivo in rats 

�� 

232 The effect of TURP on improvement of irritative symptoms in BPH patients with preoperative detrusor 

overactivity 

E. El Sherif, M. Sultan (Shibin El Koum, Egypt) 

134 Programme Book



16.00 - 17.30 Prostate cancer: Novel therapies 



Chairs: Z. Culig, Innsbruck (AT) 

J-E. Damber, Gothenburg (SE) 

�� 

�� 

233 Efficacy of pyrrole-imidazole (PI) polyamide targeting of TMPRSS2-ERG gene fusion for prostate cancer 

cells 

D. Obinata�� 

�� 

234 Antisense oligonucleotide targeting Insulin-like Growth Factor-1 Receptor (IGF-1R) enhances paclitaxel 

sensitivity in a castrate-resistant and paclitaxel-resistant prostate cancer model 

�� 

235 Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing 

AR degradation and repression of FKBP52 in castrate resistant prostate cancer model 

H. Matsumoto�� 

�� 

236 The combination of carbidopa plus bicalutamide suppresses androgen-receptor transactivation, induces 

apoptosis and delays castration-resistant prostate cancer progression 

�� 

�� 

237 The multikinase inhibitor sorafenib suppresses AR expression and signaling and induces apoptosis of 

castration therapy-resistant prostate cancer cells 

�� 

238 The effects of HDAC-inhibition on tumor growth and integrin driven invasion processes are augmented by 

low dosed interferon alpha in prostate cancer models in vitro and in vivo 

S.A. Wedel�� 

am Main, Germany) 

239 AKR1C3 - a potential marker and therapeutic target in castration resistance prostate cancer 

�� 

�� 

240 Vorinostat interacts with bortezomib to enhance protein ubiquitination synergistically in prostate cancer 

cells 

A. Sato�� 

241 Cdk1-cyclin B complex: A potential target for counteracting everolimus-induced resistance in prostate 

cancer 

�� 

Germany) 

242 Novel oncolytic HSV-1 for treatment of slow-growing tumors such as prostate carcinoma 

�� 


135 



243 IL-15 potentiates CD8 and NK effector cell expansion and tumour cell killing in the prostate cancer 

microenvironment 

O. Elhage�� 

244 Development of novel magnetic hyperthermia using titanium capsules for brachytherapy to treat prostate 

cancer 

T. Gondo�� 

�� 

245 Downregulation of Hsp27 using OGX-427 induces ER stress and potentiates Hsp90 inhibitors to delay 

castrate resistant prostate cancer 

�� 

246 Real-time, in vivo multiphoton microscopy imaging is a promising tool to identify prostate tissue during rat 

survival surgery 

M. Durand�� 

�� 

136 Programme Book



16.00 - 17.30 Partial nephrectomy: Outcome, ischemia and renal function 



Chairs: R.M. Scarpa, Orbassano (IT) 

O. Ukimura, Los Angeles (US) 

�� 

�� 


247 Partial versus radical nephrectomy in patients with stage I renal cell carcinoma more than 4 cm in 

diameter: Comparison of disease-specific survival 

�� 

248 Simple enucleation versus radical nephrectomy in the treatment of pt1a and pt1b renal cell carcinoma 

A. Minervini, S. Serni, G. Vittori, A. Tuccio, G. Siena, M. Salvi, A. Sebastianelli, S. Giancane, L. Masieri, 

�� 

249 A non-cancer related survival benefit is associated with partial nephrectomy 

M. Sun�� 

250 3D reconstruction of renovascular-tumor anatomy to facilitate zero-ischemia partial nephrectomy 

�� 

(Los Angeles, United States of America) 

251 Role of ischemia during elective partial nephrectomy on renal function after long term follow-up: Analysis 

on 354 patients cohort 

A. Antonelli�� 

252 Renal damage after laparoscopic partial nephrectomy in patients with normal contralateral kidney: Results 

after four year scintigraphic follow-up 

�� 

253 Changes in renal function post nephron sparing surgery due to renal cancer 

T. Erlich�� 

254 Prognostic factors influencing post-operative development of chronic kidney disease after partial 

nephrectomy in patients with small renal tumors 

�� 

* 255 Parstatin attenuates renal ischemia reperfusion injury in rats 

�� 

�� 

* 256 Functional analysis of elective nephron-sparing surgery versus radical nephrectomy for renal tumors 

larger than 4 cm 

�� 

* 257 Over 100 cases of zero-ischemia robotic/laparoscopic partial nephrectomy: Is global renal ischemia 

necessary? 

A.L. Abreu, �� 



137 






16.00 - 17.30 Prostate biopsies 2 



Chairs: J. Morote Robles, Barcelona (ES) 

H.A. Özen, Ankara (TR) 

�� 

�� 


258 Changes in serum prostate specific antigen levels and the identification of prostate cancer in a large 

managed care population 

L.P. Wallner�� 


259 Serum isoform [-2]proPSA (p2PSA) and its derivates, %p2PSA and PHI (prostate health index), are more 

accurate than the reference standard test (PSA) in men scheduled for repeat biopsy 

�� 

�� 

260 The cost-effectiveness of prostate cancer detection using Beckman Coulter Prostate Health Index 

�� 

of America) 

261 Is prostate biopsy still necessary? 

��G.M. Busetto, V. Panebianco, D. Lisi, A. Alfarone, U. Parente, A. Gentilucci, 

�� 

* 262 PCA3 can reduce repeat prostate biopsies with maintained sensitivity of detecting high-grade cancer: 

Application of an expert recommendations model to the placebo cohort of the REDUCE study 

B. Tombal, G.L. Andriole, L. Smets, H. Stoevelaar (Brussels, Lier, Belgium; St. Louis, United States of 

America) 

263 Development of novel PCA3 cut-offs for initial and repeat biopsy using different statistical approaches 

within a US-European multi institutional cohort 

M. Auprich�� 

�� 

�� 

�� 

America) 

264 The influence of metabolic syndrome on prostate cancer risk detection and its aggressiveness 

�� 

�� 

265 Association of statin use with clinicopathologic characteristics of prostate cancer 

�� 

266 Population level associations between COX-2 Inhibition by NSAID use and prostate cancer risk 

��

267 Positive association between diabetes mellitus and high grade prostate cancer detection via extended 

prostate biopsy in obese Japanese men with PSA less than 10 ng/ml 

�� 

�� 

268 Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: 

A meta-analysis on 3218 patients 

�� 

269 Efficacy vs. effectiveness study design within the European Randomized study of Screening for Prostate 

Cancer: Consequences for prostate cancer incidence, overall mortality and disease-specific mortality 

�� 

�� 

270 Procedural sedation and analgesia (PSAA) vs. local anesthesia for prostate biopsy: A prospective 

randomized trial 

�� 

151 The impact of saturation biopsy in decision making for low risk prostatic carcinoma after prior positive 

biopsy 

�� 

�� 


139 






16.00 - 17.30 Chronic pelvic pain syndrome 



Chairs: C.M. Da Silva, Oporto (PT) 

T.A. Drewa, Kielce (PL) 

�� 

�� 


* 271 A randomised controlled trial to evaluate the efficacy of botulinum toxin type A in the treatment of patients 

suffering bladder pain syndrome/interstitial cystitis with Hunner’s lesions: Preliminary results 

�� 

272 Ulcerative and non-ulcerative forms of bladder pain syndrome/IC do not differ in the intensity of LUTS and 

respond similarly to intra-trigonal Onabotulinum type A injections 

�� 

* 273 Glycosaminoglycans (GAG’s) contribute to the bladder barrier 

�� 

274 Intravesical epinephrine preserves uroplakin II expression in urinary bladder from cyclophosphamideinduced 

rat cystitis 

G.H. Lee�� 

275 IL-9 is a mediator for mast cell-T cell interaction in interstitial cystitis 

�� 

276 Sacral nerve stimulation in non-obstructive urinary retention following surgery for deep endometriosis 

M. Pastorello�� 

* 277 The role of Permixon therapy for category II/III chronic prostatitis: A prospective two-year study 

�� 

* 278 Correlation of chronic histologic prostatic inflammation (CHPI) in biopsy specimens with serum isoform 

[-2]proPSA (p2PSA), %p2PSA and PHI (prostate health index) in men undergoing prostate biopsy for 

suspected PCa 

G. Gadda�� 

�� 

279 Impact of treatment on the kinetics of the PSA in chronic prostatitis: Prospective randomized controlled 

study: Ciprofloxacin + Piroxicam vs Ciprofloxacin 

��H. Khouni�� 

La Marsa, Tunisia) 

280 The efficacy of tadalafil for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged 

patients 

��



16.00 - 17.30 Male incontinence 



Chairs: W.A. Hübner, Korneuburg (AT) 

G. Novara, Padua (IT) 

�� 

�� 


* 281 Dynamics of the pelvic floor in continent and stress urinary incontinent men after radical prostatectomy: 

A functional MRI study 

�� 

282 The key role of time in predicting post-radical prostatectomy urinary continence recovery rate: Conditional 

survival analysis 

�� 

�� 

283 Withdrawn 

284 Post-operative PDE-5 inhibitors use improves recovery of urinary continence following open bilateral 

nerve-sparing radical prostatectomy 

G. Gandaglia�� 

�� 

285 Efficacy of ultrasound-guided pelvic muscle training 

�� 

286 Efficacy of a supervised low-intensity regimen of perioperative pelvic floor muscle training in reducing 

postprostatectomy urinary incontinence: A randomized controlled trial 

E. Sacco�� 

�� 

287 Safety and efficacy of adjustable periurethral constrictor implant in patients with stress urinary 

incontinence after pelvic surgery: Results of a prospective study 

�� 

�� 

288 Treatment of post-prostatectomy male urinary incontinence with the transobturator retroluminal 

repositioning sling suspension: 3 year follow up 

�� 


289 Artificial urinary sphincter placement preserving the bulbospongiosus muscle: Is it possible to decrease 

urethral erosion/atrophy rate? 

�� 

�� 

(Valencia, Spain) 


141 



290 Evaluation of ProACT treatment in male stress urinary incontinence after radical prostatectomy: Invasive 

and non-invasive urodynamics 

E. Utomo�� 

291 Male sling adjustment: Can the retrograde leak point pressure help to reduce postoperative urethral 

lesions? 

�� 

292 Salvage therapy with artificial urinary sphincter after advance male sling failure for post-prostatectomy 

incontinence: A first clinical experience 

�� 

142 Programme Book



16.00 - 17.30 Infection miscellaneous 


Poster Session 25 

Chairs: P. Tenke, Budapest (HU) 

B. Wullt, Lund (SE) 

�� 

�� 


293 Antimicrobial prophylaxis is avoidable in minimally invasive partial nephrectomy without entry into the 

urinary tract 

�� 

�� 

294 The role of antibiotic prophylaxis in the prevention of symptomatic UTI after outpatient flexible cystoscopy 

D. Batura�� 

295 Rapid detection of the gyrA and parC mutations in fluoroquinolone-resistant pseudomonas aeruginosa 

strain by denaturing high-performance liquid chromatography in UTI patients in Japan 

M. Matsumoto�� 

�� 

296 Current trends in nosocomial pathogens’ susceptibility in Moscow University Clinic of Urology 

�� 

* 297 Multi-drug resistant hospital acquired urinary tract isolates: Prevalence and demographic properties: 

Outcome of the Global Prevalence of Infections in Urology (GPIU) Study: Six year results of a multinational, 

multicenter study 

�� 

�� 

298 Successful reduction of hospital-acquired methicillin-resistant staphylococcus aureus (MRSA) in a urology 

ward possibly due to avoidance of antimicrobial prophylaxis in minimally invasive surgery: Our 11 years 

trial 

�� 

�� 

299 Identifying risk factors for urinary infections caused by Extended-Spectrum Beta-Lactamase (ESBL) 

producing agents: Implications for treatment 

A. Garcia-Tello�� 

300 Efficiency of Uro-Vaxom in patients with urogenital tract infections 

E. Kulchavenya�� 

301 Solidago, orthosiphon and birch extracts (CISTIMEV®) are able to decrease microbial colonization and 

biofilm development in patients with indwelling urinary catheter: Microbiological and ultrastructural study 

�� 

�� 


143 



302 Early surgical intervention reduces mortality of Fournier’s gangrene: 546 cases from a nationwide 

database 

T. Sugihara�� 

�� 

303 Public awareness of human papilloma virus is dramatically insufficient in the web-networking generation 

A. Salonia�� 

�� 

304 Analysis of HPV E6/E7 mRNA expression in asymptomatic subjects: A pilot study 

�� 

144 Programme Book



16.00 - 17.30 Renal tumours: Basic research 2 



Chairs: T. Klatte, Vienna (AT) 

E. Oosterwijk, Nijmegen (NL) 

�� 

�� 


305 Does dose-dependent targeting of fibroblast growth factor (FGF) receptor 1 (FGFR1) impact on growth of 

renal cell carcinoma? 

�� 

306 The SWI/SNF nucleosome-remodeling gene PBRM1 – another tumor suppressor gene in renal cell 

carcinomas? 

�� 

307 Functional analysis and target identification of specific miRNAs involved in development of metastases in 

renal cell carcinoma 

�� 

308 Effect of genetic polymorphisms on susceptibility and aggressiveness of clear cell renal cell carcinoma 

�� 

�� 

* 309 Transcriptome analysis of renal cell carcinoma and normal kidney tissue for the identification of new 

diagnostic and prognostic biomarkers 

�� 

�� 

310 UCP-3 uncoupling protein confers hypoxia resistance in renal epithelial cells and is upregulated in renal 


�� 

311 A pharmacogenomic scoring system predicting median time-to-progression on sunitinib as first line 

treatment in patients with metastatic renal cell carcinoma 

�� 

�� 

�� 

312 Significance of epithelial-mesenchymal transition markers in the prognosis of patients with renal cell 

carcinoma who underwent radical nephrectomy 

�� 

313 Role of molecular markers in nephrectomy specimen as prognosticators for patients with metastatic renal 

cell carcinoma in the era of targeted therapy 

D. You�� 

314 MiR200c as outcome predictor of renal cell cancer patients with tumor thrombus of the inferior vena cava 

(IVC) 

�� 


145 



* 315 Prediction of TKI-therapy response in patients with metastatic renal cell carcinoma by serum proteomics 

M. Walter�� 

�� 

146 Programme Book



16.00 - 17.30 Living donor kidney transplant and outcomes 



Chairs: P. Di Tonno, Bari (IT) 

M. Musquera Felip, Toronto (CA) 

�� 

�� 


316 Pre-operative assessment of living renal transplant donors with state-of-the-art imaging modalities: 

Computed tomography angiography vs. magnetic resonance angiography in 118 patients 

�� 

(Berlin, Germany) 

317 Transvaginally notes-assisted living donor nephrectomy 

�� 

�� 

318 Kidney transplantation of living-unrelated and ABO-incompatible donor-recipient combinations 

�� 

�� 

319 Randomized trial of 2-site versus hand-assisted laparoscopic donor nephrectomy 

��S.H. Hong (Seoul, South 

Korea) 

320 Surgical technique evolution of live donor nephrectomy in the last 8 years in our center 

�� 

�� 

321 Does the primary allograft nephrectomy influence the outcome of subsequent renal transplants? 

�� 

�� 

322 Does multiorgan versus kidney only cadaver organ procurement affect graft outcomes? 

�� 

�� 

323 Renal transplantation with donors older than 70 year: Does age matter? 

L.S.O. Marconi�� 

324 Complex living donor kidney transplant. Results, complications and graft survival 

�� 

�� 

* 325 The challenge of live kidney donor evaluation: Percentage of exclusions 

A. Breda�� 

Spain) 


147 



* 326 Fate of the accessory renal arteries of grafts with multiple renal arteries during live-donor renal allotransplantation 

�� 

(Mansoura, Egypt) 

* 327 Dual renal transplantation of marginal kidneys (age extremes) 

�� 

148 Programme Book



17.45 - 19.15 Innovation in laparoscopic robotics: The handheld Kymerax Robot – Benefits and 

clinical experience page 391 

Room 353 - Level 3 �� 


17.45 - 19.15 Case-based update on the optimal management of bone metastases from 

prostate cancer page 382 

Room Bleu - Level 2 �� 

17.45 - 19.15 OAB: New solutions for an old challenge page 383 

Room Concorde Centre - Level 4 Sponsored by ASTELLAS 

17.45 - 19.15 The longer the better: Treatment of BPH symptoms with Serenoa repens 

(safety and efficacy) page 384 

Room 251 - Level 2 �� 

17.45 - 19.15 Reviving naturalness - ED management then and now page 385 

Room 252 A/B - Level 2 �� 

17.45 - 19.15 Nocturia with nocturnal polyuria now and in the future page 386 

Room Bordeaux - Level 3 �� 

17.45 - 19.15 Evidence and rationale for initial treatment of patients with symptomatic BPH at risk of 

progression page 387 

eURO Auditorium - Level 1 �� 

17.45 - 19.15 Moving forward in prostate cancer: Hormones and beyond page 388 

Room Concorde Paris - Level 4 �� 

17.45 - 19.15 Confronting the challenges of Tuberous Sclerosis Complex: Strategies for treatment and 

management of associated angiomyolipomas page 389 

Room 242 A/B - Level 2 �� 

17.45 - 19.15 The guidelines offer more than antibioprophylaxis to manage recurrent urinary 

tract infections page 390 

Room Maillot - Level 2 �� 


149 


�� 

�� 

�� 

�� 

� 

�� 

� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

��

Sunday, 26 February - EAU Programme 


07.30 - 11.00 Functional urology 


Chairs: C.R. Chapple, Sheffield (GB) 

P. Radziszewski, Warsaw (PL) 

07.30 - 08.00 Highlight session 1 

Oncology 

A. Govorov, Moscow (RU) 

Female urology 

F.A. Van Der Aa, Leuven (BE) 

Stone disease 

B.W. Turney, Oxford (GB) 

08.00 - 08.05 Introduction Functional urology 


08.05 - 08.15 Update OAB treatment in the male 

N. Thiruchelvam, Cambridge (GB) 


The aims of this session are to gain an understanding of the contemporary treatment of the overactive 

bladder in the male. Gender differences, the role of bladder outflow obstruction and concomitant treatment 

of benign prostatic hypertrophy will be reviewed. 

Objectives: The audience will understand the prevalence of overactive bladder and how they differ in the 

sexes - despite a similar prevalence and impact on quality of life, there is a considerable difference in healthseeking 

treatment in men. The pathophysiology of the overactive bladder differs in the male and the role of 

bladder outflow obstruction, benign prostatic hypertrophy and metabolic syndrome will be explained. There 

will be emphasis on conservative and pharmacological treatment of the overactive bladder in the male. Risks 

of acute urinary retention in pharmacological treatment and the overactive bladder in treatment of localised 

prostate cancer will be discussed. 

08.15 - 08.25 Update What is new in pharmacotherapy 

K-D. Sievert, Tübingen (DE) 

08.25 - 08.35 Update Botulinum toxin: Coming of age? 



Onabotulinum toxin A (OnabotA), one of the botulinum toxin type A brands, is already approved to treat 

urinary incontinence caused by neurogenic detrusor overactivity (NDO). Nevertheless, it was commonly 

offered to NDO patients refractory to anti-muscarinic treatment before being licensed. Likewise, OnabotA is 

being offered as an off-label treatment to OAB/IDO patients refractory to pharmacological treatment. Several 

RCTs indicate that OnabotA is superior to placebo in improving urgency, urgency incontinence and voiding 

frequency. The onset of the effect is fast. Dose-finding studies favour the use of 100 U over higher doses. Data 

from OnabotA regulatory phase III trials are expected soon. 


151 

Sunday

Sunday 

08.35 - 08.45 Update Neuromodulation 


J.P.F.A. Heesakkers, Nijmegen (NL) 


The treatment of lower urinary tract dysfunction in neurogenic and non-neurogenic patients is well 

established. Since the introduction of sacral nerve stimulation at the end of the last century, more good data 

about the working mechanism, indication, techniques and results are available. Moreover, new techniques 

and ways of application of electro-stimulation to the innervation system of the lower urinary tract have been 

recently introduced. The latest data on these treatment modalities will be presented in this lecture. 

08.45 - 09.10 Case discussion Which therapy for which patient 

Moderators: C.R. Chapple, Sheffield (GB) 


Panel: F.R. Cruz, Porto (PT) 


M. Lucas, Swansea (GB) 


N. Thiruchelvam, Cambridge (GB) 


The aim is to highlight current views relating to the management of a case of male and a case of female 

incontinence, which will then be discussed more fully with regard to the evidence by the subsequent 

presentation on the EAU guidelines. 

09.10 - 09.30 EAU Guidelines Office What do the new guidelines say? 



The newly published guideline, on management of Urinary Incontinence, has been produced using the new 

evidence based methodology which is being rolled out to all guideline groups. This is pragmatic advice for 

working urologists; some predictable and some controversial, but all based on evidence or consensus. There 

are clear care pathways that are supported by, and provide easy links to, the evidence. This presentation 

will describe how the guidelines have been produced, showing new guideline development software, and 

highlight areas of particular clinical interest. 

09.30 - 09.45 State-of-the-art lecture Female sexual dysfunction 

A. Graziottin, Milan (IT) 


Background: Urologists have (at least) three good reasons to increase their knowledge on Female Sexual 

Dysfunction (FSD): 

1. To increase their understanding of a challenging topic, in a cultural perspective; 

2. To get more info on the “she-partner” issues while treating male sexual dysfunction and couple 

implications, especially in ED and premature ejaculation; 

3. To understand the pathophysiology and common background behind the high comorbidity between sexual 

pain disorders and arousal disorders, on one side, and bladder pain syndrome, recurrent cystitis/post-coital 

cystitis and urge symptoms, on the other, to increase their diagnostic and therapeutic skill in addressing 

women’s bladder problems. 

Aims: To select the most relevant evidence on female sexual dysfunction with a practical diagnostic and 

therapeutic perspective, useful in the daily clinical activity. Key predisposing, precipitating and maintaining 

factors of FSD will be briefly reviewed. Special attention will be devoted to the clinical diagnosis of 

dyspareunia/vulvodynia, of vaginal dryness/arousal disorders and their relation to bladder problems. The 

importance of investigating the comorbidity of bladder symptoms with Irritable Bowel Syndrome (IBS) and 

constipation; with the hyperactive pelvic floor and dyspareunia/vaginismus; with elevated vaginal pH and

low estrogen status (in amenorrhea, post partum and menopause) will be finally considered with a few 

therapeutic tips and tricks suggestions. 

09.45 - 09.55 Update Incontinence associated with prolapse 

F.C. Burkhard, Berne (CH) 


To determine the relationship between prolapse and incontinence. Which type of incontinence is associated 

with vaginal prolapse. How and when to treat incontinence associated with prolapse and will incontinence 

improve after prolapse surgery. 

09.55 - 10.05 Update Laparoscopic surgery for pelvic floor dysfunction 

P.T. Piechaud, Bordeaux (FR) 

10.05 - 10.40 Case discussion Complications of sling and prolapse surgery 

Moderator: J.W. Thüroff, Mainz (DE) 

Panel: D. Castro-Diaz, Santa Cruz de Tenerife (ES) 


D. Pushkar, Moscow (RU) 

10.40 - 11.00 Société Internationale d’Urologie (SIU) lecture What is proven in surgery for pelvic organ prolapse and 

urinary incontinence 

J.W. Thüroff, Mainz (DE) 


Options for surgical correction of urinary incontinence and pelvic organ prolapse and combinations thereof 

are presented in relation to classification and grading of the different pathophysiological entities. Evidence 

based medicine (EBM) criteria are used to present and compare outcomes and surgical complications of the 

variety of different surgical approaches including implantation of alloplastic tapes and meshes. With focus 

on prospective randomised studies – where available – and meta-analysis thereof, risk factors for surgical 

failure and complications are presented. The aim is to present an overview of currently available surgical 

techniques and their risk-benefit ratio in the light of the recent FDA warning concerning the use of synthetic 

meshes in genitourinary reconstructive surgery. 


153 

Sunday

Sunday 




09.15 - 10.45 Urinary tests for urothelial carcinoma 



Chairs: P-U. Malmström, Uppsala (SE) 

D. Yates, Sheffield (GB) 

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes 

in length, followed by 2 minutes for discussion. 

328 Genome-wide analysis of CpG island methylation in bladder cancer identifies novel biomarkers for 

diagnosis and prediction of progression 

R. Kandimalla, A.G. Van Tilborg, R. Masius, L. Kompier, D. Stumpel, R. Stam, C. Bangma, E.C. Zwarthoff 

(Rotterdam, The Netherlands) 

329 Study of methylation pattern of thirteen genes in urine samples for the non-invasive detection of bladder 

cancer 

A.G. Van Der Heijden, L. Mengual, M. Ingelmo-Torres, M.J. Ribal, A. Alcaraz, J.A. Schalken, J.A. Witjes 

(Nijmegen, The Netherlands; Barcelona, Spain) 

330 Fluorescence in situ hybridization (FISH) for determination of chromosomal aberrations in tumor cells in 

patients with bladder cancer and in urothelial cells of healthy people 

A. Khachaturyan, V. Matveev, A. Karseladze, B. Kamolov (Moscow, Russia) 

331 Evaluation of urinary proepithelin as a potential biomarker for bladder cancer detection and prognosis in 

Egyptian patients 

M. Selmy, G. Ibrahim, T. El-Serafi, A. Ghobeish (Ismailia, Egypt) 

332 Diagnosis of urothelial cell carcinoma by immunocytochemical detection of minichromosome maintenance 

protein 2 (MCM-2) in cells retrieved from urine 

K. Saeb-Parsy, A. Wilson, M. Corcoran, S. Chilcott, M. McKean, B. Thottakam, B. Rai, G. Nabi, D. Rana, 

M. Perera, J. N’Dow, D. Neal, N. Coleman (Cambridge, Aberdeen, Manchester, United Kingdom) 

333 Comparison of cytokeratin 20 with visual cytology and DNA image analysis in voided urine samples as 

diagnostic tools for bladder carcinoma 

S.E. Abouhashem, E.S. Saba, M.M. Saad (Zagazig, Egypt) 

334 MicroRNAs (miR-96 and miR-183) detection in urine serves as tumor markers for diagnosis and prognosis 

in patients with urothelial carcinoma 

H. Enokida, Y. Yamada, T. Chiyomaru, S. Tatarano, H. Yoshino, K. Nishiyama, N. Seki, M. Nakagawa 

(Kagoshima, Chiba, Japan) 

335 MicroRNAs in urine supernatant: Useful tumor markers for the diagnosis of bladder cancer 

D.Z. Zhang, K.M. Lau, S.Y. Chan, G. Wang, C.C. Szeto, K.H. Yip, C.F. Ng (Shatin, Hong Kong) 

336 What are the incidences of malignancy in patients referred with visible and non visible haematuria? 

C.R. Lunt, J.E. McCabe, M.V.P. Fordham, P.A. Cornford, R. Hamm, K.F. Parsons (Crewe, Prescot, Liverpool, 


337 Gene expression profiling for progressive non-muscle invasive urothelial cell carcinoma of the bladder 

A.G. Van Der Heijden, L. Mengual, M.J. Ribal, A. Alcaraz, J.J. Lozano, P.L. Fernández, J.A. Schalken, 

J.A. Witjes (Nijmegen, The Netherlands; Barcelona, Spain)

338 Human papillomavirus and bladder cancer: Meta-analysis 

A Jimenez-Pacheco, M. Exposito-Ruiz, M. Arrabal-Polo, A. Jimenez-Pacheco, C. Lahoz-Garcia, M. Arrabal- 

Martin (Granada, Jaen, Spain) 

339 Validation study of a noninvasive test for diagnosis and aggressiveness assessment of bladder cancer 

L. Mengual, M.J. Ribal, J.J. Lozano, M. Ingelmo-Torres, M. Burset, P.L. Fernandez, A. Alcaraz (Barcelona, 

Spain) 


155 

Sunday

Sunday 




09.15 - 10.45 Nerve-sparing radical prostatectomy and hormonal issues 



Chairs: K. Touijer, New York (US) 




340 Cavernosal nerve preservation during robot assisted radical prostatectomy is a graded rather than an 

all-or-none phenomenon: Objective demonstration by assessment of residual nerve tissue on surgery 

specimens 

O. Schatloff, S. Chauhan, D. Kameh, A. Sivaraman, R. Valero, F. Ortega, Y.H. Ko, K.J. Palmer, V.R. Patel 

(Celebration, United States of America) 

341 Surgical, oncologic and functional outcomes in patients undergoing salvage robotic-assisted laparoscopic 

radical prostatectomy for the treatment of recurrent prostate cancer 

A.P. Labanaris, V. Zugor, C. Wagner, A. Schuette, P. Lange, J.H. Witt (Gronau, Germany) 

342 Use of multiparametric MR with neurovascular bundle evaluation to optimize the oncological and 

functional management of patients considered for nerve sparing radical prostatectomy 

F. Minisola, A. Sciarra, V. Panebianco, A. Alfarone, S. Cattarino, A. Gentilucci, M. Innocenzi, M. Ravaziol, 

U. Parente, S. Salciccia, V. Gentile (Rome, Italy) 

343 Effect of risk-stratified approach to nerve-sparing on early return of continence after robotic assisted 

laparoscopic prostatectomy 

A. Srivastava, P. Sooriakumaran, B. Chugtai, R. Lee, M. Durand, D. Brooks, N. Harneja, A. Tewari (New York, 


344 Nerve grafting with an allograft during radical prostatectomy: Prospective, randomized, blinded study 

C. Vollmer, M. Horstmann, C. Padevit, H. John (Winterthur, Switzerland) 

345 Radical salvage prostatectomy for locally recurrent prostate cancer after low dose brachytherapy 

D. Porres-Knoblauch, D. Pfister, R. Epplen, C. Piper, A. Heidenreich (Aachen, Germany) 

346 Sex hormone-binding globulin level in patients with prostate cancer treated with radical prostatectomy 

J. Kim, C. Song, H. Ahn (Seoul, South Korea) 

347 Early versus late serum testosterone and related hormone profile after radical prostatectomy 

A. Celma, J.M. Bastaros, G.M. Delgado, F. Agreda, J. Planas, C.X. Raventos, J. Placer, I.M. De Torres, J. Carles, 

J. Morote (Barcelona, Spain) 

348 Neoadjuvant luteinizing-hormone-releasing hormone agonist plus estramustine phosphate in high-risk 

prostate cancer patients: A propensity score analysis 

T. Koie, K. Mitsuzuka, T. Yoneyama, S. Narita, S. Kawamura, H. Yamamoto, S. Hatakeyama, S. Kudoh, 

N. Kamimura, T. Tochigi, T. Habuchi, Y. Arai, C. Ohyama (Hirosaki, Sendai, Akita, Natori, Japan) 

349 Risk of biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and 

alpha-blockers 

T.J. Murtola, T.L.J. Tammela (Tampere, Finland)

350 Radical prostatectomy with long neoadjuvant hormonal therapy can be effective for high-risk localized 

prostate cancer patients 

M. Kato, T. Tsuzuki, R. Hattori, M. Gotoh (Nagoya, Japan) 


157 

Sunday

Sunday 




09.15 - 10.45 Prostate cancer: High risk disease 



Chairs: M. Graefen, Hamburg (DE) 

B. Rocco, Milan (IT) 


in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed 


* 351 Seminal vesicle invasion: What type of adjuvant treatment should be proposed? 

C. Bastide, D. Rossi, L. Salomon, P. Mouracade, F. Rozet, X. Cathelineau, A. Forgues, M. Roupret, A. Masson- 

Lecomte, M. Peyromaure, J. Rigaud, S. Larue, C. Pfister, R. Bonniol, J.J. Patard, T. Bessede, F. Staerman, 

L. Kamdoum, M. Soulié, J.B. Beauval (Marseille, Paris, Nantes, Rouen, Reims, Toulouse, France) 

352 Long term follow up for patients with seminal vesicle invasion (pT3b) after minimally invasive radical 

prostatectomy 

A. Forgues, F. Rozet, A. Ouzzane, R.E. Sanchez-Salas, E. Barret, M. Galiano, D. Prapotnich, X. Cathelineau 

(Paris, France) 

353 Prognostic stratification of patients with PSA greater than 20 ng/ml undergoing radical prostatectomy 

S. Kawakami, M. Yano, T. Yamada, S. Yamamoto, S. Urakami, Y. Fujii, J. Yonese, I. Fukui, N. Numao, K. Saito, 

F. Koga, K. Kihara (Kawagoe, Tokyo, Japan) 

354 Impact of radical prostatectomy in high risk prostate cancer patients 

A. Naselli, C. Introini, F. Germinale, F. Bertolotto, P. Puppo (Genoa, Italy) 

* 355 Radical prostatectomy for very high risk T3b/4 prostate cancer – results of a multiinstitutional experience 

M. Spahn, P. Gontero, A. Briganti, B. Kneitz, P. Bader, C.Y. Hsu, H. Van Poppel, D Frohneberg, S. Joniau 

(Würzburg, Karlsruhe, Germany; Turin, Milan, Italy; Leuven, Belgium) 

356 Oncologic outcomes in patients undergoing robot-assisted laparoscopic radical prostatectomy for clinical 

locally advanced T3a prostate cancer 

A.P. Labanaris, V. Zugor, C. Wagner, P. Lange, J.H. Witt (Gronau, Germany) 

357 High risk prostate with pT3-tumor and positive surgical margin - relevance for clinical failure and prostate 

cancer mortality: Results of a prospective single institution series 

M. Spahn, A. Briganti, U. Capitanio, P. Gontero, B. Burkhard, P. Bader, D. Frohneberg, S. Joniau (Würzburg, 

Karlsruhe, Germany; Milan, Turin, Italy; Leuven, Belgium) 

358 Prospective trial with radical prostatectomy and intraoperative radiation therapy for clinical locally 

advanced prostate cancer: Clinical aspects and results after 6 years experience 

G. Marchioro, M. Krengli, A. Volpe, M. Vidali, R. Tarabuzzi, S. Zaramella, F. Varvello, A. Ballarè, D. Beldì, 

G. Apicella, C. Terrone (Novara, Italy) 

359 Competing mortality contributes to excess mortality in patients with high risk lymph node positive 

prostate cancer treated with radical prostatectomy 

M. Fröhner, A. Scholz, R. Koch, M.P. Wirth (Dresden, Aue, Germany)

360 Radical prostatectomy in immunosuppressed transplant patients: Surgical morbidity, disease 

characteristics, and prognostic aspects of 18 patients 

P. Schriefer, A. Haese, U. Michl, G. Salomon, T. Schlomm, H. Heinzer, H. Huland, M. Graefen, T. Steuber 

(Hamburg, Germany) 

* 361 Predicting prostate cancer specific mortality in high risk prostate cancer. A novel preoperative nomogram 

including the new biomarker micro-RNA 221 

M. Spahn, F. Abdollah, S. Joniau, P. Ströbel, P. Gontero, M. Schubert, B. Kneitz, A. Briganti (Würzburg, 

Mannheim, Germany; Milan, Turin, Italy; Leuven, Belgium) 

* 362 Outcome of multimodality treatment of cT4 very high-risk prostate cancer with radical cystectomy as initial 

step: A multi-institutional outcome study of 62 patients 

M. Spahn, S. Joniau, F. Abdollah, M. Tutolo, E. Di Trapani, P. Gontero, B. Kneitz, P. Bader, D. Frohneberg, 

H. Van Poppel, R.J. Karnes (Würzburg, Karlsruhe, Germany; Leuven, Belgium; Milan, Turin, Italy; Rochester, 



159 

Sunday

Sunday 




09.15 - 10.45 Bladder pharmacology 



Chairs: C.D. Cruz, Porto (PT) 

P. Hedlund, Lund (SE) 




363 Dose-dependent effect of a selective β3 adrenoreceptor agonist (CL-316,243) on the bladder contractility 

and the micturition frequency in female rats 

J.B. Beauval, P. Lluel, M.A. Guardia-Llorens, V. Guilloteau, T.D. Westfall, S. Palea, X. Gamé (Toulouse, 

France) 

* 364 Effect of a selective β3-adrenergic agonist (CL-316, 243) on cystometric parameters in conscious spinal 

cord injured female rats 

J.B. Beauval, V. Guilloteau, M. Capelini, A. Naudin, M. Guerard, P. Lluel, S. Palea, P. Rischmann, X. Gamé 

(Toulouse, France) 

* 365 TRPV1 and TRPV4 antagonists have synergistic effect for treating bladder overactivity in rats 

A. Charrua, C.D. Cruz, F. Cruz (Porto, Portugal) 

366 TRPV1 and TRPV4 expression in bladder neurons during normal condition and during cystitis 

A. Charrua, M. Boudes, D. De Ridder, C.D. Cruz, F. Cruz (Porto, Portugal; Leuven, Belgium) 

367 The role of miRNA in bladder contractility 

B. Uvelius, M. Karbalaei Sadegh, M. Ekman, C. Rippe, K. Swärd, S. Albinsson (Malmö, Lund, Sweden) 

368 BDNF sequestration improves bladder function in spinal cord injured animals 

B. Frias, A. Charrua, J. Santos, S. Allen, F. Cruz, C. Cruz (Porto, Portugal; Bristol, United Kingdom) 

369 Evidence for a functional role of connexin 43 and 45 in human neurogenic detrusor overactivity 

V. Phé, D. Behr-Roussel, S. Oger-Roussel, E. Chartier-Kastler, T. Ghoneim, T. Lebret, G. Karsenty, 

E. Compérat, P. Camparo, P. Validire, F. Giuliano (Paris, Orsay, Suresnes, Marseille, Garches, France) 

370 Is there a local bladder effect of oral cannabinoid agonists? 

S. Katagigiotis, R. Kavia, G. Gonzales, F. Dimitriadis, E. Ioannidis, C.J. Fowler, A. Lambropoulos, 

A. Apostolidis (Thessaloniki, Greece; London, United Kingdom) 

371 Intrathecal FAAH inhibition modifies urodynamic parameters during continuous cystometry in awake rats 

C. Fullhase, G. Gandaglia, F. Benigni, C. Gratzke, C. Stief, P. Hedlund (Munich, Germany; Milan, Italy) 

* 372 Chronic FAAH inhibition reduces urodynamic signs of detrusor overactivity in female rats 

G. Gandaglia, F. Strittmatter, F. Benigni, G. La Croce, M. Moschini, C. Gratzke, P. Hedlund (Milan, Italy; 


373 Role of myosin light chain kinase and Rho kinase in carbachol-induced contractions of human detrusor 

smooth muscle 

C. Protzel, T. Kirschstein, K. Porath, T. Sellmann, R. Koehling, O.W. Hakenberg (Rostock, Germany)

374 Botulinum neurotoxin A (BoNT/A) attenuates bladder afferent nerve firing and prevents ATP release from 

the urothelium 

D.M. Daly, V.M. Collins, N.G. McKay, D.J. Sellers, C.R. Chapple, D. Grundy (Sheffield, United Kingdom; 

Queensland, Australia) 


161 

Sunday

Sunday 




09.15 - 10.45 Stones: Flexible URS 



Chairs: B. Dore, Poitiers (FR) 

A. Tasca, Vicenza (IT) 



375 Retrograde intrarenal surgery (RIRS) in the treatment of renal calculi 

G. Giusti, R. Peschechera, A. Conti, G. Taverna, M. Seveso, P. Graziotti (Milan, Italy) 

376 Results after 1116 consecutive procedures of flexible ureterorenoscopy (fURS) of the upper urinary tract 

W.M. Harik, P. Liske, V. Zimmermanns, S. Lahme (Pforzheim, Germany) 

377 FURS improved: How to achieve superior results in flexible ureterorenoscopic treatment of renal calculi? 

M. Schoenthaler, K. Wilhelm, P. Ardelt, A. Katzenwadel, U. Wetterauer, A. Miernik (Freiburg, Germany) 

378 Flexible ureterorenoscopy for the treatment of renal stones: An outcome analysis 

A. Bosio, P. Destefanis, A. Bisconti, M. Carchedi, A. Buffardi, E. Alessandria, E. Dalmasso, C. Ceruti, 

D. Fontana (Turin, Italy) 

379 How high is the intraluminal pressure in the renal pelvis during flexible ureterorenoscopy? 

H.U. Jung, P.J. Osther (Fredericia, Denmark) 

380 Is flexible ureterorenoscopy (fURS) suitable for treatment of stone masses greater than 100mm² in the 

upper urinary tract? 

W.M. Harik, P. Liske, V. Zimmermanns, S. Lahme (Pforzheim, Germany) 

381 A prospective randomized controlled study to analyze the safety and efficacy of percutaneous 

nephrolithotrypsy (PCNL) and retrograde intrarenal surgery (RIRS) in the treatment of renal stones over 2 

cm in diameter 

P. Bryniarski, A. Paradysz, M. Zyczkowski, A. Kupilas, K. Nowakowski, R. Bogacki (Zabrze, Poland) 

382 Bilateral retrograde intrarenal surgery (RIRS) for renal calculi up to 2 cm 


383 Same-session bilateral flexible retrograde intrarenal surgery for the treatment of renal calculi 

C. Verrier, P. Mozer, J. Parra, J. Casenave, F. Richard, M.O. Bitker, P. Conort (Paris, France) 

384 Endourological approach to renal calyceal diverticulum stones (CDS): Comparison of effectiveness and 

morbidity of flexible ureterorenoscopy (fURS) and minimal-invasive percutaneous nephrolithotomy 

(MPCNL) in 48 cases 

S. Kurzidim, V. Zimmermanns, P. Liske, S. Lahme (Pforzheim, Germany) 

385 What should we measure? Predicting outcomes with flexible ureteroscopy for large renal stones 

W.J.G. Finch, R. Johnston, N. Shah, O. Wiseman (Cambridge, United Kingdom) 

386 Flexible uretero-renoscopy: Comparison between basket extraction and spontaneous passage following 

laser disintegration of renal and upper ureteral stones 

Y.M. Eldemerdash, A.R. El-Nahas, A.M. Shoma (Mansoura, Egypt)

387 Robotic use of the commercially available flexible ureterorenoscopes with a new user friendly control 

system 

R. Saglam, E. Koruk, A.S. Kabakci, Z. Tokatli (Ankara, Turkey) 


163 

Sunday

Sunday 




09.15 - 10.45 Foreskin, hypospadias and testis 



Chairs: M. Eissa, Cairo (EG) 

W.F.J. Feitz, Nijmegen (NL) 




388 Topical betamethasone versus clobetasol in pediatric patients with phimosis: A prospective randomized 

clinical trial 

B.S.P. Carvalho, R.E. Lopes, E.M. Araújo, R.A.L. Vasconcelos, M. Leal, J.G.B. Alves, A.A. Calado (Recife, 

Brazil) 

389 Biochemical analysis of phimotic foreskin in patients that used hyaluronidase and betamethasone as 

topical treatment 

L.A. Favorito, J.P. Rosado, L.E.M. Cardoso, F.J.B. Sampaio (Rio de Janeiro, Brazil) 

390 Ontogeny of the human prepuce 

L.A. Favorito, W.S. Silva Costa, F.J.B. Sampaio (Rio de Janeiro, Brazil) 

391 De-circumcising the past: Aulus Cornelius Celcus’ contribution to epispasm during the Hellenistic period 

(323 BCE–146 BCE) 

R. Nair, S. Sriprasad (Datford, United Kingdom) 

* 392 Quantitative measurement of the androgen receptor in prepuces of boys with and without hypospadias 

R. Pichler, G. Djedovic, V. Hauser, E. Richter, H. Fritsch, G. Klinglmair, H. Klocker, R. Müller, C. Radmayr, 

W. Horninger, J. Oswald (Innsbruck, Austria) 

393 Glanuplasty in children with hypospadias under normal anatomy – a clue to successful hypospadias 

correction 

T.N. Garmanova, Y.E. Rudin, D.V. Marukhnenko (Moscow, Russia) 

* 394 Glandular resection and central embedding – bringing grace to hypospadia repair 

P.U. Ardelt, T. Glaser, M. Schoenthaler, E.W. Gerharz, A. Frankenschmidt (Freiburg, Frankfurt, Germany) 

395 Evaluation of distally folded onlay flap in repair of distal penile hypospadias 

E.R. Elsayed, S.M. Khalil, K.M. Abd Alsamad, M.H. Abdallah (Zagazig, Egypt) 

396 Comparative study of different techniques of neourethral coverage using dartos fascia after tubularized 

incised plate urethroplasty 

A.E. Shalaby, A.M.S. Shahin, M.A. Maarouf, R.E. Elsaid, S.A.S. Khalil (Ismailia, Zagazig, Egypt) 

397 Buccal versus lingual mucosal graft urethroplasty for complex hypospadias repair 

A.M. Maarouf, E.R. Elsayed, A. Taelab, E. Salem, W. Shabana, S.A.S. Khalil, A.M.S. Shahin, M. Eladl 

(Zagazig, Egypt) 

398 Comparison of testicular volume in children under age 2 with undescended testis or hydrocele 

P.H. Song, S.J. Yang, D.H. Kwon, J.W. Choi, H.T. Kim, K.H. Moon, J.S. Hyun, T.G. Kwon, H.C. Jung (Daegu, 

Jinju, South Korea)

399 Epididymal anomalies in children with cryptorchidism or hydrocele 

S.O. Kim, S.W. Na, D.H. Yoo, I.S. Hwang, K.J. Oh, S.I. Jung, T.W. Kang, D.D. Kwon, K. Park, S.B. Ryu 

(Gwangju, South Korea) 

400 Laparoscopic orchiectomy for testicular nubbin in impalpable testis: Our new strategy 

Y. Naitoh, A. Kawauchi, J. Soh, K. Kamoi, T. Miki (Kyoto, Japan) 


165 

Sunday

Sunday 




09.15 - 10.45 Testis and penis 



Chairs: P.J. Nyirády, Budapest (HU) 

E. Solsona, Valencia (ES) 



401 Genital Lichen Sclerosus/Balanitis Xerotica Obliterans in men with penile carcinoma - a critical analysis 

P. Philippou, M. Shabbir, D. Ralph, P. Malone, R. Nigam, A. Alex, A. Muneer, S. Minhas (London, United 

Kingdom) 

402 Patients with penile cancer and a history of herniorrhaphy – does lymphatic drainage change? 

A. Ciudin, M.G. Diaconu, J.M. Corral, J. Huguet, J.B. Alcover, M.J. Ribal, A. Alcaraz (Barcelona, Spain) 

403 A combination of a taxane plus cisplatin and 5-fluorouracile (T-PF) in advanced penile squamous cell 

carcinoma (pSCC): Results of a monoinstitutional study 

N. Nicolai, A. Necchi, M. Colecchia, M. Catanzaro, L. Piva, D. Biasoni, S. Stagni, T. Torelli, A. Milani, D. Raggi, 

P. Giannatempo, B. Paolini, R. Salvioni (Milan, Italy) 

404 Effective penile block for circumcision: Circular plus ventral upwards infiltration is an easy and feasible 

technique 

E. Malkoc, F. Ates, S. Uguz, F. Dursun, F. Can, K.V. Baykal (Tekirdag, Istanbul, Turkey) 

405 Primary carcinoma of the male urethra – diagnosis and treatment 

C. Gingu, S. Patrascoiu, C. Surcel, C. Chibelean, M. Harza, V. Zogas, C. Balsanu, A. Dick, C. Mirvald, F. Lupu, 

L. Domnisor, I. Sinescu (Bucharest, Romania) 

406 Residual tumor resections (RTR) in patients with germ cell tumor relapse and salvage-chemotherapy (GCT) 

C. Winter, C. Bingöl, P. Albers (Düsseldorf, Germany) 

407 Laparoscopic retroperitoneal lymph node dissection (L-RPLND) in clinical stage I non-seminomatous germcell 

tumours of the testis (NSGCTT): Towards the mini-invasive single strategy option 

N. Nicolai, D. Biasoni, M.A. Catanzaro, S. Stagni, T. Torelli, L. Piva, A. Milani, A. Necchi, D. Raggi, 

P. Giannatempo, M. Colecchia, B. Paolini, R. Salvioni (Milan, Italy) 

408 Organ sparing technique without ischemia for testicular tumors 

N. Leonhartsberger, R. Pichler, B. Stöhr, H. Steiner (Innsbruck, Austria) 

409 Long-term results of post-chemotherapeutic laparoscopic retroperitoneal lymph node dissection in 100 

NSGCT patients 

H. Steiner, R. Pichler, B. Stöhr, R. Peschel, N. Leonhartsberger (Innsbruck, Austria) 

410 Reproductive function analysis and morphological assessment of the germinal epithelium of adult rats 

submitted to testicular torsion before and during puberty 

C. Ribeiro, R.M. Lange, J.L. Medeiros Jr, D.B. De Souza, W.S. Costa, M.A. Pereira-Sampaio, F.J.B. Sampaio 

(Rio de Janeiro, Niteroi, Brazil) 

411 A scoring system for testicular torsion: Decreasing costs and therapeutic delay 

J.A.B.A. Barbosa, C.M. Oliveira, B.C. Tiseo, C.C. Passerotti, M. Srougi, H.T. Nguyen, A.B. Retik (Boston, 

United States of America; Sao Paulo, Brazil)

412 Snail shell appearance of epididymis is a reliable sign of testicular loss after testicular torsion 

M.M. Oh, D.G. Moon, M.G. Park, J.W. Kim, J.H. Bae, H.S. Park, J.J. Kim, Y.J. Lee, J.G. Lee, J.H. Kim (Seoul, 

Busan, South Korea) 


167 

Sunday

Sunday 




09.15 - 10.45 Brachy- and radiotherapy 



Chairs: L. Trojan, Mannheim (DE) 

T. Wiegel, Ulm (DE) 




413 Permanent interstitial low-dose rate brachytherapy for patients with localized prostate cancer – a 

systematic review of randomized and non-randomized controlled clinical trials 

F. Peinemann, U. Grouven, C. Bartel, S. Sauerland, H. Borchers, M. Pinkawa, A. Heidenreich, S. Lange 

(Cologne, Viersen, Aachen, Germany) 

* 414 Brachytherapy for the treatment recurrence prostate cancer after radical prostatectomy. A phase II trial 

F. Gomez Veiga, I. Gomez, L. Castelo, S. Pertega, A. Mariño, C. Fernandez, A. Candal, J. Casas, 

A. Zarraonaindia, S. Pita, V. Abal (A Coruña, Spain) 

415 Quality of life (QL) after interstitial brachytherapy (IB) in patients (pts) treated for localized prostate cancer 

(LPC): Medium-term outcomes from a prospective monoinstitutional study 

O. Caffo, G. Fellin, S. Mussari, C. Divan, F. Coccarelli, F. Ziglio (Trento, Italy) 

416 Routine cystoscopy prior to low dose rate prostate brachytherapy: Is it justified? 

N.J. Mehan, J. Bucci, Y. Chin, D. Malouf (Sydney, Australia) 

* 417 Evaluation of survival outcomes in patients given early salvage radiotherapy of 70 Gy after post-radical 

prostatectomy biochemical failure vs high-dose-rate brachytherapy boost 

J.R. Cortes-Gonzalez, M. Hjelm-Eriksson, E. Castellanos, G. Cohn-Cedermark, S. Levitt, B. Lennernäs, 

K.M. Kälkner, S. Nilsson (Stockholm, Gothenburg, Sweden; Minneapolis, United States of America) 

418 Time matters - the development of 4D brachytherapy 

E. Chadwick, S. Javed, R.W. Laing, S.E.M. Langley (Guildford, United Kingdom) 

419 Radiotherapy and concomitant docetaxel in very high risk prostatic cancer: Initial experience in the first 30 

cases 

A. Guttilla, R. Bortolus, F. Zattoni, A. Garbeglio, M. Arcicasa, G. Catalano, F. Zattoni (Padua, Aviano, 

Pordenone, Italy) 

* 420 Salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. A national Danish 

study 

M. Ervandian, M. Høyer, S.E. Petersen, L. Sengeløv, S. Hansen, M. Holmberg, J. Svejstrup, P.M. Petersen, 

M. Borre (Aarhus, Herlev, Odense, Aalborg, Copenhagen, Denmark) 

* 421 Identifying patients at real risk of dying from prostate cancer. A novel risk score for the selection of 

patients candidate for adjuvant radiation therapy 

F. Abdollah, U. Capitanio, N. Passoni, N. Suardi, R. Matloob, L.F. Da Pozzo, E. Farina, N. Di Muzio, 

C. Cozzarini, A. Briganti (Milan, Italy) 

422 Value of adjuvant radiotherapy in prostate cancer pT2 with positive margins and postoperative PSA below 

0.2 ng/ml 

R. Bonniol, E. Lelong, L. Nkhali, B. Dubray, A. Benyoucef, C. Pfister (Rouen, France)

423 Quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer 

A. Goineau, V. Marchand, S. Bourdin, E. Rio, L. Campion, A. Lisbona, M.A. Mahé, S. Supiot (St Herblain, 

Paris, France) 


169 

Sunday

Sunday 




09.15 - 10.45 Prostate cancer: Novel biomarkers 1 



Chairs: R.J. Bryant, Oxford (GB) 

H.G. Lilja, New York (US) 



424 ERG immunocytochemistry can identify prostate cancer patients prior to prostate biopsy 

R.P. Pal, E.J. Hollox, L. Cresswell, J.H. Pringle, C.D. Veal, R. Hew, J.K. Mellon, R.C. Kockelbergh, J.G. Barwell 

(Leicester, United Kingdom) 

425 ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after 

radical prostatectomy for prostate cancer 

A.M. Hoogland, G. Jenster, W.M. Van Weerden, J. Trapman, T. Van Der Kwast, M.J. Roobol, F.H. Schröder, 

M.F. Wildhagen, G.J.L.H. Van Leenders (Rotterdam, The Netherlands; Toronto, Canada) 

426 Urine TMPRSS2: ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are 

correlated to the results of prostatic biopsies in men at risk of prostate cancer 

J.N. Cornu, G. Cancel-Tassin, C. Egrot, C. Gaffory, F. Haab, O. Cussenot (Paris, France) 

427 Correlation between ERG rearrangement and PTEN loss with capsular penetration in prostate cancer 

L. Brosh, E. Abril, C. Cortez, A. Algotar, W. Meek, E. Dexter, R. Dittamore, B. Dalkin, R. Nagle, G. Pestano 

(Tucson, United States of America) 

428 Involvement of molecular factors in the prognosis of prostate cancer patients treated with radical 

prostatectomy according to status of the TMPRSS2-ERG fusion gene 

J. Rubio-Briones, A. Fernandez-Serra, A. Calatrava, J. Casanova, L. Rubio-Martinez, A. Gomez-Ferrer, 

A. Collado, M. Ramirez, Z. Garcia-Casado, J. Dominguez-Scrig, I. Iborra, E. Solsona, J.A. Lopez-Guerrero 

(Valencia, Spain) 

429 PCR-based detection of circulating tumor cells in prostate cancer - preliminary experience 

T. Todenhöfer, J. Hennenlotter, S. Feyerabend, U. Kühs, J. Fetisch, S. Aufderklamm, G. Gakis, A. Stenzl, 

C. Schwentner (Tübingen, Langenhagen, Germany) 

430 Cell cycle progression genes differentiate indolent from aggressive prostate cancer 

S.M. Stone, J. Cuzick, J.E. Reid, D. Mesher, D.M. Berney, H. Møller, V.O. Speights, G. Fisher, A. Gutin, 

G.P. Swanson, J.S. Lanchbury (Salt Lake City, Temple, San Antonio, United States of America; London, United 

Kingdom) 

431 Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary 

radical prostatectomy cohort 

M.R. Cooperberg, J.P. Simko, J.E. Cowan, J.E. Reid, S. Bhatnagar, A. Gutin, J.S. Lanchbury, S.M. Stone, 

P.R. Carroll (San Francisco, Salt Lake City, United States of America) 

432 Endothelin-1 (ET-1) and nuclear factor-kappa B (NF-κB) are directly interrelated and predict biochemical 

recurrence of hormone naive prostate cancer after radical prostatectomy 

P.J. Vlachostergios, G. Kakkas, G. Moutzouris, F. Karasavvidou, K. Kapatou, D.D. Daliani, M. Melekos, 

C.N. Papandreou (Larissa, Greece)

433 High NRBP1 expression in prostate cancer is associated with poor clinical outcomes and increased cancer 

cell growth 

C. Ruiz, M. Oeggerli, M. Germann, G.N. Thalmann, T. Gasser, A. Bachmann, L. Bubendorf, C.A. Rentsch 

(Basel, Berne, Switzerland) 

434 Four loci at 11q12, 10q26, 3p11.2, and 2p11 are associated with prostate cancer susceptibility in the 

Japanese population 

S. Akamatsu, R. Takata, C.A. Haiman, T. Inoue, A. Takahashi, M. Kubo, M. Furihata, N. Kamatani, J. Inazawa, 

G.K. Chen, L.L. Marchand, L.N. Kolonel, H. Yamada, S. Egawa, T. Fujioka, B.E. Henderson, T. Habuchi, 

O. Ogawa, Y. Nakamura, H. Nakagawa (Kyoto, Morioka, Yokohama, Nankoku, Tokyo, Akita, Japan; Los 

Angeles, Honolulu, United States of America) 

435 Circulating microRNAs are associated with the development and progression of prostate cancer 

R.J. Bryant, T. Pawlowski, J.W.F. Catto, G. Marsden, R.L. Vessella, B. Rhees, C. Kuslich, T. Visakorpi, 

F.C. Hamdy (Oxford, Sheffield, United Kingdom; Phoenix, Seattle, United States of America; Tampere, 

Finland) 

436 Let-7b is down-regulated in high risk prostate cancer and correlates with clinical failure 

M. Schubert, B. Kneitz, S. Kneitz, C.J. Scholz, S. Joniau, H. Van Poppel, H. Riedmiller, M. Spahn (Würzburg, 

Germany; Leuven, Belgium) 

437 Polymorphisms inside MicroRNAs and MicroRNA target sites predict clinical outcomes in prostate cancer 

patients receiving androgen-deprivation therapy 

S.P. Huang, B.Y. Bao, J.B. Bao, C.N. Huang, Y.S. Pu, T.Y. Chang, Y.H. Lan, T.L. Lu, H.Z. Lee, S.H. Juang, 

L.M. Chen, C.J. Hsieh (Kaohsiung, Taichung, Taipei, Taiwan) 


171 

Sunday

Sunday 


11.00 - 12.00 Andrology 




Chair: I. Eardley, Leeds (GB) 

11.00 - 11.20 State-of-the-art lecture Genital dermatology 

C. Bunker, London (GB) 


Effective practice of male genital dermatology entails the exclusion of sexually transmitted disease, the 

mitigation or relief of sexual dysfunction (male dyspareunia), the minimisation of urological dysfunction and 

the reduction or abolition of the risk of penis cancer. The diagnosis, differential diagnosis and management 

of the principal genital dermatoses will be discussed; psoriasis, Zoon’s acute balanitis, lichen planus, lichen 

sclerosus and carcinoma in situ. 

11.20 - 11.40 State-of-the-art lecture Sperm retrieval in the 21st century 



Sperm retrieval in combination with IVF/ICSI is the only medical procedure for an azoospermic man to father 

a child. Different techniques, especially TEsticular Sperm Extraction (TESE), have evolved over time and 

have improved the chance for sperm retrieval. In Obstructive Azoospermia (OA), open and percutaneous 

techniques have been successfully used to retrieve elongated spermatids in nearly 100%. In Non-Obstructive 

Azoospermia (NOA), meaning a deficiency of spermatogenesis, the retrieval rate is significantly lower at 

about 50%. Unfortunately, a prediction for the success in these cases is not really given, high serum FSH and 

small testicular volumes do not exclude a successful sperm retrieval. Technically a multifocal TESE and the 

addition of microsurgical techniques (M-TESE) is suggested. Pre-conditions for a successful TESE programme 

are cryopreservation facilities, a genetic analysis preoperatively including y-deletions and Klinefelter-S. For 

TESE a testicular score evaluating elongated spermatids seems to be of practical use. Evidence for Testicular 

Intraepithelial Neoplasia (TIN) should be evaluated. Postoperatively a consecutive hypogonadism has to be 

considered. 

11.40 - 12.00 State-of-the-art lecture Modern concepts of penile rehabilitation following radical prostatectomy 

J.P. Mulhall, New York (US) 


- To appreciate the pathophysiology of erectile dysfunction after radical prostatectomy. 

- To understand the concept of venous leak. 

- To understand the concept of cavernosal oxygenation. 

- To appreciate the animal data supporting penile rehabilitation. 

- To understand the human data supporting and refuting penile rehabilitation.



11.00 - 12.00 Update in paediatric urology 


Chair: G.A. Bogaert, Leuven (BE) 

11.00 - 11.20 State-of-the-art lecture Clinical management of nocturnal enuresis 

G. Läckgren, Uppsala (SE) 


Nocturnal enuresis in a child >5 years of age may be a significant stress factor for the child and the family 

and needs a proper evaluation and treatment. Nocturnal polyuria, bladder overactivity and high arousal 

threshold are the main pathogenic causes behind enuresis and often these factors may overlap. The primary 

evaluation should include a proper history and voiding chart and does not primarily demand sofisticated 

diagnostic procedures. 

The strategy for the treatment must be easy to follow and based on the motivation and wishes of the patient 

and their family. The first line treatment should include: Bladder and bowel advice and if needed followed 

by enuresis alarm and/or desmopressin - treatment. Children with therapy resistent enuresis (20-25% of 

the patients) usually have nocturnal detrusor overactivity combined with a high arousal threshold. These 

children should be referred to specialised centres. Aspects on the different steps in the treatment of enuresis 

are going to be presented and discussed. 

11.20 - 11.40 State-of-the-art lecture Paediatric urologic advanced imaging: Techniques and applications 

G. Sebag, Paris (FR) 


MR urography (MRU) is an advanced non ionizing imaging technique particularly promising in paediatric 

urology as it can potentially provide both morphological and functional information in a single examination. 

While the contribution of MRU to the anatomical evaluation of uropathies and hydronephrosis is well 

accepted, its contribution to functional evaluation remains controversial as there is no complete consensus 

on how to perform functional MRU. 

Different approaches have been proposed including: 

- which sequences to use 

- when to inject Gadolinium chelates and Furosemide 

- MR post processing (several freely downloadable software) 

- MR functional parameter 

- Split Renal Function (SRF) assessment using the right-left renal parenchyma volume ratio, the area under 

the enhancing curve method, the Rutland-Patlak plot or a combination of both i.e. Rutland-Patlak plot 

weighted by renal volumes 

- Excretion using excretory renogram shape according to O’Reilly categories, time intervals including Renal 

Transit Time (RTT) Calyceal Transit Time (CTT). 

Pros and cons will be discussed and illustrated as well as tips and tricks. 

11.40 - 12.00 State-of-the-art lecture Robotics in paediatric urology: Challenges, indications and tricks 

L.H. Olsen, Aarhus (DK) 


The main indication for robotics in paediatric urology is dismembered pyeloplasty in congenital 

hydronephrosis. While the standard access to an open pyeloplasty is through the retroperitoneal route most 

centres using robotics, access the kidney transperitoneally in order to avoid the constraints dictated by the 

small retroperitoneal space. Retroperitoneoscopic robotic access, which also offers a route for performing 


173 

Sunday

Sunday 


heminephrectomy, will be described in detail. Additionally, robotic surgery for Muellerian duct remnants, 

Mitrofanoff procedure and transvesical access will be discussed.



11.00 - 12.00 Renal cancer - Choice of treatment 


Chair: P.F.A. Mulders, Nijmegen (NL) 

11.00 - 11.20 State-of-the-art lecture Nephron sparing approaches 

M. Kuczyk, Hanover (DE) 


The nephron-sparing approach even for renal cell cancer of clinical stage T1b has been implemented in 

the most recent version of the EAU guidelines. Therefore, the first aim of this presentation is to discuss 

the oncological safety of this treatment strategy in addition to a positive impact on the patients´ clinical 

prognosis during the long-term run, the latter possibly resulting from a better preservation of renal function. 

The second aim is to discuss whether one of the available surgical treatment options e.g. open, laparoscopic 

or robot-assisted partial nephrectomy might reveal a more or less obvious clinical benefit for the individual 

patient. 

11.20 - 11.40 State-of-the-art lecture Intergrating surgical and medical therapy 

A. Bex, Amsterdam (NL) 


Targeted Therapy (TT) has improved the management of advanced and metastatic RCC. For the first time 

partial responses are not only observed at metastatic sites, but in primary tumours. This has renewed interest 

in combining TT with surgery in the metastatic and non-metastatic setting. Treatment sequencing strategies 

and ongoing studies, both phase II and randomised phase III for metastatic and non-metastatic RCC will 

be highlighted. Selection of patients, downsizing primary tumours to facilitate nephron sparing surgery or 

resection of bulky lesions and the safety of surgery in combination with targeted therapy will be discussed. 

11.40 - 12.00 State-of-the-art lecture Individualising therapy based on molecular markers 

T. Powles, London (GB) 


The identification of molecular markers associated with response and resistance to targeted therapy is 

urgently required in renal cancer. Currently a series of markers are under evaluation. Tissue, plasma, germ 

line material have been collected and analysed. Functional imaging data is also available. The preliminary 

results are mixed with some markers requiring further evaluation and others looking less promising. The 

aim of this lecture is to cover these issues and outline a direction for the future. 


175 

Sunday

Sunday 




11.00 - 12.00 Infection and inflammation in urology 



11.00 - 11.20 State-of-the-art lecture Infection and inflammation following prostate biopsy: Results from a large 

prospective study 

D.J. Rosario, Sheffield (GB) 


This study evaluated generalisable rates of patient-reported adverse events, associated healthcare contact 

during the 35 days following TRUS-Bx biopsy and attitudes to future biopsies. 

Patient-reported outcomes of adverse events of an observational cohort study of 1147 men receiving primary 

biopsy were collected in a structured questionnaire at baseline and over 35 days and coupled with review of 

medical records. A high response rate at seven and 35 days at 1090 (95%) and 1018 (89%) respectively was 

a particular strength of this study. The data from this study will be presented and implications for practice 

discussed. 

11.20 - 11.40 State-of-the-art lecture Old infections and new challenges: Revisiting urogenitial tuberculosis 

E. Kulchavenya, Novosibirsk (RU) 


Aims: To compare epidemiology of urogenital tuberculosis (UGTB), to reveal modern features of UGTB, to 

improve the diagnostic and results of the therapy of the disease. 

Objectives: One of the main reasons for late diagnosis of UGTB is an atypical clinical feature; it is hidden by 

the mask of another disease. Most common masks will be estimated, diagnostic algorithm will be offered. 

The frequency of culture-positive cases decreased, mostly because of inappropriate antibacterial therapy 

for UTI – we shall discuss the way of improving of the diagnostic. Prostate tuberculosis is overlooked in 

thousands of men; the role of prostate biopsy in the diagnostic of prostate tuberculosis will be disclosed. 

11.40 - 12.00 State-of-the-art lecture Urinary tract infection: Rapid diagnosis 

J. Liao, Stanford (US) 


Urinary Tract Infection (UTI) is a common bacterial infection that affects all patient demographics. Definitive 

diagnosis requires urine culture and the associated antimicrobial susceptibility testing, in which urine 

samples are sent to centralised clinical microbiological laboratories and has a typical delay of 2-3 days. Due 

to this delay, physicians often prescribe antibiotics empirically based on symptoms and historic antimicrobial 

susceptibility data. Such practice has contributed to injudicious use of antibiotics and rise in multi-drug 

resistant pathogens. In this talk, we describe the development of a biosensor-based approach for rapid 

molecular diagnosis of UTI. Currently, we have achieved successful pathogen identification within 1 hour 

and antimicrobial susceptibility testing within 3 hours. Using microfluidics technology to automate sample 

preparation steps, we anticipate in the future to be able to translate the rapid biosensor-appraoch for UTI 

diagnosis to the point-of-care settings, leading to better management of UTI.



11.00 - 12.00 Transplant and cancer: Controversies and challenges 


Chair: F.J. Burgos Revilla, Madrid (ES) 

Panel: M. Giessing, Düsseldorf (DE) 

G. Karam, Nantes (FR) 

J.D. Olsburgh, London (GB) 


The aim of the session is to discuss the contoversial issues in kidney donation and transplantation processes 

and establish the optimal management in basis to Guidelines recommendations and panel expert 

experience. 

The objectives will be focused in different situations of: 

- Donation: Donors with increased PSA levels, deceased or living donors with Renal Cell Carcinomas (RCC), 

donors with previous history of neoplasia. Which should be the criteria for accepting these donors and 

using the kidneys for transplantation? 

- Recipients with previous history of neoplasia represent a dilemma regarding the moment for inclusion 

in the waiting list, specially considering that immunosuppression may increase the risk of neoplasia 

recurrence. The waiting time for inclusion depending on the type, stage and grade of the tumour will be 

discussed. 

- The risk of cancer development after kidney transplantation and immunosuppression is higher than in the 

general population. However, the criteria for treatment of these tumours can be influenced by previous 

organ transplantation and it is a matter of controversy. A review of urological neoplasia treatment (kidney 

- native and graft -, prostate, bladder) in the kidney transplant population will be updated in relation to 

specific clinical situations presented by the chairman and answered by the panel in an interactive session. 


177 

Sunday

Sunday 




11.00 - 12.00 History of urology in France 


Chair: D. Schultheiss, Giessen (DE) 

11.00 - 11.20 State-of-the-art lecture French urologists in the 19th century 

P.E. Van Kerrebroeck, Maastricht (NL) 


Aims: To present important French urologists active during the 19th century in France and critically analyse 

the relevance of their contributions. 

Objectives: The development of Urology in France during the 19th century will be discussed in view of earlier 

activities in the field of lithotomy and lithotripsy. Starting with Jean Civiale, the work of Félix Guyon, the first 

worldwide to have a chair in Urology, will be presented as well as the innovations of Charrière, Nélaton, 

Beniqué and many others. Finally, the role of Joaquin Albarran, the successor to Guyon, as transition to 

Urology of the 20th century will be described. 

11.20 - 11.40 State-of-the-art lecture The urologist and his instrument maker 

M. Zykan, Vienna (AT) 


At the beginning of the 19th century the young Swiss Joseph Benoit Charrière moved to Paris to train as an 

apprentice cutler. Due to his talent and diligence he became one of the most renowned instrument makers 

of his time. The presentation deals with Charrière’s success story and reveals some of his “victories” as well 

as some of his “struggles”. Working together with the most famous Parisian surgeons, Charrière took great 

effort in the development of instruments to improve urological diagnosis and therapy. Although Charrière 

became head of the largest and most important surgical instrument making company he was involved in a 

number of quarrels and even law suits. The one between him and Leroy D’Etiolles reveals the fierce struggle 

for priority. 

11.40 - 12.00 State-of-the-art lecture The wall paintings of the ‘Salle de Garde’: A remarkable tradition in French 

hospitals 

T. Lebret, Suresnes (FR) 


From time immemorial wall paintings have been common for exorcising fear, sex and death. For more 

than 150 years the walls of ‘Salle de Garde’ (common room used by interns for resting) have been covered 

by paintings by famous artists including Bellaery-Desfontaines, Louis Français, Toulouse-Lautrec and 

Gustave Doré. Artistic fashion has influenced these artists therefore many styles including Art Noveau, Art 

Deco, surrealism, Cubism and Cartoon are expressed. There is a predominant humoristic sexual element 

in the paintings and urological themed illustrations which were relevant to the residents training are often 

depicted. These ephemeral works of art represented resident life and are a real cultural heritage of French 

medical history.



11.00 - 12.00 Urogenital imaging: A session by the European Society of Urogenital 

Radiology 


Chair: G. Heinz-Peer, Vienna (AT) 

11.00 - 11.20 State-of-the-art lecture Multiparametric MR imaging: A further step in diagnosing and follow-up of 


F. Cornud, Paris (FR) 


The first objective of this presentation is to show how multiparametric MRI can localise tumour foci of 

prostate cancer and how it can help to predict tumour volume and Gleason score in patients diagnosed with 

a low-risk tumour. 

The second objective is to show why it may be time to consider MRI prior to initial biopsy to detect potentially 

aggressive tumours by targeted biopsies using a deformable TRUS-MRI image fusion system and to consider 

biopsy deferment in patients with no MRI abnormality. The final goal is to show how MRI could be used as a 

triage test to avoid over-diagnosis of insignificant cancer and under-estimation of significant tumours. 

11.20 - 11.40 State-of-the-art lecture New aspects in imaging hematuria 

G. Heinz-Peer, Vienna (AT) 


Hematuria is the term for presence of an abnormal amount of blood in the urine and may be a symptom of 

an underlying serious disease. Subgroups include visible (macroscopic or gross) and invisible (microscopic) 

hematuria. Many patients with microscopic hematuria have no abnormalities following extensive 

investigations. 

The possibility of a distinction between nephrological and urological causes is important to allow correct 

specialist referral at an early stage. 

The aim of management should be prompt detection and treatment of serious underlying causes of hematuria, 

whilst minimising the number of tests conducted in patients with benign causes. CT-Urography can accurately 

detect malignant lesions and stones of the urinary tract. Tumours of the urothelium (transitional cell 

carcinomas) are by far the most common causes of macroscopic, painless hematuria. Bladder malignancies, 

comprising approximately 95% of all such lesions. When a clinical diagnosis of bladder cancer is suspected 

initial investigation includes lower urinary tract endoscopy. Flexible cystourethroscopy allows assessment 

of the entire urethra and the entire urinary bladder. Usually after endoscopic visualisation of a bladder 

tumour, the histopathologic diagnosis and initial treatment of the tumour are achieved by TUR (transurethral 

resection). Limitations of conventional cystoscopy include diminished visualisation of the bladder neck and 

within diverticula and technical difficulties in patients with urinary diversion. Cystoscopy is contraindicated in 

patients with bacteriuria, acute cystitis, urethritis, prostatitis, obstructive prostatic hypertrophy, and stricture 

or rupture of the urethra. In rare cases complications like iatrogenic injury to the urethra and bladder as well 

as urinary sepsis may occur due to cystoscopy. 

This lecture aims to bring to the modern urologist new approaches in evaluation of hematuria. The strengths 

of new imaging techniques, especially Split-Bolus CT-Urography, will be discussed. This presentation is a 

must for the elder resident and the younger urologist beginning his/her career but also for well trained 

urologists. The participants will get insight into when and how to refer patients with hematuria for imaging 

studies. 


179 

Sunday

Sunday 

11.40 - 12.00 State-of-the-art lecture Recent advances in pelvic floor imaging in patients with urinary incontinence 


C. Alt, Heidelberg (DE) 


Pelvic floor dysfunction, associated with a variety of symptoms like urological, gynecological and intestinal 

disorders can strongly affect quality of life. Regarding urological symptoms, urinary stress incontinence 

and urge incontinence are the leading ones, commonly associated with traction or pulsion cystocele. For 

therapy planning, the depiction of all involved parts of entire pelvis will be essential. With dynamic MRI, 

the entire pelvis and the position relationship of the pelvic organs can be visualised. This lecture presents 

how to perform and evaluate dynamic MRI and demonstrates the handling with this information for therapy 

planning.



11.00 - 13.00 Surgery in Motion 


Moderators: M. Graefen, Hamburg (DE) 

F. Montorsi, Milan (IT) 


H.G. Van Der Poel, Amsterdam (NL) 



11.05 - 11.25 Transvaginal nephrectomy 


11.25 - 11.45 Single port nephrectomy 

J.H. Kaouk, Cleveland (US) 

11.45 - 12.05 Preserving the urethral sphincter length during prostatectomy 

T. Schlomm, Hamburg (DE) 

12.05 - 12.25 Nerve preservation with special attention for the prostatic artery 

V.P. Patel, Celebration (US) 

12.25 - 12.45 Intracorporal robot diversion 

P. Wiklund, Stockholm (SE) 



181 

Sunday

Sunday 




12.15 - 13.45 Tips and tricks in robotic prostatic surgery 



Chairs: H.P. Beerlage, ‘s-Hertogenbosch (NL) 

R.J.A. Van Moorselaar, Amsterdam (NL) 

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion. 

V15 Management of difficult anatomy during RARP: The median lobe 

S. Chauhan, O. Schatloff, K.J. Palmer, A. Sivaraman, V.R. Patel (Celebration, United States of America) 

V16 Management of anterior, posterior and median lobes during robot assisted radical prostatectomy 

S. Chauhan, O. Schatloff, K.J. Palmer, A. Sivaraman, V.R. Patel (Celebration, United States of America) 

V17 Noose technique for securing the dorsal venous complex during robotic prostatectomy using the V-Loc 

suture 

C.M. Chin (Singapore, Singapore) 

V18 V-loc barbed suture for hemostasis and reconstruction in robotic surgery 

A. El Hajj, W. Massoud, N. Mentine, M. Fourati, F. Girard, M. Fennouri, O. Dumonceau, H. Baumert (Paris, 

France) 

V19 V-loc suture for posterior reconstruction and vesicourethral anastomosis during robotic prostatectomy 

C.M. Chin (Singapore, Singapore) 

V20 The role of prostatic vasculature as an intraoperative landmark for nerve sparing during robot assisted 

radical prostatectomy 

O. Schatloff, S. Chauhan, R. Valero, Y.H. Ko, A. Sivaraman, R.F. Coelho, M.A. Orvieto, B. Rocco, D. Kameh, 

K.J. Palmer, V.R. Patel (Celebration, United States of America) 

V21 Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: Usefulness of 

the fourth arm 

G. Fournier, M.A. Perrouin Verbe, G. Papin, V. Joulin, C. Deruelle, A. Valeri (Brest, France)



12.15 - 13.45 Screening for urothelial carcinoma: Methods and implications 



Chairs: M. Babjuk, Prague (CZ) 

R.T. Bryan, Birmingham (GB) 




438 Financial and clinical outcomes of the introduction of a rapid-access one-stop haematuria clinic to a UK 

teaching hospital 

V. Kasivisvanathan, S. Ivaz, M. Gulati, R. Harvey, R. Kucheria, D. Hrouda (London, United Kingdom) 

439 Non-invasive detection of bladder cancer by electromagnetic interaction 

F. Esperto, C. Kastner, K. Patel, C. De Nunzio, A. Tubaro (Rome, Italy; Cambridge, United Kingdom) 

440 CT cistography in the detection of bladder tumors: A new non-invasive technique? 

G.M. Busetto, V. Panebianco, G. Antonini, R. Giovannone, M. Di Placido, V. Gentile, R. Passariello, E. De 

Berardinis (Rome, Italy) 

441 CT-urography as tailored-imaging for urologic pathologies 

F. Lanzi, S. Agostini, E. Bertelli, L. Masieri, S. Giancane, C. Giannessi, L.E. Quattrone, M. Carini, I. Menchi 

(Florence, Italy) 

442 Increased rates of false positive urine based bladder cancer markers due to impaired renal function 

T. Todenhöfer, J. Hennenlotter, M. Witstruk, G. Gakis, S. Aufderklamm, U. Kühs, A. Stenzl, C. Schwentner 

(Tübingen, Germany) 

443 Stratifying risk in asymptomatic microscopic hematuria 

R.K. Loo, S.F. Lieberman, J.M. Slezak, S.J. Jacobsen (Downey, Portland, Pasadena, United States of America) 

444 Predictive value of urine-based tumor markers in a bladder cancer screening population 

S. Banek, C. Schwentner, D. Tager, M. Nasterlack, G. Leng, B. Pesch, K.D. Sievert, F. Eberle, C. Wiens, 

K.G. Bierfreund, T. Brüning, A. Stenzl (Tübingen, Bochum, Ludwigshafen, Leverkusen, Germany) 

445 Diagnostic accuracy of photodynamic diagnosis of upper urinary tract transitional cell cancer (UUT-TCC): 

A prospective cohort study 

O. Aboumarzouk, E. Mains, S. Ahmad, B. Somani, G. Nabi, S. Kata (Dundee, United Kingdom) 

446 Narrow-band imaging (NBI) in flexible cystoscopy improves diagnosis of bladder pathology in the 

outpatient clinic 

J.B. Jensen, S. Høyer (Aarhus, Denmark) 

* 447 Outcomes of a European bladder cancer screening program using home hematuria testing and molecular 

markers 

C.H. Bangma, S. Loeb, X. Zhu, S. El Bouazzaoui, J. Refos, K. Van Der Keur, S. Tjin, C. Franken, E. Zwarthoff, 

M. Roobol (Rotterdam, The Netherlands; New York, United States of America) 


183 

Sunday

Sunday 

* 448 Hereditary urothelial carcinomas of the upper urinary tract are underestimated and misclassified as 

sporadic tumours: Results of the French Collaborative Database on UUT-UCC 

F. Audenet, P. Colin, D.R. Yates, A. Ouzzane, G. Pignot, J.A. Long, B. Albouy, M. Roumiguié, V. Phé, 

S. Crouzet, H. Bensadoun, N. Hoarau, C. Maurin, L. Guy, A. Ruffion, F. Delage, L. Cormier, N. Brichart, 

S. Droupy, E. Xylinas, F. Saint, P.O. Faïs, A. Houlgatte, M.D. Azemar, M. Rouprêt (Paris, Lille, Grenoble, 

Rouen, Toulouse, Suresnes, Lyon, Caen, Angers, Marseille, Clermont-Ferrand, Brest, Dijon, Tours, Nîmes, 

Creteil, Amiens, Reims, France) 

184 Programme Book



12.15 - 13.45 Radical prostatectomy: Complications and learning curve 



Chairs: J. Rassweiler, Heilbronn (DE) 

V. Ravery, Paris (FR) 




449 Postoperative lymphoceles after radical prostatectomy and pelvic lymphadenectomy: Are there any 

predictors? 

A. Hegele, T. Laumeier, P. Olbert, F. Brüning, R. Hofmann (Marburg, Germany) 

450 What prevents lymphocele development after laparoscopic radical prostatectomy? 

Y. Yasumizu, A. Miyajima, T. Maeda, T. Takeda, M. Hasegawa, E. Kikuchi, M. Oya (Tokyo, Japan) 

* 451 Therapeutic algorithm for the management of pelvic lymphoceles after radical prostatectomy based on 

multicentre community based retrospective study 

W.Y. Khoder, M. Trottmann, M. Seitz, A. Buchner, C.G. Stief, A.J. Becker (Munich, Germany) 

452 Incidence of symptomatic lymphoceles after radical prostatectomy depends on surgical method, extent of 

resection and body mass index 

D. Schilling, J. Hennenlotter, J. Mundhenk, D. Selbherr, J.C. Martzog, C. Schwentner, A. Stenzl (Tübingen, 

Germany) 

453 Leapfrog volume thresholds and perioperative complications after radical prostatectomy 

Q.D. Trinh, J. Sammon, M. Bianchi, K.R. Ghani, J. Jhaveri, W. Jeong, J. Schmitges, S. Sukumar, A. Dabaja, 

P.K. Agarwal, C.G. Rogers, J.O. Peabody, M. Menon, M. Sun (Detroit, United States of America; Montreal, 

Canada; Hamburg, Germany) 

* 454 Intraoperative and postoperative complications encountered in patients undergoing robotic-assisted 

laparoscopic radical prostatectomy. An analysis of 3000 consecutive cases 

A.P. Labanaris, V. Zugor, C. Wagner, A. Schuette, P. Lange, H. Witt (Gronau, Germany) 

455 Evaluation of the learning curve in robotic assisted radical prostatectomy for patients with organ confined 


Z. Bütow, C.H. Ohlmann, J. Kamradt, M.W.W. Janssen, S. Siemer, S. Gräber, M. Stöckle (Homburg/Saar, 

Germany) 

* 456 Thromboembolic events following surgical procedures for prostate cancer 

M. Van Hemelrijck, H. Garmo, L. Holmberg, P. Stattin, J. Adolfsson (London, United Kingdom; Umea, 

Stockholm, Sweden) 

* 457 Secondary partial rupture of the vesicourethral anastomosis following robot-assisted laparoscopic radical 

prostatectomy. Diagnosis, therapy and functional outcomes 

A.P. Labanaris, J.H. Witt, C. Wagner, P. Lange, V. Zugor (Gronau, Germany) 

458 Simple method of preventing postradical retropubic prostatectomy inguinal hernia 

H. Koike, H. Matsui, Y. Shibata, M. Hatori, K. Ito, K. Suzuki (Maebashi, Japan) 


185 

Sunday

Sunday 

459 Dedicated fellowship in console surgery accelerates but not suppresses the learning curve in RALP 

N. Doumerc, M. Roumiguie, N. Mingat, X. Game, C. Mazerolles, P. Rischmann, P.D. Strycker, B. Malavaud 

(Toulouse, France; Sydney, Australia) 

460 Robot assisted laparoscopic prostatectomy (RALP): The learning curve of the nodal dissection 

H.G. Van Der Poel, B.K. Kroon, A. Bex, W. De Blok, C. Tillier, H.M. Van Muilekom (Amsterdam, The 

Netherlands) 

186 Programme Book



12.15 - 13.45 Management of NDO: Botulinum toxin, antimuscarinics and more 



Chairs: E. Chartier-Kastler, Paris (FR) 

P. Dasgupta, London (GB) 




* 461 Efficacy of onabotulinumtoxinA in neurogenic detrusor overactivity is independent of concomitant 

anticholinergic use 

K.D. Sievert, J. Heesakkers, D. Ginsberg, F. Cruz, B. Jenkins, C. Thompson, W. Lam, C. Haag-Molkenteller 

(Tübingen, Germany; Nijmegen, The Netherlands; Los Angeles, Irvine, United States of America; Porto, 

Portugal) 

462 Minimal effective dose (MED) of onabotulinumtoxinA (onaBoNT-A) and abobotulinumtoxinA (aboBoNT-A) 

in a rat model of neurogenic detrusor overactivity (NDO) 

D. Behr-Roussel, S. Oger, B. Pignol, E. Pham, A. Le Maux, P.E. Chabrier, P. Picaut, S. Caisey, S. Companie, 

F. Giuliano, P. Denys (Orsay, Les Ulis, Garches, France) 

* 463 Comparison of two different Botulinumtoxin A products (Xeomin, Botox) used for detrusor injection in 

patients with bladder overactivity (BO) – a prospective randomized double-blind study 

C. Hampel, D. D’Andrea, R. Gillitzer, J.W. Thüroff, F. Roos (Mainz, Darmstadt, Germany) 

464 Does dose reduction of Botulinum toxin-A affect quality of life in patients with multiple sclerosis? 

M. Hussain, M. Helal, J. Ocholur, R. Hamid (London, United Kingdom) 

465 Normal human urothelial cell lines express onabotulinumtoxinA SV2 high affinity receptors 

A. Giannantoni, C. Amantini, S. Proietti, V. Farfariello, A. Vianello, G. Santoni, M. Porena (Perugia, 

Camerino, Italy) 

466 Results of botulinum toxin: A switch after first detrusor injection failure as a treatment of neurogenic 

detrusor overactivity 

X. Game, M. Roumiguié, J. Guillotreau, N. Doumerc, B. Bordier, F. Sallusto, B. Malavaud, P. Rischmann 

(Toulouse, France) 

* 467 Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Preliminary 

results from the SONIC urodynamic study 

G. Amarenco, M. Sutory, H. Fagertun, M. Wright, G. Compion, D. De Ridder (Paris, France; Brno, Czech 

Republic; Leiderdorp, The Netherlands; Staines, United Kingdom; Leuven, Belgium) 

468 Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in 

patients affected by Multiple Sclerosis: Long term follow up 

S. Proietti, E. Lepri, L. Lepri, C. Lolli, M. Gubbiotti, A. Giannantoni (Perugia, Italy) 

469 Double dose of solifenacin for the treatment of neurogenic detrusor overactivity 

C. Persu, P.A. Geavlete (Bucharest, Romania) 

470 Neuro-urological practice in spinal injuries units in UK and Eire and EAU Neurogenic Lower Urinary Tract 

Dysfunction guidelines 

J. Burki, S. Banka, R. Hamid, P.J.R. Shah (London, United Kingdom) 


187 

Sunday

Sunday 

471 Urethral versus suprapubic catheter for patients with spinal cord injury induced neurogenic bladder: 

A study applying the eleven-year comprehensive nationwide database of Taiwan 

C.C. Lin, A.T.L. Lin, H.M. Wei, T.J. Chen (Taipei, Taiwan) 

472 Spontaneous contractile activity of human neurogenic bladder strips: Can we predict a correlation 

between clinical factors, urodynamics and histological features? 

V. Phé, S. Oger-Roussel, D. Behr-Roussel, P. Denys, E. Compérat, F. Giuliano, E. Chartier-Kastler (Paris, 

Orsay, Garches, France) 

188 Programme Book



12.15 - 13.45 Sexual dysfunction: Basic research 



Chairs: D. Behr-Roussel, Orsay (FR) 

C.S.R. Costa, Porto (PT) 



473 Increased expression of oxidative stress markers in human diabetic cavernosal tissue 

A.Castela, R. Soares, P. Van Antwerpen, K. Zouaoui Boudjeltia, T. Roumeguere, P. Gomes, P. Vendeira, 

R. Virag, C.S.R Costa (Porto, Portugal; Brussels, Charleroi, Belgium; Paris, France) 

474 Investigation of the effects of the level of glycemic control on erectile function and pathophysiological 

mechanisms in diabetic rats 

H.M. Lee, S.Y. Cho, S.W. Kim (Seoul, South Korea) 

475 Effects of chronic stress on penile corpus cavernosum of rats 

D.B. De Souza, D. Silva, C.M. Cortez, B.M. Gregório, W.S. Costa, F.J.B. Sampaio (Rio de Janeiro, Brazil) 

476 Adrenomedullin mediates adipose tissue-derived stem cells-induced restoration of erectile function in 

diabetic rats 

H. Nishimatsu, E. Suzuki, S. Kumano, A. Nomiya, A. Niimi, M. Suzuki, T. Fujimura, H Fukuhara, Y Enomoto, 

A Ishikawa, H. Kume, Y. Igawa, Y. Hirata, Y. Homma (Tokyo, Japan) 

477 Expression of a distinct set of chemokine-receptors may be responsible for homing of adipose tissuederived 

stem cells towards the major pelvic ganglion following cavernous nerve injury 

M. Albersen, J. Berkers, P. Dekoninck, J. Deprest, D. De Ridder, F. Van Der Aa (Leuven, Belgium) 

478 Establishment of immortalized rat penile cavernous endothelial cells using retroviral vector encoding 

v-myc 

Y.S. Song, H.J. Lee, S.W. Doo, W.J. Yang, S.U. Kim, S.J. Lee (Seoul, South Korea) 

479 Cavernous nerve injury induces significant chemokine-gene upregulation in the rat major pelvic ganglion 

M. Albersen, J. Berkers, P. Dekoninck, J. Deprest, D. De Ridder, F. Van Der Aa (Leuven, Belgium) 

480 Nerve injury-induced protein 1 (Ninjurin 1) is a novel therapeutic target for cavernous nerve injuryinduced 

erectile dysfunction 

G.N. Yin, W.J. Kim, H.R. Jin, M.J. Choi, K.M. Song, M.H. Kwon, D.K. Kim, J.K. Ryu, J.K. Suh (Incheon, South 

Korea) 

481 The role of intracavernosal injection of adipose tissue derived mesenchymal stem cells to improve erectile 

functions after bilateral cavernous nerve injury in rats 

N. Mangir, C. Akbal, F. Simsek, T. Tarcan, L. Turkeri (Istanbul, Turkey) 

482 Comparative analysis of periprostatic implantation and intracavernosal injection of adipose tissue-derived 

stem cells for erectile function recovery in a rat model of cavernous nerve injury 

D. You, C. Lee, M.J. Jang, J. Lee, N. Suh, I.G. Jeong, D.W. Sohn, S.W. Kim, Y.H. Ji, S. Park, T.Y. Ahn, C.S. Kim 

(Seoul, Ulsan, South Korea) 


189 

Sunday

Sunday 

483 Impairment of bladder neck innervation upon bladder outlet obstruction contributes to the development of 

erectile dysfunction 

A.P. Malykhina, S. Chang, Q. Lei, J. Hypolite, A. Seftel (Glenolden, Camden, United States of America) 

484 Effectiveness of intracavernous delivery of adenovirus encoding Smad7 gene on erectile function in the 

mouse model of cavernous nerve injury 

K.M. Song, J.S. Chung, M.J. Choi, H.R. Jin, G.N. Yin, M.H. Kwon, J.M. Park, W.J. Kim, J.K. Ryu, J.K. Suh 

(Incheon, Busan, South Korea) 

485 Withdrawn 

486 Repair of erectile dysfunction using human telomerase reverse transcriptase immortalized human 

endothelial precursor cells from fetal brain vasculature transplanted into the cavernous nerve injured 

corpora cavernosa of rats 

Y.S. Song, H.J. Lee, S.W. Doo, W.J. Yang, S.U. Kim, S.J. Lee (Seoul, South Korea) 

190 Programme Book



12.15 - 13.45 Stones: URS 



Chairs: E.K. Bres-Niewada, Warsaw (PL) 

T. Sulser, Zürich (CH) 




487 Effects by Y27632 on blood pressure and intraureteral pressures of the obstructed and normal rat ureter in 

vivo 

L. Villa, F. Benigni, P. Hedlund (Milan, Italy) 

* 488 Evaluation of innovative techniques for ureterorenoscopy 

A.V. Rawandale, C.S. Kurane, L.G. Patni, N. Sude, P.A. Patil (Dhule, India) 

489 The pushing and pulling forces needed to move the ureteroscope in the ureter are influenced by a safety 

guidewire 

O. Ulvik, N.M. Ulvik (Bergen, Norway) 

490 Optimal power settings for holmium:yag lithotripsy 

J. Sea, L.M. Jonat, B. Chew, J. Qiu, B. Wang, J. Hoopman, T. Milner, J.M.H. Teichman (Vancouver, Canada; 

Austin, Dallas, United States of America) 

491 Fragmentation without extraction in ureteral stones: Outcomes of 238 cases 

C. Goktas, R. Horuz, O. Akca, C.A. Cetinel, S. Albayrak, K. Sarica (Istanbul, Turkey) 

492 Post-ureteroscopic stenting: Validation of the Endoluminal Ureteral Injury Scale (EUIS) on 435 patients 

A. Miernik, K. Wilhelm, E. Farin, P. Ardelt, U. Wetterauer, M. Schoenthaler (Freiburg, Germany) 

493 Comparisons with emergency and elective ureteroscopic removal of stone 

D.H. Kim, K.S. Cho, W.S. Ham, Y.T. Kim, H.S. Moon, H.Y. Choi, S.Y. Park (Seoul, South Korea) 

494 Ureteroscopy with and without safety guidewire 

O. Ulvik, K. Rennesund, P. Gjengstø, N.M. Ulvik (Bergen, Oslo, Norway) 

495 The effects of the presence and the degree of hydronephrosis on ureteroscopic stone treatment in adults 

A.E. Zumrutbas, I.C. Acar, D. Bolat, O.L. Tuncay (Denizli, Turkey) 

496 Assessment of efficiency and safety of retrograde contact electropulse lithotripsy: Simple pilot multicenter 

study 

V.S. Boshchenko, A.V. Gudkov, V.Y. Afonin, A.V. Petlin (Tomsk, Russia) 

497 A comparison of stone cone versus lidocaine jelly in prevention of ureteral stone migration during 

ureteroscopic lithotripsy 

M.G. Soliman, T.A. Gameel, A.R. Ramadan, M. Al-Kathiri, A. Omar, H. El-Tatawy (Tanta, Egypt) 

498 Outcomes of retrograde intrarenal lithotripsy in pelvic kidneys 

M. Binbay, A. Skolarikos, A. Unsal, T. Knoll, G.M. Preminger, T. Akman, A. Wang, A.Y. Muslumanoglu 

(Istanbul, Ankara, Turkey; Athens, Greece; Sindelfingen, Germany; Durham, United States of America) 


191 

Sunday

Sunday 

499 PCNL and URS in renal allografts: A single center experience with 2016 renal transplants 

F. Branco, V. Cavadas, L. Osorio, M. Silva-Ramos, A. Lhamas, A. Fraga (Porto, Portugal) 

192 Programme Book



12.15 - 13.45 Reflux, UTI, OAB, hydronephrosis, Wilms tumor, exstrophy and 

varicocele 



Chairs: S.W. Han, Seoul (KR) 

J. Seibold, Tübingen (DE) 



500 Long-term impact of unilateral diffuse renal parenchymal lesion in infants with primary vesicoureteral 

reflux: Outcome of 10 years follow up 

K. Moriya, T. Mitsui, H. Tanaka, T. Kitta, K. Nonomura (Sapporo, Japan) 

501 Withdrawn 

502 Implication of renal scar and estimated glomerular filtration rate in infants after febrile urinary tract 

infection 

K. Moriya, T. Mitsui, H. Tanaka, T. Kitta, K. Nonomura (Sapporo, Japan) 

503 The ultrasonographic evolution of the hydronephrosis and renal parenchyma thickness in patients with 

congenital ureteropelvic junction (UPJ) obstruction who underwent pyeloplasty 

Y.A. Ferreira, E.M. Araújo, J.P.M. Ribeiro-Neto, J.G.B. Alves, L.F. Nóbrega, A.A. Calado (Recife, Brazil) 

504 Laparoendoscopic single-site pyeloplasty-matched pair analysis between laparoendoscopic single-site 

surgery (LESS) and standard laparoscopic pyeloplasty 

Y. Naitoh, A. Kawauchi, J. Soh, K. Kamoi, T. Miki (Kyoto, Japan) 

505 Treatment of complex kidney stone in children: Miniperc vs standard PNL? 

E. Ozden, Y. Bostancı, A. Sırtbas, G. Genc, Y.K. Yakupoglu, O. Ozkaya, S. Sarıkaya (Samsun, Turkey) 

506 Misdiagnosis in Wilms tumor: Concerns on the use of preoperative chemotherapy 

R.J. Duarte, L.M. Cristofani, F.T. Denes, A.M. Giron, V. Odone-Filho, M. Srougi (Sao Paulo, Brazil) 

507 Can it be possible to spare the adrenal gland at radical nephrectomy in children diagnosed of Wilms’ 

tumor 

J. Kim, J. Ryu, S.C. Kim, S. Park, Y.H. Ji, K.S. Kim (Seoul, Busan, Ulsan, South Korea) 

508 Impact of surgery and chemotherapy over renal function in bilateral Wilms tumor patients 

R.J. Duarte, L.M. Cristofani, A.M. Giron, F.T. Denes, V. Odone-Filho, U. Tannuri, M. Srougi (Sao Paulo, Brazil) 

509 Clinical outcomes in adults with bladder exstrophy: A 20 year follow up 

A.D. Gupta, D.N. Wood, C.R.J. Woodhouse (Baltimore, United States of America; London, United Kingdom) 

510 Evaluation of pharmacokinetics (PK) and safety of fesoterodine 4-and 8-mg once-daily in an 8-week study 

in pediatric patients with overactive bladder (OAB) 

B. Malhotra, A. El-Tahtawy, E. Wang, A. Darekar, D. Scholfield, T. Crook, P.P. Reddy (New York, Cincinnati, 

United States of America; Sandwich, United Kingdom) 

511 Comparison of local anaesthetic effects of lidocaine versus tramadol and the effect of child anxiety on pain 

level in circumcision procedure 

A. Tuncel, F. Polat, M. Balci, Y. Aslan, O. Sacan, C. Kisa, A. Atan (Ankara, Turkey) 


193 

Sunday

Sunday 

512 Adolescent varicocele: Long term outcome after inguinal varicocelectomy with loupe magnification 

E.S. Moursy, A.M. Abu-Zeid (Sohag, Egypt) 

513 There is no benefit for pubertal/schoolboys screening and treatment of varicoceles in regards for adult 

paternity chance 

C. Orye, G. De Win, G. Bogaert (Leuven, Belgium) 

194 Programme Book



12.15 - 13.45 Penile cancer 



Chairs: O.W. Hakenberg, Rostock (DE) 

M.J.A. Perry, London (GB) 



514 P16INK4a is a marker of good prognosis in primary invasive penile squamous cell carcinoma: A multiinstitutional 

study 

M. May, S. Brookman-May, M. Burger, H.M. Fritsche, A. Ebersdobler, O.W. Hakenberg, S. Gunia (Straubing, 

Regensburg, Rostock, Bad Saarow, Germany) 

515 Cancer-specific survival of T1a and T1b squamous cell carcinoma of the penis - based on TNM (2009) 

classification 

H.M. Alnajjar, M.J.A. Perry, R.W. Rees, C.M. Corbishley, N.A. Watkin (London, United Kingdom) 

516 Long-term oncological outcome following conservative surgery for penile cancer 

P. Philippou, M. Shabbir, D. Ralph, P. Malone, R. Nijam, A. Muneer, S. Minhas (London, United Kingdom) 

517 Dynamic sentinel lymph node biopsy in patients with invasive squamous cell carcinoma of the penis: 

A prospective study of the outcome of 500 inguinal basins assessed in a single institution 

W. Lam, H. Alnajjar, S. La-Touche, M.J.A. Perry, C. Corbishley, J. Pilcher, S. Heenan, N.A. Watkin (London, 


518 Dynamic sentinel lymph node biopsy at the time of primary surgery; impact on morbidity and outcome 

S. Banerjee, M. Rafiq, K.K. Sethia, V. Kumar (Norwich, United Kingdom) 

519 A hybrid radioactive and fluorescent tracer for sentinel node biopsy in penile carcinoma as a potential 

replacement for blue dye 

O.R. Brouwer, H.G. Van Der Poel, N. Van Den Berg, B.W. Van Rhijn, A. Bex, W. Meinhardt, R.A. Valdés 

Olmos, F.W.B. Van Leeuwen, S. Horenblas (Amsterdam, The Netherlands) 

520 Anatomic aspects of inguinal lymph nodes applied to lymphadenectomy in penile cancer 

L.A. Favorito, F.J.B. Sampaio, J.P.M. Carvalho (Rio de Janeiro, Brazil) 

521 Endoscopic inguinofemoral lymphadenectomy for penile malignancies – extended follow-up 

C. Schwentner, T. Todenhöfer, D. Schilling, S. Aufderklamm, J. Mundhenk, S. Alloussi, G. Gakis (Tübingen, 

Germany) 

522 Prognostic significance of extracapsular spread and its extent in inguinal nodes in penile cancer 

H.M. Alnajjar, B. Tinwell, R. Rajab, G. Kousparos, M.J.A. Perry, C.M. Corbishley, N.A. Watkin (London, United 

Kingdom) 

523 Optimal follow up arrangements for invasive squamous carcinoma of the penis 

H.M. Alnajjar, M.J.A. Perry, R.W. Rees, C.M. Corbishley, N.A. Watkin (London, United Kingdom) 


195 

Sunday

Sunday 




12.15 - 13.45 Vaginal surgery: Prolapse, urethral diverticulae and fistulae 



Chairs: D.J.M.K. De Ridder, Leuven (BE) 





* 524 Doctor! Will I be dry? Factors determining recurrence after vesicovaginal fistula repair 

A. Abdullah, A. Javed, S. Syed, N. Farooqui (Karachi, Pakistan) 

525 The uses and outcomes of martius fat pad in female urology 

M. Hussain, A. Wilson, R. Hamid, J.L. Ockrim, P.J.R. Shah, T.J. Greenwell (London, United Kingdom) 

526 Transvaginal vesicovaginal fistula repair with transurethral resection of fistula 

S.D. Kim, J.H. Yun, T.H. Kim, K.S. Min , W.Y. Cho (Busan, South Korea) 

* 527 Preoperative urinary incontinence is the main risk factor for post-operative incontinence in women who 

underwent pelvic organ prolapse repair 

E. Costantini, M. Lazzeri, V. Bini, L. Mearini, A. Zucchi, M. Del Zingaro, E. Frumenzio, M. Porena (Perugia, 

Italy) 

528 Surgical correction of uro-genital prolapse: A randomized trial of open surgery vs laparoscopy. Preliminary 

report 

E. Costantini, E. Nunzi, A. Zucchi, A. Pietropaolo, E. Frumenzio, M. Porena, L. Mearini (Perugia, Italy) 

* 529 Associated stress incontinence and pelvic organ prolapse: Combined or separated treatment? Data from a 

cohort of patients treated with a coated mesh by vaginal route 

I. Ouzaid, V. Phé, E. Xylinas, A. Vidart, A. Haertig, M.O. Bitker, E. Chartier-Kastler, F. Cour (Paris, France) 

530 Mid-term outcome of robotic mesh sacrocolpopexy for the repair of pelvic organ prolapse 

M.J. Belsante, S. Murray, B.E. Dillon, P.E. Zimmern (Dallas, Texas, Tulsa, Oklahoma, United States of 

America) 

531 Apical and posterior compartment recurrence after concurrent total hysterectomy and anterior vaginal 

wall suspension for bladder with uterine prolapses 

P.E. Zimmern, D. Lee, B.E. Dillon, K. Bradshaw (Dallas, Texas, United States of America) 

532 Relationships between uro-genital prolapse staging, symptoms, and quality of life 

P. Rouvellat, L. Wagner, F. Thibault, R. De Tayrac, S. Droupy, P. Costa (Toulouse, Nimes, Nancy, France) 

533 Clinical usefulness of voiding cystourethrography using 16-MDCT for the diagnosis of female urethral 

diverticula 

S.J. Son, I.S. Kim, J.S. Paick, S.W. Kim (Seoul, South Korea) 

534 Transvaginal ultrasonography and urethral diverticula: A diagnostic and therapeutic tool 

S. Crivellaro, M. Abbinante, A. Palazzetti, L. Tosco, B. Frea (Udine, Italy)

535 Double balloon urethrography for diagnosing urethral diverticula in women - is it still relevant in the 21st 

century? 

T. Erlich, O. Portnoy, N.D. Kitrey, Y. Mor, J. Ramon, J. Golomb (Ramat Gan, Israel) 


197 

Sunday

Sunday 




12.15 - 13.45 Prostate cancer: Novel biomarkers 2 



Chairs: G. Jenster, Rotterdam (NL) 

T. Schlomm, Hamburg (DE) 



536 Soluble circulating receptor endoglin (ENG) in patients with different prostate biopsy diagnosis 

F.A.X.E.M. Pina, G. Figueiredo, N. Linet, F. Botelho, I. Lopes, R. Cruz, F. Cruz, H. Barros (Porto, Portugal) 

537 The value of plasmatic determination of matrix metalloproteinase 9 as a diagnostic marker in prostate 

cancer. Closing the controversies 

I. González Rodríguez, R. Gil Ugarteburu, M. Rivas Del Fresno, I. Fernández García, A. Tardón (Gijón, León, 

Oviedo, Spain) 

538 PAR1 differential expression as a biomarker of prostate cancer progression 

A. El Atmani, J. Caradec, N. Nicolaiew, Y. Allory, A. De La Taille, F. Vacherot, P. Eschwege, P. Manivet, 

J.C. Kouyoumdjian, S. Loric (Creteil, Nancy, France) 

539 Early detection of prostate cancer using cd24 as a potential biomarker 

R. Morag, I. Naumov, D. Kazanov, L. Galazan, O. Toledano, B. Boursi, M. Lev, S. Kraus, J. Ramon, A. Nadir 

(Ramat Gan, Tel Aviv, Israel) 

540 Non-invasive epigenetic profiling for the early detection of prostate cancer 

A.S. Perry, D. Moran, E. Bolton, F. O’Kelly, J. Thurman, A. Meunier, D. Hollywood, T.H. Lynch (Dublin, Ireland) 

541 MiRNA profiling in the screening of potential biomarkers for prostate cancer diagnosis 

J. Rubio-Briones, A. Fernandez-Serra, I. Casanova-Salas, J. Casanova, L. Rubio-Martinez, P. Soriano, 

Z. Garcia-Casado, I. Iborra, E. Solsona, J.A. Lopez-Guerrero (Valencia, Spain) 

542 Zinc a2-glygoprotein (ZAG) detected in the urine of patients as a potential novel biomarker for the early 

diagnosis for prostate cancer. Preliminary results 

I. Katafigiotis, S. Tyritzis, K. Stravodimos, C. Alamanis, C. Constantinides (Athens, Greece) 

543 Methylation of Kallikrein-related peptidases as novel diagnostic and prognostic biomarkers for prostate 

cancer 

E. Olkhov, T.H. Van Der Kwast, K. Kron, V. Pethe, H. Ozcelik, L. Briollais, N.E. Fleshner, E.P. Diamandis, 

A.R. Zlotta, B. Bapat (Toronto, Canada) 

544 Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease 

extension 

H. Miyake, M. Muramaki, M. Fujisawa (Kobe, Japan) 

545 Tumor-associated stromal cells expressed EP2 receptor and EP3 receptor correlate with malignant 

aggressiveness and outcome through angiogenesis and lymphangiogenesis in prostate cancer 

Y. Miyata, T. Matsuo, K. Ohba, S. Sakai (Nagasaki, Japan) 

546 Localization of fibroblast growth factor 9 in prostate cancer cells Is associated with postoperative 

recurrence 

J. Teishima, K. Shoji, T. Hayashi, K. Miyamoto, S. Ohara, A. Matsubara (Hiroshima, Japan)

547 DNA-PKcs expression predicts response to radiotherapy in prostate cancer 

P. Bouchaert, S. Guérif, J. Irani, P. Debiais, J. Godet, G. Fromont (Poitiers, France) 

548 The gastrin/cholecystokinin-B receptor on prostate cells – a novel target for bifunctional prostate cancer 

imaging 

S. Heckl, A. Sturzu, S. Sheik, U. Klose, H. Echner, H. Kahlbacher, M. Deeg, M. Horger, J. Hennenlotter, 

T. Todenhöfer, T. Nägele, U. Ernemann, A. Stenzl, C. Schwentner (Tübingen, Germany) 

549 Prediction of survival in metastatic prostate cancer patients by single nucleotide polymorphisms of cancerassociated 

genes 

Y. Horikawa, N. Tsuchiya, S. Matsui, T. Kamba, S. Narita, K. Mitsuzuka, S. Hatakeyama, T. Inoue, S. Saito, 

C. Oyama, Y. Arai, O. Ogawa, T. Habuchi (Akita, Tokyo, Kyoto, Sendai, Hirosaki, Okinawa, Japan) 


199 

Sunday

Sunday 




14.00 - 15.30 Challenging robotic surgery 



Chairs: I.J. De Jong, Groningen (NL) 



V22 Robot-assisted intracorporeal ileal conduit urinary diversion 

J. Sammon, J. Jhaveri, S. Sukumar, C. Fitzgerald, M. Ehlert, A. Friedman, P.K. Agarwal, J.O. Peabody (Detroit, 


V23 Robotic ileal interposition: A completely intracorporeal technique 

W.E.F. Isac, S. Chalikonda, E. Rizkala, R. Khanna, R. Autorino, S. Hillyer, H. Laydner, A. Kassab, R.A. Yakoubi, 

J.A. Long, J. Guillotreau, G.P. Haber, J. Kaouk, R.J. Stein (Cleveland, United States of America) 

V24 Robotic enterocystoplasty after prostatocystectomy for urothelial cancer: Description of the technique 

A. El Hajj, D. Vordos, A. Defourmestraux, N. Gillion, L. Salomon, A. Hoznek, R. Yiou, C.C. Abbou, A. De La 

Taille (Creteil, France) 

V25 Robotic radical cystectomy with neoadjuvant chemotherapy 

R.J. Valero, E. Barret, R.S. Sanchez Salas, N. Miranda, F. Rozet, A. Ouzzane, M. Galiano, H. Davila, 

M. Sanchez Encinas, M. Saad, X. Cathelineau (Paris, France; Caracas, Venezuela) 

V26 Robot assisted laparoscopic cystectomy with bladder replacement 

F. Girard, W. Massoud, R. Thani-Gasalam, M. Fourati, A. El Hajj, M. Fenouri, O. Dumonceau, M. Ceddaha, 

H. Baumert (Paris, France) 

V27 Robot-assisted retroperitoneal lymph node dissection: Modified nerve-sparing left sided template 

K.R. Ghani, J. Jhaveri, Q.D. Trinh, E. Kheterpal, A. Dabaja, M. Ehlert, F. Muhletaler, M. Menon, A. Bhandari 

(Detroit, United States of America) 

V28 Complications during robot-assisted kidney surgery 

Q.D. Trinh, S. Sukumar, K.R. Ghani, J. Sammon, W. Jeong, J. Jhaveri, F. Muhletaler, M. Ehlert, M. Menon, 

C.G. Rogers (Detroit, United States of America)



14.00 - 15.30 Staging and predicting outcomes from urothelial carcinoma 



Chairs: P. Bastian, Munich (DE) 

L. Mengual, Barcelona (ES) 



550 Cancer-specific survival after nephroureterectomy for upper urinary tract urothelial carcinoma: External 

validation of a predictive nomogram using a French collaborative national database 

D.R. Yates, P. Colin, A. Ouzzane, G. Pignot, T. Seisen, J. Guillotreau, V. Phe, S. Crouzet, N. Hoareau, 

C. Marchand, P.O. Fais, E. Xylinas, S. Hurel, H. Bensadoun, F. Saint, L. Guy, A. Arvin-Berod, L. Cormier, 

G. Karsenty, F. Bruyere, A. Houlgatte, O. Cussenot, M. Rouprêt (Paris, France) 

551 Precystectomy nomogram predicting pathological local extent in patients with bladder cancer 

L.V. Mirylenka, O.G. Sukonko, A.V. Pravorov, A.I. Rolevich (Minsk, Grodno, Belarus) 

552 Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract 


H. Fajkovic, E.K. Cha, C. Jeldres, G. Donner, T.F. Chromecki, V. Margulis, N. Giacomo, Y. Lotan, J.D. Raman, 

W. Kassouf, C. Seitz, K. Bensalah, A. Weizer, E. Kikuchi, M. Roscigno, M. Remzi, K. Matsumoto, E. Breinl, 

A. Pycha, V. Ficarra, F. Montorsi, D. Scherr, S.F. Shariat (Sankt Poelten, Graz, Vienna, Korneuburg, Austria; 

New York, Dallas, Hershey, Michigan, United States of America; Montreal, Canada; Padua, Milan, Bolzano, 

Italy; Rennes, France; Tokyo, Sagamihara, Japan) 

553 Predictive model of disease free survival after radical cystectomy 

G. Simone, R. Papalia, M. Ferriero, S. Guaglianone, E. Castelli, D. Collura, G. Muto, M. Gallucci (Rome, 

Turin, Italy) 

554 Upstaging of urothelial cancer at the time of radical cystectomy – associated factors and effect on outcome 

P. Turker, P.J. Bostrom, M. Wraclowski, B. Van Rhijn, H. Kortekangas, C. Kuk, N.E. Fleshner, M.A. Jewett, 

A. Finelli, T. Van Der Kwast, A. Evans, J. Sweet, M. Latu, A. Zlotta (Istanbul, Turkey; Turku, Finland; Toronto, 

Canada) 

555 Race is not a barrier to good quality of care after radical nephroureterectomy for upper tract urothelial 

carcinoma 

N. Hanna, A. Abdo, P. Perrotte (Montreal, Canada) 

556 Accuracy of ureteroscopic biopsy for upper tract urothelial carcinoma: A retrospective study comparing 

biopsy and final pathologic results 

A. Arvin-Berod, G. Fiard, D. Pasquier, M. Decaussin-Petrucci, N. Bossard, B. Riche, C. Thuillier, B. Boillot, 

N. Terrier, J.L. Descotes, Ph. Paparel, J.J. Rambeaud, A. Ruffion, J.A. Long (Grenoble, Lyon, France) 

557 Tumour regression after neoadjuvant chemotherapy independently predicts survival in urothelial cancer of 

the bladder 

R. Seiler, A. Fleischmann, G.N. Thalmann (Berne, Switzerland) 


201 

Sunday

Sunday 

558 Perinodal lymphovascular invasion displays the strongest predictor for cancer-specific mortality in lymph 

node positive patients with urothelial carcinoma of the bladder 

S. Brookman-May, M. Burger, M. May, S. Denzinger, M. Gierth, S. Siegert, J. Giedl, A. Agaimy, M.P. Wirth, 

F. Hofstädter, W.F. Wieland, A. Hartmann, H.M. Fritsche (Regensburg, Straubing, Munich, Erlangen, 

Dresden, Germany) 

559 Evaluation of (18)FDG-PET/CT for preoperative lymph-node staging of bladder cancer 

J. Van Essen, J. Grosse, R. Epplen, D. Pfister, A. Heidenreich (Aachen, Germany) 

560 Prospective study of the diagnostic ability of diffusion-weighted (DW) magnetic resonance imaging (MRI) 

and CT scan in the detection of lymph node invasion in bladder cancer 

E. De La Peña, C. Blázquez, B. López, D. García, C. Capitán, V. Hernández, C. Llorente (Madrid, Spain) 

561 MAGE expression is associated with features of biologically aggressive urothelial carcinoma of the bladder 

E.K. Cha, B. Volkmer, F. Khani, M. Rink, Y.T. Chen, D.S. Scherr, M.A. Rubin, J.M. Mosquera, R. Hautmann, 

R. Kuefer, S.F. Shariat, B.D. Robinson (New York, United States of America; Kassel, Ulm, Göppingen, 

Germany) 

562 The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients 

with bladder urothelial carcinoma: A prospective study 

M.G. Park, J.K. Yeo, D.Y. Cho, M.M. Oh, D.G. Moon, D.K. Yoon, H.S. Park, J.Y. Park, J.H. Bae, S.S. Park (Seoul, 

South Korea) 

202 Programme Book



14.00 - 15.30 Radical prostatectomy: Improvement of surgical technique 



Chairs: C.P. Evans, Sacramento (US) 

M. Ramirez Backhaus, Valencia (ES) 




563 Transvesical single-port laparoscopic radical prostatectomy for organ-confined prostate cancer: An initial 

experience of 20 cases 

X. Gao, J. Pang, J. Si-Tu, C. Hu, W.T. Huang, X.Q. Wen, J.M. Zheng, L.Y. Li (Guangzhou, China) 

* 564 The improvement of continence recovery by tadalafil after bilateral nerve-sparing robot-assisted radical 

prostatectomy: A randomized study with 1 year follow-up 

A.V. Govorov, D.Y. Pushkar (Moscow, Russia) 

565 Early oncological and functional results of the first 100 patients undergoing the Bocciardi approach for 

RALP, a totally Retzius-sparing technique 

A. Galfano, E. Strada, A. Ascione, G. Petralia, S. Grimaldi, G. Prestini, A.M. Bocciardi (Milan, Italy) 

566 Robotic-assisted transperitoneal and open surgical retropubic prostatectomy – a single surgeon 

comparison 

M. Musch, U. Roggenbuck, Y. Davoudi, H. Loewen, M. Yanovskiy, V. Klevecka, D. Kroepfl (Essen, Wuppertal, 

Germany) 

567 Robot-assisted laparoscopic radical prostatectomy in patients with prostate glands > 100 gr. surgical, 

oncologic and functional outcomes 

A. Labanaris, J.H. Witt, C. Wagner, P. Lange, V. Zugor (Gronau, Germany) 

568 Does running suture of vesico-urethral anastomosis improve recovery of continence in patients with 

retropubic radical prostatectomy? A randomized study compared with conventional interrupted suture 

H. Mastuyama, S. Sakano, T. Hara, H. Matsumoto, Y. Kawai, Y. Miyachika, J. Nishijima (Ube, Japan) 

* 569 Bilateral preservation of the seminal vesicles during a radical prostatectomy induces painful orgasm and 

reduces sexual health 

A. Mogorovich, A. Nilsson, S. Carlsson, M. Jonsson, L. Haendler, T. Nyberg, S.I. Tyritzis, G. Steineck, 

P. Wiklund (Pisa, Italy; Stockholm, Sweden; Athens, Greece) 

570 The effect of preoperative cancer aggressiveness on learning curve among high volume surgeons 

performing radical retropubic prostatectomy: You never stop getting better in challenging cases 

A. Gallina, N. Fossati, U. Capitanio, F. Abdollah, N. Passoni, F. Pellucchi, E. Farina, G. Guazzoni, P. Rigatti, 

A. Briganti (Milan, Italy) 

* 571 Immunohistochemical mapping study of periprostatic nerves – can we preserve pro-erectile 

parasympathetic nerves with an high anterior release in radical prostatectomy? 

R. Ganzer, J.U. Stolzenburg, W.F. Wieland, J. Bründl (Regensburg, Leipzig, Germany) 


203 

Sunday

Sunday 

* 572 Frozen section navigated radical prostatectomy significantly increase the frequency of nerve-sparing 

without compromising oncological outcome 

T. Schlomm, P. Tennstedt, C. Huxhold, L. Budäus, T. Steuber, A. Haese, G. Salomon, G. Sauter, S. Minner, 

H. Huland, M. Graefen (Hamburg, Germany) 

573 Impact of bladder neck sparing and prostate size on recovery of early continence after laparoscopic radical 

prostatectomy 

A.S. Gözen, T. Oksay, M. Ates, M. Hruza, M. Schulze, J.J. Rassweiler (Heilbronn, Germany; Isparta, Afyon, 

Turkey) 

204 Programme Book



14.00 - 15.30 Lower urinary tract symptoms and quality of life 



Chairs: D. Castro-Diaz, Santa Cruz de Tenerife (ES) 

E. Kocjancic, Chicago (US) 




* 574 Relationship between sleep disorders and impairment of QOL in OAB patients with nocturia 

M. Yoshida, M. Takeda, S. Takahashi, O. Nishizawa, M. Gotoh, N. Masumori (Kumamoto, Yamanashi, Tokyo, 

Matsumoto, Nagoya, Sapporo, Japan) 

575 Comparison of nocturia response to desmopressin treatment between patients with increased and normal 

nocturnal bladder capacity index 

T. Hajdinjak, J. Leskovar (Murska Sobota, Maribor, Slovenia) 

576 Effects of desmopressin acetate for the treatment of nocturnal polyuria and related sleep quality in men 

S.O. Kim, B.H. Yun, D.H. Yoo, I. Hwang, E.C. Hwang, K.J. Oh, S.I. Jung, T.W. Kang, D.D. Kwon, K. Park, 

S.B. Ryu (Gwangju, South Korea) 

577 Patient attitudes and patterns of treatment utilization in a European population with overactive bladder 

symptoms 

F. Cruz, P. Denys, M. Jiménez-Cidre, D. Globe, M. Signori (Porto, Portugal; Garches, France; Madrid, Spain; 

Irvine, California, United States of America) 

578 Effect of treatment response on the decision to escalate antimuscarinic dose in elderly subjects with 

overactive bladder 

A. Wagg, V. Khullar, M. Oelke, D. Marschall-Kehrel, M.C. Michel, A. Darekar, C. Ebel-Bitoun (Edmonton, 

Canada; London, Sandwich, United Kingdom; Hanover, Frankfurt, Germany; Amsterdam, The Netherlands; 

Paris, France) 

579 Health-related quality of life in patients with overactive bladder 

R. Dmochowski, U. Mehnert, D.O. Sussman, S. MacDiarmid, D. Globe, M. Signori (Nashville, Tennessee, 

Stratford, New Jersey, Greensboro, North Carolina, Irvine, California, United States of America; Zurich, 

Switzerland) 

580 Life-style diseases affect on the prevalence rate of OAB in female patients visiting primary care doctors 

M. Yoshida, J. Kudoh, O. Yamaguchi (Kumamoto, Kohriyama, Japan) 

581 Lower urinary tract symptoms and urinary incontinence in a population-based 85-years old cohort 

C. Wehrberger, S. Madersbacher, S. Jungwirth, P. Fischer, K.H. Tragl (Vienna, Austria) 

582 Withdrawn 

583 Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: 

A multicenter, open-label, prospective observational study 

D.S. Yoo, H. Ji-Yeon, L. Chun-Woo, K. Do-Jung, C. Dae-Hyun, W.H. Park, M.S. Choo (Seoul, Incheon, South 

Korea) 


205 

Sunday

Sunday 

584 Quality of life of Multiple Sclerosis patients: Translation and validation of the Spanish version of Qualiveen 

A. Ciudin, L. Peri, M.G. Diaconu, A. Franco, A. Alcaraz (Barcelona, Spain) 

585 Preliminary analysis of Spanish patients with overactive bladder: Data from a national registry 

F.P. Rodríguez Escovar, S. Arlandis, M. Esteban, M.A. Jiménez Cidre, F. Villacampa (Barcelona, Valencia, 

Toledo, Madrid, Spain) 

206 Programme Book



14.00 - 15.30 Sexual dysfunction: Diagnosis and treatment 



Chairs: K. Hatzimouratidis, Thessaloniki (GR) 

Y. Reisman, Amstelveen (NL) 



586 Sexual changes after POP repair. Is hysterectomy a key element? 

E. Costantini, M. Lazzeri, L. Mearini, E. Frumenzio, L. Lepri, V. Bini, A. Zucchi (Perugia, Italy) 

587 Validity of the premature ejaculation diagnostic tool (PEDT) in four subgroups of premature ejaculation 

syndrome: Data from the Korean Internet Sexuality Survey - Part I 

S.H. Song, W.S. Choi, J.S. Chang, A. Ro Kim, J. Yeon, J.G. Suh, S.Y. Cho, S.B. Lee, H. Jeong, J.S. Paick, H. Son 

(Seoul, South Korea) 

588 Comparison of efficacy of electric stimulation and topical EMLA cream in treatment of premature 

ejaculation: Prospective and comparative study 

F. Mallat, W. Hmida, A. Hidoussi, A. Slama, M. Jaidane, N. Ben Sorba, A.F. Mosbah (Sousse, Tunisia) 

589 Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and 

psychosomatic symptoms in men with late onset hypogonadism 

A.D.J. Yassin, Y. El Douaihy, P. Gosh, A. Schulman, J. Abraham, R. Shabsigh, A. Yassin (Braunschweig, 

Norderstedt-Hamburg, Germany; Brooklyn, United States of America) 

590 Testosterone replacement therapy with testosterone undecanoate long acting intramuscular injections is 

associated with reduction in obesity 

Y. El Douaihy, A.D.J. Yassin, R. Pinkhasov, K. Prawat, R. Shabsigh, A.A. Yassin (Brooklyn, United States of 

America; Braunschweig, Norderstedt-Hamburg, Germany) 

591 Safety of administration of parenteral testosterone undecanoate to mainly elderly men for 48 months 

A. Haider (Bremerhaven, Germany) 

592 Intramuscular testosterone undecanoate for substitution in male hypogonadism – longterm treatment of 

13.5 years: Metabolic efficacy and safety 

M. Zitzmann, F. Saad, E. Nieschlag, S. Kliesch (Münster, Germany; Ajman, United Arab Emirates) 

593 A prospective study of the effect of 5-alpha-reductase inhibitor (dutasteride) treatment on serum free 

testosterone level and aging male symptoms in Japanese patients with benign prostatic hyperplasia 

T. Maeda, E. Kikuchi, M. Hasegawa, T. Ando, Y. Yasumizu, G. Kaneko, H. Nagata, A. Miyajima, K. Nakagawa, 

M. Oya (Tokyo, Japan) 

594 The key role of time in predicting post-radical prostatectomy erectile function recovery rate: Conditional 

survival analysis 

F. Abdollah, E. Di Trapani, M. Tutolo, A. Saccà, A. Salonia, N. Passoni, N. Fossati, F. Ferrari, D. Dario, 

P. Capogrosso, R. Colombo, P. Rigatti (Milan, Italy) 

595 Is the Oral Glucose Tolerance Test a valid tool for diabetes mellitus screening in males with erectile 

dysfunction? 

M. Piqueras Bartolome, E. García-Cruz, J. Romero Otero, M. Giménez Alvárez, L. Díez Sicilia, P. Luque, 

J.M. Corral, A. Rodríguez Antolín, A. Alcaraz (Barcelona, Madrid, Spain) 


207 

Sunday

Sunday 

596 Withdrawn 

597 The efficacy of low-intensity extracorporeal shock waves for ED patients who respond to oral therapy: 

A randomized, double-blind, placebo-controlled study 

I. Gruenwald, B. Appel, A. Kilchevski, Y. Vardi (Haifa, Israel) 

598 Deep dorsal venous embolization for veno-occlusive erectile dysfunction: Long-term results and patient 

selection criteria 

A.M.S. Shahin, A. Maarouf, S.A.S. Khalil, A.E. Shalaby (Zagazig, Ismailia, Egypt) 

599 Coated implants and “no touch” surgical technique decreases risk of infection in inflatable penile 

prosthesis implantation to 0.46% 

E.A. Salem, F. Eid, S. Wilson (Zagazig, Egypt; New York, California, United States of America) 

208 Programme Book



14.00 - 15.30 Invasive bladder cancer: Technique of surgery 



Chairs: B. Bochner, New York (US) 

M. Brausi, Modena (IT) 



600 Patients with unexpected lymph node (LN) positive bladder cancer: Outcome with radical cystectomy (RC) 

and extended pelvic lymphadenectomy alone 

P. Zehnder, S. Daneshmand, E.C. Skinner, U.E. Studer, G. Miranda, J. Cai, D.G. Skinner, G.N. Thalmann, 

I.S. Gill (Berne, Switzerland; Los Angeles, United States of America) 

601 Stage specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy 

G. Simone, R. Papalia, M. Ferriero, S. Guaglianone, D. Collura, E. Castelli, G. Muto, M. Gallucci (Rome, 

Turin, Italy) 

602 The extent of lymphadenectomy in radical cystectomy for bladder cancer influences disease-free survival 

D. Tilki, H. Abol-Enein, A. Mosbah, M. El-Baz, A. Shokeir, A. Nabeeh, M. Ghoneim (Munich, Germany; 

Mansoura, Egypt) 

603 Clinical nodal staging scores for bladder cancer: A proposal for preoperative risk-assessment 

M. Rink, B. Ehdaie, E.K. Cha, J. Hansen, R. Svatek, T.F. Chromecki, H. Fajkovic, G. Novara, S. Daneshmand, 

Y. Fradet, Y. Lotan, A.I. Sagalowsky, P.J. Bastian, W. Kassouf, H.M. Fritsche, M. Burger, J. Izawa, D. Tilki, 

F. Abdollah, F.K. Chun, G. Sonpavde, M. Fisch, D. Scherr, M. Gonen, S.F. Shariat (New York, San Antonio, Los 

Angeles, Dallas, Houston, United States of America; Hamburg, Munich, Regensburg, Germany; Padua, Italy; 

Quebec City, Montreal, London, Canada) 

604 The “I-Pouch”: First results of a new ileal neobladder technique 

G. Gakis, M.F. Abdelhafez, T. Todenhöfer, A. Stenzl (Tübingen, Germany) 

605 Radical cystectomy with W-shaped orthotopic ileal neobladder constructed with non-absorbable titanium 

staples – long term follow–up 

S.G. Kravchick, L. Lobic, A. Paz, E. Srepnov, S. Cytron (Ashkelon, Israel) 

606 The orthotopic N-shaped ileal neobladder: Complications and voiding patterns in 121 consecutive patients 

T. De Sutter, S. Joniau, F. Van Der Aa, H. Van Poppel (Leuven, Belgium) 

607 Long acting sandostatin can eliminate routine pouch irrigation and suprapubic catheter using in ileal 

neobladder 

M.H. Khorrami, M.H. Izad Panahi, F. Farahini Isfahani, M.R. Gharaati, M. Zargham, M. Mohammadi, M. Hadi 

(Isfahan, Iran) 

608 A multi-institutional study on risk factors of urethral recurrence in female patients with ileal neobladder 

G. Gakis, B. Ali-El-Dein, M. Babjuk, G. Thalmann, J. Hrbácek, P. Macek, A.A. Shaaban, A. Stenzl (Tübingen, 

Germany; Mansoura, Egypt; Prague, Czech Republic; Bern, Switzerland) 

609 Elevated lactate-dehydrogenase level and positive frozen section analysis are independent risk factors for 

positive final urethral margins at radical cystectomy 

T. Todenhöfer, M. Renninger, J. Mundhenk, M.F. Abdelhafez, A. Stenzl, G. Gakis (Tübingen, Germany) 


209 

Sunday

Sunday 

610 Oncological outcomes of positive surgical margin locations in pn0 m0 bladder cancer 

Y. Neuzillet, T. Lebret, G. Defortescu, H. Toledano, T. Murez, R. Thuret, G. Pignot, M. Bruzzi, M. Rouprêt, 

T. Seisen, J. Rode, L. Salomon, C. Deboudt, J. Rigaud, J. Berger, A. Descazeaud, P. Bigot, T. Pichon, 

D. Rossi, M. Moulin, L. Cormier, M. Dusaud, X. Durand, N. Brichart, F. Bruyere, B. Rouget, H. Wallerand, 

F. Kleinclauss, M. Soulie, C. Pfister (Suresnes, Rouen, Toulouse, Montpellier, Paris, Creteil, Nantes, Limoges, 

Angers, Marseille, Dijon, Tours, Bordeaux, Besançon, France) 

210 Programme Book



14.00 - 15.30 Strictures and urethroplasty 1 



Chairs: A. El-Kassaby, Cairo (EG) 

L. Martínez-Piñeiro, Madrid (ES) 




611 How long should patients keep the transurethral catheter in situ after internal urethrotomy? Preliminary 

results of a prospective randomised study 

D.P. Nguyen, G. Giannarini, U.E. Studer, G.N. Thalmann (Berne, Switzerland) 

612 Single stage repair of obliterated anterior urethral strictures by combined buccal mucosa graft and 

longitudinal dorsal penile skin flap 

V. Kojovic, M. Acimovic, C. Tulic, M. Djordjevic (Belgrade, Serbia) 

613 Staged substitution urethroplasty of long anterior urethral stricture using buccal mucosa graft 

M.A. Selim, O.A. Abdel Gawad (Menoufiya, Egypt) 

614 Non-transecting anastomotic bulbar urethroplasty 

R.A. Largo, S. Brunnschweiler, T. Sulser, A. Müller (Zurich, Switzerland) 

615 MR urethrography versus conventional cystourethrography in diagnosis of urethral stricture disease with 

surgical findings correlation 

E. Elsayed, M. Abdallah, H. Abdelrahman, M. Abou Elezz, A. Ragheb (Zagazig, Egypt) 

616 Long term results of lingual mucosal grafts for repairing long anterior urethral strictures 

S.A. Elgamal, M.O. Abu Farha, A.S. Elabd, A.M. Tawfik, M.G. Soliman (Tanta, Egypt) 

617 Dorsal onlay urethroplasty using buccal mucosa graft or penile skin flap for management of long anterior 

urethral strictures: A prospective randomized study 

S.A. Elgamal, H.A. Aldaqadossi, M.O. Abu Farha, M.G. Soliman (Tanta, Fayoum, Egypt) 

618 Urethral “sphincter” strictures post TURP - dorsal buccal mucosa onlay graft repair 

C. Gingu, S. Patrascoiu, C. Surcel, C. Chibelean, M. Harza, C. Balsanu, A. Dick, F. Lupu, L. Domnisor, 

I. Sinescu (Bucharest, Romania) 

619 Staged urethroplasty: Is there still an indication? 

D. Pfalzgraf, L. Kluth, C.P. Reiss, S. Riechardt, O. Engel, M. Fisch, R. Dahlem (Hamburg, Germany) 

620 The incidence and management of ureteric strictures following 950 renal transplants in a single centre in 

the UK 

C. Poullis, C. Bach, J. Masood, I. Junaid (London, United Kingdom) 

* 621 Tissue-engineered buccal mucosa urethroplasty. Outcome of our first 10 patients 

G. Ram-Liebig, O. Engel, B. Schwaiger, P. Reiss, D. Pfalzgraf, R. Dahlem, M. Fisch (Dresden, Hamburg, 

Germany) 


211 

Sunday

Sunday 




14.00 - 15.30 Diagnostic tests in bladder function 



Chairs: J.W. Kim, Seoul (KR) 




622 Is there concordance in the measurement of bladder capacity among bladder diary, uroflowmetry and 

filling cystometry? 

L. López-Fando, M.A. Jiménez, M. Esteban, L. Prieto, D. Castro, A. Franco, J. Salinas, C. Gutierrez, 

S. Arlandis, G. Ifu (Madrid, Toledo, Alicante, Tenerife, Barcelona, Valencia, Spain) 

623 Association between blood vessel changes of bladder mucosa and storage symptoms in female stress 

urinary incontinence patients 

D.Y. Kim, Y.J. Park, L.H. Sung, J.C. Kim (Daegu, Seoul, South Korea) 

624 Reliability of pelvic floor muscle EMG values measured in healthy volunteers using a new device: The 

Multiple Array Probe (MAPLe) 

P.J. Voorham-Van Der Zalm, H.C. Voorham, C.W.L. Van Den Bos, M.C. De Ruiter, T.J. Ouwerkerk, H. Putter, 

M. Wasser, A. Webb, R.C.M. Pelger (Leiden, The Netherlands) 

625 Withdrawn 

626 Impact of urethral catheter size during voiding in women: Obstructive or not? 

P. Nelson, F. Valentini, P.E. Zimmern (Paris, France; Dallas, Texas, United States of America) 

627 Etiology and prognosis of acute female urinary retention 

W.T. Kao, Y.H. Fan, T.L. Lin, K.K. Chen (Taipei, Taiwan) 

628 Clinical and urodynamical differences among women with overactive bladder according to the presence of 

detrusor overactivity 

S.J. Jeong, J.K. Lee, M.S. Jeong, J. Bae, B.K. Lee, Y.M. Choo, J.J. Oh, S.C. Lee, C.W. Jeong, C.Y. Yoon, S.K. Hong, 

S.S. Byun, S.E. Lee (Seongnam, Seoul, South Korea) 

629 Urge perception index: Impact on diagnosis of overactive bladder for quantitative assessment of the 

urinary sensory dysfunction in the analysis of bladder diaries 

A. Fujihara, O. Ukimura, H. Honjo, T. Iwata, T. Ueda, K. Kamoi, A. Kawauchi, T Miki (Kyoto, Japan; Los 

Angeles, California, United States of America) 

630 Decrease of maximum flow rate during intubated flow could be the consequence of a urethral reflex 

F.A. Valentini, G. Robain, D.S. Hennebelle, P.P. Nelson (Paris, France) 

631 Overactive bladder syndrome: Seeking the effectiveness in the assessment of urgency 

M.A. Jiménez, L. López-Fando, M. Esteban, L. Prieto, D. Castro, A. Franco, J. Salinas, C. Gutierrez, 

S. Arlandis, G. Ifu (Madrid, Toledo, Alicante, Tenerife, Barcelona, Valencia, Spain) 

632 OAB symptoms in women: Do all instruments measure the same? 

M.A. Jiménez, L. López-Fando, M. Esteban, L. Prieto, A. Franco, D. Castro, J. Salinas, C. Gutierrez, 

S. Arlandis, G. Ifu (Madrid, Toledo, Alicante, Barcelona, Tenerife, Valencia, Spain)

633 Development of nomograms for post-void residual urine in children aged 4 to 12 years 

S.J. Chang, S.S. Yang (New Taipei, Taiwan) 


213 

Sunday

Sunday 




14.00 - 15.30 BPH: Surgical technique and new medical strategy 



Chairs: K.M. Anson, London (GB) 

T. Esen, Istanbul (TR) 




* 634 Real incidence of complications following surgical management of benign prostatic hyperplasia: 

A prospective analysis of a nation-wide registry of 262898 patients 

J.N. Cornu, Y. Merlière, E. Vicaut, A. Fournier, C. Hodée, M. Aout, L. Duchet, L. Gauffriau, D. Polton, 

B. Lukacs (Paris, France) 

635 First randomized controlled trial to compare rapid vs. gradual decompression of urinary retention – the 

mythical danger of rapid emptying of the extended bladder 

S. Boettcher, D.A. Lazica, S. Roth (Wuppertal, Germany) 

636 Differences in the visuomotor control of experts and novices performing a virtual reality TURP 

E.A. Bright, S.J. Vine, M.R. Wilson, J.S. McGrath (Exeter, United Kingdom) 

637 Holmium laser enucleation versus transurethral resection of the prostate 1-year follow-up results of a 

randomized clinical trial 

A.A. Hussein, A.M. Eltabey (Cairo, Benha, Egypt) 

638 Comparison of clinical results between bipolar TURP and holmium laser enucleation of the prostate 

(HoLEP) based on the initial experience in patients with obstructive BPH 

S. Choi, J.M. Chung (Busan, South Korea) 

639 The bipolar plasma enucleation of the prostate versus open prostatectomy in cases of prostates over 80 ml 

– a prospective, randomized comparison 

B. Geavlete, R. Multescu, C. Moldoveanu, D. Georgescu, F. Stanescu, M. Jecu, P.A. Geavlete (Bucharest, 

Romania) 

640 Millin suprapubic adenomectomy obsolete or still gold standard in the era of laparoscopic or laser 

enucleation for BPH? Results of a series of 240 consecutive cases and a post-operative hospital stay of 4.6 

days 

P.E. Briant, M. Vinet, S. Genevois, D. Champetier, N. Morel-Journel, P. Paparel, P. Paul, A. Ruffion (Lyon, 

France) 

641 Monotherapy with tadalafil or tamsulosin for moderate-to-severe lower urinary tract symptoms 

suggestive of benign prostatic hyperplasia (LUTS/BPH): Results from an international, double-blind, 

placebo-controlled trial 

M. Oelke, F. Giuliano, V. Mirone, L. Xu, D. Cox, L. Viktrup (Hanover, Germany; Garches, France; Naples, Italy; 

Indianapolis, United States of America) 

642 Tadalafil 5 mg once daily improves lower urinary tract symptoms suggestive of benign prostatic 

hyperplasia in men without erectile dysfunction 

C. Roehrborn, G. Broderick, G. Brock, L. Xu, L. Viktrup (Dallas, Jacksonville, Indianapolis, United States of 

America; London, Canada)

643 Efficacy and safety of simultaneous administration of mirodenafil once daily and an alpha blocker in 

men with unsatisfactory improvement of lower urinary tract symptoms despite the alpha blocker mono 

therapy: A multicenter, open-label, prospective study 

C.Y. Oh, J.S. Cho, C. Yoo, D.Y. Yang, B.H. Chung, S.H. Lee, D.H. Lee, M.S. Cheong (Cheuncheon, Seoul, South 

Korea) 

644 Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors (pde5-is) alone or 

in combination with alpha blockers for lower urinary tract symptoms (LUTS) secondary to benign prostatic 

hyperplasia (BPH) 

M. Gacci, G. Corona, M. Salvi, L. Vignozzi, K.T. McVary, S.A. Kaplan, C.G. Roehrborn, S. Serni, V. Mirone, 

M. Carini, M. Maggi (Florence, Bologna, Naples, Italy; Chicago, New York, Dallas, United States of America) 


215 

Sunday

Sunday 




14.00 - 15.30 Cancer Initiating Cells (CICs) and Epithelial Mesenchymal Transition 

(EMT) 



Chairs: M. Cecchini, Berne (CH) 

H.Y. Leung, Glasgow (GB) 



645 Transcriptome profiling of the bone microenvironment during the development of osteolytic bone 

metastasis 

J. Hensel, A. Wetterwald, G. Van Der Pluijm, R. Temanni, M.G. Cecchini, G.N. Thalmann (Berne, Switzerland; 

Leiden, The Netherlands) 

646 HER2 overcomes PTEN (loss) induced senescence to cause aggressive prostate cancer 

I. Ahmad, R. Patel, O.J. Sansom, H.Y. Leung (Glasgow, United Kingdom) 

647 Fer kinase regulates prostate cancer cell migration through α-dystroglycan glycosylation 

T. Yoneyama, K. Angata, B. Xingfeng, S. Hatakeyama, Y. Tobisawa, K. Mori, H. Yamamoto, K. Imanishi, 

N. Tokui, T. Okamoto, N. Sugiyama, Y. Suzuki, S. Kudo, T. Yoneyama, T. Koie, N. Kamimura, C. Ohyama, 

S. Chanda, M. Fukuda (Hirosaki, Tsukuba, Japan; La Jolla, United States of America) 

648 Fibulin-5 is down regulated in invasive growing primary prostate carcinoma cells 

V. Jung, M. Saar, C.E. Hach, J. Kamradt, M. Stöckle, G. Unteregger (Homburg/Saar, Germany) 

649 LaminA/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell 

growth, migration and invasion through the PI3K/AKT/PTEN pathway 

G. Schaefer, L. Kong, H. Bu, Y. Zhang, Y. Zhang, H. Klocker (Innsbruck, Austria; Beijing, China) 

650 The omega-6 arachidonic acid induces an amoeboid phenotype involved in transendothelial migration: 

Putative function of the Ephrin Receptor A2 

T. Tawadros, J.A. Roulson, C. Hart, N. Clarke, M. Brown (Manchester, Salford, United Kingdom) 

651 Evidence for an early interaction of the RANKL pathway and mesenchymal stromal cells in bone marrow of 

patients with localized prostate cancer 

T. Todenhöfer, J. Hennenlotter, A. Hohneder, S. Grimm, B. Schmiedel, H.J. Bühring, G. Gakis, A. Stenzl, 

C. Schwentner (Tübingen, Germany) 

652 Harnessing the biological activity of circulating prostate cancer cells 

F.L. Carvalho, Z. Rasheed, E. Antonarakis, B. Simons, W. Matsui, D.M. Berman (Baltimore, United States of 

America) 

653 The biological and functional role of prostate cancer exosomes 

D. Duijvesz, N. Naimi, M. Peltola, C.Y.L. Versluis, T.M. Luider, K.S.I. Pettersson, G. Jenster (Rotterdam, The 

Netherlands; Turku, Finland) 

654 Crucial role of Dickkopf-3 in prostate morphogenesis in vitro and in vivo 

Y. Kawano, D. Romero, N. Bengoa, N. Maltry, M. Walker, M. Eto, J. Waxman, N. Niehrs, R. Kypra (London, 

United Kingdom; Bilbao, Spain; Heidelberg, Germany; Kumamoto, Japan)

655 WNT pathway in prostate cancer: Expression profile and regulation by bisphosphonates 

S. Thiele, M. Rauner, C. Goettsch, T.D. Rachner, P. Benad, S. Füssel, K. Erdmann, C. Hamann, G.B. Baretton, 

M.P. Wirth, F. Jakob, L.C. Hofbauer (Dresden, Würzburg, Germany) 

656 HES6 interacts with Notch signaling in prostate cancer progression 

L. Carvalho, M. Berman (Baltimore, United States of America) 

657 Expression of the stem cell associated and intermediate filament protein nestin during organogenesis of 

the prostate 

J.A. Ceder, M.W. Aalders, R.M. Hoffman, P.A. Abrahamsson, J.A. Schalken, J.A. Ceder (Malmö, Sweden; 

Nijmegen, The Netherlands; San Diego, United States of America) 

658 The identification of novel prostate stem and progenitor cell markers 

J.A. Ceder, M.W. Aalders, M.C.W. Voller, P.A. Abrahamsson, J.A. Schalken, J.A. Ceder (Malmö, Sweden; 

Nijmegen, The Netherlands) 


217 

Sunday

Sunday 




15.00 - 17.00 dVP 3D Video and live narration 


Sponsored by INTUITIVE SURGICAL


15.45 - 17.15 LESS 




Chairs: E. Barret, Paris (FR) 

R. Rabenalt, Düsseldorf (DE) 


V29 Right LESS partial nephrectomy 

A. Alcaraz, L. Peri, M. Musquera, E. Garcia-Cruz, M.G. Diaconu, M.J. Ribal (Barcelona, Spain) 

V30 Simultaneous LESS bilateral nephrectomy 

A. Alcaraz, L. Peri, M. Musquera, L. Izquierdo, M. Perez, D. Gosalbez, M.J. Ribal (Barcelona, Spain) 

V31 LESS (laparoendoscopic single site surgery) pyeloplasty without special devices 

L. Curcio, A.C. Ahouagi, J. Renteria, L. Andrade (Rio de Janeiro, Brazil) 

V32 Difficulties of the single port laparoscopic surgery, how to come round them and adapt the surgical 

gestures with the example of sacrocolpopexies 

E. Drapier, A. Smirnoff, L. De Poncheville (La Rochelle, France) 

V33 Second generation instruments for robotic single site kidney surgery: Early experience in a cadaver model 

R. Autorino, H.K. Laydner, R. Yakoubi, A. Kassab, W. Isac, E. Rizkala, R.J. Stein, J.H. Kaouk (Cleveland, United 


V34 LESS radical cystectomy 

M. Abdelhakiem, A. Abdalla, A. El Feel, A. Abdelhakiem (Cairo, Egypt) 

V35 LESS living donor nephrectomy 

A. Alcaraz, M. Musquera, Ll. Peri, A. Ciudin, E. Garcia-Cruz, M.J. Ribal (Barcelona, Spain) 


219 

Sunday

Sunday 




15.45 - 17.15 Novel therapeutic approaches in urothelial carcinoma 



Chairs: M. Knowles, Leeds (GB) 

J.A. Witjes, Nijmegen (NL) 



659 A preclinical placebo controlled efficacy study with the combination of saP21 and siCCL2 in an in vivo 

monitored orthotopic mouse bladder cancer model 

W.J. Liu, J. Jin, H.F. Wang, L.Q. Zhou, L.L. Liang, Z.S. He, J.R. Hao, Y.L. Guo (Beijing, China) 

660 Effect of hexyl aminolevulinate on antitumor activity of apaziquone in human bladder cell lines 

G. Reddy, S. Chawla, S. Fruchtman (Irvine, United States of America) 

661 Enhanced tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and 

their effects on the morphology of the bladder urothelium 

C. Mugabe, R.T. Liggins, P.A. Raven, A.I. So, M.E. Gleave, D.E. Brooks, H.M. Burt (Vancouver, Canada) 

662 Activation of the Wnt signalling pathway synergises with either PI3K or MAPK activation to lead to 

urothelial cell carcinomas (UCC) with differing treatment requirements 

I. Ahmad, H.Y. Leung, O.J. Sansom (Glasgow, United Kingdom) 

663 Phase I clinical study of survivin-derived peptide vaccine with interferon alpha therapy for advanced 

urothelial cancer 

T. Tanaka, H. Kitamura, T. Torigoe, Y. Hirohashi, N. Masumori, N. Sato, T. Tsukamoto (Sapporo, Japan) 

664 MAGE-A3 and PRAME: New targets for antigen-specific cancer immunotherapeutics (ASCI) in bladder 

cancer? 

H. Van Poppel, S. Joniau, E. Lerut, D. D’Agostino, O. Gruselle, T. Coche, V. Brichard, P. Therasse (Leuven, 

Rixensart, Belgium) 

665 Pharmacokinetics and toxicity of R-837 and TMX-202 after intravesical and intravenous administration: 

A pre-clinical study in naive rats 

J. Falke, H.C. Arentsen, C.A. Hulsbergen-Van De Kaa, R. Maj, E. Oosterwijk, J.A. Witjes (Nijmegen, The 

Netherlands; Bioggio, Switzerland) 

666 Wild-type reovirus as new oncolytic agent against bladder cancer – results of an in vitro study 

S.H. Alloussi, S. Banek, J. Hennenlotter, J. Seibold, C. Schwentner, A. Stenzl (Tübingen, Germany) 

667 Bladder cancer: Could statins be part of the solution? Evidences from an experimental study 

B. Parada, A. Figueiredo, F. Reis, P. Nunes, L. Campos, P. Antunes, A. Mota, F. Teixeira (Coimbra, Portugal) 

668 BCG strain and administration protocol influence local T cell response and anti-tumor activity in the 

treatment of bladder cancer 

C. Biot, J.R. Gsponer, A. Bachmann, C.A. Rentsch, M.L. Albert (Paris, France; Basel, Switzerland)

669 The tumour suppressor gene, AIMP3 sensitises bladder cancer to chemo/radiotherapy in vitro and is a 

prognostic marker for overall survival in patients treated with radiotherapy for muscle invasive disease 

P.M.S. Gurung, M. Williamson, C. West, N. Counsell, A. Ahmed, F. Benthani, A. Feber, P. Dewinter, 

S.C. Short, T. Powles, P. Hoskin, A. Freeman, J.R.W. Masters, J.D. Kelly (London, Manchester, United 

Kingdom) 

670 Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer stem cells 

M. Tatokoro, F. Koga, S. Yoshida, H. Fukushima, S. Kawakami, Y. Fujii, L. Neckers, K. Kihara (Tokyo, Japan; 

Bethesda, United States of America) 


221 

Sunday

Sunday 




15.45 - 17.15 Radical prostatectomy: Quality of life and quality control 



Chairs: M. Muntener, Zurich (CH) 

R.E. Sanchez Salas, Paris (FR) 




671 The impact of sexual desire on sexual health related quality of life following radical prostatectomy: 

A 5-year follow up study in Japan 

S. Namiki, S. Ishidoya, A. Ito, Y. Arai (Sendai, Japan) 

672 Health related quality of life after laparoscopic radical prostatectomy and robot assisted laparoscopic 

prostatectomy 

V. Berge, R.E. Berg, J.R. Hoff, N. Wessel, S. Karlsen, L.M. Eri (Oslo, Norway) 

673 Open versus robotic-assisted radical prostatectomy: A comparison of urinary and sexual quality of life 

outcomes 

K.A. Beattie, S. Chopra, R. Thanigasalam, S. Egger, J. Symons, A.M. Haynes, J. Matthews, C. Yuen, 

P. Brenner, R.L. Sutherland, K.K. Rasiah, P.D. Stricker (Sydney, Australia) 

* 674 Fear of progression among long-term prostate cancer survivors: Illness perceptions, patients’ presumed 

cause of prostate cancer and family history as potential predictors 

K. Herkommer, A. Dinkel, A. Hahn, B. Marten-Mittag, P. Herschbach, J. Gschwend (Munich, Germany) 

675 Baseline functional status is predictive of decisional regret and satisfaction following robotic 

prostatectomy 

H.J. Lavery, D. Sebrow, A.R. Hobbs, N.E. Mohamed, M.A. Diefenbach, A.W. Levinson, D.B. Samadi (New 

York, United States of America) 

676 Monitoring validated quality of life outcomes following prostatectomy: Initial description of a novel online 

questionnaire 

D. Sebrow, H.J. Lavery, J. Brajtbord, A.R. Hobbs, A.W. Levinson, D.B. Samadi (New York, United States of 

America) 

* 677 The effect of hospital vs. surgical volume on outcomes after radical prostatectomy: A head-to-head 

comparison using decision-curve analyses 

Q.D. Trinh, S.F. Shariat, J. Sammon, M. Bianchi, W. Jeong, J. Schmitges, K.R. Ghani, J. Jhaveri, S. Sukumar, 

A. Dabaja, M. Ehlert, P.K. Agarwal, C.G. Rogers, J.O. Peabody, M. Menon, M. Sun (Detroit, New York City, 

United States of America; Montreal, Canada; Hamburg, Germany) 

678 Differences in perioperative outcomes between African American and Caucasian patients after radical 

prostatectomy 

Q.D. Trinh, J. Sammon, K.R. Ghani, W. Jeong, J. Schmitges, J. Jhaveri, S. Sukumar, A. Friedman, M. Ehlert, 

F. Muhletaler, A. Dabaja, P.K. Agarwal, C.G. Rogers, J.O. Peabody, M. Menon, P. Perrotte (Detroit, United 

States of America; Hamburg, Germany; Montreal, Canada) 

* 679 Perioperative outcomes of robot-assisted radical prostatectomy vs. open radical prostatectomy 

Q.D. Trinh, J. Sammon, K.R. Ghani, W. Jeong, J. Jhaveri, S. Sukumar, A. Dabaja, A. Friedman, M. Ehlert, 

F. Muhletaler, P.K. Agarwal, C.G. Rogers, J.O. Peabody, M. Menon (Detroit, United States of America)

680 Relationship between blood loss, blood transfusion and biochemical recurrence-rates: Assessment of 

17347 radical prostatectomy patients 

K. Boehm, L. Budaeus, P. Tennstedt, K. Kuehne, H. Heinzer, G. Salomon (Hamburg, Germany) 

681 Remarkably little influence of depression, worry and anxiety on preoperative function in patients 

scheduled for radical retropubic prostatectomy 

U.H.G. Michl, M. Graefen, A. Haese, G. Salomon, H. Heinzer, Th. Schlomm, Th. Steuber, H. Huland, 

A. Krueger (Hamburg, Germany) 

* 682 Long-term radical prostatectomy outcomes among participants from the ERSPC Rotterdam 

S. Loeb, X. Zhu, F.H. Schröder, M. Roobol (New York, United States of America; Rotterdam, The Netherlands) 


223 

Sunday

Sunday 




15.45 - 17.15 Hot topics in the management of OAB 



Chairs: C.A.L. D’Ancona, Campinas (BR) 





* 683 Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of 

mirabegron in overactive bladder (OAB) 

C.R. Chapple, S. Kaplan, H.D. Mitcheson, J. Klecka, J. Cummings, T. Drogendijk, C. Dorrepaal, N.E. Martin 

(Sheffield, United Kingdom; New York, Watertown, Deerfield, United States of America; Plzen, Czech 

Republic; Leiderdorp, The Netherlands) 

684 Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder 

(OAB): Post-hoc analysis of a prospective, randomised European–Australian phase III trial 

V. Khullar, J. Cambronero, J. Angulo, M. Wooning, M.B. Blauwet, C. Dorrepaal, N.E. Martin (London, United 

Kingdom; Madrid, Spain; Leiderdorp, The Netherlands; Deerfield, United States of America) 

685 The beta-3 adrenoceptor agonist solabegron is safe and effective for improving symptoms of overactive 

bladder 

E.H. Ohlstein, M.C. Michel, A. Von Keitz (Malvern, United States of America; Amsterdam, The Netherlands; 

Marburg, Germany) 

686 Randomised, double-blind, placebo-controlled study to assess the ocular safety of mirabegron in 

normotensive IOP research subjects 

N. Martin, R.A. Lewis, R. Vogel, N. Sheth, B. Sargent, D. Swearingen, S. Rasmussen, G. Hantsbarger, 

G.D. Novack (Deerfield, Sacramento, Sarasota, Tempe, San Rafael, United States of America) 

687 Treatment with fesoterodine versus tolterodine for reducing symptom bother in elderly patients with 

overactive bladder including urgency urinary incontinence 

T. Schneider, A. Bergqvist, J. Wang, A. Wagg, C. Ebel-Bitoun (Mulheim, Germany; Sollentuna, Sweden; New 

York, United States of America; Edmonton, Canada; Paris, France) 

688 Persistence of solifenacin combination treatment in men with overactive bladder symptoms after 

tamsulosin monotherapy 

Y.S. Lee, K.S. Lee, W.H. Park, J.C. Kim, S. Hong, B.H. Chung, C.S. Kim, J.G. Lee, D.K. Kim, C.H. Park, J.K. Park 

(Seoul, Incheon, Daejeon, Daegu, Jeonju, South Korea) 

689 Solifenacin and cognitive function in elderly people with mild cognitive impairment: The SENIOR study 

A.S. Wagg, M. Dale, R. Tretter, B. Stowe, G. Compion (Edmonton, Canada; Blackpool, Staines, United 

Kingdom; Leiderdorp, The Netherlands) 

* 690 Can baseline characteristics of subjects with overactive bladder predict responsiveness to antimuscarinic 

treatment 

S. Herschorn, S. Kaplan, J.T. Wang, F. Ntanios (Toronto, Canada; New York, United States of America) 

691 Reasons for switching antimuscarinic therapy: Results from a European cross-sectional survey of 

physicians and patients with OAB 

G. Compion, J. Jackson, J. Janes (Staines, Macclesfield, United Kingdom)

* 692 The Zurich experiences including 10 year results of 253 cases treated with botulinum-A toxin injections 

into the detrusor muscle for overactive bladder refractory to anticholinergics 

D.M. Schmid, S. Roy-Guggenbuehl, R. Groebli-Bolleter, T. Sulser (Zurich, Switzerland) 

693 Intravesical administration of resiniferatoxin for treatment OAB with increased bladder sensation 

Y. Mirkin, D. Bedretdinova, I. Eizenakh, O. Malinina (Moscow, Russia) 

694 A novel, patient-managed neuromodulation system (PMNS) using a transdermal patch for treatment of 

overactive bladder (OAB) with urgency urinary incontinence (UUI) 

M. Phillips, T. Sotelo, D. Altman, M. Kennelly, S. MacDiarmid, K. Peters (Washington, Charlotte, Greensboro, 

Royal Oak, United States of America; Stockholm, Sweden) 



Sunday

Sunday 




15.45 - 17.15 Sexual dysfunction: Miscellaneous 



Chairs: V. Mirone, Naples (IT) 

E. Wespes, Brussels (BE) 



695 Terazosin-induced alterations in catalase expression and lipid peroxidation in the rat seminal vesicles 

E. Patris, G. Deliconstantinos, A. Kyroudi-Voulgari, I. Anastasiou, D. Perea, D. Mitropoulos (Alexandroupolis, 


696 Premature ejaculation: A prospective randomized study to compare pelvic floor rehabilitation and 

dapoxetine, a novel selective serotonin reuptake inhibitor 

A.L. Pastore, G. Palleschi, A. Leto, F. Iori, C. Leonardo, V. Petrozza, L. Pacini, A. Carbone (Latina, Rome, Italy) 

697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization 

A.V. Khelaia, G.G. Bochorishvili, L.G. Managadze (Tbilisi, Georgia) 

698 Clinical analysis in young patient with persistent sexual dysfunctions after finasteride assumption to 

prevent male pattern hair loss 

C. Trombetta, G. Mazzon, G. Liguori, G. Ollandini, S. Cauci, G. Toffoli, E. Erika (Trieste, Udine, Aviano, Italy) 

699 High blood pressure accelerates penile arterial insufficiency in young erectile dysfunction patients. A 

window of opportunity for preventing vascular disease 

C. Fasoulakis, N. Ioakeimidis, D. Rompolis, A. Katevatis, C. Vlachopoulos, K. Rokkas, A. Rempelakos, 

C. Stefanadis (Athens, Greece) 

700 Association between lower urinary tract symptoms and sexual dysfunction assessed using the Core Lower 

Urinary Tract Symptom Score and International Index of Erectile Function-5 questionnaires 

M. Nakamura, T. Fujimura, M. Nagata, C. Hosoda, M. Suzuki, H. Fukuhara, Y. Enomoto, H. Nishimatsu, 

H. Kume, Y. Igawa, Y. Homma (Tokyo, Japan) 

701 Efficacy and safety of avanafil for the treatment of erectile dysfunction: Results of a multicenter, 

randomized, double-blind, placebo-controlled trial 

J.K. Park, C. Zhao, S.W. Kim, D.Y. Yang, J.J. Kim, N.C. Park, S.W. Lee, J.S. Paick, T.Y. Ahn, K.H. Moon, 

W.S. Chung, K.S. Min, J.K. Suh, J.S. Hyun, K. Park (Jeonju, Seoul, Busan, Daeegu, Incheon, Jinju, Kwangju, 

South Korea) 

702 Should physicians prescribe PDE5 inhibitors to sexually healthy males without erectile dysfunction? 

I. Gruenwald, B. Appel (Haifa, Israel) 

703 The efficacy and safety of combination of injectable testosterone undecanoate and once-daily dose of 

tadalafil 5mg in the treatment of erectile dysfunction with testosterone deficiency syndrome 

M.G. Park, J.K. Yeo, D.Y. Cho, S.S. Park, K.S. Kang, M.M. Oh, J.H. Bae, D.G. Moon (Seoul, South Korea) 

704 Safety and efficacy of tadalafil 5 mg administered once daily in men with erectile dysfunction and lower 

urinary tract symptoms 

S.W. Sungwoo, J.M. Jeman, K.H. Kwang Hyun, J.H. Ju Hyun, D.S. Dalsan, T.Y. Tai Young, Y.H. Young Hwan, 

S.C. Sungchan (Seoul, Ulsan, South Korea)

705 Effects of tadalafil (TAD) or tamsulosin (TAM) on erectile function in men with lower urinary tract 

symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Results from a multicenter, doubleblind, 

randomized, placebo (PLA)-controlled 12-week study 

F. Giuliano, M. Oelke, V. Mirone, S. Watts, D. Cox, L. Viktrup (Garches, France; Hanover, Germany; Naples, 

Italy; Indianapolis, United States of America) 

706 Cytokines gene expression in the tunica albuginea in patients with Peyronie’s disease. Pilot study with a 

control group 

C. Pavone, V. Serretta, G. Caruana, D. Abbadessa, G. Scaduto, P. Colomba, R. Alessandro (Palermo, Italy) 

707 Tunica albuginea allograft: A new rat model of Peyronie’s disease with penile curvature and cartilage 

formation 

L. Ferretti, T. Fandel, X. Qiu, L. Banie, G. Lin, S. Droupy, T.F. Lue (Bordeaux, Nîmes, France; San Francisco, 



227 

Sunday

Sunday 




15.45 - 17.15 Invasive bladder cancer: Reducing morbidity of surgery 



Chairs: F. Gaboardi, Milan (IT) 




708 Robotic radical cystectomy in the elderly: Is there a benefit from this minimal invasive procedure? 

M. Saar, J. Kamradt, S. Van Heemskerk, A. Treiyer, C. Ohlmann, S. Siemer, M. Stöckle (Homburg/Saar, 

Germany) 

709 Robot assisted radical cystectomy (RARCx) including extended pelvic lymph node dissection (PLND) and 

intracorporal urinary diversion as standard procedure 

M. Annerstedt, G. Lam, K. Steven (Copenhagen, Denmark) 

710 A comparison of early complications between open and robot-assisted radical cystectomy 

H.J. Kim, H.H. Sung, B. Park, B.H. Park, S.I. Seo, S.S. Jeon, H.Y. Choi, H.M. Lee, B.C. Jung (Seoul, South 

Korea) 

711 Laparoscopic radical cystectomy with orthotopic neobladder ad Studer - advantages and disadvantages. 

Initial experience with fifty patients 

D.I.M. Shishkov, B.J. Kasabov, D.I.V. Mateev, V.A.S. Angelov, A.R. Sarachev (Plovdiv, Bulgaria; Essen, 

Germany) 

712 Long term oncologic control after laparoscopic radical cystectomy in men: A single-center experience 

E. Xylinas, I. Ouzaid, G. Ploussard, N. Gillion, D. Vordos, A. Hoznek, Y. Allory, L. Salomon, C.C. Abbou, A. De 

La Taille (Creteil, France) 

713 Robotic assisted versus laparoscopic radical cystectomy: A single institution direct comparison 

M. Saad, R.E. Sanchez-Salas, R. Favaretto, E. Barret, M. Galiano, F.L. Ortega, F. Rozet, X. Cathelineau (Paris, 

France) 

714 Enhanced recovery programme for radical cystectomy - a novel rectus sheath catheter and gesia system 

T.J. Dutton, M.O. Daugherty, R. Mason, R. Pocock, J.S. McGrath (Exeter, United Kingdom) 

715 Fast-track program for robotic-assisted laparoscopic cystectomy – improvement of postoperative recovery? 

M. Saar, J. Kamradt, C.H. Ohlmann, S. Herwerth, S. Siemer, M. Stöckle (Homburg/Saar, Germany) 

716 Enhanced recovery protocol for patients undergoing radical cystectomy: Results in 469 consecutive patients 

J.J. Aning, R. Thurairaja, E. Waine, E. Otto, A.J. Koupparis, E.W. Rowe, D.A. Gillatt (Bristol, United Kingdom) 

717 A new, simple and effective fast track concept for patients undergoing radical cystectomy for bladder 

cancer 

A. Karl, A. Buchner, E. Weninger, A. Becker, M. Seitz, M. Staehler, T. Grimm, C.G. Stief (Munich, Germany) 

718 Clinical outcomes and prognostic factors in patients with urachal carcinoma 

H.M. Bruins, O. Visser, M. Ploeg, C. Hulsbergen-Vandekaa, J.A. Witjes (Nijmegen, Utrecht, The Netherlands)

719 Differences in patterns of prostatic stromal involvement between primary and progressive muscle invasive 

bladder tumours 

A. Ciudin, J. Huguet, M. Musquera, M.J. Ribal, A. Alcaraz (Barcelona, Spain) 

720 Surgical postoperative complications after open radical cystectomy: Using a standardized classification 

A.M. Autran-Gomez, I. Izawa, J. Chin (London On, Canada) 


229 

Sunday

Sunday 




15.45 - 17.15 Strictures and urethroplasty 2 



Chairs: T.J. Greenwell, London (GB) 




721 Histological assessment of urethral involvement in male patients with lichen sclerosus: A preliminary 

report 

G. Barbagli, F. Mirri, G. Romano, S. Sansalone, M. Gallucci, M. Lazzeri (Arezzo, Montevarchi, Rome, 

Florence, Italy) 

722 Urethroplasty for full-length Lichen Sclerosus related strictures - evolution of the dorsal graft technique 

D.E. Andrich, A.R. Mundy (London, United Kingdom) 

723 Does DVUT influence on the subsequent open urethroplasty results? 

M.I. Kogan, V.V. Mitusov, V.V. Krasulin, A.V. Shangichev, V.P. Gluhov (Rostov on Don, Russia) 

724 Resection with end to end anastomosis versus onlay urethroplasty for bulbar urethral strictures: Long term 

follow up of 162 patients in a single center experience 

T. Olsen Ekerhult, K. Lindqvist, R. Peeker, L. Grenabo (Gothenburg, Sweden) 

725 Longitudinal evaluation of erectile function following urethral reconstruction 

K. Vander Eeckt, N. Lumen, F. Van Der Aa, S. Joniau (Leuven, Ghent, Belgium) 

726 Quality of life before and after urethroplasty 

K. Vander Eeckt, F. Van Der Aa, N. Lumen, S. Joniau (Leuven, Ghent, Belgium) 

727 One-stage bulbar urethroplasty using ventral oral mucosal onlay grafting techniques: Retrospective 

analysis of a high volume center in a homogenous group 

O. Engel, L. Kluth, A. Soave, P. Reiss, R. Dahlem, S. Ahyai (Hamburg, Germany) 

728 Perineal-reanastomosis for the treatment of recurrent anastomotic strictures: Outcome and patient 

satisfaction 

C.P. Reiss, D. Pfalzgraf, L. Kluth, O. Balzer, A. Soave, O. Engel, S. Riechardt, M. Fisch, R. Dahlem (Hamburg, 

Germany) 

729 Withdrawn 

730 Urethroplasty after failed open repair – functional results and patient satisfaction 

D. Pfalzgraf, L. Kluth, C.P. Reiss, S. Riechardt, O. Engel, M. Fisch, R. Dahlem (Hamburg, Germany)



15.45 - 17.15 New insights into bladder control 



Chairs: A. Apostolidis, Thessaloniki (GR) 

G. Van Koeveringe, Maastricht (NL) 




* 731 Effect of alpha-1 adrenoceptor antagonist and phosphodiesterase type-5 inhibitor on c-Fos and nerve 

growth factor expression in the central micturition areas: Hypertension associated rat model 

J.K. Oh, K.H. Kim, S.J. Yoon, H. Jung, T.B. Kim, K.J. Chung, C.H. Kwon, Y.G. Na (Incheon, Seoul, Daejeon, 

South Korea) 

732 Efficacy of α1-AR antagonists in patients undergoing prostate 125I brachytherapy for prostate carcinoma: 

A randomized trial involving pressure flow study 

N. Shimizu, M. Yasuda, Y. Yamamoto, T. Minami, T. Hayashi, M. Nozawa, K. Yoshimura, T. Ishii, H. Uemura, 

K. Nakamatsu (Osaka-Sayama, Japan) 

733 Tamsulosin ameliorates aging-induced memory impairment through increasing of neurogenesis in the 

hippocampus of rats 

S.J. Yoon, H. Jung, T.B. Kim, K.J. Chung, J.K. Oh, C.H. Kwon, Y.G. Na, J.B. Choi (Incheon, Seoul, Daejeon, 

Suwon, South Korea) 

734 Spinal α1-adrenoceptors regulate peristalsis of the obstructed and normal rat ureter in vivo 

L. Villa, C. Fullhase, P. Hedlund (Milan, Italy; Munich, Germany) 

* 735 Sildenafil increases vaginal lubrication irrespective of the hormonal status and independently of the 

neuronal isoform of nitric oxide synthase pathway 

X. Game, O. Bouali, M. Roumiguié, Y. Barreira, G. Escourrou, P. Rischmann, B. Malavaud (Toulouse, France) 

* 736 Effects of sildenafil, a phosphodiesterase type 5 inhibitor, on the primary single afferent activity of the rat 

bladder 

N. Aizawa, Y. Homma, Y. Igawa (Tokyo, Japan) 

737 The effect of cyclic nucleotides on Ca sensitization induced by muscarinic stimulation in pig detrusor 

smooth muscle 

N. Shahab, S. Kajioka, M. Hayashi, T. Yunoki, S. Naito (Fukuoka, Japan) 

* 738 Stimulation of the cyclic AMP/cyclic GMP signalling enhances the relaxation exerted by phosphodiesterase 

(PDE) inhibitors of isolated human detrusor smooth muscle 

G.T. Kedia, F. Bodmann, M.A. Kuczyk, S. Ückert (Hanover, Germany) 

739 Phosphodiesterase isoenzymes in the human urethra: Relation to neuronal nitric oxide synthase-, VIP- and 

CGRP-containing nerves 

G.T. Kedia, S. Ückert, M. Oelke, M.A. Kuczyk, P. Hedlund (Hanover, Germany; Milan, Italy) 

740 Phosphodiesterase type 5 is expressed in human and rat lower urinary tract tissues and its inhibition with 

tadalafil improves prostate gland oxygenation in spontaneously hypertensive rats 

A. Morelli, E. Sarchielli, P. Comeglio, S. Filippi, R. Mancina, M. Gacci, L. Vignozzi, M. Carini, G. Vannelli, 

M. Maggi (Florence, Italy) 


231 

Sunday

Sunday 

741 Degarelix reduces urodynamic changes in a rat model for experimental detrusor overactivity and causes 

more efficient voiding 

G. Gandaglia, F. Benigni, G. La Croce, M. Moschini, F. Strittmatter, E. Colli, K.E. Andersson, P. Hedlund 

(Milan, Italy; Munich, Germany; Copenhagen, Denmark; Winston Salem, United States of America) 

742 The functional role of EP4 receptors in the rat urinary bladder with bladder outlet obstruction 

H. Zakoji, M. Beppu, H. Kobayashi, M. Yoshiyama, M. Takeda, I. Araki (Yamanashi, Shizuoka, Seta, Japan) 

232 Programme Book



15.45 - 17.15 BPH: Medical therapy 



Chairs: J. Barkin, Toronto (CA) 

S. Madersbacher, Vienna (AT) 



743 Actual prescription rate of BPH-related medications after surgery for symptomatic BPH: Data from a 

nationwide registry 

J.N. Cornu, Y. Merlière, E. Vicaut, A. Fournier, C. Hodée, M. Aout, L. Duchet, L. Gauffriau, D. Polton, 

B. Lukacs (Paris, France) 

744 Effect of short-term treatment with silodosin on ejaculatory function in sexually active men with benign 

prostate hyperplasia 

S.J. Park, G.W. Jung, J.H. Seo (Busan, South Korea) 

745 Randomized controlled trial of nocturia in patients with benign prostatic hyperplasia with overactive 

bladder using an alpha-blocker combined with a novel antichorinergic, imidafenacin; GOOD-NIGHT Study 

K. Kuratsukuri, A. Tsujimura, H. Akino, N. Oguchi, Y. Kitagawa, N. Segawa, S. Tamada, H. Tuji, A. Watanabe, 

M. Urashima, A. Okuyama, H. Uemura, Y. Katsuoka, T. Nakatani, M. Namiki, H. Fuse, T. Matsuda, 

O. Yokoyama (Osaka, Japan) 

746 Efficacy of combination therapy with tamsulosin OCAS and solifenacin in NEPTUNE: Results from a 

randomised, phase 3 trial in men with LUTS 

M. Drake, C. Chapple, P. Van Kerrebroeck, M. Speakman, M. Klaver, K. Van Charldorp, K. Traudtner (Bristol, 

Sheffield, Taunton, United Kingdom; Maastricht, Leiderdorp, The Netherlands) 

747 Incidence of benign prostatic hyperplasia clinical progression over time in the combination of avodart and 

tamsulosin (CombAT) study 

M. Emberton, C.G. Roehrborn, A. Tubaro, T. Wilson, R. Castro (London, United Kingdom; Dallas, Texas, 

Durham, North Carolina, King of Prussia, Pennsylvania, United States of America; Rome, Italy) 

748 Effect of baseline variables on acute urinary retention and surgery related to benign prostatic hyperplasia 

in men from the combination of avodart and tamsulosin (CombAT) study 

S. Madersbacher, C.G. Roehrborn, J. Barkin, A. Tubaro, T. Wilson, R. Castro (Vienna, Austria; Dallas, Texas, 

Durham, North Carolina, King of Prussia, Pennsylvania, United States of America; Toronto, Canada; Rome, 

Italy) 

749 Dutasteride, who is it more effective for? Second to fourth digit ratio, its relationship with the prostate 

volume reduction by dutasteride treatment 

T.B. Kim, J.K. Oh, K.H. Kim, H. Jung, S.J. Yoon (Incheon, South Korea) 

750 Efficacy of dutasteride on storage and voiding functions in patients with benign prostatic hyperplasia: 

A pressure-flow study 

Y. Matsukawa, R. Hattori, M. Kato, Y. Yoshino, T. Yamamoto (Nagoya, Japan) 

751 Success and failure of discontinuous alpha blocker therapy in patients with LUTS; selection criteria for cost 

saving in developing countries 

M. Bulbul (Beirut, Lebanon) 


233 

Sunday

Sunday 

752 Effects of discontinuation of medication on LUTS in men with BPH improving symptoms following 

medication of alfa 1-blockade 

K. Ogura, S. Atsushi, Y. Miyazaki, H. Sawazaki (Otsu, Japan) 

753 Is combination therapy with an anticholinergic agent and an α1-adrenoceptor antagonist useful as 

first-line treatment in patients with benign prostatic hyperplasia complicated by overactive bladder? A 

randomized, prospective, comparative study using a urodynamic study 

Y. Matsukawa, R. Hattori, T. Mazima, T. Yamamoto, Y. Yoshino, M. Gotoh (Nagoya, Japan) 

754 Efficacy and safety of combination of alfuzosin and low dose udenafil once daily versus monotherapy in 

patients with comorbid lower urinary tract symptoms and erectile dysfunction: Randomized prospective 

open-label study 

D.Y. Kim, Y.J. Park, L.H. Sung, J.C. Kim (Daegu, Seoul, South Korea) 

755 Effects of the long-term treatment with silodosin in men with LUTS suggestive of BPH. A 9-month, openlabel 

extension study 

T. Tammela, C.R. Chapple (Tampere, Finland; Sheffield, United Kingdom) 

234 Programme Book



15.45 - 17.15 Prostate cancer: Pathology, biopsy and predictors in active 

surveillance 



Chairs: M.R. Cooperberg, San Francisco (US) 

M. Fröhner, Dresden (DE) 




* 756 Bilaterally positive biopsy cores are associated with non-organ confined disease in prostate cancer 

patients eligible for active surveillance 

R.A. Largo, S. Gfeller, M. Tremp, K. Rufibach, T. Sulser, M. Müntener (Zurich, Switzerland) 

* 757 Pathological results in patients eligible for six international active surveillance protocols 

A. El Hajj, G. Ploussard, C. Radulescu, A. Defourmestraux, N. Gillion, D. Vordos, A. Hoznek, R. Yiou, 

Y. Allory, A. De La Taille, C.C. Abbou, L. Salomon (Creteil, France) 

* 758 Predictors of poor quality of life in patients in active surveillance 

L. Bellardita, T. Rancati, D. Villani, C. Marenghi, C. Magnani, T. Magnani, R. Salvioni, N. Nicolai, S. Villa, 

R. Valdagni (Milan, Italy) 

759 Transperineal sector biopsies: Their role in active surveillance 

R. Popert, L. Vyas, J. Kinsella, B. Challacombe, D. Cahill (London, United Kingdom) 

760 Performance of different selection criteria for inclusion in an active surveillance program in prostate 

cancer 

V. Hernández, E. De La Peña, F.J. Díaz, C. Blazquez, J.M. De La Morena, C. Llorente (Madrid, Spain) 

* 761 How to expand the indication criteria for active surveillance without compromising cancer control. The 

importance of the extent of biopsy sampling 

N. Suardi, U. Capitanio, A. Gallina, F. Abdollah, D. Di Trapani, M. Tutolo, G. Gandaglia, G. Guazzoni, 

P. Rigatti, A. Briganti (Milan, Italy) 

762 The risk of upstaged disease increased with the body mass index in low risk prostate cancer patients 

eligible for active surveillance 

G. Ploussard, Y. Bayoud, A. De La Taille, X. Durand, E. Xylinas, Y. Allory, F. Vacherot, S. Terry, A. Claude, 

L. Salomon (Creteil, Paris, France) 

763 Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer 

patients eligible for active surveillance 

G. Ploussard, A. De La Taille, S. Terry, Y. Allory, I. Ouzaïd, F. Vacherot, C. Abbou, L. Salomon (Creteil, France) 

* 764 Centralized revision of diagnostic pathologic slides for prostate cancer patients on active surveillance: Is it 

just time and resource consuming or do we really need it 

M. Colecchia, M.F. Alvisi, B. Paolini, N. Nicolai, S. Villa, R. Salvioni, C. Marenghi, T. Rancati, R. Valdagni 

(Milan, Italy) 

765 Does initial prostate functional MRI impact on treatment choice for patients on active surveillance? 

G. Coffin, G. Ploussard, A. Cortesse, P. Meria, E. Tariel, F. Gaudez, F. Dubosq, L. Bastien, E. De Kerviller, 

A. Pluvinage, J. Verine, P. Mongiat-Artus, F. Desgrandchamps (Paris, France) 


235 

Sunday

Sunday 

766 Redefining intermediate risk prostate cancer using Gleason score 

M. Pollard, H.J. Lavery, A.R. Hobbs, S. Hall, A.W. Levinson, D.B. Samadi (New York, United States of 

America) 

236 Programme Book



17.30 - 19.00 Holmium Laser Enucleation of the Prostate (HoLEP) - the true alternative to TURP and 

open prostatectomy page 397 

Room 243 - Level 2 Sponsored by LUMENIS 


17.30 - 19.00 Injecting DIGNITY into your neurogenic detrusor overactivity (NDO) patient treatment paradigm 

- The role of botulinum toxin type A page 392 

Room Maillot - Level 2 Sponsored by ALLERGAN 

17.30 - 19.00 Revolution in the management of male LUTS? page 393 

Room Bordeaux - Level 3 Sponsored by ASTELLAS 

17.30 - 19.00 New data on ADT for prostate cancer: What does it mean for your patients? page 394 

Room Concorde Neuilly - Level 4 Sponsored by FERRING PHARMACEUTICALS 

17.30 - 19.00 Non muscle invasive bladder cancer management in 2012: From recommendations to real life 

clinical practice page 395 

Room 251 - Level 2 Sponsored by IPSEN/PHOTOCURE 

17.30 - 19.00 Redefining treatment standards in metastatic castration-resistant prostate cancer page 396 

Room Concorde Centre - Level 4 Sponsored by JANSSEN PHARMACEUTICAL COMPANIES OF 

JOHNSON & JOHNSON 

17.30 - 19.00 Sifting through the evidence in GU malignancies: A day in the clinic page 398 

Room 242 A/B - Level 2 Sponsored by NOVARTIS 

17.30 - 19.00 Finding a way forward in OAB care page 399 

Room Bleu - Level 2 Sponsored by PFIZER 

17.30 - 19.00 LUTS - BPH: From guidelines to the clinical practice page 400 

Room Concorde Paris - Level 4 Sponsored by RECORDATI 

17.30 - 19.00 Optimising the management of senior adults with prostate cancer page 401 

Room 252 A/B - Level 2 Sponsored by SANOFI ONCOLOGY 


237 

Sunday

Monday, 27 February - EAU Programme 


07.30 - 11.00 Technology and new techniques in urology: An update 


Chairs: W. Artibani, Verona (IT) 

G. Janetschek, Salzburg (AT) 

07.30 - 08.00 Highlight session 2 

Andrology 

A. Salonia, Milan (IT) 

Prostate disease 

M. Spahn, Würzburg (DE) 

Reconstruction 

D.E. Andrich, Kingston upon Thames (GB) 

08.00 - 08.05 Introduction Technology and new techniques in urology: An update 


08.05 - 08.20 State-of-the-art lecture Optimising the outcome of PCNL 

A. Hoznek, Creteil (FR) 


Percutaneous nephrolithotomy (PCNL) is the first line treatment for large or complex kidney stones. Though 

it is an effective and safe treatment, urologists have continuously sought to increase its efficacy while 

diminishing its morbidity. 

Technical improvements have been proposed for each step of the procedure. Besides the classical prone 

position, supine position is gaining increasing acceptance especially in Europe. Diminishing tract size and 

number, alternative dilatation methods (balloon), the use of small caliber devices (mini-perc) and flexible 

instruments are aimed at minimising renal parenchymal trauma. Novel fragmentation and extraction devices 

have also been developed. And lastly, tubeless PCNL has been suggested to improve postoperative patient 

comfort and shorten hospital stay. The rationale of all these aspects of PCNL will be discussed and the 

contemporary literature critically analysed. 

08.20 - 08.30 Update New aspects in ureteroscopy 

M.S. Michel, Mannheim (DE) 


Ureterorenoscopy is an increasing procedure for diagnosis in the upper urinary tract and for treating 

urolithiasis. Due to reduction in size and new materials as well as using micochips instead of fiberoptical 

or optical systems ureterorenoscopy can be performed with less trauma and improved results combined 

with a significantly improved durability of the instruments itself. In terms of new imaging modalities new 

instruments have been developed recently for improved diagnosis of tumors in the upper urinary tract. 

In addition new x-ray modalities like the Uro Dyna-CT have been introduced very recently offering new 

interventional 3D-imaging reconstruction modalities in order to improve the success of ureterorenoscopic 

procedures in terms of radiation dose, or-time and intraoperative stone free rate. These rapid technological 

developments will significantly support the role of ureterorenoscopy as the most dominant procedure in 

endourological treatment of urolithiasis. 


239 

Monday

Monday 

08.30 - 08.40 Update SWL: Do we still need the technology? 




The introduction of SWL during the early 1980s dramatically changed the management of urinary tract 

stones. Recently traditional indications for SWL have been challenged by endoscopic procedures due 

to technological developments. These advances have resulted in evolving indications for the endoscopic 

management of upper urinary tract stone disease. Furthermore, it has been claimed that the development 

of newer-generation SWL-machines with the aim to improve the procedure not unequivocally lead to better 

treatment outcomes. Recent studies have indicated, however, that 3rd and 4th generation lithotriptors not 

only were able to meet the “gold standard” of the Dornier HM3, but also with the additional advantages of 

better stone localisation including in line imaging using both fluoroscopy and ultrasound, possibilities of 

using dual focus, multifunctional tables, and offering high patient comfort (i.e. treatment without general 

anesthesia) at a significantly lower cost. Furthermore, substantial progress has occurred with regard to SWLtreatment 

strategies unrelated to the specific shock wave technology, including I) strategies for better patient 

selection based on imaging predicting stone fragility and composition, II) strategies for increasing SWLefficacy 

including decreased frequency delivery of shock waves and ‘adjuvant’ medical treatment to increase 

stone fragment clearance, and III) strategies for decreasing SWL-induced trauma including pre-treatment 

shock waves at low KV, injury protecting drugs and infection prevention. By applying these strategies to the 

treatment organisation, SWL outcome may be optimised substantially, placing both SWL and endoscopical 

procedures as highly needed technologies in the selective individualised management of stone patients. 

08.40 - 09.15 Case discussion Stone disease 

Moderator: O. Traxer, Paris (FR) 

Panel: M.R. Desai, Naidad (IN) 


D.A. Tolley, Edinburgh (GB) 

09.15 - 09.35 State-of-the-art lecture The role of simulation in training 



With reduction in training hours, evolving technology and increasing patient expectations, the role of 

simulation is integral to the development of the next generation of surgeons. This lecture will discuss 

the science behind simulation in both technical and non-technical skills. It will familiarise the audience 

to validation, structured assessments, human factors and psychometrics. The launch of a new programme 

- SIMULATE and its integration into the urological curriculum will be of considerable interest to the EAU 

membership. The ultimate aim is to enhance the safety of patients under our care. 

09.35 - 09.45 Update Simulation in urology and the EAU 



Practical training in medicine is often performed in a patient-setting. This results in increased risks for the 

patient. Training in a mentor-student real life setting also renders implementation of objective skills criteria 

problematic. Simulated training is mandatory to overcome these hurdles in medical training and certification. 

The EAU has started to provide a programme of web-based training in laparoscopy complemented by a 

hands-on assessment of skills (E-BLUS, European Basic Laparoscopic Urological Skills programme). In this 

set-up both theoretical and skills assessment is implemented. The initial exams were taken during EUREP 

2011 and were only for residents in their last year. It may well be that in the future a repetitive assessment 

for all urologists will be required. This presentation will highlight the implementation of simulation based 

training and certification.

09.45 - 10.05 State-of-the-art lecture From laparoscopy to robotics: 20 years of minimally invasive surgery 


10.05 - 10.25 American Urological Association (AUA) lecture Regenerative medicine: New approaches to healthcare 

A. Atala, Winston-Salem (US) 


Patients with diseased or injured organs may be treated with grafts or transplanted organs. There is a severe 

shortage of donor organs which is worsening yearly due to the aging population. Regenerative medicine 

and tissue engineering apply the principles of cell transplantation, material sciences, and bioengineering 

to construct biological substitutes that may restore and maintain normal function in diseased and injured 

tissues. Stem cells may offer a potentially limitless source of cells for tissue engineering applications and 

are opening new options for therapy. Recent advances that have occurred in regenerative medicine will be 

reviewed and applications of these new technologies that may offer novel therapies for patients with endstage 

tissue and organ failure will be described. 

After attending this lecture, participants should be able to describe the field of tissue engineering and 

regenerative medicine, appraise the current state of cell research, and explain some of the current research 

and clinical applications. 

10.25 - 11.00 Debate and case discussion Choice of minimally invasive surgery 

Moderator: A. Alcaraz, Barcelona (ES) 

Panel: C-C. Abbou, Creteil (FR) 




241 

Monday

Monday 




09.15 - 10.45 Urothelial carcinoma: Upper tract disease and outcomes from surgery 



Chairs: M. Remzi, Vienna (AT) 

M.E. Sullivan, Oxford (GB) 



767 Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: 

A multicenter analysis of 742 patients 

J. Mauermann, Y. Fradet, W. Kassouf, R. Rendon, N. Jacobsen, A. Fairey, J. Izawa, A. Kapoor, P. Black, 

S. Tanguay, J. Chin, A. So, J.B. Lattouf, D. Bell, F. Saad, E. Matsumoto, D. Drachenberg, I. Cagiannos, 

L. Lacombe (Quebec City, Montreal, Halifax, Edmonton, London, Hamilton, Vancouver, Winnipeg, Ottawa, 

Canada) 

768 Concomitant CIS is a risk factor for the occurrence of progressive bladder cancer after nephroureterectomy 

in patients with upper urinary tract urothelial cancer 

T. Majima, R. Hattori, S. Yamada, S. Ishida, O. Kamihira, O. Matsuura, M. Gotoh, T. Tsuzuki (Nagoya, 

Okazaki, Komaki, Japan) 

769 A novel bulldog clamp technique for management of a distal ureter and bladder cuff during laparoscopic 

nephroureterectomy 

S.H. Hong, Y.S. Choi, W.J. Bae, J.H. Bae, H.J. Cho, J.Y. Lee, S.W. Kim, T.K. Hwang (Seoul, South Korea) 

770 Propensity-score matched comparison of perioperative outcomes between open and laparoscopic 

nephroureterectomy: A national series 

N. Hanna, A. Abdo, C. Jeldres, S.F. Shariat (Montreal, Canada; New York, United States of America) 

771 Prognostic impact of positive surgical margins after nephroureterectomy for upper urinary tract urothelial 

carcinoma: A retrospective multicentric study of 692 patients 

P. Colin, A. Ouzzane, G. Pignot, F. Audenet, B. Albouy, J. Guillotreau, V. Phe, S. Crouzet, N. Hoareau, 

C. Marchand, P.O. Fais, E. Xylinas, H. Bensadoun, F. Saint, G. Laurent, A. Arvin-Berod, L. Cormier, 

G. Karsenty, A. Houlgatte, J.N. Cornu, M. Rouprêt (Lille, Paris, Rouen, Toulouse, Suresnes, Lyon, Angers, 

Reims, Marseille, Creteil, Caen, Amiens, Clermont-Ferrand, Grenoble, Dijon, France) 

772 Distal ureterectomy for urothelial carcinoma of the distal ureter: A single institutional experience 

O. Dalpiaz, G. Ehrlich, G. Gallé, K. Pummer, R. Zigeuner (Graz, Austria) 

773 Ureteral obstruction in advanced malignancies: Prognostic factors 

M.D. Cordeiro, M.F. Dall Oglio, A. Crippa Santana, R.R. Pessoa, D. Chade, C.B. Murta, M. Srougi (São Paulo, 

Brazil) 

774 External validation of current nomograms in invasive bladder cancer and proposal of a new prognostic 

models for survival after radical cystectomy based on preoperative haematological disorders 

T. Todenhöfer, M. Renninger, D. Schilling, C. Schwentner, A. Stenzl, G. Gakis (Tübingen, Germany)

775 Female gender is associated with worse cancer-specific survival after radical cystectomy for urothelial 

bladder carcinoma: Multicenter analysis of 2,483 patients 

W. Otto, M. May, H.M. Fritsche, C. Bolenz, L. Trojan, E. Herrmann, A. Tiemann, S.C. Müller, J. Ellinger, 

A. Buchner, C.G. Stief, D. Tilki, S. Brookman-May, S. Denzinger, W.F. Wieland, T. Höfner, M. Hohenfellner, 

A. Haferkamp, J. Roigas, M. Zacharias, P.J. Bastian, M. Burger (Regensburg, Straubing, Mannheim, Münster, 

Bonn, Munich, Heidelberg, Frankfurt, Berlin, Germany) 

776 Is concomitant carcinoma in situ a relative contraindication to neoadjuvant chemotherapy for muscle 

invasive TCC bladder? 

M.S. Ahmad, N. Vasdev, A.C. Thorpe, J. Whiteway (Newcastle upon Tyne, Middlesbrough, United Kingdom) 

777 Types of urinary diversion have no impact on eGFR decreasing rate 

S. Hatakeyama, H. Yamamoto, S. Kudo, T. Yoneyama, T. Koie, N. Kamimura, C. Ohyama (Hirosaki, Japan) 


243 

Monday

Monday 




09.15 - 10.45 Pelvic lymph node dissection at radical prostatectomy and general 

issues 



Chairs: P. Bader, Karlsruhe (DE) 

G. Giannarini, Pisa (IT) 




778 Radical prostatectomy (RP) with extended pelvic lymphadenectomy (EPLND) for pt3b-t4 prostate cancer 

(Pca): Long-term results of a single centre 

M.A. Brausi, G.D. De Luca, M. Gavioli, G. Peracchia, G. Verrini, M. Viola, A. Romano (Carpi, Italy) 

779 Nodal yield during robotic-assisted laparoscopic radical prostatectomy. Is there an improvement with 

surgical expertise? 

A. Gallina, N. Suardi, N. Buffi, A. Cestari, M. Sangalli, U. Capitanio, G. Gadda, G. Lista, A. Larcher, L. Broglia, 

G. Guazzoni (Milan, Italy) 

* 780 Models assessing the need for pelvic lymph node dissection cannot be reliably used in men with prostate 

cancer previously treated with surgery for benign prostatic enlargement 

U. Capitanio, A. Gallina, N. Suardi, M. Tutolo, N.M. Passoni, F. Abdollah, D. Di Trapani, V. Di Girolamo, 

P. Rigatti, A. Briganti (Milan, Italy) 

781 Interval of freedom from biochemical relapse in patients with recurrent prostate cancer after salvage 

extended lymph node dissection. Experience at the Kiel University Hospital 

D.K. Osmonov, A. Aksenov, M. Naumann, K.P. Jünemann (Kiel, Germany) 

782 Lymph node dissection during robot assisted laparoscopic prostatectomy. A comparison of indications and 

outcome from a nationwide database 

B.K. Kroon, C. Tillier, M. Busstra, S.O. Klaver, J.W. Mazel, J.P.M. Sedelaar, E. Te Slaa, T.R.A.H. Tuytten, 

A.N. Vis, C.J. Wijburg, H.G. Van Der Poel (Amsterdam, Rotterdam, Hoofddorp, Nijmegen, Zwolle, Maastricht, 

Arnhem, The Netherlands) 

783 A re-assessment of 30-, 60- and 90-day mortality after radical prostatectomy 

J. Hansen, M. Rink, J. Spethmann, Z. Tian, P.I. Karakiewicz (Hamburg, Germany; Montreal, Canada) 

784 Why the outcomes of initial cases of open and robotic surgeons cannot be compared? Importance of 

patients selection 

A. Briganti, A. Gallina, N. Suardi, N. Buffi, A. Salonia, A. Cestari, M. Sangalli, G. Gadda, G. Lista, 

G. Lughezzani, G. Guazzoni (Milan, Italy) 

* 785 Outcomes after various primary treatment for non-metastasised prostate cancer. A report from the 

European randomized screening trial for prostate cancer (ERSPC) 

S. Carlsson, S. Moss, A. Auvinen, L.J. Denis, M.K. Kwiatkowski, V. Nelen, F. Recker, M.J. Roobol, 

F.H. Schröder, T.L.J. Tammela, K.J.E. Hugosson (New York, United States of America; Surrey, United 

Kingdom; Tampere, Finland; Antwerp, Belgium; Arau, Switzerland; Rotterdam, The Netherlands; 

Gothenburg, Sweden)

* 786 Impact of extent of positive margins on different outcome parameters in 1712 treatment-naïve patients 

after pT2-4 N0 radical prostatectomy 

J. Mauermann, V. Fradet, H. Hovington, L. Lacombe, T. Dujardin, R. Tiguert, Y. Fradet (Quebec City, Canada) 

787 Oral dabigatran etexilate for the prevention of venous thromboembolism after robotic prostatectomy 

V.M.J. Säily, A. Rannikko, A. Petas, R. Lassila, K. Taari (Helsinki, Finland) 

788 Influence of anaesthesiological technique on cancer control after radical prostatectomy (RP) 

J. Schiffmann, M. Roiss, T. Kessler, P. Tennstedt, I. Blanc, D. Reuter, A. Goetz, I. Thederan, H. Huland, 

M. Graefen (Hamburg, Germany) 

* 789 Radical prostatectomy in Austria from 1992-2009, a nation-wide analysis of 33.580 cases 

C. Wehrberger, I. Berger, M. Willinger, S. Madersbacher (Vienna, Austria) 


245 

Monday

Monday 




09.15 - 10.45 Prostate cancer: Diagnosis 



Chairs: B.M Carey, Leeds (GB) 

T. Loch, Flensburg (DE) 




790 Trans-perineal sector biopsies (TPSB): The technique and morbidity 

L. Vyas, J.E. Kinsella, B. Challacombe, D. Cahill, R. Popert (London, United Kingdom) 

791 Computer-assisted analysis of transrectal ultrasound (C-TRUS/ANNA) guided biopsies of the prostate in 

patients with no prior biopsies 

B. Grabski, A. Loch, U. Paul, B. Wefer, L. Bäurle, T. Loch (Flensburg, Germany) 

792 A CAD system for prostate cancer detection on MRI 

C. Fiori, F. Russo, E. Armando, S. Mazzetti, A. Vignati, V. Giannini, F. Mele, M. De Luca, F. Porpiglia, D. Regge 

(Orbassano, Candiolo, Italy) 

793 Prospective validation of Koelis° Urostation in targeting foci suspicious for prostate cancer on multimodal 

MRI 

D. Portalez, V. Misrai, B. Elman, J.M. Lhez, A. Malavaud (Toulouse, France) 

794 Comparison between systematic and MRI targeted prostate biopsy for patients with no history of prostate 

cancer attending a first round of trans-rectal ultrasound biopsy procedure 

G. Coffin, G. Chevreau, R. Renard-Penna, E. Comperat, M.A. Vitrani, C. Torterotot, P. Conort, M.O. Bitker, 

P. Mozer (Paris, France) 

795 What burden of prostate cancer can radiologists rule-out on multi-parametric MRI? An analysis based on 

template prostate mapping biopsies as the reference standard 

H.U. Ahmed, N. Arumainayagam, A.P. Kirkham, C. Allen, S.A. Sohaib, A. Freeman, M. Emberton (London, 


796 Experiences with the MRI-guided biopsy of the prostate gland as second biopsy (rebiopsy) 

C. Möckel, B. Porcellini, R. Haldemann, E. Koch, S. Hailemariam, J.L. Fehr (Zurich, Switzerland) 

797 Preliminary results of a prospective, randomised trial on the value of real time elastography in the 

detection of prostate cancer 

J. Heinzelbecker, P. Nowak, P. Ströbel, A.E. Pelzer (Mannheim, Germany) 

798 Combination of real-time elastography targeted and randomized biopsy of the prostate in a prospective 

patient series 

J. Bründl, H.M. Fritsche, M. Gierth, A. Brandtner, W.F. Wieland, R. Ganzer (Regensburg, Germany) 

* 799 Subjective risk assessment for the diagnosis of prostate cancer using real time elastography (RTE) prior to 

biopsy and assessment of real time elastography for prostate cancer detection by comparing RTE based 

and grey scale ultrasound biopsies 

G. Salomon, L. Budaeus (Hamburg, Germany)

* 800 Is Histoscanning a valid tool to detect prostate cancer in repeat biopsy? 

R. Epplen, J. Van Essen, D. Porres, D. Pfister, A. Heidenreich (Aachen, Germany) 

* 801 The pocket ultrasound: The phonendoscope of the urologist 

G. Pace, G. Bozzini, C. Marenghi, S. Picozzi, L. Carmignani (Milan, Italy) 


247 

Monday

Monday 




09.15 - 10.45 Reconstructive surgery: Models and new directions 



Chairs: M.M. Fisch, Hamburg (DE) 

A. Mangera, Leicester (GB) 




802 Regeneration of smooth muscle layer is only half way to restore urinary bladder function using tissue 

engineering methods 

J. Adamowicz, K. Juszczak, J. Tworkiewicz, T. Drewa, M. Pokrywczynska, A. Marszałek, J. Bodnar, P. Thor, 

Z. Wolski (Bydgoszcz, Cracow, Poland) 

803 Does the policaprolactone-based matrice induce regeneration of urinary tract smooth muscle layer? 

T. Kloskowski, M. Bodnar, T. Kowalczyk, A. Marszałek, T. Drewa (Bydgoszcz, Warsaw, Poland) 

804 Urethra reconstructions in rabbits using tubular collagen scaffolds seeded with labeled bladder smooth 

muscle cells 

L.F. Arenas, L. Micol, D. Tiemessen, P. Frey, E.M. Versteeg, W.F. Daamen, T.H. van Kuppefelt, E. Oosterwijk, 

P. Geutjes, W. Feitz (Nijmegen, The Netherlands; Lausanne, Switzerland) 

805 Tissue engineered tubular constructs for urinary diversion in a porcine model 

P.J. Geutjes, L.A.J. Roelofs, H.R. Hoogenkamp, M. Walraven, B.B.M. Kortmann, R.P.E. De Gier, F.F. Farag, 

D.M. Tiemessen, E. Oosterwijk, T.H. Van Kuppevelt, W.F. Daamen, W.F.J. Feitz (Nijmegen, The Netherlands) 

806 Primary closure compared to bladder augmentation with a collagen scaffold in a model for bladder 

exstrophy 

L.A.J. Roelofs, B.B.M. Kortmann, R.M.H. Wijnen, A.J. Eggink, T.M. Tiemessen, A.J. Crevels, E. Oosterwijk, 

W.F. Daamen, T.H. Van Kuppevelt, P.J. Geutjes, W.F.J. Feitz (Nijmegen, Rotterdam, The Netherlands) 

807 Evaluation of biocompatibility of alloplastic materials - development of a tissue culture in vitro test system 

H. Gerullis, E. Georgas, C. Eimer, B. Lammers, P. Goretzki, B. Klosterhalfen, M. Boros, A. Ramon, T. Otto 

(Neuss, Düren, Germany; Szeged, Hungary) 

808 The electronic modular artificial urinary sphincter: Results of the cadaver study 

R. Dahlem, P. Reiss, A. Becker, D. Pfalzgraf, S. Ahyai, M. Fisch (Hamburg, Germany) 

809 Late results after a new little-invasive corporoplasty based on stratified structure of tunica albuginea for 

the treatment of congenital penile curvature 

W. Perdzynski, M. Adamek (Warsaw, Poland) 

810 Evaluation of zotarolimus-eluting metal stent in animal ureters 

P. Kallidonis, O. Andrikopoulos, I. Kyriazis, I. Georgiopoulos, C. Kalogeropoulou, P. Kitrou, A. Tsamandas, 

D. Apostolopoulos, D. Liourdi, E. Liatsikos, J.U. Stolzenburg (Patras, Greece; Leipzig, Germany) 

811 Long-term follow-up of self-expandable metal mesh stents. Are they effective to resolve ureteral 

obstruction? 

V. Gómez, V. Diez-Nicolas, R. Rodriguez-Patrón, C. Carrera, C. Bueno, S. Alvarez, I. Laso, F.J. Burgos 

(Madrid, Spain)

812 Defects in the endoderm survival and polarity of cell divisions in the mouse model for rectourethral 

malformations 

K. Xu, X. Wu, E. Shapiro, H. Huang, L. Zhang, Y. Deng, V. Mandelshtam, J. Li, H. Lepor, I.B. Grishina (New 

York, Irvine, United States of America; Changchun City, China) 

* 813 Fibrin TG-VEGF is a supporter of early angiogenesis in urinary sphincter engineering 

R.A. Largo, V. Ramakrishnan, A. Ziogas, M. Ehrbar, J. Plock, T. Sulser, D. Eberli (Zurich, Switzerland) 


249 

Monday

Monday 


250 Programme Book 


09.15 - 10.45 Prostate biopsies and imaging 



Chairs: T.R.W. Herrmann, Hanover (DE) 

P.C. Mozer, Paris (FR) 




814 Diagnostic accuracy of zonal transperineal template or MD Anderson prostate biopsies as second stage 

approach – more certainty for patients 

K. Saeb-Parsy, B. Moss, M. Mikhail, N. Papoutsoglou, A. Doble, C. Kastner (Cambridge, United Kingdom) 

815 Finger guided biopsies of palpable abnormalities: Do they add anything to a TRUS biopsy? 

S. Ramsey, P. Aslan, W. Delprado, P. Cozzi (Sydney, Maquarie Park, Australia) 

816 3D TRUS prostate biopsy recording and guidance - the Navigo system 

M. Cohen, S. Cytron, O. Nativ, A. Shmitz, B. Yudkevich, J. Shental (Afula, Ashkelon, Haifa, Israel) 

817 A head-to-head comparative study of the predictive tools for the outcome of prostate biopsy based on 

patient age, digital rectal examination and serum prostate specific antigen in a prospective French cohort 

I. Ouzaid, V. Hupertan, D.R. Yates, P. Mozer, E. Chartier-Kastler, M.O. Bitker, M. Rouprêt (Paris, France) 

818 3D modelling of the prostatic capsule for simultaneous display of biopsy cores 

M. Hruza, O. Kalthoff, M. Schulze, J. Rassweiler (Heilbronn, Germany) 

819 Should transperineal template guided prostate biopsies be used as gold standard for diagnosis of prostate 

cancer? 

S. Javed, B. John, E. Chadwick, B. Montgomery, S. Bott, S. Langley (Guildford, Camberley, United Kingdom) 

820 The detection rates of Real-Time-Elastography (RTE) and multiple core biopsies in the diagnosis of prostate 

cancer. A comparison after 283 patients 

O. Lenherr, P Liske, S Lahme, A. Fayyazi (Pforzheim, Germany) 

821 Magnetic resonance image-guided prostate biopsy versus transperineal template prostate biopsy in the 

diagnosis of clinically significant prostate cancer 

V. Kasivisvanathan, R. Dufour, C.M. Moore, H.U. Ahmed, A. Freeman, S. Charman, C. Allen, J. Van Der 

Meulen, M. Emberton (London, United Kingdom) 

822 Are early repeat biopsies associated with an increased risk of complications? 

S. Van Den Heuvel, S. Loeb, X. Zhu, P.C.M.S. Verhagen, F.H. Schröder, C.H. Bangma, M.J. Roobol (Rotterdam, 

The Netherlands; New York, United States of America) 

* 823 Multiparametric ultrasound of the prostate: A new imaging approach using contrast enhanced transrectal 

ultrasound in combination with real-time elastography to detect prostate cancer 

M. Brock, B. Löppenberg, C. Von Bodman, R.J. Palisaar, T. Deix, J. Noldus, T. Eggert (Herne, Germany)

* 824 Multi-parametric magnetic resonance imaging in the diagnosis and characterization of prostate cancer 

prior to first biopsy in men at risk: The PROMIS study 

H.U. Ahmed, R. Gabe, R. Kaplan, C. Parker, M. Emberton (London, United Kingdom) 

* 825 Complications of initial prostate biopsy in a European randomized screening trial 

S. Van Den Heuvel, S. Loeb, X. Zhu, P.C.M.S. Verhagen, F.H. Schröder, C.H. Bangma, M.J. Roobol (Rotterdam, 

The Netherlands; New York, United States of America) 



Monday

Monday 




09.15 - 10.45 History of urology 



Chairs: I. Romics, Budapest (HU) 

D. Schultheiss, Giessen (DE) 



826 Historical aspects of ultrasound in urology 

H. Nemade, A. Rao, J. Makanjoula, P. Thompson (London, United Kingdom) 

827 Diagnostics of erectile dysfunction in the middle ages in Europe 

Z. Kopa (Budapest, Hungary) 

828 Open cystotomy for bladder cancer. From necessity to obscurity; the rise and fall of an historical operation 

S.M. La-Touche, R.C. Kockelbergh, J.C. Goddard (Leicester, United Kingdom) 

829 Depiction of venereal diseases on wax models in the Moulage museums of Paris and Athens 

E. Poulakou-Rebelakou, M. Karamanou, A. Rempelakos, G. Androutsos (Athens, Greece) 

830 Centenary of the Spanish Urological Association (1911-2011): Reasons for 100 years of scientific progress 

and professional prosperity 

L. Fariña, R. Vela Navarrete, L.A. Rioja Sanz, J. Carballido, F. Jimenez Cruz, A. Allona, O. Leyva, J. Castiñeiras 


831 The history of gender reassignment - from mythology to modern day 

P. Kumar, C. Luo, T.R. Terry (London, Leicester, United Kingdom) 

832 On Frère Jacques “lateral incision” 

S. Musitelli (Zibido San Giocomo, Italy) 

833 Oral history for urology and the urologist: A new field of research easily accessible 

F. Moll, M. Krischel, T. Halling, H. Fangerau (Cologne, Ulm, Germany) 

834 Lord Lister and his legacy 

A.M.A.I. Nandasena, P. Thompson (London, United Kingdom) 

835 Diego Rivera: His art and illness 

J. Moreno-Palacios, J. Moreno-Aranda (Mexico City, Mexico) 

836 The Journal d’Urologie Médicale et Chirurgicale was founded 100 years ago 

J.J. Mattelaer (Kortrijk, Belgium) 

837 Establishing the evidence in medicine: Where did randomised controlled trials come from? 

T.B.P. Madden, K.F. Parsons (Liverpool, United Kingdom)



09.15 - 10.45 Prostate cancer: Molecular and (epi)genetic basis 



Chairs: A. Bjartell, Malmö (SE) 

S. Füssel, Dresden DE) 




838 The protein ps20 increases tumorigenic potential in prostate cancer epithelial cells 

O. Hickman, C. Galustian, A. Vyakarnum, R.A.G. Smith, P. Dasgupta (London, United Kingdom) 

839 RalGAP, the inactivator of Ral small GTPase, suppresses the progression of prostate cancer 

R. Saito, T. Kobayashi, M. Nakashima, Y. Matsui, N. Shibasaki, T. Kanno, T. Inoue, H. Nishiyama, 

R. Shirakawa, H. Horiuchi, O. Ogawa (Kyoto, Tsukuba, Sendai, Japan) 

840 Reciprocal regulation between a tumor suppressor DAB2IP and an oncogene Skp2 in human prostate cells 

Y.S. Tsai, K.J. Wu, K.H. Chang, S.F. Tseng, N. Sharifi, J.T. Hsieh, T.S. Tzai (Tainan, Taiwan; Dallas, United States 

of America) 

841 Farnesyl pyrophosphate synthase – the target enzyme of zoledronic acid is increasingly expressed in 

prostate cancer tissue 

T. Todenhöfer, J. Hennenlotter, U. Kühs, V. Gerber, S. Aufderklamm, G. Gakis, A. Stenzl, C. Schwentner 

(Tübingen, Germany) 

842 Tumor suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase 

(PNP) in prostate cancer 

S. Kojima, T. Chiyomaru, K. Kawakami, H. Yoshino, H. Enokida, N. Nohata, M. Fuse, T. Ichikawa, Y. Naya, 

M. Nakagawa, N. Seki (Ichihara, Kagoshima, Chiba, Japan) 

843 Tumor suppressive miRNA-145-mediated novel cancer pathways in prostate cancer 

M. Fuse, T. Chiyomaru, H. Enokida, H. Yoshino, N. Nohata, S. Sakamoto, M. Nakagawa, T. Ichikawa, N. Seki 

(Chiba, Kagosima, Kagoshima, Japan) 

844 The biomarker miR-221 regulates STAT1 signaling in prostate cancer by targeting IRF2 

M. Spahn, M. Krebs, M. Schubert, H. Riedmiller, B. Kneitz (Würzburg, Germany) 

845 MiR-148a is an androgen responsive microRNA that promotes prostate cancer cell growth by repressing 

CAND1 expression 

T. Murata, K. Takayama, T. Urano, T. Fujimura, K. Horie-Inoue, S. Takahashi, Y. Ouchi, Y. Homma, S. Inoue 

(Tokyo, Hidaka, Japan) 

846 Dysregulation of miR-205 is involved in progression of high risk prostate carcinoma, predicts recurrencefree 

survival and inhibits expression of target oncogenes HER2/neu and HER3 

M. Spahn, C. Kalogirou, C.J. Scholz, S. Kneitz, H. Riedmiller, B. Kneitz (Würzburg, Germany) 

847 Overexpression of ribosomal RNA in prostate cancer is common but not linked to rDNA promoter 

hypomethylation 

M. Uemura, T. Yoshida, K. Hatano, M. Sato, A. Kawashima, Y. Nakai, H. Takayama, N. Nonomura, A.M. De 

Marzo (Suita, Japan; Baltimore, United States of America) 



Monday

Monday 

* 848 Differential gene expression profiling in proliferative inflammatory atrophia compared to prostate 

carcinoma and high grade prostatic intraneoplasia using frozen microdissected tissues 

M.T. Quiles, M.A. Arbós, I.M. De Torres, C. Blázquez, J. Reventós, J. Morote (Barcelona, Spain) 

* 849 Over-expression of a novel microRNA, miR-24, affects prostate cancer cell growth and proliferation, and 

contributes to radio-senstivity of prostate cancer cells in vitro 

F. O’Kelly, A.S. Perry, A. Meunier, S. Wong, D. Hollywood, L. Marignol, T.H. Lynch (Dublin, Ireland) 

254 Programme Book



09.15 - 10.45 Stones: Medical treatment and research 



Chairs: S. Oehlschläger, Dresden (DE) 

H.G. Tiselius, Stockholm (SE) 



850 Identification of novel antilithiatic cationic proteins from human calcium oxalate renal stone matrix by 

MALDI TOF MS 

S.K. Singh, K.P. Aggarwal, S. Tandon, P. Pathak, C. Tandon (Chandigarh, Solan, Noida, India) 

851 Hypercalciuria, hyperoxaluria and hypocitraturia screening from random urine samples in patients with 

calcium lithiasis 

M. Arrabal-Polo, M. Arrabal-Martin, A. Jimenez-Pacheco, S. Arias-Santiago, S. Gonzalez-Torres, C. Lahoz- 

Garcia, A. Zuluaga-Gomez (Granada, Spain) 

852 M-CSF is a novel preventive agent against renal stone disease by inducing anti-inflammatory macrophages 

K. Taguchi, A. Okada, Y. Fujii, K. Niimi, T. Kobayashi, S. Hamamoto, M. Hirose, Y. Itoh, T. Yasui, K. Tozawa, 

S. Sasaki, Y. Hayashi, K. Kohri (Nagoya, Japan) 

853 Hyperoxaluria-induced tubular ischemia: The effects of verapamil and vitamin E on apoptotic changes with 

an emphasis on renal papilla in rat model 

O. Tanriverdi, T. Dilek, A. Mustafa, E. Isin Dogan, M. Cengiz, S. Kemal (Istanbul, Turkey) 

854 Androgen receptor knock-out mice suppress excretion of oxalate in urine and oxalate synthesize 

S. Takahashi, S. Aruga, T. Matsumoto, Y. Homma, S. Shigeaki (Tokyo, Japan) 

855 Proteomic analysis of human calcium oxalate renal stone by 2-D PAGE and in vitro analysis of bioactivity of 

the proteins 

S.K. Singh, K.P. Aggarwal, S. Tandon, C. Tandon (Chandigarh, Solan, India) 

856 Calcium oxalate crystals could be englobed by macrophages during kidney stone formation in vitro and in 

vivo models 

A. Okada, K. Taguchi, Y. Hirose, K. Niimi, Y. Fujii, T. Kobayashi, M. Usami, S. Hamamoto, M. Hirose, Y. Itoh, 

T. Yasui, K. Tozawa, K. Kohri (Nagoya, Japan) 

857 Escherichia coli infection induces mucosal damage and expression of proteins promoting urinary stone 

formation 

T. Djojodimedjo, D.M. Soebadi, S. Soetjipto (Surabaya, Indonesia) 

858 Genetic profile of cystinuria in a UK population – the detection of new pathological mutations 

K.A. Wong, C. Pardy, R. Mein, K. Morloh, F. Flinter, K. Thomas (London, United Kingdom) 

859 The importance of citrate and the calcium/citrate ratio in patients with calcium renal lithiasis and severe 

lithogenesis 

M.A. Arrabal-Polo, M. Arrabal-Martin, A. Jimenez-Pacheco, S. Arias-Santiago, C. Lahoz-García, M. Camara- 

Ortega, A. Zuluaga-Gomez (Granada, Spain) 



Monday

Monday 

860 Uric acid is the main component of kidney stones in patients with autosomal dominant polycystic kidney 

disease (ADPKD) - a study based on stone composition, morphology and infrared spectophotometry 

analysis 

I. Nikolov, O. Ivanovski, M. Daudon, A. Sikole, B. Knebelman (Skopje, Macedonia; Paris, France) 

861 Tribulus terrestris extract as curative agent in experimentally induced urolithiasis 

A. Aggarwal, M. Gandhi, S.K. Singh, S.K. Singla, C. Tandon (Solan, Chandigarh, India) 

862 Prophylactic effect of Tribulus terrestris fruits on experimentally induced urolithiasis in rats 

A. Aggarwal, S.K. Singla, S.K. Singh, C. Tandon (Solan, Chandigarh, India) 

256 Programme Book



10.00 - 16.00 Robotic surgery 


10.00 -12.00 Live surgery: da Vinci partial nephrectomy 

14.00 -16.00 Live surgery: da Vinci prostatectomy 

Sponsored by INTUITIVE SURGICAL 



Monday

Monday 




11.00 - 12.00 Cancer induced bone disease 


Chair: B. Tombal, Brussels (BE) 

11.00 - 11.20 State-of-the-art lecture Biology 

C. Edwards, Oxford (GB) 


Prostate cancer metastases predominantly affect the skeleton and are a major cause of morbidity and 

mortality. The bone marrow provides a unique specialised micro-environment that supports both prostate 

cancer cell growth, and the development of the associated bone disease. Despite many recent advances, 

the mechanisms that mediate these processes remain poorly understood. This presentation will discuss our 

current understanding of the pathogenesis of cancer-induced bone disease, including novel mechanisms 

to support tumour growth and/or bone disease within the bone micro-environment, and novel therapeutic 

targets. 

11.20 - 11.40 State-of-the-art lecture Patient evaluation 

G.N. Thalmann, Berne (CH) 


Prostate cancer, but also other cancers, have a propensity to metastasise to the bone and bone marrow. 

This lecture will 

- Provide an update on diagnostic tools in urological cancer related bone disease 

- Try to help clinicians identify patients at risk of bone involvement and skeletal related events 

11.40 - 12.00 State-of-the-art lecture Prevention and treatment 

T.A. Borkowski, Warsaw (PL) 


Bone metastases are a major cause of morbidity in men with advanced and castrate-resistant prostate cancer 

(CRPC). Prevention of bone metastasis is a major unmet medical need. Some trials suggested that there 

might be a benefit from osteoclast inhibition. A randomised placebo-controlled trial of zoledronic acid and 

denosumab in men with castration-resistant nonmetastatic prostate cancer will be discussed. 

The presentation will review results of the available studies concerning prevention of skeletal related events 

as well as other key aspects of bone health management in the continuum of care for prostate cancer 

patients.



11.00 - 12.00 Genital cancer in the male 


Chair: P. Albers, Düsseldorf (DE) 

11.00 - 11.20 State-of-the-art lecture Revisiting retroperitoneal lymph node dissection 



For a long time, Retro Peritoneal Lymph Node Dissection (RPLND) has been an important part in the 

management of patients with Nonseminomatous Testicular Germ Cell Tumours (NSGCT). According to the 

current guidelines of the European Association of Urology primary nerve-sparing RPLND plays a minor role for 

the management of clinical stage I NSGCT. In clinical stage IIA, marker negative NSGCT, nsRPLND represents 

an equivalent therapeutic option to active surveillance or systemic chemotherapy. Postchemotherapy RPLND, 

however, plays an important and integral part of the multimodality treatment of patients with advanced 

TGCT. It is the current consensus that PC-RPLND should be performed in all patients with visible residual 

masses independent on their size and anatomical location. 

It is the aim of the current presentation to distribute information 

- on the rationale and indication of PC – RPLND 

- management of small residual lesions < 1cm 

- on the extent of the surgical template 

- on the management of extraretroperitoneal metastases 

- on the necessity of adjunctive and vascular reconstructive surgery 

- on the indication for redo and desperation surgeries 

11.20 - 11.40 State-of-the-art lecture Late effects of treatment 

S.D. Fossa, Oslo (NO) 


The objective of the lecture is to inform urologists and oncologists about the risk of late adverse effects 

related to modern treatment of testicular and penile cancer and how some of these complications can be 

reduced by risk-adapted treatment, appropriate follow-up and patient education. On the other hand, both 

the patient and his doctor have to understand that the treatment of a life-threatening malignancy has its 

price, as for example the possibility of impaired sexual life. 

11.40 - 12.00 State-of-the-art lecture Penile preserving surgery 

S. Minhas, London (GB) 


The aim of this lecture, will be to provide a comprehensive overview of the techniques of penile preserving 

surgery. Penile preserving surgery with reconstruction can be offered to most men with penile carcinoma. 

There will be particular emphasis on the long term outcome, including oncological safety and quality of life 

outcomes of penile preserving surgery. 



Monday

Monday 




11.00 - 12.00 BPH: Primum non nocere 


Chair: O. Reich, Munich (DE) 

11.00 - 11.20 State-of-the-art lecture Who does NOT need BPH treatment and how to find out? 



The presentation will address two aspects, i.e. which patient does not need BPH-treatment (i) because his 

symptom status and progression risk do not justify BPH-treatment and he is better managed by a watchful 

waiting strategy and (ii) because his lower urinary tract symptoms are not caused by benign prostatic 

obstruction but e.g. by detrusor overactivity or non-urological pathomechanisms such as nocturnal polyuria 

or cardiac/renal failure. Unnecessary treatment puts the patient at risk for treatment related side effects/ 

complications and induces avoidable costs. The presentation will discuss both issues emphasising the need 

for a proper diagnosis including assessment of progression risk, frequency-volume-charts and pressure flow 

studies in selected cases. 

11.20 - 11.40 State-of-the-art lecture How ‘harmful’ is medical treatment for BPH? 



The current paradigm of BPH treatment consists of treating initially with drugs and to operate when the 

drugs are no longer effective or when a complication occurs. Inside this paradigm, the medical management 

for BPH is nowadays driven essentially by the quality of life. Symptoms are no longer sufficient to start a 

treatment: They must be associated with a degree of bother, to an impairment of the quality of life. Are we 

sure that we are right? 

The objective of this lecture is to the challenge this paradigm. 

Indeed medical treatment can be harmful in two ways: 

- Directly by their own side effects, vaso-active or sexual for alpha-blockers or 5 alpha-reductase inhibitor 

(5ARI), that the patient must endure for years impairing on their own the patient’s quality of life, but also 

for the 5ARI, by an increased risk of aggressive prostate cancer; 

- Indirectly by delaying the time of surgery, this delay damaging the bladder functions through bladder wall 

lesions that might not fully reverse. 

Considering these evidences one can propose an alternative management to the classical paradigm: Start the 

medical treatment early, as soon as symptoms occur, by changing drugs whenever necessary according to 

their tolerance and effectiveness, and propose surgery early, in the case of failure. 

11.40 - 12.00 State-of-the-art lecture Which therapies for BPH are ‘mininally invasive’? 



The most significant recent technical modification of TURP is the incorporation of bipolar technology. At the 

same time laser treatment has challenged TURP due to advances in laser technology, better understanding 

of the tissue-laser interactions and growing clinical experience. 

The aim is to provide all the necessary information to help urologists distinguish one laser from another, 

highlight the evolution from coagulation to vaporisation, resection and enucleation, and to critically evaluate 

the role of different laser modalities versus (bipolar) TURP in the treatment for BPH by using an evidencebased 

approach.



11.00 - 12.00 The personalised treatment of urinary stone disease 


Chairs: F. Keeley, Bristol (GB) 


11.00 - 11.15 State-of-the-art lecture Imaging for urolithasis 

K.M. Anson, London (GB) 


Tailoring radiological regimes for individual stone patients is critical to provide the clinician with the most 

appropriate rapid diagnostic tool whilst reducing radiation exposure and inconvenience for the patient. 

Whilst the evidence supporting the use of CTKUB for the evaluation of acute loin pain is compelling followup 

imaging strategies are much more poorly understood. 

Digitally acquired KUB plain films are increasingly poor at identifying small calculi and inexperienced 

ultrasound performance can overestimate both the presence of, and size of calculi. On the other hand 3D 

CT PCNL protocols can provide breathtaking images which can help improve surgical performance. An 

understanding of which modality to employ, and when, for individual patients is critical for the successful 

management of urinary stone disease in 2012. 

Discussion 

11.15 - 11.30 State-of-the-art lecture How far are current treatment concepts for renal stones evidence supported? 



Evaluating the level of evidence in stone management one might be disappointed, since in only very few 

stone management areas, including imaging and pain management, the level of evidence may be based on 

meta-analyses of randomised controlled trials (evidence level 1a). This is not an expression of low research 

activity within the stone field, but rather an expression of difficulties in designing meaningful trials that reflect 

daily clinical practice due to the great variability of the stone disease for instance regarding stone burden, 

stone composition, renal anatomy and patient body habitus. Numerous well-conducted clinical studies with 

consistent data in the areas of medical management, SWL, ureteroscopic and percutaneous stone removal 

are available, however, representing a sound basis for a valid individualised approach to stone management. 

This lecture will document the level of evidence of different stone management approaches and highlight 

areas in which further research is desirable. 

Discussion 

11.30 - 11.45 State-of-the-art lecture How to deal with residual fragments after stone therapy? 

C. Seitz, Vienna (AT) 


The clinical significance of residual fragments following stone removal will be adressed. Indications and 

methods of stone removal are also presented. 


261 

Monday

Monday 

Discussion 

11.45 - 12.00 State-of-the-art lecture Is it all about intervention? Metabolic evaluation and medical treatment for stone 

formers 


M. Straub, Munich (DE) 


Aims: 

- Identification of patients at high recurrence risk 

- Risk-guided work-up of any stone patient 

- Risk-depended recurrence prevention 

Objectives: 

- Basic analysis for all stone patients 

- Stone specific work-up for patients at high risk 

- Update general preventive measures – what is evidence based? 

- Medical treatment – stone specific pharmacological recurrence prevention 

Discussion



11.00 - 12.00 Female stress incontinence 


Chairs: F.R. Cruz, Porto (PT) 


11.00 - 11.20 State-of-the-art lecture Urodynamics prior to SIU surgery: Pros and cons 



Invasive urodynamics underpin our understanding of bladder dysfunction and remain an integral part of the 

care pathway for many patients with incontinence. However, correlation with symptoms is imperfect, invasive 

tests carry risk and evidence is lacking on the extent to which urodynamic findings affect management 

decisions or the outcome of treatment. The presentation will review the evidence and present consensus 

views on the role of urodynamics before surgery for stress incontinence. 

11.20 - 11.40 State-of-the-art lecture Should one individualise sling type? 



Slings for female stress urinary incontinence constitute today a crowded family, ranging from conventional 

autologous fascial pubo-vaginal slings, to suprapubic mid-uretral tapes, to transobturator mid-urethral 

tapes, to single incision slings. Are there differential indications to the various kinds of slings? Do we have 

enough evidence to match a patient to a specific sling procedure? The presentation will try to give an answer 

based on present knowledge. 

11.40 - 12.00 State-of-the-art lecture Prolapse and SIU surgery: Seperated or combined? What is the evidence in 2012? 



263 

Monday

Monday 




11.00 - 12.00 Joint EAU-European Society of Surgical Oncology Session 


Chair: T.M. De Reijke, Amsterdam (NL) 

11.00 - 11.20 State-of-the-art lecture Rectal cancer surgery and ways to preserve potency -, sphincter and bladder 

function 

C. J.H. Van De Velde, Leiden (NL) 


- Incontinence problems after rectal cancer treatment are common and can have a major impact on quality 

of life. 

- Patients should be informed about the surgical option, LAR and APR, and about their potential outcomes. 

- Surgical nerve damage may play a major role in the development of faecal and urinary incontinence, with 

an additional effect of radiotherapy. 

- Faecal incontinence can worsen over time in case of radiotherapy. 

- Several non-surgical and surgical therapies of incontinence problems are available: Conservative therapies 

should be the first line choice. 

11.20 - 11.40 State-of-the-art lecture Recurrent cervical cancer: What are the surgical treatment modalities and what 

are the implications for the genito-urinary tract? 

V.D. Matei, Milan (IT) 

11.40 - 12.00 State-of-the-art lecture How to deal with the urinary tract following pelvic exenteration with or without 

radiation? 

M.M. Fisch, Hamburg (DE) 


Pelvic exenteration requires urinary diversion. An overview is given on the standard techniques currently 

used. Complication rates and outcome are presented. Urinary diversion within an irradiated field is associated 

with higher complication rates. The literature is discussed and solutions are offered using unirradiated parts 

of the bowel with high implantation of the ureters.



11.00 - 12.00 Molecular diagnostics in bladder cancer 


Chair: J.A. Schalken, Nijmegen (NL) 

11.00 - 11.05 Introduction Where biomarkers and clinical unmet needs meet? 

J.A. Schalken, Nijmegen (NL) 

11.05 - 11.20 State-of-the-art lecture The translation of GWAS studies into clinical practice 

H.H.M. Vermeulen, Nijmegen (NL) 


Genome-Wide Association Studies (GWAS) have revolutionised the field of complex disease genetics in the 

past five years: Over 1,400 loci have been identified for more than 200 traits. Three GWAS for Urinary Bladder 

Cancer (UBC) susceptibility have so far led to the identification of nine new loci that have been extensively 

replicated in independent samples. GWAS for UBC prognosis and treatment response are still awaited. The 

aim of this presentation is to provide a concise overview of the current status with regard to UBC GWAS 

findings and their implications for translational research. 

11.20 - 11.35 State-of-the-art lecture Molecular prognostic factors for bladder cancer 

C.P.N. Dinney, Houston (US) 


Bladder cancer is unique in that the pT0 status after neoadjuvant chemotherapy serves as an immediate 

surrogate for outcome, and urine and tissue are readily available for correlative studies that can link “marker 

expression” with response. However, it is difficult to imagine further survival improvement with conventional 

approaches, apart from the ability to predict response to conventional chemotherapy and a more rationale 

treatment selection. Critical to success in advancing the field is the timely evaluation of new approaches to 

staging and therapy. 

The aim of this presentation is to provide rationale for employing the neoadjuvant setting to understand the 

relevant biology of bladder cancer and how this knowledge will improve “staging” to guide both conventional 

and novel therapeutic approaches. 

11.35 - 11.50 State-of-the-art lecture New diagnostic markers for bladder cancer 

M.J. Ribal Caparros, Barcelona (ES) 


In combination, cystoscopy and cytology are the standard methods used to detect and monitor bladder 

urothelial carcinoma (UC). Cystoscopy is an invasive technique that has a high sensitivity (91%), although 

it can overlook flat malignancies such as Tis. Cytology has the advantage of being non-invasive with a high 

specificity (90-96%), but it lacks sensitivity (11 to 76%), especially for low grade disease. 

All these limitations of the current diagnostic methods have prompted a search for more reliable noninvasive 

markers for detecting and predicting the biological behaviour of UC. Finding a non-invasive marker 

of UC would be enormously useful in clinical practice. The implementation of diagnostic and prognostic 

markers for bladder cancer in clinical practice would improve patients’ quality of life and outcome. It would 

allow a reduction in the number of invasive cystoscopies, it could prioritise high risk patients for an urgent 

cystoscopy or transurethral resection or could delay or prolong the interval between examinations in low 

risk patients. 


265 

Monday

Monday 


The objectives of our session would be to analyse current non-invasive markers in UC, its role in clinical 

practice and to describe future strategies. 

11.50 - 12.00 Discussion How to design studies to validate the utility of bladder cancer biomarkers?



11.00 - 12.00 EAU Guidelines Office: An update 


Chair: K.F. Parsons, Liverpool (GB) 


K.F. Parsons, Liverpool (GB) 

11.05 - 11.15 State-of-the-art lecture Controversies in stone management 

C. Türk, Vienna (AT) 


Diagnosis, treatment and metabolic evaluation of urolithiasis: A core business for urologists. Once again 

technical developments are changing both, diagnostic imaging and therapeutic interventions. Computed 

tomography compete against intravenous urography and ESWL compete against endourologic and 

laparoscopic procedures for stone removal. This presentations aims to compare the techniques available 

based on the current recommendation in the recently updated guideline. 

11.15 - 11.30 State-of-the-art lecture Building an antibiotic prophylaxis policy in urological surgery 



Antibiotic prophylaxis (ABP) is one of several important measures to prevent infectious complications after 

surgery. A few systematic reviews of the literature have revealed evidence for ABP in only two common 

urological interventions: Transrectal core prostate biopsy (LE 1b, GR A) and TURP (LE 1a, GR A). For all other 

procedures there are conflicting data. The European Section of Infection in Urology (ESIU) has classified the 

different urological procedures according to the surgical site contamination level and suggested an ABP 

policy accordingly. This report aims at demonstrating the building of a model and presenting a strategy for 

ABP that eventually has to be validated in large prospective longitudinal quality control studies. 

11.30 - 12.00 Controversies in prostate cancer – case presentations 

Chair: A. Heidenreich, Aachen (DE) 


The EAU guidelines in the diagnosis and management of prostate cancer are updated annually. It is the aim 

of the EAU guidelines to improve the quality of patient care by providing the counseling uro-oncologists, 

radiation oncologist and urologist with an armentarium of evidence-based information with regard to the 

most appropriate treatment of an individual patient. However, there is usually more than one guideline 

recommended treatment option available and it is the art of the physician to identify the therapy which 

is optimal for both the biological aggressiveness of the prostate cancer and the individual necessity of the 

patient. It is the aim of the current session to demonstrate the various guideline recommended treatment 

options for a couple of clinical scenarios with controversial approaches in order to support the audience with 

practical tips of the trade how to use the guidelines in daily routine. 

11.30 - 11.40 Case 1: Low risk prostate cancer 

Panel: M. Mason, Cardiff (GB) 

N. Mottet, Saint Etienne (FR) 


267 

Monday

Monday 

11.40 - 11.50 Case 2: cT3 prostate cancer 


Panel: P. Bastian, Munich (DE) 

M. Bolla, Grenoble (FR) 

11.50 - 12.00 Case 3: Metastatic prostate cancer 

Panel: V. Matveev, Moscow (RU) 

F. Zattoni, Padova (IT)



14.00 - 17.00 European Urological Scholarship Programme (EUSP) Session 






14.10 - 14.20 Outcome of one year of EUSP programme: Poll from the hosts and applicants 


14.20 - 15.40 Final report of four EUSP scholars 

14.20 - 14.40 Near InfraRed Spectroscopy (NIRS) as a novel non-invasive diagnostic method for detrusor overactivity 

F. Farag, Nijmegen (NL) 

14.40 - 15.00 Urethral reconstruction using tissue engineering techniques 

L.F. Arenas Da Silva, Tübingen (DE) 

15.00 - 15.20 Pharmacological unmasking of epigenetically modified genes for identification of therapeutic targets and 

putative biomarkers in urological malignancies 

O. Ikromov, Namangan (UZ) 

15.20 - 15.40 Identification, propagation and differentiation of putative stem cells in normal urothelial (NHU) cells in 

vitro 

F. Wezel, York (GB) 

15.40 - 15.45 Award presentation: Best scholar 


15.45 - 16.00 Interactive discussion with past EUSP scholars 


16.00 - 16.20 New insights on erectile dysfunction 


16.20 - 16.30 The future of EUSP 


16.30 - 17.00 EUSP cocktail for all scholars and hosts 

Foyer bleu (level 2) 


269 

Monday

Monday 




12.15 - 13.45 Laparoscopic renal surgery 



Chairs: J. Adshead, London (GB) 

M. Brehmer, Stockholm (SE) 


V36 Right laparoscopic radical nephrectomy for a stage pT3b renal tumor 

M.J. Ribal, L. Peri, M. Musquera, M. Perez, A. Alcaraz (Barcelona, Spain) 

V37 KTP laser laparoscopic partial nephrectomy versus conventional laparoscopic partial nephrectomy in pigs. 

Randomized controlled trial 

J. Rioja, M. Hurtado, F. Soria, L. Plaza, F.M. Sanchéz-Margallo, I. Díaz-Güemes, F. Pérez, M.P. Laguna, 

J. Usón, L.A. Rioja (Zaragoza, Cáceres, Spain; Amsterdam, The Netherlands) 

V38 Simultaneous double partial nephrectomy for a double ipsilateral tumor 

J.A. Peña, J.M. López, M. Cosentino, J. Azuero, J. Palou, H. Villavicencio (Barcelona, Spain) 

V39 The robot assisted pyleoplasty 

M. Akkoeze, D. Kusche (Recklinghausen, Germany) 

V40 Pyeloplasty using the novel da Vinci single site robotic platform for the surgical treatment of ureteropelvic 

junction obstruction: The technique 

N.M. Buffi, A. Cestari, M. Lazzeri, G. Lughezzani, G. Lista, A. Larcher, M. Sangalli, G. Guazzoni (Milan, Italy) 

V41 Salvage laparoscopic pyeloplasty after failed open pyeloplasty of a retrocaval ureter 

A.W. Branco, L.C. Stunitz, S. Nichele (Curitiba, Brazil) 

V42 Robotic assisted uretero-ureteral (receiver-donor) anastomosis 

J. Hauser, J. Schwartz, S. Tran, C.E. Iselin (Geneva, Switzerland) 

V43 Laparoscopic partial nephrectomy for foreign body simulating renal cancer 

R.C. Sanseverino, G. Napodano, O. Intilla, U. Di Mauro, T. Realfonso (Nocera Inferiore, Italy)



12.15 - 13.45 Advanced urothelial carcinoma 



Chairs: N. Mottet, Saint Etienne (FR) 

C.N. Sternberg, Rome (IT) 



863 Phase II study of personalized peptide vaccination for standard therapy-resistant urothelial carcinoma 

patients 

S. Suekane, M. Noguchi, F. Moriya, T. Sasada, S. Matsueda, K. Itoh, K. Matsuoka (Kurume, Japan) 

864 Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic 

urothelial carcinoma previously treated with cisplatin-based chemotherapy 

M. Ikeda, K. Matsumoto, K. Tabata, S. Minamida, T. Fujita, T. Satoh, M. Iwamura, S. Baba (Sagamihara, 

Japan) 

865 Carboplatin-based neoadjuvant chemotherapy for non-organ confined bladder cancer: An useful regimen 

in cisplatin-unfit patients? 

L.S. Mertens, R.P. Meijer, B.W. Van Rhijn, A.M. Bergman, J.M. Kerst, A. Bex, H.G. Van Der Poel, 

W. Meinhardt, S. Horenblas (Amsterdam, The Netherlands) 

866 Second-line treatment of advanced urothelial cancer – safety of combinatory treatment with paclitaxel and 

RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09) 

G. Niegisch, M. Retz, A. Hartmann, M. Thalgott, J. Gschwend, F. Vom Dorp, M. Stöckle, C. Ohlmann, 

M. Bögemann, S. Balabanov, C. Ohmann, P. Albers (Düsseldorf, Munich, Erlangen, Essen, Homburg, 

Münster, Hamburg, Germany) 

867 Neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with 

muscle-invasive bladder cancer: A propensity score analysis 

T. Koie, T. Okamoto, Y. Suzuki, Y. Tobisawa, T. Yoneyama, K. Mori, H. Yamamoto, S. Hatakeyama, S. Kudoh, 

T. Yoneyama, N. Kamimura, C. Ohyama (Hirosaki, Japan) 

868 Histologic subtypes of bladder cancer influence overall survival of patients treated by radical cystectomy 

and adjuvant cisplatin-based chemotherapy 

B. Keck, H. Taubert, S. Wach, R. Stoehr, F. Kunath, S. Bertz, J. Lehmann, M. Stöckle, A. Hartmann, B. Wullich 

(Erlangen, Kiel, Homburg, Germany) 

869 Online image guided radiation therapy (IGRT) for patients with invasive bladder cancer using in-room plan 

selection: 3 years of clinical experience 

H. Bickerstaffe, M.J.A.M. De Wildt, P.P. Van De Toorn, G.J. Meijer (Eindhoven, The Netherlands) 

870 Higher excess mortality rate in women than in men with invasive bladder cancer 

S. Jahnson, O. Hagberg, S. Holmäng, F. Liedberg, B. Ljungberg, P.U. Malmström, H. Wijkström, W. Mansson 

(Linköping, Lund, Gothenburg, Växjö, Umeå, Uppsala, Stockholm, Malmö, Sweden) 

871 Diffusion-weighted MRI predicts sensitivity to chemoradiation in muscle-invasive bladder cancer 

F. Koga, S. Yoshida, S. Kobayashi, C. Ishii, H. Tanaka, Y. Fujii, H. Tanaka, H. Masuda, K. Saito, Y. Komai, 

S. Kawakami, K. Kihara (Tokyo, Japan) 


271 

Monday

Monday 

872 External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for 

patients undergoing radical cystectomy for muscle invasive urothelial carcinoma of the bladder 

H.M. Fritsche, M. May, M. Burger, P. Nuhn, W. Otto, A. Buchner, C. Bolenz, E. Herrmann, J. Ellinger, 

T. Höfner, D. Tilki, J. Roigas, M. Zacharias, L. Trojan, A. Haferkamp, C. Gilfrich, L. Hertle, M. Hohenfellner, 

S.C. Müller, C.G. Stief, W.F. Wieland, P.J. Bastian (Regensburg, Straubing, Munich, Mannheim, Münster, 

Bonn, Heidelberg, Berlin, Frankfurt, Germany) 

272 Programme Book



12.15 - 13.45 Radical prostatecomy: Pathological issues and surgical margins 



Chairs: M. Colombel, Lyon (FR) 

M. Menon, Detroit (US) 




* 873 A tertiary Gleason pattern at radical prostatectomy is associated with adverse histopathological features 

H. Isbarn, L.H. Budäus, S.A. Ahyai, F.K.H. Chun, G. Sauter, T. Schlomm, G. Salomon, T. Steuber, A. Haese, 

R. Dahlem, M. Fisch, H. Heinzer, H. Huland, M. Graefen (Hamburg, Germany) 

874 The impact of prostate weight and a nerve-sparing operation on the positive surgical margin rate in organ 

confined prostate cancer in patients undergoing a robotic assisted radical prostatectomy 

Z. Bütow, C.H. Ohlmann, J. Kamradt, M.W.W. Janssen, S. Siemer, S. Gräber, M. Stöckle (Homburg/Saar, 

Germany) 

875 Comparison of positive surgical margin rate and biochemical recurrence free survival rate between 

retropubic radical prostatectomy and robot assisted radical prostatectomy by a single surgeon: Propensity 

score matching analysis 

D.S. Yoo, W.S. Kim, J.W. Kim, H.J. Ahn (Seoul, South Korea) 

* 876 Comparative analyses of surgical modalities for the management of prostate cancer: A multi-institutional 

study of positive surgical margin rates on 22,403 patients operated on in the new millennium 

P. Sooriakumaran, I. Heus, S.F. Shariat, A. Srivastava, M. Rink, R. Sanchez-Salas, F. Chun, T. Chromecki, 

T. Nyberg, A. Nilsson, S. Carlsson, P. Nyirady, G. Novara, K. Slawin, X. Cathelineau, D.I. Lee, D. Skarecky, 

T. Ahlering, C.G. Eden, A. Mottrie, P. Stricker, N. Kraischits, C. Seitz, D.E. Neal, P. Wiklund, E.W. Steyerburg, 

M. Roobol, A.K. Tewari (New York, Paris, Houston, Philadelphia, Irvine, United States of America; 

Rotterdam, The Netherlands; Hamburg, Germany; Stockholm, Sweden; Budapest, Hungary; Padua, Italy; 

Paris, France; Guildford, Cambridge, United Kingdom; Aalst, Belgium; New South Wales, Australia; Vienna, 

Austria) 

877 Positive surgical margins after minimally-invasive radical prostatectomy in pT2 and pT3a population could 

be considered as pathological upstaging 

A. Ouzzane, F. Rozet, R.E. Sanchez-Salas, R. Valero, M. Sanchez Encinas, N. Miranda, M. Galiano, E. Barret, 

D. Prapotnich, X. Cathelineau (Paris, France) 

878 Rate, location and predictive factors of positive surgical margins in high-risk patients undergoing robot 

assisted radical prostatectomy 

O. Schatloff, A. Sivaraman, S. Chauhan, F. Ortega, K.J. Palmer, V.R. Patel (Celebration, United States of 

America) 

* 879 Impact of percent tumor volume and surgical margin status on biochemical recurrence in patients with 

extraprostatic disease following radical prostatectomy 

D. You, Y.M. Cho, I.G. Jeong, C. Song, J.H. Hong, C.S. Kim, H. Ahn (Seoul, South Korea) 

880 Prevalence of PSA recurrence after radical prostatectomy of localised prostate cancer with positive 

resection margin depends on the pathological stage and on the Gleason score: Long term results of a 

retrospective, single center study 

M. Ladurner Rennau, V. Skradski, H. Klocker, W. Horninger, J. Bektic (Innsbruck, Austria) 


273 

Monday

Monday 

881 Biological significance of tumor percentage involvement in radical prostatectomy specimens: Study of its 

prognostic significance in biochemical recurrence 

J.L. Ruiz-Cerda, R. Rogel Berto, A.M. Soto Poveda, E.J. Moran Pascual, M. Martinez Sarmiento, C.D. Vera 

Donoso, J.F. Jimenez Cruz (Valencia, Spain) 

* 882 Determining the optimal tumor volume cut-off for prediction of biochemical recurrence after radical 

prostatectomy in high-risk prostate cancer patients 

F. Castiglione, M. Albersen, A. Russo, F. Abdollah, N. Passoni, A. Gallina, N. Suardi, A. Cestari, G. Guazzoni, 

P. Rigatti, A. Briganti (Milan, Italy; Leuven, Belgium) 

274 Programme Book



12.15 - 13.45 Prostate cancer: Prognosis 



Chairs: A. Gallina, Milan (IT) 

F. Secin, Buenos Aires (AR) 




883 Precision of 3-dimensional cancer mapping by stereotactic image-based tracking technique of each biopsy 

trajectory in correlation with step-section analysis of prostatectomy specimen 

P.M. Lewandowski, S. Leslie, A. Sherrod, A. Villers, I.S. Gill, O. Ukimura (Los Angeles, United States of 

America; Lille, France) 

884 Prebiopsy multi-parametric MRI can substantially reduce unnecessary prostate biopsy in men with PSA 

less than 10 ng/mL and a normal digital rectal examination 

N. Numao, S. Yoshida, Y. Komai, C. Ishii, M. Kagawa, H. Takeshita, Y. Nakanishi, T. Kijima, M. Tatokoro, 

M. Sakura, M. Yokoyama, J. Ishioka, Y. Matsuoka, F. Koga, K. Saito, H. Masuda, S. Kawakami, K. Kihara 

(Tokyo, Saitama, Japan) 

885 Pre-biopsy MRI can accurately determine prostate cancer location when compared to saturation biopsy 

results, allowing focused biopsy regimes 

H.M. Simpson, K. Ekwuame, D. Hughes, N.J. Parr, H. Zakhour (Wirral, United Kingdom) 

886 What is the added value of routine pelvic MRI in prostate cancer evaluation in daily practice? 

I. Ouzaid, E. Xylinas, O. Belas, M. Bouanane, A. Rahmouni, G. Ploussard, C.C. Abbou, A. De La Taille, 

L. Salomon (Creteil, France) 

887 Local failure after whole-gland salvage therapy with sonablate high intensity focused ultrasound in radiorecurrent 


A.M. Autran-Gomez, A. Alzaharani, J. Izawa, J. Chin (London, Canada) 

888 High intensity focused ultrasound at 3 MHz delays onset of androgen deprivation therapy in locally 

advanced prostate cancer 

C.G. Chaussy, S.F.M. Thüroff (Munich/Regensburg, Munich, Germany) 

889 Preliminary clinical experience of photodynamic diagnosis for the detection of positive surgical margins 

during radical prostatectomy 

H. Fukuhara, K. Inoue, T. Shuin (Nankoku, Japan) 

890 18F-Choline PET/CT for early detection of prostate cancer recurrence after radical prostatectomy 

G. Simone, R. Papalia, M. Ferriero, S. Guaglianone, R. Sciuto, C.L. Maini, M. Gallucci (Rome, Italy) 

891 Is [11C]choline PET/CT recommended for restaging prostate cancer patients after radical prostatectomy 

when PSA is lower than 1 ng/ml? 

R. Garcia Parra, M. Picchio, G. Giovacchini, A. Briganti, L. Gianolli, C. Messa (Milan, Italy) 

* 892 Detection of bone metastases from prostate cancer: A prospective study of 99mTc-MDP bone scintigraphy, 

18F-Fluorocholine PET/CT, 18F-Fluoride PET/CT compared with MRI 

M.H. Poulsen, H. Petersen, P.F. Høilund-Carlsen, J.S. Jakobsen, O. Gerke, J. Karstoft, S. Walter (Odense, 

Denmark) 


275 

Monday

Monday 

* 893 Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate 

cancer: Results of a sequential PET/CT study in 22 patients 

R. Schiavia, V. Vagnoni, D. Romagnoli, C. Pultrone, C. Rocca, R. Cividini, B. Bizzarri, E. Brunocilla, 

F. Manferrari, M. Garofalo, G. Martorana (Bologna, Italy) 

* 894 Current use of MRI in the management of prostate cancer and conformity of exams and reports with 

current recommendations – results from the EAU Section of Urological Imaging (ESUI) survey 

J. Walz, M. Ferreira Coelho, P. Geavlete, H. Heynemann, T. Loch, C. Trombetta, H. Wijkstra (Marseille, France; 

Lisbon, Portugal; Bucarest, Romania; Halle, Flensburg, Germany; Triest, Italy; Amsterdam, The Netherlands) 

276 Programme Book



12.15 - 13.45 Prognostic biomarkers in urothelial carcinoma 



Chairs: H.-M Fritsche, Regensburg (DE) 

M. Rouprêt, Paris (FR) 



895 Invasive human bladder tumor cells form invadopodia that is initiated by macular expression of forminbinding 

protein(FBP) 17 

Y. Hayato, S. Mihoko, Y. Tohru, O. Akiko, H. Shingo, K. Shigemasa, Y. Takahiro, H. Yasuhiro, K. Takuya, 

K. Noritaka, S. Hisao, F. Tomihisa, T. Shigeru, O. Chikara (Hirosaki, Japan) 

896 Defining molecular subtypes of urothelial carcinoma using tissue microarrays 

G. Sjödahl, K. Lövgren, M. Fernö, M. Höglund (Lund, Sweden) 

897 Transitional cell bladder cancer proteomic mapping and risk of progression 

I. Galante Romo, L.A. San José Manso, J. Casado Varela, A. López Farré, J. Blázquez Izquierdo, A. Hernando 

Arteche, J. Sanz Ortega, J. Carballido Rodríguez, C.M. Olivier Gómez (Madrid, Spain) 

898 The endocannabinoid system modifies growth of human bladder cancer cells via cannabinoid 2 receptor 

engagement 

A. Bettiga, G. Colciago, L. Rocchini, M. Aureli, S. Sonnino, P. Hedlund, P. Rigatti, F. Montorsi, F. Benigni 


899 4N1K-containing protein expression was associated with maligant potential, progression, and survival via 

regulation of angiogenesis in urothelial cancer of the upper urinary tract 

Y. Miyata, K. Ohba, T. Matsuo, H. Sakai (Nagasaki, Japan) 

900 Prognostic value of circulating tumor cells in non muscle invasive bladder cancer: A CellSearch analysis 

P. Gazzaniga, A. Gradilone, E. De Berardinis, C. Nicolazzo, A. Petracca, A. Farcomeni, G.M. Busetto, 

V. Gentile, L. Frati, E. Cortesi (Rome, Italy) 

901 Non-muscle invasive bladder cancer and circulating tumor cells: Individuation and prognostic value 

G.M. Busetto, R. Giovannone, G. Antonini, M. Di Placido, A. Petracca, C. Nicolazzo, P. Gazzaniga, V. Gentile, 

E. De Berardinis (Rome, Italy) 

902 Prognostic significance of Snail expression in upper tract urothelial cancer and the biological role for 

tumor cell invasion 

E. Kikuchi, T. Kosaka, S. Mikami, A. Miyajima, S. Shirotake, Y. Okada, M. Oya (Tokyo, Japan) 

903 Circulating tumour cells can not predict clinical or nodal stage, but survival after radical cystectomy for 

urothelial carcinoma of the bladder 

M. Rink, A. Soave, F.K. Chun, S. Minner, L.A. Kluth, M.G. Friedrich, H. Heinzer, S.A. Ahyai, R. Heuer, 

O. Engel, S.F. Shariat, K. Pantel, M. Fisch, S. Riethdorf (Hamburg, Krefeld, Germany; New York, United 


904 Copy number alterations in urothelial carcinomas: Their clinicopathological significance and correlation 

with DNA methylation alterations 

N. Nishiyama, E. Arai, R. Nagashio, H. Fujimoto, F. Hosoda, T. Shibata, T. Tsukamoto, S. Yokoi, I. Imoto, 

J. Inazawa, Y. Kanai (Tokyo, Sapporo, Japan) 


277 

Monday

Monday 

905 Hypoxia is independently associated with poor outcome in urothelial bladder cancer patients treated with 

radical cystectomy 

P.J. Bostrom, J. Thoms, B.W.G. Van Rhijn, O. Ahmed, O. Stakhovskyi, D. Margel, A. Evans, T. Mirtti, J. Sykes, 

M. Pintilie, M. Laato, M. Milosevic, A.R. Zlotta, R.G. Bristow (Toronto, Canada; Helsinki, Turku, Finland) 

906 Bladder cancer micro environment influences maturation signature in lymphatic endothelial cells (LECs) by 

VEGF-C 

C. Poyet, I. Banzola, T. Linto, T. Sulser, M. Provenzano (Zurich, Switzerland) 

278 Programme Book



12.15 - 13.45 Prostate cancer: Biomarkers 



Chairs: G. Ploussard, Paris (FR) 

D. Ulmert, Malmö (SE) 



907 Single nucleotide polymorphisms are associated with variation of PSA levels in a control population 

J.N. Cornu, C. Egrot, P. Sèbe, F. Haab, G. Cancel-Tassin, O. Cussenot (Paris, France) 

908 An initial serum PSA level less than 5 ng/ml at diagnosis does not correlate with tumor volume in low risk 

prostate cancer patients. Implications for conservative treatments 

F. Castiglione, M. Albersen, E. Di Trapani, F. Abdollah, A. Gallina, N. Fossati, M. Freschi, P. Capogrosso, 

G. Guazzoni, P. Rigatti, A. Briganti (Milan, Italy; Leuven, Belgium) 

909 Clinical cut-offs of isoform [-2]proPSA (p2PSA) derivatives, namely %p2PSA and PHI (Prostate Health 

Index) for guiding biopsy decision in Caucasian population 

G. Lughezzani, M. Lazzeri, V. Scattoni, A. Larcher, G. Gadda, L. Nava, G. Lista, V. Bini, M. Freschi, L. Rigatti, 

P. Rigatti, G. Guazzoni (Milan, Perugia, Italy) 

910 Isoform [-2]proPSA (p2PSA) and its derivates, %p2PSA and PHI values differ between BPH, ASAP, HG-PIN 

and PCa in a set of contemporary men undergoing prostate biopsy 

G. Lista, G. Lughezzani, M. Lazzeri, V. Scattoni, L. Nava, A. Centemero, A. Losa, F. Fabbri, V. Bini, P. Rigatti, 

G. Guazzoni (Milan, Perugia, Italy) 

911 Biopsy-specific PCA3-based prostate biopsy nomograms are highly accurate 

F.K. Chun, J. Hansen, A. De La Taille, H. Van Poppel, M. Marberger, A. Stenzl, P.F.A. Mulders, H. Huland, 

C.C. Abbou, A.B. Stillebroer, M.P.M.Q. Van Gils, J.A. Schalken, Y. Fradet, L.S. Marks, W. Ellis, A.W. Partin, 

A. Haese, K. Pummer, M. Auprich (Hamburg, Tübingen, Germany; Creteil, France; Leuven, Belgium; Vienna, 

Graz, Austria; Nijmegen, The Netherlands; Quebec City, Canada; Culver City, Seattle, Baltimore, United 


912 Comparison of PHI (Prostate Health Index) and PCA3 assay in the prediction of prostate biopsy (PBx) 

outcome in patients who have undergone initial and repeated prostatic biopsies 

V. Scattoni, M Lazzeri, S. De Luca, E. Bollito, D. Randone, G. Lughezzani, A. Larcher, G. Lista, G. Gadda, 

C. Maccagnano, P. Rigatti, G. Guazzoni (Milan, Turin, Italy) 

913 Prospective multicenter evaluation of PCA3+TMPRSS2-ERG as a diagnostic and prognostic marker panel 

for prostate cancer 

G.H.J.M. Leyten, D. Hessels, E.B. Cornel, T.M. De Reijke, H. Vergunst, P. Kil, B.C. Knipscheer, I.M. Van Oort, 

P.F.A. Mulders, J.A. Schalken (Nijmegen, Hengelo, Amsterdam, Tilburg, Emmen, The Netherlands) 

914 Increased peripheral cd4+cd25highfoxp3+ treg in prostate cancer patients is correlated with PSA 

Y. Akin, S. Koksoy, S. Yucel, T. Erdogru, M. Baykara, A. Ciftcioglu (Antalya, Turkey) 

915 A useful novel parameter to evaluate the indication of prostate biopsy in PSA levels 4-10ng/dl: P574R 

polimorphism genotyping 

R. Gil-Ugarteburu, I. González-Rodríguez, M. Rivas Del Fresno, J.R. Pérez-Carral, A. Fernández Somoano, 

A. Tardón García (Gijon, Oviedo, Spain) 


279 

Monday

Monday 

916 PSA velocity per prostate volume: A novel tool for prostate biopsy prediction 

T.H. Kim, J.H. Kim, H.S. Jung, K.D. Kim, Y.T. Moon, S.C. Myung, I.H. Chang (Seoul, South Korea) 

917 Prevalence and prognostic value of circulating tumor cells in blood of patients with localized prostate 

cancer prior to radical prostatectomy 

T. Steuber, T. Schlomm, H. Heinzer, U. Michl, S. Riethdorf, K. Pantel, S. Riethdorf (Hamburg, Germany) 

918 Prostate-specific antigen kinetics in patients with bone metastases from castration-resistant prostate 

cancer receiving zoledronic acid therapy 

F. Saad, J. Perez, S. Segal, J. Eastham (Montreal, Canada; Florham Park, New York, United States of America) 

280 Programme Book



12.15 - 13.45 Renal tumours: Diagnosis and prognosis 



Chairs: S. Egawa, Tokyo (JP) 





919 High nuclear grade has strong prognostic significance in patients with pathologic T1a renal cell carcinoma 

K. Suzuki, R. Mizuno, S. Mikami, N. Tanaka, K. Kanao, K. Shinoda, H. Kono, E. Kikuchi, H. Nagata, 

H. Asanuma, A. Miyajima, K. Nakagawa, M. Oya (Tokyo, Japan) 

920 Cytosolic HMGB1 expression in human renal clear cell cancer indicates higher pathological T stages and 

tumor grades 

T. Takeuchi, K. Sakazume, A. Tonooka, M. Zaitsu, K. Mikami, T. Uekusa (Kawasaki, Japan) 

921 Current patterns of gender related differences in renal cell carcinoma; true differences or influenced by 

overall survival in general population? 

M.N. Hew, R. Zonneveld, I.P.E.D. Kümmerlin, D.O. Opondo, J.J.M.C.H. De La Rosette, M.P. Laguna 

(Amsterdam, The Netherlands) 

922 Incidence and oncological outcome of renal cell carcinoma in hemodialysis patients detected by annual 

computed tomography (CT) screening 

S. Hatakeyama, Y. Suzuki, H. Yamamoto, S. Kudo, T. Yoneyama, T. Koie, N. Kamimura, H. Saitoh, T. Funyu, 

C. Ohyama (Hirosaki, Japan) 

923 The number of organs affected by distant metastases is an independent predictor of cancer specific 

survival in renal cell carcinoma patients 

U. Capitanio, R. Matloob, C. Carenzi, N. Suardi, F. Castiglione, D. Angiolilli, E. Di Trapani, L.F. Da Pozzo, 

M. Roscigno, P. Rigatti, R. Bertini (Milan, Bergamo, Italy) 

924 Three Tesla MRI biphasic angiography is applicable method for preoperative assessment of vascular 

supply in renal tumour surgery 

M. Hora, P. Stransky, I. Travnicek, T. Urge, V. Eret, J. Klecka, B. Kreuzberg, J. Baxa, E. Ferdova, H. Mirka, 

O. Hes, J. Ferda (Pilsen, Czech Republic) 

925 Withdrawn 

926 Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma 

F. Bertagna, F. Motta, M. Bertoli, G. Bosio, S. Fisogni, R. Tardanico, V. Ferrari, A. Antonelli, C. Simeone, 

S. Cosciani Cunico, R. Giubbini (Brescia, Italy) 

927 Sentinel node detection in renal cell carcinoma. A feasibility study 

A.M. Sherif, E. Eriksson, M. Thörn, J. Vasko, L. Öhberg, K. Riklund, B. Ljungberg (Stockholm, Umeå, Sweden; 

Otago, New Zealand) 

928 Targeting CAIX: Indium-111 labeled cG250 as a diagnostic tool for renal masses and lesions suspected for 

metastasis of clear cell renal cell carcinoma 

C.H.J. Muselaers, E. Oosterwijk, O.C. Boerman, W.J.G. Oyen, P.F.A. Mulders (Nijmegen, The Netherlands) 


281 

Monday

Monday 

* 929 The role for needle biopsy in treatment decision making for T1a renal tumors: The Toronto experience 

O. Stakhovskyi, H. Chung, K.A. Fernandes, A. Finelli, A.R. Zlotta, N. Fleshner, M. Robinette, J. Trachtenberg, 

M.J. Leveridge, M.A.S. Jewett (Toronto, Canada) 

* 930 A prospective in-vivo phase-I study on optical coherence tomography for renal tumor differentiation 

K. Barwari, D.M. De Bruin, D.J. Faber, T.G. Van Leeuwen, J.J.M.C.H. De La Rosette, M.P. Laguna (Amsterdam, 

The Netherlands) 

282 Programme Book



12.15 - 13.45 Prostate cancer: AR signalling 



Chairs: H. Klocker, Innsbruck (AT) 

I. Mills, Oslo (NO) 




931 Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor 

downregulation 

E. Kashiwagi, A. Yokomizo, M. Shiota, S. Tanaka, J. Inokuchi, S. Naito (Fukuoka, Japan) 

932 Finasteride: Promoter or repressor of initiated prostate epithelial cells? 

Y. Niu, R.B. Ge, Z.W. Wang, A.F. Olumi (Beijing, China; Boston, United States of America) 

933 The intriguing role of fibroblast in finasteride’s function on prostate cancer cells 

Y.N. Niu, Z.W. Wang, R.B. Ge, A.F. Olumi (Beijing, China; Boston, United States of America) 

* 934 Androgen receptor expression is induced by docetaxel in prostate cancer cells 

M.V. Tinzl, B. Chen, S. Chen, P.A. Abrahamsson, N. Dizeyi (Malmö, Sweden; Boston, United States of 

America) 

935 A novel androgen receptor regulatory loop: Posttranscriptional androgen receptor regulation through the 

midline 1 ribonuclear protein complex 

U. Demir, A. Koehler, G. Schaefer, A. Wunderlich, R. Schneider, M.R. Schweiger, S. Schweiger, H. Klocker 

(Innsbruck, Austria; Berlin, Germany; Dundee, United Kingdom) 

936 Peroxiredoxin 2 in nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer 

cells 

A. Yokomizo, M. Shiota, E. Kashiwagi, A. Takeuchi, N. Fujimoto, T. Uchiumi, S. Naito (Fukuoka, Kitakyushu, 

Japan) 

937 Concordance of ERG gene rearrangements and ERG protein expression in PIN lesions in prostate needle 

biopsies 

D. Nagy, R. Nagle, K. Garsha, K. Christopherson, J. Riley, U. Sathyanarayana, C. Cortez, K. Smith, 

K. Pozarowski, S. Yun, R. Dittamore, N. Palanisamy, M. Sokoloff, F. Demichelis, M. Rubin, P. Miller, 

G. Pestano (Tucson, Ann Arbor, New York, United States of America) 

938 Androgen production in periprostatic adipose tissue in prostate cancer patients 

Y. Shibata, S. Arai, H. Koike, H. Matsui, K. Ito, S. Honma, K. Suzuki (Maebashi, Ohta, Kawasaki, Japan) 

939 Up-regulated 17,20-lyase activity in human castration resistant prostate cancer 

T. Kosaka, A. Miyajima, T. Maeda, E. Kikuchi, H. Nagata, M. Oya (Tokyo, Japan) 

940 Polymorphisms of the enzymes of the metabolism of oestrogens and prostate cancer 

L. Brureau, M. Romana, P. Blanchet, L. Multigner (Pointe-à-Pitre, Guadeloupe) 


283 

Monday

Monday 

941 Comparative assessment of steroids serum levels in European and African-Caribbean men using gas 

chromatography - mass spectrometry 

F. Giton, J. Fiet, J.N. Cornu, O. Cussenot, A. Bélanger, S. Urien, A. Oliva, P. Blanchet, L. Multigner (Creteil, 

Paris, Pointe-à-Pitre, France; Québec City, Canada; Rosario, Argentina) 

* 942 The androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in 

man 

N.L. Sharma, C.E. Massie, A. Ramos-Montoya, H.E. Scott, R. Stark, A.Y. Warren, I.G. Mills, D.E. Neal 

(Cambridge, United Kingdom) 

284 Programme Book



12.15 - 13.45 Stones: Diagnostics and ESWL 



Chairs: N.P. Buchholz, London (GB) 

C. Imbimbo, Naples (IT) 



943 Validation of Randall’s plaque theory by using the unenhanced abdominal CT 

A. Ciudin, M.P. Luque, R. Salvador, M.G. Diaconu, J.B. Alcover, J.R. Alvarez-Vijande, A. Alcaraz (Barcelona, 

Spain) 

944 Dose reduced dual energy computed tomography for the differentiation of uric acid and non-uric acid 

stones 

A. Miernik, M. Schoenthaler, K. Wilhelm, G. Pache, S. Bulla (Freiburg, Germany) 

945 Patients at high risk of developing stone disease can be identified by using the unenhanced abdominal CT 

A. Ciudin, M.P. Luque, R. Salvador, M.G. Diaconu, J.B. Alcover, J.R. Alvarez-Vijande, A. Alcaraz (Barcelona, 

Spain) 

946 Prospective randomized study comparing escalating and constant energy output in SWL in the treatment of 

patients with renal stones 

R. Talic, D. Rabah, M. Seida (Riyadh, Saudi Arabia) 

947 Transmission of lithotriptor shock waves into the patient - assessment of the coupling quality by video 

monitoring in clinical practice 

S. Walther, C. Bohris, A. Roosen, M. Dickmann, Y. Hocaoglu, S. Sandner, M. Bader, C.G. Stief (Munich, 

Wessling, Germany) 

948 NGAL as a renal injury marker: A prospective randomized trial using Wolf Piezolith 3000 

M. Gelosa, G. Zanetti, D. Varisco, A. Grasso, M. Rastaldi, P. Messa, D. Croci, M. Ferruti, J. Roncali, F. Rocco 

(Milan, Vimercate, Italy) 

949 A prospective study examining the incidence of bacteriuria and urinary tract infection post-shockwave 

lithotripsy: The case against universal antibiotic prophylaxis 

J.D. Wiesenthal, D. Ghiculete, M. Ordon, K.T. Pace, R.J.D.A. Honey (Toronto, Canada) 

950 Use of a passive acoustic sensor to predict success of ESWL treatment based on initial 500 shocks 

K.A. Wong, F. Fedele, D. Phillips, H. MacFarlane, T. Leighton, A. Coleman, K.A. Thomas (London, Highfield, 


951 Body mass index and buttock circumference were independent predictors of extracorporeal shock wave 

lithotripsy disintegration failure for different level of ureteral calculi 

C.H. Liao, T.K. Yang (Taipei, Taiwan) 

952 Efficacy of Dornier official technical training for SWL treatment at the university hospital 

S. Hamamoto, A. Okada, K. Taguchi, Y. Hirose, K. Niimi, Y. Fujii, R. Ando, T. Kobayashi, M. Usami, M. Hirose, 

Y. Itoh, T. Yasui, K. Tozawa, K. Kohri (Nagoya, Japan) 

953 Evaluation of the ESWL-induced renal injury by urinary TNF-α, IL-1α and IL-6 

C. Goktas, A. Coskun, Z. Bicik, R. Horuz, I. Unsal, M. Serteser (Istanbul, Turkey) 


285 

Monday

Monday 

954 Influence of clinical therapy and nutritional counseling in urinary lithiasis recurrence 

P.C. Damasio, J.L. Amaro, H.A. Yamamoto, N.B. Cunha, P.R. Kawano, T. Assis, J. Goldberg, C.R. Amaro 

(Botucatu, Brazil) 

286 Programme Book



14.00 - 15.30 Miscellaneous 



Chairs: P.A. Geavlete, Bucharest (RO) 

A. Hoznek, Creteil (FR) 


V44 Nerve- and seminal vesicle sparing radical cystectomy: A new technique 

R.E. Hautmann, R.C. De Petriconi, S.K.H. Schaefers, W. Ebert, S.H. Hautmann (Ulm, Germany) 

V45 Thulium:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer 

M. Wolters, M.W. Kramer, S. Jutzi, M. Stöhrer, J. Becker, U. Nagele, T. Bach, A.J. Gross, M.A. Kuczyk, 

T.R.W. Herrmann (Hanover, Hamburg, Germany; Hall in Tyrol, Austria) 

V46 The bipolar plasma enucleation of the prostate – an innovative technique in large BPH 

P.A. Geavlete, B.F. Geavlete, D.R. Multescu, D.A. Georgescu, V.A. Mirciulescu (Bucharest, Romania) 

V47 Ultrasound guidance of the morcellation after HoLEP: An innovation to shorten and ensure the procedure 

J.R. Pérez-Carral, A. Martín Huéscar, I. González Rodriguez, P. Benito García, S. Fernández-Pello, J. Cuervo 

Calvo (Gijón, Spain) 

V48 Nephroureterectomy with primary endoscopic approach of the intramural ureter using bipolar plasma 

vaporization 

P.A. Geavlete, D.A. Georgescu, D.R. Multescu, B.F. Geavlete (Bucharest, Romania) 

V49 Staghorn kidney calculi: Reversed open sandwich therapy 

N. Macchione, P. Bernardini, M. Neganov, Y. Hussein I.m., M. Montanari (Milan, Italy) 

V50 Withdrawn 

V51 Laparoscopic management of urinary tract trauma is feasible in many circumstances: A multi-institution 

perspective 

G.L. Martin, R. Weston, G. Coughlin, D. Cahill, D. Moon, D.G. Murphy (Melbourne, Brisbane, Australia; 



287 

Monday

Monday 




14.00 - 15.30 Non-muscle invasive urothelial cancer: High risk disease and 

technologies 



Chairs: B. Geavlete, Bucharest (RO) 

O.Y. Yossepowitch, Petach Tikva (IL) 



955 A prospective, randomized comparison between the hexaminolevulinate blue light and the standard white 

light cystoscopy concerning the long term recurrence rates in non-muscle invasive bladder cancer cases 

B. Geavlete, R. Multescu, F. Stanescu, D. Georgescu, M. Jecu, C. Moldoveanu, P.A. Geavlete (Bucharest, 

Romania) 

956 Low incidence of residual disease at early re-TURBT following initial PDD-TURBT for high grade NMIBC 

does not justify routine early re-TURBT in all – results of a multicentre observational study 

A. Zachou, C. Bunce, H. Mostafid, J. Cresswell, M. Crundwell, A. Shamsuddin, R.A. Hurle, S. Stewart, 

L.J. Hartley, R. Donat, P. Mariappan (London, Basingstoke, Middlesbrough, Exeter, Bridgend, Edinburgh, 


957 Long-term reduction in bladder cancer recurrence with hexaminolevulinate enabled fluorescence 

cystoscopy 

M. Burger, A. Stenzl, L. Mynderse, M. Kriegmair, A.J. Witjes, M. Soloway, A. Karl, H.B. Grossman 

(Regensburg, Rochester, Munich-Planegg, Miami, Houston, United States of America; Tübingen, Munich, 

Germany; Nijmegen, The Netherlands) 

958 Value of hexaminolevulinate fluorescent cystoscopy and resection in the management of non-muscle 

invasive bladder cancer 

P.I. Tomescu, P.O. Dragoescu, M.A. Enache, C. Maria, A. Panus, N.A. Dragoescu, S.D. Enache, I.E. Plesea 

(Craiova, Romania) 

959 Narrow band imaging cystoscopy and bipolar plasma vaporization versus standard cystoscopy and 

monopolar resection in cases of large non-muscle invasive bladder tumors – a prospective, randomized, 

long term study 

B. Geavlete, R. Multescu, F. Stanescu, D. Georgescu, M. Jecu, C. Moldoveanu, P.A. Geavlete (Bucharest, 

Romania) 

960 A randomized prospective trial to assess impact of TUR performed in narrow band imaging modality on 

non muscle invasive bladder cancer recurrence 

A. Naselli, C. Introini, F. Germinale, F. Bertolotto (Genoa, Italy) 

961 Low level laser therapy and photo-dynamic therapy in combination with standard treatment can enhance 

survival in patients with non-muscle invasive bladder cancer 

B. Alekseev, M.P. Golovashchenko, K.M. Nyushko, Y. Andreeva, A.A. Teplov, E.V. Filonenko (Moscow, Russia) 

962 The BCG strain used is relevant for recurrence-free survival: A randomized phase III study comparing 

Immucyst® versus Oncotice® 

F. Birkhäuser, C.A. Rentsch, U.E. Studer, M.L. Albert, G.N. Thalmann (Berne, Basel, Switzerland; Paris, 

France)

963 Impact of bladder neck involvement on progression in patients with non-muscle invasive bladder cancer: 

A validation study 

S. Kobayashi, Y. Fujii, F. Koga, M. Yokoyama, M. Sakura, J. Ishioka, Y. Matsuoka, N. Numao, K. Saito, 

H. Masuda, K. Kihara (Tokyo, Japan) 

964 Recurrence and progression in patients who were tumor-free at the first and second cystoscopy following 

bacillus Calmette-Guerin treatment 

S. Holmäng (Gothenburg, Sweden) 

965 The long term outcome of high risk non-muscle invasive bladder cancer 

F. Thomas, N. Rubin, J. Goepel, M.F. Abbod, D. Rosario, J.W.F. Catto (Sheffield, United Kingdom) 

966 Is there a difference in quality of life between BCG and intravesical chemotherapy? Results of a 

randomized phase II study 

P. Gontero, A. Gurioli, A. Mehnert, M. Schmid, L. Kluth, G. Pappagallo, F. Sogni, F. Sanguedolce, 

G. Martorana, M. Oderda (Turin, Noale, Novara, Bologna, Italy; Hamburg, Germany) 


289 

Monday

Monday 




14.00 - 15.30 Radical prostatectomy: PSA, nomograms and predictors of oncological 

outcome 



Chairs: A. Govorov, Moscow (RU) 

S.G. Joniau, Leuven (BE) 




* 967 Validation of D’Amico criteria for low risk prostate cancer 

D. Milonas, A. Grybas, I. Gudinaviciene, M. Kimcius, D. Trumbeckas, M. Jievaltas (Kaunas, Lithuania) 

968 Oncological outcomes of patients undergoing robot-assisted laparoscopic radical prostatectomy after 

previous failure of active surveillance for prostate cancer 

A.P. Labanaris, C. Wagner, P. Lange, J.H. Witt, V. Zugor (Gronau, Germany) 

969 Stage T0 prostate cancer after robot-assisted laparoscopic radical prostatectomy. Preoperative 

clinicopathologic characteristics and oncologic outcomes 

A.P. Labanaris, V. Zugor, C. Wagner, P. Lange, J.H. Witt (Gronau, Germany) 

970 Clinical and pathological outcome after radical and nerve sparing anterograde prostatectomy for bioptic 

Gleason score ≥ 7 and PSA ≥ 10 ng/ml 

M. Lanciotti, L. Masieri, C. Giannessi, S. Giancane, F. Lanzi, G. Vignolini, A. Minervini, A. Lapini, M. Carini, 

S. Serni, G. Vittori (Florence, Italy) 

971 Oncological and functional outcomes of patients eligible for active surveillance treated with radical 

prostatectomy 

A. Russo, M. Tutolo, D. Di Trapani, A. Gallina, V. Scattoni, A. Briganti, A. Salonia, M. Freschi, R. Colombo, 

N. Suardi (Milan, Italy) 

972 Withdrawn 

973 Perfect cancer control after radical prostatectomy for patients with pathologically confirmed insignificant 


J. Hansen, B. Schwaiger, H. Isbarn, M. Rink, L.A. Kluth, A. Becker, J. Schmitges, M. Fisch, H. Huland, 

M. Graefen, F.K. Chun, S.A. Ahyai (Hamburg, Germany) 

974 Long-term prediction of biochemical recurrence in patients with pathologically organ confined prostate 

cancer 

J. Hansen, B. Schwaiger, H. Isbarn, M. Rink, L.A. Kluth, J. Schmitges, T. Steuber, H. Huland, M. Fisch, 

M. Graefen, F.K. Chun, S.A. Ahyai (Hamburg, Germany) 

975 Value of perineural invasion, lymphovascular invasion and multicentricity in radical prostatectomy 

specimens as a predictors of biochemical relapse in organ-confined prostate cancer 

M. Allué, A. Borque, L.M. Esteban, G. Sanz, J. Del Amo, R. Ponz, J. Morote (Barcelona, Zaragoza, Almunia, 

Bilbao, Spain)

976 A multi-institutional study comparing biochemical recurrence rates on 20,614 patients operated on in the 

new millennium 

P. Sooriakumaran, I. Heus, S.F. Shariat, A. Srivastava, M. Rink, R. Sanchez-Salas, F. Chun, T. Chromecki, 

T. Nyberg, A. Nilsson, S. Carlsson, P. Nyirady, C. Seitz, N. Kraischits, G. Novara, K. Slawin, X. Cathelineau, 

D.I. Lee, D. Skarecky, T. Ahlering, C.G. Eden, A. Mottrie, P. Stricker, D.E. Neal, P. Wiklund, E.W. Steyerburg, 

M. Roobol, A.K. Tewari (New York, Houston, Philadelphia, Irvine, United States of America; Rotterdam, The 

Netherlands; Paris, France; Hamburg, Germany; Stockholm, Sweden; Budapest, Hungary; Vienna, Austria; 

Padua, Italy; Guildford, Cambridge, United Kingdom; Aalst, Belgium; New South Wales, Australia) 

* 977 Postoperative nomogram predicting the probability of biochemical recurrence after radical prostatectomy 

for prostate cancer 

M. Allué, A. Borque, L.M. Esteban, G. Sanz, J. Del Amo, R. Ponz, J. Morote (Barcelona, Zaragoza, Bilbao, 

Spain) 


291 

Monday

Monday 




14.00 - 15.30 HIFU, cryotherapy and androgen deprivation therapy 



Chairs: T.M. De Reijke, Amsterdam (NL) 

A.S. Merseburger, Hanover (DE) 




978 Robotic high intensity focused ultrasound at 3 MHz, in localized prostate cancer: Side effects of 704 

patients within 10 years 

S.F.M. Thüroff, C.G. Chaussy (Munich, Munich/Regensburg, Germany) 

* 979 Localized prostate cancer control with primary HIFU therapy: Outcomes from 5663 men followed with the 

@-registry 

A. Blana, V. Berge, S. Brown, C. Chaussy, R. Ganzer, S. Crouzet, G. Pasticier, A. Paulesu, C.N. Robertson, 

S.F.M. Thüroff, J.F. Ward, A. Gelet (Fuerth, Regensburg, Munich, Germany; Oslo, Norway; Stockport, United 

Kingdom; Lyon, Bordeaux, France; Como, Italy; Durham, Huston, United States of America) 

980 Oncological outcomes of high-intensity focused ultrasound for localized prostate cancer in 1098 

consecutive patients 

A. Gelet, S. Crouzet, O. Rouviere, L. Poissonnier, J.Y. Chapelon, X. Martin (Lyon, France) 

* 981 Survival analysis of patients following prostate cancer treatment with high intensity focused ultrasound 

(HIFU) during a treatment period of 13 years 

R. Ganzer, H.M. Fritsche, A. Brandtner, J. Bründl, D. Koch, W.F. Wieland (Regensburg, Fürth, Germany) 

982 Multicentric oncologic outcomes of salvage HIFU for local failure after external beam radio therapy: 7 years 

biochemical survival of 929 patients 

S. Crouzet, S. Brown, V. Berge, C. Chaussy, R. Ganzer, A. Paulesu, C. Robertson, S.F.M. Thüroff, A. Gelet, 

J.F. Ward, A. Blana (Lyon, France; Stockport, United Kingdom; Oslo, Norway; Munich, Regensburg, Fuerth, 

Germany; Como, Italy; Durham, Huston, United States of America) 

983 Outcome predictor after cryoablation of prostate cancer using 17 gauge cryoneedles technology is the 3 

month posttherapy PSA level 

U.K.Fr. Witzsch, S. Hieronymi, W. Dillenburg, E.W. Becht (Frankfurt, Germany) 

984 Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients 

S. Inoue, K. Ikeda, K. Hieda, K. Shoji, H. Masumoto, K. Miyamoto, K. Kobayashi, T. Hayashi, M. Kajiwara, 

J. Teishima, A. Matsubara (Hiroshima, Japan) 

* 985 ADT for volume reduction, symptom relief and quality of life improvement in men with prostate cancer: 

Degarelix versus goserelin plus bicalutamide 

K. Axcrona, S. Aaltomaa, C.M. Da Silva, H. Ozen, J.E. Damber, L.B. Tanko, E. Colli, P. Klarskov (Oslo, Norway; 

Kuopio, Finland; Porto, Portugal; Ankara, Turkey; Gothenburg, Sweden; Copenhagen, Herlev, Denmark) 

986 Prognostic predictors in prostate cancer cases with biochemical progression after surgery treated with 

intermittent androgen deprivation (IAD) 

A. Alfarone, A. Sciarra, S. Salciccia, S. Cattarino, U. Parente, F. Minisola, A. Gentilucci, M. Innocenzi, 

M. Ravaziol, V. Gentile (Rome, Italy)

* 987 Intermittent androgen deprivation therapy: Duration of the first off treatment interval as a predictor of 

disease progression and prostate cancer death 

R.E. Sanchez-Salas, D. Prapotnich, F.P. Secin, E. Barret, F. Rozet, M. Galiano, X. Cathelineau (Paris, France; 

Buenos Aires, Argentina) 

988 The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: 

A single-center, prospective, open label, observational study 

K.K. Park, D.H. Lee, M.S. Chung, S.H. Lee, B.H. Chung (Yongin, Seoul, South Korea) 

989 Total hospital costs of the primary treatment of prostate cancer: A contemporary experience of a 

multidisciplinary cancer center 

H.J. Lavery, D. Sebrow, A.R. Hobbs, A.W. Levinson, D.B. Samadi (New York, United States of America) 


293 

Monday

Monday 




14.00 - 15.30 LUTS: Can we improve the accuracy of the diagnosis? 



Chairs: C. Gratzke, Munich (DE) 

Y. Igawa, Tokyo (JP) 



990 Change of urinary nerve growth factor levels after 12 weeks antimuscarinic therapy in patients with 

overactive bladder 

S.Y. Lee, S.W. Lee, J.S. Ahn, H.S. Lee, W.H. Park, W.J. Cho, K.S. Lee (Goyang, Seoul, Incheon, Gwangju, South 

Korea) 

991 Nerve growth factor released from the bladder in-vitro and in-vivo: Effect of bladder outlet obstruction 

and α1-blocker 

H. Akino, K. Nagase, N. Watanabe, K. Tanase, H. Ito, Y. Aoki, N. Oyama, Y. Miwa, O. Yokoyama (Fukui, Japan) 

992 Chronic hyperlipidemia-induced increase in nerve growth factor release from bladder causes to bladder 

dysfunction in rabbits 

M. Yoshida, K. Masunaga, T. Nagata, T. Haba, M. Migita, Y. Miyamoto, J. Kudoh (Kumamoto, Tokyo, Japan) 

993 High urinary levels of nerve growth factor and brain-derived neurotrophic factor in women with 

overactive bladder syndrome normalize after lifestyle intervention and antimuscarinic therapy 

T. Antunes-Lopes, R. Pinto, S. Carvalho-Barros, F. Botelho, P. Diniz, C. Martins-Silva, C. Duarte-Cruz, F. Cruz 

(Porto, Portugal) 

994 OnabotulinumtoxinA intradetrusorial injections modulates bladder expression of NGF, TrkA, p75 and 

TRPV1 in patients with detrusor overactivity 

A. Giannantoni, C. Amantini, S. Proietti, V. Farfariello, V. Nardicchi, G. Santoni, M. Porena (Perugia, 

Camerino, Italy) 

995 Value of nerve growth factor levels in overactive bladder syndrome – alterations after botulinum toxin 

therapy 

S. Knippschild, C. Frohme, P. Olbert, R. Hofmann, A. Hegele (Marburg, Germany) 

996 Elevated urinary CXCL10 correlates with symptom severity in patients with ulcer type interstitial cystitis 

Y. Igawa, A. Nomiya, T. Homma, N. Aizawa, H. Nishimatsu, S. Akahane, Y. Homma (Tokyo, Azumino, Japan) 

997 Urinary levels of noradrenaline are increased in patients with bladder pain syndrome/interstitial cystitis 

and are decreased by intratrigonal onabotulinum toxin type A injection 

R.M.C.A. Pinto, T.A. Lopes, J.F.A. Silva, P. Dinis, F.M.R. Cruz (Porto, Portugal) 

998 Quantitative near-infrared spectroscopy in the non-invasive diagnosis of bladder outlet obstruction in men 

with lower urinary tract symptoms 

F. Farag, J. Meletiadis, W.F.J. Feitz, J.P.F.A. Heesakkers (Nijmegen, The Netherlands; Athens, Greece) 

999 Differential effects of micturition/nociceptive reflex on the neurotransmitter regulation of the 

periaqueductal gray (PAG) between anesthetized and awake rats 

T. Kitta, M. Matsumoto, H. Tanaka, T. Mitsui, M. Yoshioka, H. Togashi, K. Nonomura (Hokkaido, Tobetsu, 

Sapporo, Japan)

1000 Cortical response after electrical stimulation of the lower urinary tract – a feasibility study 

F. Gregorini, J. Wöllner, M. Schubert, A. Curt, T.M. Kessler, U. Mehnert (Zurich, Switzerland) 

1001 Diffusion tensor MRI and tractography of the sacral plexus 

A. Jansonius, P.K.N. Van Der Jagt, A. Leemans, P. Dik (Utrecht, The Netherlands) 


295 

Monday

Monday 




14.00 - 15.30 How to improve prostate cancer staging? 



Chairs: S. Brewster, Oxford (GB) 

A. Villers, Lille (FR) 




1002 The 2011 national comprehensive cancer network guidelines recommendations for pelvic lymph node 

dissection in prostate cancer patients are not accurate. A plea for renewal 

F. Abdollah, N. Suardi, A. Gallina, U. Capitanio, A. Salonia, N. Finocchio, M. Ferschi, S. Corti, V. Di Girolamo, 

R. Colombo, G. Guazzoni, A. Briganti (Milan, Italy) 

1003 Is EAU guideline reliable in detecting bone metastases in men with Gleason score 7 prostate cancer? 

R.R. Marri, H. Kanona, N.K. Lynn (Shrewsbury, United Kingdom) 

1004 Is the preoperative urinary prostate cancer gene 3 (PCA3) score’s associated with Gleason score dependent 

tumor volume and Gleason pattern specific tumor volume? 

M. Auprich, F.K.H. Chun, K. Mayrhofer, A. Haese, S. Mannweiler, J.F. Ward, S.T. Gutschi, R. Babaian, 

K. Pummer, H. Augustin (Graz, Austria; Hamburg, Germany; Houston, United States of America) 

1005 Seminal vesicle biopsy: An useful staging procedure 

R. Montoya-Chinchilla, A. Rosino-Sánchez, T. Fernández-Aparicio, B. Pietricica, M.C. Cano-García, 

G. Hidalgo-Agulló, L. Reina-Alcaina, E. Izquierdo-Morejón, A. Romero-Hoyuela, G. Hita-Villaplana, 

B. Miñana-Lopez (Murcia, Spain) 

1006 The impact of a robotic programme on prostate cancer stage migration at a single tertiary referral center 

A. Briganti, N. Suardi, A. Gallina, N. Buffi, M. Sangalli, G. Gadda, G. Lughezzani, A. Larcher, A. Cestari, 

G. Guazzoni (Milan, Italy) 

1007 Pre-prostatic tissue removed during robotic assisted lymph node dissection for prostate cancer contains 

lymph nodes 

J. Blarer, M. Kurz, C. Vollmer, C. Padevit, D. Pfofe, H. John, M. Horstmann (Winterthur, Switzerland) 

1008 Can hybrid imaging agents also help determine if the location of intraprostatic tracer deposits affect 

sentinel node mapping in prostate cancer patients? 

O.R. Brouwer, T. Buckle, R.A. Valdés Olmos, H.G. Van Der Poel, F.W.B. Van Leeuwen (Amsterdam, The 

Netherlands) 

1009 Lymph node pathway visualization in real time by laparoscopic radioisotope- and fluorescence- guided 

sentinel lymph node dissection in prostate cancer staging 

S. Jeschke, L. Lusuardi, A. Myatt, S. Hruby, G. Janetschek (Salzburg, Austria) 

1010 Value of 18F-Choline PET/CT in detection of lymph-node metastases in patients with PSA failure after 

radical prostatectomy: Histological verification after secondary lymphadenectomy 

D. Tilki, O. Reich, J. Silchinger, W. Khoder, A.J. Becker, C.G. Stief, M. Seitz (Munich, Germany) 

* 1011 Sentinel node procedure for lymph node staging in prostate cancer 

L. Van Den Bergh, E. Lerut, C.M. Deroose, F. Ameye, K. Haustermans, H. Van Poppel, S. Joniau (Leuven, 

Belgium)

* 1012 Evaluation of lymph node recurrent prostate cancer with integrated [11C]choline PET/CT in patients with 

PSA failure after radical prostatectomy: Validation by histological analysis 

M. Tutolo, N. Suardi, M. Picchio, N. Passoni, A. Gallina, D. Di Trapani, E. Di Trapani, F. Abdollah, V. Scattoni, 

C. Messa, G. Giovacchini, L. Gianolli, M. Freschi, A. Briganti (Milan, Italy) 

* 1013 Topography of molecularbiological micrometastases in lymph nodes of prostate cancer patients treated 

with radical prostatectomy and extended lymphadenectomy 

M.M. Heck, R. Nawroth, M. Bandur, M. Souchay, L. Vitzthum, G. Weirich, T. Schuster, M. Thalgott, 

J. Gschwend, M. Retz (Munich, Germany) 


297 

Monday

Monday 




14.00 - 15.30 Renal tumours: Prognosis 



Chairs: A. Haferkamp, Frankfurt am Main (DE) 

G. Zhu, Beijing (CN) 




1014 External validation of a nomogram using RENAL nephrometry score for predicting high grade renal cell 

carcinoma 

H.K. Wang, Y. Zhu, J.Y. Wang, X.D. Yao, S.L. Zhang, B. Dai, H.L. Zhang, Y.J. Shen, C.F. Wang, D.W. Ye 

(Shanghai, China) 

1015 Collecting system invasion and Fuhrman grading but not tumour size facilitate prognostic stratification of 

patients with pt2 renal cell carcinoma – can the current 7th edition of TNM classification be improved? 

S. Brookman-May, M. May, R. Zigeuner, T. Chromecki, S.F. Shariat, M. Burger, W.F. Wieland, L. Cindolo, 

M.P. Wirth, S. Pachernik, S. Zastrow (Regensburg, Straubing, Dresden, Heidelberg, Germany; Graz, Austria; 

New York, United States of America; Vasto, Italy) 

1016 Does radiologic stage predict pathologic stage and cancer specific survival according to revised 7th TNM 

version in renal cancer? 

I.C. Acar, S.Y. Eskicorapci, O. Yaycioglu, T. Divrik, S. Yazici, A. Demirtas, T.A. Ozkan, G. Faydaci, L. Turkeri 

(Denizli, Adana, Izmir, Kastamonu, Kayseri, Kocaeli, Istanbul, Ankara, Turkey) 

1017 Influence of obesity, smoking, and hypertension on overall survival in patients with renal cell carcinoma: 

A 14-year retrospective cohort study 

J.S. Ahn, B. Park, J.E. Lee, H.J. Kim, H.H. Sung, B.H. Park, S.Y. Lee, B.C. Jeong, S.I. Seo, S.S. Jeon, H.Y. Choi, 

H.M. Lee (Seoul, Goyang, South Korea) 

1018 The role of diabetes mellitus and obesity in localized and metastatic RCC 

S. Steffens, C. Von Klot, H. Eggers, C. Seidel, G. Wegener, M. Schrader, M.A. Kuczyk, A.J. Schrader (Hanover, 

Ulm, Germany) 

1019 Thrombocytosis is associated with a significant increase in cancer specific death rate after nephrectomy 

for patients with renal cell carcinoma 

S. Brookman-May, M. May, M. Burger, S. Denzinger, W. Otto, B. Hoschke, W.F. Wieland, W. Rößler, V. Wenzl, 

S. Kohlschreiber, T. Chromecki, S. Pahernik, M. Hohenfellner, R. Zigeuner (Regensburg, Straubing, Cottbus, 

Heidelberg, Germany; Graz, Austria) 

1020 Clinical variables for predicting stage IV renal cell carcinoma patients who will not benefit from 

cytoreductive nephrectomy 

Y. Ohno, J. Nakashima, M. Ohori, H. Okubo, K. Shimodaira, Y. Sawada, M. Tachibana (Tokyo, Japan) 

1021 A simplified 2 or 3 graded Fuhrman grading system for clear cell renal cell carcinoma could predict cancerspecific-survival 

as accurate as the traditional 4 graded system in patients from 2 tertiary care centers in 

Europe 

A. Becker, J. Hansen, C. Eichelberg, R. Heuer, C.P. Meyer, M. Adam, K. Kampel-Kettner, M.C. Kainz, 

T. Chromecki, J. Jesche, R. Zigeuner, K.H.F. Chun (Hamburg, Germany; Graz, Austria)

1022 Novel nomogram and formula to predict renal function after radical nephrectomy 

M. Yokoyama, Y. Fujii, H. Takeshita, M. Sakura, J. Ishioka, Y. Iimura, K. Saito, F. Koga, H. Masuda, A. Noro, 

K. Kihara (Tokyo, Saitama, Japan) 

1023 Comparison of co-morbidity at baseline and renal function outcome in patients with surgery for renal 

masses and matched living renal donors 

M.N. Hew, E.R. Cordeiro, D.O. Opondo, F.J. Bemelmans, M.M. Idu, J.J.M.C.H. De La Rosette, M.P. Laguna 

(Amsterdam, The Netherlands) 

* 1024 Risk stratification model for chronic kidney disease stage III or greater after radical nephrectomy in T1b 

RCC: Implications for partial nephrectomy 

D. Choi, S. Yoo, S. Kim, C. Song, H. Hong, C. Kim, H. Ahn (Seoul, South Korea) 

* 1025 Ten years after the development of the University of California Los Angeles Integrated Staging System: 

What have we learned from external validation studies? 

Y. Zhu, D.W. Ye (Shanghai, China) 


299 

Monday

Monday 




14.00 - 15.30 Stones: Open and percutaneous 



Chairs: V. Bucuras, Timisoara (RO) 

P. Chlosta, Kielce (PL) 



1026 Percutaneous nephrolithotomy in the United Kingdom: Results of a prospective data registry 

J.N. Armitage, S.O. Irving, N.A. Burgess (Norwich, United Kingdom) 

1027 The relative renal anatomy in the prone-flexed position for percutaneous nephrolithotomy: A proof of 

concept for our modified position 

J.D. Wiesenthal, E.H. Ng, M. Ordon, D. Ghiculete, K.T. Pace, R.J.D.A. Honey (Toronto, Canada) 

1028 Combined supine PCNL and ECIRS (Endoscopic Combined Intra-Renal Surgery) is the treatment of choice 

for complex stones in the morbidly obese (BMI >35) 

N.S. Awsare, M. Ghei, V.R. Rajkumar, P.A. Jones (Swansea, United Kingdom) 

1029 Biochemical and haemodynamic changes in flank free modified supine position versus prone position 

during percutaneous nephrolithotomy 

E. Desoky, M. Kamel, A. Zaied, A. Alayman, A. Shahin, H. Kamel, M. Eldessouky (Zagazig, Egypt) 

1030 Percutaneous nephrolithotomy in children in different age groups 

S. Guven, A. Frattini, B. Onal, M. Desai, E. Montanari, J. Kums, M. Garofalo, J. De La Rosette (Konya, 

Istanbul, Turkey; Parma, Milan, Bologna, Italy; Nadiad, India; Zwolle, Amsterdam, The Netherlands) 

1031 The minimally invasive PCNL (MIP): Comparison study between the management of small and large sized 

renal stones 

M.F. Abdelhafez, A. Stenzl, D. Schilling (Tübingen, Germany) 

1032 Minimal invasive PCNL (MPCNL) - proven efficiency and safety after more than 650 consecutive patients 

V. Zimmermanns, S. Kurzidim, P. Liske, S. Lahme (Pforzheim, Germany) 

1033 “Tubeless” is beautiful… and definitely safe 


1034 Tubeless procedure with “one step” tract dilatation versus standard percutaneous nephrolithotomy: 

Prospective randomized comparison of 2 various techniques of percutaneous nephrolithotomy in 100 

consecutive patients in lateral modified decubitus position 

K. Moufid, N. Abakka, Y. El Harrech, O. Ghoundal, D. Touiti, M. Lezrek (Marrakech, Morocco) 

1035 The experience of mini-PCNL in the treatment of large impacted proximal ureter stones 

J.M. Guo, Q.L. Long, Z.B. Xu, G.M. Wang (Shanghai, China) 

1036 Exit strategies following percutaneous nephrolithotomy (PCNL) 

L. Cormio, G. Ibarlucea Gonzalez, D. Tolley, M. Sofer, A. Muslumanoglu, H.C. Klingler, J. Stolzenbrug, J. De La 

Rosette (Foggia, Italy; Bizkaia, Spain; Edinburgh, United Kingdom; Tel-Aviv, Israel; Istanbul, Turkey; Vienna, 

Austria; Leipzig, Germany; Amsterdam, The Netherlands)

1037 Post operative infection rates in low risk PCNL patients with and without antibiotic prophylaxis. A matched 

case control study 

S. Gravas, E. Montanari, P. Geavlete, B. Onal, A. Skolarikos, M. Pearle, Y. Sun, J. De La Rosette (Larissa, 

Athens, Greece; Milan, Italy; Bucharest, Romania; Istanbul, Turkey; Dallas, United States of America; 

Changhai, China; Amsterdam, The Netherlands) 

1038 Blood transfusion, embolisation and nephrectomy following percutaneous nephrolithotomy (PCNL), 

a series of 568 patients 

R.J. Cetti, S.R. Keoghane, M. Harris, J. Anderson, A.E. Rogers, B.H. Walmsley (Portsmouth, United Kingdom) 

1039 Colon perforation during percutaneous renal surgery: A ten year experience in a single endourology centre 

S. Kachrilas, C. Bach, F. Zaman, N. Dickens, A. Papatsoris, J. Masood, N. Buchholz (London, United Kingdom; 



301 

Monday

Monday 




15.45 - 17.15 Video Award Session 



Chairs: I.J. De Jong, Groningen (NL) 

R.J.A. Van Moorselaar, Amsterdam (NL) 


V28 Prize for the Best Video published in the EUVJ 2011 

Complications during robot-assisted kidney surgery 

Q.D. Trinh, S. Sukumar, K.R. Ghani, J. Sammon, W. Jeong, J. Jhaveri, F. Muhletaler, M. Ehlert, M. Menon, 

C.G. Rogers (Detroit, United States of America) 

V51 Third Video Prize 

Laparoscopic management of urinary tract trauma is feasible in many circumstances: A multi-institution 

perspective 

G.L. Martin, R. Weston, G. Coughlin, D. Cahill, D. Moon, D.G. Murphy (Melbourne, Brisbane, Australia; 


V32 Second Video Prize 

Difficulties of the single port laparoscopic surgery, how to come round them and adapt the surgical 

gestures with the example of sacrocolpopexies 

E. Drapier, A. Smirnoff, L. De Poncheville (La Rochelle, France) 

V33 First Video Prize 

Second generation instruments for robotic single site kidney surgery: Early experience in a cadaver model 

R. Autorino, H.K. Laydner, R. Yakoubi, A. Kassab, W. Isac, E. Rizkala, R.J. Stein, J.H. Kaouk (Cleveland, United 

States of America)



15.45 - 17.15 Non-muscle invasive urothelial cancer: Low risk and clinical trials 



Chairs: P. Gontero, Turin (IT) 

S. Holmäng, Gothenburg (SE) 




1040 Smoking status at diagnosis and outcome of intermediate-risk non muscle-invasive bladder carcinoma 

(NMI-BC) treated by TUR and adjuvant intravesical chemotherapy 

V. Serretta, V. Altieri, G. Morgia, G. Carrieri, A. Di Lallo, M. Battaglia, R. Allegro (Palermo, Naples, Catania, 

Foggia, Campobasso, Bari, Italy) 

1041 Safety and efficacy of an active surveillance program in recurrent non-muscle invasive bladder tumors. 

Results of an extended series 

E. De La Peña, V. Hernandez, C. Blazquez, M.D. Martin, C. Capitan, J. Martinez De Hurtado, C. Llorente 


1042 Transvesical blockade of obturator nerve to prevent adductor muscle contraction during transurethral 

resection of bladder tumor 

M.H. Khorrami, F. Farahini, M.H. Izadpanahi, M. Zargham, M. Mohammadi, M.R. Gharaati, M. Hadi, A. Javid 

(Isfahan, Iran) 

1043 Routine cystoscopic surveillance is ineffective in preventing death due to bladder cancer in patients with 

low risk disease 

K.D. Linton, D.J. Rosario, F. Thomas, N. Rubin, M.F. Abbod, J.W.F. Catto (Sheffield, United Kingdom) 

1044 Single or two instillations of pirarubicin as prophylaxis for recurrence after transurethral resection of Ta 

and T1 transitional cell bladder cancer: A prospective, randomized controlled study 

T. Saika, T. Tsushima, N. Yasutomo, K. Takeda, H. Kumon (Hiroshima, Okayama, Takamatsu, Japan) 

1045 Intravesical adjuvant electromotive drug administration (EMDA®) of mitomycin-C in patients with 

intermediate-risk non-muscle invasive bladder cancer: A randomized controlled trial 

S.M. Di Stasi, C. Verri, E. Liberati, F. Micali, F. Masedu, G. Zampa, M. Valenti (Rome, L’Aquila, Italy) 

1046 Quality control in transurethral resection of bladder tumors (TURBT) – predicting presence of detrusor 

muscle (DM) in the surgical specimen and its impact on oncological outcomes 

O. Shoshany, D. Margel, J. Baniel, R. Mano, D. Kedar, S. Zilber, O. Yossepowitch (Petach Tikva, Israel) 

1047 Operative time is associated with perioperative TURB complications: A modified Clavien classification 

system analysis 

C. De Nunzio, C. Leonardo, L. Cindolo, R. Autorino, R. Miano, A. Cantiani, A. Cicione, R. Damiano, M. De 

Sio, C. Di Palma, M. Falsaperla, G. Maugeri, S. Perdonà, F. Presiccia, G. Simonelli, A. Tubaro (Rome, Vasto, 

Naples, Catanzaro, Catania, Italy) 

1048 Comparison of endoscopic management and laparoscopic nephroureterectomy for non-invasive upper tract 

urothelial cancer (UTUC): 20-year single centre experience 

M.L. Cutress, G.D. Stewart, E.C.G. Tudor, E.A. Egong, S. Wells-Cole, S. Phipps, B.G. Thomas, S.A. McNeill, 

A.C.P. Riddick, D.A. Tolley (Edinburgh, United Kingdom) 


303 

Monday

Monday 

1049 Surgeon-volume and outcome relation in transurethral resection of bladder tumour (TURBT) 

S. Alkhateeb, N.E. Fleshner, M.A.S. Jewett, J. Trachtenberg, A.R. Zlotta, A. Finelli (Toronto, Canada) 

* 1050 Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. 

Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer 

M.A. Brausi, J.R. Oddens, R.J. Sylvester, A.V. Bono, C. Van De Beek, G. Van Andel, P. Gontero, W. Hoeltl, 

L. Turkeri, S. Collette, W. Oosterlinck (Modena, Varese, Novara, Italy; ‘s-Hertogenbosch, Maastricht, 

Amsterdam, The Netherlands; Brussels, Ghent, Belgium; Vienna, Austria; Istanbul, Turkey) 

* 1051 Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin versus intravesical 

mitomycin-C for prevention of recurrences in patients with non-muscle-invasive bladder cancer: Results 

from a prospective randomized phase III trial 

R.J.M. Lammers, W.P.J. Witjes, M.H.C. Janzing-Pastors, C.T.M. Caris, J.A. Witjes (Nijmegen, Arnhem, The 

Netherlands) 

304 Programme Book



15.45 - 17.15 Radical prostatectomy: Outcome on erectile function and continence 



Chairs: F. Montorsi, Milan (IT) 

M. Spahn, Würzburg (DE) 




* 1052 Urethral length and diameter of the external urethral sphincter as predictors of continence after 

laparoscopic radical prostatectomy 

K. Minami, Y. Ooishi, M. Azumi, T. Harabayashi, S. Nagamori (Sapporo, Japan) 

1053 Factors for prediction of the return of urinary continence after radical prostatectomy 

A. Wallerstedt, S. Carlsson, T. Thorsteinsdottir, E. Haglind, U. Wilderäng, G. Steineck, P. Wiklund (Stockholm, 

Gothenburg, Sweden) 

* 1054 A novel tool for the prediction of urinary incontinence after bilateral nerve sparing radical prostatectomy 

F. Abdollah, A. Gallina, N. Suardi, U. Caitanio, G. La Croce, M. Tutolo, E. Farina, N. Finocchio, A. Salonia, 

A. Briganti (Milan, Italy) 

* 1055 Predicting an individual’s risk of urinary incontinence one year following robot-assisted radical 

prostatectomy 

J. Sammon, Q.D. Trinh, K.R. Ghani, P. Ravi, S. Sukumar, J. Jhaveri, W. Jeong, P.K. Agarwal, C.G. Rogers, 

H. Stricker, J.O. Peabody, M. Menon (Detroit, United States of America) 

1056 Effect of advanced age (> 70 yrs) on prostate cancer characteristics, survival and postoperative continence 

in patients undergoing radical prostatectomy 

I. Kunz, U. Roggenbuck, V. Klevecka, M. Musch, D. Kroepfl (Essen, Germany) 

1057 Delayed versus immediate radical prostatectomy in intermediate and high grade prostate cancer patients – 

postoperative (functional) outcomes 

J. Hansen, M. Rink, O. Balzer, J. Spethmann, T. Steuber, P. Perrotte (Hamburg, Germany; Montreal, Canada) 

1058 Functional outcomes with robot assisted radical prostatectomy (RALP) in preoperatively high risk prostate 

cancer patients 

A. Sivaraman, V. Patel, K. Palmer, R. Coelho, S. Chauhan, O. Schatloff, F. Ortega, B. Rocco, M. Orvieto 

(Celebration, United States of America) 

1059 The impact of nerve preservation on potency outcomes following robot-assisted radical prostatectomy – a 

propensity score matching analysis 

A. Sivaraman, V. Patel, K. Palmer, R. Coelho, O. Schatloff, S. Chauhan, M. Orvieto (Celebration, United States 

of America) 

1060 Erectile function after robot-assisted laparoscopic radical prostatectomy with compete excision of the 

neurovascular bundles. Will every patient become impotent? 

A.P. Labanaris, C. Wagner, A. Schuette, P. Lange, J.H. Witt (Gronau, Germany) 

1061 Accurate prediction of erectile function following robot-assisted radical prostatectomy 

K.R. Ghani, M. Diaz, J. Sammon, W. Jeong, J. Jhaveri, S. Sukumar, A. Dabaja, H. Stricker, P.K. Agarwal, 

C.G. Rogers, J.O. Peabody, M. Menon (Detroit, United States of America) 


305 

Monday

Monday 

* 1062 Sexual satisfaction within 6 months after radical prostatectomy: Does the quality of erections represent the 

quality of the relationship? 

S.N. Tran, C. Rollini, G. Wirth, F. Bianchi-Demicheli, C.E. Iselin (Geneva, Switzerland) 

306 Programme Book



15.45 - 17.15 BioEngineering in functional urology 



Chairs: K-D. Sievert, Tübingen (DE) 

P. Zimmern, Dallas (US) 




* 1063 In vivo electromagnetic stimulation supports muscle regeneration after stem cell injection by boosting 

muscular metabolism and stimulating nerve ingrowth 

M.N.L. Stölting, C. Handschin, A. Becskei, T. Sulser, D. Eberli (Zurich, Basel, Switzerland) 

1064 Noninvasive electromagnetic stimulation for stress urinary incontinence improves regeneration of skeletal 

muscle, increases nerve ingrowth and acetylcholine receptor clustering 

M.N.L. Stölting, C. Handschin, A. Becskei, T. Sulser, D. Eberli (Zurich, Basel, Switzerland) 

* 1065 Examining the effect of subjecting a tissue engineered pelvic floor repair material to fixed and dynamic 

stress during its production to improve the biomechanical properties for future use in stress urinary 

incontinence and pelvic organ prolapse 

A. Mangera, S. Roman, A.J. Bullock, C.R. Chapple, S. MacNeil (Sheffield, United Kingdom) 

1066 Microstructural and micromechanical studies of surgical mesh materials 

A. Smith, E. Meletis, R. Eberhart, P.E. Zimmern, H. Tibbals (Dallas, United States of America) 

1067 Biomechanical and histological effects of coating a polypropylene mesh with a purified collagen gel 

R.T. Siniscalchi, B.C. Vidal, M. Melo, L.C. Maciel, A. Prudente, P.C.R. Palma, I.M. Dal Fabbro, C.L.Z. Riccetto 

(Campinas, Brazil) 

1068 Improved biocompatibility of meshes used for hernia, incontinence and organ prolapse repair by plasma 

coating – results of in vitro and in vivo studies 

H. Gerullis, C. Eimer, E. Georgas, B. Lammers, P. Goretzki, B. Klosterhalfen, M. Boros, A. Ramon, T. Otto 

(Neuss, Düren, Germany; Szeged, Hungary) 

* 1069 Bone marrow mesenchymal stromal cell therapy for restoration of bladder wall defects 

J. Corcos, W. Mahfouz, O. Loutochin, J. Galipeau (Montreal, Canada; Atlanta, United States of America) 

1070 Rat bone marrow derived mesenchymal stem cell therapy in a Parkinsonian animal model of detrusor 

overactivity 

L. Campeau, R. Soler, M. Nomiya, K.E. Andersson (Winston-Salem, United States of America; Sao Paulo, 

Brazil) 

1071 Muscle regeneration and tracking of human muscle precursor cells by MRI in vivo 

F. Azzabi, V. Jovaisaite, J. Njiwa, A. Boss, R. Rudin, T. Sulser, D. Eberli (Zurich, Switzerland) 

* 1072 Functional and morphological changes of the urinary bladder in mice suffering from atherosclerosis 

T. Bschleipfer, A. Dannenmaier, W. Weidner, A.C. Langheinrich, M. Kampschulte (Giessen, Germany) 


307 

Monday

Monday 




15.45 - 17.15 Reconstructive surgery: Lessons and outcomes 



Chairs: H. Abol-Enein, Mansoura (EG) 

N. Lumen, Ghent (BE) 



1073 The surgical correction of bladder neck contracture (BNC) following the treatment of prostate cancer 

A.R. Mundy, D.E. Andrich (London, United Kingdom) 

1074 Artificial urinary sphincter AMS 800 after urethroplasty 

K.A.M. Sayedahmed, T. Jachertz, B.T. Kaftan, J. Riepenhusen, R. Olianas (Luenebueg, Germany) 

1075 The impact of vaginal mesh position on the functional outcomes of pelvic organ prolapse repair 

N.M. Sumerova, N.V. Tupikina, V.A. Malkhasjan, G.R. Kasyan, D.Y. Pushkar (Moscow, Russia) 

1076 Secondary intussuscepted ileal nipple valve in continent cutaneous urinary diversion: Surgical technique 

and long-term results 

A. Kocot, M. Spahn, D. Vergho, A. Loeser, H. Riedmiller (Würzburg, Germany) 

1077 Withdrawn 

1078 Laparoscopic augmentation ileocystoplasty: Urodynamic findings and long-term outcome 

M. Abdelhakiem, A. Abdalla, A. El Feel, A. Abdelhakiem (Cairo, Egypt) 

1079 What is the most optimal follow up strategy for pelvi-ureteric junction obstruction (PUJO) treated with 

pyeloplasty? A 10 year single centre analysis 

R.K. Narahari, A. Abroaf, A. Abdelbacky, N.A. Soomro, S.T. Hasan (Newcastle upon Tyne, United Kingdom) 

1080 First clinical pyeloplasty series employing the novel da Vinci single site robotic platform for the surgical 

treatment of uretero-pelvic junction obstruction: Feasibility and preliminary results 

A. Cestari, N.M. Buffi, M. Sangalli, G. Lughezzani, G. Lista, A. Larcher, M. Lazzeri, P. Rigatti, G. Guazzoni 


1081 Long-term outcomes of ileal ureter substitute at a single institution 

J.L. Richard, S. Wenske, G.W. Hruby, G.J. Decastro, M.C. Benson, M.A. Ordonez (New York, United States of 

America) 

1082 Double face onlay island preputial skin flap with augmented glanuloplasty for hypospadias repair 

M. Zaki, W.G. Sad, M. Mostafa, A. Rashed (Sohag, Egypt) 

1083 Detrusor myectomy: Longterm functional results 

M.Z. Aslam, M. Agarwal (Cardiff, United Kingdom) 

1084 Transvaginal urethral diverticulectomy using small intestinal submucosa interposition graft 

K. De Baets, A.M.A. De Vylder (Leuven, Belgium; ‘s Hertogenbosch, The Netherlands) 

1085 Primary and re-implant inflatable penile prosthesis: An analysis of patient and partner´s satisfaction 

E. Lledo-Garcia, J. Jara-Rascon, J. Piñero, G. Ogaya-Pinies, R. Molina, I. Moncada-Iribarren, C. Hernandez- 

Fernandez (Madrid, Spain)



15.45 - 17.15 Prostate cancer: Active surveillance 



Chairs: M.J. Roobol, Rotterdam (NL) 

S.F. Shariat, New York (US) 




* 1086 Outcomes of initially expectantly managed patients with low- or intermediate-risk screen-detected 

localized prostate cancer 

M. Bul, R.C.N. Van Den Bergh, X. Zhu, C.H. Bangma, F.H. Schröder, M.J. Roobol (Rotterdam, The 

Netherlands) 

1087 Radical prostatectomy results after initial active surveillance 

M. Bul, X. Zhu, C.H. Bangma, M.J. Roobol (Rotterdam, The Netherlands) 

1088 Pathological and biochemical outcomes after radical prostatectomy in men with low risk prostate cancer 

meeting PRIAS criteria 

K. Mitsuzuka, S. Narita, T. Yoneyama, S. Kawamura, T. Tochigi, T. Habuchi, C. Ohyama, Y. Arai (Sendai, Akita, 

Hirosaki, Natori, Japan) 

1089 Pathological outcomes of radical prostatectomy in candidates for active surveillance using the PRIAS 

criteria 



1090 Defining the risk of disease progression following radical prostatectomy in candidates for active 

surveillance using the PRIAS criteria 



1091 Prostate re-biopsy outcomes and change in QOL status at 1-year after active surveillance in Japanese 

prostate cancer patients - from a Japanese AS study and the PRIAS-JAPAN 

M. Sugimoto, H. Hirama, Y. Kakehi (Kagawa, Japan) 

1092 5-alpha reductase inhibitors diminish the rate of progression in men with low risk prostate cancer on 

active surveillance 

A. Finelli, G. Trottier, N. Lawrentschuk, R.J. Sowerby, A.R. Zlotta, L. Radomski, N. Timilshina, A. Evans, 

T.H. Van Der Kwast, A. Toi, M.A.S. Jewett, J. Trachtenberg, N.E. Fleshner (Toronto, Canada) 

* 1093 An international multi-center study examining re-classification rates of patients with prostate cancer 

suitable active surveillance whom underwent radical prostatectomy 

L.M. Wong, R. Johnston, D.E. Neal, A. Warren, N. Shah, C. Hovens, S.L. Goldenberg, M.E. Gleave, 

A.J. Costello, N.M. Corcoran (Cambridge, United Kingdom; Melbourne, Australia; Vancouver, Canada) 

* 1094 Outcome following surveillance of men with screen-detected prostate cancer. Results from the Gothenburg 

randomised population-based prostate cancer screening trial 

R. Arnsrud Godtman, E. Holmberg, A. Khatami, J. Stranne, K.J.E. Hugosson (Gothenburg, Sweden) 


309 

Monday

Monday 

1095 Oncological Outcome in patients candidates to active surveillance undergoing radical prostatectomy. 

Influence from upgrading 

F. Gomez Veiga, S. Breijo, S. Pertega, J. Dacal, J. Ponce, A. Zarraonaindia, J. Casas, L. Busto, I. Barghouty, 

S. Pita, V. Abal (A Coruña, Spain) 

1096 The natural history of untreated prostate MRI lesions in an active surveillance prostate cancer population – 

260 patient-years 

D.J. Stevens, C. Moore, H. Ahmed, C. Allen, A. Kirkham, J. Van Der Meulen, M. Emberton (London, United 

Kingdom) 

1097 Oncologic outcome after active treatment in men initially on active surveillance: Impact of populationbased 

screening on prostate cancer progression. The experience of the Swiss arm of the ERSPC 

D. Seiler, M. Randazzo, F. Chun, H. Isbarn, S. Ahyai, A. Huber, R. Grobholz, M. Baumgartner, F. Recker, 

M. Kwiatkowski (Aarau, Switzerland; Hamburg, Germany) 

310 Programme Book



15.45 - 17.15 Adrenals and trauma 



Chairs: F. Greco, Halle Saale (DE) 

V. Joulin, Brest (FR) 




1098 Outcomes of emergency renal embolisation - 7 year single centre analysis 

R.K. Narahari, S. Patel, P.J. Haslam, A.M. O’Riordan, S.T. Hasan, T.J. Dorkin (Newcastle upon Tyne, United 

Kingdom) 

1099 Ultra-conservative management of high grade renal trauma in the urban setting 

C.L.A. Negro, J. Makanjuola, H. Nemade, D. Sharma (London, United Kingdom) 

1100 Renal trauma in the previously injured kidney 

E. Serafetinides, A. Ploumides, N. Mourmouras, G. Garaganis, P. Pavlakis, I. Kariotis, P. Melides, D. Delakas 

(Athens, Greece) 

1101 Ureteral strictures as a complication of aortic reconstruction 

B. Komyakov, V.A. Ochelenko (Saint-Petersburg, Russia) 

1102 Management of renal trauma, could the recent revision of the current American Association for The 

Surgery of Trauma Organ Injury Scale make a difference? 

M.A. Lakmichi, R. Jarir, N. Bentani, R. Zehraoui, B. Wakrim, B. Sadiki, Z. Dahami, S.M. Moudouni, I. Sarf 

(Marrakech, Morocco) 

* 1103 Efficacy of nitinol metallic stents for treatment of ureteral obstruction 

B.K. Komyakov, B.G. Guliev, A.V. Zagazeshev (Saint-Petersburg, Russia) 

* 1104 Quality of life in trauma patients following renal injury 

E. Serafetinides, H. Konstandinidis, G. Garaganis, P. Pavlakis, N. Mourmouras, I. Kariotis, P. Melides, 

D. Delakas (Athens, Greece) 

1105 Does nephrectomy during adrenalectomy for adrenal cancer improve oncological results? 

C. Fiori, F. Daffara, S. Defrancia, B. Zaggia, G. Peraga, A. Berruti, M. Terzolo, S. Leboulleux, E. Baudin, 

F. Porpiglia (Orbassano, Italy; Villejuif, France) 

1106 Perioperative outcomes of laparoscopic vs. open adrenalectomy: A population-based analysis 

J. Sammon, W. Jeong, K.R. Ghani, J. Jhaveri, A. Friedman, C. Jeldres, P. Perrotte, Q.D. Trinh (Detroit, United 

States of America; Montreal, Canada) 

1107 Technical difficulties of transumbilical laparoendoscopic single-site adrenalectomy: Comparison with 

conventional laparoscopic adrenalectomy 

A. Miyajima, M. Ishida, T. Maeda, Y. Yasumizu, G. Kaneko, E. Kikuchi, M. Oya (Tokyo, Japan) 

1108 Differential diagnosis between carcinomas and adenomas of the adrenal cortex in children 

V.P. Paschoalin, F. Chahud, J.B.J. Bessa, A. Cologna, R. Silva, S. Tucci Junior, A.C. Pereira Martins (Ribeirão 

Preto, Brazil) 


311 

Monday

Monday 

* 1109 Does laparoendoscopic single-site adrenalectomy in patients with unilateral pheochromocytoma increase 

surgical risk? A case control study 

T. Maeda, A. Miyajima, E. Kikuchi, M. Hasegawa, Y. Yasumizu, G. Kaneko, T. Kosaka, K. Nakagawa, M. Oya 

(Tokyo, Japan) 

* 1110 Preliminary experience of laparoscopic simultaneous bilateral adrenalectomy for patients with 

aldosterone-producing adenoma 

S. Ishidoya, A. Ito, Y. Kawasaki, M. Miyazato, Y. Kaiho, F. Satoh, R. Morimoto, K. Takase, Y. Arai (Sendai, 

Yuzawa, Nishihara, Japan) 

312 Programme Book



15.45 - 17.15 Renal tumours: Minimally invasive treatments and surveillance 



Chairs: A. Häcker, Mannheim (DE) 

F. Keeley, Bristol (GB) 




1111 Percutaneous cryoablation of renal tumours: Outcome analysis of 139 tumours in 118 patients 

D.J. Breen, A. Abbas, B. Shepherd, J.A. Anderson, T.J. Bryant, N. McGill, S.L. George, R.C. Lockyer, 

M.C. Hayes (Southampton, United Kingdom) 

1112 Laparoscopic renal mass cryoablation: Relation between comorbidity and post-operative complications 

B.W. Lagerveld, M.M. Van Dijk, A.P. Noe, J.A. Van Der Zee (Amsterdam, The Netherlands) 

1113 Radiofrequency ablation versus nephron sparing surgery in patients with solitary kidneys: Oncologic and 

functional outcomes 

S. Joniau, T. Meert, F. Vandercruysse, L. De Wever, F. Claus, R. Oyen, H. Van Poppel (Leuven, Belgium) 

1114 Microwaves induced thermoablation (MWTA) of small solid renal masses: Results of a phase I study 

R. Bartoletti, P. Gontero, A. Simonato, T. Cai, N. Mondaini, E. Meliani, G. Carmignani (Florence, Turin, 

Genoa, Trento, Italy) 

1115 Efficacy and tolerance of vascular targeted photodynamic therapy (TOOKAD® Soluble: WST-11) in normal 

renal tissue in swine 

T.A. Leslie, R.W. Ritchie, L. Fiette, N. Borenstein, M.E. Sullivan (Oxford, Paris, United Kingdom; Arcueil, 

France) 

1116 Long follow up schedule is necessary for patients with T1 renal cancer after surgery 

Y. Naya, K. Araki, T. Suyama, K. Nakamura, K. Kaga, S. Sakamoto, M. Inahara, H. Masuda, S. Kojima, 

N. Nihei, T. Ichikawa, T. Igarashi (Ichihara, Chiba, Japan) 

1117 Analysis of long term progression for patients treated prior with active surveillance 

F.C. Roos, S. Holtappels, W. Brenner, A. Neisius, C. Thomas, J.W. Thüroff (Mainz, Germany) 

1118 Active surveillance of small renal masses offers short-term oncologic efficacy equivalent to radical and 


N.S. Patel, D.W. Cranston, Z. Ahktar, C. George, A. Jones, A. Leiblich, A. Protheroe, M.E. Sullivan (Oxford, 


1119 Optimisation of renal cryotherapy by temporary occlusion of arterial inflow. An animal study 

J. Auriol, S. Combelle, C. Mazerolles, H. Rousseau, B.A. Malavaud (Toulouse, France) 

* 1120 Increasing rates of active surveillance relative to surgical management in patients diagnosed with 

T1aN0M0 renal cell carcinoma 

M. Sun, N. Hanna, Z. Tian, P.I. Karakiewicz (Montreal, Canada) 

* 1121 7-year experience with radiofrequency ablation for small renal masses: Oncologic and functional outcomes 

S. Joniau, F. Vandercruysse, T. Meert, L. De Wever, F. Claus, R. Oyen, H. Van Poppel (Leuven, Belgium) 


313 

Monday

Monday 




17.30 - 19.00 Practical and live procedure workshop for managing patients with neurogenic 

bladder page 402 

Room 353 - Level 3 Sponsored by ALLERGAN and PORGES, a COLOPLAST Division 


17.30 - 19.00 Back to the future with hormonal therapy for CRPC page 403 

eURO Auditorium - Level 1 Sponsored by ASTELLAS 

17.30 - 19.00 GAGs therapy of urinary tract infections: Clinical and economic issues page 404 

Room Concorde Neuilly - Level 4 Sponsored by IBSA INSTITUT BIOCHIMIQUE SA 

17.30 - 19.00 Title to be confirmed 

Room Bordeaux - Level 3 Sponsored by SANOFI 

17.30 - 19.00 Focal treatment and quality of life: Localized prostate cancer 

Vascular Targeted Photodynamic (VTP) therapy with TOOKAD ® soluble page 405 

Room Concorde Paris - Level 4 Sponsored by STEBA BIOTECH

Tuesday, 28 February - EAU Programme 


08.00 - 12.45 Personalised treatment for low and intermediate risk prostate cancer 



F.C. Hamdy, Oxford (GB) 

08.00 - 10.00 Souvenir session by the EAU Scientific Congress Office 

Oncology 

X. Cathelineau, Paris (FR) 

Prostate disease 

A. De La Taille, Creteil (FR) 

Neurourology and voiding dysfunction 


Trauma 


Stone disease 


Andrology 

I. Eardley, Leeds (GB) 

Incontinence 


Paediatrics 

G.A. Bogaert, Leuven (BE) 

10.00 - 10.05 Introduction Personalised treatment for low and intermediate risk prostate cancer 


10.05 - 10.15 Update The PIVOT trial - What have we learnt? 

T.J. Wilt, Minneapolis (US) 


Know the long-term comparative mortality effectiveness from a randomised trial of radical prostatectomy 

versus observation for men with clinically localised prostate cancer detected in the early PSA era 

Know how the the long-term comparative mortality effectiveness from a randomised trial of radical 

prostatectomy versus observation may vary (or not) by patient and tumour characteristics for men with 

clinically localised prostate cancer detected in the early PSA era 

10.15 - 10.25 Update SPCG4: Messages after 15 years 

L. Holmberg, Uppsala (SE) 


The results from a median follow-up of 15 years in the SPCG4 study will be presented and discussed. The 

presentation will include mortality and recurrence data as well as self reported symptoms and quality of 


315 

Tuesday

Tuesday 


life. Data from a health economy evaluation will be shown. The data will be discussed in the light of today’s 

clinical domain of prostate cancer diagnosis. 

10.25 - 10.35 Update The experience and impact of prostate biopsy: Evidence from the ProtecT and PROBE studies 

J. Donovan, Bristol (GB) 

10.35 - 11.15 Debate The relevance of co-morbidity in managing early prostate cancer 

Moderator: F.C. Hamdy, Oxford (GB) 

Panel: J. Donovan, Bristol (GB) 

L. Holmberg, Uppsala (SE) 


T.J. Wilt, Minneapolis (US) 

11.15 - 11.35 Personalised therapy for the prostate cancer patient 

11.15 - 11.25 State-of-the-art lecture The role of imaging 

H.U. Ahmed, London (GB) 


The current diagnostic and therapeutic pathway in prostate cancer is reliant on the PSA-Transrectal biopsy 

paradigm. This strategy is ‘blind’ to the location of clinically significant lesions - something that is unique 

amongst solid organ cancers. This therefore leads to the well known problems that have been often debated. 

This lecture will aim to a) review the rationale and evidence on using state-of-the-art imaging, other than 

B-mode ultrasound, to visualise the prostate prior to biopsy and b) discuss the phased evaluation of these 

imaging modalities in order to provide level I evidence to change standard practice. 

11.25 - 11.35 State-of-the-art lecture The role of biomarkers 

A. De La Taille, Creteil (FR) 


One of the main challenges for urologists is to decrease the overdiagnosis and overtreatment of prostate 

cancer due to PSA screening. Unfortunately, despite the use of PSA, DRE, prostate biopsy characteristics, 

MRI and nomograms, one third of patients with so called insignificant prostate cancer have a lethal disease. 

The goal of the presentation is to evaluate the current and future potential biomarkers such as PCA3, gene 

fusion, proPSA, microRNA, genetic alterations and circulating tumour cells for the detection of significant 

prostate cancer. 

11.35 - 11.50 MDV3100, an androgen receptor signaling inhibitor (ARSI), improves overall survival in patients with 

prostate cancer post docetaxel: Results from the Phase 3 AFFIRM study 

P.F.A. Mulders, Nijmegen (NL) 


MDV3100, a novel androgen receptor signaling inhibitor (ARSI), competitively inhibits binding of androgens 

to the androgen receptor (AR), inhibits AR nuclear translocation, and inhibits association of the AR with DNA. 

MDV3100 was selected for development based on activity in prostate cancer cell model systems with overexpressed 

AR, and was found to be active in a Phase 1-2 trial enrolling pre- and post-chemotherapy treated 

patients with progressive castration resistant disease (CRPC). 

The AFFIRM trial evaluated whether MDV3100 could prolong overall survival in patients with CRPC post 

docetaxel based chemotherapy. In a randomised, double-blind, placebo-controlled, multinational Phase 3 

study (NCT00974311), 1199 patients who had received ≤ 2 regimens of docetaxel-based chemotherapy were 

randomised 2:1 to MDV3100 160 mg/day or matching placebo. The results of the trial with regard to overall 

survival, progression free survival and safety will be presented. 

11.50 - 12.05 Urological Research Section (URS) lecture Androgen axis in prostate cancer - from bench to bedside 

C.P. Evans, Sacramento (US)


- To briefly review the androgen axis. 

- To understand aberrant activation of the androgen receptor. 

- Appreciate mechanism of next-generation anti-androgens and resistance to this pathway. 

- To understand intracrine androgen biosynthesis and role of abiraterone. To learn how resistance to 

abiraterone occurs. 

- Exposure to the role of the N-terminal domain of the androgen receptor as a novel target. 

- Learn a role for the oncogene Src kinase in aberrant activation of the androgen receptor and potential role 

in overcoming resistance to other new therapies. 

- To understand autophagy and its role in resistance to prostate cancer targeted therapy. 

12.05 - 12.40 Late breaking news 

12.05 - 12.15 Degarelix as neoadjuvant hormone therapy in patients with prostate cancer: Results from a phase IIIb 

randomised, comparative trial versus goserelin plus bicalutamide 

M. Mason, Cardiff (GB) 

12.15 - 12.25 Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Baseline 

data from the SHRINK study 


12.25 - 12.40 Screening for prostate cancer: A critical update from ERSPC at 11 years’ follow up 

F. Schröder, Rotterdam (NL) 

12.40 -12.45 Closing remarks 



317 

Tuesday

KI12619 

�� 

�� 

�� 

Urinary 

Stones 

Diagnosis, Treatment, 

and Prevention of Recurrence 

�� 

Alb��ans-Göran Tiseliu��oswitha Siener 

Bernd Hoppe 

Urinary 

Stones y 

Diagnosis, Treatment, 

and Prevention o��urrence 

3rd, revised and enlarged edition ion 

X + 232 p., 36 fi g., 16 in color, soft cover, 2009 

CHF 69.– / EUR 58.– / USD 81.00 

ISBN 978–3–8055–9149–2 

e-ISBN 978–3–8055–9150–8 

Prices subject to change 

EUR price for Germany, USD price for USA only 

www.karger.com/urinary_stones_3 

inary stones 3 

�� 

Editors 

M.P. Wirth Dresden 

M. Porena Perugia 

O.W. Hakenberg Rostock 

D. Castro-Diaz 

Santa Cruz de Tenerife 

More information at: www.karger.com/uin 

�� 

Subscriber 

�� 

�� 

�� 

�� 

Selected Articles 

�� 

�� 

for Authors 

�� 

�� 

�� 

Recommendation

ESU Courses, 25 February 

ESU Course 1 

14.30 - 17.30 Prostate cancer – Screening, diagnosis and staging 

Room 352 A - Level 3 

Screening 


Diagnosis 


Staging 


Chair: F.C. Hamdy, Oxford (GB) 


The incidence of prostate cancer has increased dramatically over the last 10 to 15 years and it is now the 

most common cancer in males in developed countries. The increase is mainly caused by the growing use 

of opportunistic screening or case-finding based on the use of prostate-specific antigen (PSA) testing in 

serum. Using this approach, prostate cancer is detected 5 to 10 years before giving rise to symptoms and on 

average 17 years before causing the death of the patient. While this has led to detection of prostate cancer 

at a potentially curable stage, it has also led to substantial overdiagnosis, i.e. detection of cancers that 

would not surface clinically in the absence of screening. This is confounded by recent evidence that screening 

reduces disease-specific mortality. A major challenge is thus to identify the cases that need to be treated 

while avoiding diagnosing patients who will not benefit from being diagnosed and who will only suffer from 

the stigma of being a cancer patient. Therefore, prognostic markers, which can predict those patients who 

need to be diagnosed and those who do not, are of major importance. This course is designed for urological 

trainees and established urologists, who wish to update themselves on the latest information regarding 

screening, diagnosis and staging in prostate cancer. The course allows interaction with the audience and is 

in part based on case-scenarios for discussion with the delegates, followed by state-of-the-art presentations. 

In addition, emphasis will be placed on controversial issues and recent progress in terms of diagnostic tools, 

staging procedures and prognostic factors. At the end of the course, the participants should have obtained 

good insights on the following: 

�� 

�� 

�� 

�� 

Registration fee excluding VAT 

EAU members € 46 

Non-EAU members € 67 

�� 

A pre- and post knowledge test will be part of this course programme. 


319 

ESU & Hands-on

ESU & Hands-on 



ESU Course 2 

14.30 - 17.30 Female pelvic floor problems 

Room 352 B - Level 3 

Case presentation 

E.J. Messelink, Groningen (NL) 

Conservative treatment 

E.J. Messelink, Groningen (NL) 

Surgical treatment 

J. Deprest, Leuven (BE) 

Complications 

F.C. Burkhard, Berne (CH) 

Chair: E.J. Messelink, Groningen (NL) 


This is a clinically oriented, case centred, practical course on female pelvic floor problems. Using a case 

history of a patient, attention will first be paid to the diagnostic features that are available. What is the 

indication, when do we use it and how do we interpret the results that were found in our case-patient. After 

that we will discuss the conservative treatment options. The options we have and the way we use them. We’ll 

make a decision whether our case-patient should be treated with one of these options. Thirdly the surgical 

treatment options that are at hand for female pelvic floor problems will be shown and evaluated. What 

operation might be a good one for our case-patient. The last part of this course will deal with complications. 

What complications are seen, how can we avoid them and how do deal with the complications that we are 

confronted with. 




��


ESU Course 3 

14.30 - 17.30 Update on stone disease 


Introduction 



F. Millán-Rodríguez, Barcelona (ES) 

Ureteroscopy 


SWL - Back to basics 

N.P. Buchholz, London (GB) 

Percutaneous nephrolithotripsy 


Chair: M. Marberger, Vienna (AT) 

Interactive case presentations to demonstrate modern stone management 


Modern stone therapy has eliminated much of the previously devastating burden of upper tract urolithiasis, 

and is gradually also changing the clinical presentation. Complex stones are becoming rarer, and therapy is 

moving to the outpatient setting. Nevertheless, successful management requires competence in all aspects 

of stone management. The challenge today is employing the ideal approach for the specific situation. 

After a brief review of new developments present treatment strategies are demonstrated in detailed case 

presentations. 




�� 


321 

ESU & Hands-on




ESU Course 4 

14.30 - 17.30 Retropubic radical prostatectomy – Tips, tricks and pitfalls 


Surgical anatomy 


Chair: H. Van Poppel, Leuven (BE) 

Step by step radical retropubic prostatectomy 


Tips, tricks and pitfalls 


Treatment of complications 


Discussion and interaction 

Faculty 


In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating 

localised prostate cancer. Although laparoscopic, eventually robot assisted, radical prostatectomy is getting 

more popular in selected centres, and the open surgical approach is still the most often performed operative 

procedure in many countries throughout Europe. Localised prostate cancer is being more and more detected 

in its earlier stages and surgery undoubtedly offers the best local control. The urologist’s surgical skill must be 

outstanding and the urological community is responsible for guaranteeing optimal surgical quality through 

adequate training. The competition with external beam radiotherapy, brachytherapy and novel minimally 

invasive techniques like cryosurgery and HIFU, should encourage young urologists to optimally perform the 

surgical resection with the best possible tumour control and the least impact on continence and potency. 

This course aims to bring to the modern urologist the different technical steps of the classical ‘retropubic 

prostatectomy’ with an emphasis on the preservation of continence and potency and discusses the special tips 

and tricks that must enable every contemporary urologist to obtain good results with minimal complications. 

Also, the prevention and treatment of complications are discussed. 

This teaching course is a must for the elder resident and the younger urologist beginning his career but well 

trained urologists who do not treat many patients with localised prostate cancer, will benefit. The participants 

will get inside the detailed surgical anatomy, the pre-operative measures and the intra-operative steps of a 

very systematic and safe operation. Also the experienced uro-oncological surgeon will enjoy the tricks and 

pitfalls and will learn how to solve intra- and postoperative complications. 




�� 

A pre- and post knowledge test will be part of this course programme.


ESU Course 5 

14.30 - 17.30 Office management of male sexual dysfunction 


Diagnostics - What is necessary? 


Testosterone replacement 

C. Stief, Munich (DE) 

Oral therapy for ED 


Therapy of ED when pills fail 

D. Ralph, London (GB) 

Chair: C. Stief, Munich (DE) 

Medical therapy for premature ejaculation 


Surgical topics: Penile implants, priapism, Peyronie’s 

D. Ralph, London (GB) 

What to do after radical prostatectomy? 



The course is aimed at providing practical advice on how to diagnose and treat a patient with premature 

ejaculation or ED. It will allow an up-to-date understanding of the underlying mechanisms of the erectile 

process and the aetiology of ED. The recent development of various orally available drugs with different 

modes of action and distinctly different side-effect profiles enables individually tailored therapies. However, 

an individually adopted regimen requires an adequate work up that will be comprehensively presented. 

Although currently available and future oral drugs will be covered in depth, alternative options such as 

testosterone supplementation, local pharmacotherapy or various devices will be presented with special 

emphasis since their adequate indication and appropriate use by the urologist makes the distinctive 

difference in comparison to other specialists in the field. The indications for, and specific aspects for penile 

prosthesis will be discussed since prostheses still represent an important option for select patients. Then, 

specific topics with high practical importance as the cardiovascular patient with ED or the post-prostatectomy 

case will be covered. 

The course will be very interactive allowing in-depth information on the various aspects of the cutting edge 

of ED. 




�� 


323 

ESU & Hands-on




ESU Course 6 

14.30 - 17.30 Robot-assisted laparoscopic prostatectomy 


Introduction 


Chair: P.T. Piechaud, Bordeaux (FR) 

General principles of robotic radical prostatectomy 



Step by step procedure 

Bladder neck approach 



Posterior dissection 



Lateral dissection 




Break 

Apex and DVC 




Anastomosis 




Lymphadenectomy 


Specific situations 

P.T. Piechaud, Bordeaux (FR)

Postoperative complications 


Anatomical and functional results 


Conclusion 



The course about the technique of robotic radical prostatectomy has for main goal to give the participants all 

the technical elements of this surgery. 

The procedure will be described step by step by the various speakers. 

Different versions of the standard technique will be also described. 

The technique of this surgery in particular situations will be precised (prostatecomy post TURP, salvage 

prostatectomy). 

The main complications of this surgery will be explained and an analysis of the anatomical and functional 

results will be presented at the end of the course. 




�� 



ESU & Hands-on


ESU Courses, 26 February 


ESU Course 7 

08.30 - 11.30 Management of small renal tumours 


Active surveillance 

P. Gontero, Turin (IT) 

Ablative therapies 


Surgery 


Chair: D. Jacqmin, Strasbourg (FR) 


The aims of this course are to review the various therapeutic strategies in small localised RCC. 

The techniques such as surgery (open and laparoscopy) radical and nephron sparing, cryotherapy, 

radiofrequency and HIFU will be presented. Their respective indications including surveillance will be 

discussed. An overview of the published results will be presented and analysed. Interaction is the most 

important way to have an efficient course. 

Video and clinical cases will be used as a tool to stimulate exchange. 

We hope to meet you in Paris during the EAU Annual Congress to enjoy lots of discussions on this interesting 

topic. 




��


ESU Course 8 

08.30 - 11.30 Laparoscopic and robot-assisted laparoscopic radical cystectomy 


Chair: P. Wiklund, Stockholm (SE) 

Introduction laparoscopic cystectomy; Pre-surgery considerations 

R.F. Van Velthoven, Brussels (BE) 

Introduction robot-assisted laparoscopic cystectomy 


Female cystectomy 

J. Rassweiler, Heilbronn (DE) 

Male cystectomy 


Lymph node dissection 


Extracorporeal urinary diversion 


Intracorporeal urinary diversion 


Outcome after laparoscopic cystectomy; Oncological, functional and complications 


Outcome after robot-assisted laparoscopic cystectomy; Oncological, functional and complications 



At the conclusion of this educational activity, participants should be able to: 

�� 

radical cystectomy with extended lymph node dissection. 

�� 

cystectomy and extended pelvic lymph node dissection. 

�� 

creation of an intracorporeal and extracorporeal urinary diversion. 

�� 

laparoscopic radical cystectomy. 




�� 


327 

ESU & Hands-on




ESU Course 9 

08.30 - 11.30 Advanced course on upper tract laparoscopy (UPJ, adrenal and 

stones) 


Chair: G. Janetschek, Salzburg (AT) 

Transperitoneal approach to the kidney and adrenal gland: Standard technique and modifications 


Retroperitoneoscopy: Lateral and posterior approach 


Dismembered pyeloplasty: Technique, problems, complications 

H. Baumert, Paris (FR) 

Non-dismembered pyeloplasty: Indication, technique 


Adrenalectomy 


Partial adrenalectomy 


Stone surgery 


Questions and discussion 

Faculty 


Surgery of the kidney and adrenal gland by means of laparoscopy has become standard of care. Most 

frequently this surgery is performed transperitoneally; this approach has been standardized. However, the 

anatomy of the right and left side differs substantially which has to be taken into consideration. Also several 

modifications have been developed such as a direct approach to the left renal pelvis through the colonic 

mesentery. Retroperitoneoscopy is an alternative which should be mastered as well. 

Adrenalectomy was the first widely recognized indication for laparoscopy in urology, and open surgery 

has almost vanished for this indication. Partial adrenalectomy may be considered as an alternative 

in benign solitary tumours such as Conn adenoma but is strongly recommended in familial bilateral 

pheochromocytoma. 

For the treatment of UPJ obstruction laparoscopy has to compete with both open surgery and endopyelotomy. 

Compared to open surgery the results are the same but morbidity is lower. Morbidity of endopyelotomy is 

lower, however, but the results are not as good in the long-term. The technique of dismembered and nondismembered 

pyeloplasty will be discussed in detail.

Laparoscopic stone surgery is usually not a first line therapy. In specific situations it may be helpful, 

however. 

All the mentioned techniques will be presented in an interactive way. Essential steps will be highlighted by 

video clips. 




�� 


329 

ESU & Hands-on




ESU Course 10 

08.30 - 11.30 Advanced course on laparoscopic nephrectomy 


Introduction 

H.P. Beerlage, ‘s-Hertogenbosch (NL) 

V. Pansadoro, Rome (IT) 

Indications for laparoscopic nephrectomy 


Transperitoneal access 


Extraperitoneal access 



Chair: V. Pansadoro, Rome (IT) 

Transperitoneal safe control of the renal pedicle 


Extraperitoneal safe control of the renal pedicle 


Hemostatis 


High energy tools 


Critical view of safety 


Indications and technique for partial nephrectomy 


Indications and technique for partial nephrectomy. The Padua score 


Pedicle control. Advantages and disadvantages of the different systems. (Vascular clamp, tourniquet, 

bulldog clamp) 

V. Pansadoro, Rome (IT)

Classical laparoscopy or robotic enucleation? 



Parenchymal clamping 


Surgical tips for the nephroureterectomy 


Conversions 


Vascular emergencies during renal surgery 



Conclusion 




Different access to radical nephrectomy will be discussed. 

Best way to control the pedicle with the different approaches. 

Indications and surgical technique to partial nephrectomy. 

Pedicle control and efficient hemostasis. 

All the subjects will be discussed from a practical point of view with tips, tricks and pitfalls. 




�� 


331 

ESU & Hands-on




ESU Course 11 

08.30 - 11.30 Painful bladder / chronic pelvic pain; In men and women 


Welcome 

J.J. Wyndaele, Antwerp (BE) 

Chair: J.J. Wyndaele, Antwerp (BE) 

Neurophysiology of chronic pelvic pain, causes and confusable diseases 


Chronic Prostatitis and chronic pelvic pain in men 

Clinical picture, diagnosis and classical treatment 

J.C. Nickel, Kingston (CA) 

Innovative treatment 

R. Posch-Zimmermann, Salzburg (AT) 

Bladder Pain Syndrome BPS/IC clinical picture and diagnosis 


Bladder Pain Syndrome BPS/IC 

Clinical picture, diagnosis and actual treatment 


Innovative treatment 

R. Posch-Zimmermann, Salzburg (AT) 

Discussion and conclusion 

Faculty 


Painful diseases of the pelvis are not rare. The clinical entity is not an easy one, both in diagnosis and in 

treatment. Interactions between organs complicate the approach. The list of ‘confusable’ diseases is long and 

the most direct way to the most probable diagnosis needs to be determined while avoiding the danger of 

overlooking another dangerous pathology. 

An increase in knowledge has been important during the last couple of years. The scope of the course is to 

bring participants up to date, so that after the course they can perform the most optimal evaluation of the 

patients with chronic pelvic pain and give the treatment best adapted to our actual knowledge. 




��


ESU Course 12 

08.30 - 11.30 Lower urinary tract dysfunction and urodynamics 


The scientific basics of urodynamics 

P. Abrams, Bristol (GB) 

Chair: P. Abrams, Bristol (GB) 

Urodynamics - Getting philosophy and technique correct 


Urodynamics in neurourology 


Urodynamics in female urology 


Urodynamics in the child and in men 



Having attended the course, the attendee should: 

�� 

�� 

�� 

�� 




�� 


333 

ESU & Hands-on




ESU Course 13 

12.00 - 15.00 Robot surgery in urology – How to start 


Introduction 


Why robotics in urology 

B.S.E.P. Van Cleynenbreugel, Leuven (BE) 

Financial aspects of robotics 

M. Stöckle, Homburg (DE) 

Hardware requirements 


Instrumental preparation/sterilisation 


Training for robotics 

M. Stöckle, Homburg (DE) 

Initial tips and tricks for RALP 


Expanding the robotic repertoire 


Take home messages 


Chair: H.G. Van Der Poel, Amsterdam (NL) 


Minimal invasive surgical procedures require expertise and equipment not always present in all urological 

practices. The speed of introduction of robot-assisted surgical applications in urology urges urologist to join 

�� 

�� 

�� 

�� 

system. 

During the course three experienced robotic surgeons from differently sized institutes will address these 

questions. The course will address the basics for a robotic programme and allows for interaction on specific 

questions. 

After the course you should be able to oversee what is needed in your department to make a robot 

programme feasible.




�� 


335 

ESU & Hands-on




ESU Course 14 

12.00 - 14.00 Surgical management of locally advanced and metastatic renal cancer 


Radical nephrectomy for T3 and T4 disease 

Z. Kirkali, Bethesda (US) 

Metastasectomy in mRCC 


Chair: Z. Kirkali, Bethesda (US) 

Timing of surgery and systemic therapy in mRCC 

Z. Kirkali, Bethesda (US) 

Surgery for local recurrence and palliative surgery 



Although most renal cancers are small and incidentally found, still some patients present with locally 

advanced or even metastatic renal cell carcinoma (RCC). In addition, one third of patients treated for localized 

RCC develop local or systemic recurrences. 

�� 

well as nonsurgical and systemic therapies. Although we have now at least 7 drugs with proven efficacy in 

metastatic RCC, surgery still remains to be the only curative therapy. 

The aim of this course is to highlight the role of the urologist in the management of locally advanced and 

metastatic RCC. Surgery for locally advanced disease particularly in patients with vena caval thrombus is a 

challenging situation and tips and tricks of this type of surgery will be presented. In metastatic patients, the 

place of nephrectomy and metastasectomy, palliative surgery and surgery for local recurrences will also be 

dealt with. The timing and sequencing of surgery and medical therapies in metastatic RCC is another issue 

which will be addressed. At the end of the course the attendees will be able to understand and learn: 

�� 

vena cava thrombus 

�� 

�� 

This course is an excellent opportunity to learn what the urologist can offer to renal cancer patients with 

difficult tumours and metastatic RCC. The course is an ideal opportunity for all; residents, the practicing 

urologist and the oncologic urologist. Don’t miss this course if you see patients with advanced RCC in your 

practice! 




��


ESU Course 15 

12.00 - 14.00 Laparoscopy for beginners 


Indications for laparoscopy 

A.D. Joyce, Leeds (GB) 

Instrumentation and haemostasis 


Chair: A.D. Joyce, Leeds (GB) 

Peritoneal access and effects of pneumoperitoneum 

A.D. Joyce, Leeds (GB) 

Avoiding complications 



Urologists interested in undertaking laparoscopy must be properly trained in order to minimise the risk of 

potential complications and to ensure patient safety. Currently training in urological laparoscopy is limited 

due to several factors: 

�� 

�� 

�� 

All of which restrict the trainee from access to high quality training. This course aims to provide the potential 

trainee with the recognised core knowledge with regard to case selection, correct use of the equipment and 

imaging systems, and the important protocols for accessing and exiting the abdomen, including how to 

recognise and avoid potential complications prior to starting with the skills acquisition. The central highlight 

of the course is the use of video clips to illustrate many of the essential points and to promote discussion 

amongst the delegates. 




�� 


337 

ESU & Hands-on




ESU Course 16 

12.00 - 14.00 Testicular cancer 


Testis cancer – Early stages 

N.W. Clarke, Manchester (GB) 

Testis cancer – Case discussion 

N.W. Clarke, Manchester (GB) 

Testis cancer – Advanced stages 

P. Albers, Düsseldorf (DE) 

Testis cancer – Case discussion 


Chair: P. Albers, Düsseldorf (DE) 


�� 

this ESU course will provide the auditorium with the latest information on diagnostic tools, staging and 

treatment of testis cancer stage by stage. In early-stage cancer, organ-sparing surgery, the question of 

testicular microlithiasis, the conflicting issue of testis biopsy and current histopathological prognostic factors 

for surveillance and individualised treatment options will be discussed with the auditorium including case 

presentations. The role of conventional as well as laparoscopic RPLND in early stages will be clarified. 

In advanced-stage cancer, the course participants will learn about stage by stage treatment according to 

IGCCCG classification. Detailed information on chemotherapy regimens and the handling of side-effects will 

be provided. In this section of the course, tips and tricks of residual tumour resection will be presented 

using case reports and intraoperative pictures. In addition, salvage strategies will be discussed in cases of 

treatment failures. Participants will have enough time to ask questions and discuss their own cases. 




��


ESU Course 17 

12.00 - 14.00 Minimally invasive prostate cancer therapy 


Introduction 

S.F.M. Thüroff, Munich (DE) 

Brachytherapy – Update 2012 

S. Machtens, Bergisch Gladbach (DE) 

Questions and answers 

Chair: S.F.M. Thüroff, Munich (DE) 

HIFU therapy – Update 2012: Why TUR before? 



Focal brachy - Who, how and the difference to standard treatment 



Focal HIFU – No TUR, outlook to the future 



Clinical cases and discussion 



Conclusion 



Today, earlier diagnosis of localized prostate cancer has caused a trend to more low risk, early stage and 

elevated number of prostate cancers at first diagnosis. While surgery and radiation therapy are the „golden 

standard“ therapies choosen by the urologist, modern less invasive technologies are greeted with ever 

more enthusiasm by patients. This simply creates a dilemma. In this course about minimal invasive PCa 

therapy status quo and long term results, indispensible for correct oncological evidence based evaluation are 

reported, as well as presentation and discussion of pilotstudies in specific indications, not yet subject to local 

minimal invasive treatment today. 

Brachytherapy and HIFU are clinically and routinely available for urologists and derserving attention. 

Urologists have to be informed about their potential and validity to give „up to date“ informations to their 

patients. 


339 

ESU & Hands-on



This course will demonstrate on one side technologies, their results and complications on the other side 

highlight why in selected cases „hightech prostate cancer therapy“ might be equal or superior to conventional 

therapeutic approaches. Discussion of „focal therapy of PCa“ and specially clinical cases as exchange of 

�� 




��


ESU Course 18 

12.00 - 14.00 Metastatic prostate cancer 


First and second line hormonal therapy 

K. Pummer, Graz (AT) 

Chemotherapy and targeted therapies 

K. Miller, Berlin (DE) 

Chair: K. Pummer, Graz (AT) 


The aims of this course are to provide state-of-the-art information about the design, the indication and 

the optimal timing of current hormone therapy regimens including the possible role of the 6-months 

LHRH depots and the LHRH antagonists. In addition, the place and precise design of second-line hormonal 

manipulations will be presented. 

The role of chemotherapy will be critically discussed at the time of hormone resistance and as a first line 

treatment in selected patients. 

Additionally the role and the mechanism of action of experimental targeted therapies will be briefly 

reviewed. 

The presentations will be based on interactive cases to be discussed with the course participants and there 

will be time for questions and answers. 




�� 


341 

ESU & Hands-on




ESU Course 19 

15.30 - 17.30 Robot renal surgery 


Introduction 


Pyeloplasty 

G. Guazzoni, Milan (IT) 

Chair: A. Mottrie, Aalst (BE) 

Clinical cases UPJ obstruction; Nephrectomy for RCC 

J. Hubert, Nancy (FR) 

Partial nephrectomy 


Clinical cases RCC; Nephroureterectomy 

J. Hubert, Nancy (FR) 

Conclusion 

G. Guazzoni, Milan (IT) 


1. Explain the advantages of robotics over classical laparoscopy in surgery of the upper urinary system 

�� 

3. Discuss difficult clinical cases 




��


ESU Course 20 

14.30 - 17.30 How to write a manuscript and get it published in European Urology 


Chair: F. Montorsi, Milan (IT) 

How to get your manuscript published in European Urology 


Why publishing (and publishing on European Urology) is important for you 

C. Gratzke, Munich (DE) 

Clinical research original article: How to write the introduction and methods section 

G. Novara, Padova (IT) 

The importance of statistical design and analysis 

R.J. Sylvester, Brussels (BE) 

Clinical research original article: How to write the results and discussion sections 

J.W.F. Catto, Sheffield (GB) 

Clinical research original article: The editor’s tricks 


How to write a basic research article to be relevant for the readers of European Urology 


How your submission will be evaluated by European Urology reviewers: Reviewer template and publication 

guidelines 

J.W.F. Catto, Sheffield (GB) 

Surgery in Motion: How to combine the best possible manuscript and video for the Surgery in Motion 

Section 

D. Murphy, Melbourne (AU) 



The objectives of the course are to provide the principles of writing the two key types of publication: the 

review article and the clinical study report. Specifically covered will be how to decide whether you should 

actually publish your data and how to choose the most suitable journal once that decision is made. The ‘How 

to do it’ for a scientific paper will represent the core of the course. This will be illustrated with case studies 

on each aspect of the paper with a workshop style discussion with attendees. How to use references in your 

article and the different options for easy referencing will also be discussed. The tips and tricks section will 

provide ‘insider’ information to help in your writing. Finally, we all have to deal with reviewer’s comments 

and information will be presented on how this should be carried out to best advantage. Attendees are 


343 

ESU & Hands-on



expected to leave the course with a full knowledge of the fundamental requirements to be successful in 

having a scientific paper accepted by a major journal. 




��


ESU Course 21 

14.30 - 17.30 Vaginal surgery for urologists 


Chair: D. Pushkar, Moscow (RU) 

SUI – Anatomical considerations and surgical results in 2012 


Mini Slings start, compare, use? 


Vaginal surgery for POP: Anatomical considerations 


New procedures for POP - Recent data of mesh use 


Management of complications 

Faculty 

Urogenital fistulae, urethral loss and urethral diverticulae 

Faculty 

Video clips and interactive discussion 

Faculty 


Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is 

to employ scientific principles, published information and clinical experience to describe and position newly 

developed techniques in current clinical practice. 

Main theories of the development of stress urinary incontinence (SUI) will be explored with the audience 

in an interactive format. Special attention will be given to new techniques that use synthetics tapes in SUI 

surgery. This course will also cover the management of complications of surgery for stress incontinence. 

This course will include detailed coverage of pelvic anatomy so that urologist may better understand and 

apply modern surgical approaches to pelvic prolapse. Vaginal approach to prolapse and the use of different 

meshes will be covered in a critical way based upon personal experience. 

Management of vesicovaginal fistulas and some rare conditions will be shown both during podium and video 

presentations. 

An interactive course means active participation by the audience and participants are encouraged to prepare 

and present interesting and challenging clinical cases for consultation by the faculty. After this course, 

participants should know how to apply the newest technique in patients with stress incontinence, prolapse 

and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those 

who are just starting their careers. 


345 

ESU & Hands-on






�� 



ESU Course 22 

14.30 - 17.30 Radical cystectomy and orthotopic bladder substitution – Surgical 

tricks and management of complications 


Chair: U.E. Studer, Berne (CH) 

Preoperative investigations and selection of patients for orthotopic bladder substitution 

J.E. Gschwend, Munich (DE) 

Arguments for nerve sparing cystectomy with orthotopic bladder substitution 

A. Stenzl, Tübingen (DE) 

How to do a nerve-sparing cystectomy in male and female patients, surgical tricks to avoid complications 

with orthotopic bladder substitution 

U.E. Studer, Berne (CH) 

Tips on how to obtain good functional results in female patients 

A. Stenzl, Tübingen (DE) 

Active post-operative management is the most important step 

U.E. Studer, Berne (CH) 

How to treat complications during follow-up 


Discussion 


In this course, special emphasis is placed on patient selection and on practical surgical steps: on how to 

do meticulous pelvic lymph node dissection and nerve-sparing cystectomy in male and female patients, as 

well as how to do various types of orthotopic bladder substitutes with good long-term functional results. 

The course is aimed to be interactive with 50% of the time reserved for questions and discussions with the 

audience. At the end of the course, participants should know all the essential and practical steps needed in 

order to achieve good results with cystectomy and orthotopic bladder substitution. 




�� 


347 

ESU & Hands-on




ESU Course 23 

14.30 - 17.30 Surgery or radiotherapy for localised and locally advanced prostate 

cancer 


Localised prostate cancer 

Introduction 


Chair: B. Djavan, New York (US) 

Treatment options and strategies in localised prostate cancer 


How to use nomograms and networks 

A. Bossi, Villejuif (FR) 

Oncological and functional results of radical prostatectomy 


Oncology results of radiation therapy 


Advanced prostate cancer 

Radiotherapy with or without hormonal treatment in advanced PCA 


Results of radical prostatectomy for T3 disease 


Radiotherapy after radical prostatectomy (adjuvant and for PSA-increase) 


Take home messages 



�� 

requires a multitude of various information and inputs. In localised disease old habits have been jeopardised 

and surgical management seems to be fused with active surveillance in an increasing number of patients 

with good prognosticators. This course will summarise the decision process and indications for patients 

with clinically localised disease and help select the optimal treatment based on most recent oncological and 

functional data.

In locally advanced disease, growing evidence supports the notion of radical surgery to improve outcome. 

US and European data endorse this policy in a selected group of patients. New radiation protocols and 

strategies combined with hormone therapy offer as much adequate alternatives. In the second part of this 

course, controversies regarding the optimal management of locally advanced prostate cancer patients will be 

discussed and clear recommendations made to facilitate patient counselling and treatment. 




�� 



349 

ESU & Hands-on




ESU Course 24 

14.30 - 17.30 Flexible ureterorenoscopy and retrograde intrarenal surgery: 

Instrumentation, technique, tips and tricks, indications 


Chair: O. Traxer, Paris (FR) 

Welcome message and introduction of the course 

O. Traxer, Paris (FR) 

Instrumentation: Endoscopes 


Instrumentation: Laser and Lithotripsy devices 

M. Grasso, New York (US) 

Instrumentation: Disposable (wires, retrieving devices, UAS, irrigation devices and others) 


Technique: Stones 


Technique: Urothelial tumours and strictures 

M. Grasso, New York (US) 

Tips and tricks and special circumstances 


Indications (guidelines) and clinical cases 


Conclusions 



This course will teach the principles of evidence based medicine (EBM) in the context of daily decisionmaking 

in urology. We will introduce urology-relevant resources to search and retrieve the latest clinical 

research studies and provide the tools to systematically evaluate these studies for the quality of evidence 

they provide. In practical exercises, we will first demonstrate how to assess a study’s methodological 

strengths and weaknesses to determine how much confidence we can place in its results. Second, we will 

analyze the actual study results and the degree of certainty with which they are reported. Finally, we will 

discuss important considerations when deciding whether the results of a given study can and should be 

applied to the care of an individual patient.

A workshop-style, interactive format is chosen to teach this course. The educational objective is to empower 

participants to independently search and appraise clinical research studies and retrieve high quality evidence 

as it becomes available. This course is therefore of exceptional value to all urologists that are seeking 

to enhance their EBM skills and thereby improve patient care. 




�� 


351 

ESU & Hands-on




ESU Course 25 

08.30 - 11.30 The infertile couple - Urological aspects 


Diagnostic work-up, medical treatment 


Chair: W. Aulitzky, Vienna (AT) 

Pathophysiology, diagnosis and treatment of varicocele 

W. Aulitzky, Vienna (AT) 

Microsurgical refertilisation 

W. Aulitzky, Vienna (AT) 

Sperm retrieval techniques and genetic aspects of IVF/ICSI 



This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern 

reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion 

for both partners, focussing on the possible urological, hormonal and genetic causes of male infertility. In 

terms of therapy, this course will provide updated information on evidence based data and will discuss the 

importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain 

�� 

depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will 

also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and 

gatekeeper for the treatment of the infertile couple. 




�� 



ESU Course 26 

14.30 - 17.30 Single port surgery and hybrid procedures 


Instrumentation - Access 

E. Liatsikos, Patras (GR) 

Chair: E. Liatsikos, Patras (GR) 

Nephrectomy: Single port, hybrid technique (3mm, transvaginal) 


Pyeloplasty: Single port, hybrid technique 

A.S. Gözen, Heilbronn (DE) 

Adrenalectomy: Single port 


Partial nephrectomy: Single port, hybrid technique 


Robotic single port: Upper tract, prostatectomy 


Complications - How do we avoid them? 


Why single port? Are you convinced? 



The objective is to introduce single port surgery principles to the attendees. The presentations are made 

in a step by step fashion so that everyone can have a clear idea of the procedures, and can be exposed to 

tips and tricks that would make these procedures more appealing to them. The true indications of single 

port are presented as well as its integration with other hybrid procedures. Three mm instruments or hybrid 

transvaginal approach are also issues that are addressed. The main purpose of this course is to convince the 

attendees about the usefulness and feasibility of single port surgery and its combination with other hybrid 

procedures. Single port surgery should not be considered a “mission impossible” and this is certainly the 

main goal of our endeavor. 




�� 


353 

ESU & Hands-on




ESU Course 27 

08.30 - 11.30 Diagnosis and management of Non-Muscle Invasive Bladder Cancer 

(NMIBC) 


Introduction and objective of course 


Chair: J.A. Witjes, Nijmegen (NL) 

Diagnosis of bladder cancer (including markers and importance of TUR) and case discussion 

J. Palou Redorta, Barcelona (ES) 

New diagnostic tools such as PDD and NBI 


Guideline treatment and follow-up including case discussion 


Comments on guideline treatment recommendations including case example and discussion 


BCG failures and treatment options, including case discussion 


What to do with extravesical urothelial cancer and case discussion 

J. Palou Redorta, Barcelona (ES) 

Closure and evaluation 


�� 

problems seen in daily practice, when dealing with patients with non muscle-invasive bladder cancer 

(NMIBC). Comments and suggestions were minor, so we decided to follow the same topics, obviously 

updated with current literature. Although the emphasis is on the EAU guideline and its recommendations, 

we often see patients in daily practice that do not fit into guideline rules and need a different approach. We 

will present potential options for these patients and discuss cases like that with the audience to illustrate the 

possibilities beyond the guideline diagnosis and treatment solutions. 

Joan Palou from Barcelona will start with the standard diagnostics such as white light cystoscopy, cytology 

and (re-)TUR technique. He will also address the never ending story on urinary markers. In the second lecture, 

Marko Babjuk from Prague (chairman of the EAU NMIBC guideline) will discuss diagnostic innovations like 

PDD and NBI. Before the break, Fred Witjes from Nijmegen will deal with guidelines risk classification and 

�� 

After the break, Marko Babjuk will comment on some of the recommendations, such as the need for 

one immediate intravesical instillation in all patients, BCG toxicity, and the current view on the value of 

maintenance BCG, illustrated with cases. Next, Fred Witjes will address a major problem in clinical practice:

What to do with BCG failures. Finally, Joan Palou will end the course with discussion of urothelial carcinoma 

outside the bladder, its implications and therapy. 

The objective is that after the course, attendees will know when to follow the guideline in NMIBC, when 

there are points of discussion, and what potential alternatives might be. 




�� 



355 

ESU & Hands-on




ESU Course 28 

08.30 - 11.30 Advanced management of urethral stricture disease 


Chair: C.R. Chapple, Sheffield (GB) 

Management of anterior urethral stricture disease – An evidence based approach 


Urethroplasty for posterior urethral injuries – An evidence based approach 


New developments in urethral stricture disease 

G. Barbagli, Arezzo (IT) 

Round table discussion 


· To be able to counsel and advise a patient on the therapeutic options available. 

· To review the treatments available for urethral stricture disease and to do so in the context of different 

patient based scenarios, in an interactive fashion. 

· To provide a clearer understanding of the role and potential for both anastomotic and substitution 

urethroplasty in the management of urethral stricture disease. 

· To review the different materials and techniques used in substitution urethroplasty 

· To outline the principles of the surgical management of patients with urethras that have been injured by 

trauma. 

Participants of the course will obtain a clear view on the current role of surgery for the management of 

urethral stenosis affecting both the anterior and posterior urethra in contemporary clinical practice. 




�� 



ESU Course 29 

08.30 - 11.30 Interventional therapies for BPH 


Introduction 


Chair: K.M. Anson, London (GB) 

The science behind the devices (what you need to know) 


Open prostatectomy and the evolution of HoLEP 

R.M. Kuntz, Berlin (DE) 

Update on TURP and bipolar technologies 

T.E. Bjerklund Johansen, Århus (DK) 

Update on Laser Technologies 


Update on microwave and novel therapies 


Case discussion (illustrating the patient, prostate and technological factors that influence decision making) 


�� 

prostate tissue 

�� 

�� 

�� 

and delegate participation 

�� 

of treatment modalities 




�� 


357 

ESU & Hands-on




ESU Course 30 

08.30 - 11.30 Paediatric urology for the adult urologist: A practical update 


Chair: J.M. Nijman, Groningen (NL) 

Obstructive uropathy: What to do when, from neonate till puberty 

G.A. Bogaert, Leuven (BE) 

How to deal with congenital malformations of the external genitalia, when is surgery indicated and how 

to do it 

S. Tekgül, Ankara (TR) 

Urinary infection, reflux and voiding dysfunction: New insights in pathology, diagnostic work-up and 

management 



During this course an update is provided on common problems of the genito-urinary tract in children 

by means of state-of-the-art lectures, cases and interactive participation. Also the interaction between 

paediatric urologist, adult urologist, gynaecologist and paediatrician will be discussed. Corrections of 

congenital malformations of the urogenital tract have major implications for the quality of life, but also for 

long-term follow-up, future interventions and treatment of complications. Over the past few years our ideas 

about treatment of reflux and obstructive uropathy have changed; many so-called dogmas had to be revised. 

During this 3 hour course we will try to give an overview of the latest developments in the field of paediatric 

urology, focussing on topics of interest to the general urologist. 

The course is of particular interest to general urologists and those in training. Participants are encouraged to 

participate in the course as much as possible and there will be ample time for discussion and presentation 

of cases. 




�� 



ESU Course 31 

12.00 - 14.00 Renal transplantation: Technical aspects, diagnosis and management 

of early and late urological complications 


Chair: F.J. Burgos Revilla, Madrid (ES) 

Selection and urological preparation of transplant recipients; Surgical aspects of nephrectomy in living and 

deceased donor 


Laparoscopic living donor nephrectomy: Technical aspects and controversies 

F.J. Burgos Revilla, Madrid (ES) 

Avoiding complications by proper techniques of renal transplantation: Tricks and tips 


How to diagnose and manage postoperative and long-term complications following renal transplantation 

F.J. Burgos Revilla, Madrid (ES) 


Given the dramatic improvement in short- and long-term graft and patient survival, renal transplantation 

has become the most effective treatment of end stage renal failure. Recipients considered for transplantation 

are currently older and pose more problems than in the past, in some cases requiring specific urological 

preparation. We would like to share our experience concerning the selected items with the audience. These 

include how to select and to prepare transplant recipients with surgical or urological problems, how to 

choose the most safe technique for performing deceased donor and living donor nephrectomy, how to deal 

with unusual situations of renal procurement or transplantation and finally, for urologists, how to diagnose 

and manage postoperative and long-term urological and other complications. 




�� 


359 

ESU & Hands-on




ESU Course 32 

12.00 - 14.00 Advanced course on laparoscopic prostatectomy 


Introduction 

J-U. Stolzenburg, Leipzig (DE) 

Chair: J-U. Stolzenburg, Leipzig (DE) 

Anatomy of the prostate and urethral sphincter 


Anatomy of the neurovascular bundles and fascias - extrafascial, interfascial, intrafascial – where is the 

difference 


Operative set-up, access, trocar position: Extra versus transperitoneal approach 



Pelvic lymphadenectomy – How to perform 


Steps of the procedure (video): Endoscopic extraperitoneal radical prostatectomy 


Steps of the procedure (video): Transperitoneal laparoscopic radical prostatectomy 


How can we reduce the positive margins? 



Management of complications (based on real cases) 



Tips and tricks for difficult cases 



Conclusion 



�� 

approaches the results of radical prostatectomy are based on our understanding of the prostatic anatomy.

Thus, we will first give precise information on the anatomy of the prostate, the sphincter muscle, fascias 

and the bundles in order to have a better understanding of the operative laparoscopic anatomy. The experts 

will then go through each step of the surgery. For this, short well-selected video clips will be presented and 

discussed e.g. the best way to perform the space for the extraperitoneal approach, how to spare the bladder 

neck, to make easy dorsal vein complex control, the apical dissection and the anastomosis. Different aspects 

(interfascial, intrafascial) of nerve-sparing surgery will be addressed. The participants will be aware of the 

risk of complications or difficulties for each part of the procedure. The tricks for shortening the operative time 

will also be discussed. Finally, complications and their management will be addressed and discussed on the 

basis of real cases. At the end of the session, the participants, if they are beginners, should have a better 

comprehension of each step of the technique. If they are experienced, the course should help to improve 

their technique by picking out some important tricks. 




�� 


361 

ESU & Hands-on




ESU Course 33 

12.00 - 14.00 Management and outcome in invasive and locally advanced bladder 

cancer 


Chair: A. Alcaraz, Barcelona (ES) 

Cystectomy in the management of bladder invasive and locally advanced bladder cancer 


Case discussion on cystectomy in the management of bladder invasive and locally advanced bladder cancer 

B. Malavaud, Toulouse (FR) 

Bladder sparing approaches to muscle invasive bladder cancer 


Case discussion on bladder sparing approaches to muscle invasive bladder cancer 


Cytotoxic chemotherapy in bladder cancer: Neoadjuvant and adjuvant setting and treatment of metastatic 

disease 



Bladder cancer is the second most common oncological malignancy in Europe. Invasive and locally advanced 

bladder tumour is the urological malignancy with the highest mortality. 

The course will begin with the definition of the disease and different prognostic factors. Among 

prognosticators of outcome will be discussed the role of early cystectomy in T1 patients with poor prognosis 

indicators and the limitations of cystectomy in elderly and poor performance status patients. The course will 

continue with the discussion of the different treatment options. Rationale for considering cystectomy as gold 

standard, as well as a clear definition of multidisciplinary strategies for bladder sparing treatments with 

special emphasis in patient selection and potential limitations will be discussed. Finally, the role of systemic 

chemotherapy in the neoadjuvant and adjuvant to cystectomy setting will be presented, as well as in the 

treatment of metastatic disease. 

Specially recommended for elder residents and young urologists starting their career in the field of urooncology. 

Also experienced uro-oncological surgeons will benefit from this course through an update, 

focused on clinical issues and a practical approach. 

At the conclusion of this course, the participants should get better insights in terms of: 

- Stratifying the patients with invasive and locally advanced bladder cancer in different groups of risk. 

- Understanding the rationales outcome and limitations of cystectomy and bladder sparing treatments. 

- Defining the current role of neoadjuvant and adjuvant chemotherapy for invasive and locally advanced 

bladder cancer. 

- Measuring the benefits of systemic chemotherapy in terms of progression free survival and overall 

survival.




�� 


363 

ESU & Hands-on




ESU Course 34 

12.00 - 14.00 Urinary tract and genital trauma 


Introduction 


Blunt and penetrating renal trauma 


Chair: L. Martínez-Piñeiro, Madrid (ES) 

Ureteric, bladder, and genital (penile and testicular) trauma. Aetiology, diagnosis and treatment 



1. To review the current classifications of renal, bladder and genital trauma 

�� 

3. To provide a clearer understanding of the role of the treatments which are available for specific patient 

scenarios 

4. To interact with the audience and discuss together management and treatment of real cases 

Participants of the course will obtain a clear view on the current management of blunt and penetrating 

injuries affecting the kidney, bladder or genitals in contemporary clinical practice. 

More than 50% of the time of the course will be spent with the discussion of real clinical cases. 




��


ESU Course 35 

12.00 - 14.00 Ultrasound for the urologist - TRUS and TRUS guided biopsies 


Indications for TRUS and biopsy 

P. Hammerer, Braunschweig (DE) 

Chair: P. Hammerer, Braunschweig (DE) 

Practical aspects of TRUS and TRUS guided biopsies 

P. Hammerer, Braunschweig (DE) 

Indications for rebiopsy 


Update on new technical developments 



The purpose of this ESU course is to define the optimal transrectal ultrasound and to discuss new ultrasound 

techniques for prostate cancer detection, as well as defining a new standard for transrectal ultrasoundguided 

prostate biopsies. In addition, techniques to reduce morbidity and to increase patient acceptance will 

be discussed. Transrectal ultrasound has been performed for more than 15 years, and this technique is now 

an important part of prostate cancer diagnosis and staging. Anatomic studies of prostatectomy specimens 

that defined the zonal anatomy of the prostate and provided a detailed mapping of the tumour location 

have increased our understanding of transrectal ultrasound images, as well as enabling optimal placement 

of the biopsy needles. The stage migration revealed by PSA-based screening has resulted in most tumours 

being non-palpable at diagnosis. Therefore in the PSA arena, with tumours at an early stage (non-palpable 

and sometimes ultrasonografically isoechoic) transrectal ultrasound is needed to enable sampling of all 

relevant areas of the prostate including those that appear normal. The systematic sampling of the prostate 

by the sextant biopsy technique improved the detection rate of prostate cancer over sampling hypoechoic or 

palpable suspicious lesions. However, in men with initially negative biopsies a second set of sextant biopsies 

�� 

for sampling of larger prostates and they advocated additional samples. Will an increase of prostate biopsies 

�� 

biopsy protocols, it seems likely that discomfort for the patient would be increased. What can be done to 

�� 

are now available to provide anaesthesia in men undergoing prostate biopsies. 




�� 


365 

ESU & Hands-on




ESU Course 36 

14.30 - 16.30 Medical uro-oncology 


Chair: G. Mickisch, Bremen (DE) 

Application of chemotherapeutic agents in prostate cancer 

G. Mickisch, Bremen (DE) 

Application of novel hormonal strategies in prostate cancer 

S. Osanto, Leiden (NL) 

Immunotherapy, antibody-based therapy and tumour vaccination 

G. Mickisch, Bremen (DE) 

Small molecules as novel anticancer agents: “Smart drugs” in renal cancer 

S. Osanto, Leiden (NL) 


Modern urologic oncology consists of surgical and medical principles which are strongly interconnected to 

each other by neoadjuvant, adjuvant, or combination strategies such as cytoreductive surgery and systemic 

medical therapies. The knowledge of the practising urologist on systemic therapies has thus evolved to be 

of utmost importance. 

This holds true for the established chemotherapeutic agents with regard to prostate and bladder cancer 

as well as for new targeted agents in renal cell carcinoma. The encouraging treatment results with newly 

available agents in medical treatment of urological malignancies urges the urologist not only to take notice of 

these developments but also to understand their mechanisms. Even more important is to learn how to select 

patients for the wide variety of distinct novel agents and combinatory managements. 

This course is an excellent opportunity to learn what a modern urologist can offer to patients with advanced 

and difficult to treat common urological malignancies such as prostate, bladder or renal cell cancer. In 

particular, principles as well as tips and tricks in timing and application of the new agents and management 

of side effects will be interactively discussed. There will be an overview of the different targets that can be 

identified in malignant cells for current and future therapies, special attention will be paid to the use of 

so-called small molecules or ‘smart drugs’, and pivotal clinical trial data with these agents will be critically 

evaluated. 




��


ESU Course 37 

13.30 - 15.30 Post-surgical urinary incontinence in males 


Etiology and workup 


Chair: M.M. Fisch, Hamburg (DE) 

Management of overactive bladder and conservative management of stress incontinence 


Surgical management of stress incontinence 





Post-surgical incontinence has a severe impact on the social life of the patient. This course will answer 

the questions, how much and which investigations are needed for an adequate diagnosis and what the 

therapeutic options are that can we offer to the patient. The available conservative therapy is described and 

data on success and failure rates are provided. There is also a focus on new and alternative treatment options. 

The surgical procedures to solve the problem are presented and data of the literature critically analysed. The 

main part of the course will be the interactive case discussion with the panel and participants. 

At the end of the course the participants should know: 

�� 

�� 

�� 

patient 




�� 


367 

ESU & Hands-on




ESU Course 38 

14.30 - 16.30 General neuro-urology 


Introduction 


Diagnostics 

M.J. Drake, Bristol (GB) 

Therapy 



Chair: F.R. Cruz, Porto (PT) 


The course aims at introducing neuro-urology to urologists and other caregivers in training and at refreshing 

the topic to those who consider this subspeciality important for their current clinical practice. 

For many urologists neuro-urology is a less well known subspeciality that is considered less appealing 

due to the use of a specific terminology, methods of diagnosis and evaluation and a treatment that very 

frequently requires individualisation. For many urologists neuro-urology is not part of their training. However 

as patients with micturition problems of neurogenic cause have nowadays a life span very close to that of 

normal individuals, expertise in this field will be an inevitable requisite for the average urologist. 

Terminology has been updated in recent years and its familiarity is necessary not only in order to facilitate 

communication between caregivers but also to increase access to relevant literature. This will be the object of 

a complete review. Investigation is a decisive part of the management of patients with micturition problems 

of neurogenic origin. This is not intended as a urodynamic course but rather as a useful session in which the 

use of urodynamic and other tools will be clarified. Finally, management of these patients will be reviewed, 

from the more classic to the more experimental approaches, always keeping in mind that the expected 

audience will be the average urologist who is willing to increase their knowledge in the field. Thus the 

different therapeutic approaches will be presented in a more practical and useful way instead of a classical 

pharmacological approach. This is expected to facilitate the transfer the available information into everyday 

practice. Particular attention will be given to the use of botulinum toxin. Ultimately, different conditions will 

be simulated in order to rehearse the main topics. 

By the end of the course it is expected that participants will be able to adequately investigate and manage 

the most frequent neuro-urological situations. 




��


09.00 – 14.30 ESU/ERUS/ESUT Hands-on training Robot-assisted urologic surgery 

courses 


Course directors: A. Mottrie, Aalst (BE) 


09.00 – 10.30 Hands-on training Robot-assisted urologic surgery course 1 

Tutors: H. John, Zurich (CH) 

J. Witt, Gronau (DE) 


Tutors: A. Breda, Barcelona (ES) 

N.M. Buffi, Milan (IT) 


Tutors: B. Challacombe, London (GB) 

TBD 


The European School of Urology (ESU), EAU Robotic Urology Section (ERUS) and the EAU Section of Uro- 

�� 

February and will be performed on two Mimic dV-Trainer simulators. 

The main aims of this 90 minutes course are improving the participants´ control-skills and hand-eyecoordination 

and objective benchmarking of console performance and an introduction into standardized 

surgical steps in robot-assisted procedures will be. 

Therefore, each course is limited to the small number of 6 participants, to facilitate an optimal training 

setting with only 3 participants per tutor. 

Registration fee excluding VAT € 25 


369 

ESU & Hands-on



09.00 - 11.00 ESU/ESUT Hands-on training Laparoscopy/LESS course 1 



Course directors: G. Janetschek, Salzburg (AT) 



Chair: E. Liatsikos, Patras (GR) 

Tutors: R.T. Bardan, Timisoara (RO) 

J. Cresswell, Middlesbrough (GB) 

T. Frede, Müllheim (DE) 

U. Nagele, Hall In Tirol (AT) 


Laparoscopic procedures are continuously evolving in urology based on the increasing expertise of urologic 

surgeons. This includes ablative procedures, such as radical nephrectomy as well as reconstructive 

techniques, such as pyeloplasty. Some advanced procedures (i.e. radical prostatectomy, radical cystectomy) 

have both, ablative and reconstructive steps. Since the number of centres with laparoscopic expertise is 

still limited in Europe, laparoscopic training programmes have become very important. Hands-on training 

courses at the pelvi-trainer represent one of the main steps of such courses. Finally, all remaining questions 

can be answered and discussed with all tutors including the demonstration of tips and tricks. 


Supported by an unrestricted educational grant from KARL STORZ GMBH & CO.KG and COOK MEDICAL


12.00 - 14.00 ESU/ESUT Hands-on training Laparoscopy/LESS course 2 





Chair: J-T. Klein, Heilbronn (DE) 

Tutors: T. Erdogru, Istanbul (TR) 

T.R.W. Herrmann, Hanover (DE) 

L. Salomon, Creteil (FR) 

C. Schwentner, Tübingen (DE) 


Laparoscopic procedures are continuously evolving in urology based on the increasing expertise of urologic 

surgeons. This includes ablative procedures, such as radical nephrectomy as well as reconstructive 

techniques, such as pyeloplasty. Some advanced procedures (i.e. radical prostatectomy, radical cystectomy) 

have both, ablative and reconstructive steps. Since the number of centres with laparoscopic expertise is 

still limited in Europe, laparoscopic training programmes have become very important. Hands-on training 

courses at the pelvi-trainer represent one of the main steps of such courses. Finally, all remaining questions 

can be answered and discussed with all tutors including the demonstration of tips and tricks. 


Supported by an unrestricted educational grant from KARL STORZ GMBH & CO.KG and COOK MEDICAL 


371 

ESU & Hands-on



15.00 - 17.00 ESU/ESUT Hands-on training Transurethral Therapy of LUTS - Bipolar 

TURP course 1 






Chair: P.J. Conort, Paris (FR) 

Tutors: A. De La Taille, Creteil (FR) 

S. Gravas, Larissa (GR) 

A. Meneghini, Adria (IT) 


The European School of Urology (ESU) and the EAU Section of Uro-Technology (ESUT) offer an intensive handson 

training course with different models focussing on the endoscopic management of LUTS. The delegates 

will be taken through a sequential programme of Bipolar TURP using normal endoscopic instruments in 

different models. A video demonstrating the different steps and tasks of the procedures will be presented 

and afterwards the delegates will be instructed according to their level of experience in small teams at 

the models. Finally, all remaining questions can be answered and discussed with all tutors including the 

demonstration of tips and tricks. 




09.00 - 11.00 ESU/ESUT Hands-on training Transurethral Therapy of LUTS - Bipolar 

TURP course 2 





Chair: R. Muschter, Rotenburg (DE) 

Tutors: V. Bucuras, Timisoara (RO) 




The European School of Urology (ESU) and the EAU Section of Uro-Technology (ESUT) offer an intensive handson 

training course with different models focussing on the endoscopic management of LUTS. The delegates 

will be taken through a sequential programme of Bipolar TURP using normal endoscopic instruments in 

different models. A video demonstrating the different steps and tasks of the procedures will be presented 

and afterwards the delegates will be instructed according to their level of experience in small teams at 

the models. Finally, all remaining questions can be answered and discussed with all tutors including the 

demonstration of tips and tricks. 




373 

ESU & Hands-on



12.00 - 13.30 ESU/ESUT/EULIS Hands-on training Ureterorenoscopy course 1 






Chair: P.J. Osther, Fredericia (DK) 

Tutors: A. Breda, Barcelona (ES) 

G.G. Giusti, Basiglio (IT) 



The European School of Urology (ESU), the EAU Section of Uro-Technology (ESUT) and the EAU Section 

of Urolithiasis (EULIS) offer an intensive hands-on training course with different models focussing on the 

endoscopic management of urolithiasis. The delegates will be taken through a sequential programme of 

Ureterorenoscopy using normal endoscopic instruments in different models. The use of various guide-wires, 

baskets and intracorporeal lithotripters will be demonstrated. The ESUT and the EULIS faculty consist of 

experienced surgeons in the field of Ureterorenoscopy. A video demonstrating the different steps and tasks 

of the procedures will be presented and afterwards the delegates will be instructed according to their level 

of experience in small teams at the models. Finally, all remaining questions can be answered and discussed 

with all tutors including the demonstration of tips and tricks. 




14.00 - 15.30 ESU/ESUT/EULIS Hands-on training Ureterorenoscopy course 2 





Chair: O. Traxer, Paris (FR) 

Tutors: C. Scoffone, Orbassano (IT) 

A. Skolarikos, Athens (GR) 

D. Teber, Heidelberg (DE) 


The European School of Urology (ESU), the EAU Section of Uro-Technology (ESUT) and the EAU Section 

of Urolithiasis (EULIS) offer an intensive hands-on training course with different models focussing on the 

endoscopic management of urolithiasis. The delegates will be taken through a sequential programme of 

Ureterorenoscopy using normal endoscopic instruments in different models. The use of various guide-wires, 

baskets and intracorporeal lithotripters will be demonstrated. The ESUT and the EULIS faculty consist of 

experienced surgeons in the field of Ureterorenoscopy. A video demonstrating the different steps and tasks 

of the procedures will be presented and afterwards the delegates will be instructed according to their level 

of experience in small teams at the models. Finally, all remaining questions can be answered and discussed 





375 

ESU & Hands-on



09.00 - 10.30 ESU/ESUT Hands-on training in Transurethral therapy of LUTS - 

Green light laser course 1 






Chair: O. Reich, Munich (DE) 

Tutors: G.J. Alivizatos, Athens (GR) 

F. Gomez Sancha, Madrid (ES) 

F. Schiefelbein, Wurzburg (DE) 


The European School of Urology (ESU) and the EAU Section of Uro-Technology (ESUT) offer an intensive 

hands-on training course with different models focussing on the endoscopic management of LUTS. The 

delegates will be taken through a sequential programme of Green-light-laser vaporisation using normal 

endoscopic instruments in different models. A video demonstrating the different steps and tasks of the 

procedures will be presented and afterwards the delegates will be instructed according to their level of 

experience in small teams at the models. Finally, all remaining questions can be answered and discussed 



Supported by an unrestricted educational grant from AMERICAN MEDICAL SYSTEMS








Chair: T. Sulser, Zürich (CH) 

Tutors: A. Skolarikos, Athens (GR) 

U. Witzsch, Frankfurt am Main (DE) 

TBD 










Supported by an unrestricted educational grant from AMERICAN MEDICAL SYSTEMS 


377 

ESU & Hands-on










Chair: A. Bachmann, Basel (CH) 

Tutors: N. Barber, Canterbury (GB) 

S. Carl, Emmendingen (DE) 











Supported by an unrestricted educational grant from AMERICAN MEDICAL SYSTEMS


Sponsored Session 

16.00 - 17.30 Guiding lights and rising stars: Present and future directions in RCC 

and CRPC 


Symposium 

Chairs: T. Eisen, Cambridge (GB) 


Welcome and introduction 


Guiding lights in mRCC: Current treatment options 


Adjuvant therapy for RCC: Light on the horizon? 

T. Eisen, Cambridge (GB) 

Q&A session: RCC 

Current challenges in treating CRPC 


A multidisciplinary approach to treating CRPC: A radiation oncologist’s perspective 

S. Nilsson, Stockholm (SE) 

Rising stars: Innovations in treating bone metastases in CRPC 

C. Parker, Sutton (GB) 

Q&A session: CRPC 

Summary and close 

T. Eisen, Cambridge (GB) 


The treatment of metastatic renal cell carcinoma (mRCC) and castrate-resistant prostate cancer (CRPC) has 

progressed substantially in recent years: targeted therapies are now a mainstay of mRCC treatment, and 

there have been considerable advances in the management of CRPC. With so many agents available and 

several more in clinical development, the challenge is how best to use these therapies in clinical practice, 

in order to achieve the optimal patient outcomes. Against this backdrop, a faculty of experts will discuss 

treatment options and strategies to manage mRCC and CRPC, both now and in the future. The panel will 

evaluate the potential of targeted agents in the adjuvant setting in locally advanced RCC, and will discuss the 

need for additional therapies to treat CRPC, with emphasis on the emerging role of novel agents. 

Sponsored by BAYER HEALTHCARE 


379 

Sponsored Sessions

Sponsored Sessions 




16.00 - 17.30 Cryo - a true minimally invasive treatment: Current evidence and 

future development 


Workshop 


Welcome 


Salvage cryo - an alternative to hormone treatment after radiation failure? 


The key question in prostate cancer: Active surveillance or focal therapy in low risk disease? 

D. Greene, Sunderland (GB) 

How to do it - ensuring a safe learning curve and proctoring programme for cryoablation 

U. Witzsch, Frankfurt am Main (DE) 

The future of focal therapy: MRI based diagnosis and focal cryoablation 

J. Barentsz, Nijmegen (NL) 


Summing up and close 



The workshop will provide an up-to-date discussion of the evidence for using cryoablation in prostate cancer; 

as salvage treatment, as true primary total and as experimental focal treatment. Special focus will be set on 

salvage cryoablation as an alternative to early hormone treatment after radiation therapy failure, and on the 

role of focal treatment versus active surveillance in low risk disease. 

Upon the completion of the workshop, the delegate should understand the role and technique of cryoablation 

as a true treatment alternative in prostate cancer. The delegate will also have obtained a view of what will be 

the future in MRI guided diagnosis and true focal treatment of prostate cancer. 

Sponsored by GALIL MEDICAL



16.00 - 17.30 5mm HD and 3D - What does the future hold in MIS? 


Symposium 

Chairs: J-U. Stolzenburg, Leipzig (DE) 

Introduction 


HD - The next generation 

3D a milestone 

3D video 

3D nerve sparing EERPE 


3D in complex laparoscopic procedures 


3D basics and future: What is possible in the medical and consumer world 

Discussion 


Introducing the first clinical experiences with 3D and discussing the changes in laparoscopic training while 

it advances. 

Sponsored by OLYMPUS 


381 

Sponsored Sessions





17.45 - 19.15 Case-based update on the optimal management of bone metastases 

from prostate cancer 


Symposium 

Chair: M.R. Smith, Boston (US) 

An innovation in bone-targeted therapy for clinical practice 

M.R. Smith, Boston (US) 

Expert opinion on clinical challenges in the management of bone metastases 

A. Briganti, Milan (IT) 

S. Oudard, Paris (FR) 


Is prevention of bone metastases possible? 

M.R. Smith, Boston (US) 


The aim of this educational symposium is to examine the potential of bone-targeted therapies for the 

treatment of bone metastases from prostate cancer. Patient case studies will be used to illustrate and address 

common questions and challenges faced by urologists treating patients with bone metastases in the clinic. 

Prostate cancer is one of the tumour types most likely to metastasise to bone, with potentially serious and 

debilitating consequences known as skeletal-related events (SREs). SREs (radiation to bone, pathological 

fracture, spinal cord compression, and surgery to bone) represent a major burden, being associated with 

morbidity and decreased quality of life as well as substantial health resource utilisation. 

Underlying SREs are pathological changes in the bone and, in particular, a disruption in the normal balance 

of bone remodelling. When tumour cells metastasise to bone, changes in the bone microenvironment can 

result in a ‘vicious cycle’ of bone destruction and tumour growth. Denosumab inhibits RANK Ligand which 

blocks the formation, function and survival of bone-resorbing osteoclasts - a key step in this ‘vicious cycle’. 

Data from three pivotal studies have demonstrated that RANK Ligand inhibition with denosumab significantly 

delays time to first SRE and reduces the total number of SREs compared with the standard of care, zoledronic 

acid, in patients with bone metastases from solid tumours, including prostate cancer. 

With the recent European approval of denosumab 120 mg every 4 weeks for prevention of SREs in adults with 

bone metastases from solid tumours, now is a timely opportunity to explore clinical challenges and decisions 

faced by urologists treating prostate cancer patients with bone metastases. The case-based experience 

exchange session will aim to answer common clinical questions on the use of bone-targeted therapies such 

as which agent to use, when to start, practicalities of administration, and special considerations for patients 

with comorbidities. 

An important clinical question is whether earlier use of bone-targeted therapies can prevent tumour 

metastasis to bone. A recent Phase III study in men with castration-resistant prostate cancer at high risk 

of bone metastases demonstrated that denosumab significantly prolonged bone metastasis-free survival vs 

placebo. The final, forward-looking presentation will provide an update on this topic. 

Sponsored by AMGEN



17.45 - 19.15 OAB: New solutions for an old challenge 


Symposium 

Chair: W. Artibani, Verona (IT) 

Chairman’s introduction 


Patient pictures 

C. Kelleher, London (GB) 

Debate: Diagnostic tools: Old vs new 


Debate: Diagnostic tools: Old vs new 

M.J. Speakman, Taunton (GB) 

Prescribing choices for the future 


Panel discussion 


This satellite symposium proposed by Astellas offers a programme that will explore future trends and 

opportunities in the treatment of OAB; a therapy area that in recent years has received increasing recognition 

for its impact on patients’ quality of life. The programme will examine recent clinical and market research, 

identifying different patient populations with the aim of understanding their respective needs. This will be 

followed by an interactive session focussing on diagnostic tools, considering how effective use of current 

and prospective techniques could have a positive impact on patient outcomes for the future. The symposium 

will conclude by reviewing the latest scientific evidence regarding the pathophysiology of OAB in order to 

understand how current prescribing options could be maximised to good effect. It will also look at new 

prescribing agents on the horizon, which may further add to the urologist’s armamentarium for treating OAB 

patients. This symposium seeks to include cutting edge research, the latest scientific knowledge and a faculty 

of leading minds in international urology. 

Sponsored by ASTELLAS 


383 

Sponsored Sessions





17.45 - 19.15 The longer the better: Treatment of BPH symptoms with Serenoa 

repens (safety and efficacy) 


Symposium 

Chair: F.M.J. Debruyne, Arnhem (NL) 

Introduction 


How can the mechanism of action of Serenoa repens be explained? 

P.A. Geavlete, Bucharest (RO) 

Outcomes of 1, 2 and 3 year studies conducted with Prostamol uno 

J. Breza Sr., Bratislava (SK) 

Safety profile - an important topic especially for younger BPH sufferers 


Progression of BPH symptoms in patients with and without treatment 

A.Z. Vinarov, Moscow (RU) 

Close 



BPH is a progressive and protracted disorder requiring continuous treatment that is well-tolerated. Several 

pharmacological treatment options are currently available to urologists when choosing appropriate therapy 

for LUTS symptoms associated with BPH. 

During this interactive satellite symposium, a faculty of experts will present an overview of current evidence 

focusing on Serenoa repens and its efficacy, tolerability and suitability for long-term use. Discussion will 

be based on the results of recent studies intended to illustrate the value of Serenoa repens for treating BPH 

symptoms in the daily practice of urologists from a wide range of countries. 

Sponsored by BERLIN CHEMIE AG/MENARINI



17.45 - 19.15 Reviving naturalness - ED management then and now 


Symposium 


Human sexual behaviour - Timeless? 

Discussion 

Relentless - Experts’ appraisal on current management of ED 

Discussion 

Future of ED treatment - Dimensionless? 

Discussion 

Closing commentary 


The Eli Lilly satellite symposium ‘Reviving naturalness – ED management then and now’ will provide insights 

into the cultural differences of human sexual behaviour, the age-dependent habits in the course of time and 

the cultural, social and medical reasons behind the habits. 

The faculty will reflect on the development of medical therapeutic options for the treatment of erectile 

dysfunction (ED), aspects of effectiveness and safety as well as the impact of the respective treatments on 

affected men’s and couples’ (sexual) quality of life. 

An outlook will be given on the research and development of non-pharmacological approaches restoring 

erectile function. 

Sponsored by ELI LILLY AND COMPANY 


385 

Sponsored Sessions





17.45 - 19.15 Nocturia with nocturnal polyuria now and in the future 


Symposium 

Chair: P.E. Van Kerrebroeck, Maastricht (NL) 


P.E. Van Kerrebroeck, Maastricht (NL) 

State of the art in nocturia 

J. Weiss, New York (US) 

The impact of nocturia 

N. Stanley, Norwich (GB) 

Future research directions in nocturia 

C. Graugaard-Jensen, Aarhus N (DK) 

Panel discussion 


This Ferring Pharmaceuticals sponsored symposium aims to provide an overview of nocturia and its impact 

on patient wellbeing, and to explore what the future might hold for patients with this highly bothersome – 

and increasingly prevalent – condition. The symposium will: 

Summarise what we have learned about the aetiology and pathophysiology of nocturia to date and how 

unmet needs for efficient nocturia treatments have driven scientific research (Jeffrey Weiss, USA) 

Review how sleep disturbance impacts on patients with nocturia (Neil Stanley, UK) 

Provide an overview of current clinical research in nocturia and potential future directions in important areas 

of research for this condition (Charlotte Graugaard Jensen, Denmark). 

Sponsored by FERRING PHARMACEUTICALS



17.45 - 19.15 Evidence and rationale for initial treatment of patients with 

symptomatic BPH at risk of progression 


Symposium 

Chair: M. Emberton, London (GB) 

Session outline 


Insights from 5ARI studies on high grade prostate cancer and PSA management 

G. Andriole, St. Louis (US) 


Management of BPH with combination therapy: Rationale and the latest evidence in perspective 


Implications for day-to-day BPH management 

Q&A Session 


As part of the landmark 27th Annual EAU Congress, GlaxoSmithKline will support a satellite symposium 

titled ‘Evidence and rationale for initial treatment of patients with symptomatic BPH at risk of progression’. 

The evidence based supporting doctors’ choice of optimal medical management of men with BPH has evolved 

considerably over recent years. The first presentation of this symposium will put into perspective high grade 

prostate cancer findings from major 5ARI studies as well as highlighting a new approach to monitoring PSA 

to optimize the detection of prostate cancer in men treated for BPH. 

In the following presentation, the faculty will review the evidence from large controlled clinical trials of 5ARI 

+ alpha-blocker combination therapy as an initial medical treatment in men with BPH symptoms at risk of 

disease progression 

The symposium will conclude with a discussion on the impact for day-to-day clinical practice of the new 

evidence and recommendations. 

Sponsored by GLAXOSMITHKLINE 


387 

Sponsored Sessions





17.45 - 19.15 Moving forward in prostate cancer: Hormones and beyond 


Symposium 

Chair: C-C. Abbou, Creteil (FR) 

Introduction: Prostate cancer: A lethal disease for some patients. How to identify, what are the options? 


Localised prostate cancer: Which options for patients with high risk profile? 

N. James, Birmingham (GB) 

New insights into tumour biology - preliminary results 


Castrate resistant prostate cancer: Established and evolving treatment paradigm - hormones and beyond 

A. Armstrong, Durham (US) 


Chaired by Prof. Claude Abbou (France), this symposium discusses current practice and future developments 

in prostate cancer management. A review of clinical evidence in the management of high-risk prostate 

cancer is presented by Prof. Nicholas James (UK), including clinical practice and management guidelines 

and with particular reference to node-positive (N1) disease. Prof. Luis Martínez-Piñeiro (Spain) provides 

an update on advances in the use of biomarkers to define aggressive disease, describing recent data on 

PCA3 and TMPRSS2-ERG gene fusion biomarkers in hormone-naïve patients with metastatic disease. Prof. 

Andrew Armstrong (USA) discusses mechanisms for development of castrate-resistant prostate cancer and 

how, beyond hormone therapy, cancer progression may be halted. At a time of exciting advancements in the 

management of prostate cancer, an informative and stimulating discussion is promised. 

Sponsored by IPSEN



17.45 - 19.15 Confronting the challenges of Tuberous Sclerosis Complex: Strategies 

for treatment and management of associated angiomyolipomas 


Symposium 


J.R. Sampson, Cardiff (GB) 

Presentation of significant advances in the understanding of the cell biology of renal lesions from patients 

with TSC, and recent results from clinical trials 

J.J. Bissler, Cincinnati (US) 

Clinical aspects of TSC renal disease: Pharmacological and surgical interventions: TSC renal cystic disease 


Clinical aspects of TSC renal disease: Pharmacological and surgical interventions: TSC-associated renal 

AMLs 

J.J. Bissler, Cincinnati (US) 

Clinical aspects of TSC renal disease: Pharmacological and surgical interventions: Fat-poor renal lesions 

C. Kingswood, Brighton (GB) 

Targeted therapy: New agents on the horizon for TSC renal involvement 

M.H. Shen, Cardiff (GB) 

Current therapies vs mTOR inhibition: Virtual patient case presentation 

How do we improve multidisciplinary collaboration to optimise the management of patients with sporadic 

and TSC-associated renal AML? 

C. Kingswood, Brighton (GB) 

Expert panel discussion 

Close 


Sponsored by NOVARTIS 


389 

Sponsored Sessions





17.45 - 19.15 The guidelines offer more than antibioprophylaxis to manage 

recurrent urinary tract infections 


Symposium 

Chair: K.G. Naber, Straubing (DE) 

Bacterial resistance and safety issues in UTI management and prevention 

J. Garau, Barcelona (ES) 

Alternative strategies in the EAU guidelines for the prophylaxix of uncomplicated cystitis: A rationale 

B. Wullt, Lund (SE) 

The immunotherapy with OM-89 reduces the need of antibiotics: Clinical evidence and consequence in daily 

practice 

K.G. Naber, Straubing (DE) 


Uncomplicated urinary tract infections (UTIs), especially cystitis in women, are very common and impose 

a substantial disease burden worldwide. While acute episodes can be successfully treated with timely and 

appropriate administration of antibiotics (ABs), they often fail to prevent recurrences; pathogenic bacteria 

re-establish and symptoms reappear within a few months. Use of ABs also for prevention can lead to new 

resistant strains due to a selective pressure. It becomes therefore crucial to use ABs prudently to delay the 

rise of bacterial resistance facing worldwide and spare them for acute and more serious infections of the 

urinary tract. The European Association of Urology (EAU) guidelines on urological Infections recommend 

antibioprophylaxis only when non-antimicrobial measures have failed. Among these, the immunoactive 

prophylaxis is a valid alternative. In particular bacterial lysates of Escherichia coli (OM-89) is the most 

developed and best studied non-antimicrobial prophylaxis and therefore recommended with a Grade B in 

the EAU guidelines. 

Sponsored by OM PHARMA



17.45 - 19.15 Innovation in laparoscopic robotics: The handheld Kymerax Robot – 

Benefits and clinical experience 


Workshop 

Chair: G. Janetschek, Salzburg (AT) 


Prof. Dr. Günter Janetschek, Director of the Department of Urology and Andrology at Paracelsus Medical 

University Salzburg, Austria will discuss the benefits of operating with Kymerax. He will share his technique 

of applying the articulating tip technology to perform surgical procedures with precision, mobility and 

automation unrivalled by conventional laparoscopy. 

While focusing on urologic procedures, the clinical experience Prof. Janetschek will share is applicable for all 

surgeons interested in using a handheld robotic instrument to perform gynaecologic, urologic and general 

surgical procedures. 

Sponsored by TERUMO 


391 

Sponsored Sessions





17.30 - 19.00 Injecting DIGNITY into your neurogenic detrusor overactivity (NDO) 

patient treatment paradigm - The role of botulinum toxin type A 


Symposium 

Chair: E. Chartier-Kastler, Paris (FR) 


E. Chartier-Kastler, Paris (FR) 

Outcomes in NDO - The DIGNITY Study with botulinum toxin type A 


Practical aspects of using botulinum toxin type A in NDO 

R. Hamid, London (GB) 

Clinical challenges in the management of NDO - Case study review 

K.P. Jünemann, Kiel (DE) 

Service models for managing NDO referrals 


Final remarks and meeting close 



- Communicate data for new therapeutic option in the treatment of NDO in multiple sclerosis (MS) and spinal 

cord injury (SCI) patients – the DIGNITY trial data with botulinum toxin type A 

- Emphasise current burden of disease with NDO and unmet needs 

- Demonstrate utilisation of botulinum toxin type A in clinical practice through interactive case studies 

- Emphasise importance of early recognition of NDO and early referrals to preserve QOL and ensure 

involvement of all members of the multidisciplinary team caring for the patient 

Sponsored by ALLERGAN



17.30 - 19.00 Revolution in the management of male LUTS? 


Symposium 

Chair: M.J. Drake, Bristol (GB) 

Introduction 


Management of male LUTS: Past, present and future 

A. De La Taille, Paris (FR) 

Unravelling the origin of voiding and storage LUTS for a better diagnosis 

S.G.G. De Wachter, Maastricht (NL) 

Liberating ideas on LUTS management: Treating storage symptoms in men 

M. Oelke, Hanover (DE) 

Discussion and closing remarks 



Lower urinary tract symptoms (LUTS) are a complex condition in ageing men. Despite high prevalence, the 

burden of LUTS remains relatively unrecognised. The current view of the urological community on various 

challenges in the management of male LUTS will be explored. During the symposium, guidance on best 

practice for diagnosing and treating men with LUTS will be given. New data will be presented on the 

treatment of LUTS patients with substantial storage symptoms. 



393 

Sponsored Sessions





17.30 - 19.00 New data on ADT for prostate cancer: What does it mean for your 

patients? 


Symposium 

Chairs: J. Irani, Poitiers (FR) 



J. Irani, Poitiers (FR) 


Joining forces: Androgen deprivation and radiotherapy 

M. Mason, Cardiff (GB) 

Continuous ADT: A hard habit to break? 


GnRH antagonists: Building the clinical profile 


When castration is not enough: New approaches 

N. Shore, Myrtle Beach (US) 

Concluding remarks 



To present the latest data on androgen deprivation therapy for prostate cancer, in a clinically meaningful way 

that will facilitate improved patient care. 

Sponsored by FERRING PHARMACEUTICALS



17.30 - 19.00 Non muscle invasive bladder cancer management in 2012: From 

recommendations to real life clinical practice 


Symposium 

Chair: D. Jacqmin, Strasbourg (FR) 

Chair’s welcome and introduction 


The importance of guidelines in bladder cancer management 


Patient management in real life setting 

Longer term follow up and patient impact 

M. Burger, Regensburg (DE) 

Panel discussion and closing remarks 



This symposium, led by a distinguished faculty, will allow delegates to consider the key challenges in bladder 

cancer management in 2012. The symposium will explore the issue of adherence to relevant guidelines and 

how these actually relate to everyday clinical practice. A review of the latest data from two important clinical 

trials will evaluate the role of Hexvix in today’s management of patients with bladder cancer, providing 

an understanding of what this means to the practising clinician and to their patients. There will be an 

opportunity for discussion and debate with the faculty. 

Sponsored by IPSEN/PHOTOCURE 


395 

Sponsored Sessions





17.30 - 19.00 Redefining treatment standards in metastatic castration-resistant 



Symposium 

Chair: K. Miller, Berlin (DE) 



The metastatic CRPC patient: What are the unmet clinical needs 

G.M. Ahlgren, Malmö (SE) 

Current perspectives on chemotherapy in metastatic CRPC 

M. De Santis, Vienna (AT) 

Expanding therapeutic options with novel androgen biosynthesis inhibitors in metastatic CRPC 

K. Fizazi, Villejuif (FR) 

Update on new non-chemotherapy agents in metastatic CRPC 


How are recent advances affecting daily clinical practice? A multidisiplinary panel discussion including a 

patient case 

Case presenter: A.S. Merseburger, Hanover (DE) 

Panel: G. Ahlgren, Malmö (SE) 


M. De Santis, Vienna (AT) 

K. Fizazi, Villejuif (FR) 


Close 


Sponsored by JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON


Workshop 

17.30 - 19.00 Holmium Laser Enucleation of the Prostate (HoLEP) -the true 

alternative to TURP and open prostatectomy 


Symposium 

Chairs: R.M. Kuntz, Berlin (DE) 

B. Lukacs, Paris (FR) 

Evolution of HoLEP 

T. Aho, Cambridge (GB) 

Safety and efficacy of HoLEP 

R.L.J. Naspro, Bergamo (IT) 

HoLEP experience in France: QUAPELLA -Quality of Prostate Enucleation with Lumenis Laser 

M. Fourmarier, Aix en Provence (FR) 

Financial aspects of HoLEP 

P. Miller, Redhill (GB) 

HoLEP learning curve 

S. Ahyai, Hamburg (DE) 

HoLEP tips and tricks 


Summary 

B. Lukacs, Paris (FR) 

Q & A 

Sponsored by LUMENIS 


397 

Sponsored Sessions





17.30 - 19.00 Sifting through the evidence in GU malignancies: A day in the clinic 


Symposium 

Chairs: B. Escudier, Villejuif (FR) 



B. Escudier, Villejuif (FR) 


Treatment sequencing and selection in mRCC: Case vignettes on optimising patient benefit 

T. Powles, London (GB) 

Treating with TKIs in mRCC: From resistance to resensitisation 

C. Porta, Pavia (IT) 

Improving bone-related outcomes in GU malignancies: Emerging role for bone-targeted therapies 

F. Saad, Montreal (CA) 

Interactive panel discussion 

Moderators: B. Escudier, Villejuif (FR) 



Goal: This symposium will incorporate interactive learning formats to discuss current treatment challenges in 

managing and treating GU malignancies, with an emphasis on improving patient outcomes. 

Objectives: 

- Compare and contrast the clinical evidence supporting different therapeutic sequences of targeted agents 

in patients with metastatic RCC 

- Explore mechanisms of resistance to VEGFr-TKIs and emerging clinical data on TKI resensitisation in 

metastatic RCC 

- Assess the role of bisphosphonate and other bone-targeted therapies in patients with bone metastases in 

GU malignancies 

Sponsored by NOVARTIS



17.30 - 19.00 Finding a way forward in OAB care 


Symposium 

Chair: I. Milsom, Gothenburg (SE) 

Introduction: Finding a way forward for patients with OAB/UUI 

I. Milsom, Gothenburg (SE) 

Importance of dose flexibility 

P. Ellsworth, Rhode Island (US) 

Tailoring care for your patients 

F. Haab, Paris (FR) 

Physician-patient interaction: A live demonstration 

Engaging patients: A way forward 

V. Khullar, London (GB) 

Q&A 


During this interactive Pfizer-sponsored satellite symposium, an international panel of experts will present 

developments in the treatment of overactive bladder (OAB) and urgency urinary incontinence (UUI), with a 

focus on the importance of physician-patient communication and increasing patients’ engagement in their 

treatment and management. 

The experts will discuss real-life practice, providing evidence of the potential benefits of individualised 

dosing and the importance of efficacy on bladder diary endpoints, such as UUI. The panel will also address 

other important goals of OAB treatment, such as improvements in health-related quality of life as measured 

by patient-reported outcome tools. 

This symposium will also address the significance of goal setting when managing patients with OAB/UUI and 

highlight the importance of an individualized or tailored approach to therapy. 

Sponsored by PFIZER 


399 

Sponsored Sessions





17.30 - 19.00 LUTS - BPH: From guidelines to the clinical practice 


Symposium 

Chair: C.R. Chapple, Sheffield (GB) 

Opening remarks 


Silodosin - a selective option 


A case of nocturia 

C. Llorente, Madrid (ES) 

M. Rouprêt, Paris (FR) 

A case of cardiovascular disease 

A. Govorov, Moscow (RU) 


A case of erectile dysfunction 

A. Petrolekas, Athens (GR) 

A. Salonia, Milan (IT) 

Round table and conclusions from the clinical cases 

Overall conclusions 



This symposium explores the role of silodosin, a novel alpha blocker for the treatment of BPH symptoms, and 

includes new pharmacological data relating to this highly selective compound. 

The faculty will present case studies which highlight the benefits seen with silodosin in LUTS/BPH patients 

and explore the link to its pharmacological properties. They will discuss the guidelines for appropriate 

management of LUTS/BPH patients, including alpha-blocker use as monotherapy in first line treatment, and 

in combination for patients with concomitant conditions. The faculty will also discuss their experience in 

these clinical situations. 

The audience will be encouraged to participate in these discussions and after the symposium they will be 

able to consider how silodosin might fit within their current clinical practice. 

Sponsored by RECORDATI



17.30 - 19.00 Optimising the management of senior adults with prostate cancer 


Symposium 

Chair: J.M. Fitzpatrick, Dublin (IE) 

Senior adults with prostate cancer: A call to action 

J.M. Fitzpatrick, Dublin (IE) 

Optimal curative therapy for localised prostate cancer in older men: Radical prostatectomy 

M. Graefen, Hamburg (DE) 

Optimal curative therapy for localised prostate cancer in older men: Radiation therapy 

H. Payne, London (GB) 

Management of advanced prostate cancer in senior adults in the new CRPC landscape 

M. Aapro, Genolier (CH) 

The importance of patient care in optimising treatment outcomes in senior adults 

F. Scotté, Paris (FR) 

Summary and close 

J.M. Fitzpatrick, Dublin (IE) 


- Instigate a call to action by reviewing current evidence that senior adults with localised prostate cancer 

are undertreated 

- Discuss curative treatment modalities for localised prostate cancer in senior adults 

- Review the evidence supporting the optimal risk/benefit profile of chemotherapy in senior adults with 


- Highlight the importance of individualised patient care in maximising outcomes for senior adults with 


Sponsored by SANOFI ONCOLOGY 


401 

Sponsored Sessions





17.30 - 19.00 Practical and live procedure workshop for managing patients with 

neurogenic bladder 


Workshop 

Chair: P. Denys, Garches (FR) 


P. Denys, Garches (FR) 

Neurogenic bladder: An overview 

A. Giannantoni, Perugia (IT) 

New avenue in the treatment of neurogenic bladder - botulinum toxin type A 

K. Everaert, Ghent (BE) 

Live demonstration - injecting botulinum toxin type A in the neurogenic bladder, using Bonee needle 

G. Karsenty, Marseille (FR) 

Practical insights for improving outcomes including needle selection 


Final remarks and meeting close 

P. Denys, Garches (FR) 


- Provide an overview of the phase III data for botulinum toxin type A in neurogenic detrusor overactivity 

(NDO) – the DIGNITY Study 

- Presentations of practical guidance on the use of botulinum toxin type A in clinical practice before and after 

the injection 

- Demonstration, via a live video link, of the botulinum toxin type A injection procedure in the bladder of 

patients with NDO 

- Discussions on appropriate needle selection to improve outcomes 

Sponsored by ALLERGAN and PORGES, a COLOPLAST Division



17.30 - 19.00 Back to the future with hormonal therapy for CRPC 


Symposium 

Chairs: N.W. Clarke, Manchester (GB) 

C.N. Sternberg, Rome (IT) 

G. De Meerleer, Ghent (BE) 


N. James, Birmingham (GB) 


A. Widmark, UmeÅ (SE) 


This symposium will focus on presentations and panel discussions addressing the current definition, 

epidemiology, and patient demographics of those with castration resistant prostate cancer (CRPC). Results 

of past, present and future hormonal therapy, symptomatic treatments and novel compounds for the 

management of CRPC will be discussed and debated by our panel of urologists, medical oncologists, and 

radiation oncologists. We plan an informative, interactive and insightful session for all those who care for 

CRPC patients. 



403 

Sponsored Sessions





17.30 - 19.00 GAGs therapy of urinary tract infections: Clinical and economic issues 


Symposium 

Chair: P.F. Bassi, Rome (IT) 

The scenario of urinary tract infections 

P.F. Bassi, Rome (IT) 

Urinary tract infections: An economic isue 

R. Tarricone, Milan (IT) 

The rationale of GAGs therapy in urinary tract infections 

M. Lazzeri, Milan (IT) 

Management of recurrent infections with IALURIL 

M. Romancik, Bratislava (SK) 

Final remarks 

P.F. Bassi, Rome (IT) 

Discussion 


Standard management of urinary tract infections (UTIs) includes continuous antimicrobial therapy, however 

non-antibiotic based prevention strategies are desirable. The positive outcomes obtained with a combination 

of hyaluronic acid and chondroitin sulfate, administered intravesically with the aim of restoring the integrity 

of the glycosaminoglycan (GAG) layer of the urothelium, in reducing the rate of UTIs in female patients 

with a history of recurrent infections, suggest that such therapeutic approach might be beneficial. Given 

the increased pressure for cost containment in healthcare systems a faculty of experts will discuss health 

resources utilization of women with recurrent UTIs and evaluate the implication of this therapeutic option. 

Sponsored by IBSA INSTITUT BIOCHIMIQUE SA



17.30 - 19.00 Focal treatment and quality of life: Localized prostate cancer 

Vascular Targeted Photodynamic (VTP) therapy with TOOKAD ® soluble 


Symposium 

Chairs: P. Scardino, New York (US) 


Welcome and opening remarks: The rationale for focal therapy of prostate cancer: A unique opportunity 

today 

P. Scardino, New York (US) 


Suitability of focal therapy for PSA-detected localized prostate cancer in the UK 


Urology evolving. The essentials of the Mechanism of Action of TOOKAD® Soluble: Exploring optimal 

treatment conditions by targeting the tissue’s vasculature 


Phase II Meta-analysis Data revealed on TOOKAD® Soluble and Long term follow-up: The new treatment 

option for the management of Low Risk Localized Prostate Cancer in the era of targeted therapies 


J. Trachtenberg, Toronto (CA) 

Urologists, minimally invasive therapy and targeted agents: Applying clinical evidence to clinical practice: 

The Phase III program 

TBC 

Establishing focal therapy on a firm foundation: Design of the US phase III clinical trial 

P. Scardino, New York (US) 

Panel discussion with question and answer session 


Different therapeutic approaches are currently applied to the different stages of tumour progression. Surgery 

or radiotherapy or focal treatments (cryoablation or HiFu) are usually employed at the early localised stage 

for removing the tumor and surrounding tissue. In the last decade a new therapeutic approach, aiming 

at the tumor vasculature has gained increasing use. TOOKAD® Soluble is the first-in-class Focal Vascular 

Occluding Agent (VOA) for a novel, focal therapeutic modality that enables ablation of the prostatic tumour 

tissue second to occlusion of the entire tumour vasculature in a few minutes of treatment. At the conclusion 

of this symposium, participants will gain new information on this molecule: TOOKAD® Soluble have a good 

understanding of the pharmacology, efficacy, safety and tolerability of the product as well as the Phase III 

protocols. 

Sponsored by STEBA BIOTECH 


405 

Sponsored Sessions

Saturday, 25 February 


08.30 - 10.30 Catheter management 


Chair: V. Geng, Lobbach (DE) 

08.30 - 08.50 History of catheterisation 

J. Mattelaer, Kortrijk (BE) 

08.50 - 09.10 Catheterisation: Insertion and removal procedure of urethral and suprapubic 

M. Vandewinkel, Malle (BE) 

09.10 - 09.30 Care of the catheter: What is the evidence? 

V. Geng, Lobbach (DE) 

09.30 - 09.50 Bladder washout, instillation and irrigation 

M. Gea-Sánchez, Lleida (ES) 

09.50 - 10.10 Indwelling catheter and prevention of urinary tract infection 

S.V. Lauridsen, Copenhagen (DK) 

10.10 - 10.30 Practices and nurse’s knowledge and skills concerning indwelling catheterisation in specialised healthcare 

S. Salomaa, Lahti (FI) 


In the pre-congress workshop catheter management we want to give some insights into the content of the 

new EAUN Evidence-based Guidelines for Best Practice in Health Care about indwelling catheters. 

The participants should: 

- Learn about the history of catheterisation 

- Learn about the procedures from insertion, removal as well as care of the catheters, bladder washouts and 

instillations 

- Know the risk of urinary tract infection (UTI) in combination with indwelling catheters as well as the 

prevention of UTI 

- Hear about nursing knowledge and catheterisation 


407 

EAUN Meeting

EAUN Meeting 




08.30 - 10.30 Urodynamics 


Chair: U.L.M. Haase, Nieuwegein (NL) 

08.30 - 09.05 Standard and advanced evaluation and interpretations 

W. Schaefer, Pittsburg (US) 

09.05 - 09.40 Case study 

J. Groen, Rotterdam (NL) 

09.40 - 10.15 Ambulatory and video-urodynamics 

D.A.W. Janssen, Nijmegen (NL) 



Urodynamic testing provides extremely valuable and useful information for the care of urologic patients with 

voiding dysfunction, however it can be daunting to perform and interpret. This EAUN workshop will take the 

participant through an overview of the process from set up to interpretation. 

Objectives: 

- Focus on the importance of Urodynamics in Urology diagnosis. 

- Highlight the importance of correct training to carry out this test. 

- Expose participants to the practical aspects of set up. 

- Demonstrate case studies to “pull it all together” 

- Provide attendess with a chance to ask questions.



11.00 - 13.00 Optimisation of peri-operative care in advanced bladder cancer 

surgery 


Chair: S. Hieronymi, Frankfurt am Main (DE) 

11.00 - 11.20 Approaching the cystectomy pathway 

K. Olsen, Hjortshøj (DK) 

I. Søndergaard, Århus N (DK) 

11.20 - 11.40 Importance of nutritional status and measurements 

M. Borre, Århus N (DK) 

11.40 - 12.00 Pre and post-operative exercise; The Danish training approach 

P. Eriksen, Århus N (DK) 

12.00 - 12.20 Pre-operative stoma care 

B. Kiesbye, Risskov (DK) 

12.20 - 12.40 Post-operative follow up (cancer follow up) 

I. Søndergaard, Århus N (DK) 



Objectives: To introduce the audience to fast-track pathways in urology practice 

- To understand the main principles in a fast-track concept 

- Update the audience on evidence based segments in the cystectomy pathway that can possibly improve 

patient-outcomes 

- Ask the question every day; “what matters and what is the matter?” and why is the patient still on the 

ward? 


409 






11.00 - 13.00 Incontinent patients - Transfer from hospital to home care and back 


Chair: B.T. Jensen, Århus (DK) 

11.00 - 11.30 Optimising the connection between primary and secondary sector for the benefit of the incontinent patient 

A. Christensen, Taastrup (DK) 

11.30 - 12.00 Economic aspects of healthcare 

R. De Graaff, Heemstede (NL) 

12.00 - 12.50 The transition of incontinent patients in my country: 

12.00 - 12.10 Danish experience 

A. Vestermark, Hjørring (DK) 

12.10 - 12.20 Irish experience 

M. Power, Galway (IE) 

12.20 - 12.30 Belgian experience 

R. Pieters, Ghent (BE) 

12.30 - 12.40 Austrian experience 

D. Mair, Innsbruck (AT) 

12.40 - 12.50 Estonian experience 

I. Persidski, Tallin (EE) 



Objectives: To improve the transition between hospital and homecare settings to secure the rehabilitation 

for the incontinent patient 

- An approach to optimise the cooporation between primary and secondary sector managing incontinence 

- Introduce the audience to the significant relation between incontinence and socio-economics aspects in 

society. 

- Inform the audience about the huge diversity in Europe on how to support the incontinent patient.



13.15 - 14.15 Optimising care for bladder cancer patients 


Symposium 

Chair: F. Charnay-Sonnek, Strasbourg (FR) 

13.15 - 13.20 Welcome and introduction 

F. Charnay-Sonnek, Strasbourg (FR) 

13.20 - 13.35 The burden of bladder cancer: A patient perspective 

K. Chatterton, London (GB) 

13.35 - 13.55 Improving patient outcomes 

C.J. Bunce, Barnet (GB) 

13.55 - 14.10 The role of the nurse in optimising patient care 

R.N. Knudsen, Århus N (DK) 

14.10 - 14.15 Panel discussion and closing remarks 

Sponsored by IPSEN & PHOTOCURE 


411 






14.30 - 15.00 Nursing solutions in difficult cases: Case studies 


Chair: S.V. Lauridsen, Copenhagen (DK) 

14.30 - 14.40 DC12-01: Parasitic infestation in the urologic patient 

N. Love-Retinger, New York (US) 


14.45 - 14.55 DC12:-02: Penile cancer: Treatment of lymphoedema after removal of lymph nodes 

M. Johansen, Copenhagen (DK) 



14.30 - 15.15 State-of-the-art lecture: Cystectomy and bladder reconstruction: The 

nurse’s role in France 


A. Daif, Suresnes (FR) 

N. Kouzmina, Suresnes (FR) 


- To highlight the importance of the nurses’s role before and after a cystectomy and bladder reconstruction 

- To introduce the nurse consultation to the audience 

- To focus on the advantages of having a well-informed patient (advantages for the patient and for nurses) 

EAUN Opening Ceremony 

15.15 - 15.30 EAUN Opening Ceremony 



K. Fitzpatrick, Dublin (IE)



15.30 - 15.45 Evidence-based Guidelines for Best Practice in Health Care: 

Catheterisation - Indwelling catheters in adults, urethral and 

suprapubic - Introduction of the new EAUN guideline 


S.V. Lauridsen, Copenhagen (DK) 


The aim of this session is to present the new guideline on “Catheterisation - Indwelling catheters in adults, 

urethral and suprapubic” and to explain how this evidence-based guideline was developed. The guideline 

presents the newest knowledge regarding care of the indwelling catheter and during this session some 

highlights will be presented. We will also address how nurses can use this guideline in daily practice. 


413 






16.00 - 17.00 The practical and motivational side of teaching men intermittent 

catheterisation: A workshop naming the challenges met while 

teaching men intermittent self-catheterisation 


Symposium 

Chair: B.T. Jensen, Århus (DK) 

Panel: 

E. Chappel, Essex (GB) 

J.T. Marley, Portadown (IE) 

A. Vestermark, Hjørring (DK) 


The main objective of this workshop is to address the psychological and motivational aspects of teaching 

men intermittent self catheterisation via a combination of lecture, cases and discussion building upon theory 

and demonstration. 

The workshop begins with a short review of the theory supporting Clean Intermittent Catheterisation (CIC) 

and a demonstration of how to teach CIC by using a catheterisation model and a SpeediCath® Compact male 

catheter. The workshop is devoted to guiding the audience towards a successful outcome when teaching 

CIC. 

Welcome Reception 

17.00 - 18.00 Welcome Reception 

Foyer Bordeaux - Level 3 

Sponsored by COLOPLAST AS 

The welcome reception is only accessible for delegates who are registered for the 13th EAUN Meeting 

The Welcome Reception is sponsored by COLOPLAST AS and the EAUN

Sunday, 26 February 

Sponsored Workshop 

08.30 - 10.30 Safety in urinary catheterisation. Transurethral and suprapubic 

drainage 


Challenges in reducing high urinary nonsocomial infection rate 

W. Vance, Beelitz-Heilstatten (DE) 

Discussion 

Safe maintenance of transurethral and suprapubic catheters 

M. Rew, Sheffield (GB) 

Discussion 

Safety approach in suprapubic percutaneous catheterisation 

C. Kümmel, Göttingen (DE) 

Discussion 

A new approach for urinary nosocomial infection reduction with single catheterisation 

P. Van De Poel, Sittard (NL) 

Discussion 


Welcome to the B.Braun session, with a unique safety concept in urinary catheterisation. The aim is to 

provide to patients and healthcare professionals global solutions to prevent Urinary Tract Infection in urinary 

catheterisation. Following the latest guidelines this workshop will give an overview about safety procedures 

including the challenges in reducing urinary nosocomial infection rates. The treatment of choice with a new 

approach in single catheterisation, the safety concerns in suprapubic percutaneous catheterisation and the 

self-maintenance of indwelling and suprapubic catheters will then be reviewed. The positionning of the 

respective procedures will be completed and discussed with healthcare professionals. 

Sponsored by B.BRAUN 


415 






08.30 - 09.30 Understanding principles, side effects and their management in 

targeted therapies for metastasised Renal Cell Cancer (mRCC), a new 

challenge for urology nurses 


L. Wood, Cleveland (US) 


Aims: To provide urology nurses with information regarding the principles of targeted therapy in renal cancer 

and the management of side effects associated with these therapies. 

Objectives: 

- Identify current and investigational therapies used to treat renal cell carcinoma. 

- Discuss nursing management strategies for treatment-related side effects associated with therapies for 

renal cell carcinoma. 

09.30 - 10.00 EAUN Fellowships: Everything you always wanted to know about 

fellowships 


Chair: S. Vahr, Copenhagen (DK) 

09.30 - 09.40 Host experience 

W.M. De Blok, Amsterdam (NL) 

09.40 - 09.50 Fellow experience 

S.J. Borg, B’kara (MT) 



The EAUN fellowship programme is a programme especially developed for nurses. With this programme it 

is possible to find out what is going on in other clinics concerning urology nursing. “Fellows” and “hosts” 

that have participated in the EAUN fellowship programme will present their experiences. Willem de Blok, 

Netherlands Cancer Institute (NVI-AKL), will present his experience as host for the fellowship of Mr. Bruce 

Turner who visited the NKI-AVL in 2009 and Mrs. Bente Thoft Jensen (and 2 colleagues) in 2011. Simon Borg 

will present his experience as fellow in the Homerton Hospital NHS Foundation Trust in London in 2011. There 

will be ample opportunity to ask questions, bring forward hindrances and propose new possibilities for this 

programme. The EAUN board would like to adapt to the needs of the members to ensure the members will 

benefit fully of this opportunity to exchange knowledge and develop daily practice.



11.00 - 13.00 Shopping for tools to optimise nursing care in cancer patients 


Exercise for the cancer patient 

F. Dimeo, Berlin (DE) 

Erectile dysfunction in prostate cancer 

W. Hurn, Bristol (GB) 

Spinal cord compression 

H.A.M. Van Muilekom, Leiden (NL) 

The importance of nutrition in the cancer patient 

M. Borre, Århus N (DK) 


The Market Place Session key objectives are to explore with nurses some of the wider aspects of cancer 

related issues for patients, the causes, diagnostic and assessment approaches and offer practical tools to 

allow nurses to address these issues, in order to help optimise patient care. 

To achieve these goals, the Market Place Session will involve 4 workshops that will run in parallel, with each 

speaker delivering an interactive presentation for 20 minutes, followed by 10 minutes of audience discussion. 

Delegates will rotate between the 4 speakers. 

The sessions will aim to encourage questions and discussion with the nursing audience, sharing knowledge 

and learning between urology nursing colleagues where the potential for clinical development and education 

within their own clinical areas can be considered. 


417 





ESU Course 1 

11.00 - 13.30 Writing an abstract, making a poster 


Chair: N. Suardi, Milan (IT) 

Faculty: J.T. Marley, Portadown (IE) 

N. Suardi, Milan (IT) 


How to write an abstract 


How to make a poster 


Closing remarks – Take home messages 


The course will enable the participants to write an abstract according to the EAU standards as well as to 

prepare a poster to clearly illustrate the results of a scientific study. The course will explain how to structure 

an abstract in its different parts (introduction, materials and methods, results and conclusion). Finally, 

examples of good and bad posters will be shown and discussed.



14.00 - 14.30 State-of-the-art lecture: Innovative interactive multimedia techniques 

in urology care - A big step forward or still one step too far? 


M. Vesterby, Silkeborg (DK) 


A Danish Model for Healthcare Innovation: “How to Make a Hippopotamus Jump” 

In this talk, you will be presented with the stories, experiences and results of an innovation project, which 

took place at the hospital and at the homes of patients. The goal has been to create solutions for needs that 

were identified during fast track procedures for orthopedic patients. The project tried to minimise anxiety for 

the patients and their caregivers/support persons and helped put the combination of pre-operative resources, 

patient empowerment, and Information and Communication Technology (ICT) on the agenda in the Danish 

Healthcare sector. The project has resulted in new procedures for education of patients and support persons. 

These procedures have given the involved departments a significant cost reduction and are now spreading to 

other areas of treatment and hospitals in Denmark and abroad. You will be presented with a brief summary 

of the use of ICT in the healthcare sector today and what to expect in the future. You will also hear about one 

method for creating the space and means for revolutionary innovation in the healthcare sector, i.e. making 

the hippo jump, based on an interdisciplinary model for innovation with a holistic approach. 


419 





ESU Course 2 

14.00 - 16.30 Urinary infections 


Chair: H.M. Çek, Istanbul (TR) 

UTI (microbiology, resistance issues, antibiotics) 


Healthcare associated infections in urology (including infections acquired during hospital stay, outpatient 

procedures, long term healthcare facilities and treatment at home) 

H.M. Çek, Istanbul (TR) 

Coffee break 

Catheter care in urological practice and in general practice 

M.E. Jacob, Dublin (IE) 

Urosepsis (as a serious complication of healthcare associated infections; early signs of urosepsis and initial 

management of urosepsis) 


Clinical cases



14.45 - 16.30 Poster Session 


Chairs: V. Geng, Lobbach (DE) 

S. Hieronymi, Frankfurt am Main (DE) 

p1 Optimising intravesical therapy in octogenarians with non-muscle invasive bladder cancer 

K. Chatterton, S. Amery, G. Zisengwe, A. Mukwahuri, J. Kinsella, T.S. O’Brien, F. Dickinson (London, United 

Kingdom) 

p2 Development of an evidence based central hospital Bladder Catheterisation Protocol 

J.G.L. Cobussen-Boekhorst, A. Pacilly, I. Kwaaitaal (Nijmegen, The Netherlands) 

p3 Evidence based guideline for urinary catheterization, selection of catheter type, meatal cleansing and 

selection of fluid in the catheter balloon in adult persons admitted to hospitals or outpatient clinics 

B.R. Villumsen, H. Bro, B.M. Pedersen, M. Svejstrup, S. Lomborg (Holstebro, Viborg, Herning, Denmark) 

p4 Comparison of hydrogen peroxide dressing combined with povidone iodine versus povidone iodine alone 

in the management of Fournier’s gangrene 

A. Wanzam, M. Gyereh, A. Afoko (Tamale, Ghana) 

p5 Nurse specialist assisting in robotic surgery 

J. Petersson, B.S. Laursen (Aalborg, Denmark) 

p6 Use of clean intermittent catheterization (CIC) in the control of hospital acquired infections following 

prolonged use of indwelling urinary catheters 

M. Gyereh, E. Yahaya, A. Wamzam, A. Afoko (Tamale, Ghana) 

p7 Proactive management of patients with bone metastases secondary to urological malignancies: Best 

practice and useful tools 

L. Drudge-Coates, T. Jensen (London, United Kingdom; Århus, Denmark) 

p8 Significance of nursing measuring nutritional status in cystectomy patients, a retrospective analysis 

N. Love-Retinger, M. Borre, M. Kent, D. Sjoberg, G. Dalbagni, B. Thoft Jensen (New York, United States of 

America; Århus, Denmark) 

p9 The role of the surgical nurse in the surgery of living donors’ kidney 

G. Viladomat, I. Pueyo, C. Ayet (Barcelona, Spain) 


421 






16.45 - 17.30 State-of-the-art lecture: Assessment and management of 

osteonecrosis of the jaw 


T. Taylor, London (GB) 


This session will explain how to assess and manage patients presenting with, or at risk of developing, 

Osteonecrosis of the Jaw (ONJ). It will include: 

- The reasons why ONJ affects the jaws specifically 

- The signs the clinician should look out for 

- What to tell the patient to expect if it does occur 

- The symptoms the patient may expect if an ONJ develops 

- Risk factors that predispose to ONJ 

- Strategies for prevention 

- Practical tips for ongoing management 

- Treatment options available if ONJ develops



16.45 - 17.45 EAUN Nursing Research Competition 


Chair: R. Pieters, Ghent (BE) 

Report from the research competition winner of 2010 

16.45 - 16.55 Adherence to fast-track programmes within urology nursing care 2008-2010 

E. Grainger, Århus (DK) 


The nominees of 2012 and their research projects 

17.00 - 17.10 RP12-01 Avoiding urinary tract infections in patients practising intermittent catheterisation 

H.J. Mulder, Groningen (NL) 


17.15 - 17.25 RP12-02 Which factors make clean intermittent (self)catheterisation 

J.G.L. Cobussen-Boekhorst, Nijmegen (NL) 

E. Van Wijlick, Nijmegen (NL) 

17.25 - 17.30 Discussion 

17.30 - 17.45 Making a research plan: What is possible and what you need to know 

E. Grainger, Århus (DK) 

J.T. Marley, Portadown (IE) 


423 



Monday, 27 February 



10.15 - 11.15 Indwelling vs. intermittent catheterisation in voiding difficulties: What 

does it mean for patients, caregivers and society? 


Symposium 

Chair: R. Peeker, Gothenburg (SE) 

10.15 - 10.30 Hassan - A movie about love, sex and lust for life! 

10.30 - 10.45 Indwelling vs. intermittent catheterisation - differences for the patient, caregivers and society - What are 

the obstacles? 

R. Peeker, Gothenburg (SE) 

10.45 - 11.00 Indwelling catheter, only when needed - A project in Jönköping Sweden 

I. Erlandsson, Jönköping (SE) 



Background: In the western part of the world, Clean Intermittent Catheterisation (CIC) is considered the 

treatment of choice for many voiding disorders. In other parts of the world, old outdated methods such 

as pressure voiding and indwelling catheters (IC) are still being used. However, the usage of indwelling 

catheters is widespread also in the western health care system, despite the fact that experience has told us 

that CIC is a better choice. What are the consequences of this outdated approach for the caregivers, patients 

and society? What can be done to make a change in approach? 

Aim: To show real life consequences of catheterisation, for different stakeholders. Valuable discussions 

concerning what practical measures can be made to ensure indwelling catheter use is kept at a minimum 

level. 

Objective: Elevate intermittent catheterisation in favour of indwelling catheterisation and consequently show 

how intermittent catheterisation can be a life saver. To give inspiration to work with projects in order to break 

old treatment patterns. 

Sponsored by ASTRA TECH



11.30 - 12.00 State-of-the-art lecture: Ketamine-associated ulcerative cystitis, 

a new clinical entity 


P. Sau-Kwan, Hong Kong (HK) 


The first 10 cases of ketamine-induced damage to the urinary tract (ketamine uropathy) in Hong Kong were 

reported in 2007. These young patients usually presented with dysuria, frequency, urge incontinence and 

painful haematuria. The condition was usually mistaken for bacterial cystitis and given multiple courses of 

oral antibiotics of no avail. The functional bladder capacity could be reduced to as small as 15 ml, driving 

the patient diaper dependant. Marked inflammatory changes with telangiectasis in the bladder mucosa 

were seen under cystoscope. Urodynamically these patients were either suffering from detrusor overactivity, 

poor compliant bladder or both conditions, with or without vesicoureteric reflux. Unilateral or bilateral 

hydronephrosis could be detected in up to 15% of the patients. In a few patients papillary necrosis was 

detected, while in some others the urinary tract was further complicated by ureteric stricture. 






Quiz 

12.30 - 12.45 EAUN Urology Nursing Quiz 



U.L.M. Haase, Nieuwegein (NL) 


Test your urology nursing knowledge. The winner receives a free registration for the 14th International EAUN 

meeting in Milan, Italy



12.45 - 13.15 State-of-the-art lecture: Focal cryoablation of prostate cancer 


12.45 - 12.50 For who is focal cryoablation a suitable therapy; how to exclude multifocal cancer 


H. Laws, Sunderland (GB) 

12.50 - 13.00 What is meant by focal cryoablation? 



13.00 - 13.10 Follow up 





Following minimal invasive therapies, the request for focal treatment soon increased. This of course includes 

an increased demand for nerve sparing procedures in the treatment of prostate cancer (PCA) to preserve 

potency and continence. But what does focal cryoablation of the prostate mean in detail? 

This session will present the currently available focal treatments in PCA, and then focus on the different 

possibilities in focal cryoablation of the prostate. It will also look at what the European Study Group of 

Cryosurgical ablation of prostate cancer (ESGCP) recommends as the best treatment to start with. 

Cryobiology and the technique will be explained and how to guide patients through their decision pro or con 

focal cryoablation. The follow up afterwards will complete this overview and should enable the audience to 

go home with increased knowledge about this inspiring treatment option. 


427 






13.15 - 13.45 EAUN Annual General Meeting (AGM) 


Chair: K. Fitzpatrick, Dublin (IE) 

W.M. De Blok, Amsterdam (NL) 

L. Drudge-Coates, London (GB) 

V. Geng, Lobbach (DE) 

U.L.M. Haase, Nieuwegein (NL) 


B.T. Jensen, Århus (DK) 

S.V. Lauridsen, Copenhagen (DK)



14.00 - 15.45 Poster Session 


Chairs: L. Drudge-Coates, London (GB) 

B.T. Jensen, Århus (DK) 

p10 Teaching self-catheterization for patients with neurogenic bladder. Nursing experiences from a spinal cord 

unit 

M. Kloeser, B. Domurath (Bad Wildungen, Germany) 

p11 The impact of incontinence on the dependency scale, the care profile and the financing of Belgian 

residential nursing homes 

S. Deryckere, K.C.M. Everaert, J. Trybou, R.G. Pieters (Ghent, Belgium) 

p12 Acute pain outcomes after open and minimally invasive robotic-assisted surgery for localised prostate 

cancer 

H. Crowe, E. Beale, J. Lee, M. Botti (Melbourne, Australia) 

p13 Advising the patient’s radical prostatectomy in the East-Tallinn Central Hospital urology department 

A. Komp, I. Persidski (Tallinn, Estonia) 

p14 Long-term effects of pelvic floor muscle training (PFMT) vs extracorporeal magnetic innervation (ExMI) on 

post-prostatectomy urinary incontinence 

S. Terzoni, E. Montanari, C. Mora, C. Ricci, A. Destrebecq (Milan, Italy) 

p15 Introducing a nurse–led transperineal saturation prostate biopsy service 

J.E. Kinsella, L. Fleure, L. Vyas, P. Acher, P. Kumar, R. Popert, D. Cahill (London, United Kingdom) 

p16 Prostate cancer follow up. Do patients and health professionals want the same thing? 

I.B. Vieira, H. Taylor (Gillingham, United Kingdom) 

p17 Mobile Advice & Testing Service (MATS): Introduction of a novel, nurse-led prostate cancer education and 

testing service 

H.R. Crowe, P. Bugeja, A. Wootten, D. Murphy, B. Challacombe, A.J. Costello (Melbourne, East Melbourne, 

Australia; London, United Kingdom) 

p18 The impact of a nurse led urinary Memokath TM stent follow up clinic 

N.J. Dickens, S. Kachrilas, C. Bach, P. Kumar, N.P. Buchholz, J. Masood (London, United Kingdom) 


429 






16.15 - 16.30 Award Session 


Chair: K. Fitzpatrick, Dublin (IE) 

· First Prize for the Best EAUN Poster Presentation 

· Second Prize for the Best EAUN Poster Presentation 

· Third Prize for the Best EAUN Poster Presentation 

· Prize for the Best EAUN Nursing Research Project 

· Prize for the winner of EAUN Urology Nursing Quiz 

The Prizes for the Best EAUN Poster Presentations are supported by unrestricted educational grants from 

AMGEN 

The Prize for the Best EAUN Nursing Research Project is supported by an unrestricted educational grant 

from FERRING PHARMACEUTICALS

EAU Membership 

What are benefits of being 

a member of the European 

Association of Urology? 

EAU Members benefit from many advantages: 

Publications 

� �� 

�� 

�� 

� �� 

��- 

�� 

�� 

�� 

� �� 

�� 

��- 

�� 

� �� 

�� 

�� 

� �� - 

�� 

�� 

� �� 

�� 

� �� 

��- 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

��- 

�� 

�� 

EAU Education Programme 

EAU Members will receive regular information on all 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

��- 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 


431 

About EAU


EAU Offices 

EAU Board 

Executive Committee 

Secretary General 

�� 

Adjunct Secretary General 

Executive Member related to 

Science 

�� 

Adjunct Secretary General 

Executive Member related to 

Education 

�� 

Treasurer and Executive Member 

related to Communication 

�� 

Board Members 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

Offices related to education 

EAU Education Office (ESU) 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

Ex-officio Members 

�� 

�� 


�� 

�� 

EU-ACME Office 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

European Urological Scholarship 

Programme Office 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 


Ex-officio ESUT 

�� 

Ex-officio Young Urologists Office 

�� 

Ex-officio Research Foundation 

�� 

�� 

Guidelines Office 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

Young Urologists Office 

Chairman 

�� 

Chair Italian Resident Organisation 

�� 

Chair UK Resident Organisation 

�� 

Chair French Resident Organisation 

�� 

Chair Turkish Resident Organisation 

�� 

Chair German Resident 

Organisation 

�� 

�� 

Chair Spanish Resident 

Organisation 

�� 

ESRU Secretary 

�� 

ESRU Chair 

�� 

ESRU Chair Elect 

��ˇg�� 

Young Urologists 

�� 

�� 

�� 

Offices related to science 

Regional Office 

Chairman 

�� 

Scientific Congress Office 

Chairman 

�� 

Members 

�� 

�� 

��

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 


�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

Video Congress Committee 

Chairman 

�� 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

Section Office 

Chairman 

�� 

Chairmen Sections 

�� 

�� 

�� 

�� 

�� 

�� 

� �� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

Offices related to communication 

History Office 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

Offices related to the governance 

International Relations Office 

Chairman 

�� 

Consultants 

�� 

�� 

�� 

�� 

Membership Office 

Chairman 

�� 

Strategy Planning Office 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

�� 

Search & Nomination Committee 

2011 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

Additional 

EAU Foundation for Urological 

Research 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

Ex-officio Member 

�� 

Academy of Urology 

Chairman 

�� 

Members 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 


Offical journal of the EAU 

Editor in chief 

�� 


433 

About EAU


Historical Overview EAU Congresses 

�� Padua, Italy 

�� Prague, Czech Republic 

�� Monte Carlo, Monaco 

�� Athens, Greece 

�� Vienna, Austria 

�� Copenhagen, Denmark 

�� Budapest, Hungary 

�� London, United Kingdom 

�� Amsterdam, The Netherlands 

�� Genoa, Italy 

�� Berlin, Germany 

�� Paris, France 

�� Barcelona, Spain 

�� Stockholm, Sweden 

�� Brussels, Belgium 

�� Geneva, Switzerland 

�� Birmingham, United Kingdom 

�� Madrid, Spain 


�� Istanbul, Turkey 


�� Berlin, Germany 

�� Milan, Italy 

�� Stockholm, Sweden 

�� Barcelona, Spain 



434 Programme Book

Abstract authors 

A 

Aalders M.W. 657, 658 

Aaltomaa S. 985 

Abakka N. 1034 

Abal V. 414, 1095 

Abbadessa D. 706 

Abbaraju J. 97 

Abbas A. 1111 

Abbinante M. 285, 534 

Abbod M.F. 965, 1043 

Abbou C.C. 263, 712, 757, 763, 886, 

911, 1089, 1090, V24 

Abd Alsamad K.M. 395 

Abd-Elraheem A. 179 

Abdalla A. 1078, V34 

Abdallah M.H. 395, 615 

Abdel Gawad O.A. 613 

Abdel-Karim A.M. 94 

Abdel-Meguid T. 57 

Abdelbacky A. 1079 

Abdelhafez M.F. 604, 609, 1031 

Abdelhakiem A. 1078, V34 

Abdelhakiem M. 1078, V34 

Abdelrahman H. 615 

Abdo A. 555, 770 

Abdollah F. 122, 150, 282, 284, 361, 

362, 421, 570, 594, 603, 761, 

780, 882, 908, 1002, 1012, 1054 

Abdou A. 292 

Abdullah A. 524 

Abe M. 244 

Abel P.D. 20 

Abol-Enein H. 194, 602 

Abou Elezz M. 615 

Abouhashem S.E. 333 

Aboumarzouk O. 445 

Abraham J. 589 

Abrahamsson P.A. 657, 658, 934 

Abreu A.L.C. 18, 250, 257, V6 

Abril E. 427 

Abroaf A. 1079 

Abu Farha M.O. 616, 617 

Abu-Nasra N. 226 

Abu-Zeid A.M. 512 

Acar I.C. 495, 1016 

Acimovic M. 612 

Adam M. 1021 

Adamek M. 809 

Adamowicz J. 802 

Addla S.K. 153 

Addonisio P. 304 

Adolfsson J. 456 

Adorini L. 4 

Afonin V.Y. 101, 496 

Agaimy A. 558 

Agarwal M. 1083 

Agarwal P.K. 134, 453, 677, 678, 

679, 1055, 1061, V22 

Aggarwal A. 246 

Aggarwal A. 861, 862 

Aggarwal K.P. 850, 855 

Agostini S. 441 

Agreda F. 264, 347 

Agrogiannis G. 12 

Ahktar Z. 1118 

Ahlering T. 876, 976 

Ahmad I. 646, 662 

Ahmad M.S. 776 

Ahmad S. 445 

Ahmed A. 669 

Ahmed H.U. 20, 22, 24, 795, 821, 

824, 1096 

Ahmed K. 63 

Ahmed O. 905 

Ahn H.J. 265, 313, 346, 875, 879, 

1024 

Ahn J.H. 313 

Ahn J.S. 34, 990 

Ahn T.Y. 482, 701 

Ahouagi A.C. V31 

Ahyai S.A. 157, 727, 808, 873, 903, 

973, 974, 1097 

Aizawa N. 736, 996 

Akahane S. 996 

Akamatsu S. 434 

Akbal C. 481 

Akca O. 491 

Akhvlediani N.D. 141 

Akiko O. 895 

Akilov F.A. 222 

Akin Y. 914 

Akino H. 745, 991 

Akkoeze M. V14, V39 

Akman T. 498 

Al Ghamdi S. 184 

Al Kamal I. 306 

Al-Kathiri M. 497 

Ala-Opas M.Y. 131 

Alamanis C. 542 

Alayman A. 1029 

Albayrak S. 491 

Albers P. 128, 406, 866 

Albersen M. 284, 477, 479, 882, 908 

Albert M.L. 668, 962 

Albinsson S. 367 

Albo M.E. 171 

Albouy B. 448, 771 

Alcaraz A. 212, 215, 317, 320, 324, 

329, 337, 339, 402, 584, 595, 

719, 943, 945, V29, V30, V35, 

V36 

Alcover J.B. 402, 943, 945 

Aldaoud N. 1122 

Aldaqadossi H.A. 617 

Alekseev B. 961 

Alessandria E. 378 

Alessandro R. 706 

Alex A. 401 

Alfarone A. 261, 342, 986 

Algotar A. 427 

Alhalabi F. 193 

Ali A.S.M. 41, 183 

Ali-El-Dein B. 608 

Aliaev U.G. 141 

Alidjanov J.F. 222 

Alkhateeb S. 1049 

Allaf M. 94 

Allam M.N. 177 

Allegro R. 1040 

Allen C. 24, 795, 821, 1096 

Allen S. 368 

Allona A. 830 

Allory Y. 538, 712, 757, 762, 763, 

1089, 1090 

Alloussi S. 521, 666 

Allsopp T.J. 184 

Allué M. 975, 977 

Alnajjar H.M. 515, 517, 522, 523 

Altieri V. 1040 

Altinkilic B. 48 

Altintas F. 270 

Altman D. 694 

Alumkal J. 124 

Alvarez S. 811 

Alvarez-Vijande J.R. 317, 320, 324, 

943, 945 

Alves J.G.B. 388, 503 

Numbers refer to abstract numbers 


435 

Indices

Indices 


Alvisi M.F. 764 

Alzaharani A. 887 

Amantini C. 465, 994 

Amarenco G. 467 

Amaro C.R. 954 

Amaro J.L. 954 

Ameye F. 1011 

Amsellem-Ouazana D. 169 

Anastasiou I. 695 

Anderson D. 63 

Anderson J. 1038 

Andersson K.E. 3, 7, 741, 1070 

Ando M. 51, 59 

Ando R. 952 

Ando T. 593 

Andrade L. V31 

Andreeva Y. 961 

Andretta E. 276 

Andrich D.E. 722, 1073 

Andrikopoulos O. 218, 255, 810 

Andriole G.L. 262 

Androutsos G. 829 

Angata K. 647 

Angelov V.A.S. 711 

Angiolilli D. 923 

Angulo J.C. 167, 299, 684 

Angusti T. 252 

Aning J.J. 716 

Anjum F. 97 

Annerstedt M. 709 

Anoopkumar-Dukie S. 184 

Ansieau J.P. 144 

Antonarakis E. 652 

Antonelli A. 251, 926 

Antonini G. 440, 901 

Antunes P. 138, 667 

Antunes-Lopes T. 993 

Aoki S. 205 

Aoki Y. 991 

Aout M. 634, 743 

Apicella G. 358 

Apostolidis A. 370 

Apostolopoulos D. 810 

Appel B. 597, 702 

Arai E. 904 

Arai S. 938 

Arai Y. 139, 348, 549, 671, 1088, 

1110 

Arakawa S. 295 


Araki I. 742 

Araki K. 1116 

Arap M. 62 

Araújo E.M. 388, 503 

Arbós M.A. 848 

Arcicasa M. 419 

Ardelt P. 69, 377, 394, 492 

Arenas L.F. 804 

Arentsen H.C. 665 

Arias-Santiago S. 99, 851, 859 

Arikan O. 98 

Arlandis S. 585, 622, 631, 632 

Armagan A. V12 

Armand-Lefevre L. 38 

Armando E. 14, 792 

Armitage J.N. 1026 

Armstrong A.J. 126 

Arnsrud Godtman R. 1094 

Aron M. 250, 257, V6 

Arrabal-Martin M.A. 99, 338, 851, 

859 

Arrabal-Polo M.A. 99, 338, 851, 

859 

Arrighi N. 251 

Arseniev A.V. 101 

Aruga S. 854 

Arumainayagam N. 795 

Arustamov D.L. 222 

Arvin-Berod A. 550, 556, 771 

Asakuma J. 196 

Asano T. 196, 205, 240 

Asano T. 196, 240 

Asanuma H. 919 

Ascione A. 565 

Ashour N. 167 

Aslam M.Z. 1083 

Aslan P. 815 

Aslan Y. 511 

Assis T. 954 

Atan A. 511 

Ates F. 404 

Ates M. 573 

Atis G. 98 

Atkinson J.D. V4 

Atsushi S. 752 

Audenet F. 308, 448, 771 

Aufderklamm S. 429, 442, 521, 841 

Auges M. 220 

Augustin H. 1004 

Auprich M. 263, 911, 1004 

Aureli M. 898 

Auriol J. 1119 

Autorino R. 25, 30, 94, 216, 1047, 

V23, V33 

Autran-Gomez A.M. 720, 887 

Auvinen A. 152, 266, 785 

Awsare N.S. 1028 

Axcrona K. 985 

Ayache A. V5 

Azemar M.D. 448 

Azuero J. V38 

Azuma H. 75 

Azumi M. 1052 

Azzabi F. 1071 

Azzouzi A.R. 308 

B 

Baba S. 864 

Babaian R. 1004 

Babjuk M. 608 

Bach C. 64, 103, 620, 1039 

Bach T. V45 

Bachmann A. 433, 668 

Bader M. 947 

Bader P. 355, 357, 362 

Bae J. 628 

Bae J.H. 412, 501, 562, 625, 703 

Bae J.H. 319, 769 

Bae W.J. 319, 485, 769 

Baekelandt F. 142 

Bahl A. 83, 129 

Bahn D. 18 

Balabanov S. 866 

Balci M. 511 

Baldazzi V. 77 

Ballario R. 276 

Ballarè A. 358 

Balsanu C. 405, 618 

Balsmeyer U. V8 

Balzer O. 728, 1057 

Bamberg M. 310 

Bandur M. 1013 

Banek S. 444, 666 

Banerjee S. 518 

Bang W.J. 230 

Bangma C.H. 53, 145, 149, 328, 447, 

822, 825, 1086, 1087 

Banie L. 707 

Numbers refer to abstract numbers

Baniel J. 1046 

Banka S. 470 

Bannowsky A. 19 

Banzola I. 906 

Bao B.Y. 437 

Bao J.B. 437 

Bapat B. 543 

Barakat T.S. 194 

Barbagli G. 721, V8 

Barbieri B. 121 

Barbieri L. 284 

Barbosa J.A.B.A. 411 

Barbouti O. 22 

Baretton G.B. 655 

Barghouty I. 1095 

Barkin J. 748 

Barratt D. 24 

Barreira Y. 735 

Barret E. 17, 151, 352, 713, 877, 

987, V25 

Barros H. 536 

Bartel C. 413 

Bartesch C. 7 

Barthelmebs M. 195 

Bartkuhn M. 50 

Bartoletti R. 188, 301, 304, 1114 

Bartsch G. 241 

Barwari K. 930 

Barwell J.G. 424 

Basibuyuk I. V12 

Bassi P. 286 

Bastarós J.M. 264, 347 

Bastian P.J. 603, 775, 872 

Bastide C. 351 

Bastien L. 765 

Battaglia M. 1040 

Batura D. 294 

Baudin E. 1105 

Bauer R.M. 281, 288 

Baumert H. 144, V5, V18, V26 

Baumgartner M. 1097 

Bäurle L. 791 

Baxa J. 924 

Baykal K.V. 404 

Baykara M. 914 

Bayoud Y. 762 

Bazzi W. 94 

Beattie K.A. 673 

Beauval J.B. 351, 363, 364 

Bebin M. 74, 80 

Becht E.W. 983 

Becker A. 808, 973, 1021 

Becker A. 281, 451, 717, 1010, V7 

Becker J. V45 

Beckmann C. 3, 7 

Becskei A. 1063, 1064 

Bedke J. 76, 310 

Bedretdinova D. 693 

Behnsawy H.M. 160 

Behr-Roussel D. 369, 462, 472 

Beier J. V10 

Bektic J. 880 

Bélanger A. 941 

Belas O. 886 

Beldì D. 358 

Belkoff L. 126 

Bell D. 767 

Bellardita L. 758 

Bellec L. 144 

Bellinzoni P. 259 

Belousov I.I. 45 

Belousova E. 74, 80 

Belsante M.J. 530 

Beltran J. 212 

Belussi D. 137 

Bemelmans F.J. 1023 

Ben Sorba N. 588 

Ben-Naoum K. 175 

Benad P. 655 

Benchikh El Fegoun A. 38, 154 

Bengoa N. 654 

Benigni F. 5, 107, 231, 284, 371, 

372, 487, 741, 898 

Benito García P. V47 

Benjamin L. 223 

Benn J. 68 

Benrais N. 279 

Bensadoun H. 448, 550, 771 

Bensalah K. 552 

Benson M.C. 1081 

Bentani N. 1102 

Benthani F. 669 

Benyoucef A. 422 

Beppu M. 742 

Beraud C. 195 

Béraud C. 204 

Berezyak T.I. 185 

Berg R.E. 672 

Bergamini L. 70 

Berge V. 672, 979, 982 

Berger A.K. 250, 257 

Berger I. 789 

Berger J. 144, 311, 610 

Berger R. 253 

Bergin S. 36 

Bergman A.M. 865 

Bergmann M. 48 

Bergqvist A. 687 

Berkers J. 311, 477, 479 

Berman M. 652, 656 

Bernardini P. V49 

Berney D.M. 430 

Bernhard J.C. 144 

Berruti A. 1105 

Bertagna F. 926 

Bertelli E. 441 

Bertini R. 95, 137, 923 

Bertoli M. 926 

Bertolo R. 252 

Bertolotto F. 354, 960 

Bertz S. 868 

Bessa J.B.J. 1108 

Bessede T. 351 

Best S. 94 

Bethry A. 195 

Bettiga A. 898 

Beukers W. 165 

Beuselinck B. 311 

Bex A. 78, 460, 519, 865 

Bhandari A. V27 

Bhatnagar S. 431 

Bhayani S. 26, 28, 31, 35 

Bianchi M. 84, 453, 677 

Bianchi-Demicheli F. 1062 

Biasoni D. 403, 407 

Bicik Z. 953 

Bickerstaffe H. 869 

Bieche I. 169 

Bierfreund K.G. 444 

Bigot P. 144, 610 

Binbay M. 498 

Bingöl C. 406 

Bini V. 259, 527, 586, 909, 910 

Biot C. 668 

Birkhäuser F. 962 

Birtle A. 129 

Bisconti A. 378 



437 

Indices

Indices 


Bissler J. 80 

Bitker M.O. 6, 308, 383, 529, 794, 

817 

Bizic M. V9 

Bizzarri B. 893 

Bjerklund-Johansen T.E. 21, 37, 297 

Black P. 767 

Blaheta R. 238, 241 

Blana A. 979, 982 

Blanc I. 788 

Blanchet P. 940, 941 

Blancho G. 211 

Blanker M.H. 116 

Blarer J. 1007 

Blauwet M.B. 684 

Blazquez C. 760, 1041 

Blenk B. 192 

Blenk H. 192 

Blok B.F.M. 290 

Blok C. 165 

Blum H. 49 

Blumenstengel K. 79 

Blázquez C. 848 

Blázquez C. 560 

Blázquez Izquierdo J. 897 

Bocciardi A.M. 565 

Bochorishvili G.G. 697 

Bode C. 315 

Bodmann F. 738 

Bodnar J. 802 

Bodnar M. 803 

Boehm K. 680 

Boerman O.C. 928 

Boettcher S. 635 

Bogacki R. 381 

Bogaert G. 513 

Bögemann M. 866 

Bohris C. 947 

Boillot B. 556 

Bokemeyer C. 128 

Bolat D. 495 

Bolenz C. 775, 872 

Bollini S. 138 

Bollito E. 912 

Bolton E. 540 

Bolwien C. 102 

Bondarenko V.M. 191 

Bongers R. 52 

Bonniol R. 351, 422 


Bono A.V. 1050 

Borchers H. 413 

Bordier B. 466 

Borenstein N. 1115 

Borghesi M. 121 

Boros M. 807, 1068 

Borque A. 975, 977 

Borre M. 420 

Bortolus R. 419 

Bosch J.L.H.R. 116, 197 

Boshchenko V.S. 101, 496 

Bosio A. 378 

Bosio G. 926 

Boss A. 1071 

Bossard N. 556 

Bostanci Y. 505 

Bostrom P.J. 554, 905 

Botelho F. 536, 993 

Bott S. 819 

Bottomley D. 129, 130 

Bouaita M. 38 

Bouali O. 735 

Bouanane M. 886 

Bouchaert P. 547 

Boudes M. 366 

Boukaram M. 175 

Bourdin S. 423 

Boursi B. 539 

Bouzlakas I. 83 

Bozzini G. 268, 801 

Bracarda S. 83 

Bradshaw K. 531 

Brajtbord J. 676 

Brakemeier S. 80 

Branchereau J. 211 

Branco A.W. 94, V41 

Branco F. 499 

Brandtner A. 798, 981 

Brasse D. 204 

Braun N. 310 

Brausi M. 70, 132, 778, 1050 

Breda A. 325 

Breen D.J. 1111 

Breijo S. 1095 

Breinl E. 552 

Brenner P. 673 

Brenner W. 256, 1117 

Briant P.E. 640 

Brichard V. 664 

Brichart N. 448, 610 

Brierly R. 47 

Briganti A. 122, 148, 158, 231, 355, 

357, 361, 421, 570, 761, 780, 

784, 882, 891, 908, 971, 1002, 

1006, 1012, 1054 

Bright E.A. 636 

Briollais L. 543 

Bristow R.G. 905 

Brito A.H. 62 

Brizhatyuk E. 300 

Brock G. 642 

Brock M. 823 

Broderick G. 642 

Broglia L. 779 

Brookman-May S. 514, 558, 775, 

1015, 1019 

Brooks D. 246, 343 

Brooks D.E. 661 

Brosh L. 427 

Brosman S. 126 

Brouwer O.R. 519, 1008 

Brown K.F. 68 

Brown M. 650 

Brown S. 979, 982 

Brubaker L.B. 171, 172, 176 

Bruce J. 124 

Bruins H.M. 718 

Brunnschweiler S. 614 

Brunocilla E. 121, 893 

Brureau L. 940 

Bruyere F. 144, 550, 610 

Bruzzi M. 610 

Bryant R.J. 435 

Bryant T.J. 1111 

Bryniarski P. 381 

Bründl J. 571, 798, 981 

Brüning F. 449 

Brüning T. 444 

Bschleipfer T. 1072 

Bu H. 649 

Bubendorf L. 433 

Bucci J. 416 

Buchholz N. 64, 103, 1039 

Buchner A. 451, 717, 775, 872 

Buckle T. 1008 

Budde K. 80, 316 

Budäus L.H. 572, 680, 799, 873 

Bueno Bravo C. 321, 811 


Buffardi A. 378 

Buffi N.M. 29, 31, 35, 278, 779, 784, 

1006, 1080, V40 

Bühring H.J. 651 

Bul M. 149, 269, 1086, 1087 

Bulbul M. 751 

Bulla S. 944 

Bullock A.J. 1065 

Bunce C. 956 

Buono R. 5, 107, 231 

Burger M. 514, 558, 603, 775, 872, 

957, 1015, 1019 

Burgess N.A. 1026 

Burgio K. 115 

Burgos Revilla F.J. 321, 811 

Burkhard B. 357 

Burki J. 470 

Burset M. 339 

Burt H.M. 661 

Busch J. 72 

Busetto G.M. 261, 440, 900, 901 

Busstra M. 782 

Busto L. 1095 

Bütow Z. 455, 874 

Byun H.K. 228 

Byun B.B. 33, 283, 582, 628 

C 

Cabanac F. 220 

Cacho J. 299 

Caciagli P. 301 

Cadeddu J.A. 94 

Caffo O. 415 

Cagiannos I. 767 

Cahill D. 63, 759, 790, V51 

Cai J. 600 

Cai T. 188, 301, 304, 1114 

Caisey S. 462 

Caitanio U. 1054 

Calado A.A. 388, 503 

Calais Da Silva Junior F.M.V. 132 

Calais Da Silva Senior F.E.C. 132 

Calatrava A. 428 

Caliolo C. 16 

Camara-Ortega M. 859 

Cambronero J. 684 

Camparo P. 369 

Campeau L. 1070 

Campion L. 423 

Campos L.C.N. 322, 323, 327, 667 

Can F. 404 

Canat L. 98 

Cancel-Tassin G. 6, 10, 308, 426, 

907 

Candal A. 414 

Cano-García M.C. 1005 

Cantiani A. 1047 

Caola I. 301 

Capelini M. 364 

Capitán C. 560, 1041 

Capitanio U. 95, 137, 150, 357, 421, 

570, 761, 779, 780, 923, 1002 

Capogrosso P. 150, 594, 908 

Caradec J. 538 

Carballido Rodríguez J. 830, 897 

Carbone A. 696 

Carchedi M. 378 

Cardoso L.E.M. 2, 389 

Carducci M.A. 126 

Carenzi C. 95, 137, 923 

Carini M. 4, 77, 113, 119, 136, 248, 

441, 644, 740, 970 

Caris C.T.M. 1051 

Carles J. 264, 347 

Carlsson S. 269, 785 



Carmignani G. 1114 

Carmignani L. 268, 801 

Carmona L.M. 155 

Carrera C. 811 

Carrieri G. 1040 

Carroll P.R. 431 

Carter T. 24 

Cartwright R. 115 

Caruana G. 706 

Carvalho B.S.P. 388 

Carvalho L. 652, 656 

Carvalho J.P.M. 520 

Carvalho-Barros S. 993 

Casadei A. 60 

Casado Varela J. 897 

Casanova Ramón-Borja J. 289, 428, 

541 

Casanova-Salas I. 541 

Casas J. 414, 1095 

Casellato S. 268 

Casenave J. 383 

Cash H. 72 

Caskurlu T. 98 

Castagna G. 303 

Castela A. 473 

Castellanos E. 417 

Castelli E. 553, 601 

Castelo L. 414 

Castelo D.J.S. 322 

Castiglione F. 95, 284, 303, 882, 

908, 923 

Castiñeiras J. 830 

Castro D. 622, 631, 632 

Castro R. 747, 748 

Catalano G. 419 

Catanzaro M. 403, 407 

Cathelineau X. 17, 151, 351, 352, 

713, 876, 877, 976, 987, V25 

Cattarino S. 261, 342, 986 

Catto J.W.F. 166, 435, 965, 1043 

Cauci S. 698 

Cavadas V. 499 

Cavarretta I. 284 

Cecchini M.G. 645 

Ceddaha M. V26 

Ceder J.A. 657, 657, 658, 658 

Cek M. 37, 297 

Cellai I. 4 

Celma A. 264, 347 

Cengiz M. 853 

Centemero A. 910 

Ceresoli F. 137 

Cerna M. 50 

Ceruti C. 378 

Cestari A. 29, 31, 35, 259, 779, 784, 

882, 1006, 1080, V40 

Cetinel C.A. 491 

Cetti R.J. 1038 

Cha E.K. 552, 561, 603 

Chabrier P.E. 462 

Chade D. 773 

Chadwick E. 418, 819 

Chahud F. 1108 

Chai T.C. 171 

Chaimovitsh O. 226 

Chalikonda S. V23 

Challacombe B. 63, 759, 790 

Champetier D. 640 

Chan S.Y. 335 

Chanda S. 647 



439 

Indices

Indices 


Chang H.C. 55 

Chang I.H. 916 

Chang J.S. 587 

Chang K.H. 840 

Chang R.T.M. 47 

Chang S.J. 633 

Chang S. 483 

Chang T.Y. 437 

Changhong Y. 146 

Chao C.R. 258 

Chapelon J.Y. 980 

Chapple C.R. 109, 374, 683, 746, 

755, 1065 

Charfeddine B. 279 

Charman S. 821 

Charrua A. 365, 366, 368 

Chartier-Kastler E. 369, 472, 529, 

817 

Chauhan S. 340, 878, 1058, 1059, 

V15, V16, V20 

Chaussy C.G. 888, 978, 979, 982 

Chawla S. 660 

Chazan B. 187 

Chen B. 934 

Chen G.K. 434 

Chen H.W. 120 

Chen H. 206 

Chen K.K. 627 

Chen L.M. 437 

Chen Q.H. 106 

Chen S. 934 

Chen T.J. 471 

Chen Y.T. 561 

Cheng H. 236 

Cheon J. 66 

Cheong M.S. 643 

Chervinsky L. 226 

Chess-Williams R. 109, 184 

Chevreau G. 794 

Chew B. 490 

Chiang Y.J. 120 

Chiba K. 51, 59, 90 

Chibelean C. 405, 618 

Chikara O. 895 

Chilcott S. 332 

Chin C.M. V17, V19 

Chin J. 720, 767, 887 

Chin Y. 416 

Chira C. V13 


Chiyomaru T. 334, 842, 843 

Cho D.Y. 562, 703 

Cho H.J. 319, 485, 769 

Cho J.S. 643 

Cho K.S. 43, 230, 493 

Cho S.Y. 474, 587 

Cho S.Y. 219 

Cho W.J. 990 

Cho W.Y. 526 

Cho Y.H. 42 

Cho Y.M. 313, 879 

Cho Y.S. 117, 118, 227 

Chodacki A. 130 

Choe J.H. 181 

Choi D. 1024 

Choi H.Y. 23, 34, 156, 710, 972, 1017 

Choi H.Y. 43, 493, V50 

Choi J.D. 34 

Choi J.W. 225, 398 

Choi J.B. 117, 219, 733 

Choi K.H.C. 217 

Choi M.J. 480, 484 

Choi S. 638 

Choi W.S. 587 

Choi W.S. 224 

Choi Y.D. 230 

Choi Y.S. 319, 485, 769 

Choo G.Y. 190 

Choo M.S. 32, 583 

Choo Y.M. 283, 582, 628 

Chopra S. 673 

Choudat L.C. 154 

Chowdhury S. 89, 129 

Christopherson K. 937 

Chromecki T.F. 552, 603, 876, 976, 

1015, 1019, 1021 

Chu S.H. 120 

Chugtai B. 343 

Chun F.K. 157, 263, 603, 873, 876, 

903, 911, 973, 974, 976, 1004, 

1021, 1097 

Chun-Woo L. 583 

Chung B.H. 643, 688, 988 

Chung H. 929 

Chung H. 229 

Chung H.C. 228 

Chung J.H. V50 

Chung J.M. 638 

Chung J.S. 484 

Chung K.J. 731, 733 

Chung M.S. 988 

Chung W.S. 701 

Cicione A. 1047 

Ciftcioglu A. 914 

Cindolo L. 94, 1015, 1047 

Ciofu C. 292 

Ciudin A. 212, 402, 584, 719, 943, 

945, V35 

Cividini R. 893 

Claes B. 311 

Clairac G. 169 

Clark R. 126 

Clarke N. 650 

Claude A. 762 

Claus F. 1113, 1121 

Clementi M.C. 303 

Coccarelli F. 415 

Coche T. 664 

Coelho R. 1059 

Coelho R.F. 1058, V20 

Coffin G. 765, 794 

Cohen M. 187, 226, 816 

Cohn-Cedermark G. 417 

Colciago G. 898 

Colecchia M. 403, 407, 764 

Coleman A. 950 

Coleman N. 332 

Colin P. 448, 550, 771 

Collado Serra A. 289, 428 

Collette S. 1050 

Colli E. 741, 985 

Collins V.M. 374 

Collura D. 553, 601 

Cologna A. 1108 

Colomba P. 706 

Colombo F. 60 

Colombo R. 122, 150, 282, 594, 971, 

1002 

Colombo Jr J.R. 62 

Coman I. V13 

Combelle S. 1119 

Comeglio P. 4, 740 

Companie S. 462 

Comperat E. 794 

Compion G. 467, 689, 691 

Compérat E. 369, 472 

Conort P. 383, 794 

Constantinides C. 12, 542 


Conti A. 375, 382, 1033 

Cooperberg M.R. 431 

Coquard C. 195, 204 

Corbishley C.M. 515, 517, 522, 523 

Corcoran M. 332 

Corcoran N.M. 1093 

Corcos J. 1069 

Cordeiro E.R. 1023 

Cordeiro M.D. 773 

Cormican M. 36 

Cormier L. 448, 550, 610, 771 

Cormio L. 1036 

Corn P. 124 

Cornel E.B. 913 

Cornford P.A. 336 

Cornu J.N. 6, 10, 288, 292, 426, 634, 

743, 771, 907, 941 

Corona G. 113, 119, 644 

Corral J.M. 402, 595 

Cortes-Gonzalez J.R. 417 

Cortesi E. 900 

Cortesse A. 765 

Cortez C. 427, 937 

Cortez C.M. 475 

Corti S. 251 

Corti S. 1002 

Cosciani Cunico S. 251, 926 

Cosentino M. V38 

Coskun A. 953 

Costa C.S.R 473 

Costa P. 175, 532 

Costa W.S. 2, 114, 410, 475 

Costantini E. 527, 528, 586 

Costello A.J. 1093 

Cotté F.E. 223 

Coughlin G. V51 

Counsell N. 669 

Cour F. 529 

Cowan J.E. 431 

Cox D. 641, 705 

Cozzarini C. 421 

Cozzi P. 815 

Cozzoli A. 251 

Cranston D.W. 1118 

Crepel M. 144 

Cresswell J. 956 

Cresswell L. 424 

Crevels A.J. 806 

Crippa Santana A. 773 

Crisan N. V13 

Cristofani L.M. 506, 508 

Crivellaro S. 285, 534 

Croci D. 948 

Crook T. 510 

Cross A. 130 

Crouzet S. 94, 448, 550, 771, 979, 

980, 982 

Crundwell M. 956 

Cruz C.D. 365, 366, 368 

Cruz F. 272, 365, 366, 368, 461, 536, 

577, 993, 997 

Cruz R. 536 

Cubas G. 212 

Cuervo Calvo J. V47 

Culig Z. 237 

Cummings J. 683 

Cunha N.B. 954 

Curcio L. V31 

Curt A. 1000 

Cury J. 65 

Cussenot O. 6, 10, 292, 308, 426, 

550, 907, 941 

Cutress M.L. 1048 

Cutrupi V. 301 

Cuzick J. 430 

Cytron S. 277, 605, 816 

D 

Da Pozzo L.F. 95, 122, 137, 421, 923 

Da Silva C.M. 985 

Daamen W.F. 804, 805, 806 

Dababneh H. 121 

Dabaja A. 134, 453, 677, 678, 679, 

1061, V3, V27 

Dabbagh V. 153 

Dacal J. 1095 

D’Addessi A. 286 

Dae-Hyun C. 583 

Daffara F. 1105 

D’Agostino D. 664 

Dahami Z. 1102 

Dahlem R. 619, 621, 727, 728, 730, 

808, 873 

Dai B. 1014 

Dal Fabbro I.M. 1067 

Dale M. 689 

Daliani D.D. 432 

Dalkin B. 427 

Dall Oglio M.F. 773 

Dalmasso E. 378 

Dalpiaz O. 772 

Dalsan D.S. 704 

Dalton E. 22 

Daly D.M. 374 

Damasio P.C. 954 

Damber J.E. 126, 985 

Damian D. 21 

Damiano R. 1047 

D’Andrea D. 463 

Daneshmand S. 600 

Daneshmand S. 603 

Dannenmaier A. 1072 

Darekar A. 510, 578 

Dario D. 594 

Dasgupta P. 63, 243, 838 

Dash A. 39 

Daudon M. 860 

Daugherty M.O. 714 

Davey A.K. 184 

Davidson S.R.H. 15 

Davila H. V25 

Davoudi Y. 566 

Davydov M.I. 88 

De Angelis P. 287 

De Baets K. 1084 

De Berardinis E. 440, 900, 901 

De Blok W. 460 

De Bono J. 129 

De Bruin D.M. 930 

De Bruin R. 78 

De Dominicis C. 16 

De Gier R.P.E. 805 

De Gorski A. 27 

De Jong I.J. 149 

De Kerviller E. 765 

De Koning H.J. 260 

De La Fuente V. 215 

De La Morena J.M. 760 

De La Peña E. 560, 760, 1041 

De La Rosette J. 921, 930, 1023, 

1030, 1036, 1037 

De La Taille A. 263, 538, 712, 757, 

762, 763, 886, 911, 1089, 1090, 

V24 

De Lorenzis E. 287 

De Luca G. 70, 778 

De Luca M. 792 



441 

Indices

Indices 


De Luca S. 912 

De Marzo A.M. 847 

De Muinck Keizer-Schrama S.M.P.F. 

53 

De Naeyer G. 26 

De Nunzio C. 439, 1047 

De Poncheville L. V32 

De Reijke T.M. 913 

De Ridder D. 366, 467, 477, 479 

De Ruiter M.C. 624 

De Sio M. 1047 

De Souza D.B. 114, 410, 475 

De Sutter T. 606 

De Tayrac R. 532 

De Torres I.M. 264, 347, 848 

De Vylder A.M.A. 1084 

De Weijert M.C.A. 309 

De Wever L. 1113, 1121 

De Wildt M.J.A.M. 869 

De Win G. 513 

De Zeeuw S. 290 

Debiais P. 547 

Deboudt C. 610 

Debre B. 169 

Decastro G.J. 1081 

Decaussin-Petrucci M. 556 

Deeg M. 548 

Defortescu G. 610 

Defourmestraux A. 757, 1089, 1090, 

V24 

Defrancia S. 1105 

Deger S. 316 

Deho F. 137 

Deiana G. 137 

Deix T. 823 

Dekhnich A.V. 186 

Dekoninck P. 477, 479 

Del Amo J. 975, 977 

Del Pozo G. 207 

Del Zingaro M. 527 

Delage F. 448 

Delakas D. 1100, 1104 

Delgado G.M. 264, 347 

D’Elia C. 188 

Deliconstantinos G. 695 

Delprado W. 815 

Demichelis F. 937 

Demir U. 935 

Demirtas A. 1016 


Demkow T. 130 

Denes F.T. 506, 508 

Deng Y. 812 

Denham D. 260 

Denis L.J. 785 

Denys P. 462, 472, 577 

Denzinger S. 558, 775, 1019 

Deprest J. 477, 479 

Deroose C.M. 1011 

Deruelle C. V21 

Derweesh I.H. 94 

Desai M. 1030 

Desai M. 250, 257, V6 

Descazeaud A. 311, 610 

Descotes J.L. 556 

Desgrandchamps F. 765 

Desoky E. 1029 

Destefanis P. 378 

Dewinter P. 669 

Dexter E. 427 

Di Girolamo V. 780, 1002 

Di Lallo A. 1040 

Di Mauro U. V43 

Di Muzio N. 421 

Di Palma C. 1047 

Di Placido M. 440, 901 

Di Silverio F. 261 

Di Stasi S.M. 1045 

Di Trapani D. 95, 137, 282, 761, 780, 

971, 1012 

Di Trapani E. 95, 282, 362, 594, 908, 

923, 1012 

Diab D.E. 177 

Diaconu M.G. 402, 584, 943, 945, 

V29 

Diamandis E.P. 543 

Diaz J.M. 325 

Diaz M. 1061 

Díaz F.J. 760 

Díaz-Güemes I. V37 

Dick A. 405, 618 

Dickens N. 64, 1039 

Dickinson L. 24 

Dickinson T. 178 

Dickmann M. 947 

Diederichs G. 316 

Diefenbach M.A. 675 

Dietel A. 71 

Diez-Nicolas V. 811 

Díez Nicolás V. 321 

Díez Sicilia L. 595 

Dik P. 1001 

Dilek T. 853 

Dillenburg W. 983 

Dillon B.E. 180, 530, 531 

Dimitriadis F. 370 

Dimov A.M. 296 

Dinis P. 272, 993, 997 

Dinkel A. 674 

Dirieck N. 211 

Ditrolio J. 189 

Dittamore R. 427, 937 

Divan C. 415 

Divrik T. 1016 

Dizeyi N. 934 

Djedovic G. 392 

Djojodimedjo T. 857 

Djordjevic M. 612, V9 

Dmochowski R. 579 

Do M. 71 

Do-Jung K. 583 

Doble A. 814 

Dobrota F. V13 

Doganca T. 270 

Doglioni C. 122 

Dohle G.R. 53 

Dominguez Escrig J. 289, 428 

Dominique S. 154 

Domnisor L. 405, 618 

Donat R. 956 

Donner G. 552 

Doo S.W. 478, 486 

Dorkin T.J. 1098 

Dormoy V. 195, 204 

Dorrepaal C. 683, 684 

Dotan Z. 253 

Doumerc N. 459, 466 

Drachenberg D. 767 

Dragoescu N.A. 958 

Dragoescu P.O. 958 

Drake M. 746 

Drapier E. V32 

Drewa T. 802, 803 

Dridi M. 279 

Driyanska V.E. 185 

Drogendijk T. 683 

Drouin S.J. 6 

Droupy S. 175, 448, 532, 707 


Dröge A. 76 

Duarte R.J. 62, 65, 506, 508 

Duarte-Cruz C. 993 

Dubosq F. 765 

Dubray B. 422 

Duchet L. 634, 743 

Dudek A. 239 

Dudziec E. 166 

Dufour R. 821 

Duijvesz D. 653 

Dujardin T. 786 

Dumonceau O. V5, V18, V26 

Dumont Martínez R. 289 

Dumortier C. 38 

Durand M. 246, 343 

Durand X. 610, 762 

Durkan G. 36 

Dursun F. 404 

Dusaud M. 610 

Dutton T.J. 714 

Dvorakova-Hortova K. 50 

E 

Eardley I. 47 

Eastham J. 918 

Ebel-Bitoun C. 578, 687 

Eberhart R. 1066 

Eberle F. 444 

Eberli D. 813, 1063, 1064, 1071 

Ebersdobler A. 514 

Echner H. 548 

Edelstein H. 187 

Eden C.G. 876, 976 

Egawa S. 434, 1122 

Egger S. 673 

Eggers H. 1018 

Eggert T. 823 

Eggink A.J. 806 

Egong E.A. 1048 

Egrot C. 10, 426, 907 

Ehdaie B. 603 

Ehlert M. 134, 677, 678, 679, V1, 

V22, V27, V28 

Ehrbar M. 813 

Ehrlich G. 772 

Eichelberg C. 83, 157, 1021 

Eid F. 599 

Eilers Y. 102 

Eimer C. 807, 1068 

Eizenakh I. 693 

Ekman M. 367 

Ekwuame K. 885 

El Atat R. 154 

El Atmani A. 538 

El Bouazzaoui S. 447 

El Douaihy Y. 589, 590 

El Feel A. 1078, V34 

El Hajj A. 144, 757, 1089, 1090, V5, 

V18, V24, V26 

El Harrech Y. 1034 

El Helou E. 154 

El Sherif E. 232 

El-Bahnasy A.M. 104 

El-Baz M. 602 

El-Diasty T. 194 

El-Gamal O. 104, 179 

El-Hefnawy A.S. 326 

El-Nahas A.R. 194, 386 

El-Sayed D.E. 177 

El-Serafi T. 331 

El-Tahtawy A. 510 

El-Tatawy H. 497 

Elabd A.S. 616 

Eladl M. 397 

Elbir F. V12 

Eldemerdash Y.M. 386 

Elder J.S. V3 

Eldessouky M. 1029 

Elgamal S.A. 616, 617 

Elhage O. 243 

Ellinger J. 775, 872 

Ellis W. 263, 911 

Elman B. 793 

Elsaid R.E. 396, 598 

Elsalmy S. 94 

Elsayed E.R. 91, 395, 397, 615 

Eltabey A.M. 637 

Emberton M. 22, 24, 747, 795, 821, 

824, 1096 

Enache M.A. 958 

Enache S.D. 958 

Engel O. 619, 621, 727, 728, 730, 

903 

Engelken F. 316 

Enokida H. 162, 334, 842, 843 

Enomoto Y. 476, 700 

Epplen R. 345, 559, 800 

Erb H. 237 

Erdem M.R. V12 

Erdmann K. 655 

Erdogru T. 914 

Eret V. 924 

Eri L.M. 672 

Erika E. 698 

Erikson S. 135 

Eriksson E. 927 

Erlich T. 253, 535 

Ernemann U. 548 

Ersoz C. V12 

Ervandian M. 420 

Esa A. 125 

Eschwege P. 538 

Escourrou G. 735 

Escudier B. 81 

Eskicorapci S.Y. 1016 

Esperto F. 439 

Esteban L.M. 975, 977 

Esteban M. 585, 622, 631, 632 

Eto M. 75, 654 

Ettinger S. 235 

Evans A. 905, 1092 

Evans A. 554 

Exposito-Ruiz M. 338 

Eziyi A.K. 194 

F 

Fabbri F. 29, 910 

Faber D.J. 930 

Facundo C. 325 

Fagertun H. 467 

Fahlenkamp D. V8 

Fairey A. 767 

Fais P.O. 550, 771 

Fajkovic H. 552, 603 

Falke J. 665 

Falsaperla M. 1047 

Fan Y.H. 627 

Fandel T. 707 

Fangerau H. 833 

Farag F. 805, 998 

Farahat Y.A. 104 

Farahini Isfahani F. 607, 1042 

Farcomeni A. 900 

Farfariello V. 465, 994 

Farin E. 69, 492 

Farina E. 122, 421, 570, 1054 

Fariña L. 830 



443 

Indices

Indices 


Farooqui N. 524 

Fasoulakis C. 699 

Favaretto R. 713 

Favorito L.A. 114, 389, 390, 520 

Favro M. 287 

Faydaci G. 1016 

Fayyazi A. 820 

Fazli L. 235, 236 

Faïs P.O. 448 

Feber A. 669 

Fedele F. 950 

Fehr J.L. 796 

Feitz W.F.J. 804, 805, 806, 998 

Fellin G. 415 

Fennouri M. V18, V26 

Ferda J. 924 

Ferdova E. 924 

Fernandes K.A. 929 

Fernandez C. 414 

Fernandez-Serra A. 428, 541 

Fernández P.L. 337, 339 

Fernández García I. 537 

Fernández Rodríguez A. 321 

Fernández Somoano A. 915 

Fernández-Aparicio T. 1005 

Fernández-Pello S. V47 

Fernö M. 896 

Ferrari M. 282, 303, 594 

Ferrari V. 926 

Ferreira Y.A. 503 

Ferreira Coelho M. 894 

Ferretti L. 707 

Ferriero M. 553, 601, 890 

Ferruti M. 948 

Ferschi M. 1002 

Fetisch J. 429 

Feyerabend S. 76, 429 

Fiard G. 556 

Ficarra V. 26, 31, 35, 552 

Fiet J. 941 

Fiette L. 1115 

Fiev D.N. 141 

Figueiredo A.J.C. 138, 322, 323, 

327, 667 

Figueiredo G. 536 

Figurin K.M. 88 

Filippi S. 4, 740 

Filonenko E.V. 961 

Finch W.J.G. 385 


Finelli A. 554, 929, 1049, 1092, 1122 

Finke S. 210 

Finocchio N. 284, 1002, 1054 

Fiori C. 14, 252, 792, 1105 

Fiorito C. 155 

Fisch M. 157, 603, 619, 621, 728, 

730, 808, 873, 903, 973, 974 

Fischer K. 93 

Fischer P. 581 

Fischereder M. 80 

Fisher G. 430 

Fisogni S. 926 

Fitzgerald C. V22 

Fizazi K. 127 

Flamini R. 74 

Fleischmann A. 159, 557 

Fleshner N.E. 543, 554, 929, 1049, 

1092, 1122 

Flinter F. 858 

Flomenbaum D. 246 

Fontana D. 378 

Fordham M.V.P. 336 

Forest S. 30 

Forghani E. 182 

Forgues A. 351, 352 

Fornara P. 93, 94 

Forsberg G. 126 

Fossati N. 107, 282, 570, 594, 908 

Fosså S. 130 

Fourati M. V5, V18, V26 

Fournier A. 634, 743 

Fournier G. V21 

Fowler C.J. 370 

Fradet V. 786 

Fradet Y. 263, 603, 767, 786, 911 

Fraga A. 499 

Fragkopoulou C. 153 

Franceschelli A. 60 

Franco A. 584, 622, 631, 632 

Franken C. 447 

Frankenfeld S. 114 

Frankenschmidt A. 394 

Franz D. 74 

Frati L. 900 

Frattini A. 1030 

Frea B. 96, 285, 534 

Freeman A. 22, 669, 795, 821 

Frencher Jr. S.K. 258 

Freschi M. 122, 278, 908, 909, 971, 

1012 

Frey P. 804 

Frias B. 368 

Fridman E. 253 

Friedersdorff F. 72, 316 

Friedman A. 134, 678, 679, 1106, 

V3, V22 

Friedrich M.G. 903 

Fritsch H. 392 

Fritsche H.M. 514, 558, 603, 775, 

798, 872, 981 

Frohlich M.W. 123 

Frohme C. 995 

Frohneberg D. 148, 158, 355, 357, 

362 

Fromont G. 547 

Frost M. 74, 80 

Fruchtman S. 660 

Frumenzio E. 527, 528, 586 

Fröhner M. 359 

Fujihara A. 629 

Fujii Y. 852, 856, 952 

Fujii Y. 90, 92, 143, 267, 298, 353, 

670, 871, 963, 1022 

Fujimoto H. 904 

Fujimoto N. 936 

Fujimura T. 233, 302, 476, 700, 845 

Fujioka T. 434 

Fujisawa M. 51, 59, 75, 160, 201, 

234, 254, 295, 312, 544, 1077 

Fujita T. 864 

Fujiwara K. 233 

Fujiwara T. 318 

Fukayama M. 164 

Fukuda M. 647 

Fukuda N. 233 

Fukuhara H. 889 

Fukuhara H. 242, 476, 700 

Fukui I. 267, 353 

Fukushima H. 267, 670 

Fuller T.F. 72, 316 

Fullhase C. 371, 734 

Funk R. V8 

Funyu T. 922 

Furihata M. 434 

Furriel F.G.T. 322 

Furukawa J. 201, 234, 254, 312, 

1077 

Furuya Y. 198 


Fuse H. 745 

Fuse M. 842, 843 

Fushimi K. 302 

Fürst C. 58 

Füssel S. 655 

G 

Gabe R. 824 

Gabr H. 91 

Gacci M. 4, 113, 119, 644, 740 

Gadda G. 29, 259, 278, 779, 784, 

909, 912, 1006 

Gaeta M. 268 

Gaffory G. 308, 426 

Gajda M. 166, 202 

Gakis G. 429, 442, 521, 604, 608, 

609, 651, 774, 841 

Galante Romo I. 897 

Galazan L. 539 

Galeano Álvarez C. 321 

Galfano A. 565 

Galiano M. 17, 151, 352, 713, 877, 

987, V25 

Galipeau J. 1069 

Gallina A. 122, 150, 284, 570, 761, 

779, 780, 784, 882, 908, 971, 

1002, 1006, 1012, 1054 

Gallucci M. 553, 601, 721, 890 

Gallé G. 772 

Galustian C. 243, 838 

Gameel T.A. 497 

Gamé X. 363, 364, 459, 466, 735 

Gancane S. 113 

Gandaglia G. 122, 282, 284, 371, 

372, 741 

Gandaglia G. 761 

Gandhi M. 861 

Ganzer R. 571, 798, 979, 981, 982 

Gao X. 563 

Garaganis G. 1100, 1104 

Garbeglio A. 419 

Garcia Parra R. 891 

Garcia-Casado Z. 428, 541 

Garcia-Tello A. 299 

Garcia-Vargas J. 130 

García D. 560 

García-Cruz E. 595, V29, V35 

Garmanova T.N. 393 

Garmo H. 456 

Garofalo M. 893, 1030 

Garsha K. 937 

Gasser T. 433 

Gaudez F. 765 

Gauffriau L. 634, 743 

Gausa L. 325 

Gavioli M. 778 

Gazzaniga P. 900, 901 

Ge R.B. 932, 933 

Geavlete B. 639, 955, 959, V46, V48 

Geavlete P.A. 469, 639, 894, 955, 

959, 1037, V46, V48 

Gelet A. 979, 980, 982 

Gelosa M. 948 

Genc G. 505 

Genevois S. 640 

Gentile G. 60 

Gentile V. 261, 342, 440, 900, 901, 

986 

Gentilucci A. 261, 342, 986 

Georgas E. 807, 1068 

George C. 1118 

George D. 124 

George S.L. 1111 

Georgescu D. 639, 955, 959, V46, 

V48 

Georgiopoulos I. 71, 218, 255, 810 

Gerber V. 841 

Gerharz E.W. 394 

Gerke O. 892 

Germann M. 433 

Germinale F. 354, 960 

Gertner M.R. 15 

Gerullis H. 807, 1068 

Geutjes P. 804, 805, 806 

Gfeller S. 756 

Ghani K.R. 134, 453, 677, 678, 679, 

1055, 1061, 1106, V1, V3, V27, 

V28 

Gharaati M.R. 607, 1042 

Ghei M. 1028 

Ghiculete D. 949, 1027 

Ghobeish A. 331 

Ghoneim M.A. 326, 602 

Ghoneim T. 369 

Ghorbel J. 279 

Ghoundal O. 1034 

Ghozzi S. 279 

Giacomo N. 35, 552 

Giancane S. 119, 248, 441, 970 

Giannantoni A. 465, 468, 994 

Giannarini G. 611 

Giannatempo P. 403, 407 

Giannessi C. 113, 119, 441, 970 

Giannini V. 792 

Gianolli L. 891, 1012 

Giedelman C. 94 

Giedl J. 558 

Gierth M. 558, 798 

Gil Ugarteburu R. 537, 915 

Gilfrich C. 872 

Gill I.S. 18, 142, 250, 257, 600, 883, 

V6 

Gillatt D.A. 716 

Gillion N. 712, 757, 1089, 1090, V24 

Gillitzer R. 463 

Gimel P. 144 

Giménez Alvárez M. 595 

Gingrich J.R. 126 

Gingu C. 405, 618 

Ginsberg D. 461 

Giovacchini G. 891, 1012 

Giovannone R. 261, 440, 901 

Girard F. V5, V18, V26 

Giron A.M. 506, 508 

Giton F. 941 

Giubbini R. 926 

Giuliano F. 369, 462, 472, 641, 705 

Giusti G. 375, 382, 1033 

Gjengstø P. 494 

Glaser T. 394 

Gleave M.E. 235, 236, 245, 661, 

1093 

Globe D. 577, 579 

Gluhov V.P. 723 

Goddard J.C. 828 

Godet J. 547 

Goebell P. 79, 128 

Goepel J. 965 

Goettsch C. 655 

Goetz A. 788 

Goineau A. 423 

Goktas C. 491, 953 

Goldberg J. 954 

Goldenberg S.L. 1093 

Golomb J. 535 

Golovashchenko M.P. 961 

Gomelsky A. 180 



445 

Indices

Indices 


Gomes H.L. 2 

Gomes P. 473 

Gomez I. 414 

Gómez Dos Santos V. 321, 811 

Gomez Veiga F. 414, 1095 

Gomez-Ferrer A. 289, 428 

Gondo T. 203, 244 

Gonen M. 603 

Gontero P. 148, 158, 355, 357, 361, 

362, 966, 1050, 1114 

Gonzales G. 370 

Gonzalez-Torres S. 99, 851 

González Rodríguez I. 537, 915, V47 

Gonçalves F. 132 

Goode P.S. 115 

Gopal Rao G. 294 

Gore M. 81 

Goretzki P. 807, 1068 

Gormley E.A. 171 

Gosalbez D. V30 

Gosh P. 589 

Goto A. 164 

Gotoh M. 108, 350, 574, 753, 768 

Gottardo F. 52 

Göttinger J. 3 

Gouttefangeas C. 76 

Govorov A.V. 564, 1122 

Gözen A.S. 573 

Gozzi C. 281, 288 

Grabe M. 37, 297 

Grabski B. 791 

Gradilone A. 900 

Graefen M. 148, 157, 158, 360, 572, 

681, 788, 873, 973, 974 

Grant G.D. 184 

Grasso A. 948 

Gratzke C. 1, 3, 7, 8, 110, 371, 372 

Gravas S. 1037 

Gray D. 80 

Graziotti P. 375, 382, 1033 

Greco F. 93, 94 

Green J.S.A. 68 

Greenwell T.J. 525 

Gregorini F. 1000 

Gregório B.M. 2, 114, 475 

Grenabo L. 724 

Gres P. 175 

Grigoryan Z. 296 

Grimaldi S. 565 


Grimm M.O. 166, 202, 210, 307, 315 

Grimm S. 651 

Grimm T. 717 

Grishina I.B. 812 

Grobholz R. 1097 

Groebli-Bolleter R. 692 

Groen J. 290 

Gross A.J. V45 

Gross N. 41 

Grosse J. 559 

Grossman H.B. 957 

Grouven U. 413 

Gruenwald I. 597, 702 

Grundy D. 374 

Gruschwitz T. 210 

Gruselle O. 664 

Grybas A. 967 

Gräber S. 455, 874 

Grünwald V. 83 

Gschwend J. 128, 674, 866, 1013 

Gsponer J.R. 668 

Guaglianone S. 553, 601, 890 

Guardia-Llorens M.A. 363 

Guazzoni G. 29, 259, 278, 570, 761, 

779, 784, 882, 908, 909, 910, 

912, 1002, 1006, 1080, V40 

Gubbiotti M. 468 

Gudima I.A. 191 

Gudinaviciene I. 967 

Gudkov A.V. 101, 496 

Gudmundsson E.O. 135 

Guerard M. 364 

Guilloteau V. 363, 364 

Guillotreau J. 25, 30, 216, 466, 550, 

771, V23 

Guirado L. 325 

Gujadhur R. 47 

Gulati M. 438 

Guliev B.G. 1103 

Gulino G. 286 

Gunia S. 514 

Guo J.M. 1035 

Guo Y.L. 275, 659 

Gupta A.D. 509 

Gurbuz C. 98 

Gurioli A. 966 

Gurung P.M.S. 22, 669 

Gutierrez C. 622, 631, 632 

Gutin A. 430, 431 

Gutschi S.T. 1004 

Guttilla A. 419 

Guven S. 1030 

Guy L. 448, 550 

Guérif S. 547 

H 

Ha H.K. 56 

Ha U.S. 42 

Haab F. 6, 10, 288, 292, 308, 426, 

907 

Haag-Molkenteller C. 461 

Haba T. 992 

Haber G.P. 25, 30, 94, 216, V23 

Habuchi T. 348, 434, 549, 1088 

Hach C.E. 648 

Hadi M. 607, 1042 

Haefner T. 71 

Haendler L. 569 

Haertig A. 529 

Haese A. 157, 263, 360, 572, 681, 

873, 911, 1004 

Haferkamp A. 238, 241, 775, 872 

Hagberg O. 870 

Häggman M. 126 

Haglind E. 1053 

Hah Y.S. 230 

Hahn A. 674 

Haider A. 591 

Haider M.A. 15 

Hailemariam S. 796 

Haiman C.A. 434 

Hajdinjak T. 575 

Hakama M. 152 

Hakenberg O.W. 168, 373, 514 

Haldemann R. 796 

Hall J. 41, 183 

Hall S. 766 

Halling T. 833 

Ham B.K. 625 

Ham W.S. 43, 230, 493 

Hamajima N. 9 

Hamamoto S. 852, 856, 952 

Hamann C. 655 

Hamdy F.C. 435 

Hamid A.R.A.H. 239 

Hamid R. 464, 470, 525 

Hamm B. 316 

Hamm R. 336 


Hammers H. 124 

Hampel C. 256, 463 

Han D.H. 94 

Han W.K. 275 

Han W.K. 217 

Handa H. 244 

Handschin C. 1063, 1064 

Hanna N. 84, 86, 555, 770, 1120 

Hansen J. 157, 603, 783, 911, 973, 

974, 1021, 1057 

Hansen S. 420 

Hantsbarger G. 686 

Hao J.R. 659 

Haqq C.M. 127 

Hara I. 125 

Hara T. 568 

Harabayashi T. 1052 

Harada K. 201, 254, 312 

Harik W.M. 376, 380 

Harneja N. 343 

Harraz A.M. 326 

Harris F. 153 

Harris M. 1038 

Hart C. 650 

Hartley L.J. 956 

Hartmann A. 558, 866, 868 

Harvey R. 438 

Harza M. 405, 618 

Hasan S.T. 1079, 1098 

Hasegawa M. 450, 593, 1109 

Hashimoto T. 146, 203, 244 

Haslam P.J. 1098 

Hatakeyama S. 348, 549, 647, 777, 

867, 922 

Hatano K. 847 

Hatano T. 244 

Hatori M. 458 

Hattori R. 108, 350, 750, 753, 768 

Haukka J. 115 

Hauser J. 27, V42 

Hauser V. 392 

Haustermans K. 1011 

Hautmann R.E. 561, V44 

Hayakawa M. 196 

Hayashi M. 737 

Hayashi T. 732 

Hayashi T. 546, 984 

Hayashi Y. 852 

Hayato Y. 895 

Hayes M.C. 1111 

Haynes A.M. 673 

Hazebroek F.W.J. 53 

Hazell S. 20 

He Z.S. 659 

Heck M.M. 1013 

Heckl S. 548 

Hedlund P. 3, 5, 7, 107, 231, 371, 

372, 487, 734, 739, 741, 898 

Heenan S. 517 

Heesakkers J.P.F.A. 273, 461, 998 

Hegele A. 449, 995 

Heidenreich A. 128, 345, 413, 559, 

800 

Heijnsdijk E.A.M. 260 

Heinrich D. 130 

Heinzelbecker J. 797 

Heinzelmann J. 307 

Heinzer F. 110 

Heinzer H. 157, 360, 680, 681, 873, 

903, 917 

Helal M. 464 

Helle S.I. 130 

Henderson B.E. 434 

Hennebelle D.S. 630 

Hennelotter J. 76 

Hennenberg M. 1, 3, 7, 8, 110 

Hennenlotter J. 310, 429, 442, 452, 

548, 651, 666, 841 

Hensel J. 645 

Hercegovac A. 165 

Herkommer K. 674 

Herman M. 343 

Hermieu J.F. 154 

Hernandez V. 1041 

Hernandez-Fernandez C. 207, 209, 

1085 

Hernando Arteche A. 897 

Hernowo B. 54 

Hernández V. 560, 760 

Herrmann E. 775, 872 

Herrmann T.R.W. 133, V45 

Herschbach P. 674 

Herschorn S. 690 

Hertle L. 872 

Hervouet J. 211 

Herwerth S. 715 

Hes O. 924 

Hessels D. 913 

Heuer R. 157, 903, 1021 

Heus I. 876, 976 

Hew M.N. 921, 1023 

Hew R. 424 

Heynemann H. 894 

Hickman O. 838 

Hidaka H. 162 

Hidalgo-Agulló G. 1005 

Hidoussi A. 588 

Hieda K. 984 

Hieronymi S. 983 

Higano C.S. 123 

Hillyer S. 25, 28, 30, 216, V23 

Hinoue M. 214 

Hirama H. 1091 

Hirata Y. 476 

Hirohashi Y. 199, 663 

Hirose M. 852, 856, 952 

Hirose Y. 856, 952 

Hisao S. 895 

Hita-Villaplana G. 1005 

Hjelm-Eriksson M. 417 

Hlasny E. 15 

Hmida W. 588 

Hoarau N. 448, 550, 771 

Hobbs A.R. 675, 676, 766, 989 

Hobisch A. 237 

Hocaoglu Y. 947 

Hoda R. 93 

Hodée C. 634, 743 

Hoeltl W. 1050 

Hofbauer L.C. 655 

Hoff J.R. 672 

Hoffman R.M. 657 

Hofmann R. 449, 995 

Höfner T. 775, 872 

Hofstädter F. 558 

Höglund M. 896 

Hohenfellner M. 775, 872, 1019 

Hohneder A. 651 

Høilund-Carlsen P.F. 892 

Hollox E.J. 424 

Hollywood D. 540, 849 

Holmberg E. 269, 1094 

Holmberg L. 456 

Holmberg M. 420 

Holmäng S. 870, 964 

Holtappels S. 1117 

Homma T. 996 



447 

Indices

Indices 


Homma Y. 164, 242, 302, 476, 700, 

736, 845, 854, 996 

Honeck P. 73 

Honey R.J.D.A. 949, 1027 

Hong H. 313, 879, 1024 

Hong S.H. 319, 485, 769 

Hong S. 230, 688 

Hong S.K. 33, 224, 283, 582, 628 

Honjo H. 9, 629 

Honma S. 938 

Hoogenkamp H.R. 805 

Hoogland A.M. 425 

Hoopman J. 490 

Hopt U.T. 73 

Hora M. 924 

Horenblas S. 78, 519, 865 

Horger M. 548 

Horie-Inoue K. 233, 845 

Horiguchi A. 196 

Horiguchi H. 302 

Horikawa Y. 549 

Horiuchi H. 839 

Horninger W. 392, 880 

Horstmann M. 344, 1007 

Horuz R. 491, 953 

Hoschke B. 1019 

Hoskin P. 130, 669 

Hosoda C. 700 

Hosoda F. 904 

Hossain H. 46 

Hosseinnia S. 135 

Hou J. 242 

Houlgatte A. 448, 550, 771 

Hovens C. 1093 

Hovington H. 786 

Howard M.E. 115 

Høyer M. 420 

Høyer S. 446 

Hoznek A. 712, 757, 1089, 1090, 

V24 

Hrbácek J. 608 

Hrouda D. 438 

Hrstic P. 76 

Hruby G.W. 1081 

Hruby S. 1009 

Hruza M. 573, 818 

Hsieh C.J. 437 

Hsieh J.T. 840 

Hsieh J.T. 55 


Hsu C.Y. 148, 158, 355 

Hsu J.Y. 258 

Hsu Y. 174 

Hu C. 563 

Hu Y. 24 

Huang C.N. 437 

Huang E. 257 

Huang H. 812 

Huang J.T. 260 

Huang S.P. 437 

Huang W.T. 563 

Huber A. 1097 

Huber S. 310 

Hubert J. 144 

Hübner W.A. 291 

Hudak L. 238 

Huebner A. 79 

Hughes D. 885 

Hughs Hallett A. 67 

Hugosson J. 269, 785, 1094 

Huguet J. 320 

Huguet Pérez J. 317, 324, 402, 719 

Huland H. 157, 360, 572, 681, 788, 

873, 911, 973, 974 

Hull L. 67 

Hulsbergen-Van De Kaa C.A. 665, 

718 

Humanes B. 207, 209 

Hung A.J. 18, 250 

Hupertan V. 154, 817 

Hurel S. 550 

Hurle R.A. 956 

Hurtado M. V37 

Hussain M. 124 

Hussain M. 464, 525 

Hussein A.A. 637 

Hussein I.M. Y. V49 

Hutson T.E. 81 

Huxhold C. 572 

Hwang E.C. 576 

Hwang I.S. 399, 576 

Hwang T.K. 319, 485, 769 

Hypolite J. 483 

Hyun J.S. 398, 701 

I 

Ibarlucea Gonzalez G. 1036 

Ibishev H.S. 61, 191 

Iborra Juán I. 289, 428, 541 

Ibraheem E. 177 

Ibrahim G. 331 

Ichikawa T. 842, 843, 1116 

Idu M.M. 1023 

Ifu G. 622, 631, 632 

Igarashi T. 1116 

Igawa Y. 476, 700, 736, 996 

Iimura Y. 1022 

Ikawa K. 40 

Ikeda K. 233 

Ikeda K. 984 

Ikeda M. 864 

Ikromov O. 306 

Imai K. 163 

Imanishi K. 647 

Imanishi M. 125 

Imoto I. 904 

Inagaki T. 125 

Inahara M. 1116 

Inazawa J. 434, 904 

Ingelmo-Torres M. 329, 339 

Innocenzi M. 261, 342, 986 

Ino Y. 242 

Inokuchi J. 931 

Inoue K. 889 

Inoue R. 244 

Inoue S. 233, 845 

Inoue S. 984 

Inoue T. 434, 839 

Inoue T. 549 

Intilla O. V43 

Introini C. 354, 960 

Ioakeimidis N. 699 

Ioannidis E. 370 

Iori F. 696 

Irani J. 547 

Irving S.O. 47, 1026 

Isac W. 30, V23, V33 

Isbarn H. 873, 973, 974, 1097 

Iseki R. 146 

Iselin C.E. 27, 1062, V42 

Ishida M. 1107 

Ishida S. 768 

Ishidoya S. 671, 1110 

Ishii C. 871, 884 

Ishii T. 732 

Ishikawa A 476 

Ishikawa N. 318 

Ishioka J. 13, 90, 92, 293, 884, 925, 


963, 1022 

Isin Dogan E. 853 

Issac C. 111 

Ito A. 139, 671, 1110 

Ito A. 233 

Ito H. 991 

Ito K. 458, 938 

Ito K. 196, 240 

Ito M. 267 

Itoh K. 863 

Itoh Y. 852, 856, 952 

Ivanovski O. 860 

Ivaz S. 438 

Iwai M. 164 

Iwamura M. 139, 864 

Iwata T. 629 

Izad Panahi M.H. 607, 1042 

Izawa J. 603, 720, 767, 887 

Izquierdo Reyes L. 317, 320, V30 

Izquierdo-Morejón E. 1005 

J Jachertz T. 1074 

Jackson J. 691 

Jacobsen N. 767 

Jacobsen S.J. 258, 443 

Jacobus S.J. 85 

Jacqmin D. 195, 204 

Jahnson S. 870 

Jaidane M. 588 

Jakob F. 655 

Jakobsen J.S. 892 

James N.D. 129, 130 

Jandrig B. 306 

Janes J. 691 

Janetschek G. 58, 1009 

Jang H.A. 66 

Jang M.J. 482 

Jannink S. 309 

Jans J.J.M. 197 

Jansen C.F.J. 273 

Jansonius A. 1001 

Janssen D.A.W. 273 

Janssen M.W.W. 455, 874 

Janzing-Pastors M.H.C. 1051 

Jara-Rascon J. 1085 

Jarir R. 1102 

Javed A. 524 

Javed S. 418, 819 

Javid A. 1042 

Jaw F.S. 55 

Jayaratna I. V6 

Jecu M. 639, 955, 959 

Jeldres C. 87, 552, 770, 1106 

Jeman J.M. 704 

Jenkins B. 461 

Jensen J.B. 446 

Jenster G. 425, 653 

Jeon S.S. 23, 34, 156, 710, 972, 1017 

Jeong B.C. 34, 94, 156, 972, 1017 

Jeong C.W. 33, 283, 582, 628 

Jeong H. 587 

Jeong I.G. 482, 879 

Jeong M.S. 628 

Jeong S.J. 283, 582, 628 

Jeong W. 134, 453, 677, 678, 679, 

1055, 1061, 1106, V1, V3, V28 

Jesche J. 1021 

Jeschke S. 1009 

Jewett M.A.S. 554, 929, 1049, 1092 

Jhaveri J. 134, 453, 677, 678, 679, 

1055, 1061, 1106, V1, V3, V22, 

V27, V28 

Ji Y.S. 225 

Ji Y.H. 482, 507 

Ji-Yeon H. 583 

Jiang B.T. 206 

Jievaltas M. 967 

Jimenez Cruz F. 830, 881 

Jimenez-Pacheco A. 99, 338, 851, 

859 

Jimenez-Pacheco A. 338 

Jiménez-Cidre M.A. 577, 585, 622, 

631, 632 

Jin H.R. 480, 484 

Jin J. 11, 275, 659 

Jo D.G. 181 

Johannessen D.C. 130 

John B. 819 

John H. 344, 1007 

Johnson J.R. 39 

Johnson T.M. 115 

Johnston B. 39 

Johnston R. 385, 1093 

Jolivet S. 38 

Jonat L.M. 490 

Jones A. 1118 

Jones K.M. 115 

Jones P.A. 1028 

Jones R. 129 

Joniau S. 96, 142, 148, 158, 355, 

357, 361, 362, 436, 606, 664, 

725, 726, 1011, 1113, 1121 

Jonsson M. 569 

Joo J.M. 228 

Joo K.J. 117, 118, 227 

Joo Y.M. 33 

Joulin V. V21 

Jovaisaite V. 1071 

Jozwiak S. 74 

Ju S.H. 156 

Ju Hyun J.H. 704 

Juang S.H. 437 

Juengel E. 238 

Jun K.K. 190 

Junaid I. 103, 620 

Jung B.C. 23, 710 

Jung G.W. 744 

Jung H.B. 230 

Jung H. 731, 733, 749 

Jung H.C. 225, 398 

Jung H.U. 379 

Jung H.S. 916 

Jung J.H. 228 

Jung J.L. 144 

Jung S.I. 399, 576 

Jung V. 648 

Jungwirth S. 581 

Junker K. 166, 202, 210, 307, 315 

Juszczak K. 802 

Jutzi S. V45 

K 

Kabakci A.S. 387 

Kachralis S. 103 

Kachrilas S. 64, 1039 

Kaftan B.T. 1074 

Kaga K. 1116 

Kagawa M. 884 

Kahlbacher H. 548 

Kaiho Y. 1110 

Kainz M.C. 1021 

Kajikawa H. 125 

Kajioka S. 737 

Kajiwara M. 984 

Kakehi Y. 1091 

Kakies C. 168 



449 

Indices

Indices 


Kakkas G. 432 

Kälkner K.M. 417 

Kallidonis P. 71, 94, 218, 255, 810 

Kalogeropoulou C. 810 

Kalogirou C. 314, 846 

Kalthoff O. 818 

Kamai T. 75 

Kamal I. 326 

Kamal M.M. 326 

Kamatani N. 434 

Kamba T. 75, 549 

Kamdoum L. 351 

Kameh D. 340, V20 

Kamel H. 1029 

Kamel M. 1029 

Kamihira O. 768 

Kamimura N. 348, 647, 777, 867, 

922 

Kamoi K. 400, 504, 629 

Kamolov B. 330 

Kampel-Kettner K. 1021 

Kampschulte M. 48, 1072 

Kamradt J. 455, 648, 708, 715, 874 

Kanai Y. 904 

Kanao K. 919 

Kandimalla R. 328 

Kaneko G. 140, 593, 1107, 1109 

Kang J.H. 34 

Kang J.Y. 224 

Kang K.S. 703 

Kang S.H. 66 

Kang S.G. 66 

Kang S.H. 184 

Kang T.W. 399, 576 

Kanno T. 839 

Kanona H. 1003 

Kantoff P.W. 123 

Kao W.T. 627 

Kaouk J.H. 25, 28, 30, 94, 216, V23, 

V33 

Kapatou K. 432 

Kaplan J.R. 85 

Kaplan R. 824 

Kaplan S.A. 644, 683, 690 

Kapoor A. 767 

Karadimou A. 311 

Karakiewicz P.I. 84, 86, 249, 783, 

1120 

Karam G. 211 


Karamanou M. 829 

Karasavvidou F. 432 

Karavitakis M. 20 

Karbalaei Sadegh M. 367 

Karcz W.K. 73 

Kariotis I. 1100, 1104 

Karl A. 717, 957 

Karlsen S. 672 

Karnes R.J. 362 

Karseladze A. 330 

Karsenty G. 369, 550, 771 

Karstoft J. 892 

Kasabov B.J. 711 

Kashiwagi E. 931, 936 

Kasivisvanathan V. 438, 821 

Kassab A. 216, V23, V33 

Kassouf W. 552, 603, 767 

Kastner C. 439, 814 

Kasyan G.R. 271, 1075 

Kata S. 445 

Katafigiotis I. 542 

Katagigiotis S. 370 

Katevatis A. 699 

Kato M. 350, 750 

Katsuoka Y. 745 

Kattan M.W. 146 

Katz T. 226 

Katzenwadel A. 377 

Kavia R. 370 

Kawabata M. 295 

Kawai T. 164 

Kawai Y. 568 

Kawakami K. 842 

Kawakami S. 143, 267, 298, 353, 

670, 871, 884 

Kawamura C. 214 

Kawamura S. 348, 1088 

Kawano P.R. 954 

Kawano Y. 654 

Kawasaki Y. 1110 

Kawashima A. 847 

Kawauchi A. 9, 139, 400, 504, 629 

Kazanov D. 539 

Keck B. 868 

Kedar D. 1046 

Kedia G.T. 738, 739 

Keller H. V10 

Kelly B.D. 36 

Kelly J.D. 669 

Kemal S. 853 

Kenji K.S. 146 

Kennelly M. 694 

Kenton K. 171, 174 

Keoghane S.R. 1038 

Kerst J.M. 865 

Kessler T.M. 1000 

Kessler T. 788 

Khachaturyan A. 330 

Khalil S.A.S. 395, 396, 397, 598 

Khan A. 47 

Khan M.S. 63 

Khan N. 63 

Khani F. 561 

Khanna R. V23 

Khatami A. 1094 

Khelaia A.V. 697 

Kheoh T. 127 

Kheradmand F. 36 

Kheterpal E. V27 

Khiari R. 279 

Khoder W. 451, 1010, V7 

Khorrami M.H. 607, 1042 

Khorrami S. 113, 119 

Khouni H. 279 

Khullar V. 578, 684 

Kihara K. 13, 90, 92, 143, 267, 293, 

298, 353, 670, 871, 884, 925, 

963, 1022 

Kijima T. 13, 293, 298, 884 

Kikuchi E. 140, 450, 552, 593, 902, 

919, 939, 1107, 1109 

Kil P. 149, 913 

Kilchevski A. 597 

Kilic M. 98 

Kilinski R. 48 

Kilpeläinen T. 152 

Kim C.S. 313, 482, 688, 879, 1024 

Kim D.H. 43, 493 

Kim D.K. 480, 688 

Kim D.Y. 623, 754 

Kim F.J. 94 

Kim G.N. 173 

Kim H.G. 190 

Kim H.H. 32, 82 

Kim H.J. 82, 283 

Kim H.J. 23, 34, 156, 710, 972, 1017 

Kim H.T. 225, 398 

Kim H.W. 219, 230 


Kim I.S. 533 

Kim J.H. 412, 501 

Kim J.H. 181 

Kim J.J. 66, 412, 501, 625, 701 

Kim J.Y. 173 

Kim J.C. 219, 623, 688, 754 

Kim J.H. 916 

Kim J.W. 412, 501, 625 

Kim J.W. 265, 346, 507, 875 

Kim K.D. 916 

Kim K.H. 731, 749 

Kim K.S. 507 

Kim K.T. 32 

Kim S. 42 

Kim S. 1024 

Kim S. 81 

Kim S.B. 85 

Kim S.C. 507 

Kim S.D. 526 

Kim S.H. 219 

Kim S.H. 224 

Kim S.J. 319, 485 

Kim S.O. 399, 576 

Kim S.U. 478, 486 

Kim S.W. 319, 474, 482, 485, 533, 

701, 769 

Kim T.B. 731, 733, 749 

Kim T.H. 526, 916 

Kim W.S. 875 

Kim W. 228 

Kim W. 972 

Kim W.J. 480, 484 

Kim Y.T. 43, 493, V50 

Kimcius M. 967 

Kimura T. 318 

Kingswood C. 74, 80 

Kinoshita S. 295 

Kinsella J.E. 759, 790 

Kirchhoff S.M. 281 

Kirkham A. 24, 795, 1096 

Kirschstein T. 373 

Kisa C. 511 

Kitagawa M. 125 

Kitagawa Y. 745 

Kitakoji K. 9 

Kitamura H. 163, 199, 663 

Kitrey N.D. 535 

Kitrou P. 810 

Kitta T. 500, 502, 999 

Kiyoshima K. 161 

Klarskov P. 985 

Klaver M. 746 

Klaver S.O. 782 

Klecka J. 683, 924 

Kleinclauss F. 610 

Klevecka V. 566, 1056 

Kliesch S. 52, 592 

Kliment J. 130, 132 

Klingler H.C. 1036 

Klinglmair G. 392 

Klocker H. 392, 649, 880, 935 

Klose U. 548 

Kloskowski T. 803 

Klosterhalfen B. 807, 1068 

Kluth L.A. 619, 727, 728, 730, 903, 

966, 973, 974 

Knebelman B. 860 

Kneitz B. 314, 355, 361, 362, 436, 

844, 846 

Kneitz S. 436, 846 

Kniemeyer O. 210, 315 

Knippschild S. 995 

Knipscheer B.C. 913 

Knoll T. 73, 498 

Ko Y.H. 66, 340, V20 

Kobayashi H. 742 

Kobayashi K. 984 

Kobayashi S. 13, 871, 963 

Kobayashi T. 852, 856, 952 

Kobayashi T. 839 

Koch D. 981 

Koch E. 796 

Koch R. 359 

Kocjancic E. 182 

Kockelbergh R.C. 424, 828 

Kocot A. 1076 

Koehler A. 935 

Koehling R. 373 

Koga F. 13, 90, 92, 143, 267, 293, 

298, 353, 670, 871, 884, 925, 

963, 1022 

Kogan M.I. 45, 61, 191, 723 

Kohlschreiber S. 1019 

Kohri K. 852, 856, 952 

Kohrman M. 74 

Koie T. 348, 647, 777, 867, 922 

Koike H. 198, 458, 938 

Kojima S. 842, 1116 

Kojima Y. 214 

Kojovic V. 612, V9 

Kok E.T. 116 

Koksoy S. 914 

Kolonel L.N. 434 

Komai Y. 871, 884 

Kompier L. 328 

Komura T. 125 

Komyakov B. 1101, 1103 

Kondo T. 9 

Kong L. 649 

Kono H. 919 

Konstandinidis H. 1104 

Koo K.C. 230 

Kopa Z. 827 

Korf B. 74 

Kortekangas H. 554 

Kortmann B.B.M. 805, 806 

Koruk E. 387 

Kosaka T. 902, 939, 1109 

Koska M. 79 

Koupparis A.J. 716 

Kousparos G. 522 

Kouyoumdjian J.C. 538 

Kovylina M. 1122 

Kowalczyk T. 803 

Kozlov R.S. 186 

Kraischits N. 876, 976 

Kramer M.W. V45 

Kranse R. 53 

Krasulin V.V. 723 

Kraus S. 539 

Kraus S.R. 171, 174 

Krause H. 306 

Kravchick S.G. 277, 605 

Krebs M. 844 

Krebs S. 49 

Krengli M. 358 

Kreuzberg B. 924 

Kriegmair M. 957 

Krischel M. 833 

Kroepfl D. 566, 1056 

Kroeze S.G.C. 197 

Kron K. 543 

Kroon B.K. 78, 460, 782 

Krueger A. 681 

Kruijssen L.W.J. 197 

Kröger N. 315 

Kubo M. 434 



451 

Indices

Indices 


Kucharczyk W. 15 

Kucheria R. 438 

Kuczyk M.A. 133, 738, 739, 1018, 

V45 

Kudo S. 647, 777, 922 

Kudoh J. 580, 992 

Kudoh S. 348, 867 

Kuefer R. 561 

Kuehne K. 680 

Kühs U. 429, 442, 841 

Kujala P. 152 

Kuk C. 554, 1122 

Kulchavenya E. 300 

Kumano S. 476 

Kumar P. 103, 831 

Kumar S. 129 

Kumar V. 518 

Kume H. 164, 302, 476, 700 

Kümmerlin I.P.E.D. 921 

Kumon H. 1044 

Kums J. 1030 

Kunath F. 868 

Kundin V.Y. 185 

Kunz I. 1056 

Kuperman R. 74 

Kupilas A. 381 

Kurane C.S. 100, 221, 488 

Kuratsukuri K. 745 

Kuroda K. 196 

Kuroiwa K. 161 

Kurosch M. 241 

Kuruma H. 235 

Kurz M. 1007 

Kurzidim S. 384, 1032 

Kusche D. V14, V39 

Kusek J.W. 171 

Kuslich C. 435 

Kusuda Y. 201, 254, 312 

Kwak C. 82 

Kwang Hyun K.H. 704 

Kwiatkowski M.K. 785, 1097 

Kwon C.H. 117, 118, 227, 731, 733 

Kwon D.D. 399, 576 

Kwon D.H. 225, 398 

Kwon J.B. 173 

Kwon M.H. 480, 484 

Kwon T.G. 398 

Kyllo R.L. 28 

Kypra R. 654 


Kyriazis I. 218, 255, 810 

Kyroudi-Voulgari A. 695 

Kyu Han W. 94 

L 

La Croce G. 122, 372, 741, 1054 

La-Touche S. 517, 828 

Laajili A. 279 

Laato M. 905 

Labanaris A.P. 341, 356, 454, 457, 

567, 968, 969, 1060 

Lachman B. 226 

Lacombe L. 767, 786 

Ladurner Rennau M. 880 

Lafuma A. 223 

Lagerveld B.W. 1112 

Laguna M.P. 921, 930, 1023, V37 

Lahme S. 105, 376, 380, 384, 820, 

1032 

Lahoz-García C. 99, 338, 851, 859 

Laing R.W. 418 

Lakmichi M.A. 1102 

Lam G. 709 

Lam W. 461, 517 

Lamb B.W. 68 

Lambrecht A. 102 

Lambrechts D. 311 

Lambropoulos A. 370 

Lammers B. 807, 1068 

Lammers R.J.M. 1051 

Lamoureux F. 236, 245 

Lan Y.H. 437 

Lanchbury J.S. 430, 431 

Lanciotti M. 248, 970 

Lang H. 195, 204 

Lang J.M. 144 

Lange P. 341, 356, 454, 457, 567, 

968, 969, 1060 

Lange R.M. 410 

Lange S. 413 

Langheinrich A.C. 48, 1072 

Langley S.E.M. 418, 819 

Lantoine-Adam F. 111 

Lanz M. 41, 183 

Lanzi F. 77, 441, 970 

Lapini A. 77, 248, 970 

Larcher A. 29, 259, 278, 779, 909, 

912, 1006, 1080, V40 

Largo R.A. 614, 756, 813 

Larue S. 351 

Lasalle M. 189 

Laske K. 76 

Laso I. 811 

Lassila R. 787 

Latil A. 111 

Lattouf J.B. 767 

Latu M. 554 

Lau K.M. 335 

Laufer M. 253 

Laumeier T. 449 

Laurent G. 771 

Lavery H.J. 675, 676, 766, 989 

Lawrentschuk N. 1092 

Laydner H.K. 30, 216, V23, V33 

Lazaro A. 207, 209 

Lazica D.A. 635 

Lazzeri M. 29, 259, 278, 527, 586, 

721, 909, 910, 912, 1080, V40 

Le Maux A. 462 

Leal M. 388 

Lebas Bernardet S. 211 

Leboulleux S. 1105 

Lebret T. 369, 610 

Lee B.K. 33, 283, 582, 628 

Lee C. 482 

Lee D. 180, 531 

Lee D.H. 230, 313 

Lee D.I. 876, 976 

Lee D.H. 643, 988 

Lee D.H. 219 

Lee G.H. 274 

Lee H.D. 181 

Lee H.E. 32 

Lee H.H. 217, 230 

Lee H.J. 478, 486 

Lee H.L. 224 

Lee H.M. 474 

Lee H.M. 23, 34, 156, 224, 710, 972, 

1017 

Lee H.S. 990 

Lee H.Z. 437 

Lee J. 482 

Lee J.E. 1017 

Lee J.G. 66, 147, 412, 501, 625, 688 

Lee J.K. 283, 582, 628 

Lee J.L. 313 

Lee J.S. 181 

Lee J.Y. 319, 485, 769 


Lee J.W. 173 

Lee J.Y. 94 

Lee K.S. 688, 990 

Lee R. 343 

Lee R. 31, 35 

Lee S.B. 587 

Lee S.C. 33, 283, 582, 628 

Lee S.E. 33, 283, 582, 628 

Lee S.J. 478, 486 

Lee S.H. 643, 988 

Lee S.W. 94 

Lee S.W. 701 

Lee S.W. 34, 990 

Lee S.Y. 124 

Lee S.Y. 34, 156, 972, 990, 1017 

Lee W.K. 173 

Lee Y.J. 412 

Lee Y.J. 82, 582 

Lee Y.S. 688 

Leemans A. 1001 

Lehmann J. 868 

Lei Q. 483 

Leiblich A. 1118 

Leighton T. 950 

Lelong E. 422 

Lemack G.E. 171, 178, 180 

Leng G. 444 

Lenherr O. 820 

Lennernäs B. 417 

Leonardo C. 16, 696, 1047 

Leonhartsberger N. 408, 409 

Lepor H. 812 

Lepri E. 468 

Lepri L. 468, 586 

Lerut E. 311, 664, 1011 

Leskovar J. 575 

Leslie S. 883 

Leslie T.A. 1115 

Leto A. 696 

Leung H.Y. 646, 662 

Leung R. 246 

Lev M. 539 

Leveridge M.J. 929 

Levinson A.W. 675, 676, 766, 989 

Levitt S. 417 

Levy E. 189 

Lewandowski P.M. 257, 883, V6 

Lewis R.A. 686 

Leyten G.H.J.M. 913 

Leyva O. 830 

Lezrek M. 1034 

Lhamas A. 499 

Lhez J.M. 793 

Lho Y.S. 190 

Li F. 51, 59 

Li J. 25 

Li J. 812 

Li J.H. 127 

Li L.Y. 563 

Li X. 11 

Liang L.L. 275, 659 

Liao C.H. 951 

Liatsikos E. 71, 94, 218, 255, 810 

Liberati E. 1045 

Libon C. 111 

Lidereau R. 169 

Lieberman S.F. 443 

Liedberg F. 870 

Liggins R.T. 661 

Liguori G. 698 

Limido L. 276 

Limmer S. 8 

Lin A.T.L. 471 

Lin C.C. 471 

Lin G. 707 

Lin K.J. 120 

Lin T.L. 627 

Lindner U. 15 

Lindner V. 195, 204 

Lindqvist K. 724 

Linet N. 536 

Linto T. 906 

Linton K.D. 1043 

Liourdi D. 218, 810 

Lisbona A. 423 

Lisi D. 261 

Liske P. 105, 376, 380, 384, 820, 

1032 

Liss M.A. 39 

Lista F. 299 

Lista G. 29, 779, 784, 909, 910, 912, 

1080, V40 

Litman H.J. 171 

Liu K.L. 120 

Liu W.J. 11, 275, 659 

Liu X.H. 206 

Livni N. 20 

Ljungberg B. 135, 870, 927 

Lledo-Garcia E. 207, 209, 1085 

Llorente C. 560, 760, 1041 

Lluel P. 363, 364 

Lobic L. 605 

Loch A. 791 

Loch T. 19, 791, 894 

Lockwood G. 1122 

Lockyer R.C. 1111 

Loeb S. 447, 682, 822, 825 

Loeser A. 314, 1076 

Loewen H. 566 

Logue J. 130 

Lokshin K. 296 

Lolli C. 468 

Long J.A. 216, 448, 556, V23 

Long K.P. 11 

Long Q.L. 1035 

Loo R.K. 258, 443 

Lopes I. 536 

Lopes R.E. 388 

Lopes T.A. 272, 997 

López B. 560 

López J.M. V38 

López Farré A. 897 

López-Fando L. 622, 631, 632 

Lopez-Guerrero J.A. 428, 541 

Löppenberg B. 823 

Loric S. 538 

Losa A. 910 

Losinno F. 60 

Lotan Y. 552, 603 

Loutochin O. 1069 

Lövgren K. 896 

Lozano J.J. 337, 339 

Lu T.L. 437 

Lucet J.C. 38 

Luciani L.G. 188 

Ludden C. 36 

Lue T.F. 707 

Lueck A. 79 

Lughezzani G. 29, 259, 278, 784, 

909, 910, 912, 1006, 1080, V40 

Luider T.M. 653 

Lukacs B. 10, 223, 634, 743 

Lukacz E. 174 

Lum J. 97 

Lumen N. 725, 726, V11 

Lundon D.J. 36 

Lundstam S. 135 



453 

Indices

Indices 


Lundstedt S.O. 131 

Lunt C.R. 336 

Luo C. 831 

Lupu F. 405, 618 

Luque M.P. 595, 943, 945 

Lusuardi L. 1009 

Lydon A. 129 

Lynch T.H. 540, 849 

Lynn N.K. 1003 

M 

Maarouf A.M. 396, 397, 598 

Maarouf J. 279 

Määttänen L. 152 

Maccagnano C. 912 

Macchione N. V49 

MacDiarmid S. 579, 694 

Macek P. 608 

MacFarlane H. 950 

Maciel L.C. 1067 

MacNeil S. 1065 

Madden T.B.P. 837 

Maddison B. 67 

Madersbacher S. 581, 748, 789 

Maeda T. 450, 593, 939, 1107, 1109 

Maga T. 259 

Maggi M. 4, 113, 119, 644, 740 

Magheli A. 316 

Magnani C. 758 

Magnani T. 758 

Magri V. 44 

Mahfouz W. 1069 

Mahé M.A. 423 

Maini C.L. 890 

Mains E. 445 

Maiolo V. 60 

Maj R. 665 

Majima T. 768 

Majstorovic M. V9 

Makanjoula J. 826, 1099 

Makarevic J. 238, 241 

Malavaud A. 459, 466, 735, 793, 

1119 

Malhotra B. 510 

Malik Z. 129 

Malila N. 152 

Malinina O. 693 

Malkhasjan V.A. 1075 

Malkoc E. 404 


Mallat F. 588 

Malmström P.U. 870 

Malone P. 401, 516 

Malossini G. 188, 301, 304 

Malouf D. 416 

Maltry N. 654 

Malykhina A.P. 483 

Managadze L.G. 697 

Mancina R. 740 

Mandelshtam V. 812 

Manea C.N. V13 

Manferrari F. 121, 893 

Manfredi M. 14, 252 

Mangel L. 83 

Mangera A. 1065 

Mangir N. 481 

Manivet P. 538 

Mannina M. 70 

Mannweiler S. 1004 

Mano R. 1046 

Mansson W. 870 

Mantella A. 136, 248 

Marangi F. 286 

Marazioti A. 218 

Marberger M. 127, 263, 911 

Marchand C. 550, 771 

Marchand L.L. 434 

Marchand V. 423 

Marchioro G. 148, 158, 358 

Marconi L.S.O. 323, 327 

Marcén Letosa R. 321 

Mardiak J. 83 

Marenghi C. 801 

Marenghi C. 758, 764 

Margel D. 905, 1046 

Margulis V. 552 

Maria C. 958 

Mariappan P. 956 

Marignol L. 849 

Mariño A. 414 

Markland A.D. 115, 174 

Marks L.S. 263, 911 

Maroof A.M. 177 

Marras E. 44 

Marri R.R. 1003 

Marschall-Kehrel D. 578 

Marschner N. 79 

Marsden G. 435 

Marsh H. 97 

Marszałek A. 802, 803 

Marten-Mittag B. 674 

Martin G.L. V51 

Martin M.D. 1041 

Martin N. 683, 684, 686 

Martin X. 144, 980 

Martinez De Hurtado J. 1041 

Martinez Sarmiento M. 881 

Martins-Silva C. 993 

Martorana G. 121, 893, 966 

Martzog J.C. 452 

Martín Huéscar A. V47 

Marukhnenko D.V. 393 

Masedu F. 1045 

Mashiah A. 226 

Masieri L. 77, 248, 441, 970 

Masius R. 328 

Mason M. 129 

Mason R. 714 

Masood J. 64, 103, 620, 1039 

Massfelder T. 195, 204 

Massie C.E. 942 

Masson S. 129 

Masson-Lecomte A. 351 

Massoud W. V5, V18, V26 

Masters J.R.W. 669 

Mastuyama H. 568 

Masuda H. 13, 90, 92, 143, 267, 293, 

298, 871, 884, 925, 963, 1022, 

1116 

Masumori N. 163, 199, 574, 663 

Masumoto H. 984 

Masunaga K. 992 

Mateev D.I.V. 711 

Mateo E. 299 

Matloob R. 137, 303, 421, 923 

Matsubara A. 75, 546, 984 

Matsuda S. 302 

Matsuda T. 139, 745 

Matsueda S. 863 

Matsui H. 198, 458, 938 

Matsui S. 549 

Matsui W. 652 

Matsui Y. 170, 839 

Matsukawa Y. 108, 750, 753 

Matsumoto E. 767 

Matsumoto H. 235, 568 

Matsumoto K. 552, 864 

Matsumoto M. 999 


Matsumoto M. 295 

Matsumoto T. 854 

Matsuo T. 545, 899 

Matsuoka K. 863 

Matsuoka Y. 13, 92, 143, 267, 293, 

884, 925, 963 

Matsushita K. 51, 59 

Matsuura O. 768 

Matsuyama H. 125, 235 

Mattelaer J.J. 836 

Matthews J. 673 

Matveev V.B. 88, 330 

Mauermann J. 767, 786 

Maugeri G. 1047 

Maurin C. 448 

May M. 514, 558, 775, 872, 1015, 

1019 

Mayrhofer K. 1004 

Mazel J.W. 782 

Mazerolles C. 459, 1119 

Mazima T. 753 

Mazzanti R. 77 

Mazzetti S. 792 

Mazzoli S. 188, 304 

Mazzon G. 698 

McCabe J.E. 336 

McCarthy P. 36 

McDermott C. 184 

McGill N. 1111 

McGrath J.S. 636, 714 

McKay N.G. 374 

McKean M. 332 

McNeill S.A. 1048 

McVary K.T. 644 

Meacci F. 188, 304 

Mearini L. 527, 528, 586 

Medeiros Jr J.L. 410 

Meek W. 427 

Meert T. 1113, 1121 

Mehan N.J. 416 

Mehnert A. 966 

Mehnert U. 579, 1000 

Meijer G.J. 869 

Meijer R.P. 865 

Mein R. 858 

Meinhardt W. 519, 865 

Meißner P. 58 

Mejean A. 144 

Méjean A. 308, 311 

Mele F. 14, 252, 792 

Melekos M. 432 

Meletiadis J. 998 

Meletis E. 1066 

Meliani E. 1114 

Melides P. 1100, 1104 

Mellado B. 83 

Mellon J.K. 424 

Melo M. 1067 

Menchi I. 441 

Mengual L. 329, 337, 339 

Menon M. 134, 453, 677, 678, 679, 

1055, 1061, V1, V27, V28 

Mentine N. V18 

Meria P. 765 

Merlière Y. 634, 743 

Mertens L.S. 865 

Mesher D. 430 

Messa C. 891, 1012 

Messa P. 948 

Meunier A. 540, 849 

Meyer B. 202 

Meyer C.P. 1021 

Miano R. 1047 

Micali F. 1045 

Michael M. 21 

Michaelson D. 124 

Michel M.C. 578, 685 

Michl U. 360, 681, 917 

Micol L. 804 

Miernik A. 69, 73, 102, 377, 492, 

944 

Mierzwiak J. 193 

Migita M. 992 

Mihalakis A. 12 

Mihoko S. 895 

Mikami K. 112, 920 

Mikami S. 902, 919 

Mikhail M. 814 

Miki T. 9, 400, 504, 629 

Milani A. 403, 407 

Miller D. 50 

Miller K. 72, 128, 306, 316 

Miller P. 937 

Mills I.G. 942 

Milner T. 490 

Milonas D. 967 

Milosevic M. 905 

Min K.S. 526, 701 

Minami K. 1052 

Minami T. 732 

Minamida S. 864 

Minault D. 211 

Minervini A. 136, 248, 970 

Mingat N. 459 

Minhas S. 401, 516 

Minich A.A. 247 

Minisola F. 342, 986 

Minner S. 572, 903 

Miranda G. 600 

Miranda N. 17, 151, 877, V25 

Mirciulescu V.A. V46 

Mirka H. 924 

Mirkin Y. 693 

Mirone V. 641, 644, 705 

Miroshnichenko E.A. 191 

Mirri F. 721 

Mirtti T. 905 

Mirvald C. 405 

Mirylenka L.V. 247, 551 

Misrai V. 793 

Mitcheson H.D. 683 

Mitre A.I. 62 

Mitropoulos D. 12, 695 

Mitsui T. 500, 502, 999 

Mitsuzuka K. 348 

Mitsuzuka K. 549, 1088 

Mittino I. 287 

Mitusov V.V. 723 

Miwa Y. 991 

Miyachika Y. 568 

Miyajima A. 140, 450, 593, 902, 919, 

939, 1107, 1109 

Miyake H. 51, 59, 75, 160, 201, 234, 

254, 312, 544, 1077 

Miyamoto K. 546, 984 

Miyamoto Y. 992 

Miyata Y. 545, 899 

Miyazaki Y. 752 

Miyazato M. 1110 

Mizuno R. 919 

Miñana-Lopez B. 1005 

Moalli P. 174 

Möckel C. 796 

Mogorovich A. 569 

Mohamed N.E. 675 

Mohammadi M. 607, 1042 

Mohammed N. 93 



455 

Indices

Indices 


Mohee A. 47 

Moldoveanu C. 639, 955, 959 

Molina A. 127 

Molina R. 1085 

Molina W.R. 94 

Molinié V. 311 

Moll F. 833 

Møller H. 430 

Molon A. 276 

Moncada-Iribarren I. 1085 

Mondaini N. 188, 301, 1114 

Mongiat-Artus P. 765 

Monrós Lliso J.L. 289 

Montanari E. 44, 1030, 1037, V49 

Montgomery B. 819 

Montorsi F. 29, 552, 898 

Montoya-Chinchilla R. 1005 

Moon D. V51 

Moon D.G. 147, 412, 501, 562, 625, 

703 

Moon G. 229 

Moon H.S. 43, 493, V50 

Moon K.H. 225, 398, 701 

Moon Y.T. 916 

Moore C.M. 821, 1096 

Mor Y. 253, 535 

Morag R. 539 

Moran D. 540 

Moran S. 124 

Moran Pascual E.J. 881 

Moreira P.N.S.B. 138, 322, 327 

Morel-Journel N. 640 

Morelli A. 4, 113, 119, 740 

Moreno-Aranda J. 835 

Moreno-Palacios J. 835 

Moretti D. 303 

Morgia G. 1040 

Mori K. 647, 867 

Morikawa N. 40 

Morikawa T. 164 

Morikawa Y. 198 

Morimoto R. 1110 

Morita S. 164 

Moriya F. 863 

Moriya K. 500, 502 

Morloh K. 858 

Morote J. 264, 347, 848, 975, 977 

Morozova O.A. 296 

Morris D. 36 


Mortimer P. 124 

Mosaheb N. 19 

Mosbah A. 602 

Mosbah A.F. 588 

Moschini M. 150, 372, 741 

Mosquera J.M. 561 

Moss B. 814 

Moss S. 785 

Mostafa M. 1082 

Mostafid H. 956 

Mota A. 138, 322, 323, 327, 667 

Motta F. 926 

Mottrie A. 26, 31, 35, 876, 976 

Motzer R.J. 81 

Moudouni S.M. 1102 

Moufid K. 1034 

Moulin M. 610 

Mouracade P. 351 

Mourey E. 144 

Mourmouras N. 1100, 1104 

Moursy E.S. 512 

Moutzouris G. 432 

Mozer P. 383, 794, 817 

Mtui J. 246 

Mueller L. 79 

Mugabe C. 661 

Muhletaler F. 134, 678, 679, V1, 

V27, V28 

Muir G.H. 155 

Mukherjee S. 246 

Mulders P.F.A. 127, 200, 263, 309, 

911, 913, 928 

Müller A. 614 

Müller R. 392 

Müller S.C. 128, 775, 872 

Multescu R. 639, 955, 959, V46, V48 

Multigner L. 940, 941 

Münch F. 192 

Mundhenk J. 452, 521, 609 

Mundy A.R. 722, 1073 

Muneer A. 401, 516 

Müntener M. 756 

Murakami Y. 164 

Muramaki M. 201, 254, 312, 544, 

1077 

Murata T. 233, 845 

Murata Y. 233 

Murez T. 610 

Murphy D.G. V51 

Murray S. 193, 530 

Murta C.B. 773 

Murtola T.J. 266, 349 

Musch M. 566, 1056 

Muselaers C.H.J. 928 

Musitelli S. 832 

Muslumanoglu A. 498, 1036 

Musquera Felip M. 215, 212, 317, 

320, 324, 719, V29, V30, V35, 

V36 

Mussari S. 415 

Mustafa A. 853 

Muto G. 553, 601 

Muyshondt C. 175 

Myatt A. 1009 

Mynderse L. 957 

Myung S.C. 916 

N 

Na S.W. 399 

Na Y.G. 731, 733 

Nabeeh A. 602 

Naber K.G. 37, 192 

Nabi G. 332, 445 

Naboka Y.L. 191 

Nadir A. 539 

Nagamori S. 1052 

Nagao K. 125, 309 

Nagao T. 244 

Nagase H. 233 

Nagase K. 991 

Nagashio R. 904 

Nagata H. 593, 919, 939 

Nagata M. 164, 700 

Nagata T. 992 

Nagele U. V45 

Nägele T. 548 

Nagle R. 427, 937 

Nagy D. 937 

Naimi N. 653 

Nair R. 391 

Naito S. 75, 161, 737, 931, 936 

Naitoh Y. 400, 504 

Najari B.B. 157 

Nakagawa H. 434 

Nakagawa K. 139, 140, 593, 919, 

1109 

Nakagawa M. 162, 334, 842, 843 

Nakagawa T. 244 


Nakai Y. 847 

Nakama-Peeples A. 39 

Nakamatsu K. 732 

Nakamoto M. 250 

Nakamura K. 1116 

Nakamura K. 40, 205 

Nakamura M. 700 

Nakamura T. 75 

Nakamura Y. 434 

Nakanishi Y. 884 

Nakano Y. 295 

Nakao M. 9 

Nakashima J. 146, 203, 1020 

Nakashima M. 170, 839 

Nakatani T. 745 

Namiki M. 745 

Namiki S. 671 

Nandasena A.M.A.I. 834 

Nandwani G.M. 153 

Napodano G. V43 

Narahari R.K. 1079, 1098 

Nardicchi V. 994 

Narita S. 348, 549, 1088 

Naselli A. 354, 960 

Naspro R. 137 

Nasterlack M. 444 

Nativ O. 816 

Naudin A. 364 

Naumov I. 539 

Nava L. 259, 278, 909, 910 

Navarro R. 212 

Nawroth R. 1013 

Naya Y. 842, 1116 

N’Dow J. 332 

Neal D.E. 332, 876, 942, 976, 1093 

Necchi A. 403, 407 

Neckers L. 670 

Neganov M. V49 

Negro C.L.A. 155, 1099 

Neisius A. 1117 

Nelen V. 785 

Nelson P.P. 626, 630 

Nemade H. 826, 1099 

Nepple K.G. 28 

Neri M. 70 

Nesi G. 113, 119, 188 

Neuzillet Y. 610 

Neves L.C. 65 

Neymeyer J. 72 

Ng C. 250 

Ng C.F. 335 

Ng E.H. 1027 

Nguyen D.P. 611 

Nguyen H.T. 411 

Nguyen T. 111 

Nichele S. V41 

Nicolai N. 403, 407, 758, 764 

Nicolaiew N. 538 

Nicolazzo C. 900, 901 

Niegisch G. 866 

Niehrs N. 654 

Nieschlag E. 592 

Nigam R. 401 

Nihei N. 1116 

Niimi A. 476 

Niimi K. 852, 856, 952 

Nijam R. 516 

Nijkamp M.W. 197 

Nikolas H. V7 

Nikolov I. 860 

Nilsson A. 569, 876, 976 

Nilsson S. 130, 417 

Nishijima J. 568 

Nishikawa G. 40 

Nishimatsu H. 302, 476, 700, 996 

Nishimura K. 75 

Nishioka T. 125 

Nishiyama H. 170, 839 

Nishiyama K. 162, 334 

Nishiyama N. 904 

Nishizawa O. 574 

Nitta T. 198 

Niu Y. 932, 933 

Njiwa J. 1071 

Nkhali L. 422 

Nóbrega L.F. 503 

Noe A.P. 1112 

Noguchi M. 863 

Nohata N. 842, 843 

Nojima M. 163 

Noldus J. 823 

Nomiya A. 476, 996 

Nomiya M. 1070 

Nonomura A. 80 

Nonomura K. 500, 502, 999 

Nonomura N. 214, 847 

Nordle O. 126 

Noritaka K. 895 

Noro A. 90, 1022 

Norton P. 171 

Novack G.D. 686 

Novara G. 26, 31, 603, 876, 976 

Nowak P. 797 

Nowakowski K. 381 

Nozawa M. 125, 732 

Ntanios F. 690 

Nuhn P. 872 

Nukui A. 318 

Numao N. 13, 92, 143, 267, 293, 

353, 884, 925, 963 

Nunes P.T.C. 138, 322, 667 

Nunzi E. 528 

Nurse D. 155 

Nuttall M. 67 

Nyberg T. 569, 876, 976 

Nyirady P. 876, 976 

Nyushko K.M. 961 

O 

Obek C. 270 

Obinata D. 233 

O’Brien T.S. 89 

O’Bryan-Tear C.G. 130 

Ochelenko V.A. 1101 

Ocholur J. 464 

Ockrim J.L. 525 

Oda Y. 161 

Oddens J.R. 1050 

Oderda M. 966 

Odone-Filho V. 506, 508 

Oeggerli M. 433 

Oelke M. 578, 641, 705, 739 

Ogawa O. 75, 170, 434, 549, 839 

Ogawa T. 125 

Ogaya-Piniés G. 207, 209, 1085 

Oger-Roussel S. 369, 462, 472 

Oguchi N. 745 

Ogura K. 752 

Oh C.Y. 643 

Oh J.J. 33, 283, 582, 628 

Oh K.J. 399, 576 

Oh J.K. 731, 733, 749 

Oh M.M. 412, 501, 562, 625, 703 

Oh S.J. 237 

Ohara S. 546 

Ohba K. 545, 899 

Öhberg L. 927 



457 

Indices

Indices 


Ohlmann C. 455, 708, 715, 866, 874 

Ohlstein E.H. 685 

Ohmann C. 866 

Ohno Y. 146, 203, 1020 

Ohori M. 146, 203, 244, 1020 

Ohyama C. 348, 647, 777, 867, 922, 

1088 

Okada A. 852, 856, 952 

Okada K. 51, 59 

Okada Y. 902 

Okamoto T. 647, 867 

O’Kelly F. 540, 849 

Oksay T. 573 

Okubo H. 1020 

Okubo H. 146 

Okumi M. 214 

Okuyama A. 745 

Olbert P. 449, 995 

Olianas R. 1074 

Oliva A. 941 

Oliveira C.M. 411 

Oliveira L.P. 114 

Olivier Gómez C.M. 897 

Olkhov E. 543 

Ollandini G. 698 

Olsen Ekerhult T. 724 

Olumi A.F. 932, 933 

Omar A. 497 

Ona V. V13 

Onal B. 1030, 1037 

Ondet V. 10 

Ooishi Y. 1052 

Oomens E. 149 

Oosterlinck W. 1050, V11 

Oosterwijk E. 200, 309, 665, 804, 

805, 806, 928 

Oosterwijk-Wakka J.C. 200 

Opondo D.O. 921, 1023 

Ordon M. 949, 1027 

Ordonez M.A. 1081 

O’Riordan A.M. 1098 

Ortega F.L. 340, 713, 878, 1058 

Orvieto M.A. 1058, 1059, V20 

Orye C. 513 

Osmonov D.K. 781 

Osorio L. 499 

Osther P.J. 379 

O’Sullivan J.M. 130 

Oswald J. 392 


Otremba B. 128 

Otto E. 716 

Otto T. 807, 1068 

Otto W. 775, 872, 1019 

Ouchi Y. 845 

Oudard S. 81, 311 

Ouwerkerk T.J. 624 

Ouzaïd I. 529, 712, 763, 817, 886 

Ouzzane A. 17, 151, 352, 448, 550, 

771, 877, V25 

Oya M. 140, 450, 593, 902, 919, 939, 

1107, 1109 

Oyama C. 549 

Oyama N. 991 

Oyen R. 1113, 1121 

Oyen W.J.G. 928 

Ozcelik H. 543 

Ozdemir F. 270 

Ozden E. 505 

Ozen H. 985 

Ozkan T.A. 1016 

Ozkaya O. 505 

P 

Pace G. 801 

Pace K.T. 949, 1027 

Pache G. 944 

Pacini L. 696 

Padevit C. 344, 1007 

Padilla W.O. 182 

Pahernik S. 1015, 1019 

Paick J.S. 533, 587, 701 

Paick S.H. 190 

Pal R.P. 424 

Palagin I.S. 186 

Palanisamy N. 937 

Palazzetti A. 285, 534 

Palea S. 363, 364 

Palisaar R.J. 823 

Palleschi G. 696 

Palma P.C.R. 1067 

Palmer K. 1058, 1059 

Palmer K.J. 340, 878, V15, V16, V20 

Palou J. V38 

Pandey A. V10 

Panebianco V. 261, 342, 440 

Pang J. 563 

Panneerselvam A. 83 

Pantel K. 903, 917 

Panus A. 958 

Paolini B. 403, 407, 764 

Papalia R. 553, 601, 890 

Papandreou C.N. 432 

Papapetropoulos A. 218 

Paparel Ph. 556, 640 

Papatsoris A. 64, 1039 

Papin G. V21 

Papoutsoglou N. 814 

Pappagallo G. 966 

Parada B. 138, 322, 323, 327, 667 

Paradowska A.S. 48, 50 

Paradysz A. 381 

Paras L. 58 

Pardy C. 858 

Paredes D. 215 

Parente U. 261, 342, 986 

Paridaens R. 311 

Park B.H. 23, 156, 710, 972, 1017 

Park B.J. 224 

Park B.S. 23, 34, 156, 710, 972, 

1017 

Park C.H. 688 

Park H.J. 117, 118, 227 

Park H.J. 56, 280, 596 

Park H.K. 190 

Park H.S. 66, 412, 501, 562, 625 

Park J. 229 

Park J.K. 688, 701 

Park J.M. 82 

Park J.M. 484 

Park J.Y. 147, 562 

Park K. 399, 576, 701 

Park K.K. 988 

Park M.G. 412, 501, 562, 703 

Park M.S. 147 

Park N.C. 56, 280, 596, 701 

Park S. 482, 507 

Park S.H. 485 

Park S.H. 181 

Park S.J. 744 

Park S.S. 562, 703 

Park S.Y. 43, 493, V50 

Park W.H. 583, 688, 990 

Park Y.H. 32, 82 

Park Y.J. 623, 754 

Parker C. 130, 824 

Parr N.J. 885 

Parra J. 383 


Parsons K.F. 336, 837 

Partin A.W. 263, 911 

Paschoalin V.P. 1108 

Pasquier D. 556 

Passariello R. 261, 440 

Passerotti C.C. 62, 411 

Passoni N.M. 122, 282, 421, 570, 

594, 780, 882, 1012 

Pasticier G. 979 

Pastore A.L. 696 

Pastorello M. 276 

Patard J.J. 144, 351 

Patel A. 89 

Patel K. 439 

Patel N.S. 1118 

Patel R. 646 

Patel S. 1098 

Patel V.R. 340, 878, 1058, 1059, V15, 

V16, V20 

Pathak P. 850 

Patil M. 250 

Patil P.A. 100, 221, 488 

Patki P. 67 

Patni L.G. 100, 221, 488 

Patrascoiu S. 405, 618 

Patris E. 695 

Paul P. 640 

Paul U. 791 

Paulesu A. 979, 982 

Pavlakis K. 12 

Pavlakis P. 1100, 1104 

Pavone C. 706 

Pawlowski T. 435 

Paz A. 605 

Peabody J.O. 134, 453, 677, 678, 

679, 1055, 1061, V22 

Pearle M. 1037 

Peeker R. 724 

Pei Y. 80 

Peinemann F. 413 

Peled R. 277 

Pelger R.C.M. 624 

Pellucchi F. 570 

Pelte M.F. 27 

Peltola M. 653 

Pelzer A.E. 797 

Peng Y.F. 11 

Penna F.J. V3 

Peracchia G. 778 

Peraga G. 1105 

Percy A.G. 85 

Perdonà S. 1047 

Perdzynski W. 809 

Perea D. 695 

Pereira Martins A.C. 1108 

Pereira-Sampaio M.A. 410 

Perepanova T.S. 186 

Perera M. 332 

Perez J. 918 

Pérez F. V37 

Pérez Márquez M. 215, 324 

Pérez-Carral J.R. 915, V47 

Perez Marquez M. 320, V30, V36 

Peri L. 584, V29, V30, V35, V36 

Peri Cusí L. 212, 215, 317, 320, 324 

Perkash I.P. 729 

Perkins A.P. 184 

Perletti G. 44 

Perrin P. 220 

Perrotte P. 87, 555, 678, 1057, 1106 

Perrouin Verbe M.A. V21 

Perry A.S. 540, 849 

Perry M.J.A. 515, 517, 522, 523 

Persu C. 469 

Pertega S. 414, 1095 

Pesch B. 444 

Peschechera R. 375, 382, 1033 

Peschel R. 409 

Pessoa R.R. 773 

Pestano G. 427, 937 

Petas A. 787 

Peters K. 694 

Petersen H. 892 

Petersen P.M. 420 

Petersen S.E. 420 

Peterson E.M. 39 

Pethe V. 543 

Petlin A.V. 496 

Petracca A. 900, 901 

Petralia G. 565 

Petrovskiy N.V. 141 

Petrozza V. 696 

Petrucci F. 16 

Petrylak D.P. 123 

Pettersson K.S.I. 653 

Peyrat L. 10, 292, V5 

Peyromaure M. 351 

Peña J.A. V38 

Pfalzgraf D. 619, 621, 728, 730, 808 

Pfeiffer M.F. 239 

Pfister C. 144, 351, 422, 610 

Pfister D. 345, 559, 800 

Pfister W. 192 

Pfofe D. 1007 

Pham E. 462 

Phe V. 550, 771 

Philippou P. 401, 516 

Phillips D. 950 

Phillips M. 694 

Phipps S. 1048 

Phé V. 6, 369, 448, 472, 529 

Picaut P. 462 

Picchio M. 891, 1012 

Piccinni M.P. 4 

Piccoli F. 301 

Piccorelli A. 146 

Pichler R. 392, 408, 409 

Pichon T. 610 

Pickard R.S. 41 

Pickard R.S. 183 

Picozzi S. 268, 801 

Pierorazio P. 94 

Pietricica B. 1005 

Pietropaolo A. 528 

Pignol B. 462 

Pignot G. 144, 169, 448, 550, 610, 

771 

Pilatz A. 46, 192 

Pilcher J. 517 

Pili R. 126 

Pina F.A.X.E.M. 536 

Pinkawa M. 413 

Pinkhasov R. 590 

Pintilie M. 905 

Pinto F. 286 

Pinto R. 272, 993, 997 

Piper C. 345 

Piqueras Bartolome M. 320, 595 

Pita S. 414, 1095 

Piva L. 403, 407 

Piñero J. 207, 1085 

Placer J. 264, 347 

Planas J. 347 

Plaza L. V37 

Plesea I.E. 958 

Plock J. 813 

Ploeg M. 718 



459 

Indices

Indices 


Ploumides A. 1100 

Ploussard G. 712, 757, 762, 763, 

765, 886, 1089, 1090 

Pluvinage A. 765 

Pocock R. 714 

Podio V. 252 

Poetsch M. 168 

Poggio M. 14 

Poinas G. 175 

Poirier N. 211 

Poissonnier L. 980 

Pokrywczynska M. 802 

Polat E.C. V12 

Polat F. 511 

Pollard M. 766 

Polton D. 634, 743 

Polyakov S.L. 247 

Ponce J. 1095 

Ponz R. 975, 977 

Popert R. 155, 759, 790 

Porath K. 373 

Porcellini B. 796 

Porena M. 465, 527, 528, 994 

Porpiglia F. 14, 252, 792, 1105 

Porres-Knoblauch D. 345, 800 

Portalez D. 793 

Porter J. 26, 31, 35 

Portnoy O. 535 

Porumb C. V13 

Poulakou-Rebelakou E. 829 

Poullis C. 620 

Poulsen M.H. 892 

Powles T. 669 

Poyet C. 906 

Pozarowski K. 937 

Prapotnich D. 17, 352, 877, 987 

Pravorov A.V. 551 

Prawat K. 590 

Preminger G.M. 498 

Presiccia F. 1047 

Prestini G. 565 

Prevoo W. 78 

Prieto L. 622, 631, 632 

Pringle J.H. 424 

Proietti S. 465, 468, 994 

Protheroe A. 1118 

Protzel C. 168, 373 

Provenzano M. 906 

Prudente A. 1067 


Pryalukhin A.E. 202 

Pschikhachev A.M. 296 

Pu Y.S. 437 

Pultrone C. 893 

Pummer K. 772, 911, 1004 

Puppo P. 354 

Pushkar D.Y. 271, 564, 1075, 1122 

Putter H. 624 

Pycha A. 552 

Q 

Qiu J. 490 

Qiu X. 707 

Quattrone L.E. 441 

Queimadelos A.Q. 132 

Quiles M.T. 848 

R 

Rabah D. 946 

Rachner T.D. 655 

Racioppi M. 286 

Radmayr C. 392 

Radomski L. 1092 

Radulescu C. 757, 1089, 1090 

Rafiq M. 518 

Raggi D. 403, 407 

Ragheb A. 615 

Rahhali N. 220 

Rahmouni A. 886 

Rai B. 332 

Raileanu A. 19 

Rais-Bahrami S. 94 

Rajab R. 522 

Rajkumar V.R. 1028 

Rakhmonov O.M. 222 

Ralph D. 401, 516 

Ram-Liebig G. 621, V8 

Ramadan A.R. 497 

Ramakrishnan V. 813 

Raman J.D. 552 

Rambeaud J.J. 556 

Ramirez Backhaus M. 289, 428 

Rammensee H.G. 76 

Ramon A. 807, 1068 

Ramon J. 253, 535, 539 

Ramos-Montoya A. 942 

Ramsey S. 815 

Ramón De Fata F. 167, 299 

Rana D. 332 

Rancati T. 758, 764 

Randazzo M. 1097 

Randone D. 912 

Rane A. 94 

Rannikko A. 787 

Rao A. 826 

Rashed A. 1082 

Rasheed M. 104 

Rasheed Z. 652 

Rasiah K.K. 673 

Rasmussen S. 686 

Rassweiler J. 573, 818 

Rastaldi M. 948 

Rauner M. 655 

Ravaziol M. 342, 986 

Raven P.A. 661 

Raventós C.X. 264, 347 

Ravery V. 38, 154 

Ravi P. 134, 1055 

Rawandale A.V. 100, 221, 488 

Raz R. 187 

Realfonso T. V43 

Recker F. 785, 1097 

Reddy G. 660 

Reddy P.P. 510 

Rees R.W. 515, 523 

Refos J. 447 

Regge D. 14, 792 

Rehder P. 288 

Reich O. 1010 

Reichenbach M. 49 

Reid J.E. 430, 431 

Reina-Alcaina L. 1005 

Reis F. 667 

Reiss P. 619, 621, 727, 728, 730, 808 

Reiter M. 241 

Rela M. 89 

Rempelakos A. 699, 829 

Remzi M. 552 

Renard-Penna R. 794 

Rendon R. 767 

Rennesund K. 494 

Rennie P.S. 236 

Renninger M. 609, 774 

Renteria J. V31 

Rentsch C.A. 433, 668, 962 

Retik A.B. 411 

Retz M. 866, 1013 

Reuter C. 128 


Reuter D. 788 

Reventós J. 848 

Rha K.H. 94 

Rhees B. 435 

Ribal Caparrós M.J. 317, 320, 324, 

329, 337, 339, 402, 719, V29, 

V30, V35, V36 

Ribeiro B.L.M.F. 2 

Ribeiro C. 410 

Ribeiro-Neto J.P.M. 503 

Riccetto C.L.Z. 1067 

Ricci C. 268 

Richard F. 383 

Richard J.L. 1081 

Riche B. 556 

Richstone L. 94 

Richter E. 392 

Richter H.E. 171 

Rickey L. 174 

Ricos Torrent J.V. 289 

Riddick A.C.P. 1048 

Riechardt S. 619, 728, 730 

Riedmiller H. 314, 436, 844, 846, 

1076 

Riepenhusen J. 1074 

Riethdorf S. 917, 917 

Riethdorf S. 903 

Rigatti L. 909 

Rigatti P. 29, 150, 259, 278, 282, 

303, 570, 594, 761, 780, 882, 

898, 908, 909, 910, 912, 923, 

1080 

Rigaud J. 144, 351, 610 

Riklund K. 927 

Riley J. 937 

Rini B.I. 81 

Rink M. 157, 561, 603, 783, 876, 

903, 973, 974, 976, 1057 

Rio E. 423 

Rioja J. V37 

Rioja Sanz L.A. 830, V37 

Rioux-Leclercq N. 311 

Rippe C. 367 

Rischmann P. 364, 459, 466, 735 

Ritchie R.W. 1115 

Rivas Del Fresno M. 537, 915 

Rizkala E. 30, 216, V23, V33 

Ro Kim A. 587 

Robain G. 630 

Roberts W. 91 

Robertson C.N. 979, 982 

Robertson C.R. 132 

Robinette M. 929 

Robinson B.D. 246, 561 

Robson C.N. 41 

Robson W.A. 183 

Rocca C. 121, 893 

Rocchini L. 122, 898 

Rocco B. 1058, V20 

Rocco F. 948 

Rode J. 610 

Rodríguez Antolín A. 595 

Rodríguez-Barbero J.M. 167 

Rodríguez Escovar F.P. 585 

Rodriguez-Faba O. 325 

Rodriguez-Patrón R. 811 

Roehrborn C.G. 642, 644, 747, 748 

Roelofs L.A.J. 805, 806 

Rogel Berto R. 881 

Rogers A.E. 1038 

Rogers C.G. 28, 134, 453, 677, 678, 

679, 1055, 1061, V1, V28 

Rogers E. 36 

Roggenbuck U. 566, 1056 

Roigas J. 775, 872 

Roiss M. 788 

Rokkas K. 699 

Rolevich A.I. 247, 551 

Roller C. 72 

Rollini C. 1062 

Rolo F. 138 

Romagnoli D. 121, 893 

Roman S. 1065 

Romana M. 940 

Romanenko O.A. 185 

Romano A. 778 

Romano G. 721, V8 

Romero D. 654 

Romero-Hoyuela A. 1005 

Romero Otero J. 595 

Romics I. 315 

Rompolis D. 699 

Roncali J. 948 

Roobol M.J. 145, 149, 269, 425, 447, 

682, 785, 822, 825, 876, 976, 

1086, 1087 

Roos F.C. 256, 463, 1117 

Roosen A. 1, 3, 7, 8, 110, 947 

Ropero S. 167 

Ropero Valverde J. 264 

Rosado J.P. 389 

Rosario D.J. 965, 1043 

Rosbrook B. 81 

Roscigno M. 95, 137, 552, 923 

Rosenwald A. 314 

Rosino-Sánchez A. 1005 

Rößler W. 1019 

Rossi D. 351, 610 

Roth S. 635 

Rottey S. 83 

Rouget B. 610 

Roulson J.A. 650 

Roumeguere T. 473 

Roumiguié M. 448, 459, 466, 735 

Rouprêt M. 6, 144, 308, 351, 448, 

550, 610, 771, 817, V2 

Rouquet J. 111 

Rousseau H. 1119 

Rouvellat P. 532 

Rouviere O. 980 

Rowe E.W. 716 

Roy-Guggenbuehl S. 692 

Rozenman Y. 226 

Rozet F. 17, 151, 352, 713, 877, 987 

Rozet F. 351, V25 

Rubin M. 561, 937 

Rubin N. 965, 1043 

Rubio-Briones J. 289, 428, 541 

Rubio-Martinez L. 428, 541 

Rudin R. 1071 

Rudin Y.E. 393 

Rudner J. 310 

Ruffion A. 448, 556, 640 

Rufibach K. 756 

Ruiz C. 433 

Ruiz-Cerda J.L. 881 

Ruppin S. 168 

Russo A. 95, 231, 284, 882, 971 

Russo F. 14, 792 

Russo R. 252 

Rusz A. 46 

Rutkowski M. 291 

Rutz B. 1, 7, 8, 110 

Ryan C. 124 

Ryu J. 507 

Ryu J.K. 480, 484 

Ryu S.B. 399, 576 



461 

Indices

Indices 


S Saad F. 4, 592 

Saad F. 127, 767, 918 

Saad M. 333, 713, V25 

Saar M. 648, 708, 715 

Saba E.S. 333 

Sacan O. 511 

Sacco E. 286 

Saccà A. 282, 303, 594 

Sad W.G. 1082 

Sadiki B. 1102 

Saeb-Parsy K. 332, 814 

Sagalowsky A.I. 603 

Saglam R. 387 

Sahibzada I. 294 

Sahmoud T. 74, 80 

Saika T. 1044 

Säily V.M.J. 787 

Saint F. 448, 550, 771 

Saito H. 139 

Saito K. 13, 90, 92, 143, 267, 293, 

298, 353, 871, 884, 925, 963, 

1022 

Saito R. 170, 839 

Saito S. 549 

Saitoh H. 922 

Sakai S. 545, 899 

Sakai I. 201, 254, 312 

Sakamoto S. 843, 1116 

Sakano S. 568 

Sakazume K. 920 

Sakuma Y. 318 

Sakura M. 13, 92, 267, 293, 298, 

884, 925, 963, 1022 

Salciccia S. 261, 342, 986 

Saleh O. 136 

Salem E. 397, 599 

Salinas J. 622, 631, 632 

Sallusto F. 466 

Salome F. 144 

Salomon G. 360, 572, 680, 681, 799, 

873 

Salomon L. 144, 351, 610, 712, 757, 

762, 763, 886, 1089, 1090, V24 

Salonen A.J. 131 

Salonia A. 282, 284, 303, 594, 784, 

971, 1002, 1054 

Salvador R. 943, 945 

Salvi M. 113, 119, 136, 248, 644 


Salvioni R. 403, 407, 758, 764 

Salvitti M.R. 16 

Samadi D.B. 675, 676, 766, 989 

Samans B. 49 

Sammon J. 87, 134, 453, 677, 678, 

679, 1055, 1061, 1106, V1, V3, 

V22, V28 

Sampaio F.J.B. 2, 114, 389, 390, 410, 

475, 520 

San José Manso L.A. 897 

Sánchez-Chapado M. 167 

Sanchez Encinas M. 17, 151, 877, 

V25 

Sanchéz-Margallo F.M. V37 

Sanchez-Salas R.E. 17, 151, 352, 

713, 876, 877, 976, 987, V25 

Sandner S. 947 

Sangalli M. 259, 278, 779, 784, 

1006, 1080, V40 

Sangalli M.N. 29 

Sanguedolce F. 966 

Sanjmyatav J. 166, 202 

Sansalone S. 721 

Sanseverino R.C. V43 

Sansom O.J. 646, 662 

Santer F.R. 237 

Santi R. 113, 119 

Santoni G. 994 

Santoni G. 465 

Santos J. 368 

Sanz G. 975, 977 

Sanz Ortega J. 897 

Sarachev A.R. 711 

Sarchielli E. 740 

Sarf I. 1102 

Sargent B. 686 

Sarica K. 491 

Sartor O. 130 

Sarıkaya S. 505 

Sasada T. 863 

Sasaki S. 852 

Satake N. 203 

Sathyanarayana U. 937 

Sato A. 196, 240 

Sato F. 170 

Sato M. 847 

Sato N. 199, 663 

Satoh F. 1110 

Satoh T. 864 

Sauerland S. 413 

Sauter G. 572, 873 

Sauter M. 80 

Savini A. 121 

Savsin A. 270 

Sawada Y. 1020 

Sawazaki H. 752 

Sayedahmed K.A.M. 1074 

Scaduto G. 706 

Scapaticci E. 29 

Scattoni V. 150, 259, 278, 909, 910, 

912, 971, 1012 

Schaefer G. 649, 935 

Schagdarsurengin U. 49 

Schalken J.A. 239, 263, 273, 309, 

329, 337, 657, 658, 911, 913 

Schatloff O. 340, 878, 1058, 1059, 

V15, V16, V20 

Schatteman P. 26 

Scherr D. 157, 552, 561, 603 

Schiavina R. 121, 893 

Schiffmann J. 788 

Schilling D. 452, 521, 774, 1031 

Schips L. 94 

Schlenker B. 3 

Schlomm T. 360, 572, 681, 873, 917 

Schmetkamp H. 1 

Schmid D.M. 692 

Schmid M. 966 

Schmiedel B. 651 

Schmitges J. 84, 134, 453, 677, 678, 

973, 974 

Schneider R. 935 

Schneider T. 687 

Schoenthaler M. 69, 73, 102, 377, 

394, 492, 944 

Scholfield D. 510 

Scholz A. 359 

Scholz C.J. 436, 846 

Schostak M. 306 

Schrader A.J. 1018 

Schrader M. 1018 

Schriefer P. 360 

Schröder F.H. 145, 147, 269, 425, 

682, 785, 822, 825, 1086 

Schubert M. 361, 436, 844 

Schubert M. 1000 

Schuette A. 341, 454, 1060 

Schulman A. 589 


Schulze M. 573, 818 

Schuppe H.Ch. 50 

Schuster T. 1013 

Schwaiger B. 621, 973, 974 

Schwartz J. V42 

Schweiger M.R. 935 

Schweiger S. 935 

Schwentner C. 429, 442, 444, 452, 

521, 548, 651, 666, 774, 841 

Schöffski P. 311 

Sciarra A. 261, 342, 986 

Sciuto R. 890 

Scott H.E. 942 

Sea J. 490 

Sebastianelli A. 113, 119, 136, 248 

Sèbe P. 6, 292, 907 

Sebrow D. 675, 676, 989 

Secin F.P. 151, 987 

Sedelaar M. 239, 782 

Sedlar A. 182 

Seftel A. 483 

Segal S. 918 

Segawa N. 745 

Seguchi K. 196 

Seibel J.M. 238 

Seibold J. 666 

Seida M. 946 

Seidel C. 1018 

Seiler D. 1097 

Seiler R. 159, 557 

Seino S. 244 

Seisen T. 550, 610 

Seitz C. 552, 876, 976 

Seitz M. 451, 717, 1010 

Seke M. 130 

Seki N. 162, 334, 842, 843 

Sekine Y. 198 

Selbherr D. 452 

Selim M.A. 613 

Sellaturay S.V. 97 

Sellers D.J. 109, 374 

Selli C. 301, 304 

Sellmann T. 373 

Selmy M. 331 

Sengeløv L. 420 

Seo H.J. 173 

Seo J.H. 173 

Seo J.H. 744 

Seo J.T. 181 

Seo S.I. 23, 34, 156, 710, 972, 1017 

Serafetinides E. 1100, 1104 

Serapiao Mendes R. 212 

Serni S. 4, 113, 119, 136, 248, 644, 

970 

Seroka R. V7 

Serretta V. 706, 1040 

Serteser M. 953 

Sethia K.K. 518 

Sevdalis N. 67, 68 

Seveso M. 375, 382, 1033 

Shaaban A.A. 608 

Shabana W. 397 

Shabbir M. 401, 516 

Shabsigh R. 589, 590 

Shah G. 74, 80 

Shah N. 1093 

Shah N. 385 

Shah P.J.R. 470, 525 

Shahab N. 737 

Shahin A.M.S. 396, 397, 598, 1029 

Shalaby A.E. 396 

Shalaby I. 326 

Shamsuddin A. 956 

Shangichev A.V. 723 

Shapiro E. 812 

Shariat S.F. 157, 552, 561, 603, 677, 

770, 876, 903, 976, 1015 

Sharifi N. 840 

Sharma D. 1099 

Sharma N.L. 942 

Sheik S. 548 

Shen Y.J. 1014 

Shental J. 187, 226, 816 

Shepherd B. 1111 

Sherif A.M. 927 

Sherrod A. 883 

Sheth N. 686 

Shibasaki N. 839 

Shibata T. 904 

Shibata Y. 198, 458, 938 

Shigeaki S. 854 

Shigemasa K. 895 

Shigemura K. 295 

Shigeru T. 895 

Shigeta M. 139 

Shimizu N. 732 

Shimizu T. 163 

Shimodaira K. 1020 

Shingo H. 895 

Shinoda K. 919 

Shiota M. 161, 931, 936 

Shirakawa R. 839 

Shirakawa T. 295 

Shirotake S. 902 

Shishkov D.I.M. 711 

Shmitz A. 226, 816 

Shoji K. 546, 984 

Shokeir A.A. 194, 326, 602 

Shoma A.M. 386 

Short S.C. 669 

Shoshany O. 1046 

Shuin T. 889 

Si-Tu J. 563 

Siegert S. 558 

Siemer S. 455, 708, 715, 874 

Siena G. 136, 248 

Sievert K.D. 444, 461 

Signori M. 577, 579 

Sihombing A.T. 54 

Sikole A. 860 

Silchinger J. 1010 

Silva D. 475 

Silva J.F.A. 272, 997 

Silva R. 1108 

Silva Costa W.S. 390 

Silva-Ramos M. 499 

Silverman P. 18 

Simeone C. 251, 926 

Simko J.P. 431 

Simmons M.N. 142 

Simonato A. 1114 

Simone G. 553, 601, 890 

Simonelli G. 16, 1047 

Simons B. 652 

Simpson H.M. 885 

Simsek F. 481 

Sinasi Y. V12 

Sinescu I. 405, 618 

Singh P. 22 

Singh S.K. 850, 855, 861, 862 

Singla S.K. 861, 862 

Siniscalchi R.T. 1067 

Sirls L.T. 171, 174 

Sırtbas A. 505 

Sivaraman A. 340, 878, 1058, 1059, 

V15, V16, V20 

Sjödahl G. 896 



463 

Indices

Indices 


Skarecky D. 876, 976 

Skinner D.G. 600 

Skinner E.C. 600 

Skolarikos A. 498, 1037 

Skradski V. 880 

Slama A. 588 

Slama A. 223 

Slawin K. 876, 976 

Slezak J.M. 443 

Small E.J. 123 

Smets L. 262 

Smirnoff A. V32 

Smit F.P. 239, 309 

Smith A. 1066 

Smith K. 937 

Smith R.A.G. 243, 838 

So A.I. 661, 767 

Soares R. 473 

Soave A. 727, 728, 903 

Soebadi D.M. 857 

Soetjipto S. 857 

Sofer M. 1036 

Sogni F. 966 

Soh J. 400, 504 

Sohaib S.A. 795 

Sohn D.W. 42, 482 

Sokoloff M. 937 

Solberg A. 130 

Soler R. 1070 

Soliman M.G. 104, 179, 497, 616, 

617 

Soliman A.S. 326 

Soloway M. 957 

Solsona E. 289, 428, 541 

Solyanik I. 281 

Soma M. 233 

Somani B. 445 

Son H. 224, 587 

Son S.J. 533 

Song C. 265, 346, 879, 1024 

Song J.M. 228, 274 

Song K.M. 480, 484 

Song P.H. 225, 398 

Song S.H. 32, 224, 587 

Song Y.H. 161 

Song Y.S. 478, 486 

Sonnino S. 898 

Sonpavde G. 603 

Soomro N.A. 1079 


Sooriakumaran P. 246, 343, 876, 

976 

Soria F. V37 

Soriano P. 541 

Sotelo R. 94 

Sotelo T. 694 

Soto Poveda A.M. 881 

Souchay M. 1013 

Soulié M. 351, 610 

Soustelle L. 175 

Southgate J. 183 

Sowerby R.J. 1092 

Spahn M. 148, 158, 314, 355, 357, 

361, 362, 436, 844, 846, 1076 

Sparagana S. 74 

Speakman M. 746 

Speights V.O. 430 

Sperandio V. 193 

Spethmann J. 783, 1057 

Spiess A.N. 50 

Spinnato P. 60 

Srepnov E. 605 

Srinivasan P. 89 

Sriprasad S.I. 97, 391 

Srivastava A. 246, 343, 876, 976 

Srougi M. 62 

Srougi M. 65, 411, 506, 508, 773 

Stadler W.M. 126 

Staehler M. 717 

Staerman F. 351 

Stagni S. 403, 407 

Stakhovskyi O. 905, 929 

Stam R. 328 

Stanescu F. 639, 955, 959 

Stapf M. 307 

Stark R. 942 

Stattin P. 456 

Stefanadis C. 699 

Steffens S. 1018 

Steger K. 48, 49, 50 

Stein R.J. 25, 94, V23 

Stein R.J. 30, 216, V33 

Steineck G. 569, 1053 

Steiner H. 408, 409 

Steiner T. 210, 315 

Steinfeld K. 48 

Stenman U.H. 152 

Stenzl A. 76, 263, 310, 429, 442, 

444, 452, 548, 604, 608, 609, 

651, 666, 774, 841, 911, 957, 

1031 

Stepanova N.M. 185 

Sterling J. 246 

Steuber T. 157, 360, 572, 681, 873, 

917, 974, 1057 

Stevanovic S. 76 

Steven K. 709 

Stevens D.J. 22, 1096 

Stewart G.D. 1048 

Stewart S. 956 

Steyerburg E.W. 145, 876, 976 

Stief C.G. 1, 3, 7, 8, 110, 371, 451, 

717, 775, 872, 947, 1010, V7 

Stieger P. 48 

Stifelman M.D. 28 

Stillebroer A.B. 263, 911 

Stoddard A.M. 174 

Stoehr R. 868 

Stoevelaar H. 262 

Stolzenburg J.U. 71, 94, 218, 255, 

571, 810, 1036 

Stone S.M. 430, 431 

Stowe B. 689 

Strada E. 565 

Stranne J. 1094 

Stransky P. 924 

Stravodimos K. 542 

Stricker H. 1055, 1061 

Stricker P.D. 673, 876, 976 

Strittmatter F. 1, 3, 7, 8, 110, 372, 

741 

Strycker P.D. 459 

Ströbel P. 361, 797 

Stubendorff B. 166, 210 

Studer U.E. 600, 611, 962 

Stumpel D. 328 

Stunitz L.C. V41 

Sturzu A. 548 

Stöckle M. 455, 648, 708, 715, 866, 

868, 874 

Stöhr B. 408, 409 

Stöhrer M. V45 

Stölting M.N.L. 1063, 1064 

Suardi N. 95, 122, 150, 421, 761, 

779, 780, 784, 882, 923, 971, 

1002, 1006, 1012, 1054 

Suarez M-Falero B. 183 

Sude N. 100, 221, 488 


Suekane S. 863 

Sugandi S. 54 

Sugihara T. 302 

Sugimoto M. 1091 

Sugiyama N. 647 

Suh J.G. 587 

Suh J.K. 480, 484, 701 

Suh N. 482 

Sukhorukova M.V. 186 

Sukonko O.G. 247, 551 

Sukumar S. 28, 134, 453, 677, 678, 

679, 1055, 1061, V1, V3, V22, 

V28 

Sullivan M.E. 1115, 1118 

Sulser T. 614, 692, 756, 813, 906, 

1063, 1064, 1071 

Sultan M. 232 

Sumerova N.M. 1075 

Sumitomo M. 40, 196, 205 

Sun L. 213 

Sun M. 26, 84, 134, 249, 453, 677, 

1120 

Sun Y. 1037 

Sundar S. 129 

Sung H.H. 23, 34, 156, 710, 972, 

1017 

Sung L.H. 623, 754 

Sung Y.C. 485 

Sungchan S.C. 704 

Sungwoo S.W. 704 

Supiot S. 423 

Surcel C. 405, 618 

Susini A. 169 

Sussman D.O. 579 

Sutherland R.L. 673 

Sutory M. 467 

Suyama T. 1116 

Suzuki E. 476 

Suzuki H. 163 

Suzuki K. 198, 458, 938 

Suzuki K. 919 

Suzuki M. 476, 700 

Suzuki Y. 647, 867, 922 

Svatek R. 603 

Svejstrup J. 420 

Swanson G.P. 430 

Swearingen D. 686 

Sweet J. 554 

Swärd K. 367 

Syed S. 524 

Sykes J. 905 

Sylvester R.J. 1050 

Symons J. 673 

Syndikus I. 130 

Szendroi A. 315 

Szeto C.C. 335 

T 

Taari K.O. 131, 787 

Tabata K. 864 

Tachibana M. 146, 203, 244, 1020 

Tada M. 244 

Taelab A. 397 

Tager D. 444 

Tagirov Z.T. 61 

Taguchi K. 852, 856, 952 

Tai Young T.Y. 704 

Taieb C. 220 

Takahara S. 214 

Takahashi A. 434 

Takahashi S. 233, 574, 845 

Takahashi S. 854 

Takahiro Y. 895 

Takai S. 108 

Takase K. 1110 

Takata R. 434 

Takayama H. 847 

Takayama K. 233, 845 

Takeda K. 1044 

Takeda M. 574, 742 

Takeda T. 450 

Takeshima Y. 242 

Takeshita H. 90, 884, 1022 

Takeuchi A. 936 

Takeuchi T. 112, 920 

Takuya K. 895 

Talic R. 946 

Tamada S. 745 

Tammela T.L.J. 131, 152, 266, 349, 

755, 785 

Tanabe K. 139 

Tanagho Y.S. 28 

Tanaka A. 146 

Tanaka H. 871 

Tanaka H. 13, 500, 502, 871, 999 

Tanaka K. 295 

Tanaka N. 140, 919 

Tanaka S. 931 

Tanaka T. 199, 663 

Tanase K. 991 

Tandogdu Z. 37, 297 

Tandon C. 850, 855, 861, 862 

Tandon S. 850, 855 

Tanguay S. 767 

Tanko L.B. 985 

Tannuri U. 508 

Tanriverdi O. 853 

Tanuwidjaja D. 54 

Tarabuzzi R. 358 

Tarazi J. 81 

Tarcan T. 481 

Tardanico R. 926 

Tardón García A. 537, 915 

Tariel E. 765 

Tartaglia N. 16 

Tassi R. 77 

Tatarano S. 162, 334 

Tatokoro M. 13, 143, 293, 298, 670, 

884 

Tatsugami K. 139 

Taubert H. 868 

Taverna G. 375, 382, 1033 

Tawadros T. 650 

Tawfik A.M. 104 

Tawfik A.M. 179, 616 

Te Slaa E. 782 

Teichman J.M.H. 490 

Teishima J. 546, 984 

Teixeira F. 667 

Tejedor-Jorge A. 207, 209 

Temanni R. 645 

Tenke P. 37, 297 

Tennstedt P. 572, 680, 788 

Tennstedt S. 174 

Tepeler A. V12 

Teplov A.A. 961 

Terachi T. 139 

Terrier N. 556 

Terris B. 311 

Terrone C. 94, 287, 358 

Terry S. 762, 763 

Terry T.R. 831 

Terzolo M. 1105 

Tessarolo F. 301 

Tewari A.K. 246, 343, 876, 976 

Thalgott M. 1013 

Thalgott M. 866 



465 

Indices

Indices 


Thalmann G.N. 159, 433, 557, 600, 

608, 611, 645, 962 

Thanigasalam R. 673, V5, V26 

Thederan I. 788 

Therasse P. 664 

Thian Z. 86 

Thibault F. 532, V2 

Thiele S. 655 

Thilagarajah R. 67 

Thomas B.G. 1048 

Thomas C. 236, 256, 1117 

Thomas F. 965, 1043 

Thomas K. 858, 950 

Thomas L. 195 

Thompson C. 461 

Thompson P. 826, 834 

Thoms J. 905 

Thor P. 802 

Thorpe A.C. 776 

Thorsteinsdottir T. 1053 

Thottakam B. 332 

Thuillier C. 556 

Thurairaja R. 716 

Thuret R. 610 

Thurman J. 540 

Thörn M. 927 

Thüroff J.W. 256, 463, 1117 

Thüroff S.F.M. 888, 978, 979, 982 

Tian Z. 783, 1120 

Tibbals H. 1066 

Tiemann A. 775 

Tiemessen D. 804, 805, 806 

Tienforti D. 286 

Tiguert R. 786 

Tijani K.H. 194 

Tikkinen K.A.O. 115 

Tilki D. 602, 603, 775, 872, 1010 

Tillier C. 460, 782 

Tilloux X. 211 

Timilshina N. 1092 

Tinwell B. 522 

Tinzl M.V. 934 

Tiscione T. 188 

Tiseo B.C. 411 

Tizzani A. 148, 158 

Tjin S. 447 

Tobisawa Y. 647, 867 

Tobiume M. 205 

Tochigi T. 348, 1088 


Todenhöfer T. 429, 442, 521, 548, 

604, 609, 651, 774, 841 

Todo T. 242 

Toffoli G. 698 

Togashi H. 999 

Tohru Y. 895 

Toi A. 1092 

Tokas T. 12 

Tokatli Z. 387 

Tokui N. 647 

Toledano H. 610 

Toledano O. 539 

Tolga A. V12 

Tolkacheva T. 305 

Tolley D. 1036, 1048 

Tombal B. 148, 158, 262 

Tomescu P.I. 958 

Tomihisa F. 895 

Tonooka A. 112, 920 

Topaktas R. V12 

Torelli T. 403, 407 

Torigoe T. 199, 663 

Torreton E. 223 

Torterotot C. 794 

Tosco L. 96, 285, 534 

Totaro A. 286 

Touiti D. 1034 

Tourani J.M. 311 

Townes C.L. 41, 183 

Toyota M. 163 

Tozawa K. 852, 856, 952 

Tozlu S. 169 

Trachtenberg J. 15, 929, 1049, 1092 

Tragl K.H. 581 

Tran S. 1062, V42 

Trapman J. 425 

Traudtner K. 746 

Travnicek I. 924 

Treiyer A. 708 

Tremp M. 756 

Tretter R. 689 

Trifard F. 144 

Trinchieri A. 44 

Trinh Q.D. 87, 134, 453, 677, 678, 

679, 1055, 1106, V1, V27, V28 

Trojan L. 128, 775, 872 

Trombetta C. 698, 894 

Trottier G. 1092 

Trottmann M. 451 

Trumbeckas D. 967 

Tsai V.F.S. 55 

Tsai Y.S. 840 

Tsamandas A. 810 

Tsaur I. 238, 241 

Tseng S.F. 840 

Tsibulya O. 271 

Tsimafeyeu I. 305 

Tsopanoglou N. 255 

Tsuchiya N. 549 

Tsujimura A. 745 

Tsukamoto T. 75, 163, 199, 663, 904 

Tsushima T. 1044 

Tsuzuki T. 768 

Tsuzuki T. 350 

Tubaro A. 439, 747, 748, 1047 

Tucci Junior S. 1108 

Tuccio A. 136, 248 

Tudor E.C.G. 1048 

Tuji H. 745 

Tulic C. 612 

Tuncay O.L. 495 

Tuncel A. 511 

Tupikina N.V. 1075 

Turker P. 554 

Turkeri L. 481, 1016, 1050 

Tutolo M. 282, 362, 594, 761, 780, 

971, 1012, 1054 

Tuytten T.R.A.H. 782 

Tworkiewicz J. 802 

Tyritzis S.I. 542, 569 

Tzai T.S. 840 

U Uchiumi T. 161, 936 

Ückert S. 738, 739 

Ueda T. 629 

Ueda T. 244 

Uejima S. 125 

Uekado Y. 125 

Uekusa T. 112, 920 

Uemura H. 75, 125, 732, 745 

Uemura M. 847 

Ueyama J. 9 

Uguz S. 404 

Ukimura O. 9, 18, 250, 629, 883, V6 

Ulvik N.M. 489, 494 

Ulvik O. 489, 494 

Undre S. 67 


Unger G. 133 

Unrein A. 307 

Unsal A. 498 

Unsal I. 953 

Unteregger G. 648 

Urakami S. 353 

Urano T. 233, 845 

Urashima M. 745 

Urge T. 924 

Urien S. 941 

Usami M. 856, 952 

Usón J. V37 

Utomo E. 290 

Uvelius B. 367 

V Vacher S. 169 

Vacherot F. 538, 762, 763 

Vaessen C. 144, V2 

Vagnoni V. 893 

Valdagni R. 758, 764 

Valdés Olmos R.A. 519, 1008 

Valenti M. 1045 

Valentini F.A. 626, 630 

Valeri A. V21 

Valero R. 17, 151, 340, 877, V20, 

V25 

Validire P. 369 

Van Ahlen H. 19 

Van Andel G. 1050 

Van Antwerpen P. 473 

Van Brakel J. 53 

Van Charldorp K. 746 

Van De Beek C. 1050 

Van De Toorn P.P. 869 

Van Den Berg N. 519 

Van Den Bergh L. 1011 

Van Den Bergh R.C.N. 1086 

Van Den Bos C.W.L. 624 

Van Den Heuvel S. 822, 825 

Van Der Aa F. 477, 479, 606, 725, 

726 

Van Der Aa M.N.M. 165 

Van Der Heijden A.G. 329, 337 

Van Der Jagt P.K.N. 1001 

Van Der Keur K. 447 

Van Der Kwast T.H. 425, 543, 554, 

1092, 1122 

Van Der Meulen J. 821, 1096 

Van Der Pluijm G. 645 

Van Der Poel H.G. 460, 519, 782, 

865, 1008 

Van Der Zee J.A. 1112 

Van Diest P.J. 197 

Van Dijk M.M. 1112 

Van Doorn B. 116 

Van Essen J. 559, 800 

Van Gils M.P.M.Q. 263, 911 

Van Heemskerk S. 708 

Van Hemelrijck M. 456 

Van Kerrebroeck P. 746 

Van Kuppevelt T.H. 804, 805, 806 

Van Leenders G.J.L.H. 149, 425 

Van Leeuwen F.W.B. 519, 1008 

Van Leeuwen P.J. 269 

Van Leeuwen T.G. 930 

Van Mastrigt R. 290 

Van Melick H.H.E. 197 

Van Muilekom H.M. 460 

Van Oort I.M. 913 

Van Oostrum E. 37 

Van Poppel H. 96, 142, 148, 158, 

311, 263, 355, 362, 436, 606, 

664, 911, 1011, 1113, 1121 

Van Rhijn B. 519, 554, 865, 905 

Van Tilborg A.G. 328 

Van Vugt H.A. 149 

Van Weerden W.M. 425 

Vander Eeckt K. 725, 726 

Vandercruysse F. 1113, 1121 

Vanlangendonck R.M. V4 

Vannahme M. 47 

Vannelli G. 4, 740 

Vardi Y. 597 

Vargas R.A. 114 

Varisco D. 948 

Varley C.L. 183 

Varvello F. 358 

Vasconcelos R.A.L. 388 

Vasdev N. 776 

Vasko J. 927 

Vaughan C. 115 

Veal C.D. 424 

Veitonmäki T.P.C. 266 

Vela Navarrete R. 830 

Vendeira P. 473 

Vera Donoso C.D. 881 

Vergho D.C. 314, 1076 

Vergunst H. 913 

Verhaegh G.W. 239 

Verhagen P.C.M.S. 822, 825 

Verine J. 765 

Verkarre V. 311 

Vermeij M. 165 

Verri C. 1045 

Verrier C. 383 

Verrini G. 778 

Versluis C.Y.L. 653 

Versteeg E.M. 804 

Vessella R.L. 435 

Vianello A. 465 

Vicaut E. 634, 743 

Vidal B.C. 1067 

Vidali M. 358 

Vidart A. 529 

Vieweg M. 50 

Vignati A. 792 

Vignolini G. 970 

Vignozzi L. 4, 113, 119, 644, 740 

Viitanen J.K. 131 

Viktrup L. 641, 642, 705 

Vilaseca A. 215 

Vilaseca Cabo A. 212, 317, 324 

Villa L. 107, 150, 231, 284, 487, 734 

Villa S. 758, 764 

Villacampa F. 585 

Villani D. 758 

Villavicencio H.M. 325, V38 

Villers A. 883 

Vinarov A. 296 

Vincent C. 68 

Vine S.J. 636 

Vinet M. 640 

Viola M. 778 

Virag R. 473 

Vis A.N. 782 

Visakorpi T. 435 

Visser O. 718 

Vitrani M.A. 794 

Vittori G. 136, 248, 970 

Vittori M. 286 

Vitzthum L. 1013 

Vlachopoulos C. 699 

Vlachostergios P.J. 432 

Vogel R. 686 

Volkmer B. 128, 561 

Volkova M.I. 88 



467 

Indices

Indices 


Voller M.C.W. 658 

Völler M. 239 

Vollmer C. 344, 1007 

Volpe A. 94, 358 

Vom Dorp F. 866 

Von Bodman C. 823 

Von Eggeling F. 210, 315 

Von Keitz A. 685 

Von Klot C. 133, 1018 

Voorham H.C. 624 

Voorham-Van Der Zalm P.J. 624 

Vordos D. 712, 757, 1089, 1090, V24 

Vroom I.H. 290 

Vyakarnum A. 838 

Vyas L. 759, 790 

W Wach S. 868 

Wafa L.A. 236 

Wagenlehner F.M.E. 37, 46, 192, 

297 

Wagg A. 578, 687, 689 

Wagner A.A. 85 

Wagner C. 341, 356, 454, 457, 567, 

968, 969, 1060 

Wagner L. 175, 532 

Wahib I. 216 

Waine E. 716 

Wakrim B. 1102 

Walker M. 654 

Wallerand H. 610 

Wallerstedt A. 1053 

Wallner L.P. 258 

Wallois A. 154 

Walmsley B.H. 1038 

Walraven M. 805 

Walsh K. 36 

Walter M. 210, 307, 315 

Walter S. 892 

Walther S. 1, 3, 7, 8, 110, 947 

Walz J. 148, 158, 263, 894 

Wang A. 498 

Wang B. 490 

Wang C.F. 1014 

Wang C.X. 106 

Wang E. 510 

Wang G. 335 

Wang G.M. 1035 

Wang H.F. 659 


Wang H.K. 1014 

Wang H.H. 120 

Wang J.Y. 1014 

Wang J. 687, 690 

Wang T.M. 120 

Wang Y.B. 106 

Wang Y.S. 208 

Wang Y.T. 208, 213 

Wang Z.W. 932, 933 

Ward J.F. 979, 982, 1004 

Warre R. 109 

Warren A. 942, 1093 

Wasser M. 624 

Watanabe A. 745 

Watanabe N. 991 

Watkin N.A. 515, 522, 523 

Watkin N. 517, V11 

Watkiss J. 63 

Watts S. 705 

Waxman J. 654 

Webb A. 624 

Wedel S.A. 130, 238 

Wefer B. 791 

Wegener G. 133, 1018 

Wehrberger C. 581, 789 

Wei H.M. 471 

Weidner W. 37, 46, 48, 50, 192, 

1072 

Weikert S. 72 

Weirich G. 1013 

Weizer A. 552 

Wells-Cole S. 1048 

Wen X.Q. 563 

Weninger E. 717 

Wenske S. 1081 

Wenzl V. 1019 

Werthemann P. 72 

Wessel N. 672 

West C. 669 

Westers P. 116 

Westfall T.D. 363 

Weston R. V51 

Wetterauer U. 69, 73, 377, 492 

Wetterwald A. 645 

White W.M. 94 

Whiteway J. 776 

Whitmore J.B. 123 

Wickmann U. 307 

Widmark A. 130 

Wieland W.F. 558, 571, 775, 798, 

872, 981, 1015, 1019 

Wiens C. 444 

Wiesenthal J.D. 949, 1027 

Wiesner C. 241 

Wijburg C.J. 782 

Wijkstra H. 894 

Wijkström H. 870 

Wijnen R.M.H. 806 

Wiklund P. 569, 876, 976, 1053 

Wilderäng U. 1053 

Wildhagen M.F. 425 

Wilhelm K. 69, 102, 377, 492, 944 

Williams J.A. 81 

Williamson M. 669 

Willinger M. 789 

Wilson A. 525 

Wilson A. 332 

Wilson B.C. 15 

Wilson M.R. 636 

Wilson N. 67 

Wilson S. 599 

Wilson T. 747, 748 

Winkler M.H. 20 

Winter C. 406 

Wirth G. 1062 

Wirth M.P. 128, 359, 558, 655, 1015 

Wiseman O. 385 

Witjes J.A. 329, 337, 665, 718, 957, 

1051 

Witjes W.P.J. 1051 

Witstruk M. 442 

Witt H. 341, 356, 454, 457, 567, 968, 

969, 1060 

Witzsch U.K.Fr. 21, 983 

Wo A.M. 55 

Wolf E. 49 

Wolf G. 210 

Wolf J. 91 

Wöllner J. 1000 

Wolski Z. 802 

Wolter P. 311 

Wolters M. V45 

Wong K.A. 858, 950 

Wong L.M. 1093 

Wong S. 849 

Wood D.N. 509 

Woodhouse C.R.J. 509 

Wooning M. 684 


Wraclowski M. 554 

Wright M. 467 

Wu J. 74 

Wu K.J. 840 

Wu S.L. 11 

Wu X. 812 

Wullich B. 868 

Wunderlich A. 935 

Wunderlich H. 166, 210 

Wylie J. 129 

X Xi Z.J. 11 

Xiao Y.X. 11, 275 

Xie X.J. 178 

Xingfeng B. 647 

Xu K. 812 

Xu L. 641, 642 

Xu Z.B. 1035 

Xylinas E. 448, 529, 550, 712, 762, 

771, 886 

Y Yagisawa T. 318 

Yakoubi R. 30, 94, 216, V23, V33 

Yakupoglu Y.K. 505 

Yamada H. 434 

Yamada S. 768 

Yamada T. 353 

Yamada Y. 334 

Yamada Y. 40, 205 

Yamaguchi K. 51, 59 

Yamaguchi O. 580 

Yamamoto E. 163 

Yamamoto H.A. 954 

Yamamoto H. 348, 647, 777, 867, 

922 

Yamamoto S. 353 

Yamamoto T. 244 

Yamamoto T. 108, 750, 753 

Yamamoto Y. 732 

Yamasaki T. 162 

Yang B. 94 

Yang C. 182 

Yang D.Y. 643, 701 

Yang Y.S.C. 217 

Yang S.J. 398 

Yang S.S. 633 

Yang T.K. 951 

Yang W.J. 478, 486 

Yang Y. 49 

Yano M. 353 

Yanovskiy M. 566 

Yantisetiasti A. 54 

Yao X.D. 1014 

Yashi M. 318 

Yassin A.D.J. 589, 590 

Yassin A. 589, 590 

Yasuda M. 732 

Yasufuku T. 295 

Yasuhiro H. 895 

Yasui T. 852, 856, 952 

Yasumizu Y. 450, 593, 1107, 1109 

Yasunaga H. 302 

Yasutomo N. 1044 

Yates D.R. 308, 448, 550, 817, V2 

Yaycioglu O. 1016 

Yazawa K. 214 

Yazici S. 1016 

Ye D.W. 1014, 1025 

Yehoshua G. 91 

Yeo J.K. 562 

Yeo J.K. 703 

Yeon J. 587 

Yin G.N. 480, 484 

Yin M.J. 245 

Yinghao S. 94 

Yiou R. 757, 1089, 1090, V24 

Yip K.H. 335 

Yokoi S. 904 

Yokomizo A. 161, 931, 936 

Yokoyama M. 13, 90, 92, 143, 293, 

298, 884, 925, 963, 1022 

Yokoyama O. 745, 991 

Yonese J. 267, 353 

Yoneyama T. 348, 647, 777, 867, 

922, 1088 

Yoneyama T. 647, 867 

Yoo C. 643 

Yoo D.S. 583, 875 

Yoo D.H. 399, 576 

Yoo S. 1024 

Yoon B.I. 42 

Yoon C.Y. 283, 582, 628 

Yoon D.K. 147, 562 

Yoon S.J. 731, 733, 749 

Yoon S. 147 

Yoshida M. 574, 580, 992 

Yoshida S. 298, 670, 871, 884 

Yoshida T. 847 

Yoshimura K. 732 

Yoshino H. 162, 334, 842, 843 

Yoshino Y. 750, 753 

Yoshioka M. 999 

Yoshiyama M. 742 

Yossepowitch O. 1046 

You D. 313, 482, 879 

Young Hwan Y.H. 704 

Yu H.S. 230 

Yu W. 11 

Yucel S. 914 

Yudkevich B. 226, 816 

Yuen C. 673 

Yun B.H. 576 

Yun J.H. 526 

Yun S. 937 

Yunoki T. 737 

Z Zacchero M. 287 

Zacharias M. 775, 872 

Zachou A. 956 

Zagazeshev A.V. 1103 

Zaggia B. 1105 

Zaied A. 1029 

Zaitcev A.V. 271 

Zaitsu M. 112, 920 

Zakhour H. 885 

Zaki M. 1082 

Zakoji H. 742 

Zaman F. 64, 103, 1039 

Zampa G. 1045 

Zanetti G. 948 

Zanni G. 303 

Zanoni M. 29 

Zanotelli T. 251 

Zaramella S. 287, 358 

Zardan A. 235 

Zargham M. 607, 1042 

Zarraonaindia A. 414, 1095 

Zastrow S. 1015 

Zattoni F. 419 

Zattoni F. 419 

Zaveleva E. 305 

Zayed A.M. 177 

Zegna L. 287 

Zehnder P. 600 



469 

Indices

Indices 


Zehraoui R. 1102 

Zelenkevich I.A. 247 

Zelichenko G. 226 

Zennami K. 40 

Zerbib M. 169 

Zhai X.Y. 213 

Zhang D.Z. 335 

Zhang H.L. 1014 

Zhang L. 812 

Zhang Q. 11 

Zhang S.L. 1014 

Zhang Y. 649 

Zhang Y. 649 

Zhao C. 701 

Zhao H. 178 

Zheng J.M. 563 

Zhou H.L. 208 

Zhou L.Q. 275, 659 

Zhu X. 269, 447, 682, 822, 825, 1086, 1087 

Zhu Y. 1014, 1025 

Zigeuner R. 772, 1015, 1019, 1021 

Ziglio F. 415 

Zilber S. 1046 

Zimmermanns V. 105, 376, 380, 384, 1032 

Zimmern P.E. 178, 180, 193, 530, 531, 626, 1066 

Zini L. 144 

Ziogas A. 813 

Zitzmann M. 52, 592 

Zlotta A. 543, 554, 905, 929, 1049, 1092, 1122 

Zogas V. 405 

Zonnenberg B. 80 

Zonneveld R. 921 

Zouaoui Boudjeltia K. 473 

Zoubeidi A. 235, 245 

Zucchi A. 527, 528, 586 

Zuckerman Z. 121 

Zucman-Rossi J. 311 

Zugor V. 341, 356, 454, 457, 567, 968, 969 

Zuiverloon T.C.M. 165 

Zuluaga-Gomez A. 99, 851, 859 

Zumrutbas A.E. 495 

Zwarthoff E. 165, 328, 447 

Zyczkowski M. 381 

Zyczynski H. 171, 176 



Abstract sorted by Topic 

Adrenals 

1105, 1106, 1107, 1108, 1109, 1110 

BPH 


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 

108, 109, 110, 111, 113, 114, 119, 

231 

Evaluation 

115, 116, 117, 118, 120, 220, 221, 

222, 223, 224, 225, 226, 227, 228, 

229, 230, 232 

Intervention therapy 

634, 635, 636, 637, 638, 639, 640, 

V46, V47 


112, 219, 641, 642, 643, 644, 743, 

744, 745, 746, 747, 748, 749, 750, 

751, 752, 753, 754, 755 



624, 735, 1063, 1065, 1066, 1067 

Diagnosis 

532, 533, 535, 622, 623, 625, 626, 

627, 628, 631, 632, 691, 1068 

Treatment 

171, 172, 173, 174, 175, 176, 177, 

178, 179, 180, 181, 182, 524, 525, 

526, 527, 528, 529, 530, 531, 534, 

583, 683, 684, 686, 690, 693, 694, 

V12, V14, V32 


391, 826, 827, 828, 829, 830, 831, 

832, 833, 834, 835, 836, 837 

Infectious diseases 

36, 37, 38, 39, 40, 41, 42, 43, 44, 

45, 46, 183, 184, 185, 186, 187, 188, 

189, 190, 191, 192, 193, 194, 274, 

275, 280, 293, 294, 295, 296, 297, 

298, 299, 300, 301, 302, 303, 304 

Infertility 

48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 

58, 59, 61 

Kidney 

transplantation 


206, 207, 208, 209, 210, 211, 212 

Clinical 

213, 214, 215, 216, 217, 316, 317, 

318, 319, 320, 321, 322, 323, 324, 

325, 326, 327, 499, V35, V42 


281, 282, 283, 284, 285, 286, 287, 

288, 289, 290, 291, 292 

Neuro-urology 


363, 364, 365, 366, 367, 368, 369, 

370, 371, 373, 374, 462, 731, 733, 

734, 736, 990, 992, 994, 1000, 1001, 

1064, 1069, 1070, 1071 

Diagnosis and treatment 

276, 461, 463, 464, 466, 467, 468, 

469, 470, 471, 472, 582, 584, 692 

Non-neurogenic 

voiding dysfunction 


273, 372, 465, 737, 738, 739, 740, 

741, 742, 991, 999, 1072 

Diagnosis and treatment 

271, 272, 277, 574, 575, 576, 577, 

578, 579, 580, 581, 629, 630, 633, 

685, 687, 688, 689, 732, 993, 995, 

996, 997, 998 

Paediatrics 

388, 389, 390, 392, 393, 394, 395, 

396, 397, 398, 399, 400, 410, 411, 

412, 500, 501, 502, 503, 504, 505, 

506, 507, 508, 509, 510, 511, 512, 

513, V3 

Penis/testis 

Penile disorders (excluding 

urethra) 

401, 402, 403, 404, 514, 515, 516, 

517, 518, 519, 520, 521, 522, 523 

Testis tumours 

60, 405, 406, 407, 408, 409, V27 

Prostate cancer 

Cell biology 

233, 246, 645, 646, 647, 648, 649, 

650, 651, 652, 653, 654, 655, 656, 

657, 658, 838, 839, 840, 841, 842, 

843, 844, 845, 846, 847, 848, 849, 

931, 932, 933, 934, 935, 936, 938, 

939, 941, 942 

Novel biomarkers 

424, 425, 426, 427, 428, 429, 430, 

431, 432, 433, 434, 435, 436, 437, 

536, 537, 538, 539, 540, 541, 542, 

543, 544, 545, 546, 547, 548, 549, 

937, 940 

Basic research: Novel therapies 

234, 235, 236, 237, 238, 239, 240, 

241, 242, 243, 244, 245 

Imaging and new techniques 

790, 791, 792, 793, 794, 795, 796, 

797, 798, 799, 800, 801, 883, 884, 

885, 886, 887, 888, 889, 890, 891, 

892, 893, 894 

Management of metastatic 

disease 

121, 122, 123, 124, 125, 126, 127, 

128, 129, 130, 131, 132 

Management of non-metastatic 

disease: Active surveillance 

756, 757, 758, 759, 760, 761, 762, 

763, 764, 765, 1086, 1087, 1088, 

1089, 1090, 1091, 1092, 1093, 1094, 

1095, 1096, 1097 


disease: Focal therapy 

13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 

23, 24 


disease: Radical non surgical 

treatment 

413, 414, 415, 416, 417, 418, 419, 

420, 421, 422, 423, 880, 978, 979, 

980, 981, 982, 983, 984, 985, 986, 

987, 988, 989 


disease: Radical surgical 

treatment 

340, 341, 342, 343, 344, 345, 346, 

347, 348, 349, 350, 351, 352, 353, 

354, 355, 356, 357, 358, 359, 360, 



471 

Indices

Indices 

Abstract sorted by Topic 

361, 362, 449, 450, 451, 452, 453, 454, 455, 456, 457, 

458, 459, 460, 563, 564, 565, 566, 567, 568, 569, 570, 

571, 572, 573, 671, 672, 673, 674, 675, 676, 677, 678, 

679, 680, 681, 766, 778, 779, 780, 781, 782, 783, 784, 

785, 786, 787, 788, 789, 873, 874, 875, 876, 877, 878, 

879, 881, 882, 967, 968, 969, 970, 971, 972, 973, 974, 

975, 976, 977, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 

1059, 1060, 1061, 1062, V15, V16, V17, V18, V19, V20, 

V21, V43 

Pathology and biopsies 

146, 148, 149, 151, 153, 154, 155, 157, 265, 268, 815, 

818 

PSA and related markers 

278, 279, 907, 908, 909, 910, 911, 912, 913, 914, 915, 

916, 917, 918 

Screening/diagnosis: Diagnosis 

150, 156, 158, 259, 261, 262, 263, 270, 814, 816, 819, 

820, 821, 822, 823, 824, 825 

Screening/diagnosis: Screening 

145, 147, 152, 258, 260, 264, 266, 267, 269, 682, 817, 

1122 

Staging 

1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 

1011, 1012, 1013 

Renal tumours 


195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 

305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 

930 

Diagnosis 

919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 

1014, 1015, 1016, 1017, 1018, 1019 

Medical treatment 

74, 75, 76, 77, 78, 79, 80, 81, 82, 83 

Non surgical treatment 

1111, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 

1121 

Surgical treatment: Non organ sparing 

84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 1020, 

1021, 1022, 1023, 1024, 1025, V29, V30, V36 

Surgical treatment: Organ sparing 

25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 133, 134, 135, 

136, 137, 138, 139, 140, 141, 142, 143, 144, 247, 248, 

249, 250, 251, 252, 253, 254, 255, 256, 257, 1112, V1, 

V2, V4, V5, V6, V7, V28, V33, V37, V38 


Sexual dysfunction 


218, 473, 474, 475, 476, 477, 478, 479, 481, 482, 483, 

485, 486, 695, 698, 699, 706, 707 

Diagnosis 

586, 587, 589, 593, 594, 595, 700 

Treatment 

480, 484, 588, 590, 591, 592, 596, 597, 598, 599, 696, 

697, 701, 702, 703, 704, 705 

Stones 

ESWL 

946, 947, 948, 949, 950, 951, 952, 953 

Medical/research 

99, 100, 101, 102, 107, 850, 851, 852, 853, 854, 855, 856, 

857, 858, 859, 860, 861, 862, 943, 944, 945, 954 

Open and percutaneous 

103, 104, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 

1033, 1034, 1035, 1036, 1037, 1038, 1039, V49, V50 

Upper tract benign disease 

487 

Ureteroscopy 

97, 98, 105, 106, 375, 376, 377, 378, 379, 380, 381, 382, 

383, 384, 385, 386, 387, 488, 489, 490, 491, 492, 493, 

494, 495, 496, 497, 498 

Trauma 

1098, 1099, 1100, 1101, 1102, 1103, 1104, V51 

Unclassified and miscellaneous 

research 

62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 810 

Urethral strictures 

611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 

721, 722, 723, 724, 725, 726, 727, 728, 729, 730, V11 

Uro-genital reconstruction 

802, 803, 804, 805, 806, 807, 808, 809, 811, 812, 813, 

1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 

1082, 1083, 1084, 1085, V8, V9, V10, V13, V23, V31, V39, 

V40, V41 


Urothelial tumours 


159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 

170, 659, 660, 661, 662, 663, 664, 664, 666, 667, 668, 

669, 670, 895, 896, 897, 898, 899, 900, 901, 902, 903, 

904, 905, 906 

Diagnosis 

328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 

339, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 

448 

Management of infiltrative/advanced tumours: Non 

surgical management 

863, 864, 865, 866, 868, 869, 870, 871, 872, V44 

Management of infiltrative/advanced tumours: 

Surgical management 

555, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 

610, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 

718, 719, 720, 767, 768, 769, 770, 771, 772, 773, 774, 

775, 776, 777, 867, V22, V24, V25, V26, V34, V48 

Management of superficial tumours 

955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 

966, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 

1048, 1049, 1050, 1051, V45 

Staging 

550, 551, 552, 553, 554, 556, 557, 558, 559, 560, 561, 

562 



473 

Indices

Indices 

Sessions sorted by Topic 

Adrenals 

328, 353 

BPH 

96, 102, 239, 260, 315, 357 


57, 62, 64, 66, 98, 151, 152, 180, 239, 263, 315, 317, 

320, 345 


95, 106, 178 

Infectious diseases 

72, 99, 96, 102, 103, 176, 267 

Infertility 

65, 67, 99, 105, 172, 352 

Kidney transplantation 

62, 66, 67, 106, 107 


57, 98, 180, 151, 239, 315, 367 

Neuro-urology 

98, 151, 152, 315, 368 

Non-neurogenic voiding 

dysfunction 

98, 151, 152, 315, 332, 333 

Paediatrics 

99, 173, 315, 358 

Penis/testis 

64, 72, 99, 100, 102, 104, 105, 172, 239, 259, 315 

Prostate cancer 

59, 61, 62, 65, 67, 71, 72, 95, 100, 108, 109, 151, 172, 

179, 239, 241, 258, 267, 268, 315, 316, 317, 319, 322, 

324, 325, 334, 339, 341, 348, 360, 366 

Renal tumours 

61, 69, 71, 96, 100, 108, 109, 107, 151, 175, 239, 241, 

315, 326, 330, 331, 336, 342, 353, 366 

Sexual dysfunction 

98, 100, 152, 239, 315, 323 


Stones 

59, 61, 62, 68, 69, 95, 96, 110, 111, 151, 239, 240, 261, 

262, 267, 315, 321, 328, 350, 359, 364 

Trauma 

315 

Unclassified and miscellaneous 

research 

334, 343, 365, 337 

Urethral strictures 

62, 104, 239, 315, 356 

Uro-genital reconstruction 

69, 72, 104, 105, 239, 328, 338 

Urothelial tumours 

71, 72, 76, 77, 95, 96, 100, 103, 108, 109, 151, 179, 239, 

241, 315, 265, 266, 327, 347, 354, 362 

Numbers refer to page numbers

List of Speakers (not abstracts) 

A 

Aapro M., 401 

Abbou C-C., 71, 73, 95, 112, 241, 

269, 315, 388 

Abol-Enein H., 62, 308, 364 

Abrahamsson P-A., 73, 75, 317, 412 

Abrams P., 57, 333 

Adshead J., 270 

Ahlgren G.M., 72, 396 

Ahmed H.U., 316 

Aho T., 397 

Ahyai S., 397 

Aigrain Y., 106 

Akilov F., 69 

Al-Oraifi I., 62 

Albers P., 259, 338, 394 

Alcaraz A., 73, 96, 181, 241, 315, 

362, 381, 405 

Ali A., 84 

Ali-El-Dein B., 72 

Alivizatos G.J., 376 

Alken P., 69, 110 

Allen C., 100 

Alt C., 180 

Andersson K-E., 98 

Andreassen K.H., 110 

Andrich D.E., 104, 239 

Andriole G., 387 

Anson K.M., 214, 261, 357 

Apostolidis A., 231 

Arenas Da Silva L.F., 269 

Armstrong A., 388 

Artibani W., 61, 239, 263, 324, 383 

Atala A., 241 

Atallah K., 71 

Atug F., 69, 70 

Aulitzky W., 352 

Austoni E., 105 

Azzouzi A.R., 80 

B 

Babjuk M., 64, 72, 77, 103, 183, 354 

Bach T., 94, 110 

Bachmann A., 96, 378 

Bader P., 244 

Bangma C.H., 67 

Barbagli G., 65, 356 

Barber N., 378 

Barkin J., 233 

Barret E., 219 

Bartoletti R., 102 

Bassi P.F., 404 

Bastian P., 73, 201, 268 

Bastian P.J., 73 

Baumert H., 328, 380 

Bedretdinova D.A., 112 

Beerlage H.P., 182, 330 

Behr-Roussel D., 189 

Belgrano E., 99 

Bellmunt J., 108 

Benjelloun S., 71 

Bettocchi C., 99 

Bex A., 108, 175 

Birder L., 57 

Bishop M.C., 72 

Bissler J.J., 389 

Bjartell A., 108, 253 

Bjerggaard Jensen J., 103 

Bjerklund Johansen T.E., 102, 127, 

176, 357, 380 

Bliss D., 57 

Boccon-Gibod L., 73 

Bochner B., 209 

Bogaert G.A., 173, 315, 358 

Bolla M., 268 

Borg S.J., 416 

Borkowski T.A., 117, 258 

Borre M., 409, 417 

Bossi A., 348, 396 

Branchereau J.D.J.M., 113 

Brausi M., 108, 209 

Breda A., 66, 96, 107, 369, 374 

Breza Sr. J, 384 

Brehmer M., 270 

Bres-Niewada E.K., 191 

Brewster S., 296 

Briganti A., 382 

Brubaker L., 58, 125 

Bryan R.T., 183 

Bryant R.J., 170 

Buchholz N.P., 68, 96, 111, 285, 321 

Bucuras V., 300, 373 

Budde K., 106 

Bunce C.J., 411 

Bunker C., 172 

Burchardt M., 121 

Burger M., 395 

Burgos Revilla F.J., 106, 177, 359 

Burgu B., 112 

Burkhard F.C., 153, 320 

C 

Cai T., 103 

Carballido J., 133 

Cardozo L.D., 57 

Carey B.M., 246 

Castro-Diaz D., 153, 205 

Cathelineau X., 113, 315, 337 

Catto J.W.F., 76, 343 

Cecchini M., 216 

Çek H.M., 127, 420 

Cestari A., 96 

Chappel E., 414 

Chapple C.R., 67, 75, 112, 151, 269, 

356, 400 

Charnay-Sonnek F., 411 

Chartier-Kastler E., 187, 392 

Chatterton K., 411 

Cheon J., 59 

Chiruvella M., 64 

Chkhotua A.B., 107, 130 

Chlosta P., 300 

Christensen A., 410 

Chung M.K., 59, 60 

Clarke N.W., 108, 338, 403 

Cobussen-Boekhorst J.G.L., 423 

Colombel M., 273 

Conort P.J., 96, 372 

Cooperberg M.R., 235 

Cornud F., 179 

Costa C.S.R., 189 

Costantini E., 98 

Cottenden A., 58 

Crivellaro S., 98 

Cruz C.D., 160 

Cruz F.R., 62, 66, 151, 263, 315, 368, 

392 

Culig Z., 108, 135 

D 

D’Ancona C.A.L., 224 

Da Silva C.M., 140 

Daels F.P., 66 

Dahlem R., 104 

Daif A., 412 

Daler S., 70 

Damber J-E., 135 

Numbers refer to page numbers 


475 

Indices

Indices 


Dasgupta P., 187, 240, 324, 402 

De Blok W.M., 416, 428 

De Graaff R., 410 

De Jong I.J., 200, 302 

De La Rosette J.M.C.H., 68, 96, 260, 

326 

De La Taille A., 315, 372, 393 

De Meerleer G., 403 

De Reijke T.M., 90, 264, 292 

De Ridder D.J.M.K., 57, 153, 196, 

345 

De Santis M., 396 

De Wachter S.G.G., 393 

Debruyne F.M.J., 66, 384 

Deger S.D., 104 

Demirkesen O., 104 

Denys P., 402 

Deprest J., 320 

Desai M.R., 240 

Desgrandchamps F., 59, 260 

Di Tonno P., 106, 147 

Dimeo F., 417 

Dinis Oliveira P., 107 

Dinney C.P.N., 265 

Djavan B., 65, 75, 109, 112, 348 

Djinovic R.P., 104 

Djojodimedjo T., 68 

Dmochowski R., 98 

Donovan J., 316 

Dore B., 162 

Drake M.J., 98, 132, 368, 393 

Dreikorn K., 106 

Drewa T.A., 140 

Drudge-Coates L., 428 

Dybowski B.A., 125 

E 

Eardley I., 113, 172, 315, 323 

Edwards C., 258 

Egawa S., 281 

Eisen T., 379 

Eissa M., 72, 164 

El-Kassaby A., 211 

Ellsworth P., 399 

Emberton M., 80, 95, 387 

Erdogru T., 371 

Ergen A., 98 

Eriksen P., 409 

Erlandsson I., 424 


Escudier B., 398 

Esen T., 112, 214 

Evans C.P., 203, 316 

Everaert K., 402 

F 

Fall M., 132 

Farag F., 269 

Feitz W.F.J., 164 

Ferreira Coelho M.X., 100 

Figarov I., 70 

Figueiredo A.J., 106, 130, 359 

Fisch M.M., 104, 248, 264, 367 

Fitzpatrick J.M., 401 

Fitzpatrick K., 412, 428, 430 

Fizazi K., 76, 396 

Fornara P., 82 

Fossa S.D., 259 

Fourmarier M., 397 

Frede T., 95, 370 

Fritsche H.M., 277 

Fry C., 57 

Fröhner M., 235 

Fuller F., 107 

Fusco F., 100 

Füssel S., 253 

G 

Gaboardi F., 228 

Galan J.A., 110 

Galfano A., 133 

Gallina A., 275 

Gambaro G., 110 

Garau J., 390 

Garthwaite M., 113 

Gaston R., 96 

Gaybullayev A., 70 

Gea-Sánchez M., 407 

Geavlete B., 288 

Geavlete P.A., 92, 96, 99, 110, 287, 

384 

Geng V., 407, 421, 428 

Giannantoni A., 402 

Giannarini G., 244 

Giessing M., 106, 177 

Giusti G.G., 374 

Glina S., 66 

Gomez Sancha F., 376 

Gomez V., 106 

Gontero P., 303, 326 

Govorov A., 151, 290, 400 

Grabe M., 72, 102, 267 

Graefen M., 158, 181, 401 

Grainger E., 423 

Grasso M., 350 

Gratzke C., 294, 343, 400 

Graugaard-Jensen C., 386 

Gravas S., 115, 372 

Graziottin A., 152 

Greco F., 311 

Greene D., 380 

Greenwell T.J., 230 

Grenabo L.J.G., 104 

Groen J., 408 

Gschwend J.E., 347, 396 

Guazzoni G., 96, 342 

Gueye S.M., 72 

Guillonneau B., 71, 82, 95 

Gözen A.S., 353, 373 

H 

Ha H., 60 

Haab F., 399 

Haase U.L.M., 408, 426, 428 

Hachi K., 71 

Haferkamp A., 298 

Hakenberg O.W., 64, 195, 322 

Hamasuna R., 67 

Hamdy F.C., 315, 319, 405 

Hamid R., 392 

Hammerer P., 365 

Han D.H., 59 

Han S.W., 193 

Hanno P., 57 

Hanus T., 88 

Harabayashi T., 67 

Hatzimouratidis K., 207 

Hauptmann A., 100 

Hautmann R.E., 73, 109 

Hedlund P., 160 

Heesakkers J.P.F.A., 98, 152, 383 

Heidenreich A., 62, 108, 259, 267, 

403 

Heinz-Peer G., 179 

Herrmann T.R.W., 250, 371 

Herschorn S., 98 

Hess B., 110 

Hieronymi S., 409, 421, 427 


Holmberg L., 315 

Holmäng S., 303 

Homma Y., 67 

Hosseini S.J., 65, 230 

Hoznek A., 95, 239, 287 

Hubert J., 342 

Hurn W., 417 

Häcker A., 313 

Hübner W.A., 141 

I 

Igawa Y., 294 

Ikromov O., 269 

Imbimbo C., 285 

Irani J., 394 

J Jacob M.E., 420 

Jacqmin D., 62, 75, 92, 326, 395 

James N., 76, 388, 403 

Janetschek G., 95, 239, 328, 370, 

391 

Janssen D.A.W., 408 

Javad-Zada S., 69 

Jensen B.T., 410, 414, 428 

Jenster G., 198 

Johansen M., 412 

John H., 96 

Joniau S.G., 290, 356, 405 

Joual A., 71 

Joulin V., 311 

Joyce A.D., 337 

Jungwirth A., 99 

Junker K., 108 

Jünemann K.P., 392 

K 

Kadioglu A., 69, 70, 100 

Kakizaki H., 67 

Kang T.W., 59 

Kaouk J.H., 181, 241, 353 

Kappor R., 64 

Karam G., 106, 177 

Karsenty G., 402 

Kayal S., 62 

Keeley F., 261, 313 

Kelleher C., 383 

Khakimkhodzhaev Z., 70 

Khan S.R., 110 

Khauli R.B., 62 

Khullar V., 399 

Khvadagiani G., 113 

Kiesbye B., 409 

Kim D.K., 59 

Kim J.W., 212 

Kingswood C., 389 

Kirkali Z., 336 

Klatte T., 145 

Klein J-T., 95, 371 

Kleinclauss F., 107 

Klocker H., 283 

Knoll T., 96, 110, 112, 240, 261, 374 

Knowles M., 220 

Knudsen R.N., 411 

Kocjancic E., 205 

Kocot A., 106 

Kolbl H., 57 

Korsakova I., 69 

Kouzmina N., 412 

Kramer G., 90 

Krieger J., 72, 102 

Krombach P., 96 

Kuczyk M., 129, 175, 336, 379 

Kulchavenya E., 176 

Kulkarni J.N., 64 

Kuntz R.M., 357, 397 

Kuusk T., 113 

Kwak C., 59 

Kümmel C., 415 

L 

Laguna M.P., 61, 88, 95 

Lahme S., 110 

Larré S., 112 

Lauridsen S.V., 407, 412, 428 

Laws H., 427 

Lazzeri M., 61, 404 

Lebret T., 178 

Lee J.Z., 59 

Lee Y.G., 59 

Leung H.Y., 216 

Liao J., 176 

Liatsikos E., 96, 353, 370 

Lilja H.G., 170 

Ljungberg B., 129 

Lledo-Garcia E., 106 

Llorente C., 400 

Loch T., 96, 100, 246 

Love-Retinger N., 412 

Lucas M., 152, 212, 263 

Lukacs B., 397 

Lumen N., 104, 308 

Läckgren G., 173 

M 

Machtens S., 339 

Madersbacher S., 233, 260, 333 

Madoff R., 57 

Maher C., 57 

Mair D., 410 

Malavaud B., 96, 362 

Malmström P-U., 154 

Managadze G., 69 

Mangera A., 248 

Mansson K.G.W., 73 

Marberger M., 62, 67, 73, 113, 321, 

387 

Marley J.T., 414, 418, 423 

Martinez Bustamante L.G., 112 

Martínez-Piñeiro L., 113, 211, 364, 

388 

Mason M., 109, 267, 317, 394 

Matei V.D., 264 

Mattelaer J., 407 

Matveev V., 268 

Mendoza-Valdes A., 73 

Meneghini A., 372 

Mengual L., 201 

Menon M., 273 

Merseburger A.S., 292, 396 

Messas A., 75, 114 

Messelink E.J., 320 

Meuleman E.J.H., 100 

Michel M.S., 95, 239 

Mickisch G., 366 

Mikuz G., 108 

Miller K., 341, 396 

Miller P., 397 

Mills I., 283 

Millán-Rodríguez F., 321 

Milsom I., 57, 399 

Minervini A., 119 

Minhas S., 86, 259 

Mirone V., 65, 75, 99, 226, 269 

Moncada I., 66 

Montanari E., 113 

Montorsi F., 181, 305, 343, 394 



477 

Indices

Indices 


Moore K., 58 

Moore K.N., 57 

Morote Robles J., 138 

Mosbah A., 62 

Mottet N., 267, 271, 379 

Mottrie A., 66, 96, 113, 181, 200, 

342, 369 

Mozer P.C., 250 

Mshvildadze S.T., 107 

Mulder H.J., 423 

Mulders P.F.A., 175, 316, 398 

Mulhall J.P., 172 

Mundy A.R., 104 

Muntener M., 222 

Muradyan A., 69, 70 

Murphy D., 343 

Muschter R., 96, 373 

Musquera Felip M., 107, 147 

Mutambirwa S., 72 

Månsson K.G.W., 105 

N 

Naber K.G., 390 

Naspro R.L.J., 397 

Newman D.K., 58 

Nickel J.C., 102, 332 

Nijman J.M., 57, 61, 75, 113, 358 

Nilsson S., 379 

Nishimura K., 67 

Nonomura N., 67 

Nouira Y., 62 

Novara G., 141, 343 

Nusratulloev I., 69 

Nyirády P.J., 166 

N’Dow J.M.O., 72, 102 

O 

Oehlschläger S., 110, 255 

Oelke M., 115, 393 

Oh S.J., 59 

Okada H., 67 

Olsburgh J.D., 106, 177 

Olsen K., 409 

Olsen L.H., 173 

Oluwabunmi Olapade-Olaopa E., 

72 

Oosterwijk E., 145 

Osanto S., 366 


Osther P.J., 94, 110, 240, 261, 350, 

374 

Oudard S., 382 

Özen H.A., 109, 138 

P 

Palma P., 66 

Palminteri E., 104 

Palou Redorta J., 75, 103, 354 

Pansadoro V., 95, 104, 330 

Papatsoris A., 110 

Parker C., 379 

Parsons K.F., 267 

Patel A., 59, 67, 113, 321 

Patel V.P., 181 

Payne H., 401 

Peeker R., 424 

Peri Cusi L., 107 

Perry M.J.A., 195 

Petrolekas A., 400 

Pickard R.S., 78, 102 

Piechaud P.T., 95, 153, 228, 324 

Pieters R., 410, 423 

Pilatz A., 99 

Pini G., 95 

Ploussard G., 279 

Porpiglia F., 119, 241, 328 

Porta C., 398 

Posch-Zimmermann R., 332 

Power M., 410 

Powles T., 175, 398 

Pozzi Mucelli F., 100 

Pummer K., 341 

Purnomo B.B., 68 

Pushkar D., 98, 113, 153, 196, 263, 

345 

R 

Rabenalt R., 219 

Rabii R., 71 

Radziszewski P., 151, 263, 315, 384 

Ralph D., 323 

Ramirez Backhaus M., 203 

Rashidov M., 113 

Rassweiler J., 95, 110, 185, 327, 369 

Ravery V., 108, 185 

Rawashdeh Y.F., 102 

Reich O., 260, 376 

Reis Santos J.M., 110 

Reisman Y., 207 

Remzi M., 242 

Rew M., 415 

Ribal Caparros M.J., 96, 114, 265 

Rocco B., 158 

Romancik M., 404 

Romics I., 252 

Roobol M.J., 309 

Rosario D.J., 176 

Rosier P.F.W.M., 98 

Rouprêt M., 277, 400 

Ruf C.G.A., 112 

Rwamasirabo E., 72 

S 

Saad F., 398 

Sadighi Gilani M.A., 65 

Salomaa S., 407 

Salomon G., 100 

Salomon L., 371 

Salomon R., 106 

Salonia A., 239, 400 

Saltirov I., 110 

Sampson J.R., 389 

Sanchez Salas R.E., 222 

Sanchez-Carbayo Martin M., 123 

Sanguedolce F., 112 

Sarica K., 110 

Sau-Kwan P., 425 

Scardino P., 405 

Scarpa R.M., 137 

Scattoni V., 121, 365 

Schaefer W., 408 

Schalken J.A., 59, 265 

Schiefelbein F., 376 

Schlomm T., 181, 198 

Schmidt S.K., 112 

Schröder F., 317 

Schulman C.C., 99 

Schultheiss D., 106, 178, 252 

Schwentner C., 371 

Scoffone C., 375 

Scotté F., 401 

Sebag G., 173 

Secin F., 275 

Sedelaar J.P.M., 112 

Seibold J., 193 

Seitz C., 261 

Shakeri S., 65 


Shariat S.F., 309 

Shen M.H., 389 

Shenfeld O.Z., 104 

Shore N., 394 

Shunaigat A.N., 62 

Siener R., 110 

Sievert K-D., 104, 151, 307, 373, 400 

Sihombing A.T., 68 

Silay M.S., 112 

Singh S.K., 64 

Siracusano S., 99 

Skolarikos A., 95, 110, 375, 377 

Skrodzka M., 112 

Smith M.R., 382 

Sofikitis N., 65, 99 

Solsona E., 166 

Spahn M., 239, 305 

Speakman M.J., 383 

Stanley N., 386 

Staskin D.R., 57 

Stenzl A., 75, 347 

Sternberg C.N., 108, 271, 403 

Stief C., 323, 405 

Stolzenburg J-U., 96, 360, 381 

Straub M., 110, 262 

Studer U.E., 347 

Stöckle M., 334 

Suardi N., 418 

Sugandi S., 68 

Sullivan M.E., 242 

Sulser T., 191, 377 

Sung G.T., 59 

Sylvester R.J., 343 

Søndergaard I., 409 

T Tanabe K., 67 

Tandogdu Z., 102, 113 

Tarricone R., 404 

Tasca A., 162 

Taylor T., 422 

Tchanturaia Z., 69 

Teber D., 375 

Tekgül S., 112, 358 

Tenke P., 102, 143 

Terrone C., 106 

Thalmann G.N., 109, 258 

Thiruchelvam N., 151 

Thüroff J.W., 153 

Thüroff S.F.M., 339 

Tiselius H.G., 255 

Tolley D.A., 240 

Tombal B., 62, 258, 315, 403 

Touijer K., 71, 156, 360 

Trachtenberg J., 405 

Traxer O., 95, 111, 240, 350, 370 

Trinchieri A., 110 

Trojan L., 168 

Trombetta C., 99, 105 

Tubaro A., 57, 59, 224, 317, 378, 382 

Turmanidze N., 70 

Turney B.W., 151 

Türk C., 267 

Türkeri L.N., 117 

U Ukimura O., 137 

Ulmert D., 279 

Usupbaev A., 69 

V Vahr S., 416 

Valdagni R., 71 

Van Cleynenbreugel B.S.E.P., 334 

Van De Velde C.J.H., 264 

Van Der Aa F.A., 151, 367 

Van Der Poel H.G., 181, 240, 281, 

334 

Van Kerrebroeck P.E., 178, 386 

Van Koeveringe G., 231 

Van Moorselaar R.J.A., 182, 302 

Van Muilekom H.A.M., 417 

Van Poppel H., 65, 75, 113, 316, 322 

Van Velthoven R.F., 95, 327 

Van Wijlick E., 423 

Van der Aa F.A., 151, 367 

Vance W., 415 

Vandewinkel M., 407 

Vermeulen H.H.M., 265 

Verze P., 100 

Vesterby M., 419 

Vestermark A., 410, 414 

Villers A., 100, 296 

Vinarov A.Z., 384 

W Wagenlehner F.M.E., 84, 102, 420 

Wagg A., 57 

Waltregny D.A.O., 98 

Walz J., 99 

Watson R.W.G., 78 

Weidner W.H.G., 67, 86, 99, 172, 

352 

Wein A.J., 57 

Weiss J., 386 

Wendt-Nordahl G., 96 

Wespes E., 100, 226 

Wezel F., 269 

Whelan P., 113 

Wickham J.E.A., 73 

Widmark A., 403 

Wiegel T., 108, 168 

Wijkstra H., 100 

Wiklund P., 76, 95, 181, 327 

Wilt T.J., 315 

Wirth M., 64, 67, 75 

Witjes J.A., 220, 354, 395 

Witzsch U., 96, 377, 380 

Wood L., 416 

Wullt B., 143, 390 

Wyndaele J.J., 102, 332, 383 

X Xie L.P., 61 

Y Yates D., 154 

Yazichyan S., 69, 70 

Yin C.J., 61 

Yossepowitch O.Y., 288 

Z 

Zargar Shoshtari M.A., 65 

Zattoni F., 268 

Zhang Y., 61 

Zhu G., 61, 298 

Zimmern P., 307 

Zlotta A.R., 66, 156, 319 

Zwarthoff E.C., 123 

Zykan M., 178 



479 

Indices

Join the European Association of 

Urology, become a member, 

get involved! 

The EAU is the voice of European urologists, a non-profit 

scientific organisation dedicated to serving their members 

and representing their professional interests! 

Learn about the many benefits of being a member of the 

European Association of Urology. 

Free subscriptions to: 

EAU Scientific Journal: European Urology, 

Supplements, EAU-EBU Update Series 

EAU Newsletter: European Urology Today 

Historia Urologiae Europaeae 


European Urology Video Journal 

Member discounts on EAU products and services 

Registration benefits for EAU meetings 

EAU ID Card for 

Automatic registration of EU-ACME credit points 

Easy printing of certificates of attendance for 

Congresses and Courses 

The EAU has a number of membership categories catering 

to all professionals involved in the speciality of urology. 

We invite you to become a member today! 

www.uroweb.org

Saturday, 25 February - EAU Annual Congress

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?